No articulo,Articulo,Palabra,Tipo entidad
0,2010-019912-18,EudraCT,o
0,2010-019912-18,Nº,o
0,2010-019912-18,201001991218,o
0,2010-019912-18,Titulo,o
0,2010-019912-18,cientifico,o
0,2010-019912-18,Estudio,o
0,2010-019912-18,randomizado,o
0,2010-019912-18,doble,o
0,2010-019912-18,ciego,o
0,2010-019912-18,con,o
0,2010-019912-18,grupos,o
0,2010-019912-18,de,o
0,2010-019912-18,tratamiento,i
0,2010-019912-18,paralelos,o
0,2010-019912-18,para,o
0,2010-019912-18,evaluar,i
0,2010-019912-18,la,i
0,2010-019912-18,seguridad,i
0,2010-019912-18,y,o
0,2010-019912-18,el,o
0,2010-019912-18,efecto,o
0,2010-019912-18,sobre,o
0,2010-019912-18,el,o
0,2010-019912-18,resultado,o
0,2010-019912-18,clinico,o
0,2010-019912-18,de,o
0,2010-019912-18,tocilizumab,i
0,2010-019912-18,SC,o
0,2010-019912-18,frente,o
0,2010-019912-18,a,o
0,2010-019912-18,placebo,i
0,2010-019912-18,SC,o
0,2010-019912-18,en,o
0,2010-019912-18,combinacion,o
0,2010-019912-18,con,o
0,2010-019912-18,farmacos,i
0,2010-019912-18,antirreumaticos,i
0,2010-019912-18,modificadores,i
0,2010-019912-18,de,i
0,2010-019912-18,la,i
0,2010-019912-18,enfermedad,i
0,2010-019912-18,FAMEs,i
0,2010-019912-18,tradicionales,o
0,2010-019912-18,en,o
0,2010-019912-18,pacientes,o
0,2010-019912-18,con,o
0,2010-019912-18,artritis,i
0,2010-019912-18,reumatoide,i
0,2010-019912-18,activa,o
0,2010-019912-18,moderada,o
0,2010-019912-18,a,o
0,2010-019912-18,severa,o
0,2010-019912-18,Indicacion,o
0,2010-019912-18,cientifica,o
0,2010-019912-18,Artritis,i
0,2010-019912-18,Reumatoide,i
0,2010-019912-18,AR,i
0,2010-019912-18,Criterios,o
0,2010-019912-18,de,o
0,2010-019912-18,inclusion,o
0,2010-019912-18,Presentar,o
0,2010-019912-18,artritis,i
0,2010-019912-18,reumatoide,i
0,2010-019912-18,de,o
0,2010-019912-18,mayor,o
0,2010-019912-18,o,o
0,2010-019912-18,igual,o
0,2010-019912-18,a,o
0,2010-019912-18,6,o
0,2010-019912-18,meses,o
0,2010-019912-18,de,o
0,2010-019912-18,duracion,o
0,2010-019912-18,Recibir,o
0,2010-019912-18,tratamiento,i
0,2010-019912-18,de,i
0,2010-019912-18,forma,i
0,2010-019912-18,ambulatoria,i
0,2010-019912-18,Presentar,o
0,2010-019912-18,un,o
0,2010-019912-18,recuento,o
0,2010-019912-18,de,o
0,2010-019912-18,articulaciones,i
0,2010-019912-18,inflamadas,i
0,2010-019912-18,RAI,o
0,2010-019912-18,mayor,o
0,2010-019912-18,o,o
0,2010-019912-18,igual,o
0,2010-019912-18,a,o
0,2010-019912-18,6,o
0,2010-019912-18,recuento,o
0,2010-019912-18,de,o
0,2010-019912-18,66,o
0,2010-019912-18,articulaciones,i
0,2010-019912-18,y,o
0,2010-019912-18,de,o
0,2010-019912-18,articulaciones,i
0,2010-019912-18,dolorosas,i
0,2010-019912-18,RAD,o
0,2010-019912-18,mayor,o
0,2010-019912-18,o,o
0,2010-019912-18,igual,o
0,2010-019912-18,a,o
0,2010-019912-18,8,o
0,2010-019912-18,recuento,o
0,2010-019912-18,de,o
0,2010-019912-18,68,o
0,2010-019912-18,articulaciones,i
0,2010-019912-18,en,o
0,2010-019912-18,las,o
0,2010-019912-18,visitas,o
0,2010-019912-18,de,o
0,2010-019912-18,seleccion,o
0,2010-019912-18,y,o
0,2010-019912-18,basal,o
0,2010-019912-18,Los,o
0,2010-019912-18,pacientes,o
0,2010-019912-18,deben,o
0,2010-019912-18,estar,o
0,2010-019912-18,recibiendo,o
0,2010-019912-18,tratamiento,i
0,2010-019912-18,con,o
0,2010-019912-18,una,o
0,2010-019912-18,dosis,o
0,2010-019912-18,estable,o
0,2010-019912-18,de,o
0,2010-019912-18,los,o
0,2010-019912-18,FAMEs,i
0,2010-019912-18,permitidos,o
0,2010-019912-18,como,o
0,2010-019912-18,minimo,o
0,2010-019912-18,8,o
0,2010-019912-18,semanas,o
0,2010-019912-18,antes,o
0,2010-019912-18,de,o
0,2010-019912-18,la,o
0,2010-019912-18,visita,o
0,2010-019912-18,basal,o
0,2010-019912-18,Criterios,o
0,2010-019912-18,de,o
0,2010-019912-18,exclusion,o
0,2010-019912-18,Pacientes,o
0,2010-019912-18,sometidos,o
0,2010-019912-18,a,o
0,2010-019912-18,intervenciones,i
0,2010-019912-18,de,i
0,2010-019912-18,cirugia,i
0,2010-019912-18,mayor,i
0,2010-019912-18,incluyendo,o
0,2010-019912-18,cirugia,i
0,2010-019912-18,articular,i
0,2010-019912-18,en,o
0,2010-019912-18,las,o
0,2010-019912-18,8,o
0,2010-019912-18,semanas,o
0,2010-019912-18,previas,o
0,2010-019912-18,a,o
0,2010-019912-18,la,o
0,2010-019912-18,visita,o
0,2010-019912-18,de,o
0,2010-019912-18,seleccion,o
0,2010-019912-18,o,o
0,2010-019912-18,que,o
0,2010-019912-18,tengan,o
0,2010-019912-18,previsto,o
0,2010-019912-18,someterse,o
0,2010-019912-18,a,o
0,2010-019912-18,una,o
0,2010-019912-18,intervencion,i
0,2010-019912-18,de,o
0,2010-019912-18,este,o
0,2010-019912-18,tipo,o
0,2010-019912-18,en,o
0,2010-019912-18,los,o
0,2010-019912-18,6,o
0,2010-019912-18,meses,o
0,2010-019912-18,siguientes,o
0,2010-019912-18,a,o
0,2010-019912-18,la,o
0,2010-019912-18,randomizacion,i
0,2010-019912-18,Enfermedad,i
0,2010-019912-18,reumatica,i
0,2010-019912-18,autoinmune,i
0,2010-019912-18,distinta,o
0,2010-019912-18,de,o
0,2010-019912-18,AR,i
0,2010-019912-18,Se,o
0,2010-019912-18,permite,o
0,2010-019912-18,la,o
0,2010-019912-18,inclusion,o
0,2010-019912-18,de,o
0,2010-019912-18,pacientes,o
0,2010-019912-18,con,o
0,2010-019912-18,sindrome,i
0,2010-019912-18,de,i
0,2010-019912-18,Sjögren,i
0,2010-019912-18,secundario,i
0,2010-019912-18,asociado,o
0,2010-019912-18,a,o
0,2010-019912-18,AR,i
0,2010-019912-18,Clase,o
0,2010-019912-18,funcional,o
0,2010-019912-18,IV,o
0,2010-019912-18,definida,o
0,2010-019912-18,de,o
0,2010-019912-18,acuerdo,o
0,2010-019912-18,con,o
0,2010-019912-18,la,o
0,2010-019912-18,Clasificacion,o
0,2010-019912-18,del,o
0,2010-019912-18,ACR,o
0,2010-019912-18,del,o
0,2010-019912-18,Estado,o
0,2010-019912-18,Funcional,o
0,2010-019912-18,en,o
0,2010-019912-18,Artritis,i
0,2010-019912-18,Reumatoide,i
0,2010-019912-18,Artritis,i
0,2010-019912-18,idiopatica,i
0,2010-019912-18,juvenil,i
0,2010-019912-18,AIJ,i
0,2010-019912-18,o,o
0,2010-019912-18,artritis,i
0,2010-019912-18,reumatoide,i
0,2010-019912-18,juvenil,i
0,2010-019912-18,ARJ,i
0,2010-019912-18,yo,o
0,2010-019912-18,AR,i
0,2010-019912-18,diagnosticadas,i
0,2010-019912-18,antes,o
0,2010-019912-18,de,o
0,2010-019912-18,los,o
0,2010-019912-18,16,o
0,2010-019912-18,años,o
0,2010-019912-18,de,o
0,2010-019912-18,edad,o
0,2010-019912-18,Enfermedad,i
0,2010-019912-18,articular,i
0,2010-019912-18,inflamatoria,i
0,2010-019912-18,distinta,o
0,2010-019912-18,de,o
0,2010-019912-18,AR,i
0,2010-019912-18,en,o
0,2010-019912-18,el,o
0,2010-019912-18,pasado,o
0,2010-019912-18,o,o
0,2010-019912-18,en,o
0,2010-019912-18,la,o
0,2010-019912-18,actualidad,o
1,2010-019912-18,EudraCT,o
1,2010-019912-18,Nº,o
1,2010-019912-18,201001991218,o
1,2010-019912-18,Titulo,o
1,2010-019912-18,cientifico,o
1,2010-019912-18,Estudio,o
1,2010-019912-18,randomizado,o
1,2010-019912-18,doble,o
1,2010-019912-18,ciego,o
1,2010-019912-18,con,o
1,2010-019912-18,grupos,o
1,2010-019912-18,de,o
1,2010-019912-18,tratamiento,i
1,2010-019912-18,paralelos,o
1,2010-019912-18,para,o
1,2010-019912-18,evaluar,i
1,2010-019912-18,la,i
1,2010-019912-18,seguridad,i
1,2010-019912-18,y,o
1,2010-019912-18,el,o
1,2010-019912-18,efecto,o
1,2010-019912-18,sobre,o
1,2010-019912-18,el,o
1,2010-019912-18,resultado,o
1,2010-019912-18,clinico,o
1,2010-019912-18,de,o
1,2010-019912-18,tocilizumab,i
1,2010-019912-18,SC,o
1,2010-019912-18,frente,o
1,2010-019912-18,a,o
1,2010-019912-18,placebo,i
1,2010-019912-18,SC,o
1,2010-019912-18,en,o
1,2010-019912-18,combinacion,o
1,2010-019912-18,con,o
1,2010-019912-18,farmacos,i
1,2010-019912-18,antirreumaticos,i
1,2010-019912-18,modificadores,i
1,2010-019912-18,de,i
1,2010-019912-18,la,i
1,2010-019912-18,enfermedad,i
1,2010-019912-18,FAMEs,i
1,2010-019912-18,tradicionales,o
1,2010-019912-18,en,o
1,2010-019912-18,pacientes,o
1,2010-019912-18,con,o
1,2010-019912-18,artritis,i
1,2010-019912-18,reumatoide,i
1,2010-019912-18,activa,o
1,2010-019912-18,moderada,o
1,2010-019912-18,a,o
1,2010-019912-18,severa,o
1,2010-019912-18,Indicacion,o
1,2010-019912-18,cientifica,o
1,2010-019912-18,Artritis,i
1,2010-019912-18,Reumatoide,i
1,2010-019912-18,AR,i
1,2010-019912-18,Criterios,o
1,2010-019912-18,de,o
1,2010-019912-18,inclusion,o
1,2010-019912-18,Presentar,o
1,2010-019912-18,artritis,i
1,2010-019912-18,reumatoide,i
1,2010-019912-18,de,o
1,2010-019912-18,mayor,o
1,2010-019912-18,o,o
1,2010-019912-18,igual,o
1,2010-019912-18,a,o
1,2010-019912-18,6,o
1,2010-019912-18,meses,o
1,2010-019912-18,de,o
1,2010-019912-18,duracion,o
1,2010-019912-18,Recibir,o
1,2010-019912-18,tratamiento,i
1,2010-019912-18,de,i
1,2010-019912-18,forma,i
1,2010-019912-18,ambulatoria,i
1,2010-019912-18,Presentar,o
1,2010-019912-18,un,o
1,2010-019912-18,recuento,o
1,2010-019912-18,de,o
1,2010-019912-18,articulaciones,i
1,2010-019912-18,inflamadas,i
1,2010-019912-18,RAI,o
1,2010-019912-18,mayor,o
1,2010-019912-18,o,o
1,2010-019912-18,igual,o
1,2010-019912-18,a,o
1,2010-019912-18,6,o
1,2010-019912-18,recuento,o
1,2010-019912-18,de,o
1,2010-019912-18,66,o
1,2010-019912-18,articulaciones,i
1,2010-019912-18,y,o
1,2010-019912-18,de,o
1,2010-019912-18,articulaciones,i
1,2010-019912-18,dolorosas,i
1,2010-019912-18,RAD,o
1,2010-019912-18,mayor,o
1,2010-019912-18,o,o
1,2010-019912-18,igual,o
1,2010-019912-18,a,o
1,2010-019912-18,8,o
1,2010-019912-18,recuento,o
1,2010-019912-18,de,o
1,2010-019912-18,68,o
1,2010-019912-18,articulaciones,i
1,2010-019912-18,en,o
1,2010-019912-18,las,o
1,2010-019912-18,visitas,o
1,2010-019912-18,de,o
1,2010-019912-18,seleccion,o
1,2010-019912-18,y,o
1,2010-019912-18,basal,o
1,2010-019912-18,Los,o
1,2010-019912-18,pacientes,o
1,2010-019912-18,deben,o
1,2010-019912-18,estar,o
1,2010-019912-18,recibiendo,o
1,2010-019912-18,tratamiento,i
1,2010-019912-18,con,o
1,2010-019912-18,una,o
1,2010-019912-18,dosis,o
1,2010-019912-18,estable,o
1,2010-019912-18,de,o
1,2010-019912-18,los,o
1,2010-019912-18,FAMEs,i
1,2010-019912-18,permitidos,o
1,2010-019912-18,como,o
1,2010-019912-18,minimo,o
1,2010-019912-18,8,o
1,2010-019912-18,semanas,o
1,2010-019912-18,antes,o
1,2010-019912-18,de,o
1,2010-019912-18,la,o
1,2010-019912-18,visita,o
1,2010-019912-18,basal,o
1,2010-019912-18,Criterios,o
1,2010-019912-18,de,o
1,2010-019912-18,exclusion,o
1,2010-019912-18,Pacientes,o
1,2010-019912-18,sometidos,o
1,2010-019912-18,a,o
1,2010-019912-18,intervenciones,i
1,2010-019912-18,de,i
1,2010-019912-18,cirugia,i
1,2010-019912-18,mayor,i
1,2010-019912-18,incluyendo,o
1,2010-019912-18,cirugia,i
1,2010-019912-18,articular,i
1,2010-019912-18,en,o
1,2010-019912-18,las,o
1,2010-019912-18,8,o
1,2010-019912-18,semanas,o
1,2010-019912-18,previas,o
1,2010-019912-18,a,o
1,2010-019912-18,la,o
1,2010-019912-18,visita,o
1,2010-019912-18,de,o
1,2010-019912-18,seleccion,o
1,2010-019912-18,o,o
1,2010-019912-18,que,o
1,2010-019912-18,tengan,o
1,2010-019912-18,previsto,o
1,2010-019912-18,someterse,o
1,2010-019912-18,a,o
1,2010-019912-18,una,o
1,2010-019912-18,intervencion,i
1,2010-019912-18,de,o
1,2010-019912-18,este,o
1,2010-019912-18,tipo,o
1,2010-019912-18,en,o
1,2010-019912-18,los,o
1,2010-019912-18,6,o
1,2010-019912-18,meses,o
1,2010-019912-18,siguientes,o
1,2010-019912-18,a,o
1,2010-019912-18,la,o
1,2010-019912-18,randomizacion,i
1,2010-019912-18,Enfermedad,i
1,2010-019912-18,reumatica,i
1,2010-019912-18,autoinmune,i
1,2010-019912-18,distinta,o
1,2010-019912-18,de,o
1,2010-019912-18,AR,i
1,2010-019912-18,Se,o
1,2010-019912-18,permite,o
1,2010-019912-18,la,o
1,2010-019912-18,inclusion,o
1,2010-019912-18,de,o
1,2010-019912-18,pacientes,o
1,2010-019912-18,con,o
1,2010-019912-18,sindrome,i
1,2010-019912-18,de,i
1,2010-019912-18,Sjögren,i
1,2010-019912-18,secundario,i
1,2010-019912-18,asociado,o
1,2010-019912-18,a,o
1,2010-019912-18,AR,i
1,2010-019912-18,Clase,o
1,2010-019912-18,funcional,o
1,2010-019912-18,IV,o
1,2010-019912-18,definida,o
1,2010-019912-18,de,o
1,2010-019912-18,acuerdo,o
1,2010-019912-18,con,o
1,2010-019912-18,la,o
1,2010-019912-18,Clasificacion,o
1,2010-019912-18,del,o
1,2010-019912-18,ACR,o
1,2010-019912-18,del,o
1,2010-019912-18,Estado,o
1,2010-019912-18,Funcional,o
1,2010-019912-18,en,o
1,2010-019912-18,Artritis,i
1,2010-019912-18,Reumatoide,i
1,2010-019912-18,Artritis,i
1,2010-019912-18,idiopatica,i
1,2010-019912-18,juvenil,i
1,2010-019912-18,AIJ,i
1,2010-019912-18,o,o
1,2010-019912-18,artritis,i
1,2010-019912-18,reumatoide,i
1,2010-019912-18,juvenil,i
1,2010-019912-18,ARJ,i
1,2010-019912-18,yo,o
1,2010-019912-18,AR,i
1,2010-019912-18,diagnosticadas,i
1,2010-019912-18,antes,o
1,2010-019912-18,de,o
1,2010-019912-18,los,o
1,2010-019912-18,16,o
1,2010-019912-18,años,o
1,2010-019912-18,de,o
1,2010-019912-18,edad,o
1,2010-019912-18,Enfermedad,i
1,2010-019912-18,articular,i
1,2010-019912-18,inflamatoria,i
1,2010-019912-18,distinta,o
1,2010-019912-18,de,o
1,2010-019912-18,AR,i
1,2010-019912-18,en,o
1,2010-019912-18,el,o
1,2010-019912-18,pasado,o
1,2010-019912-18,o,o
1,2010-019912-18,en,o
1,2010-019912-18,la,o
1,2010-019912-18,actualidad,o
2,2010-019912-18,EudraCT,o
2,2010-019912-18,Nº,o
2,2010-019912-18,201001991218,o
2,2010-019912-18,Titulo,o
2,2010-019912-18,cientifico,o
2,2010-019912-18,Estudio,o
2,2010-019912-18,randomizado,o
2,2010-019912-18,doble,o
2,2010-019912-18,ciego,o
2,2010-019912-18,con,o
2,2010-019912-18,grupos,o
2,2010-019912-18,de,o
2,2010-019912-18,tratamiento,i
2,2010-019912-18,paralelos,o
2,2010-019912-18,para,o
2,2010-019912-18,evaluar,i
2,2010-019912-18,la,i
2,2010-019912-18,seguridad,i
2,2010-019912-18,y,o
2,2010-019912-18,el,o
2,2010-019912-18,efecto,o
2,2010-019912-18,sobre,o
2,2010-019912-18,el,o
2,2010-019912-18,resultado,o
2,2010-019912-18,clinico,o
2,2010-019912-18,de,o
2,2010-019912-18,tocilizumab,i
2,2010-019912-18,SC,o
2,2010-019912-18,frente,o
2,2010-019912-18,a,o
2,2010-019912-18,placebo,i
2,2010-019912-18,SC,o
2,2010-019912-18,en,o
2,2010-019912-18,combinacion,o
2,2010-019912-18,con,o
2,2010-019912-18,farmacos,i
2,2010-019912-18,antirreumaticos,i
2,2010-019912-18,modificadores,i
2,2010-019912-18,de,i
2,2010-019912-18,la,i
2,2010-019912-18,enfermedad,i
2,2010-019912-18,FAMEs,i
2,2010-019912-18,tradicionales,o
2,2010-019912-18,en,o
2,2010-019912-18,pacientes,o
2,2010-019912-18,con,o
2,2010-019912-18,artritis,i
2,2010-019912-18,reumatoide,i
2,2010-019912-18,activa,o
2,2010-019912-18,moderada,o
2,2010-019912-18,a,o
2,2010-019912-18,severa,o
2,2010-019912-18,Indicacion,o
2,2010-019912-18,cientifica,o
2,2010-019912-18,Artritis,i
2,2010-019912-18,Reumatoide,i
2,2010-019912-18,AR,i
2,2010-019912-18,Criterios,o
2,2010-019912-18,de,o
2,2010-019912-18,inclusion,o
2,2010-019912-18,Presentar,o
2,2010-019912-18,artritis,i
2,2010-019912-18,reumatoide,i
2,2010-019912-18,de,o
2,2010-019912-18,mayor,o
2,2010-019912-18,o,o
2,2010-019912-18,igual,o
2,2010-019912-18,a,o
2,2010-019912-18,6,o
2,2010-019912-18,meses,o
2,2010-019912-18,de,o
2,2010-019912-18,duracion,o
2,2010-019912-18,Recibir,o
2,2010-019912-18,tratamiento,i
2,2010-019912-18,de,i
2,2010-019912-18,forma,i
2,2010-019912-18,ambulatoria,i
2,2010-019912-18,Presentar,o
2,2010-019912-18,un,o
2,2010-019912-18,recuento,o
2,2010-019912-18,de,o
2,2010-019912-18,articulaciones,i
2,2010-019912-18,inflamadas,i
2,2010-019912-18,RAI,o
2,2010-019912-18,mayor,o
2,2010-019912-18,o,o
2,2010-019912-18,igual,o
2,2010-019912-18,a,o
2,2010-019912-18,6,o
2,2010-019912-18,recuento,o
2,2010-019912-18,de,o
2,2010-019912-18,66,o
2,2010-019912-18,articulaciones,i
2,2010-019912-18,y,o
2,2010-019912-18,de,o
2,2010-019912-18,articulaciones,i
2,2010-019912-18,dolorosas,i
2,2010-019912-18,RAD,o
2,2010-019912-18,mayor,o
2,2010-019912-18,o,o
2,2010-019912-18,igual,o
2,2010-019912-18,a,o
2,2010-019912-18,8,o
2,2010-019912-18,recuento,o
2,2010-019912-18,de,o
2,2010-019912-18,68,o
2,2010-019912-18,articulaciones,i
2,2010-019912-18,en,o
2,2010-019912-18,las,o
2,2010-019912-18,visitas,o
2,2010-019912-18,de,o
2,2010-019912-18,seleccion,o
2,2010-019912-18,y,o
2,2010-019912-18,basal,o
2,2010-019912-18,Los,o
2,2010-019912-18,pacientes,o
2,2010-019912-18,deben,o
2,2010-019912-18,estar,o
2,2010-019912-18,recibiendo,o
2,2010-019912-18,tratamiento,i
2,2010-019912-18,con,o
2,2010-019912-18,una,o
2,2010-019912-18,dosis,o
2,2010-019912-18,estable,o
2,2010-019912-18,de,o
2,2010-019912-18,los,o
2,2010-019912-18,FAMEs,i
2,2010-019912-18,permitidos,o
2,2010-019912-18,como,o
2,2010-019912-18,minimo,o
2,2010-019912-18,8,o
2,2010-019912-18,semanas,o
2,2010-019912-18,antes,o
2,2010-019912-18,de,o
2,2010-019912-18,la,o
2,2010-019912-18,visita,o
2,2010-019912-18,basal,o
2,2010-019912-18,Criterios,o
2,2010-019912-18,de,o
2,2010-019912-18,exclusion,o
2,2010-019912-18,Pacientes,o
2,2010-019912-18,sometidos,o
2,2010-019912-18,a,o
2,2010-019912-18,intervenciones,i
2,2010-019912-18,de,i
2,2010-019912-18,cirugia,i
2,2010-019912-18,mayor,i
2,2010-019912-18,incluyendo,o
2,2010-019912-18,cirugia,i
2,2010-019912-18,articular,i
2,2010-019912-18,en,o
2,2010-019912-18,las,o
2,2010-019912-18,8,o
2,2010-019912-18,semanas,o
2,2010-019912-18,previas,o
2,2010-019912-18,a,o
2,2010-019912-18,la,o
2,2010-019912-18,visita,o
2,2010-019912-18,de,o
2,2010-019912-18,seleccion,o
2,2010-019912-18,o,o
2,2010-019912-18,que,o
2,2010-019912-18,tengan,o
2,2010-019912-18,previsto,o
2,2010-019912-18,someterse,o
2,2010-019912-18,a,o
2,2010-019912-18,una,o
2,2010-019912-18,intervencion,i
2,2010-019912-18,de,o
2,2010-019912-18,este,o
2,2010-019912-18,tipo,o
2,2010-019912-18,en,o
2,2010-019912-18,los,o
2,2010-019912-18,6,o
2,2010-019912-18,meses,o
2,2010-019912-18,siguientes,o
2,2010-019912-18,a,o
2,2010-019912-18,la,o
2,2010-019912-18,randomizacion,i
2,2010-019912-18,Enfermedad,i
2,2010-019912-18,reumatica,i
2,2010-019912-18,autoinmune,i
2,2010-019912-18,distinta,o
2,2010-019912-18,de,o
2,2010-019912-18,AR,i
2,2010-019912-18,Se,o
2,2010-019912-18,permite,o
2,2010-019912-18,la,o
2,2010-019912-18,inclusion,o
2,2010-019912-18,de,o
2,2010-019912-18,pacientes,o
2,2010-019912-18,con,o
2,2010-019912-18,sindrome,i
2,2010-019912-18,de,i
2,2010-019912-18,Sjögren,i
2,2010-019912-18,secundario,i
2,2010-019912-18,asociado,o
2,2010-019912-18,a,o
2,2010-019912-18,AR,i
2,2010-019912-18,Clase,o
2,2010-019912-18,funcional,o
2,2010-019912-18,IV,o
2,2010-019912-18,definida,o
2,2010-019912-18,de,o
2,2010-019912-18,acuerdo,o
2,2010-019912-18,con,o
2,2010-019912-18,la,o
2,2010-019912-18,Clasificacion,o
2,2010-019912-18,del,o
2,2010-019912-18,ACR,o
2,2010-019912-18,del,o
2,2010-019912-18,Estado,o
2,2010-019912-18,Funcional,o
2,2010-019912-18,en,o
2,2010-019912-18,Artritis,i
2,2010-019912-18,Reumatoide,i
2,2010-019912-18,Artritis,i
2,2010-019912-18,idiopatica,i
2,2010-019912-18,juvenil,i
2,2010-019912-18,AIJ,i
2,2010-019912-18,o,o
2,2010-019912-18,artritis,i
2,2010-019912-18,reumatoide,i
2,2010-019912-18,juvenil,i
2,2010-019912-18,ARJ,i
2,2010-019912-18,yo,o
2,2010-019912-18,AR,i
2,2010-019912-18,diagnosticadas,i
2,2010-019912-18,antes,o
2,2010-019912-18,de,o
2,2010-019912-18,los,o
2,2010-019912-18,16,o
2,2010-019912-18,años,o
2,2010-019912-18,de,o
2,2010-019912-18,edad,o
2,2010-019912-18,Enfermedad,i
2,2010-019912-18,articular,i
2,2010-019912-18,inflamatoria,i
2,2010-019912-18,distinta,o
2,2010-019912-18,de,o
2,2010-019912-18,AR,i
2,2010-019912-18,en,o
2,2010-019912-18,el,o
2,2010-019912-18,pasado,o
2,2010-019912-18,o,o
2,2010-019912-18,en,o
2,2010-019912-18,la,o
2,2010-019912-18,actualidad,o
3,2010-019912-18,EudraCT,o
3,2010-019912-18,Nº,o
3,2010-019912-18,201001991218,o
3,2010-019912-18,Titulo,o
3,2010-019912-18,cientifico,o
3,2010-019912-18,Estudio,o
3,2010-019912-18,randomizado,o
3,2010-019912-18,doble,o
3,2010-019912-18,ciego,o
3,2010-019912-18,con,o
3,2010-019912-18,grupos,o
3,2010-019912-18,de,o
3,2010-019912-18,tratamiento,i
3,2010-019912-18,paralelos,o
3,2010-019912-18,para,o
3,2010-019912-18,evaluar,i
3,2010-019912-18,la,i
3,2010-019912-18,seguridad,i
3,2010-019912-18,y,o
3,2010-019912-18,el,o
3,2010-019912-18,efecto,o
3,2010-019912-18,sobre,o
3,2010-019912-18,el,o
3,2010-019912-18,resultado,o
3,2010-019912-18,clinico,o
3,2010-019912-18,de,o
3,2010-019912-18,tocilizumab,i
3,2010-019912-18,SC,o
3,2010-019912-18,frente,o
3,2010-019912-18,a,o
3,2010-019912-18,placebo,i
3,2010-019912-18,SC,o
3,2010-019912-18,en,o
3,2010-019912-18,combinacion,o
3,2010-019912-18,con,o
3,2010-019912-18,farmacos,i
3,2010-019912-18,antirreumaticos,i
3,2010-019912-18,modificadores,i
3,2010-019912-18,de,i
3,2010-019912-18,la,i
3,2010-019912-18,enfermedad,i
3,2010-019912-18,FAMEs,i
3,2010-019912-18,tradicionales,o
3,2010-019912-18,en,o
3,2010-019912-18,pacientes,o
3,2010-019912-18,con,o
3,2010-019912-18,artritis,i
3,2010-019912-18,reumatoide,i
3,2010-019912-18,activa,o
3,2010-019912-18,moderada,o
3,2010-019912-18,a,o
3,2010-019912-18,severa,o
3,2010-019912-18,Indicacion,o
3,2010-019912-18,cientifica,o
3,2010-019912-18,Artritis,i
3,2010-019912-18,Reumatoide,i
3,2010-019912-18,AR,i
3,2010-019912-18,Criterios,o
3,2010-019912-18,de,o
3,2010-019912-18,inclusion,o
3,2010-019912-18,Presentar,o
3,2010-019912-18,artritis,i
3,2010-019912-18,reumatoide,i
3,2010-019912-18,de,o
3,2010-019912-18,mayor,o
3,2010-019912-18,o,o
3,2010-019912-18,igual,o
3,2010-019912-18,a,o
3,2010-019912-18,6,o
3,2010-019912-18,meses,o
3,2010-019912-18,de,o
3,2010-019912-18,duracion,o
3,2010-019912-18,Recibir,o
3,2010-019912-18,tratamiento,i
3,2010-019912-18,de,i
3,2010-019912-18,forma,i
3,2010-019912-18,ambulatoria,i
3,2010-019912-18,Presentar,o
3,2010-019912-18,un,o
3,2010-019912-18,recuento,o
3,2010-019912-18,de,o
3,2010-019912-18,articulaciones,i
3,2010-019912-18,inflamadas,i
3,2010-019912-18,RAI,o
3,2010-019912-18,mayor,o
3,2010-019912-18,o,o
3,2010-019912-18,igual,o
3,2010-019912-18,a,o
3,2010-019912-18,6,o
3,2010-019912-18,recuento,o
3,2010-019912-18,de,o
3,2010-019912-18,66,o
3,2010-019912-18,articulaciones,i
3,2010-019912-18,y,o
3,2010-019912-18,de,o
3,2010-019912-18,articulaciones,i
3,2010-019912-18,dolorosas,i
3,2010-019912-18,RAD,o
3,2010-019912-18,mayor,o
3,2010-019912-18,o,o
3,2010-019912-18,igual,o
3,2010-019912-18,a,o
3,2010-019912-18,8,o
3,2010-019912-18,recuento,o
3,2010-019912-18,de,o
3,2010-019912-18,68,o
3,2010-019912-18,articulaciones,i
3,2010-019912-18,en,o
3,2010-019912-18,las,o
3,2010-019912-18,visitas,o
3,2010-019912-18,de,o
3,2010-019912-18,seleccion,o
3,2010-019912-18,y,o
3,2010-019912-18,basal,o
3,2010-019912-18,Los,o
3,2010-019912-18,pacientes,o
3,2010-019912-18,deben,o
3,2010-019912-18,estar,o
3,2010-019912-18,recibiendo,o
3,2010-019912-18,tratamiento,i
3,2010-019912-18,con,o
3,2010-019912-18,una,o
3,2010-019912-18,dosis,o
3,2010-019912-18,estable,o
3,2010-019912-18,de,o
3,2010-019912-18,los,o
3,2010-019912-18,FAMEs,i
3,2010-019912-18,permitidos,o
3,2010-019912-18,como,o
3,2010-019912-18,minimo,o
3,2010-019912-18,8,o
3,2010-019912-18,semanas,o
3,2010-019912-18,antes,o
3,2010-019912-18,de,o
3,2010-019912-18,la,o
3,2010-019912-18,visita,o
3,2010-019912-18,basal,o
3,2010-019912-18,Criterios,o
3,2010-019912-18,de,o
3,2010-019912-18,exclusion,o
3,2010-019912-18,Pacientes,o
3,2010-019912-18,sometidos,o
3,2010-019912-18,a,o
3,2010-019912-18,intervenciones,i
3,2010-019912-18,de,i
3,2010-019912-18,cirugia,i
3,2010-019912-18,mayor,i
3,2010-019912-18,incluyendo,o
3,2010-019912-18,cirugia,i
3,2010-019912-18,articular,i
3,2010-019912-18,en,o
3,2010-019912-18,las,o
3,2010-019912-18,8,o
3,2010-019912-18,semanas,o
3,2010-019912-18,previas,o
3,2010-019912-18,a,o
3,2010-019912-18,la,o
3,2010-019912-18,visita,o
3,2010-019912-18,de,o
3,2010-019912-18,seleccion,o
3,2010-019912-18,o,o
3,2010-019912-18,que,o
3,2010-019912-18,tengan,o
3,2010-019912-18,previsto,o
3,2010-019912-18,someterse,o
3,2010-019912-18,a,o
3,2010-019912-18,una,o
3,2010-019912-18,intervencion,i
3,2010-019912-18,de,o
3,2010-019912-18,este,o
3,2010-019912-18,tipo,o
3,2010-019912-18,en,o
3,2010-019912-18,los,o
3,2010-019912-18,6,o
3,2010-019912-18,meses,o
3,2010-019912-18,siguientes,o
3,2010-019912-18,a,o
3,2010-019912-18,la,o
3,2010-019912-18,randomizacion,i
3,2010-019912-18,Enfermedad,i
3,2010-019912-18,reumatica,i
3,2010-019912-18,autoinmune,i
3,2010-019912-18,distinta,o
3,2010-019912-18,de,o
3,2010-019912-18,AR,i
3,2010-019912-18,Se,o
3,2010-019912-18,permite,o
3,2010-019912-18,la,o
3,2010-019912-18,inclusion,o
3,2010-019912-18,de,o
3,2010-019912-18,pacientes,o
3,2010-019912-18,con,o
3,2010-019912-18,sindrome,i
3,2010-019912-18,de,i
3,2010-019912-18,Sjögren,i
3,2010-019912-18,secundario,i
3,2010-019912-18,asociado,o
3,2010-019912-18,a,o
3,2010-019912-18,AR,i
3,2010-019912-18,Clase,o
3,2010-019912-18,funcional,o
3,2010-019912-18,IV,o
3,2010-019912-18,definida,o
3,2010-019912-18,de,o
3,2010-019912-18,acuerdo,o
3,2010-019912-18,con,o
3,2010-019912-18,la,o
3,2010-019912-18,Clasificacion,o
3,2010-019912-18,del,o
3,2010-019912-18,ACR,o
3,2010-019912-18,del,o
3,2010-019912-18,Estado,o
3,2010-019912-18,Funcional,o
3,2010-019912-18,en,o
3,2010-019912-18,Artritis,i
3,2010-019912-18,Reumatoide,i
3,2010-019912-18,Artritis,i
3,2010-019912-18,idiopatica,i
3,2010-019912-18,juvenil,i
3,2010-019912-18,AIJ,i
3,2010-019912-18,o,o
3,2010-019912-18,artritis,i
3,2010-019912-18,reumatoide,i
3,2010-019912-18,juvenil,i
3,2010-019912-18,ARJ,i
3,2010-019912-18,yo,o
3,2010-019912-18,AR,i
3,2010-019912-18,diagnosticadas,i
3,2010-019912-18,antes,o
3,2010-019912-18,de,o
3,2010-019912-18,los,o
3,2010-019912-18,16,o
3,2010-019912-18,años,o
3,2010-019912-18,de,o
3,2010-019912-18,edad,o
3,2010-019912-18,Enfermedad,i
3,2010-019912-18,articular,i
3,2010-019912-18,inflamatoria,i
3,2010-019912-18,distinta,o
3,2010-019912-18,de,o
3,2010-019912-18,AR,i
3,2010-019912-18,en,o
3,2010-019912-18,el,o
3,2010-019912-18,pasado,o
3,2010-019912-18,o,o
3,2010-019912-18,en,o
3,2010-019912-18,la,o
3,2010-019912-18,actualidad,o
4,2010-019912-18,EudraCT,o
4,2010-019912-18,Nº,o
4,2010-019912-18,201001991218,o
4,2010-019912-18,Titulo,o
4,2010-019912-18,cientifico,o
4,2010-019912-18,Estudio,o
4,2010-019912-18,randomizado,o
4,2010-019912-18,doble,o
4,2010-019912-18,ciego,o
4,2010-019912-18,con,o
4,2010-019912-18,grupos,o
4,2010-019912-18,de,o
4,2010-019912-18,tratamiento,i
4,2010-019912-18,paralelos,o
4,2010-019912-18,para,o
4,2010-019912-18,evaluar,i
4,2010-019912-18,la,i
4,2010-019912-18,seguridad,i
4,2010-019912-18,y,o
4,2010-019912-18,el,o
4,2010-019912-18,efecto,o
4,2010-019912-18,sobre,o
4,2010-019912-18,el,o
4,2010-019912-18,resultado,o
4,2010-019912-18,clinico,o
4,2010-019912-18,de,o
4,2010-019912-18,tocilizumab,i
4,2010-019912-18,SC,o
4,2010-019912-18,frente,o
4,2010-019912-18,a,o
4,2010-019912-18,placebo,i
4,2010-019912-18,SC,o
4,2010-019912-18,en,o
4,2010-019912-18,combinacion,o
4,2010-019912-18,con,o
4,2010-019912-18,farmacos,i
4,2010-019912-18,antirreumaticos,i
4,2010-019912-18,modificadores,i
4,2010-019912-18,de,i
4,2010-019912-18,la,i
4,2010-019912-18,enfermedad,i
4,2010-019912-18,FAMEs,i
4,2010-019912-18,tradicionales,o
4,2010-019912-18,en,o
4,2010-019912-18,pacientes,o
4,2010-019912-18,con,o
4,2010-019912-18,artritis,i
4,2010-019912-18,reumatoide,i
4,2010-019912-18,activa,o
4,2010-019912-18,moderada,o
4,2010-019912-18,a,o
4,2010-019912-18,severa,o
4,2010-019912-18,Indicacion,o
4,2010-019912-18,cientifica,o
4,2010-019912-18,Artritis,i
4,2010-019912-18,Reumatoide,i
4,2010-019912-18,AR,i
4,2010-019912-18,Criterios,o
4,2010-019912-18,de,o
4,2010-019912-18,inclusion,o
4,2010-019912-18,Presentar,o
4,2010-019912-18,artritis,i
4,2010-019912-18,reumatoide,i
4,2010-019912-18,de,o
4,2010-019912-18,mayor,o
4,2010-019912-18,o,o
4,2010-019912-18,igual,o
4,2010-019912-18,a,o
4,2010-019912-18,6,o
4,2010-019912-18,meses,o
4,2010-019912-18,de,o
4,2010-019912-18,duracion,o
4,2010-019912-18,Recibir,o
4,2010-019912-18,tratamiento,i
4,2010-019912-18,de,i
4,2010-019912-18,forma,i
4,2010-019912-18,ambulatoria,i
4,2010-019912-18,Presentar,o
4,2010-019912-18,un,o
4,2010-019912-18,recuento,o
4,2010-019912-18,de,o
4,2010-019912-18,articulaciones,i
4,2010-019912-18,inflamadas,i
4,2010-019912-18,RAI,o
4,2010-019912-18,mayor,o
4,2010-019912-18,o,o
4,2010-019912-18,igual,o
4,2010-019912-18,a,o
4,2010-019912-18,6,o
4,2010-019912-18,recuento,o
4,2010-019912-18,de,o
4,2010-019912-18,66,o
4,2010-019912-18,articulaciones,i
4,2010-019912-18,y,o
4,2010-019912-18,de,o
4,2010-019912-18,articulaciones,i
4,2010-019912-18,dolorosas,i
4,2010-019912-18,RAD,o
4,2010-019912-18,mayor,o
4,2010-019912-18,o,o
4,2010-019912-18,igual,o
4,2010-019912-18,a,o
4,2010-019912-18,8,o
4,2010-019912-18,recuento,o
4,2010-019912-18,de,o
4,2010-019912-18,68,o
4,2010-019912-18,articulaciones,i
4,2010-019912-18,en,o
4,2010-019912-18,las,o
4,2010-019912-18,visitas,o
4,2010-019912-18,de,o
4,2010-019912-18,seleccion,o
4,2010-019912-18,y,o
4,2010-019912-18,basal,o
4,2010-019912-18,Los,o
4,2010-019912-18,pacientes,o
4,2010-019912-18,deben,o
4,2010-019912-18,estar,o
4,2010-019912-18,recibiendo,o
4,2010-019912-18,tratamiento,i
4,2010-019912-18,con,o
4,2010-019912-18,una,o
4,2010-019912-18,dosis,o
4,2010-019912-18,estable,o
4,2010-019912-18,de,o
4,2010-019912-18,los,o
4,2010-019912-18,FAMEs,i
4,2010-019912-18,permitidos,o
4,2010-019912-18,como,o
4,2010-019912-18,minimo,o
4,2010-019912-18,8,o
4,2010-019912-18,semanas,o
4,2010-019912-18,antes,o
4,2010-019912-18,de,o
4,2010-019912-18,la,o
4,2010-019912-18,visita,o
4,2010-019912-18,basal,o
4,2010-019912-18,Criterios,o
4,2010-019912-18,de,o
4,2010-019912-18,exclusion,o
4,2010-019912-18,Pacientes,o
4,2010-019912-18,sometidos,o
4,2010-019912-18,a,o
4,2010-019912-18,intervenciones,i
4,2010-019912-18,de,i
4,2010-019912-18,cirugia,i
4,2010-019912-18,mayor,i
4,2010-019912-18,incluyendo,o
4,2010-019912-18,cirugia,i
4,2010-019912-18,articular,i
4,2010-019912-18,en,o
4,2010-019912-18,las,o
4,2010-019912-18,8,o
4,2010-019912-18,semanas,o
4,2010-019912-18,previas,o
4,2010-019912-18,a,o
4,2010-019912-18,la,o
4,2010-019912-18,visita,o
4,2010-019912-18,de,o
4,2010-019912-18,seleccion,o
4,2010-019912-18,o,o
4,2010-019912-18,que,o
4,2010-019912-18,tengan,o
4,2010-019912-18,previsto,o
4,2010-019912-18,someterse,o
4,2010-019912-18,a,o
4,2010-019912-18,una,o
4,2010-019912-18,intervencion,i
4,2010-019912-18,de,o
4,2010-019912-18,este,o
4,2010-019912-18,tipo,o
4,2010-019912-18,en,o
4,2010-019912-18,los,o
4,2010-019912-18,6,o
4,2010-019912-18,meses,o
4,2010-019912-18,siguientes,o
4,2010-019912-18,a,o
4,2010-019912-18,la,o
4,2010-019912-18,randomizacion,i
4,2010-019912-18,Enfermedad,i
4,2010-019912-18,reumatica,i
4,2010-019912-18,autoinmune,i
4,2010-019912-18,distinta,o
4,2010-019912-18,de,o
4,2010-019912-18,AR,i
4,2010-019912-18,Se,o
4,2010-019912-18,permite,o
4,2010-019912-18,la,o
4,2010-019912-18,inclusion,o
4,2010-019912-18,de,o
4,2010-019912-18,pacientes,o
4,2010-019912-18,con,o
4,2010-019912-18,sindrome,i
4,2010-019912-18,de,i
4,2010-019912-18,Sjögren,i
4,2010-019912-18,secundario,i
4,2010-019912-18,asociado,o
4,2010-019912-18,a,o
4,2010-019912-18,AR,i
4,2010-019912-18,Clase,o
4,2010-019912-18,funcional,o
4,2010-019912-18,IV,o
4,2010-019912-18,definida,o
4,2010-019912-18,de,o
4,2010-019912-18,acuerdo,o
4,2010-019912-18,con,o
4,2010-019912-18,la,o
4,2010-019912-18,Clasificacion,o
4,2010-019912-18,del,o
4,2010-019912-18,ACR,o
4,2010-019912-18,del,o
4,2010-019912-18,Estado,o
4,2010-019912-18,Funcional,o
4,2010-019912-18,en,o
4,2010-019912-18,Artritis,i
4,2010-019912-18,Reumatoide,i
4,2010-019912-18,Artritis,i
4,2010-019912-18,idiopatica,i
4,2010-019912-18,juvenil,i
4,2010-019912-18,AIJ,i
4,2010-019912-18,o,o
4,2010-019912-18,artritis,i
4,2010-019912-18,reumatoide,i
4,2010-019912-18,juvenil,i
4,2010-019912-18,ARJ,i
4,2010-019912-18,yo,o
4,2010-019912-18,AR,i
4,2010-019912-18,diagnosticadas,i
4,2010-019912-18,antes,o
4,2010-019912-18,de,o
4,2010-019912-18,los,o
4,2010-019912-18,16,o
4,2010-019912-18,años,o
4,2010-019912-18,de,o
4,2010-019912-18,edad,o
4,2010-019912-18,Enfermedad,i
4,2010-019912-18,articular,i
4,2010-019912-18,inflamatoria,i
4,2010-019912-18,distinta,o
4,2010-019912-18,de,o
4,2010-019912-18,AR,i
4,2010-019912-18,en,o
4,2010-019912-18,el,o
4,2010-019912-18,pasado,o
4,2010-019912-18,o,o
4,2010-019912-18,en,o
4,2010-019912-18,la,o
4,2010-019912-18,actualidad,o
5,2010-019912-18,EudraCT,o
5,2010-019912-18,Nº,o
5,2010-019912-18,201001991218,o
5,2010-019912-18,Titulo,o
5,2010-019912-18,cientifico,o
5,2010-019912-18,Estudio,o
5,2010-019912-18,randomizado,o
5,2010-019912-18,doble,o
5,2010-019912-18,ciego,o
5,2010-019912-18,con,o
5,2010-019912-18,grupos,o
5,2010-019912-18,de,o
5,2010-019912-18,tratamiento,i
5,2010-019912-18,paralelos,o
5,2010-019912-18,para,o
5,2010-019912-18,evaluar,i
5,2010-019912-18,la,i
5,2010-019912-18,seguridad,i
5,2010-019912-18,y,o
5,2010-019912-18,el,o
5,2010-019912-18,efecto,o
5,2010-019912-18,sobre,o
5,2010-019912-18,el,o
5,2010-019912-18,resultado,o
5,2010-019912-18,clinico,o
5,2010-019912-18,de,o
5,2010-019912-18,tocilizumab,i
5,2010-019912-18,SC,o
5,2010-019912-18,frente,o
5,2010-019912-18,a,o
5,2010-019912-18,placebo,i
5,2010-019912-18,SC,o
5,2010-019912-18,en,o
5,2010-019912-18,combinacion,o
5,2010-019912-18,con,o
5,2010-019912-18,farmacos,i
5,2010-019912-18,antirreumaticos,i
5,2010-019912-18,modificadores,i
5,2010-019912-18,de,i
5,2010-019912-18,la,i
5,2010-019912-18,enfermedad,i
5,2010-019912-18,FAMEs,i
5,2010-019912-18,tradicionales,o
5,2010-019912-18,en,o
5,2010-019912-18,pacientes,o
5,2010-019912-18,con,o
5,2010-019912-18,artritis,i
5,2010-019912-18,reumatoide,i
5,2010-019912-18,activa,o
5,2010-019912-18,moderada,o
5,2010-019912-18,a,o
5,2010-019912-18,severa,o
5,2010-019912-18,Indicacion,o
5,2010-019912-18,cientifica,o
5,2010-019912-18,Artritis,i
5,2010-019912-18,Reumatoide,i
5,2010-019912-18,AR,i
5,2010-019912-18,Criterios,o
5,2010-019912-18,de,o
5,2010-019912-18,inclusion,o
5,2010-019912-18,Presentar,o
5,2010-019912-18,artritis,i
5,2010-019912-18,reumatoide,i
5,2010-019912-18,de,o
5,2010-019912-18,mayor,o
5,2010-019912-18,o,o
5,2010-019912-18,igual,o
5,2010-019912-18,a,o
5,2010-019912-18,6,o
5,2010-019912-18,meses,o
5,2010-019912-18,de,o
5,2010-019912-18,duracion,o
5,2010-019912-18,Recibir,o
5,2010-019912-18,tratamiento,i
5,2010-019912-18,de,i
5,2010-019912-18,forma,i
5,2010-019912-18,ambulatoria,i
5,2010-019912-18,Presentar,o
5,2010-019912-18,un,o
5,2010-019912-18,recuento,o
5,2010-019912-18,de,o
5,2010-019912-18,articulaciones,i
5,2010-019912-18,inflamadas,i
5,2010-019912-18,RAI,o
5,2010-019912-18,mayor,o
5,2010-019912-18,o,o
5,2010-019912-18,igual,o
5,2010-019912-18,a,o
5,2010-019912-18,6,o
5,2010-019912-18,recuento,o
5,2010-019912-18,de,o
5,2010-019912-18,66,o
5,2010-019912-18,articulaciones,i
5,2010-019912-18,y,o
5,2010-019912-18,de,o
5,2010-019912-18,articulaciones,i
5,2010-019912-18,dolorosas,i
5,2010-019912-18,RAD,o
5,2010-019912-18,mayor,o
5,2010-019912-18,o,o
5,2010-019912-18,igual,o
5,2010-019912-18,a,o
5,2010-019912-18,8,o
5,2010-019912-18,recuento,o
5,2010-019912-18,de,o
5,2010-019912-18,68,o
5,2010-019912-18,articulaciones,i
5,2010-019912-18,en,o
5,2010-019912-18,las,o
5,2010-019912-18,visitas,o
5,2010-019912-18,de,o
5,2010-019912-18,seleccion,o
5,2010-019912-18,y,o
5,2010-019912-18,basal,o
5,2010-019912-18,Los,o
5,2010-019912-18,pacientes,o
5,2010-019912-18,deben,o
5,2010-019912-18,estar,o
5,2010-019912-18,recibiendo,o
5,2010-019912-18,tratamiento,i
5,2010-019912-18,con,o
5,2010-019912-18,una,o
5,2010-019912-18,dosis,o
5,2010-019912-18,estable,o
5,2010-019912-18,de,o
5,2010-019912-18,los,o
5,2010-019912-18,FAMEs,i
5,2010-019912-18,permitidos,o
5,2010-019912-18,como,o
5,2010-019912-18,minimo,o
5,2010-019912-18,8,o
5,2010-019912-18,semanas,o
5,2010-019912-18,antes,o
5,2010-019912-18,de,o
5,2010-019912-18,la,o
5,2010-019912-18,visita,o
5,2010-019912-18,basal,o
5,2010-019912-18,Criterios,o
5,2010-019912-18,de,o
5,2010-019912-18,exclusion,o
5,2010-019912-18,Pacientes,o
5,2010-019912-18,sometidos,o
5,2010-019912-18,a,o
5,2010-019912-18,intervenciones,i
5,2010-019912-18,de,i
5,2010-019912-18,cirugia,i
5,2010-019912-18,mayor,i
5,2010-019912-18,incluyendo,o
5,2010-019912-18,cirugia,i
5,2010-019912-18,articular,i
5,2010-019912-18,en,o
5,2010-019912-18,las,o
5,2010-019912-18,8,o
5,2010-019912-18,semanas,o
5,2010-019912-18,previas,o
5,2010-019912-18,a,o
5,2010-019912-18,la,o
5,2010-019912-18,visita,o
5,2010-019912-18,de,o
5,2010-019912-18,seleccion,o
5,2010-019912-18,o,o
5,2010-019912-18,que,o
5,2010-019912-18,tengan,o
5,2010-019912-18,previsto,o
5,2010-019912-18,someterse,o
5,2010-019912-18,a,o
5,2010-019912-18,una,o
5,2010-019912-18,intervencion,i
5,2010-019912-18,de,o
5,2010-019912-18,este,o
5,2010-019912-18,tipo,o
5,2010-019912-18,en,o
5,2010-019912-18,los,o
5,2010-019912-18,6,o
5,2010-019912-18,meses,o
5,2010-019912-18,siguientes,o
5,2010-019912-18,a,o
5,2010-019912-18,la,o
5,2010-019912-18,randomizacion,i
5,2010-019912-18,Enfermedad,i
5,2010-019912-18,reumatica,i
5,2010-019912-18,autoinmune,i
5,2010-019912-18,distinta,o
5,2010-019912-18,de,o
5,2010-019912-18,AR,i
5,2010-019912-18,Se,o
5,2010-019912-18,permite,o
5,2010-019912-18,la,o
5,2010-019912-18,inclusion,o
5,2010-019912-18,de,o
5,2010-019912-18,pacientes,o
5,2010-019912-18,con,o
5,2010-019912-18,sindrome,i
5,2010-019912-18,de,i
5,2010-019912-18,Sjögren,i
5,2010-019912-18,secundario,i
5,2010-019912-18,asociado,o
5,2010-019912-18,a,o
5,2010-019912-18,AR,i
5,2010-019912-18,Clase,o
5,2010-019912-18,funcional,o
5,2010-019912-18,IV,o
5,2010-019912-18,definida,o
5,2010-019912-18,de,o
5,2010-019912-18,acuerdo,o
5,2010-019912-18,con,o
5,2010-019912-18,la,o
5,2010-019912-18,Clasificacion,o
5,2010-019912-18,del,o
5,2010-019912-18,ACR,o
5,2010-019912-18,del,o
5,2010-019912-18,Estado,o
5,2010-019912-18,Funcional,o
5,2010-019912-18,en,o
5,2010-019912-18,Artritis,i
5,2010-019912-18,Reumatoide,i
5,2010-019912-18,Artritis,i
5,2010-019912-18,idiopatica,i
5,2010-019912-18,juvenil,i
5,2010-019912-18,AIJ,i
5,2010-019912-18,o,o
5,2010-019912-18,artritis,i
5,2010-019912-18,reumatoide,i
5,2010-019912-18,juvenil,i
5,2010-019912-18,ARJ,i
5,2010-019912-18,yo,o
5,2010-019912-18,AR,i
5,2010-019912-18,diagnosticadas,i
5,2010-019912-18,antes,o
5,2010-019912-18,de,o
5,2010-019912-18,los,o
5,2010-019912-18,16,o
5,2010-019912-18,años,o
5,2010-019912-18,de,o
5,2010-019912-18,edad,o
5,2010-019912-18,Enfermedad,i
5,2010-019912-18,articular,i
5,2010-019912-18,inflamatoria,i
5,2010-019912-18,distinta,o
5,2010-019912-18,de,o
5,2010-019912-18,AR,i
5,2010-019912-18,en,o
5,2010-019912-18,el,o
5,2010-019912-18,pasado,o
5,2010-019912-18,o,o
5,2010-019912-18,en,o
5,2010-019912-18,la,o
5,2010-019912-18,actualidad,o
6,2010-019912-18,EudraCT,o
6,2010-019912-18,Nº,o
6,2010-019912-18,201001991218,o
6,2010-019912-18,Titulo,o
6,2010-019912-18,cientifico,o
6,2010-019912-18,Estudio,o
6,2010-019912-18,randomizado,o
6,2010-019912-18,doble,o
6,2010-019912-18,ciego,o
6,2010-019912-18,con,o
6,2010-019912-18,grupos,o
6,2010-019912-18,de,o
6,2010-019912-18,tratamiento,i
6,2010-019912-18,paralelos,o
6,2010-019912-18,para,o
6,2010-019912-18,evaluar,i
6,2010-019912-18,la,i
6,2010-019912-18,seguridad,i
6,2010-019912-18,y,o
6,2010-019912-18,el,o
6,2010-019912-18,efecto,o
6,2010-019912-18,sobre,o
6,2010-019912-18,el,o
6,2010-019912-18,resultado,o
6,2010-019912-18,clinico,o
6,2010-019912-18,de,o
6,2010-019912-18,tocilizumab,i
6,2010-019912-18,SC,o
6,2010-019912-18,frente,o
6,2010-019912-18,a,o
6,2010-019912-18,placebo,i
6,2010-019912-18,SC,o
6,2010-019912-18,en,o
6,2010-019912-18,combinacion,o
6,2010-019912-18,con,o
6,2010-019912-18,farmacos,i
6,2010-019912-18,antirreumaticos,i
6,2010-019912-18,modificadores,i
6,2010-019912-18,de,i
6,2010-019912-18,la,i
6,2010-019912-18,enfermedad,i
6,2010-019912-18,FAMEs,i
6,2010-019912-18,tradicionales,o
6,2010-019912-18,en,o
6,2010-019912-18,pacientes,o
6,2010-019912-18,con,o
6,2010-019912-18,artritis,i
6,2010-019912-18,reumatoide,i
6,2010-019912-18,activa,o
6,2010-019912-18,moderada,o
6,2010-019912-18,a,o
6,2010-019912-18,severa,o
6,2010-019912-18,Indicacion,o
6,2010-019912-18,cientifica,o
6,2010-019912-18,Artritis,i
6,2010-019912-18,Reumatoide,i
6,2010-019912-18,AR,i
6,2010-019912-18,Criterios,o
6,2010-019912-18,de,o
6,2010-019912-18,inclusion,o
6,2010-019912-18,Presentar,o
6,2010-019912-18,artritis,i
6,2010-019912-18,reumatoide,i
6,2010-019912-18,de,o
6,2010-019912-18,mayor,o
6,2010-019912-18,o,o
6,2010-019912-18,igual,o
6,2010-019912-18,a,o
6,2010-019912-18,6,o
6,2010-019912-18,meses,o
6,2010-019912-18,de,o
6,2010-019912-18,duracion,o
6,2010-019912-18,Recibir,o
6,2010-019912-18,tratamiento,i
6,2010-019912-18,de,i
6,2010-019912-18,forma,i
6,2010-019912-18,ambulatoria,i
6,2010-019912-18,Presentar,o
6,2010-019912-18,un,o
6,2010-019912-18,recuento,o
6,2010-019912-18,de,o
6,2010-019912-18,articulaciones,i
6,2010-019912-18,inflamadas,i
6,2010-019912-18,RAI,o
6,2010-019912-18,mayor,o
6,2010-019912-18,o,o
6,2010-019912-18,igual,o
6,2010-019912-18,a,o
6,2010-019912-18,6,o
6,2010-019912-18,recuento,o
6,2010-019912-18,de,o
6,2010-019912-18,66,o
6,2010-019912-18,articulaciones,i
6,2010-019912-18,y,o
6,2010-019912-18,de,o
6,2010-019912-18,articulaciones,i
6,2010-019912-18,dolorosas,i
6,2010-019912-18,RAD,o
6,2010-019912-18,mayor,o
6,2010-019912-18,o,o
6,2010-019912-18,igual,o
6,2010-019912-18,a,o
6,2010-019912-18,8,o
6,2010-019912-18,recuento,o
6,2010-019912-18,de,o
6,2010-019912-18,68,o
6,2010-019912-18,articulaciones,i
6,2010-019912-18,en,o
6,2010-019912-18,las,o
6,2010-019912-18,visitas,o
6,2010-019912-18,de,o
6,2010-019912-18,seleccion,o
6,2010-019912-18,y,o
6,2010-019912-18,basal,o
6,2010-019912-18,Los,o
6,2010-019912-18,pacientes,o
6,2010-019912-18,deben,o
6,2010-019912-18,estar,o
6,2010-019912-18,recibiendo,o
6,2010-019912-18,tratamiento,i
6,2010-019912-18,con,o
6,2010-019912-18,una,o
6,2010-019912-18,dosis,o
6,2010-019912-18,estable,o
6,2010-019912-18,de,o
6,2010-019912-18,los,o
6,2010-019912-18,FAMEs,i
6,2010-019912-18,permitidos,o
6,2010-019912-18,como,o
6,2010-019912-18,minimo,o
6,2010-019912-18,8,o
6,2010-019912-18,semanas,o
6,2010-019912-18,antes,o
6,2010-019912-18,de,o
6,2010-019912-18,la,o
6,2010-019912-18,visita,o
6,2010-019912-18,basal,o
6,2010-019912-18,Criterios,o
6,2010-019912-18,de,o
6,2010-019912-18,exclusion,o
6,2010-019912-18,Pacientes,o
6,2010-019912-18,sometidos,o
6,2010-019912-18,a,o
6,2010-019912-18,intervenciones,i
6,2010-019912-18,de,i
6,2010-019912-18,cirugia,i
6,2010-019912-18,mayor,i
6,2010-019912-18,incluyendo,o
6,2010-019912-18,cirugia,i
6,2010-019912-18,articular,i
6,2010-019912-18,en,o
6,2010-019912-18,las,o
6,2010-019912-18,8,o
6,2010-019912-18,semanas,o
6,2010-019912-18,previas,o
6,2010-019912-18,a,o
6,2010-019912-18,la,o
6,2010-019912-18,visita,o
6,2010-019912-18,de,o
6,2010-019912-18,seleccion,o
6,2010-019912-18,o,o
6,2010-019912-18,que,o
6,2010-019912-18,tengan,o
6,2010-019912-18,previsto,o
6,2010-019912-18,someterse,o
6,2010-019912-18,a,o
6,2010-019912-18,una,o
6,2010-019912-18,intervencion,i
6,2010-019912-18,de,o
6,2010-019912-18,este,o
6,2010-019912-18,tipo,o
6,2010-019912-18,en,o
6,2010-019912-18,los,o
6,2010-019912-18,6,o
6,2010-019912-18,meses,o
6,2010-019912-18,siguientes,o
6,2010-019912-18,a,o
6,2010-019912-18,la,o
6,2010-019912-18,randomizacion,i
6,2010-019912-18,Enfermedad,i
6,2010-019912-18,reumatica,i
6,2010-019912-18,autoinmune,i
6,2010-019912-18,distinta,o
6,2010-019912-18,de,o
6,2010-019912-18,AR,i
6,2010-019912-18,Se,o
6,2010-019912-18,permite,o
6,2010-019912-18,la,o
6,2010-019912-18,inclusion,o
6,2010-019912-18,de,o
6,2010-019912-18,pacientes,o
6,2010-019912-18,con,o
6,2010-019912-18,sindrome,i
6,2010-019912-18,de,i
6,2010-019912-18,Sjögren,i
6,2010-019912-18,secundario,i
6,2010-019912-18,asociado,o
6,2010-019912-18,a,o
6,2010-019912-18,AR,i
6,2010-019912-18,Clase,o
6,2010-019912-18,funcional,o
6,2010-019912-18,IV,o
6,2010-019912-18,definida,o
6,2010-019912-18,de,o
6,2010-019912-18,acuerdo,o
6,2010-019912-18,con,o
6,2010-019912-18,la,o
6,2010-019912-18,Clasificacion,o
6,2010-019912-18,del,o
6,2010-019912-18,ACR,o
6,2010-019912-18,del,o
6,2010-019912-18,Estado,o
6,2010-019912-18,Funcional,o
6,2010-019912-18,en,o
6,2010-019912-18,Artritis,i
6,2010-019912-18,Reumatoide,i
6,2010-019912-18,Artritis,i
6,2010-019912-18,idiopatica,i
6,2010-019912-18,juvenil,i
6,2010-019912-18,AIJ,i
6,2010-019912-18,o,o
6,2010-019912-18,artritis,i
6,2010-019912-18,reumatoide,i
6,2010-019912-18,juvenil,i
6,2010-019912-18,ARJ,i
6,2010-019912-18,yo,o
6,2010-019912-18,AR,i
6,2010-019912-18,diagnosticadas,i
6,2010-019912-18,antes,o
6,2010-019912-18,de,o
6,2010-019912-18,los,o
6,2010-019912-18,16,o
6,2010-019912-18,años,o
6,2010-019912-18,de,o
6,2010-019912-18,edad,o
6,2010-019912-18,Enfermedad,i
6,2010-019912-18,articular,i
6,2010-019912-18,inflamatoria,i
6,2010-019912-18,distinta,o
6,2010-019912-18,de,o
6,2010-019912-18,AR,i
6,2010-019912-18,en,o
6,2010-019912-18,el,o
6,2010-019912-18,pasado,o
6,2010-019912-18,o,o
6,2010-019912-18,en,o
6,2010-019912-18,la,o
6,2010-019912-18,actualidad,o
7,2010-019912-18,EudraCT,o
7,2010-019912-18,Nº,o
7,2010-019912-18,201001991218,o
7,2010-019912-18,Titulo,o
7,2010-019912-18,cientifico,o
7,2010-019912-18,Estudio,o
7,2010-019912-18,randomizado,o
7,2010-019912-18,doble,o
7,2010-019912-18,ciego,o
7,2010-019912-18,con,o
7,2010-019912-18,grupos,o
7,2010-019912-18,de,o
7,2010-019912-18,tratamiento,i
7,2010-019912-18,paralelos,o
7,2010-019912-18,para,o
7,2010-019912-18,evaluar,i
7,2010-019912-18,la,i
7,2010-019912-18,seguridad,i
7,2010-019912-18,y,o
7,2010-019912-18,el,o
7,2010-019912-18,efecto,o
7,2010-019912-18,sobre,o
7,2010-019912-18,el,o
7,2010-019912-18,resultado,o
7,2010-019912-18,clinico,o
7,2010-019912-18,de,o
7,2010-019912-18,tocilizumab,i
7,2010-019912-18,SC,o
7,2010-019912-18,frente,o
7,2010-019912-18,a,o
7,2010-019912-18,placebo,i
7,2010-019912-18,SC,o
7,2010-019912-18,en,o
7,2010-019912-18,combinacion,o
7,2010-019912-18,con,o
7,2010-019912-18,farmacos,i
7,2010-019912-18,antirreumaticos,i
7,2010-019912-18,modificadores,i
7,2010-019912-18,de,i
7,2010-019912-18,la,i
7,2010-019912-18,enfermedad,i
7,2010-019912-18,FAMEs,i
7,2010-019912-18,tradicionales,o
7,2010-019912-18,en,o
7,2010-019912-18,pacientes,o
7,2010-019912-18,con,o
7,2010-019912-18,artritis,i
7,2010-019912-18,reumatoide,i
7,2010-019912-18,activa,o
7,2010-019912-18,moderada,o
7,2010-019912-18,a,o
7,2010-019912-18,severa,o
7,2010-019912-18,Indicacion,o
7,2010-019912-18,cientifica,o
7,2010-019912-18,Artritis,i
7,2010-019912-18,Reumatoide,i
7,2010-019912-18,AR,i
7,2010-019912-18,Criterios,o
7,2010-019912-18,de,o
7,2010-019912-18,inclusion,o
7,2010-019912-18,Presentar,o
7,2010-019912-18,artritis,i
7,2010-019912-18,reumatoide,i
7,2010-019912-18,de,o
7,2010-019912-18,mayor,o
7,2010-019912-18,o,o
7,2010-019912-18,igual,o
7,2010-019912-18,a,o
7,2010-019912-18,6,o
7,2010-019912-18,meses,o
7,2010-019912-18,de,o
7,2010-019912-18,duracion,o
7,2010-019912-18,Recibir,o
7,2010-019912-18,tratamiento,i
7,2010-019912-18,de,i
7,2010-019912-18,forma,i
7,2010-019912-18,ambulatoria,i
7,2010-019912-18,Presentar,o
7,2010-019912-18,un,o
7,2010-019912-18,recuento,o
7,2010-019912-18,de,o
7,2010-019912-18,articulaciones,i
7,2010-019912-18,inflamadas,i
7,2010-019912-18,RAI,o
7,2010-019912-18,mayor,o
7,2010-019912-18,o,o
7,2010-019912-18,igual,o
7,2010-019912-18,a,o
7,2010-019912-18,6,o
7,2010-019912-18,recuento,o
7,2010-019912-18,de,o
7,2010-019912-18,66,o
7,2010-019912-18,articulaciones,i
7,2010-019912-18,y,o
7,2010-019912-18,de,o
7,2010-019912-18,articulaciones,i
7,2010-019912-18,dolorosas,i
7,2010-019912-18,RAD,o
7,2010-019912-18,mayor,o
7,2010-019912-18,o,o
7,2010-019912-18,igual,o
7,2010-019912-18,a,o
7,2010-019912-18,8,o
7,2010-019912-18,recuento,o
7,2010-019912-18,de,o
7,2010-019912-18,68,o
7,2010-019912-18,articulaciones,i
7,2010-019912-18,en,o
7,2010-019912-18,las,o
7,2010-019912-18,visitas,o
7,2010-019912-18,de,o
7,2010-019912-18,seleccion,o
7,2010-019912-18,y,o
7,2010-019912-18,basal,o
7,2010-019912-18,Los,o
7,2010-019912-18,pacientes,o
7,2010-019912-18,deben,o
7,2010-019912-18,estar,o
7,2010-019912-18,recibiendo,o
7,2010-019912-18,tratamiento,i
7,2010-019912-18,con,o
7,2010-019912-18,una,o
7,2010-019912-18,dosis,o
7,2010-019912-18,estable,o
7,2010-019912-18,de,o
7,2010-019912-18,los,o
7,2010-019912-18,FAMEs,i
7,2010-019912-18,permitidos,o
7,2010-019912-18,como,o
7,2010-019912-18,minimo,o
7,2010-019912-18,8,o
7,2010-019912-18,semanas,o
7,2010-019912-18,antes,o
7,2010-019912-18,de,o
7,2010-019912-18,la,o
7,2010-019912-18,visita,o
7,2010-019912-18,basal,o
7,2010-019912-18,Criterios,o
7,2010-019912-18,de,o
7,2010-019912-18,exclusion,o
7,2010-019912-18,Pacientes,o
7,2010-019912-18,sometidos,o
7,2010-019912-18,a,o
7,2010-019912-18,intervenciones,i
7,2010-019912-18,de,i
7,2010-019912-18,cirugia,i
7,2010-019912-18,mayor,i
7,2010-019912-18,incluyendo,o
7,2010-019912-18,cirugia,i
7,2010-019912-18,articular,i
7,2010-019912-18,en,o
7,2010-019912-18,las,o
7,2010-019912-18,8,o
7,2010-019912-18,semanas,o
7,2010-019912-18,previas,o
7,2010-019912-18,a,o
7,2010-019912-18,la,o
7,2010-019912-18,visita,o
7,2010-019912-18,de,o
7,2010-019912-18,seleccion,o
7,2010-019912-18,o,o
7,2010-019912-18,que,o
7,2010-019912-18,tengan,o
7,2010-019912-18,previsto,o
7,2010-019912-18,someterse,o
7,2010-019912-18,a,o
7,2010-019912-18,una,o
7,2010-019912-18,intervencion,i
7,2010-019912-18,de,o
7,2010-019912-18,este,o
7,2010-019912-18,tipo,o
7,2010-019912-18,en,o
7,2010-019912-18,los,o
7,2010-019912-18,6,o
7,2010-019912-18,meses,o
7,2010-019912-18,siguientes,o
7,2010-019912-18,a,o
7,2010-019912-18,la,o
7,2010-019912-18,randomizacion,i
7,2010-019912-18,Enfermedad,i
7,2010-019912-18,reumatica,i
7,2010-019912-18,autoinmune,i
7,2010-019912-18,distinta,o
7,2010-019912-18,de,o
7,2010-019912-18,AR,i
7,2010-019912-18,Se,o
7,2010-019912-18,permite,o
7,2010-019912-18,la,o
7,2010-019912-18,inclusion,o
7,2010-019912-18,de,o
7,2010-019912-18,pacientes,o
7,2010-019912-18,con,o
7,2010-019912-18,sindrome,i
7,2010-019912-18,de,i
7,2010-019912-18,Sjögren,i
7,2010-019912-18,secundario,i
7,2010-019912-18,asociado,o
7,2010-019912-18,a,o
7,2010-019912-18,AR,i
7,2010-019912-18,Clase,o
7,2010-019912-18,funcional,o
7,2010-019912-18,IV,o
7,2010-019912-18,definida,o
7,2010-019912-18,de,o
7,2010-019912-18,acuerdo,o
7,2010-019912-18,con,o
7,2010-019912-18,la,o
7,2010-019912-18,Clasificacion,o
7,2010-019912-18,del,o
7,2010-019912-18,ACR,o
7,2010-019912-18,del,o
7,2010-019912-18,Estado,o
7,2010-019912-18,Funcional,o
7,2010-019912-18,en,o
7,2010-019912-18,Artritis,i
7,2010-019912-18,Reumatoide,i
7,2010-019912-18,Artritis,i
7,2010-019912-18,idiopatica,i
7,2010-019912-18,juvenil,i
7,2010-019912-18,AIJ,i
7,2010-019912-18,o,o
7,2010-019912-18,artritis,i
7,2010-019912-18,reumatoide,i
7,2010-019912-18,juvenil,i
7,2010-019912-18,ARJ,i
7,2010-019912-18,yo,o
7,2010-019912-18,AR,i
7,2010-019912-18,diagnosticadas,i
7,2010-019912-18,antes,o
7,2010-019912-18,de,o
7,2010-019912-18,los,o
7,2010-019912-18,16,o
7,2010-019912-18,años,o
7,2010-019912-18,de,o
7,2010-019912-18,edad,o
7,2010-019912-18,Enfermedad,i
7,2010-019912-18,articular,i
7,2010-019912-18,inflamatoria,i
7,2010-019912-18,distinta,o
7,2010-019912-18,de,o
7,2010-019912-18,AR,i
7,2010-019912-18,en,o
7,2010-019912-18,el,o
7,2010-019912-18,pasado,o
7,2010-019912-18,o,o
7,2010-019912-18,en,o
7,2010-019912-18,la,o
7,2010-019912-18,actualidad,o
8,2010-019912-18,EudraCT,o
8,2010-019912-18,Nº,o
8,2010-019912-18,201001991218,o
8,2010-019912-18,Titulo,o
8,2010-019912-18,cientifico,o
8,2010-019912-18,Estudio,o
8,2010-019912-18,randomizado,o
8,2010-019912-18,doble,o
8,2010-019912-18,ciego,o
8,2010-019912-18,con,o
8,2010-019912-18,grupos,o
8,2010-019912-18,de,o
8,2010-019912-18,tratamiento,i
8,2010-019912-18,paralelos,o
8,2010-019912-18,para,o
8,2010-019912-18,evaluar,i
8,2010-019912-18,la,i
8,2010-019912-18,seguridad,i
8,2010-019912-18,y,o
8,2010-019912-18,el,o
8,2010-019912-18,efecto,o
8,2010-019912-18,sobre,o
8,2010-019912-18,el,o
8,2010-019912-18,resultado,o
8,2010-019912-18,clinico,o
8,2010-019912-18,de,o
8,2010-019912-18,tocilizumab,i
8,2010-019912-18,SC,o
8,2010-019912-18,frente,o
8,2010-019912-18,a,o
8,2010-019912-18,placebo,i
8,2010-019912-18,SC,o
8,2010-019912-18,en,o
8,2010-019912-18,combinacion,o
8,2010-019912-18,con,o
8,2010-019912-18,farmacos,i
8,2010-019912-18,antirreumaticos,i
8,2010-019912-18,modificadores,i
8,2010-019912-18,de,i
8,2010-019912-18,la,i
8,2010-019912-18,enfermedad,i
8,2010-019912-18,FAMEs,i
8,2010-019912-18,tradicionales,o
8,2010-019912-18,en,o
8,2010-019912-18,pacientes,o
8,2010-019912-18,con,o
8,2010-019912-18,artritis,i
8,2010-019912-18,reumatoide,i
8,2010-019912-18,activa,o
8,2010-019912-18,moderada,o
8,2010-019912-18,a,o
8,2010-019912-18,severa,o
8,2010-019912-18,Indicacion,o
8,2010-019912-18,cientifica,o
8,2010-019912-18,Artritis,i
8,2010-019912-18,Reumatoide,i
8,2010-019912-18,AR,i
8,2010-019912-18,Criterios,o
8,2010-019912-18,de,o
8,2010-019912-18,inclusion,o
8,2010-019912-18,Presentar,o
8,2010-019912-18,artritis,i
8,2010-019912-18,reumatoide,i
8,2010-019912-18,de,o
8,2010-019912-18,mayor,o
8,2010-019912-18,o,o
8,2010-019912-18,igual,o
8,2010-019912-18,a,o
8,2010-019912-18,6,o
8,2010-019912-18,meses,o
8,2010-019912-18,de,o
8,2010-019912-18,duracion,o
8,2010-019912-18,Recibir,o
8,2010-019912-18,tratamiento,i
8,2010-019912-18,de,i
8,2010-019912-18,forma,i
8,2010-019912-18,ambulatoria,i
8,2010-019912-18,Presentar,o
8,2010-019912-18,un,o
8,2010-019912-18,recuento,o
8,2010-019912-18,de,o
8,2010-019912-18,articulaciones,i
8,2010-019912-18,inflamadas,i
8,2010-019912-18,RAI,o
8,2010-019912-18,mayor,o
8,2010-019912-18,o,o
8,2010-019912-18,igual,o
8,2010-019912-18,a,o
8,2010-019912-18,6,o
8,2010-019912-18,recuento,o
8,2010-019912-18,de,o
8,2010-019912-18,66,o
8,2010-019912-18,articulaciones,i
8,2010-019912-18,y,o
8,2010-019912-18,de,o
8,2010-019912-18,articulaciones,i
8,2010-019912-18,dolorosas,i
8,2010-019912-18,RAD,o
8,2010-019912-18,mayor,o
8,2010-019912-18,o,o
8,2010-019912-18,igual,o
8,2010-019912-18,a,o
8,2010-019912-18,8,o
8,2010-019912-18,recuento,o
8,2010-019912-18,de,o
8,2010-019912-18,68,o
8,2010-019912-18,articulaciones,i
8,2010-019912-18,en,o
8,2010-019912-18,las,o
8,2010-019912-18,visitas,o
8,2010-019912-18,de,o
8,2010-019912-18,seleccion,o
8,2010-019912-18,y,o
8,2010-019912-18,basal,o
8,2010-019912-18,Los,o
8,2010-019912-18,pacientes,o
8,2010-019912-18,deben,o
8,2010-019912-18,estar,o
8,2010-019912-18,recibiendo,o
8,2010-019912-18,tratamiento,i
8,2010-019912-18,con,o
8,2010-019912-18,una,o
8,2010-019912-18,dosis,o
8,2010-019912-18,estable,o
8,2010-019912-18,de,o
8,2010-019912-18,los,o
8,2010-019912-18,FAMEs,i
8,2010-019912-18,permitidos,o
8,2010-019912-18,como,o
8,2010-019912-18,minimo,o
8,2010-019912-18,8,o
8,2010-019912-18,semanas,o
8,2010-019912-18,antes,o
8,2010-019912-18,de,o
8,2010-019912-18,la,o
8,2010-019912-18,visita,o
8,2010-019912-18,basal,o
8,2010-019912-18,Criterios,o
8,2010-019912-18,de,o
8,2010-019912-18,exclusion,o
8,2010-019912-18,Pacientes,o
8,2010-019912-18,sometidos,o
8,2010-019912-18,a,o
8,2010-019912-18,intervenciones,i
8,2010-019912-18,de,i
8,2010-019912-18,cirugia,i
8,2010-019912-18,mayor,i
8,2010-019912-18,incluyendo,o
8,2010-019912-18,cirugia,i
8,2010-019912-18,articular,i
8,2010-019912-18,en,o
8,2010-019912-18,las,o
8,2010-019912-18,8,o
8,2010-019912-18,semanas,o
8,2010-019912-18,previas,o
8,2010-019912-18,a,o
8,2010-019912-18,la,o
8,2010-019912-18,visita,o
8,2010-019912-18,de,o
8,2010-019912-18,seleccion,o
8,2010-019912-18,o,o
8,2010-019912-18,que,o
8,2010-019912-18,tengan,o
8,2010-019912-18,previsto,o
8,2010-019912-18,someterse,o
8,2010-019912-18,a,o
8,2010-019912-18,una,o
8,2010-019912-18,intervencion,i
8,2010-019912-18,de,o
8,2010-019912-18,este,o
8,2010-019912-18,tipo,o
8,2010-019912-18,en,o
8,2010-019912-18,los,o
8,2010-019912-18,6,o
8,2010-019912-18,meses,o
8,2010-019912-18,siguientes,o
8,2010-019912-18,a,o
8,2010-019912-18,la,o
8,2010-019912-18,randomizacion,i
8,2010-019912-18,Enfermedad,i
8,2010-019912-18,reumatica,i
8,2010-019912-18,autoinmune,i
8,2010-019912-18,distinta,o
8,2010-019912-18,de,o
8,2010-019912-18,AR,i
8,2010-019912-18,Se,o
8,2010-019912-18,permite,o
8,2010-019912-18,la,o
8,2010-019912-18,inclusion,o
8,2010-019912-18,de,o
8,2010-019912-18,pacientes,o
8,2010-019912-18,con,o
8,2010-019912-18,sindrome,i
8,2010-019912-18,de,i
8,2010-019912-18,Sjögren,i
8,2010-019912-18,secundario,i
8,2010-019912-18,asociado,o
8,2010-019912-18,a,o
8,2010-019912-18,AR,i
8,2010-019912-18,Clase,o
8,2010-019912-18,funcional,o
8,2010-019912-18,IV,o
8,2010-019912-18,definida,o
8,2010-019912-18,de,o
8,2010-019912-18,acuerdo,o
8,2010-019912-18,con,o
8,2010-019912-18,la,o
8,2010-019912-18,Clasificacion,o
8,2010-019912-18,del,o
8,2010-019912-18,ACR,o
8,2010-019912-18,del,o
8,2010-019912-18,Estado,o
8,2010-019912-18,Funcional,o
8,2010-019912-18,en,o
8,2010-019912-18,Artritis,i
8,2010-019912-18,Reumatoide,i
8,2010-019912-18,Artritis,i
8,2010-019912-18,idiopatica,i
8,2010-019912-18,juvenil,i
8,2010-019912-18,AIJ,i
8,2010-019912-18,o,o
8,2010-019912-18,artritis,i
8,2010-019912-18,reumatoide,i
8,2010-019912-18,juvenil,i
8,2010-019912-18,ARJ,i
8,2010-019912-18,yo,o
8,2010-019912-18,AR,i
8,2010-019912-18,diagnosticadas,i
8,2010-019912-18,antes,o
8,2010-019912-18,de,o
8,2010-019912-18,los,o
8,2010-019912-18,16,o
8,2010-019912-18,años,o
8,2010-019912-18,de,o
8,2010-019912-18,edad,o
8,2010-019912-18,Enfermedad,i
8,2010-019912-18,articular,i
8,2010-019912-18,inflamatoria,i
8,2010-019912-18,distinta,o
8,2010-019912-18,de,o
8,2010-019912-18,AR,i
8,2010-019912-18,en,o
8,2010-019912-18,el,o
8,2010-019912-18,pasado,o
8,2010-019912-18,o,o
8,2010-019912-18,en,o
8,2010-019912-18,la,o
8,2010-019912-18,actualidad,o
9,2010-019912-18,EudraCT,o
9,2010-019912-18,Nº,o
9,2010-019912-18,201001991218,o
9,2010-019912-18,Titulo,o
9,2010-019912-18,cientifico,o
9,2010-019912-18,Estudio,o
9,2010-019912-18,randomizado,o
9,2010-019912-18,doble,o
9,2010-019912-18,ciego,o
9,2010-019912-18,con,o
9,2010-019912-18,grupos,o
9,2010-019912-18,de,o
9,2010-019912-18,tratamiento,i
9,2010-019912-18,paralelos,o
9,2010-019912-18,para,o
9,2010-019912-18,evaluar,i
9,2010-019912-18,la,i
9,2010-019912-18,seguridad,i
9,2010-019912-18,y,o
9,2010-019912-18,el,o
9,2010-019912-18,efecto,o
9,2010-019912-18,sobre,o
9,2010-019912-18,el,o
9,2010-019912-18,resultado,o
9,2010-019912-18,clinico,o
9,2010-019912-18,de,o
9,2010-019912-18,tocilizumab,i
9,2010-019912-18,SC,o
9,2010-019912-18,frente,o
9,2010-019912-18,a,o
9,2010-019912-18,placebo,i
9,2010-019912-18,SC,o
9,2010-019912-18,en,o
9,2010-019912-18,combinacion,o
9,2010-019912-18,con,o
9,2010-019912-18,farmacos,i
9,2010-019912-18,antirreumaticos,i
9,2010-019912-18,modificadores,i
9,2010-019912-18,de,i
9,2010-019912-18,la,i
9,2010-019912-18,enfermedad,i
9,2010-019912-18,FAMEs,i
9,2010-019912-18,tradicionales,o
9,2010-019912-18,en,o
9,2010-019912-18,pacientes,o
9,2010-019912-18,con,o
9,2010-019912-18,artritis,i
9,2010-019912-18,reumatoide,i
9,2010-019912-18,activa,o
9,2010-019912-18,moderada,o
9,2010-019912-18,a,o
9,2010-019912-18,severa,o
9,2010-019912-18,Indicacion,o
9,2010-019912-18,cientifica,o
9,2010-019912-18,Artritis,i
9,2010-019912-18,Reumatoide,i
9,2010-019912-18,AR,i
9,2010-019912-18,Criterios,o
9,2010-019912-18,de,o
9,2010-019912-18,inclusion,o
9,2010-019912-18,Presentar,o
9,2010-019912-18,artritis,i
9,2010-019912-18,reumatoide,i
9,2010-019912-18,de,o
9,2010-019912-18,mayor,o
9,2010-019912-18,o,o
9,2010-019912-18,igual,o
9,2010-019912-18,a,o
9,2010-019912-18,6,o
9,2010-019912-18,meses,o
9,2010-019912-18,de,o
9,2010-019912-18,duracion,o
9,2010-019912-18,Recibir,o
9,2010-019912-18,tratamiento,i
9,2010-019912-18,de,i
9,2010-019912-18,forma,i
9,2010-019912-18,ambulatoria,i
9,2010-019912-18,Presentar,o
9,2010-019912-18,un,o
9,2010-019912-18,recuento,o
9,2010-019912-18,de,o
9,2010-019912-18,articulaciones,i
9,2010-019912-18,inflamadas,i
9,2010-019912-18,RAI,o
9,2010-019912-18,mayor,o
9,2010-019912-18,o,o
9,2010-019912-18,igual,o
9,2010-019912-18,a,o
9,2010-019912-18,6,o
9,2010-019912-18,recuento,o
9,2010-019912-18,de,o
9,2010-019912-18,66,o
9,2010-019912-18,articulaciones,i
9,2010-019912-18,y,o
9,2010-019912-18,de,o
9,2010-019912-18,articulaciones,i
9,2010-019912-18,dolorosas,i
9,2010-019912-18,RAD,o
9,2010-019912-18,mayor,o
9,2010-019912-18,o,o
9,2010-019912-18,igual,o
9,2010-019912-18,a,o
9,2010-019912-18,8,o
9,2010-019912-18,recuento,o
9,2010-019912-18,de,o
9,2010-019912-18,68,o
9,2010-019912-18,articulaciones,i
9,2010-019912-18,en,o
9,2010-019912-18,las,o
9,2010-019912-18,visitas,o
9,2010-019912-18,de,o
9,2010-019912-18,seleccion,o
9,2010-019912-18,y,o
9,2010-019912-18,basal,o
9,2010-019912-18,Los,o
9,2010-019912-18,pacientes,o
9,2010-019912-18,deben,o
9,2010-019912-18,estar,o
9,2010-019912-18,recibiendo,o
9,2010-019912-18,tratamiento,i
9,2010-019912-18,con,o
9,2010-019912-18,una,o
9,2010-019912-18,dosis,o
9,2010-019912-18,estable,o
9,2010-019912-18,de,o
9,2010-019912-18,los,o
9,2010-019912-18,FAMEs,i
9,2010-019912-18,permitidos,o
9,2010-019912-18,como,o
9,2010-019912-18,minimo,o
9,2010-019912-18,8,o
9,2010-019912-18,semanas,o
9,2010-019912-18,antes,o
9,2010-019912-18,de,o
9,2010-019912-18,la,o
9,2010-019912-18,visita,o
9,2010-019912-18,basal,o
9,2010-019912-18,Criterios,o
9,2010-019912-18,de,o
9,2010-019912-18,exclusion,o
9,2010-019912-18,Pacientes,o
9,2010-019912-18,sometidos,o
9,2010-019912-18,a,o
9,2010-019912-18,intervenciones,i
9,2010-019912-18,de,i
9,2010-019912-18,cirugia,i
9,2010-019912-18,mayor,i
9,2010-019912-18,incluyendo,o
9,2010-019912-18,cirugia,i
9,2010-019912-18,articular,i
9,2010-019912-18,en,o
9,2010-019912-18,las,o
9,2010-019912-18,8,o
9,2010-019912-18,semanas,o
9,2010-019912-18,previas,o
9,2010-019912-18,a,o
9,2010-019912-18,la,o
9,2010-019912-18,visita,o
9,2010-019912-18,de,o
9,2010-019912-18,seleccion,o
9,2010-019912-18,o,o
9,2010-019912-18,que,o
9,2010-019912-18,tengan,o
9,2010-019912-18,previsto,o
9,2010-019912-18,someterse,o
9,2010-019912-18,a,o
9,2010-019912-18,una,o
9,2010-019912-18,intervencion,i
9,2010-019912-18,de,o
9,2010-019912-18,este,o
9,2010-019912-18,tipo,o
9,2010-019912-18,en,o
9,2010-019912-18,los,o
9,2010-019912-18,6,o
9,2010-019912-18,meses,o
9,2010-019912-18,siguientes,o
9,2010-019912-18,a,o
9,2010-019912-18,la,o
9,2010-019912-18,randomizacion,i
9,2010-019912-18,Enfermedad,i
9,2010-019912-18,reumatica,i
9,2010-019912-18,autoinmune,i
9,2010-019912-18,distinta,o
9,2010-019912-18,de,o
9,2010-019912-18,AR,i
9,2010-019912-18,Se,o
9,2010-019912-18,permite,o
9,2010-019912-18,la,o
9,2010-019912-18,inclusion,o
9,2010-019912-18,de,o
9,2010-019912-18,pacientes,o
9,2010-019912-18,con,o
9,2010-019912-18,sindrome,i
9,2010-019912-18,de,i
9,2010-019912-18,Sjögren,i
9,2010-019912-18,secundario,i
9,2010-019912-18,asociado,o
9,2010-019912-18,a,o
9,2010-019912-18,AR,i
9,2010-019912-18,Clase,o
9,2010-019912-18,funcional,o
9,2010-019912-18,IV,o
9,2010-019912-18,definida,o
9,2010-019912-18,de,o
9,2010-019912-18,acuerdo,o
9,2010-019912-18,con,o
9,2010-019912-18,la,o
9,2010-019912-18,Clasificacion,o
9,2010-019912-18,del,o
9,2010-019912-18,ACR,o
9,2010-019912-18,del,o
9,2010-019912-18,Estado,o
9,2010-019912-18,Funcional,o
9,2010-019912-18,en,o
9,2010-019912-18,Artritis,i
9,2010-019912-18,Reumatoide,i
9,2010-019912-18,Artritis,i
9,2010-019912-18,idiopatica,i
9,2010-019912-18,juvenil,i
9,2010-019912-18,AIJ,i
9,2010-019912-18,o,o
9,2010-019912-18,artritis,i
9,2010-019912-18,reumatoide,i
9,2010-019912-18,juvenil,i
9,2010-019912-18,ARJ,i
9,2010-019912-18,yo,o
9,2010-019912-18,AR,i
9,2010-019912-18,diagnosticadas,i
9,2010-019912-18,antes,o
9,2010-019912-18,de,o
9,2010-019912-18,los,o
9,2010-019912-18,16,o
9,2010-019912-18,años,o
9,2010-019912-18,de,o
9,2010-019912-18,edad,o
9,2010-019912-18,Enfermedad,i
9,2010-019912-18,articular,i
9,2010-019912-18,inflamatoria,i
9,2010-019912-18,distinta,o
9,2010-019912-18,de,o
9,2010-019912-18,AR,i
9,2010-019912-18,en,o
9,2010-019912-18,el,o
9,2010-019912-18,pasado,o
9,2010-019912-18,o,o
9,2010-019912-18,en,o
9,2010-019912-18,la,o
9,2010-019912-18,actualidad,o
10,2010-019912-18,EudraCT,o
10,2010-019912-18,Nº,o
10,2010-019912-18,201001991218,o
10,2010-019912-18,Titulo,o
10,2010-019912-18,cientifico,o
10,2010-019912-18,Estudio,o
10,2010-019912-18,randomizado,o
10,2010-019912-18,doble,o
10,2010-019912-18,ciego,o
10,2010-019912-18,con,o
10,2010-019912-18,grupos,o
10,2010-019912-18,de,o
10,2010-019912-18,tratamiento,i
10,2010-019912-18,paralelos,o
10,2010-019912-18,para,o
10,2010-019912-18,evaluar,i
10,2010-019912-18,la,i
10,2010-019912-18,seguridad,i
10,2010-019912-18,y,o
10,2010-019912-18,el,o
10,2010-019912-18,efecto,o
10,2010-019912-18,sobre,o
10,2010-019912-18,el,o
10,2010-019912-18,resultado,o
10,2010-019912-18,clinico,o
10,2010-019912-18,de,o
10,2010-019912-18,tocilizumab,i
10,2010-019912-18,SC,o
10,2010-019912-18,frente,o
10,2010-019912-18,a,o
10,2010-019912-18,placebo,i
10,2010-019912-18,SC,o
10,2010-019912-18,en,o
10,2010-019912-18,combinacion,o
10,2010-019912-18,con,o
10,2010-019912-18,farmacos,i
10,2010-019912-18,antirreumaticos,i
10,2010-019912-18,modificadores,i
10,2010-019912-18,de,i
10,2010-019912-18,la,i
10,2010-019912-18,enfermedad,i
10,2010-019912-18,FAMEs,i
10,2010-019912-18,tradicionales,o
10,2010-019912-18,en,o
10,2010-019912-18,pacientes,o
10,2010-019912-18,con,o
10,2010-019912-18,artritis,i
10,2010-019912-18,reumatoide,i
10,2010-019912-18,activa,o
10,2010-019912-18,moderada,o
10,2010-019912-18,a,o
10,2010-019912-18,severa,o
10,2010-019912-18,Indicacion,o
10,2010-019912-18,cientifica,o
10,2010-019912-18,Artritis,i
10,2010-019912-18,Reumatoide,i
10,2010-019912-18,AR,i
10,2010-019912-18,Criterios,o
10,2010-019912-18,de,o
10,2010-019912-18,inclusion,o
10,2010-019912-18,Presentar,o
10,2010-019912-18,artritis,i
10,2010-019912-18,reumatoide,i
10,2010-019912-18,de,o
10,2010-019912-18,mayor,o
10,2010-019912-18,o,o
10,2010-019912-18,igual,o
10,2010-019912-18,a,o
10,2010-019912-18,6,o
10,2010-019912-18,meses,o
10,2010-019912-18,de,o
10,2010-019912-18,duracion,o
10,2010-019912-18,Recibir,o
10,2010-019912-18,tratamiento,i
10,2010-019912-18,de,i
10,2010-019912-18,forma,i
10,2010-019912-18,ambulatoria,i
10,2010-019912-18,Presentar,o
10,2010-019912-18,un,o
10,2010-019912-18,recuento,o
10,2010-019912-18,de,o
10,2010-019912-18,articulaciones,i
10,2010-019912-18,inflamadas,i
10,2010-019912-18,RAI,o
10,2010-019912-18,mayor,o
10,2010-019912-18,o,o
10,2010-019912-18,igual,o
10,2010-019912-18,a,o
10,2010-019912-18,6,o
10,2010-019912-18,recuento,o
10,2010-019912-18,de,o
10,2010-019912-18,66,o
10,2010-019912-18,articulaciones,i
10,2010-019912-18,y,o
10,2010-019912-18,de,o
10,2010-019912-18,articulaciones,i
10,2010-019912-18,dolorosas,i
10,2010-019912-18,RAD,o
10,2010-019912-18,mayor,o
10,2010-019912-18,o,o
10,2010-019912-18,igual,o
10,2010-019912-18,a,o
10,2010-019912-18,8,o
10,2010-019912-18,recuento,o
10,2010-019912-18,de,o
10,2010-019912-18,68,o
10,2010-019912-18,articulaciones,i
10,2010-019912-18,en,o
10,2010-019912-18,las,o
10,2010-019912-18,visitas,o
10,2010-019912-18,de,o
10,2010-019912-18,seleccion,o
10,2010-019912-18,y,o
10,2010-019912-18,basal,o
10,2010-019912-18,Los,o
10,2010-019912-18,pacientes,o
10,2010-019912-18,deben,o
10,2010-019912-18,estar,o
10,2010-019912-18,recibiendo,o
10,2010-019912-18,tratamiento,i
10,2010-019912-18,con,o
10,2010-019912-18,una,o
10,2010-019912-18,dosis,o
10,2010-019912-18,estable,o
10,2010-019912-18,de,o
10,2010-019912-18,los,o
10,2010-019912-18,FAMEs,i
10,2010-019912-18,permitidos,o
10,2010-019912-18,como,o
10,2010-019912-18,minimo,o
10,2010-019912-18,8,o
10,2010-019912-18,semanas,o
10,2010-019912-18,antes,o
10,2010-019912-18,de,o
10,2010-019912-18,la,o
10,2010-019912-18,visita,o
10,2010-019912-18,basal,o
10,2010-019912-18,Criterios,o
10,2010-019912-18,de,o
10,2010-019912-18,exclusion,o
10,2010-019912-18,Pacientes,o
10,2010-019912-18,sometidos,o
10,2010-019912-18,a,o
10,2010-019912-18,intervenciones,i
10,2010-019912-18,de,i
10,2010-019912-18,cirugia,i
10,2010-019912-18,mayor,i
10,2010-019912-18,incluyendo,o
10,2010-019912-18,cirugia,i
10,2010-019912-18,articular,i
10,2010-019912-18,en,o
10,2010-019912-18,las,o
10,2010-019912-18,8,o
10,2010-019912-18,semanas,o
10,2010-019912-18,previas,o
10,2010-019912-18,a,o
10,2010-019912-18,la,o
10,2010-019912-18,visita,o
10,2010-019912-18,de,o
10,2010-019912-18,seleccion,o
10,2010-019912-18,o,o
10,2010-019912-18,que,o
10,2010-019912-18,tengan,o
10,2010-019912-18,previsto,o
10,2010-019912-18,someterse,o
10,2010-019912-18,a,o
10,2010-019912-18,una,o
10,2010-019912-18,intervencion,i
10,2010-019912-18,de,o
10,2010-019912-18,este,o
10,2010-019912-18,tipo,o
10,2010-019912-18,en,o
10,2010-019912-18,los,o
10,2010-019912-18,6,o
10,2010-019912-18,meses,o
10,2010-019912-18,siguientes,o
10,2010-019912-18,a,o
10,2010-019912-18,la,o
10,2010-019912-18,randomizacion,i
10,2010-019912-18,Enfermedad,i
10,2010-019912-18,reumatica,i
10,2010-019912-18,autoinmune,i
10,2010-019912-18,distinta,o
10,2010-019912-18,de,o
10,2010-019912-18,AR,i
10,2010-019912-18,Se,o
10,2010-019912-18,permite,o
10,2010-019912-18,la,o
10,2010-019912-18,inclusion,o
10,2010-019912-18,de,o
10,2010-019912-18,pacientes,o
10,2010-019912-18,con,o
10,2010-019912-18,sindrome,i
10,2010-019912-18,de,i
10,2010-019912-18,Sjögren,i
10,2010-019912-18,secundario,i
10,2010-019912-18,asociado,o
10,2010-019912-18,a,o
10,2010-019912-18,AR,i
10,2010-019912-18,Clase,o
10,2010-019912-18,funcional,o
10,2010-019912-18,IV,o
10,2010-019912-18,definida,o
10,2010-019912-18,de,o
10,2010-019912-18,acuerdo,o
10,2010-019912-18,con,o
10,2010-019912-18,la,o
10,2010-019912-18,Clasificacion,o
10,2010-019912-18,del,o
10,2010-019912-18,ACR,o
10,2010-019912-18,del,o
10,2010-019912-18,Estado,o
10,2010-019912-18,Funcional,o
10,2010-019912-18,en,o
10,2010-019912-18,Artritis,i
10,2010-019912-18,Reumatoide,i
10,2010-019912-18,Artritis,i
10,2010-019912-18,idiopatica,i
10,2010-019912-18,juvenil,i
10,2010-019912-18,AIJ,i
10,2010-019912-18,o,o
10,2010-019912-18,artritis,i
10,2010-019912-18,reumatoide,i
10,2010-019912-18,juvenil,i
10,2010-019912-18,ARJ,i
10,2010-019912-18,yo,o
10,2010-019912-18,AR,i
10,2010-019912-18,diagnosticadas,i
10,2010-019912-18,antes,o
10,2010-019912-18,de,o
10,2010-019912-18,los,o
10,2010-019912-18,16,o
10,2010-019912-18,años,o
10,2010-019912-18,de,o
10,2010-019912-18,edad,o
10,2010-019912-18,Enfermedad,i
10,2010-019912-18,articular,i
10,2010-019912-18,inflamatoria,i
10,2010-019912-18,distinta,o
10,2010-019912-18,de,o
10,2010-019912-18,AR,i
10,2010-019912-18,en,o
10,2010-019912-18,el,o
10,2010-019912-18,pasado,o
10,2010-019912-18,o,o
10,2010-019912-18,en,o
10,2010-019912-18,la,o
10,2010-019912-18,actualidad,o
11,2010-019912-18,EudraCT,o
11,2010-019912-18,Nº,o
11,2010-019912-18,201001991218,o
11,2010-019912-18,Titulo,o
11,2010-019912-18,cientifico,o
11,2010-019912-18,Estudio,o
11,2010-019912-18,randomizado,o
11,2010-019912-18,doble,o
11,2010-019912-18,ciego,o
11,2010-019912-18,con,o
11,2010-019912-18,grupos,o
11,2010-019912-18,de,o
11,2010-019912-18,tratamiento,i
11,2010-019912-18,paralelos,o
11,2010-019912-18,para,o
11,2010-019912-18,evaluar,i
11,2010-019912-18,la,i
11,2010-019912-18,seguridad,i
11,2010-019912-18,y,o
11,2010-019912-18,el,o
11,2010-019912-18,efecto,o
11,2010-019912-18,sobre,o
11,2010-019912-18,el,o
11,2010-019912-18,resultado,o
11,2010-019912-18,clinico,o
11,2010-019912-18,de,o
11,2010-019912-18,tocilizumab,i
11,2010-019912-18,SC,o
11,2010-019912-18,frente,o
11,2010-019912-18,a,o
11,2010-019912-18,placebo,i
11,2010-019912-18,SC,o
11,2010-019912-18,en,o
11,2010-019912-18,combinacion,o
11,2010-019912-18,con,o
11,2010-019912-18,farmacos,i
11,2010-019912-18,antirreumaticos,i
11,2010-019912-18,modificadores,i
11,2010-019912-18,de,i
11,2010-019912-18,la,i
11,2010-019912-18,enfermedad,i
11,2010-019912-18,FAMEs,i
11,2010-019912-18,tradicionales,o
11,2010-019912-18,en,o
11,2010-019912-18,pacientes,o
11,2010-019912-18,con,o
11,2010-019912-18,artritis,i
11,2010-019912-18,reumatoide,i
11,2010-019912-18,activa,o
11,2010-019912-18,moderada,o
11,2010-019912-18,a,o
11,2010-019912-18,severa,o
11,2010-019912-18,Indicacion,o
11,2010-019912-18,cientifica,o
11,2010-019912-18,Artritis,i
11,2010-019912-18,Reumatoide,i
11,2010-019912-18,AR,i
11,2010-019912-18,Criterios,o
11,2010-019912-18,de,o
11,2010-019912-18,inclusion,o
11,2010-019912-18,Presentar,o
11,2010-019912-18,artritis,i
11,2010-019912-18,reumatoide,i
11,2010-019912-18,de,o
11,2010-019912-18,mayor,o
11,2010-019912-18,o,o
11,2010-019912-18,igual,o
11,2010-019912-18,a,o
11,2010-019912-18,6,o
11,2010-019912-18,meses,o
11,2010-019912-18,de,o
11,2010-019912-18,duracion,o
11,2010-019912-18,Recibir,o
11,2010-019912-18,tratamiento,i
11,2010-019912-18,de,i
11,2010-019912-18,forma,i
11,2010-019912-18,ambulatoria,i
11,2010-019912-18,Presentar,o
11,2010-019912-18,un,o
11,2010-019912-18,recuento,o
11,2010-019912-18,de,o
11,2010-019912-18,articulaciones,i
11,2010-019912-18,inflamadas,i
11,2010-019912-18,RAI,o
11,2010-019912-18,mayor,o
11,2010-019912-18,o,o
11,2010-019912-18,igual,o
11,2010-019912-18,a,o
11,2010-019912-18,6,o
11,2010-019912-18,recuento,o
11,2010-019912-18,de,o
11,2010-019912-18,66,o
11,2010-019912-18,articulaciones,i
11,2010-019912-18,y,o
11,2010-019912-18,de,o
11,2010-019912-18,articulaciones,i
11,2010-019912-18,dolorosas,i
11,2010-019912-18,RAD,o
11,2010-019912-18,mayor,o
11,2010-019912-18,o,o
11,2010-019912-18,igual,o
11,2010-019912-18,a,o
11,2010-019912-18,8,o
11,2010-019912-18,recuento,o
11,2010-019912-18,de,o
11,2010-019912-18,68,o
11,2010-019912-18,articulaciones,i
11,2010-019912-18,en,o
11,2010-019912-18,las,o
11,2010-019912-18,visitas,o
11,2010-019912-18,de,o
11,2010-019912-18,seleccion,o
11,2010-019912-18,y,o
11,2010-019912-18,basal,o
11,2010-019912-18,Los,o
11,2010-019912-18,pacientes,o
11,2010-019912-18,deben,o
11,2010-019912-18,estar,o
11,2010-019912-18,recibiendo,o
11,2010-019912-18,tratamiento,i
11,2010-019912-18,con,o
11,2010-019912-18,una,o
11,2010-019912-18,dosis,o
11,2010-019912-18,estable,o
11,2010-019912-18,de,o
11,2010-019912-18,los,o
11,2010-019912-18,FAMEs,i
11,2010-019912-18,permitidos,o
11,2010-019912-18,como,o
11,2010-019912-18,minimo,o
11,2010-019912-18,8,o
11,2010-019912-18,semanas,o
11,2010-019912-18,antes,o
11,2010-019912-18,de,o
11,2010-019912-18,la,o
11,2010-019912-18,visita,o
11,2010-019912-18,basal,o
11,2010-019912-18,Criterios,o
11,2010-019912-18,de,o
11,2010-019912-18,exclusion,o
11,2010-019912-18,Pacientes,o
11,2010-019912-18,sometidos,o
11,2010-019912-18,a,o
11,2010-019912-18,intervenciones,i
11,2010-019912-18,de,i
11,2010-019912-18,cirugia,i
11,2010-019912-18,mayor,i
11,2010-019912-18,incluyendo,o
11,2010-019912-18,cirugia,i
11,2010-019912-18,articular,i
11,2010-019912-18,en,o
11,2010-019912-18,las,o
11,2010-019912-18,8,o
11,2010-019912-18,semanas,o
11,2010-019912-18,previas,o
11,2010-019912-18,a,o
11,2010-019912-18,la,o
11,2010-019912-18,visita,o
11,2010-019912-18,de,o
11,2010-019912-18,seleccion,o
11,2010-019912-18,o,o
11,2010-019912-18,que,o
11,2010-019912-18,tengan,o
11,2010-019912-18,previsto,o
11,2010-019912-18,someterse,o
11,2010-019912-18,a,o
11,2010-019912-18,una,o
11,2010-019912-18,intervencion,i
11,2010-019912-18,de,o
11,2010-019912-18,este,o
11,2010-019912-18,tipo,o
11,2010-019912-18,en,o
11,2010-019912-18,los,o
11,2010-019912-18,6,o
11,2010-019912-18,meses,o
11,2010-019912-18,siguientes,o
11,2010-019912-18,a,o
11,2010-019912-18,la,o
11,2010-019912-18,randomizacion,i
11,2010-019912-18,Enfermedad,i
11,2010-019912-18,reumatica,i
11,2010-019912-18,autoinmune,i
11,2010-019912-18,distinta,o
11,2010-019912-18,de,o
11,2010-019912-18,AR,i
11,2010-019912-18,Se,o
11,2010-019912-18,permite,o
11,2010-019912-18,la,o
11,2010-019912-18,inclusion,o
11,2010-019912-18,de,o
11,2010-019912-18,pacientes,o
11,2010-019912-18,con,o
11,2010-019912-18,sindrome,i
11,2010-019912-18,de,i
11,2010-019912-18,Sjögren,i
11,2010-019912-18,secundario,i
11,2010-019912-18,asociado,o
11,2010-019912-18,a,o
11,2010-019912-18,AR,i
11,2010-019912-18,Clase,o
11,2010-019912-18,funcional,o
11,2010-019912-18,IV,o
11,2010-019912-18,definida,o
11,2010-019912-18,de,o
11,2010-019912-18,acuerdo,o
11,2010-019912-18,con,o
11,2010-019912-18,la,o
11,2010-019912-18,Clasificacion,o
11,2010-019912-18,del,o
11,2010-019912-18,ACR,o
11,2010-019912-18,del,o
11,2010-019912-18,Estado,o
11,2010-019912-18,Funcional,o
11,2010-019912-18,en,o
11,2010-019912-18,Artritis,i
11,2010-019912-18,Reumatoide,i
11,2010-019912-18,Artritis,i
11,2010-019912-18,idiopatica,i
11,2010-019912-18,juvenil,i
11,2010-019912-18,AIJ,i
11,2010-019912-18,o,o
11,2010-019912-18,artritis,i
11,2010-019912-18,reumatoide,i
11,2010-019912-18,juvenil,i
11,2010-019912-18,ARJ,i
11,2010-019912-18,yo,o
11,2010-019912-18,AR,i
11,2010-019912-18,diagnosticadas,i
11,2010-019912-18,antes,o
11,2010-019912-18,de,o
11,2010-019912-18,los,o
11,2010-019912-18,16,o
11,2010-019912-18,años,o
11,2010-019912-18,de,o
11,2010-019912-18,edad,o
11,2010-019912-18,Enfermedad,i
11,2010-019912-18,articular,i
11,2010-019912-18,inflamatoria,i
11,2010-019912-18,distinta,o
11,2010-019912-18,de,o
11,2010-019912-18,AR,i
11,2010-019912-18,en,o
11,2010-019912-18,el,o
11,2010-019912-18,pasado,o
11,2010-019912-18,o,o
11,2010-019912-18,en,o
11,2010-019912-18,la,o
11,2010-019912-18,actualidad,o
12,2010-019912-18,EudraCT,o
12,2010-019912-18,Nº,o
12,2010-019912-18,201001991218,o
12,2010-019912-18,Titulo,o
12,2010-019912-18,cientifico,o
12,2010-019912-18,Estudio,o
12,2010-019912-18,randomizado,o
12,2010-019912-18,doble,o
12,2010-019912-18,ciego,o
12,2010-019912-18,con,o
12,2010-019912-18,grupos,o
12,2010-019912-18,de,o
12,2010-019912-18,tratamiento,i
12,2010-019912-18,paralelos,o
12,2010-019912-18,para,o
12,2010-019912-18,evaluar,i
12,2010-019912-18,la,i
12,2010-019912-18,seguridad,i
12,2010-019912-18,y,o
12,2010-019912-18,el,o
12,2010-019912-18,efecto,o
12,2010-019912-18,sobre,o
12,2010-019912-18,el,o
12,2010-019912-18,resultado,o
12,2010-019912-18,clinico,o
12,2010-019912-18,de,o
12,2010-019912-18,tocilizumab,i
12,2010-019912-18,SC,o
12,2010-019912-18,frente,o
12,2010-019912-18,a,o
12,2010-019912-18,placebo,i
12,2010-019912-18,SC,o
12,2010-019912-18,en,o
12,2010-019912-18,combinacion,o
12,2010-019912-18,con,o
12,2010-019912-18,farmacos,i
12,2010-019912-18,antirreumaticos,i
12,2010-019912-18,modificadores,i
12,2010-019912-18,de,i
12,2010-019912-18,la,i
12,2010-019912-18,enfermedad,i
12,2010-019912-18,FAMEs,i
12,2010-019912-18,tradicionales,o
12,2010-019912-18,en,o
12,2010-019912-18,pacientes,o
12,2010-019912-18,con,o
12,2010-019912-18,artritis,i
12,2010-019912-18,reumatoide,i
12,2010-019912-18,activa,o
12,2010-019912-18,moderada,o
12,2010-019912-18,a,o
12,2010-019912-18,severa,o
12,2010-019912-18,Indicacion,o
12,2010-019912-18,cientifica,o
12,2010-019912-18,Artritis,i
12,2010-019912-18,Reumatoide,i
12,2010-019912-18,AR,i
12,2010-019912-18,Criterios,o
12,2010-019912-18,de,o
12,2010-019912-18,inclusion,o
12,2010-019912-18,Presentar,o
12,2010-019912-18,artritis,i
12,2010-019912-18,reumatoide,i
12,2010-019912-18,de,o
12,2010-019912-18,mayor,o
12,2010-019912-18,o,o
12,2010-019912-18,igual,o
12,2010-019912-18,a,o
12,2010-019912-18,6,o
12,2010-019912-18,meses,o
12,2010-019912-18,de,o
12,2010-019912-18,duracion,o
12,2010-019912-18,Recibir,o
12,2010-019912-18,tratamiento,i
12,2010-019912-18,de,i
12,2010-019912-18,forma,i
12,2010-019912-18,ambulatoria,i
12,2010-019912-18,Presentar,o
12,2010-019912-18,un,o
12,2010-019912-18,recuento,o
12,2010-019912-18,de,o
12,2010-019912-18,articulaciones,i
12,2010-019912-18,inflamadas,i
12,2010-019912-18,RAI,o
12,2010-019912-18,mayor,o
12,2010-019912-18,o,o
12,2010-019912-18,igual,o
12,2010-019912-18,a,o
12,2010-019912-18,6,o
12,2010-019912-18,recuento,o
12,2010-019912-18,de,o
12,2010-019912-18,66,o
12,2010-019912-18,articulaciones,i
12,2010-019912-18,y,o
12,2010-019912-18,de,o
12,2010-019912-18,articulaciones,i
12,2010-019912-18,dolorosas,i
12,2010-019912-18,RAD,o
12,2010-019912-18,mayor,o
12,2010-019912-18,o,o
12,2010-019912-18,igual,o
12,2010-019912-18,a,o
12,2010-019912-18,8,o
12,2010-019912-18,recuento,o
12,2010-019912-18,de,o
12,2010-019912-18,68,o
12,2010-019912-18,articulaciones,i
12,2010-019912-18,en,o
12,2010-019912-18,las,o
12,2010-019912-18,visitas,o
12,2010-019912-18,de,o
12,2010-019912-18,seleccion,o
12,2010-019912-18,y,o
12,2010-019912-18,basal,o
12,2010-019912-18,Los,o
12,2010-019912-18,pacientes,o
12,2010-019912-18,deben,o
12,2010-019912-18,estar,o
12,2010-019912-18,recibiendo,o
12,2010-019912-18,tratamiento,i
12,2010-019912-18,con,o
12,2010-019912-18,una,o
12,2010-019912-18,dosis,o
12,2010-019912-18,estable,o
12,2010-019912-18,de,o
12,2010-019912-18,los,o
12,2010-019912-18,FAMEs,i
12,2010-019912-18,permitidos,o
12,2010-019912-18,como,o
12,2010-019912-18,minimo,o
12,2010-019912-18,8,o
12,2010-019912-18,semanas,o
12,2010-019912-18,antes,o
12,2010-019912-18,de,o
12,2010-019912-18,la,o
12,2010-019912-18,visita,o
12,2010-019912-18,basal,o
12,2010-019912-18,Criterios,o
12,2010-019912-18,de,o
12,2010-019912-18,exclusion,o
12,2010-019912-18,Pacientes,o
12,2010-019912-18,sometidos,o
12,2010-019912-18,a,o
12,2010-019912-18,intervenciones,i
12,2010-019912-18,de,i
12,2010-019912-18,cirugia,i
12,2010-019912-18,mayor,i
12,2010-019912-18,incluyendo,o
12,2010-019912-18,cirugia,i
12,2010-019912-18,articular,i
12,2010-019912-18,en,o
12,2010-019912-18,las,o
12,2010-019912-18,8,o
12,2010-019912-18,semanas,o
12,2010-019912-18,previas,o
12,2010-019912-18,a,o
12,2010-019912-18,la,o
12,2010-019912-18,visita,o
12,2010-019912-18,de,o
12,2010-019912-18,seleccion,o
12,2010-019912-18,o,o
12,2010-019912-18,que,o
12,2010-019912-18,tengan,o
12,2010-019912-18,previsto,o
12,2010-019912-18,someterse,o
12,2010-019912-18,a,o
12,2010-019912-18,una,o
12,2010-019912-18,intervencion,i
12,2010-019912-18,de,o
12,2010-019912-18,este,o
12,2010-019912-18,tipo,o
12,2010-019912-18,en,o
12,2010-019912-18,los,o
12,2010-019912-18,6,o
12,2010-019912-18,meses,o
12,2010-019912-18,siguientes,o
12,2010-019912-18,a,o
12,2010-019912-18,la,o
12,2010-019912-18,randomizacion,i
12,2010-019912-18,Enfermedad,i
12,2010-019912-18,reumatica,i
12,2010-019912-18,autoinmune,i
12,2010-019912-18,distinta,o
12,2010-019912-18,de,o
12,2010-019912-18,AR,i
12,2010-019912-18,Se,o
12,2010-019912-18,permite,o
12,2010-019912-18,la,o
12,2010-019912-18,inclusion,o
12,2010-019912-18,de,o
12,2010-019912-18,pacientes,o
12,2010-019912-18,con,o
12,2010-019912-18,sindrome,i
12,2010-019912-18,de,i
12,2010-019912-18,Sjögren,i
12,2010-019912-18,secundario,i
12,2010-019912-18,asociado,o
12,2010-019912-18,a,o
12,2010-019912-18,AR,i
12,2010-019912-18,Clase,o
12,2010-019912-18,funcional,o
12,2010-019912-18,IV,o
12,2010-019912-18,definida,o
12,2010-019912-18,de,o
12,2010-019912-18,acuerdo,o
12,2010-019912-18,con,o
12,2010-019912-18,la,o
12,2010-019912-18,Clasificacion,o
12,2010-019912-18,del,o
12,2010-019912-18,ACR,o
12,2010-019912-18,del,o
12,2010-019912-18,Estado,o
12,2010-019912-18,Funcional,o
12,2010-019912-18,en,o
12,2010-019912-18,Artritis,i
12,2010-019912-18,Reumatoide,i
12,2010-019912-18,Artritis,i
12,2010-019912-18,idiopatica,i
12,2010-019912-18,juvenil,i
12,2010-019912-18,AIJ,i
12,2010-019912-18,o,o
12,2010-019912-18,artritis,i
12,2010-019912-18,reumatoide,i
12,2010-019912-18,juvenil,i
12,2010-019912-18,ARJ,i
12,2010-019912-18,yo,o
12,2010-019912-18,AR,i
12,2010-019912-18,diagnosticadas,i
12,2010-019912-18,antes,o
12,2010-019912-18,de,o
12,2010-019912-18,los,o
12,2010-019912-18,16,o
12,2010-019912-18,años,o
12,2010-019912-18,de,o
12,2010-019912-18,edad,o
12,2010-019912-18,Enfermedad,i
12,2010-019912-18,articular,i
12,2010-019912-18,inflamatoria,i
12,2010-019912-18,distinta,o
12,2010-019912-18,de,o
12,2010-019912-18,AR,i
12,2010-019912-18,en,o
12,2010-019912-18,el,o
12,2010-019912-18,pasado,o
12,2010-019912-18,o,o
12,2010-019912-18,en,o
12,2010-019912-18,la,o
12,2010-019912-18,actualidad,o
13,2010-019912-18,EudraCT,o
13,2010-019912-18,Nº,o
13,2010-019912-18,201001991218,o
13,2010-019912-18,Titulo,o
13,2010-019912-18,cientifico,o
13,2010-019912-18,Estudio,o
13,2010-019912-18,randomizado,o
13,2010-019912-18,doble,o
13,2010-019912-18,ciego,o
13,2010-019912-18,con,o
13,2010-019912-18,grupos,o
13,2010-019912-18,de,o
13,2010-019912-18,tratamiento,i
13,2010-019912-18,paralelos,o
13,2010-019912-18,para,o
13,2010-019912-18,evaluar,i
13,2010-019912-18,la,i
13,2010-019912-18,seguridad,i
13,2010-019912-18,y,o
13,2010-019912-18,el,o
13,2010-019912-18,efecto,o
13,2010-019912-18,sobre,o
13,2010-019912-18,el,o
13,2010-019912-18,resultado,o
13,2010-019912-18,clinico,o
13,2010-019912-18,de,o
13,2010-019912-18,tocilizumab,i
13,2010-019912-18,SC,o
13,2010-019912-18,frente,o
13,2010-019912-18,a,o
13,2010-019912-18,placebo,i
13,2010-019912-18,SC,o
13,2010-019912-18,en,o
13,2010-019912-18,combinacion,o
13,2010-019912-18,con,o
13,2010-019912-18,farmacos,i
13,2010-019912-18,antirreumaticos,i
13,2010-019912-18,modificadores,i
13,2010-019912-18,de,i
13,2010-019912-18,la,i
13,2010-019912-18,enfermedad,i
13,2010-019912-18,FAMEs,i
13,2010-019912-18,tradicionales,o
13,2010-019912-18,en,o
13,2010-019912-18,pacientes,o
13,2010-019912-18,con,o
13,2010-019912-18,artritis,i
13,2010-019912-18,reumatoide,i
13,2010-019912-18,activa,o
13,2010-019912-18,moderada,o
13,2010-019912-18,a,o
13,2010-019912-18,severa,o
13,2010-019912-18,Indicacion,o
13,2010-019912-18,cientifica,o
13,2010-019912-18,Artritis,i
13,2010-019912-18,Reumatoide,i
13,2010-019912-18,AR,i
13,2010-019912-18,Criterios,o
13,2010-019912-18,de,o
13,2010-019912-18,inclusion,o
13,2010-019912-18,Presentar,o
13,2010-019912-18,artritis,i
13,2010-019912-18,reumatoide,i
13,2010-019912-18,de,o
13,2010-019912-18,mayor,o
13,2010-019912-18,o,o
13,2010-019912-18,igual,o
13,2010-019912-18,a,o
13,2010-019912-18,6,o
13,2010-019912-18,meses,o
13,2010-019912-18,de,o
13,2010-019912-18,duracion,o
13,2010-019912-18,Recibir,o
13,2010-019912-18,tratamiento,i
13,2010-019912-18,de,i
13,2010-019912-18,forma,i
13,2010-019912-18,ambulatoria,i
13,2010-019912-18,Presentar,o
13,2010-019912-18,un,o
13,2010-019912-18,recuento,o
13,2010-019912-18,de,o
13,2010-019912-18,articulaciones,i
13,2010-019912-18,inflamadas,i
13,2010-019912-18,RAI,o
13,2010-019912-18,mayor,o
13,2010-019912-18,o,o
13,2010-019912-18,igual,o
13,2010-019912-18,a,o
13,2010-019912-18,6,o
13,2010-019912-18,recuento,o
13,2010-019912-18,de,o
13,2010-019912-18,66,o
13,2010-019912-18,articulaciones,i
13,2010-019912-18,y,o
13,2010-019912-18,de,o
13,2010-019912-18,articulaciones,i
13,2010-019912-18,dolorosas,i
13,2010-019912-18,RAD,o
13,2010-019912-18,mayor,o
13,2010-019912-18,o,o
13,2010-019912-18,igual,o
13,2010-019912-18,a,o
13,2010-019912-18,8,o
13,2010-019912-18,recuento,o
13,2010-019912-18,de,o
13,2010-019912-18,68,o
13,2010-019912-18,articulaciones,i
13,2010-019912-18,en,o
13,2010-019912-18,las,o
13,2010-019912-18,visitas,o
13,2010-019912-18,de,o
13,2010-019912-18,seleccion,o
13,2010-019912-18,y,o
13,2010-019912-18,basal,o
13,2010-019912-18,Los,o
13,2010-019912-18,pacientes,o
13,2010-019912-18,deben,o
13,2010-019912-18,estar,o
13,2010-019912-18,recibiendo,o
13,2010-019912-18,tratamiento,i
13,2010-019912-18,con,o
13,2010-019912-18,una,o
13,2010-019912-18,dosis,o
13,2010-019912-18,estable,o
13,2010-019912-18,de,o
13,2010-019912-18,los,o
13,2010-019912-18,FAMEs,i
13,2010-019912-18,permitidos,o
13,2010-019912-18,como,o
13,2010-019912-18,minimo,o
13,2010-019912-18,8,o
13,2010-019912-18,semanas,o
13,2010-019912-18,antes,o
13,2010-019912-18,de,o
13,2010-019912-18,la,o
13,2010-019912-18,visita,o
13,2010-019912-18,basal,o
13,2010-019912-18,Criterios,o
13,2010-019912-18,de,o
13,2010-019912-18,exclusion,o
13,2010-019912-18,Pacientes,o
13,2010-019912-18,sometidos,o
13,2010-019912-18,a,o
13,2010-019912-18,intervenciones,i
13,2010-019912-18,de,i
13,2010-019912-18,cirugia,i
13,2010-019912-18,mayor,i
13,2010-019912-18,incluyendo,o
13,2010-019912-18,cirugia,i
13,2010-019912-18,articular,i
13,2010-019912-18,en,o
13,2010-019912-18,las,o
13,2010-019912-18,8,o
13,2010-019912-18,semanas,o
13,2010-019912-18,previas,o
13,2010-019912-18,a,o
13,2010-019912-18,la,o
13,2010-019912-18,visita,o
13,2010-019912-18,de,o
13,2010-019912-18,seleccion,o
13,2010-019912-18,o,o
13,2010-019912-18,que,o
13,2010-019912-18,tengan,o
13,2010-019912-18,previsto,o
13,2010-019912-18,someterse,o
13,2010-019912-18,a,o
13,2010-019912-18,una,o
13,2010-019912-18,intervencion,i
13,2010-019912-18,de,o
13,2010-019912-18,este,o
13,2010-019912-18,tipo,o
13,2010-019912-18,en,o
13,2010-019912-18,los,o
13,2010-019912-18,6,o
13,2010-019912-18,meses,o
13,2010-019912-18,siguientes,o
13,2010-019912-18,a,o
13,2010-019912-18,la,o
13,2010-019912-18,randomizacion,i
13,2010-019912-18,Enfermedad,i
13,2010-019912-18,reumatica,i
13,2010-019912-18,autoinmune,i
13,2010-019912-18,distinta,o
13,2010-019912-18,de,o
13,2010-019912-18,AR,i
13,2010-019912-18,Se,o
13,2010-019912-18,permite,o
13,2010-019912-18,la,o
13,2010-019912-18,inclusion,o
13,2010-019912-18,de,o
13,2010-019912-18,pacientes,o
13,2010-019912-18,con,o
13,2010-019912-18,sindrome,i
13,2010-019912-18,de,i
13,2010-019912-18,Sjögren,i
13,2010-019912-18,secundario,i
13,2010-019912-18,asociado,o
13,2010-019912-18,a,o
13,2010-019912-18,AR,i
13,2010-019912-18,Clase,o
13,2010-019912-18,funcional,o
13,2010-019912-18,IV,o
13,2010-019912-18,definida,o
13,2010-019912-18,de,o
13,2010-019912-18,acuerdo,o
13,2010-019912-18,con,o
13,2010-019912-18,la,o
13,2010-019912-18,Clasificacion,o
13,2010-019912-18,del,o
13,2010-019912-18,ACR,o
13,2010-019912-18,del,o
13,2010-019912-18,Estado,o
13,2010-019912-18,Funcional,o
13,2010-019912-18,en,o
13,2010-019912-18,Artritis,i
13,2010-019912-18,Reumatoide,i
13,2010-019912-18,Artritis,i
13,2010-019912-18,idiopatica,i
13,2010-019912-18,juvenil,i
13,2010-019912-18,AIJ,i
13,2010-019912-18,o,o
13,2010-019912-18,artritis,i
13,2010-019912-18,reumatoide,i
13,2010-019912-18,juvenil,i
13,2010-019912-18,ARJ,i
13,2010-019912-18,yo,o
13,2010-019912-18,AR,i
13,2010-019912-18,diagnosticadas,i
13,2010-019912-18,antes,o
13,2010-019912-18,de,o
13,2010-019912-18,los,o
13,2010-019912-18,16,o
13,2010-019912-18,años,o
13,2010-019912-18,de,o
13,2010-019912-18,edad,o
13,2010-019912-18,Enfermedad,i
13,2010-019912-18,articular,i
13,2010-019912-18,inflamatoria,i
13,2010-019912-18,distinta,o
13,2010-019912-18,de,o
13,2010-019912-18,AR,i
13,2010-019912-18,en,o
13,2010-019912-18,el,o
13,2010-019912-18,pasado,o
13,2010-019912-18,o,o
13,2010-019912-18,en,o
13,2010-019912-18,la,o
13,2010-019912-18,actualidad,o
14,2010-019912-18,EudraCT,o
14,2010-019912-18,Nº,o
14,2010-019912-18,201001991218,o
14,2010-019912-18,Titulo,o
14,2010-019912-18,cientifico,o
14,2010-019912-18,Estudio,o
14,2010-019912-18,randomizado,o
14,2010-019912-18,doble,o
14,2010-019912-18,ciego,o
14,2010-019912-18,con,o
14,2010-019912-18,grupos,o
14,2010-019912-18,de,o
14,2010-019912-18,tratamiento,i
14,2010-019912-18,paralelos,o
14,2010-019912-18,para,o
14,2010-019912-18,evaluar,i
14,2010-019912-18,la,i
14,2010-019912-18,seguridad,i
14,2010-019912-18,y,o
14,2010-019912-18,el,o
14,2010-019912-18,efecto,o
14,2010-019912-18,sobre,o
14,2010-019912-18,el,o
14,2010-019912-18,resultado,o
14,2010-019912-18,clinico,o
14,2010-019912-18,de,o
14,2010-019912-18,tocilizumab,i
14,2010-019912-18,SC,o
14,2010-019912-18,frente,o
14,2010-019912-18,a,o
14,2010-019912-18,placebo,i
14,2010-019912-18,SC,o
14,2010-019912-18,en,o
14,2010-019912-18,combinacion,o
14,2010-019912-18,con,o
14,2010-019912-18,farmacos,i
14,2010-019912-18,antirreumaticos,i
14,2010-019912-18,modificadores,i
14,2010-019912-18,de,i
14,2010-019912-18,la,i
14,2010-019912-18,enfermedad,i
14,2010-019912-18,FAMEs,i
14,2010-019912-18,tradicionales,o
14,2010-019912-18,en,o
14,2010-019912-18,pacientes,o
14,2010-019912-18,con,o
14,2010-019912-18,artritis,i
14,2010-019912-18,reumatoide,i
14,2010-019912-18,activa,o
14,2010-019912-18,moderada,o
14,2010-019912-18,a,o
14,2010-019912-18,severa,o
14,2010-019912-18,Indicacion,o
14,2010-019912-18,cientifica,o
14,2010-019912-18,Artritis,i
14,2010-019912-18,Reumatoide,i
14,2010-019912-18,AR,i
14,2010-019912-18,Criterios,o
14,2010-019912-18,de,o
14,2010-019912-18,inclusion,o
14,2010-019912-18,Presentar,o
14,2010-019912-18,artritis,i
14,2010-019912-18,reumatoide,i
14,2010-019912-18,de,o
14,2010-019912-18,mayor,o
14,2010-019912-18,o,o
14,2010-019912-18,igual,o
14,2010-019912-18,a,o
14,2010-019912-18,6,o
14,2010-019912-18,meses,o
14,2010-019912-18,de,o
14,2010-019912-18,duracion,o
14,2010-019912-18,Recibir,o
14,2010-019912-18,tratamiento,i
14,2010-019912-18,de,i
14,2010-019912-18,forma,i
14,2010-019912-18,ambulatoria,i
14,2010-019912-18,Presentar,o
14,2010-019912-18,un,o
14,2010-019912-18,recuento,o
14,2010-019912-18,de,o
14,2010-019912-18,articulaciones,i
14,2010-019912-18,inflamadas,i
14,2010-019912-18,RAI,o
14,2010-019912-18,mayor,o
14,2010-019912-18,o,o
14,2010-019912-18,igual,o
14,2010-019912-18,a,o
14,2010-019912-18,6,o
14,2010-019912-18,recuento,o
14,2010-019912-18,de,o
14,2010-019912-18,66,o
14,2010-019912-18,articulaciones,i
14,2010-019912-18,y,o
14,2010-019912-18,de,o
14,2010-019912-18,articulaciones,i
14,2010-019912-18,dolorosas,i
14,2010-019912-18,RAD,o
14,2010-019912-18,mayor,o
14,2010-019912-18,o,o
14,2010-019912-18,igual,o
14,2010-019912-18,a,o
14,2010-019912-18,8,o
14,2010-019912-18,recuento,o
14,2010-019912-18,de,o
14,2010-019912-18,68,o
14,2010-019912-18,articulaciones,i
14,2010-019912-18,en,o
14,2010-019912-18,las,o
14,2010-019912-18,visitas,o
14,2010-019912-18,de,o
14,2010-019912-18,seleccion,o
14,2010-019912-18,y,o
14,2010-019912-18,basal,o
14,2010-019912-18,Los,o
14,2010-019912-18,pacientes,o
14,2010-019912-18,deben,o
14,2010-019912-18,estar,o
14,2010-019912-18,recibiendo,o
14,2010-019912-18,tratamiento,i
14,2010-019912-18,con,o
14,2010-019912-18,una,o
14,2010-019912-18,dosis,o
14,2010-019912-18,estable,o
14,2010-019912-18,de,o
14,2010-019912-18,los,o
14,2010-019912-18,FAMEs,i
14,2010-019912-18,permitidos,o
14,2010-019912-18,como,o
14,2010-019912-18,minimo,o
14,2010-019912-18,8,o
14,2010-019912-18,semanas,o
14,2010-019912-18,antes,o
14,2010-019912-18,de,o
14,2010-019912-18,la,o
14,2010-019912-18,visita,o
14,2010-019912-18,basal,o
14,2010-019912-18,Criterios,o
14,2010-019912-18,de,o
14,2010-019912-18,exclusion,o
14,2010-019912-18,Pacientes,o
14,2010-019912-18,sometidos,o
14,2010-019912-18,a,o
14,2010-019912-18,intervenciones,i
14,2010-019912-18,de,i
14,2010-019912-18,cirugia,i
14,2010-019912-18,mayor,i
14,2010-019912-18,incluyendo,o
14,2010-019912-18,cirugia,i
14,2010-019912-18,articular,i
14,2010-019912-18,en,o
14,2010-019912-18,las,o
14,2010-019912-18,8,o
14,2010-019912-18,semanas,o
14,2010-019912-18,previas,o
14,2010-019912-18,a,o
14,2010-019912-18,la,o
14,2010-019912-18,visita,o
14,2010-019912-18,de,o
14,2010-019912-18,seleccion,o
14,2010-019912-18,o,o
14,2010-019912-18,que,o
14,2010-019912-18,tengan,o
14,2010-019912-18,previsto,o
14,2010-019912-18,someterse,o
14,2010-019912-18,a,o
14,2010-019912-18,una,o
14,2010-019912-18,intervencion,i
14,2010-019912-18,de,o
14,2010-019912-18,este,o
14,2010-019912-18,tipo,o
14,2010-019912-18,en,o
14,2010-019912-18,los,o
14,2010-019912-18,6,o
14,2010-019912-18,meses,o
14,2010-019912-18,siguientes,o
14,2010-019912-18,a,o
14,2010-019912-18,la,o
14,2010-019912-18,randomizacion,i
14,2010-019912-18,Enfermedad,i
14,2010-019912-18,reumatica,i
14,2010-019912-18,autoinmune,i
14,2010-019912-18,distinta,o
14,2010-019912-18,de,o
14,2010-019912-18,AR,i
14,2010-019912-18,Se,o
14,2010-019912-18,permite,o
14,2010-019912-18,la,o
14,2010-019912-18,inclusion,o
14,2010-019912-18,de,o
14,2010-019912-18,pacientes,o
14,2010-019912-18,con,o
14,2010-019912-18,sindrome,i
14,2010-019912-18,de,i
14,2010-019912-18,Sjögren,i
14,2010-019912-18,secundario,i
14,2010-019912-18,asociado,o
14,2010-019912-18,a,o
14,2010-019912-18,AR,i
14,2010-019912-18,Clase,o
14,2010-019912-18,funcional,o
14,2010-019912-18,IV,o
14,2010-019912-18,definida,o
14,2010-019912-18,de,o
14,2010-019912-18,acuerdo,o
14,2010-019912-18,con,o
14,2010-019912-18,la,o
14,2010-019912-18,Clasificacion,o
14,2010-019912-18,del,o
14,2010-019912-18,ACR,o
14,2010-019912-18,del,o
14,2010-019912-18,Estado,o
14,2010-019912-18,Funcional,o
14,2010-019912-18,en,o
14,2010-019912-18,Artritis,i
14,2010-019912-18,Reumatoide,i
14,2010-019912-18,Artritis,i
14,2010-019912-18,idiopatica,i
14,2010-019912-18,juvenil,i
14,2010-019912-18,AIJ,i
14,2010-019912-18,o,o
14,2010-019912-18,artritis,i
14,2010-019912-18,reumatoide,i
14,2010-019912-18,juvenil,i
14,2010-019912-18,ARJ,i
14,2010-019912-18,yo,o
14,2010-019912-18,AR,i
14,2010-019912-18,diagnosticadas,i
14,2010-019912-18,antes,o
14,2010-019912-18,de,o
14,2010-019912-18,los,o
14,2010-019912-18,16,o
14,2010-019912-18,años,o
14,2010-019912-18,de,o
14,2010-019912-18,edad,o
14,2010-019912-18,Enfermedad,i
14,2010-019912-18,articular,i
14,2010-019912-18,inflamatoria,i
14,2010-019912-18,distinta,o
14,2010-019912-18,de,o
14,2010-019912-18,AR,i
14,2010-019912-18,en,o
14,2010-019912-18,el,o
14,2010-019912-18,pasado,o
14,2010-019912-18,o,o
14,2010-019912-18,en,o
14,2010-019912-18,la,o
14,2010-019912-18,actualidad,o
15,2010-019912-18,EudraCT,o
15,2010-019912-18,Nº,o
15,2010-019912-18,201001991218,o
15,2010-019912-18,Titulo,o
15,2010-019912-18,cientifico,o
15,2010-019912-18,Estudio,o
15,2010-019912-18,randomizado,o
15,2010-019912-18,doble,o
15,2010-019912-18,ciego,o
15,2010-019912-18,con,o
15,2010-019912-18,grupos,o
15,2010-019912-18,de,o
15,2010-019912-18,tratamiento,i
15,2010-019912-18,paralelos,o
15,2010-019912-18,para,o
15,2010-019912-18,evaluar,i
15,2010-019912-18,la,i
15,2010-019912-18,seguridad,i
15,2010-019912-18,y,o
15,2010-019912-18,el,o
15,2010-019912-18,efecto,o
15,2010-019912-18,sobre,o
15,2010-019912-18,el,o
15,2010-019912-18,resultado,o
15,2010-019912-18,clinico,o
15,2010-019912-18,de,o
15,2010-019912-18,tocilizumab,i
15,2010-019912-18,SC,o
15,2010-019912-18,frente,o
15,2010-019912-18,a,o
15,2010-019912-18,placebo,i
15,2010-019912-18,SC,o
15,2010-019912-18,en,o
15,2010-019912-18,combinacion,o
15,2010-019912-18,con,o
15,2010-019912-18,farmacos,i
15,2010-019912-18,antirreumaticos,i
15,2010-019912-18,modificadores,i
15,2010-019912-18,de,i
15,2010-019912-18,la,i
15,2010-019912-18,enfermedad,i
15,2010-019912-18,FAMEs,i
15,2010-019912-18,tradicionales,o
15,2010-019912-18,en,o
15,2010-019912-18,pacientes,o
15,2010-019912-18,con,o
15,2010-019912-18,artritis,i
15,2010-019912-18,reumatoide,i
15,2010-019912-18,activa,o
15,2010-019912-18,moderada,o
15,2010-019912-18,a,o
15,2010-019912-18,severa,o
15,2010-019912-18,Indicacion,o
15,2010-019912-18,cientifica,o
15,2010-019912-18,Artritis,i
15,2010-019912-18,Reumatoide,i
15,2010-019912-18,AR,i
15,2010-019912-18,Criterios,o
15,2010-019912-18,de,o
15,2010-019912-18,inclusion,o
15,2010-019912-18,Presentar,o
15,2010-019912-18,artritis,i
15,2010-019912-18,reumatoide,i
15,2010-019912-18,de,o
15,2010-019912-18,mayor,o
15,2010-019912-18,o,o
15,2010-019912-18,igual,o
15,2010-019912-18,a,o
15,2010-019912-18,6,o
15,2010-019912-18,meses,o
15,2010-019912-18,de,o
15,2010-019912-18,duracion,o
15,2010-019912-18,Recibir,o
15,2010-019912-18,tratamiento,i
15,2010-019912-18,de,i
15,2010-019912-18,forma,i
15,2010-019912-18,ambulatoria,i
15,2010-019912-18,Presentar,o
15,2010-019912-18,un,o
15,2010-019912-18,recuento,o
15,2010-019912-18,de,o
15,2010-019912-18,articulaciones,i
15,2010-019912-18,inflamadas,i
15,2010-019912-18,RAI,o
15,2010-019912-18,mayor,o
15,2010-019912-18,o,o
15,2010-019912-18,igual,o
15,2010-019912-18,a,o
15,2010-019912-18,6,o
15,2010-019912-18,recuento,o
15,2010-019912-18,de,o
15,2010-019912-18,66,o
15,2010-019912-18,articulaciones,i
15,2010-019912-18,y,o
15,2010-019912-18,de,o
15,2010-019912-18,articulaciones,i
15,2010-019912-18,dolorosas,i
15,2010-019912-18,RAD,o
15,2010-019912-18,mayor,o
15,2010-019912-18,o,o
15,2010-019912-18,igual,o
15,2010-019912-18,a,o
15,2010-019912-18,8,o
15,2010-019912-18,recuento,o
15,2010-019912-18,de,o
15,2010-019912-18,68,o
15,2010-019912-18,articulaciones,i
15,2010-019912-18,en,o
15,2010-019912-18,las,o
15,2010-019912-18,visitas,o
15,2010-019912-18,de,o
15,2010-019912-18,seleccion,o
15,2010-019912-18,y,o
15,2010-019912-18,basal,o
15,2010-019912-18,Los,o
15,2010-019912-18,pacientes,o
15,2010-019912-18,deben,o
15,2010-019912-18,estar,o
15,2010-019912-18,recibiendo,o
15,2010-019912-18,tratamiento,i
15,2010-019912-18,con,o
15,2010-019912-18,una,o
15,2010-019912-18,dosis,o
15,2010-019912-18,estable,o
15,2010-019912-18,de,o
15,2010-019912-18,los,o
15,2010-019912-18,FAMEs,i
15,2010-019912-18,permitidos,o
15,2010-019912-18,como,o
15,2010-019912-18,minimo,o
15,2010-019912-18,8,o
15,2010-019912-18,semanas,o
15,2010-019912-18,antes,o
15,2010-019912-18,de,o
15,2010-019912-18,la,o
15,2010-019912-18,visita,o
15,2010-019912-18,basal,o
15,2010-019912-18,Criterios,o
15,2010-019912-18,de,o
15,2010-019912-18,exclusion,o
15,2010-019912-18,Pacientes,o
15,2010-019912-18,sometidos,o
15,2010-019912-18,a,o
15,2010-019912-18,intervenciones,i
15,2010-019912-18,de,i
15,2010-019912-18,cirugia,i
15,2010-019912-18,mayor,i
15,2010-019912-18,incluyendo,o
15,2010-019912-18,cirugia,i
15,2010-019912-18,articular,i
15,2010-019912-18,en,o
15,2010-019912-18,las,o
15,2010-019912-18,8,o
15,2010-019912-18,semanas,o
15,2010-019912-18,previas,o
15,2010-019912-18,a,o
15,2010-019912-18,la,o
15,2010-019912-18,visita,o
15,2010-019912-18,de,o
15,2010-019912-18,seleccion,o
15,2010-019912-18,o,o
15,2010-019912-18,que,o
15,2010-019912-18,tengan,o
15,2010-019912-18,previsto,o
15,2010-019912-18,someterse,o
15,2010-019912-18,a,o
15,2010-019912-18,una,o
15,2010-019912-18,intervencion,i
15,2010-019912-18,de,o
15,2010-019912-18,este,o
15,2010-019912-18,tipo,o
15,2010-019912-18,en,o
15,2010-019912-18,los,o
15,2010-019912-18,6,o
15,2010-019912-18,meses,o
15,2010-019912-18,siguientes,o
15,2010-019912-18,a,o
15,2010-019912-18,la,o
15,2010-019912-18,randomizacion,i
15,2010-019912-18,Enfermedad,i
15,2010-019912-18,reumatica,i
15,2010-019912-18,autoinmune,i
15,2010-019912-18,distinta,o
15,2010-019912-18,de,o
15,2010-019912-18,AR,i
15,2010-019912-18,Se,o
15,2010-019912-18,permite,o
15,2010-019912-18,la,o
15,2010-019912-18,inclusion,o
15,2010-019912-18,de,o
15,2010-019912-18,pacientes,o
15,2010-019912-18,con,o
15,2010-019912-18,sindrome,i
15,2010-019912-18,de,i
15,2010-019912-18,Sjögren,i
15,2010-019912-18,secundario,i
15,2010-019912-18,asociado,o
15,2010-019912-18,a,o
15,2010-019912-18,AR,i
15,2010-019912-18,Clase,o
15,2010-019912-18,funcional,o
15,2010-019912-18,IV,o
15,2010-019912-18,definida,o
15,2010-019912-18,de,o
15,2010-019912-18,acuerdo,o
15,2010-019912-18,con,o
15,2010-019912-18,la,o
15,2010-019912-18,Clasificacion,o
15,2010-019912-18,del,o
15,2010-019912-18,ACR,o
15,2010-019912-18,del,o
15,2010-019912-18,Estado,o
15,2010-019912-18,Funcional,o
15,2010-019912-18,en,o
15,2010-019912-18,Artritis,i
15,2010-019912-18,Reumatoide,i
15,2010-019912-18,Artritis,i
15,2010-019912-18,idiopatica,i
15,2010-019912-18,juvenil,i
15,2010-019912-18,AIJ,i
15,2010-019912-18,o,o
15,2010-019912-18,artritis,i
15,2010-019912-18,reumatoide,i
15,2010-019912-18,juvenil,i
15,2010-019912-18,ARJ,i
15,2010-019912-18,yo,o
15,2010-019912-18,AR,i
15,2010-019912-18,diagnosticadas,i
15,2010-019912-18,antes,o
15,2010-019912-18,de,o
15,2010-019912-18,los,o
15,2010-019912-18,16,o
15,2010-019912-18,años,o
15,2010-019912-18,de,o
15,2010-019912-18,edad,o
15,2010-019912-18,Enfermedad,i
15,2010-019912-18,articular,i
15,2010-019912-18,inflamatoria,i
15,2010-019912-18,distinta,o
15,2010-019912-18,de,o
15,2010-019912-18,AR,i
15,2010-019912-18,en,o
15,2010-019912-18,el,o
15,2010-019912-18,pasado,o
15,2010-019912-18,o,o
15,2010-019912-18,en,o
15,2010-019912-18,la,o
15,2010-019912-18,actualidad,o
16,2010-019912-18,EudraCT,o
16,2010-019912-18,Nº,o
16,2010-019912-18,201001991218,o
16,2010-019912-18,Titulo,o
16,2010-019912-18,cientifico,o
16,2010-019912-18,Estudio,o
16,2010-019912-18,randomizado,o
16,2010-019912-18,doble,o
16,2010-019912-18,ciego,o
16,2010-019912-18,con,o
16,2010-019912-18,grupos,o
16,2010-019912-18,de,o
16,2010-019912-18,tratamiento,i
16,2010-019912-18,paralelos,o
16,2010-019912-18,para,o
16,2010-019912-18,evaluar,i
16,2010-019912-18,la,i
16,2010-019912-18,seguridad,i
16,2010-019912-18,y,o
16,2010-019912-18,el,o
16,2010-019912-18,efecto,o
16,2010-019912-18,sobre,o
16,2010-019912-18,el,o
16,2010-019912-18,resultado,o
16,2010-019912-18,clinico,o
16,2010-019912-18,de,o
16,2010-019912-18,tocilizumab,i
16,2010-019912-18,SC,o
16,2010-019912-18,frente,o
16,2010-019912-18,a,o
16,2010-019912-18,placebo,i
16,2010-019912-18,SC,o
16,2010-019912-18,en,o
16,2010-019912-18,combinacion,o
16,2010-019912-18,con,o
16,2010-019912-18,farmacos,i
16,2010-019912-18,antirreumaticos,i
16,2010-019912-18,modificadores,i
16,2010-019912-18,de,i
16,2010-019912-18,la,i
16,2010-019912-18,enfermedad,i
16,2010-019912-18,FAMEs,i
16,2010-019912-18,tradicionales,o
16,2010-019912-18,en,o
16,2010-019912-18,pacientes,o
16,2010-019912-18,con,o
16,2010-019912-18,artritis,i
16,2010-019912-18,reumatoide,i
16,2010-019912-18,activa,o
16,2010-019912-18,moderada,o
16,2010-019912-18,a,o
16,2010-019912-18,severa,o
16,2010-019912-18,Indicacion,o
16,2010-019912-18,cientifica,o
16,2010-019912-18,Artritis,i
16,2010-019912-18,Reumatoide,i
16,2010-019912-18,AR,i
16,2010-019912-18,Criterios,o
16,2010-019912-18,de,o
16,2010-019912-18,inclusion,o
16,2010-019912-18,Presentar,o
16,2010-019912-18,artritis,i
16,2010-019912-18,reumatoide,i
16,2010-019912-18,de,o
16,2010-019912-18,mayor,o
16,2010-019912-18,o,o
16,2010-019912-18,igual,o
16,2010-019912-18,a,o
16,2010-019912-18,6,o
16,2010-019912-18,meses,o
16,2010-019912-18,de,o
16,2010-019912-18,duracion,o
16,2010-019912-18,Recibir,o
16,2010-019912-18,tratamiento,i
16,2010-019912-18,de,i
16,2010-019912-18,forma,i
16,2010-019912-18,ambulatoria,i
16,2010-019912-18,Presentar,o
16,2010-019912-18,un,o
16,2010-019912-18,recuento,o
16,2010-019912-18,de,o
16,2010-019912-18,articulaciones,i
16,2010-019912-18,inflamadas,i
16,2010-019912-18,RAI,o
16,2010-019912-18,mayor,o
16,2010-019912-18,o,o
16,2010-019912-18,igual,o
16,2010-019912-18,a,o
16,2010-019912-18,6,o
16,2010-019912-18,recuento,o
16,2010-019912-18,de,o
16,2010-019912-18,66,o
16,2010-019912-18,articulaciones,i
16,2010-019912-18,y,o
16,2010-019912-18,de,o
16,2010-019912-18,articulaciones,i
16,2010-019912-18,dolorosas,i
16,2010-019912-18,RAD,o
16,2010-019912-18,mayor,o
16,2010-019912-18,o,o
16,2010-019912-18,igual,o
16,2010-019912-18,a,o
16,2010-019912-18,8,o
16,2010-019912-18,recuento,o
16,2010-019912-18,de,o
16,2010-019912-18,68,o
16,2010-019912-18,articulaciones,i
16,2010-019912-18,en,o
16,2010-019912-18,las,o
16,2010-019912-18,visitas,o
16,2010-019912-18,de,o
16,2010-019912-18,seleccion,o
16,2010-019912-18,y,o
16,2010-019912-18,basal,o
16,2010-019912-18,Los,o
16,2010-019912-18,pacientes,o
16,2010-019912-18,deben,o
16,2010-019912-18,estar,o
16,2010-019912-18,recibiendo,o
16,2010-019912-18,tratamiento,i
16,2010-019912-18,con,o
16,2010-019912-18,una,o
16,2010-019912-18,dosis,o
16,2010-019912-18,estable,o
16,2010-019912-18,de,o
16,2010-019912-18,los,o
16,2010-019912-18,FAMEs,i
16,2010-019912-18,permitidos,o
16,2010-019912-18,como,o
16,2010-019912-18,minimo,o
16,2010-019912-18,8,o
16,2010-019912-18,semanas,o
16,2010-019912-18,antes,o
16,2010-019912-18,de,o
16,2010-019912-18,la,o
16,2010-019912-18,visita,o
16,2010-019912-18,basal,o
16,2010-019912-18,Criterios,o
16,2010-019912-18,de,o
16,2010-019912-18,exclusion,o
16,2010-019912-18,Pacientes,o
16,2010-019912-18,sometidos,o
16,2010-019912-18,a,o
16,2010-019912-18,intervenciones,i
16,2010-019912-18,de,i
16,2010-019912-18,cirugia,i
16,2010-019912-18,mayor,i
16,2010-019912-18,incluyendo,o
16,2010-019912-18,cirugia,i
16,2010-019912-18,articular,i
16,2010-019912-18,en,o
16,2010-019912-18,las,o
16,2010-019912-18,8,o
16,2010-019912-18,semanas,o
16,2010-019912-18,previas,o
16,2010-019912-18,a,o
16,2010-019912-18,la,o
16,2010-019912-18,visita,o
16,2010-019912-18,de,o
16,2010-019912-18,seleccion,o
16,2010-019912-18,o,o
16,2010-019912-18,que,o
16,2010-019912-18,tengan,o
16,2010-019912-18,previsto,o
16,2010-019912-18,someterse,o
16,2010-019912-18,a,o
16,2010-019912-18,una,o
16,2010-019912-18,intervencion,i
16,2010-019912-18,de,o
16,2010-019912-18,este,o
16,2010-019912-18,tipo,o
16,2010-019912-18,en,o
16,2010-019912-18,los,o
16,2010-019912-18,6,o
16,2010-019912-18,meses,o
16,2010-019912-18,siguientes,o
16,2010-019912-18,a,o
16,2010-019912-18,la,o
16,2010-019912-18,randomizacion,i
16,2010-019912-18,Enfermedad,i
16,2010-019912-18,reumatica,i
16,2010-019912-18,autoinmune,i
16,2010-019912-18,distinta,o
16,2010-019912-18,de,o
16,2010-019912-18,AR,i
16,2010-019912-18,Se,o
16,2010-019912-18,permite,o
16,2010-019912-18,la,o
16,2010-019912-18,inclusion,o
16,2010-019912-18,de,o
16,2010-019912-18,pacientes,o
16,2010-019912-18,con,o
16,2010-019912-18,sindrome,i
16,2010-019912-18,de,i
16,2010-019912-18,Sjögren,i
16,2010-019912-18,secundario,i
16,2010-019912-18,asociado,o
16,2010-019912-18,a,o
16,2010-019912-18,AR,i
16,2010-019912-18,Clase,o
16,2010-019912-18,funcional,o
16,2010-019912-18,IV,o
16,2010-019912-18,definida,o
16,2010-019912-18,de,o
16,2010-019912-18,acuerdo,o
16,2010-019912-18,con,o
16,2010-019912-18,la,o
16,2010-019912-18,Clasificacion,o
16,2010-019912-18,del,o
16,2010-019912-18,ACR,o
16,2010-019912-18,del,o
16,2010-019912-18,Estado,o
16,2010-019912-18,Funcional,o
16,2010-019912-18,en,o
16,2010-019912-18,Artritis,i
16,2010-019912-18,Reumatoide,i
16,2010-019912-18,Artritis,i
16,2010-019912-18,idiopatica,i
16,2010-019912-18,juvenil,i
16,2010-019912-18,AIJ,i
16,2010-019912-18,o,o
16,2010-019912-18,artritis,i
16,2010-019912-18,reumatoide,i
16,2010-019912-18,juvenil,i
16,2010-019912-18,ARJ,i
16,2010-019912-18,yo,o
16,2010-019912-18,AR,i
16,2010-019912-18,diagnosticadas,i
16,2010-019912-18,antes,o
16,2010-019912-18,de,o
16,2010-019912-18,los,o
16,2010-019912-18,16,o
16,2010-019912-18,años,o
16,2010-019912-18,de,o
16,2010-019912-18,edad,o
16,2010-019912-18,Enfermedad,i
16,2010-019912-18,articular,i
16,2010-019912-18,inflamatoria,i
16,2010-019912-18,distinta,o
16,2010-019912-18,de,o
16,2010-019912-18,AR,i
16,2010-019912-18,en,o
16,2010-019912-18,el,o
16,2010-019912-18,pasado,o
16,2010-019912-18,o,o
16,2010-019912-18,en,o
16,2010-019912-18,la,o
16,2010-019912-18,actualidad,o
17,2010-019912-18,EudraCT,o
17,2010-019912-18,Nº,o
17,2010-019912-18,201001991218,o
17,2010-019912-18,Titulo,o
17,2010-019912-18,cientifico,o
17,2010-019912-18,Estudio,o
17,2010-019912-18,randomizado,o
17,2010-019912-18,doble,o
17,2010-019912-18,ciego,o
17,2010-019912-18,con,o
17,2010-019912-18,grupos,o
17,2010-019912-18,de,o
17,2010-019912-18,tratamiento,i
17,2010-019912-18,paralelos,o
17,2010-019912-18,para,o
17,2010-019912-18,evaluar,i
17,2010-019912-18,la,i
17,2010-019912-18,seguridad,i
17,2010-019912-18,y,o
17,2010-019912-18,el,o
17,2010-019912-18,efecto,o
17,2010-019912-18,sobre,o
17,2010-019912-18,el,o
17,2010-019912-18,resultado,o
17,2010-019912-18,clinico,o
17,2010-019912-18,de,o
17,2010-019912-18,tocilizumab,i
17,2010-019912-18,SC,o
17,2010-019912-18,frente,o
17,2010-019912-18,a,o
17,2010-019912-18,placebo,i
17,2010-019912-18,SC,o
17,2010-019912-18,en,o
17,2010-019912-18,combinacion,o
17,2010-019912-18,con,o
17,2010-019912-18,farmacos,i
17,2010-019912-18,antirreumaticos,i
17,2010-019912-18,modificadores,i
17,2010-019912-18,de,i
17,2010-019912-18,la,i
17,2010-019912-18,enfermedad,i
17,2010-019912-18,FAMEs,i
17,2010-019912-18,tradicionales,o
17,2010-019912-18,en,o
17,2010-019912-18,pacientes,o
17,2010-019912-18,con,o
17,2010-019912-18,artritis,i
17,2010-019912-18,reumatoide,i
17,2010-019912-18,activa,o
17,2010-019912-18,moderada,o
17,2010-019912-18,a,o
17,2010-019912-18,severa,o
17,2010-019912-18,Indicacion,o
17,2010-019912-18,cientifica,o
17,2010-019912-18,Artritis,i
17,2010-019912-18,Reumatoide,i
17,2010-019912-18,AR,i
17,2010-019912-18,Criterios,o
17,2010-019912-18,de,o
17,2010-019912-18,inclusion,o
17,2010-019912-18,Presentar,o
17,2010-019912-18,artritis,i
17,2010-019912-18,reumatoide,i
17,2010-019912-18,de,o
17,2010-019912-18,mayor,o
17,2010-019912-18,o,o
17,2010-019912-18,igual,o
17,2010-019912-18,a,o
17,2010-019912-18,6,o
17,2010-019912-18,meses,o
17,2010-019912-18,de,o
17,2010-019912-18,duracion,o
17,2010-019912-18,Recibir,o
17,2010-019912-18,tratamiento,i
17,2010-019912-18,de,i
17,2010-019912-18,forma,i
17,2010-019912-18,ambulatoria,i
17,2010-019912-18,Presentar,o
17,2010-019912-18,un,o
17,2010-019912-18,recuento,o
17,2010-019912-18,de,o
17,2010-019912-18,articulaciones,i
17,2010-019912-18,inflamadas,i
17,2010-019912-18,RAI,o
17,2010-019912-18,mayor,o
17,2010-019912-18,o,o
17,2010-019912-18,igual,o
17,2010-019912-18,a,o
17,2010-019912-18,6,o
17,2010-019912-18,recuento,o
17,2010-019912-18,de,o
17,2010-019912-18,66,o
17,2010-019912-18,articulaciones,i
17,2010-019912-18,y,o
17,2010-019912-18,de,o
17,2010-019912-18,articulaciones,i
17,2010-019912-18,dolorosas,i
17,2010-019912-18,RAD,o
17,2010-019912-18,mayor,o
17,2010-019912-18,o,o
17,2010-019912-18,igual,o
17,2010-019912-18,a,o
17,2010-019912-18,8,o
17,2010-019912-18,recuento,o
17,2010-019912-18,de,o
17,2010-019912-18,68,o
17,2010-019912-18,articulaciones,i
17,2010-019912-18,en,o
17,2010-019912-18,las,o
17,2010-019912-18,visitas,o
17,2010-019912-18,de,o
17,2010-019912-18,seleccion,o
17,2010-019912-18,y,o
17,2010-019912-18,basal,o
17,2010-019912-18,Los,o
17,2010-019912-18,pacientes,o
17,2010-019912-18,deben,o
17,2010-019912-18,estar,o
17,2010-019912-18,recibiendo,o
17,2010-019912-18,tratamiento,i
17,2010-019912-18,con,o
17,2010-019912-18,una,o
17,2010-019912-18,dosis,o
17,2010-019912-18,estable,o
17,2010-019912-18,de,o
17,2010-019912-18,los,o
17,2010-019912-18,FAMEs,i
17,2010-019912-18,permitidos,o
17,2010-019912-18,como,o
17,2010-019912-18,minimo,o
17,2010-019912-18,8,o
17,2010-019912-18,semanas,o
17,2010-019912-18,antes,o
17,2010-019912-18,de,o
17,2010-019912-18,la,o
17,2010-019912-18,visita,o
17,2010-019912-18,basal,o
17,2010-019912-18,Criterios,o
17,2010-019912-18,de,o
17,2010-019912-18,exclusion,o
17,2010-019912-18,Pacientes,o
17,2010-019912-18,sometidos,o
17,2010-019912-18,a,o
17,2010-019912-18,intervenciones,i
17,2010-019912-18,de,i
17,2010-019912-18,cirugia,i
17,2010-019912-18,mayor,i
17,2010-019912-18,incluyendo,o
17,2010-019912-18,cirugia,i
17,2010-019912-18,articular,i
17,2010-019912-18,en,o
17,2010-019912-18,las,o
17,2010-019912-18,8,o
17,2010-019912-18,semanas,o
17,2010-019912-18,previas,o
17,2010-019912-18,a,o
17,2010-019912-18,la,o
17,2010-019912-18,visita,o
17,2010-019912-18,de,o
17,2010-019912-18,seleccion,o
17,2010-019912-18,o,o
17,2010-019912-18,que,o
17,2010-019912-18,tengan,o
17,2010-019912-18,previsto,o
17,2010-019912-18,someterse,o
17,2010-019912-18,a,o
17,2010-019912-18,una,o
17,2010-019912-18,intervencion,i
17,2010-019912-18,de,o
17,2010-019912-18,este,o
17,2010-019912-18,tipo,o
17,2010-019912-18,en,o
17,2010-019912-18,los,o
17,2010-019912-18,6,o
17,2010-019912-18,meses,o
17,2010-019912-18,siguientes,o
17,2010-019912-18,a,o
17,2010-019912-18,la,o
17,2010-019912-18,randomizacion,i
17,2010-019912-18,Enfermedad,i
17,2010-019912-18,reumatica,i
17,2010-019912-18,autoinmune,i
17,2010-019912-18,distinta,o
17,2010-019912-18,de,o
17,2010-019912-18,AR,i
17,2010-019912-18,Se,o
17,2010-019912-18,permite,o
17,2010-019912-18,la,o
17,2010-019912-18,inclusion,o
17,2010-019912-18,de,o
17,2010-019912-18,pacientes,o
17,2010-019912-18,con,o
17,2010-019912-18,sindrome,i
17,2010-019912-18,de,i
17,2010-019912-18,Sjögren,i
17,2010-019912-18,secundario,i
17,2010-019912-18,asociado,o
17,2010-019912-18,a,o
17,2010-019912-18,AR,i
17,2010-019912-18,Clase,o
17,2010-019912-18,funcional,o
17,2010-019912-18,IV,o
17,2010-019912-18,definida,o
17,2010-019912-18,de,o
17,2010-019912-18,acuerdo,o
17,2010-019912-18,con,o
17,2010-019912-18,la,o
17,2010-019912-18,Clasificacion,o
17,2010-019912-18,del,o
17,2010-019912-18,ACR,o
17,2010-019912-18,del,o
17,2010-019912-18,Estado,o
17,2010-019912-18,Funcional,o
17,2010-019912-18,en,o
17,2010-019912-18,Artritis,i
17,2010-019912-18,Reumatoide,i
17,2010-019912-18,Artritis,i
17,2010-019912-18,idiopatica,i
17,2010-019912-18,juvenil,i
17,2010-019912-18,AIJ,i
17,2010-019912-18,o,o
17,2010-019912-18,artritis,i
17,2010-019912-18,reumatoide,i
17,2010-019912-18,juvenil,i
17,2010-019912-18,ARJ,i
17,2010-019912-18,yo,o
17,2010-019912-18,AR,i
17,2010-019912-18,diagnosticadas,i
17,2010-019912-18,antes,o
17,2010-019912-18,de,o
17,2010-019912-18,los,o
17,2010-019912-18,16,o
17,2010-019912-18,años,o
17,2010-019912-18,de,o
17,2010-019912-18,edad,o
17,2010-019912-18,Enfermedad,i
17,2010-019912-18,articular,i
17,2010-019912-18,inflamatoria,i
17,2010-019912-18,distinta,o
17,2010-019912-18,de,o
17,2010-019912-18,AR,i
17,2010-019912-18,en,o
17,2010-019912-18,el,o
17,2010-019912-18,pasado,o
17,2010-019912-18,o,o
17,2010-019912-18,en,o
17,2010-019912-18,la,o
17,2010-019912-18,actualidad,o
18,2010-019912-18,EudraCT,o
18,2010-019912-18,Nº,o
18,2010-019912-18,201001991218,o
18,2010-019912-18,Titulo,o
18,2010-019912-18,cientifico,o
18,2010-019912-18,Estudio,o
18,2010-019912-18,randomizado,o
18,2010-019912-18,doble,o
18,2010-019912-18,ciego,o
18,2010-019912-18,con,o
18,2010-019912-18,grupos,o
18,2010-019912-18,de,o
18,2010-019912-18,tratamiento,i
18,2010-019912-18,paralelos,o
18,2010-019912-18,para,o
18,2010-019912-18,evaluar,i
18,2010-019912-18,la,i
18,2010-019912-18,seguridad,i
18,2010-019912-18,y,o
18,2010-019912-18,el,o
18,2010-019912-18,efecto,o
18,2010-019912-18,sobre,o
18,2010-019912-18,el,o
18,2010-019912-18,resultado,o
18,2010-019912-18,clinico,o
18,2010-019912-18,de,o
18,2010-019912-18,tocilizumab,i
18,2010-019912-18,SC,o
18,2010-019912-18,frente,o
18,2010-019912-18,a,o
18,2010-019912-18,placebo,i
18,2010-019912-18,SC,o
18,2010-019912-18,en,o
18,2010-019912-18,combinacion,o
18,2010-019912-18,con,o
18,2010-019912-18,farmacos,i
18,2010-019912-18,antirreumaticos,i
18,2010-019912-18,modificadores,i
18,2010-019912-18,de,i
18,2010-019912-18,la,i
18,2010-019912-18,enfermedad,i
18,2010-019912-18,FAMEs,i
18,2010-019912-18,tradicionales,o
18,2010-019912-18,en,o
18,2010-019912-18,pacientes,o
18,2010-019912-18,con,o
18,2010-019912-18,artritis,i
18,2010-019912-18,reumatoide,i
18,2010-019912-18,activa,o
18,2010-019912-18,moderada,o
18,2010-019912-18,a,o
18,2010-019912-18,severa,o
18,2010-019912-18,Indicacion,o
18,2010-019912-18,cientifica,o
18,2010-019912-18,Artritis,i
18,2010-019912-18,Reumatoide,i
18,2010-019912-18,AR,i
18,2010-019912-18,Criterios,o
18,2010-019912-18,de,o
18,2010-019912-18,inclusion,o
18,2010-019912-18,Presentar,o
18,2010-019912-18,artritis,i
18,2010-019912-18,reumatoide,i
18,2010-019912-18,de,o
18,2010-019912-18,mayor,o
18,2010-019912-18,o,o
18,2010-019912-18,igual,o
18,2010-019912-18,a,o
18,2010-019912-18,6,o
18,2010-019912-18,meses,o
18,2010-019912-18,de,o
18,2010-019912-18,duracion,o
18,2010-019912-18,Recibir,o
18,2010-019912-18,tratamiento,i
18,2010-019912-18,de,i
18,2010-019912-18,forma,i
18,2010-019912-18,ambulatoria,i
18,2010-019912-18,Presentar,o
18,2010-019912-18,un,o
18,2010-019912-18,recuento,o
18,2010-019912-18,de,o
18,2010-019912-18,articulaciones,i
18,2010-019912-18,inflamadas,i
18,2010-019912-18,RAI,o
18,2010-019912-18,mayor,o
18,2010-019912-18,o,o
18,2010-019912-18,igual,o
18,2010-019912-18,a,o
18,2010-019912-18,6,o
18,2010-019912-18,recuento,o
18,2010-019912-18,de,o
18,2010-019912-18,66,o
18,2010-019912-18,articulaciones,i
18,2010-019912-18,y,o
18,2010-019912-18,de,o
18,2010-019912-18,articulaciones,i
18,2010-019912-18,dolorosas,i
18,2010-019912-18,RAD,o
18,2010-019912-18,mayor,o
18,2010-019912-18,o,o
18,2010-019912-18,igual,o
18,2010-019912-18,a,o
18,2010-019912-18,8,o
18,2010-019912-18,recuento,o
18,2010-019912-18,de,o
18,2010-019912-18,68,o
18,2010-019912-18,articulaciones,i
18,2010-019912-18,en,o
18,2010-019912-18,las,o
18,2010-019912-18,visitas,o
18,2010-019912-18,de,o
18,2010-019912-18,seleccion,o
18,2010-019912-18,y,o
18,2010-019912-18,basal,o
18,2010-019912-18,Los,o
18,2010-019912-18,pacientes,o
18,2010-019912-18,deben,o
18,2010-019912-18,estar,o
18,2010-019912-18,recibiendo,o
18,2010-019912-18,tratamiento,i
18,2010-019912-18,con,o
18,2010-019912-18,una,o
18,2010-019912-18,dosis,o
18,2010-019912-18,estable,o
18,2010-019912-18,de,o
18,2010-019912-18,los,o
18,2010-019912-18,FAMEs,i
18,2010-019912-18,permitidos,o
18,2010-019912-18,como,o
18,2010-019912-18,minimo,o
18,2010-019912-18,8,o
18,2010-019912-18,semanas,o
18,2010-019912-18,antes,o
18,2010-019912-18,de,o
18,2010-019912-18,la,o
18,2010-019912-18,visita,o
18,2010-019912-18,basal,o
18,2010-019912-18,Criterios,o
18,2010-019912-18,de,o
18,2010-019912-18,exclusion,o
18,2010-019912-18,Pacientes,o
18,2010-019912-18,sometidos,o
18,2010-019912-18,a,o
18,2010-019912-18,intervenciones,i
18,2010-019912-18,de,i
18,2010-019912-18,cirugia,i
18,2010-019912-18,mayor,i
18,2010-019912-18,incluyendo,o
18,2010-019912-18,cirugia,i
18,2010-019912-18,articular,i
18,2010-019912-18,en,o
18,2010-019912-18,las,o
18,2010-019912-18,8,o
18,2010-019912-18,semanas,o
18,2010-019912-18,previas,o
18,2010-019912-18,a,o
18,2010-019912-18,la,o
18,2010-019912-18,visita,o
18,2010-019912-18,de,o
18,2010-019912-18,seleccion,o
18,2010-019912-18,o,o
18,2010-019912-18,que,o
18,2010-019912-18,tengan,o
18,2010-019912-18,previsto,o
18,2010-019912-18,someterse,o
18,2010-019912-18,a,o
18,2010-019912-18,una,o
18,2010-019912-18,intervencion,i
18,2010-019912-18,de,o
18,2010-019912-18,este,o
18,2010-019912-18,tipo,o
18,2010-019912-18,en,o
18,2010-019912-18,los,o
18,2010-019912-18,6,o
18,2010-019912-18,meses,o
18,2010-019912-18,siguientes,o
18,2010-019912-18,a,o
18,2010-019912-18,la,o
18,2010-019912-18,randomizacion,i
18,2010-019912-18,Enfermedad,i
18,2010-019912-18,reumatica,i
18,2010-019912-18,autoinmune,i
18,2010-019912-18,distinta,o
18,2010-019912-18,de,o
18,2010-019912-18,AR,i
18,2010-019912-18,Se,o
18,2010-019912-18,permite,o
18,2010-019912-18,la,o
18,2010-019912-18,inclusion,o
18,2010-019912-18,de,o
18,2010-019912-18,pacientes,o
18,2010-019912-18,con,o
18,2010-019912-18,sindrome,i
18,2010-019912-18,de,i
18,2010-019912-18,Sjögren,i
18,2010-019912-18,secundario,i
18,2010-019912-18,asociado,o
18,2010-019912-18,a,o
18,2010-019912-18,AR,i
18,2010-019912-18,Clase,o
18,2010-019912-18,funcional,o
18,2010-019912-18,IV,o
18,2010-019912-18,definida,o
18,2010-019912-18,de,o
18,2010-019912-18,acuerdo,o
18,2010-019912-18,con,o
18,2010-019912-18,la,o
18,2010-019912-18,Clasificacion,o
18,2010-019912-18,del,o
18,2010-019912-18,ACR,o
18,2010-019912-18,del,o
18,2010-019912-18,Estado,o
18,2010-019912-18,Funcional,o
18,2010-019912-18,en,o
18,2010-019912-18,Artritis,i
18,2010-019912-18,Reumatoide,i
18,2010-019912-18,Artritis,i
18,2010-019912-18,idiopatica,i
18,2010-019912-18,juvenil,i
18,2010-019912-18,AIJ,i
18,2010-019912-18,o,o
18,2010-019912-18,artritis,i
18,2010-019912-18,reumatoide,i
18,2010-019912-18,juvenil,i
18,2010-019912-18,ARJ,i
18,2010-019912-18,yo,o
18,2010-019912-18,AR,i
18,2010-019912-18,diagnosticadas,i
18,2010-019912-18,antes,o
18,2010-019912-18,de,o
18,2010-019912-18,los,o
18,2010-019912-18,16,o
18,2010-019912-18,años,o
18,2010-019912-18,de,o
18,2010-019912-18,edad,o
18,2010-019912-18,Enfermedad,i
18,2010-019912-18,articular,i
18,2010-019912-18,inflamatoria,i
18,2010-019912-18,distinta,o
18,2010-019912-18,de,o
18,2010-019912-18,AR,i
18,2010-019912-18,en,o
18,2010-019912-18,el,o
18,2010-019912-18,pasado,o
18,2010-019912-18,o,o
18,2010-019912-18,en,o
18,2010-019912-18,la,o
18,2010-019912-18,actualidad,o
19,2010-019912-18,EudraCT,o
19,2010-019912-18,Nº,o
19,2010-019912-18,201001991218,o
19,2010-019912-18,Titulo,o
19,2010-019912-18,cientifico,o
19,2010-019912-18,Estudio,o
19,2010-019912-18,randomizado,o
19,2010-019912-18,doble,o
19,2010-019912-18,ciego,o
19,2010-019912-18,con,o
19,2010-019912-18,grupos,o
19,2010-019912-18,de,o
19,2010-019912-18,tratamiento,i
19,2010-019912-18,paralelos,o
19,2010-019912-18,para,o
19,2010-019912-18,evaluar,i
19,2010-019912-18,la,i
19,2010-019912-18,seguridad,i
19,2010-019912-18,y,o
19,2010-019912-18,el,o
19,2010-019912-18,efecto,o
19,2010-019912-18,sobre,o
19,2010-019912-18,el,o
19,2010-019912-18,resultado,o
19,2010-019912-18,clinico,o
19,2010-019912-18,de,o
19,2010-019912-18,tocilizumab,i
19,2010-019912-18,SC,o
19,2010-019912-18,frente,o
19,2010-019912-18,a,o
19,2010-019912-18,placebo,i
19,2010-019912-18,SC,o
19,2010-019912-18,en,o
19,2010-019912-18,combinacion,o
19,2010-019912-18,con,o
19,2010-019912-18,farmacos,i
19,2010-019912-18,antirreumaticos,i
19,2010-019912-18,modificadores,i
19,2010-019912-18,de,i
19,2010-019912-18,la,i
19,2010-019912-18,enfermedad,i
19,2010-019912-18,FAMEs,i
19,2010-019912-18,tradicionales,o
19,2010-019912-18,en,o
19,2010-019912-18,pacientes,o
19,2010-019912-18,con,o
19,2010-019912-18,artritis,i
19,2010-019912-18,reumatoide,i
19,2010-019912-18,activa,o
19,2010-019912-18,moderada,o
19,2010-019912-18,a,o
19,2010-019912-18,severa,o
19,2010-019912-18,Indicacion,o
19,2010-019912-18,cientifica,o
19,2010-019912-18,Artritis,i
19,2010-019912-18,Reumatoide,i
19,2010-019912-18,AR,i
19,2010-019912-18,Criterios,o
19,2010-019912-18,de,o
19,2010-019912-18,inclusion,o
19,2010-019912-18,Presentar,o
19,2010-019912-18,artritis,i
19,2010-019912-18,reumatoide,i
19,2010-019912-18,de,o
19,2010-019912-18,mayor,o
19,2010-019912-18,o,o
19,2010-019912-18,igual,o
19,2010-019912-18,a,o
19,2010-019912-18,6,o
19,2010-019912-18,meses,o
19,2010-019912-18,de,o
19,2010-019912-18,duracion,o
19,2010-019912-18,Recibir,o
19,2010-019912-18,tratamiento,i
19,2010-019912-18,de,i
19,2010-019912-18,forma,i
19,2010-019912-18,ambulatoria,i
19,2010-019912-18,Presentar,o
19,2010-019912-18,un,o
19,2010-019912-18,recuento,o
19,2010-019912-18,de,o
19,2010-019912-18,articulaciones,i
19,2010-019912-18,inflamadas,i
19,2010-019912-18,RAI,o
19,2010-019912-18,mayor,o
19,2010-019912-18,o,o
19,2010-019912-18,igual,o
19,2010-019912-18,a,o
19,2010-019912-18,6,o
19,2010-019912-18,recuento,o
19,2010-019912-18,de,o
19,2010-019912-18,66,o
19,2010-019912-18,articulaciones,i
19,2010-019912-18,y,o
19,2010-019912-18,de,o
19,2010-019912-18,articulaciones,i
19,2010-019912-18,dolorosas,i
19,2010-019912-18,RAD,o
19,2010-019912-18,mayor,o
19,2010-019912-18,o,o
19,2010-019912-18,igual,o
19,2010-019912-18,a,o
19,2010-019912-18,8,o
19,2010-019912-18,recuento,o
19,2010-019912-18,de,o
19,2010-019912-18,68,o
19,2010-019912-18,articulaciones,i
19,2010-019912-18,en,o
19,2010-019912-18,las,o
19,2010-019912-18,visitas,o
19,2010-019912-18,de,o
19,2010-019912-18,seleccion,o
19,2010-019912-18,y,o
19,2010-019912-18,basal,o
19,2010-019912-18,Los,o
19,2010-019912-18,pacientes,o
19,2010-019912-18,deben,o
19,2010-019912-18,estar,o
19,2010-019912-18,recibiendo,o
19,2010-019912-18,tratamiento,i
19,2010-019912-18,con,o
19,2010-019912-18,una,o
19,2010-019912-18,dosis,o
19,2010-019912-18,estable,o
19,2010-019912-18,de,o
19,2010-019912-18,los,o
19,2010-019912-18,FAMEs,i
19,2010-019912-18,permitidos,o
19,2010-019912-18,como,o
19,2010-019912-18,minimo,o
19,2010-019912-18,8,o
19,2010-019912-18,semanas,o
19,2010-019912-18,antes,o
19,2010-019912-18,de,o
19,2010-019912-18,la,o
19,2010-019912-18,visita,o
19,2010-019912-18,basal,o
19,2010-019912-18,Criterios,o
19,2010-019912-18,de,o
19,2010-019912-18,exclusion,o
19,2010-019912-18,Pacientes,o
19,2010-019912-18,sometidos,o
19,2010-019912-18,a,o
19,2010-019912-18,intervenciones,i
19,2010-019912-18,de,i
19,2010-019912-18,cirugia,i
19,2010-019912-18,mayor,i
19,2010-019912-18,incluyendo,o
19,2010-019912-18,cirugia,i
19,2010-019912-18,articular,i
19,2010-019912-18,en,o
19,2010-019912-18,las,o
19,2010-019912-18,8,o
19,2010-019912-18,semanas,o
19,2010-019912-18,previas,o
19,2010-019912-18,a,o
19,2010-019912-18,la,o
19,2010-019912-18,visita,o
19,2010-019912-18,de,o
19,2010-019912-18,seleccion,o
19,2010-019912-18,o,o
19,2010-019912-18,que,o
19,2010-019912-18,tengan,o
19,2010-019912-18,previsto,o
19,2010-019912-18,someterse,o
19,2010-019912-18,a,o
19,2010-019912-18,una,o
19,2010-019912-18,intervencion,i
19,2010-019912-18,de,o
19,2010-019912-18,este,o
19,2010-019912-18,tipo,o
19,2010-019912-18,en,o
19,2010-019912-18,los,o
19,2010-019912-18,6,o
19,2010-019912-18,meses,o
19,2010-019912-18,siguientes,o
19,2010-019912-18,a,o
19,2010-019912-18,la,o
19,2010-019912-18,randomizacion,i
19,2010-019912-18,Enfermedad,i
19,2010-019912-18,reumatica,i
19,2010-019912-18,autoinmune,i
19,2010-019912-18,distinta,o
19,2010-019912-18,de,o
19,2010-019912-18,AR,i
19,2010-019912-18,Se,o
19,2010-019912-18,permite,o
19,2010-019912-18,la,o
19,2010-019912-18,inclusion,o
19,2010-019912-18,de,o
19,2010-019912-18,pacientes,o
19,2010-019912-18,con,o
19,2010-019912-18,sindrome,i
19,2010-019912-18,de,i
19,2010-019912-18,Sjögren,i
19,2010-019912-18,secundario,i
19,2010-019912-18,asociado,o
19,2010-019912-18,a,o
19,2010-019912-18,AR,i
19,2010-019912-18,Clase,o
19,2010-019912-18,funcional,o
19,2010-019912-18,IV,o
19,2010-019912-18,definida,o
19,2010-019912-18,de,o
19,2010-019912-18,acuerdo,o
19,2010-019912-18,con,o
19,2010-019912-18,la,o
19,2010-019912-18,Clasificacion,o
19,2010-019912-18,del,o
19,2010-019912-18,ACR,o
19,2010-019912-18,del,o
19,2010-019912-18,Estado,o
19,2010-019912-18,Funcional,o
19,2010-019912-18,en,o
19,2010-019912-18,Artritis,i
19,2010-019912-18,Reumatoide,i
19,2010-019912-18,Artritis,i
19,2010-019912-18,idiopatica,i
19,2010-019912-18,juvenil,i
19,2010-019912-18,AIJ,i
19,2010-019912-18,o,o
19,2010-019912-18,artritis,i
19,2010-019912-18,reumatoide,i
19,2010-019912-18,juvenil,i
19,2010-019912-18,ARJ,i
19,2010-019912-18,yo,o
19,2010-019912-18,AR,i
19,2010-019912-18,diagnosticadas,i
19,2010-019912-18,antes,o
19,2010-019912-18,de,o
19,2010-019912-18,los,o
19,2010-019912-18,16,o
19,2010-019912-18,años,o
19,2010-019912-18,de,o
19,2010-019912-18,edad,o
19,2010-019912-18,Enfermedad,i
19,2010-019912-18,articular,i
19,2010-019912-18,inflamatoria,i
19,2010-019912-18,distinta,o
19,2010-019912-18,de,o
19,2010-019912-18,AR,i
19,2010-019912-18,en,o
19,2010-019912-18,el,o
19,2010-019912-18,pasado,o
19,2010-019912-18,o,o
19,2010-019912-18,en,o
19,2010-019912-18,la,o
19,2010-019912-18,actualidad,o
20,2010-019912-18,EudraCT,o
20,2010-019912-18,Nº,o
20,2010-019912-18,201001991218,o
20,2010-019912-18,Titulo,o
20,2010-019912-18,cientifico,o
20,2010-019912-18,Estudio,o
20,2010-019912-18,randomizado,o
20,2010-019912-18,doble,o
20,2010-019912-18,ciego,o
20,2010-019912-18,con,o
20,2010-019912-18,grupos,o
20,2010-019912-18,de,o
20,2010-019912-18,tratamiento,i
20,2010-019912-18,paralelos,o
20,2010-019912-18,para,o
20,2010-019912-18,evaluar,i
20,2010-019912-18,la,i
20,2010-019912-18,seguridad,i
20,2010-019912-18,y,o
20,2010-019912-18,el,o
20,2010-019912-18,efecto,o
20,2010-019912-18,sobre,o
20,2010-019912-18,el,o
20,2010-019912-18,resultado,o
20,2010-019912-18,clinico,o
20,2010-019912-18,de,o
20,2010-019912-18,tocilizumab,i
20,2010-019912-18,SC,o
20,2010-019912-18,frente,o
20,2010-019912-18,a,o
20,2010-019912-18,placebo,i
20,2010-019912-18,SC,o
20,2010-019912-18,en,o
20,2010-019912-18,combinacion,o
20,2010-019912-18,con,o
20,2010-019912-18,farmacos,i
20,2010-019912-18,antirreumaticos,i
20,2010-019912-18,modificadores,i
20,2010-019912-18,de,i
20,2010-019912-18,la,i
20,2010-019912-18,enfermedad,i
20,2010-019912-18,FAMEs,i
20,2010-019912-18,tradicionales,o
20,2010-019912-18,en,o
20,2010-019912-18,pacientes,o
20,2010-019912-18,con,o
20,2010-019912-18,artritis,i
20,2010-019912-18,reumatoide,i
20,2010-019912-18,activa,o
20,2010-019912-18,moderada,o
20,2010-019912-18,a,o
20,2010-019912-18,severa,o
20,2010-019912-18,Indicacion,o
20,2010-019912-18,cientifica,o
20,2010-019912-18,Artritis,i
20,2010-019912-18,Reumatoide,i
20,2010-019912-18,AR,i
20,2010-019912-18,Criterios,o
20,2010-019912-18,de,o
20,2010-019912-18,inclusion,o
20,2010-019912-18,Presentar,o
20,2010-019912-18,artritis,i
20,2010-019912-18,reumatoide,i
20,2010-019912-18,de,o
20,2010-019912-18,mayor,o
20,2010-019912-18,o,o
20,2010-019912-18,igual,o
20,2010-019912-18,a,o
20,2010-019912-18,6,o
20,2010-019912-18,meses,o
20,2010-019912-18,de,o
20,2010-019912-18,duracion,o
20,2010-019912-18,Recibir,o
20,2010-019912-18,tratamiento,i
20,2010-019912-18,de,i
20,2010-019912-18,forma,i
20,2010-019912-18,ambulatoria,i
20,2010-019912-18,Presentar,o
20,2010-019912-18,un,o
20,2010-019912-18,recuento,o
20,2010-019912-18,de,o
20,2010-019912-18,articulaciones,i
20,2010-019912-18,inflamadas,i
20,2010-019912-18,RAI,o
20,2010-019912-18,mayor,o
20,2010-019912-18,o,o
20,2010-019912-18,igual,o
20,2010-019912-18,a,o
20,2010-019912-18,6,o
20,2010-019912-18,recuento,o
20,2010-019912-18,de,o
20,2010-019912-18,66,o
20,2010-019912-18,articulaciones,i
20,2010-019912-18,y,o
20,2010-019912-18,de,o
20,2010-019912-18,articulaciones,i
20,2010-019912-18,dolorosas,i
20,2010-019912-18,RAD,o
20,2010-019912-18,mayor,o
20,2010-019912-18,o,o
20,2010-019912-18,igual,o
20,2010-019912-18,a,o
20,2010-019912-18,8,o
20,2010-019912-18,recuento,o
20,2010-019912-18,de,o
20,2010-019912-18,68,o
20,2010-019912-18,articulaciones,i
20,2010-019912-18,en,o
20,2010-019912-18,las,o
20,2010-019912-18,visitas,o
20,2010-019912-18,de,o
20,2010-019912-18,seleccion,o
20,2010-019912-18,y,o
20,2010-019912-18,basal,o
20,2010-019912-18,Los,o
20,2010-019912-18,pacientes,o
20,2010-019912-18,deben,o
20,2010-019912-18,estar,o
20,2010-019912-18,recibiendo,o
20,2010-019912-18,tratamiento,i
20,2010-019912-18,con,o
20,2010-019912-18,una,o
20,2010-019912-18,dosis,o
20,2010-019912-18,estable,o
20,2010-019912-18,de,o
20,2010-019912-18,los,o
20,2010-019912-18,FAMEs,i
20,2010-019912-18,permitidos,o
20,2010-019912-18,como,o
20,2010-019912-18,minimo,o
20,2010-019912-18,8,o
20,2010-019912-18,semanas,o
20,2010-019912-18,antes,o
20,2010-019912-18,de,o
20,2010-019912-18,la,o
20,2010-019912-18,visita,o
20,2010-019912-18,basal,o
20,2010-019912-18,Criterios,o
20,2010-019912-18,de,o
20,2010-019912-18,exclusion,o
20,2010-019912-18,Pacientes,o
20,2010-019912-18,sometidos,o
20,2010-019912-18,a,o
20,2010-019912-18,intervenciones,i
20,2010-019912-18,de,i
20,2010-019912-18,cirugia,i
20,2010-019912-18,mayor,i
20,2010-019912-18,incluyendo,o
20,2010-019912-18,cirugia,i
20,2010-019912-18,articular,i
20,2010-019912-18,en,o
20,2010-019912-18,las,o
20,2010-019912-18,8,o
20,2010-019912-18,semanas,o
20,2010-019912-18,previas,o
20,2010-019912-18,a,o
20,2010-019912-18,la,o
20,2010-019912-18,visita,o
20,2010-019912-18,de,o
20,2010-019912-18,seleccion,o
20,2010-019912-18,o,o
20,2010-019912-18,que,o
20,2010-019912-18,tengan,o
20,2010-019912-18,previsto,o
20,2010-019912-18,someterse,o
20,2010-019912-18,a,o
20,2010-019912-18,una,o
20,2010-019912-18,intervencion,i
20,2010-019912-18,de,o
20,2010-019912-18,este,o
20,2010-019912-18,tipo,o
20,2010-019912-18,en,o
20,2010-019912-18,los,o
20,2010-019912-18,6,o
20,2010-019912-18,meses,o
20,2010-019912-18,siguientes,o
20,2010-019912-18,a,o
20,2010-019912-18,la,o
20,2010-019912-18,randomizacion,i
20,2010-019912-18,Enfermedad,i
20,2010-019912-18,reumatica,i
20,2010-019912-18,autoinmune,i
20,2010-019912-18,distinta,o
20,2010-019912-18,de,o
20,2010-019912-18,AR,i
20,2010-019912-18,Se,o
20,2010-019912-18,permite,o
20,2010-019912-18,la,o
20,2010-019912-18,inclusion,o
20,2010-019912-18,de,o
20,2010-019912-18,pacientes,o
20,2010-019912-18,con,o
20,2010-019912-18,sindrome,i
20,2010-019912-18,de,i
20,2010-019912-18,Sjögren,i
20,2010-019912-18,secundario,i
20,2010-019912-18,asociado,o
20,2010-019912-18,a,o
20,2010-019912-18,AR,i
20,2010-019912-18,Clase,o
20,2010-019912-18,funcional,o
20,2010-019912-18,IV,o
20,2010-019912-18,definida,o
20,2010-019912-18,de,o
20,2010-019912-18,acuerdo,o
20,2010-019912-18,con,o
20,2010-019912-18,la,o
20,2010-019912-18,Clasificacion,o
20,2010-019912-18,del,o
20,2010-019912-18,ACR,o
20,2010-019912-18,del,o
20,2010-019912-18,Estado,o
20,2010-019912-18,Funcional,o
20,2010-019912-18,en,o
20,2010-019912-18,Artritis,i
20,2010-019912-18,Reumatoide,i
20,2010-019912-18,Artritis,i
20,2010-019912-18,idiopatica,i
20,2010-019912-18,juvenil,i
20,2010-019912-18,AIJ,i
20,2010-019912-18,o,o
20,2010-019912-18,artritis,i
20,2010-019912-18,reumatoide,i
20,2010-019912-18,juvenil,i
20,2010-019912-18,ARJ,i
20,2010-019912-18,yo,o
20,2010-019912-18,AR,i
20,2010-019912-18,diagnosticadas,i
20,2010-019912-18,antes,o
20,2010-019912-18,de,o
20,2010-019912-18,los,o
20,2010-019912-18,16,o
20,2010-019912-18,años,o
20,2010-019912-18,de,o
20,2010-019912-18,edad,o
20,2010-019912-18,Enfermedad,i
20,2010-019912-18,articular,i
20,2010-019912-18,inflamatoria,i
20,2010-019912-18,distinta,o
20,2010-019912-18,de,o
20,2010-019912-18,AR,i
20,2010-019912-18,en,o
20,2010-019912-18,el,o
20,2010-019912-18,pasado,o
20,2010-019912-18,o,o
20,2010-019912-18,en,o
20,2010-019912-18,la,o
20,2010-019912-18,actualidad,o
21,2010-019912-18,EudraCT,o
21,2010-019912-18,Nº,o
21,2010-019912-18,201001991218,o
21,2010-019912-18,Titulo,o
21,2010-019912-18,cientifico,o
21,2010-019912-18,Estudio,o
21,2010-019912-18,randomizado,o
21,2010-019912-18,doble,o
21,2010-019912-18,ciego,o
21,2010-019912-18,con,o
21,2010-019912-18,grupos,o
21,2010-019912-18,de,o
21,2010-019912-18,tratamiento,i
21,2010-019912-18,paralelos,o
21,2010-019912-18,para,o
21,2010-019912-18,evaluar,i
21,2010-019912-18,la,i
21,2010-019912-18,seguridad,i
21,2010-019912-18,y,o
21,2010-019912-18,el,o
21,2010-019912-18,efecto,o
21,2010-019912-18,sobre,o
21,2010-019912-18,el,o
21,2010-019912-18,resultado,o
21,2010-019912-18,clinico,o
21,2010-019912-18,de,o
21,2010-019912-18,tocilizumab,i
21,2010-019912-18,SC,o
21,2010-019912-18,frente,o
21,2010-019912-18,a,o
21,2010-019912-18,placebo,i
21,2010-019912-18,SC,o
21,2010-019912-18,en,o
21,2010-019912-18,combinacion,o
21,2010-019912-18,con,o
21,2010-019912-18,farmacos,i
21,2010-019912-18,antirreumaticos,i
21,2010-019912-18,modificadores,i
21,2010-019912-18,de,i
21,2010-019912-18,la,i
21,2010-019912-18,enfermedad,i
21,2010-019912-18,FAMEs,i
21,2010-019912-18,tradicionales,o
21,2010-019912-18,en,o
21,2010-019912-18,pacientes,o
21,2010-019912-18,con,o
21,2010-019912-18,artritis,i
21,2010-019912-18,reumatoide,i
21,2010-019912-18,activa,o
21,2010-019912-18,moderada,o
21,2010-019912-18,a,o
21,2010-019912-18,severa,o
21,2010-019912-18,Indicacion,o
21,2010-019912-18,cientifica,o
21,2010-019912-18,Artritis,i
21,2010-019912-18,Reumatoide,i
21,2010-019912-18,AR,i
21,2010-019912-18,Criterios,o
21,2010-019912-18,de,o
21,2010-019912-18,inclusion,o
21,2010-019912-18,Presentar,o
21,2010-019912-18,artritis,i
21,2010-019912-18,reumatoide,i
21,2010-019912-18,de,o
21,2010-019912-18,mayor,o
21,2010-019912-18,o,o
21,2010-019912-18,igual,o
21,2010-019912-18,a,o
21,2010-019912-18,6,o
21,2010-019912-18,meses,o
21,2010-019912-18,de,o
21,2010-019912-18,duracion,o
21,2010-019912-18,Recibir,o
21,2010-019912-18,tratamiento,i
21,2010-019912-18,de,i
21,2010-019912-18,forma,i
21,2010-019912-18,ambulatoria,i
21,2010-019912-18,Presentar,o
21,2010-019912-18,un,o
21,2010-019912-18,recuento,o
21,2010-019912-18,de,o
21,2010-019912-18,articulaciones,i
21,2010-019912-18,inflamadas,i
21,2010-019912-18,RAI,o
21,2010-019912-18,mayor,o
21,2010-019912-18,o,o
21,2010-019912-18,igual,o
21,2010-019912-18,a,o
21,2010-019912-18,6,o
21,2010-019912-18,recuento,o
21,2010-019912-18,de,o
21,2010-019912-18,66,o
21,2010-019912-18,articulaciones,i
21,2010-019912-18,y,o
21,2010-019912-18,de,o
21,2010-019912-18,articulaciones,i
21,2010-019912-18,dolorosas,i
21,2010-019912-18,RAD,o
21,2010-019912-18,mayor,o
21,2010-019912-18,o,o
21,2010-019912-18,igual,o
21,2010-019912-18,a,o
21,2010-019912-18,8,o
21,2010-019912-18,recuento,o
21,2010-019912-18,de,o
21,2010-019912-18,68,o
21,2010-019912-18,articulaciones,i
21,2010-019912-18,en,o
21,2010-019912-18,las,o
21,2010-019912-18,visitas,o
21,2010-019912-18,de,o
21,2010-019912-18,seleccion,o
21,2010-019912-18,y,o
21,2010-019912-18,basal,o
21,2010-019912-18,Los,o
21,2010-019912-18,pacientes,o
21,2010-019912-18,deben,o
21,2010-019912-18,estar,o
21,2010-019912-18,recibiendo,o
21,2010-019912-18,tratamiento,i
21,2010-019912-18,con,o
21,2010-019912-18,una,o
21,2010-019912-18,dosis,o
21,2010-019912-18,estable,o
21,2010-019912-18,de,o
21,2010-019912-18,los,o
21,2010-019912-18,FAMEs,i
21,2010-019912-18,permitidos,o
21,2010-019912-18,como,o
21,2010-019912-18,minimo,o
21,2010-019912-18,8,o
21,2010-019912-18,semanas,o
21,2010-019912-18,antes,o
21,2010-019912-18,de,o
21,2010-019912-18,la,o
21,2010-019912-18,visita,o
21,2010-019912-18,basal,o
21,2010-019912-18,Criterios,o
21,2010-019912-18,de,o
21,2010-019912-18,exclusion,o
21,2010-019912-18,Pacientes,o
21,2010-019912-18,sometidos,o
21,2010-019912-18,a,o
21,2010-019912-18,intervenciones,i
21,2010-019912-18,de,i
21,2010-019912-18,cirugia,i
21,2010-019912-18,mayor,i
21,2010-019912-18,incluyendo,o
21,2010-019912-18,cirugia,i
21,2010-019912-18,articular,i
21,2010-019912-18,en,o
21,2010-019912-18,las,o
21,2010-019912-18,8,o
21,2010-019912-18,semanas,o
21,2010-019912-18,previas,o
21,2010-019912-18,a,o
21,2010-019912-18,la,o
21,2010-019912-18,visita,o
21,2010-019912-18,de,o
21,2010-019912-18,seleccion,o
21,2010-019912-18,o,o
21,2010-019912-18,que,o
21,2010-019912-18,tengan,o
21,2010-019912-18,previsto,o
21,2010-019912-18,someterse,o
21,2010-019912-18,a,o
21,2010-019912-18,una,o
21,2010-019912-18,intervencion,i
21,2010-019912-18,de,o
21,2010-019912-18,este,o
21,2010-019912-18,tipo,o
21,2010-019912-18,en,o
21,2010-019912-18,los,o
21,2010-019912-18,6,o
21,2010-019912-18,meses,o
21,2010-019912-18,siguientes,o
21,2010-019912-18,a,o
21,2010-019912-18,la,o
21,2010-019912-18,randomizacion,i
21,2010-019912-18,Enfermedad,i
21,2010-019912-18,reumatica,i
21,2010-019912-18,autoinmune,i
21,2010-019912-18,distinta,o
21,2010-019912-18,de,o
21,2010-019912-18,AR,i
21,2010-019912-18,Se,o
21,2010-019912-18,permite,o
21,2010-019912-18,la,o
21,2010-019912-18,inclusion,o
21,2010-019912-18,de,o
21,2010-019912-18,pacientes,o
21,2010-019912-18,con,o
21,2010-019912-18,sindrome,i
21,2010-019912-18,de,i
21,2010-019912-18,Sjögren,i
21,2010-019912-18,secundario,i
21,2010-019912-18,asociado,o
21,2010-019912-18,a,o
21,2010-019912-18,AR,i
21,2010-019912-18,Clase,o
21,2010-019912-18,funcional,o
21,2010-019912-18,IV,o
21,2010-019912-18,definida,o
21,2010-019912-18,de,o
21,2010-019912-18,acuerdo,o
21,2010-019912-18,con,o
21,2010-019912-18,la,o
21,2010-019912-18,Clasificacion,o
21,2010-019912-18,del,o
21,2010-019912-18,ACR,o
21,2010-019912-18,del,o
21,2010-019912-18,Estado,o
21,2010-019912-18,Funcional,o
21,2010-019912-18,en,o
21,2010-019912-18,Artritis,i
21,2010-019912-18,Reumatoide,i
21,2010-019912-18,Artritis,i
21,2010-019912-18,idiopatica,i
21,2010-019912-18,juvenil,i
21,2010-019912-18,AIJ,i
21,2010-019912-18,o,o
21,2010-019912-18,artritis,i
21,2010-019912-18,reumatoide,i
21,2010-019912-18,juvenil,i
21,2010-019912-18,ARJ,i
21,2010-019912-18,yo,o
21,2010-019912-18,AR,i
21,2010-019912-18,diagnosticadas,i
21,2010-019912-18,antes,o
21,2010-019912-18,de,o
21,2010-019912-18,los,o
21,2010-019912-18,16,o
21,2010-019912-18,años,o
21,2010-019912-18,de,o
21,2010-019912-18,edad,o
21,2010-019912-18,Enfermedad,i
21,2010-019912-18,articular,i
21,2010-019912-18,inflamatoria,i
21,2010-019912-18,distinta,o
21,2010-019912-18,de,o
21,2010-019912-18,AR,i
21,2010-019912-18,en,o
21,2010-019912-18,el,o
21,2010-019912-18,pasado,o
21,2010-019912-18,o,o
21,2010-019912-18,en,o
21,2010-019912-18,la,o
21,2010-019912-18,actualidad,o
22,2010-019912-18,EudraCT,o
22,2010-019912-18,Nº,o
22,2010-019912-18,201001991218,o
22,2010-019912-18,Titulo,o
22,2010-019912-18,cientifico,o
22,2010-019912-18,Estudio,o
22,2010-019912-18,randomizado,o
22,2010-019912-18,doble,o
22,2010-019912-18,ciego,o
22,2010-019912-18,con,o
22,2010-019912-18,grupos,o
22,2010-019912-18,de,o
22,2010-019912-18,tratamiento,i
22,2010-019912-18,paralelos,o
22,2010-019912-18,para,o
22,2010-019912-18,evaluar,i
22,2010-019912-18,la,i
22,2010-019912-18,seguridad,i
22,2010-019912-18,y,o
22,2010-019912-18,el,o
22,2010-019912-18,efecto,o
22,2010-019912-18,sobre,o
22,2010-019912-18,el,o
22,2010-019912-18,resultado,o
22,2010-019912-18,clinico,o
22,2010-019912-18,de,o
22,2010-019912-18,tocilizumab,i
22,2010-019912-18,SC,o
22,2010-019912-18,frente,o
22,2010-019912-18,a,o
22,2010-019912-18,placebo,i
22,2010-019912-18,SC,o
22,2010-019912-18,en,o
22,2010-019912-18,combinacion,o
22,2010-019912-18,con,o
22,2010-019912-18,farmacos,i
22,2010-019912-18,antirreumaticos,i
22,2010-019912-18,modificadores,i
22,2010-019912-18,de,i
22,2010-019912-18,la,i
22,2010-019912-18,enfermedad,i
22,2010-019912-18,FAMEs,i
22,2010-019912-18,tradicionales,o
22,2010-019912-18,en,o
22,2010-019912-18,pacientes,o
22,2010-019912-18,con,o
22,2010-019912-18,artritis,i
22,2010-019912-18,reumatoide,i
22,2010-019912-18,activa,o
22,2010-019912-18,moderada,o
22,2010-019912-18,a,o
22,2010-019912-18,severa,o
22,2010-019912-18,Indicacion,o
22,2010-019912-18,cientifica,o
22,2010-019912-18,Artritis,i
22,2010-019912-18,Reumatoide,i
22,2010-019912-18,AR,i
22,2010-019912-18,Criterios,o
22,2010-019912-18,de,o
22,2010-019912-18,inclusion,o
22,2010-019912-18,Presentar,o
22,2010-019912-18,artritis,i
22,2010-019912-18,reumatoide,i
22,2010-019912-18,de,o
22,2010-019912-18,mayor,o
22,2010-019912-18,o,o
22,2010-019912-18,igual,o
22,2010-019912-18,a,o
22,2010-019912-18,6,o
22,2010-019912-18,meses,o
22,2010-019912-18,de,o
22,2010-019912-18,duracion,o
22,2010-019912-18,Recibir,o
22,2010-019912-18,tratamiento,i
22,2010-019912-18,de,i
22,2010-019912-18,forma,i
22,2010-019912-18,ambulatoria,i
22,2010-019912-18,Presentar,o
22,2010-019912-18,un,o
22,2010-019912-18,recuento,o
22,2010-019912-18,de,o
22,2010-019912-18,articulaciones,i
22,2010-019912-18,inflamadas,i
22,2010-019912-18,RAI,o
22,2010-019912-18,mayor,o
22,2010-019912-18,o,o
22,2010-019912-18,igual,o
22,2010-019912-18,a,o
22,2010-019912-18,6,o
22,2010-019912-18,recuento,o
22,2010-019912-18,de,o
22,2010-019912-18,66,o
22,2010-019912-18,articulaciones,i
22,2010-019912-18,y,o
22,2010-019912-18,de,o
22,2010-019912-18,articulaciones,i
22,2010-019912-18,dolorosas,i
22,2010-019912-18,RAD,o
22,2010-019912-18,mayor,o
22,2010-019912-18,o,o
22,2010-019912-18,igual,o
22,2010-019912-18,a,o
22,2010-019912-18,8,o
22,2010-019912-18,recuento,o
22,2010-019912-18,de,o
22,2010-019912-18,68,o
22,2010-019912-18,articulaciones,i
22,2010-019912-18,en,o
22,2010-019912-18,las,o
22,2010-019912-18,visitas,o
22,2010-019912-18,de,o
22,2010-019912-18,seleccion,o
22,2010-019912-18,y,o
22,2010-019912-18,basal,o
22,2010-019912-18,Los,o
22,2010-019912-18,pacientes,o
22,2010-019912-18,deben,o
22,2010-019912-18,estar,o
22,2010-019912-18,recibiendo,o
22,2010-019912-18,tratamiento,i
22,2010-019912-18,con,o
22,2010-019912-18,una,o
22,2010-019912-18,dosis,o
22,2010-019912-18,estable,o
22,2010-019912-18,de,o
22,2010-019912-18,los,o
22,2010-019912-18,FAMEs,i
22,2010-019912-18,permitidos,o
22,2010-019912-18,como,o
22,2010-019912-18,minimo,o
22,2010-019912-18,8,o
22,2010-019912-18,semanas,o
22,2010-019912-18,antes,o
22,2010-019912-18,de,o
22,2010-019912-18,la,o
22,2010-019912-18,visita,o
22,2010-019912-18,basal,o
22,2010-019912-18,Criterios,o
22,2010-019912-18,de,o
22,2010-019912-18,exclusion,o
22,2010-019912-18,Pacientes,o
22,2010-019912-18,sometidos,o
22,2010-019912-18,a,o
22,2010-019912-18,intervenciones,i
22,2010-019912-18,de,i
22,2010-019912-18,cirugia,i
22,2010-019912-18,mayor,i
22,2010-019912-18,incluyendo,o
22,2010-019912-18,cirugia,i
22,2010-019912-18,articular,i
22,2010-019912-18,en,o
22,2010-019912-18,las,o
22,2010-019912-18,8,o
22,2010-019912-18,semanas,o
22,2010-019912-18,previas,o
22,2010-019912-18,a,o
22,2010-019912-18,la,o
22,2010-019912-18,visita,o
22,2010-019912-18,de,o
22,2010-019912-18,seleccion,o
22,2010-019912-18,o,o
22,2010-019912-18,que,o
22,2010-019912-18,tengan,o
22,2010-019912-18,previsto,o
22,2010-019912-18,someterse,o
22,2010-019912-18,a,o
22,2010-019912-18,una,o
22,2010-019912-18,intervencion,i
22,2010-019912-18,de,o
22,2010-019912-18,este,o
22,2010-019912-18,tipo,o
22,2010-019912-18,en,o
22,2010-019912-18,los,o
22,2010-019912-18,6,o
22,2010-019912-18,meses,o
22,2010-019912-18,siguientes,o
22,2010-019912-18,a,o
22,2010-019912-18,la,o
22,2010-019912-18,randomizacion,i
22,2010-019912-18,Enfermedad,i
22,2010-019912-18,reumatica,i
22,2010-019912-18,autoinmune,i
22,2010-019912-18,distinta,o
22,2010-019912-18,de,o
22,2010-019912-18,AR,i
22,2010-019912-18,Se,o
22,2010-019912-18,permite,o
22,2010-019912-18,la,o
22,2010-019912-18,inclusion,o
22,2010-019912-18,de,o
22,2010-019912-18,pacientes,o
22,2010-019912-18,con,o
22,2010-019912-18,sindrome,i
22,2010-019912-18,de,i
22,2010-019912-18,Sjögren,i
22,2010-019912-18,secundario,i
22,2010-019912-18,asociado,o
22,2010-019912-18,a,o
22,2010-019912-18,AR,i
22,2010-019912-18,Clase,o
22,2010-019912-18,funcional,o
22,2010-019912-18,IV,o
22,2010-019912-18,definida,o
22,2010-019912-18,de,o
22,2010-019912-18,acuerdo,o
22,2010-019912-18,con,o
22,2010-019912-18,la,o
22,2010-019912-18,Clasificacion,o
22,2010-019912-18,del,o
22,2010-019912-18,ACR,o
22,2010-019912-18,del,o
22,2010-019912-18,Estado,o
22,2010-019912-18,Funcional,o
22,2010-019912-18,en,o
22,2010-019912-18,Artritis,i
22,2010-019912-18,Reumatoide,i
22,2010-019912-18,Artritis,i
22,2010-019912-18,idiopatica,i
22,2010-019912-18,juvenil,i
22,2010-019912-18,AIJ,i
22,2010-019912-18,o,o
22,2010-019912-18,artritis,i
22,2010-019912-18,reumatoide,i
22,2010-019912-18,juvenil,i
22,2010-019912-18,ARJ,i
22,2010-019912-18,yo,o
22,2010-019912-18,AR,i
22,2010-019912-18,diagnosticadas,i
22,2010-019912-18,antes,o
22,2010-019912-18,de,o
22,2010-019912-18,los,o
22,2010-019912-18,16,o
22,2010-019912-18,años,o
22,2010-019912-18,de,o
22,2010-019912-18,edad,o
22,2010-019912-18,Enfermedad,i
22,2010-019912-18,articular,i
22,2010-019912-18,inflamatoria,i
22,2010-019912-18,distinta,o
22,2010-019912-18,de,o
22,2010-019912-18,AR,i
22,2010-019912-18,en,o
22,2010-019912-18,el,o
22,2010-019912-18,pasado,o
22,2010-019912-18,o,o
22,2010-019912-18,en,o
22,2010-019912-18,la,o
22,2010-019912-18,actualidad,o
23,2010-019912-18,EudraCT,o
23,2010-019912-18,Nº,o
23,2010-019912-18,201001991218,o
23,2010-019912-18,Titulo,o
23,2010-019912-18,cientifico,o
23,2010-019912-18,Estudio,o
23,2010-019912-18,randomizado,o
23,2010-019912-18,doble,o
23,2010-019912-18,ciego,o
23,2010-019912-18,con,o
23,2010-019912-18,grupos,o
23,2010-019912-18,de,o
23,2010-019912-18,tratamiento,i
23,2010-019912-18,paralelos,o
23,2010-019912-18,para,o
23,2010-019912-18,evaluar,i
23,2010-019912-18,la,i
23,2010-019912-18,seguridad,i
23,2010-019912-18,y,o
23,2010-019912-18,el,o
23,2010-019912-18,efecto,o
23,2010-019912-18,sobre,o
23,2010-019912-18,el,o
23,2010-019912-18,resultado,o
23,2010-019912-18,clinico,o
23,2010-019912-18,de,o
23,2010-019912-18,tocilizumab,i
23,2010-019912-18,SC,o
23,2010-019912-18,frente,o
23,2010-019912-18,a,o
23,2010-019912-18,placebo,i
23,2010-019912-18,SC,o
23,2010-019912-18,en,o
23,2010-019912-18,combinacion,o
23,2010-019912-18,con,o
23,2010-019912-18,farmacos,i
23,2010-019912-18,antirreumaticos,i
23,2010-019912-18,modificadores,i
23,2010-019912-18,de,i
23,2010-019912-18,la,i
23,2010-019912-18,enfermedad,i
23,2010-019912-18,FAMEs,i
23,2010-019912-18,tradicionales,o
23,2010-019912-18,en,o
23,2010-019912-18,pacientes,o
23,2010-019912-18,con,o
23,2010-019912-18,artritis,i
23,2010-019912-18,reumatoide,i
23,2010-019912-18,activa,o
23,2010-019912-18,moderada,o
23,2010-019912-18,a,o
23,2010-019912-18,severa,o
23,2010-019912-18,Indicacion,o
23,2010-019912-18,cientifica,o
23,2010-019912-18,Artritis,i
23,2010-019912-18,Reumatoide,i
23,2010-019912-18,AR,i
23,2010-019912-18,Criterios,o
23,2010-019912-18,de,o
23,2010-019912-18,inclusion,o
23,2010-019912-18,Presentar,o
23,2010-019912-18,artritis,i
23,2010-019912-18,reumatoide,i
23,2010-019912-18,de,o
23,2010-019912-18,mayor,o
23,2010-019912-18,o,o
23,2010-019912-18,igual,o
23,2010-019912-18,a,o
23,2010-019912-18,6,o
23,2010-019912-18,meses,o
23,2010-019912-18,de,o
23,2010-019912-18,duracion,o
23,2010-019912-18,Recibir,o
23,2010-019912-18,tratamiento,i
23,2010-019912-18,de,i
23,2010-019912-18,forma,i
23,2010-019912-18,ambulatoria,i
23,2010-019912-18,Presentar,o
23,2010-019912-18,un,o
23,2010-019912-18,recuento,o
23,2010-019912-18,de,o
23,2010-019912-18,articulaciones,i
23,2010-019912-18,inflamadas,i
23,2010-019912-18,RAI,o
23,2010-019912-18,mayor,o
23,2010-019912-18,o,o
23,2010-019912-18,igual,o
23,2010-019912-18,a,o
23,2010-019912-18,6,o
23,2010-019912-18,recuento,o
23,2010-019912-18,de,o
23,2010-019912-18,66,o
23,2010-019912-18,articulaciones,i
23,2010-019912-18,y,o
23,2010-019912-18,de,o
23,2010-019912-18,articulaciones,i
23,2010-019912-18,dolorosas,i
23,2010-019912-18,RAD,o
23,2010-019912-18,mayor,o
23,2010-019912-18,o,o
23,2010-019912-18,igual,o
23,2010-019912-18,a,o
23,2010-019912-18,8,o
23,2010-019912-18,recuento,o
23,2010-019912-18,de,o
23,2010-019912-18,68,o
23,2010-019912-18,articulaciones,i
23,2010-019912-18,en,o
23,2010-019912-18,las,o
23,2010-019912-18,visitas,o
23,2010-019912-18,de,o
23,2010-019912-18,seleccion,o
23,2010-019912-18,y,o
23,2010-019912-18,basal,o
23,2010-019912-18,Los,o
23,2010-019912-18,pacientes,o
23,2010-019912-18,deben,o
23,2010-019912-18,estar,o
23,2010-019912-18,recibiendo,o
23,2010-019912-18,tratamiento,i
23,2010-019912-18,con,o
23,2010-019912-18,una,o
23,2010-019912-18,dosis,o
23,2010-019912-18,estable,o
23,2010-019912-18,de,o
23,2010-019912-18,los,o
23,2010-019912-18,FAMEs,i
23,2010-019912-18,permitidos,o
23,2010-019912-18,como,o
23,2010-019912-18,minimo,o
23,2010-019912-18,8,o
23,2010-019912-18,semanas,o
23,2010-019912-18,antes,o
23,2010-019912-18,de,o
23,2010-019912-18,la,o
23,2010-019912-18,visita,o
23,2010-019912-18,basal,o
23,2010-019912-18,Criterios,o
23,2010-019912-18,de,o
23,2010-019912-18,exclusion,o
23,2010-019912-18,Pacientes,o
23,2010-019912-18,sometidos,o
23,2010-019912-18,a,o
23,2010-019912-18,intervenciones,i
23,2010-019912-18,de,i
23,2010-019912-18,cirugia,i
23,2010-019912-18,mayor,i
23,2010-019912-18,incluyendo,o
23,2010-019912-18,cirugia,i
23,2010-019912-18,articular,i
23,2010-019912-18,en,o
23,2010-019912-18,las,o
23,2010-019912-18,8,o
23,2010-019912-18,semanas,o
23,2010-019912-18,previas,o
23,2010-019912-18,a,o
23,2010-019912-18,la,o
23,2010-019912-18,visita,o
23,2010-019912-18,de,o
23,2010-019912-18,seleccion,o
23,2010-019912-18,o,o
23,2010-019912-18,que,o
23,2010-019912-18,tengan,o
23,2010-019912-18,previsto,o
23,2010-019912-18,someterse,o
23,2010-019912-18,a,o
23,2010-019912-18,una,o
23,2010-019912-18,intervencion,i
23,2010-019912-18,de,o
23,2010-019912-18,este,o
23,2010-019912-18,tipo,o
23,2010-019912-18,en,o
23,2010-019912-18,los,o
23,2010-019912-18,6,o
23,2010-019912-18,meses,o
23,2010-019912-18,siguientes,o
23,2010-019912-18,a,o
23,2010-019912-18,la,o
23,2010-019912-18,randomizacion,i
23,2010-019912-18,Enfermedad,i
23,2010-019912-18,reumatica,i
23,2010-019912-18,autoinmune,i
23,2010-019912-18,distinta,o
23,2010-019912-18,de,o
23,2010-019912-18,AR,i
23,2010-019912-18,Se,o
23,2010-019912-18,permite,o
23,2010-019912-18,la,o
23,2010-019912-18,inclusion,o
23,2010-019912-18,de,o
23,2010-019912-18,pacientes,o
23,2010-019912-18,con,o
23,2010-019912-18,sindrome,i
23,2010-019912-18,de,i
23,2010-019912-18,Sjögren,i
23,2010-019912-18,secundario,i
23,2010-019912-18,asociado,o
23,2010-019912-18,a,o
23,2010-019912-18,AR,i
23,2010-019912-18,Clase,o
23,2010-019912-18,funcional,o
23,2010-019912-18,IV,o
23,2010-019912-18,definida,o
23,2010-019912-18,de,o
23,2010-019912-18,acuerdo,o
23,2010-019912-18,con,o
23,2010-019912-18,la,o
23,2010-019912-18,Clasificacion,o
23,2010-019912-18,del,o
23,2010-019912-18,ACR,o
23,2010-019912-18,del,o
23,2010-019912-18,Estado,o
23,2010-019912-18,Funcional,o
23,2010-019912-18,en,o
23,2010-019912-18,Artritis,i
23,2010-019912-18,Reumatoide,i
23,2010-019912-18,Artritis,i
23,2010-019912-18,idiopatica,i
23,2010-019912-18,juvenil,i
23,2010-019912-18,AIJ,i
23,2010-019912-18,o,o
23,2010-019912-18,artritis,i
23,2010-019912-18,reumatoide,i
23,2010-019912-18,juvenil,i
23,2010-019912-18,ARJ,i
23,2010-019912-18,yo,o
23,2010-019912-18,AR,i
23,2010-019912-18,diagnosticadas,i
23,2010-019912-18,antes,o
23,2010-019912-18,de,o
23,2010-019912-18,los,o
23,2010-019912-18,16,o
23,2010-019912-18,años,o
23,2010-019912-18,de,o
23,2010-019912-18,edad,o
23,2010-019912-18,Enfermedad,i
23,2010-019912-18,articular,i
23,2010-019912-18,inflamatoria,i
23,2010-019912-18,distinta,o
23,2010-019912-18,de,o
23,2010-019912-18,AR,i
23,2010-019912-18,en,o
23,2010-019912-18,el,o
23,2010-019912-18,pasado,o
23,2010-019912-18,o,o
23,2010-019912-18,en,o
23,2010-019912-18,la,o
23,2010-019912-18,actualidad,o
24,2010-019912-18,EudraCT,o
24,2010-019912-18,Nº,o
24,2010-019912-18,201001991218,o
24,2010-019912-18,Titulo,o
24,2010-019912-18,cientifico,o
24,2010-019912-18,Estudio,o
24,2010-019912-18,randomizado,o
24,2010-019912-18,doble,o
24,2010-019912-18,ciego,o
24,2010-019912-18,con,o
24,2010-019912-18,grupos,o
24,2010-019912-18,de,o
24,2010-019912-18,tratamiento,i
24,2010-019912-18,paralelos,o
24,2010-019912-18,para,o
24,2010-019912-18,evaluar,i
24,2010-019912-18,la,i
24,2010-019912-18,seguridad,i
24,2010-019912-18,y,o
24,2010-019912-18,el,o
24,2010-019912-18,efecto,o
24,2010-019912-18,sobre,o
24,2010-019912-18,el,o
24,2010-019912-18,resultado,o
24,2010-019912-18,clinico,o
24,2010-019912-18,de,o
24,2010-019912-18,tocilizumab,i
24,2010-019912-18,SC,o
24,2010-019912-18,frente,o
24,2010-019912-18,a,o
24,2010-019912-18,placebo,i
24,2010-019912-18,SC,o
24,2010-019912-18,en,o
24,2010-019912-18,combinacion,o
24,2010-019912-18,con,o
24,2010-019912-18,farmacos,i
24,2010-019912-18,antirreumaticos,i
24,2010-019912-18,modificadores,i
24,2010-019912-18,de,i
24,2010-019912-18,la,i
24,2010-019912-18,enfermedad,i
24,2010-019912-18,FAMEs,i
24,2010-019912-18,tradicionales,o
24,2010-019912-18,en,o
24,2010-019912-18,pacientes,o
24,2010-019912-18,con,o
24,2010-019912-18,artritis,i
24,2010-019912-18,reumatoide,i
24,2010-019912-18,activa,o
24,2010-019912-18,moderada,o
24,2010-019912-18,a,o
24,2010-019912-18,severa,o
24,2010-019912-18,Indicacion,o
24,2010-019912-18,cientifica,o
24,2010-019912-18,Artritis,i
24,2010-019912-18,Reumatoide,i
24,2010-019912-18,AR,i
24,2010-019912-18,Criterios,o
24,2010-019912-18,de,o
24,2010-019912-18,inclusion,o
24,2010-019912-18,Presentar,o
24,2010-019912-18,artritis,i
24,2010-019912-18,reumatoide,i
24,2010-019912-18,de,o
24,2010-019912-18,mayor,o
24,2010-019912-18,o,o
24,2010-019912-18,igual,o
24,2010-019912-18,a,o
24,2010-019912-18,6,o
24,2010-019912-18,meses,o
24,2010-019912-18,de,o
24,2010-019912-18,duracion,o
24,2010-019912-18,Recibir,o
24,2010-019912-18,tratamiento,i
24,2010-019912-18,de,i
24,2010-019912-18,forma,i
24,2010-019912-18,ambulatoria,i
24,2010-019912-18,Presentar,o
24,2010-019912-18,un,o
24,2010-019912-18,recuento,o
24,2010-019912-18,de,o
24,2010-019912-18,articulaciones,i
24,2010-019912-18,inflamadas,i
24,2010-019912-18,RAI,o
24,2010-019912-18,mayor,o
24,2010-019912-18,o,o
24,2010-019912-18,igual,o
24,2010-019912-18,a,o
24,2010-019912-18,6,o
24,2010-019912-18,recuento,o
24,2010-019912-18,de,o
24,2010-019912-18,66,o
24,2010-019912-18,articulaciones,i
24,2010-019912-18,y,o
24,2010-019912-18,de,o
24,2010-019912-18,articulaciones,i
24,2010-019912-18,dolorosas,i
24,2010-019912-18,RAD,o
24,2010-019912-18,mayor,o
24,2010-019912-18,o,o
24,2010-019912-18,igual,o
24,2010-019912-18,a,o
24,2010-019912-18,8,o
24,2010-019912-18,recuento,o
24,2010-019912-18,de,o
24,2010-019912-18,68,o
24,2010-019912-18,articulaciones,i
24,2010-019912-18,en,o
24,2010-019912-18,las,o
24,2010-019912-18,visitas,o
24,2010-019912-18,de,o
24,2010-019912-18,seleccion,o
24,2010-019912-18,y,o
24,2010-019912-18,basal,o
24,2010-019912-18,Los,o
24,2010-019912-18,pacientes,o
24,2010-019912-18,deben,o
24,2010-019912-18,estar,o
24,2010-019912-18,recibiendo,o
24,2010-019912-18,tratamiento,i
24,2010-019912-18,con,o
24,2010-019912-18,una,o
24,2010-019912-18,dosis,o
24,2010-019912-18,estable,o
24,2010-019912-18,de,o
24,2010-019912-18,los,o
24,2010-019912-18,FAMEs,i
24,2010-019912-18,permitidos,o
24,2010-019912-18,como,o
24,2010-019912-18,minimo,o
24,2010-019912-18,8,o
24,2010-019912-18,semanas,o
24,2010-019912-18,antes,o
24,2010-019912-18,de,o
24,2010-019912-18,la,o
24,2010-019912-18,visita,o
24,2010-019912-18,basal,o
24,2010-019912-18,Criterios,o
24,2010-019912-18,de,o
24,2010-019912-18,exclusion,o
24,2010-019912-18,Pacientes,o
24,2010-019912-18,sometidos,o
24,2010-019912-18,a,o
24,2010-019912-18,intervenciones,i
24,2010-019912-18,de,i
24,2010-019912-18,cirugia,i
24,2010-019912-18,mayor,i
24,2010-019912-18,incluyendo,o
24,2010-019912-18,cirugia,i
24,2010-019912-18,articular,i
24,2010-019912-18,en,o
24,2010-019912-18,las,o
24,2010-019912-18,8,o
24,2010-019912-18,semanas,o
24,2010-019912-18,previas,o
24,2010-019912-18,a,o
24,2010-019912-18,la,o
24,2010-019912-18,visita,o
24,2010-019912-18,de,o
24,2010-019912-18,seleccion,o
24,2010-019912-18,o,o
24,2010-019912-18,que,o
24,2010-019912-18,tengan,o
24,2010-019912-18,previsto,o
24,2010-019912-18,someterse,o
24,2010-019912-18,a,o
24,2010-019912-18,una,o
24,2010-019912-18,intervencion,i
24,2010-019912-18,de,o
24,2010-019912-18,este,o
24,2010-019912-18,tipo,o
24,2010-019912-18,en,o
24,2010-019912-18,los,o
24,2010-019912-18,6,o
24,2010-019912-18,meses,o
24,2010-019912-18,siguientes,o
24,2010-019912-18,a,o
24,2010-019912-18,la,o
24,2010-019912-18,randomizacion,i
24,2010-019912-18,Enfermedad,i
24,2010-019912-18,reumatica,i
24,2010-019912-18,autoinmune,i
24,2010-019912-18,distinta,o
24,2010-019912-18,de,o
24,2010-019912-18,AR,i
24,2010-019912-18,Se,o
24,2010-019912-18,permite,o
24,2010-019912-18,la,o
24,2010-019912-18,inclusion,o
24,2010-019912-18,de,o
24,2010-019912-18,pacientes,o
24,2010-019912-18,con,o
24,2010-019912-18,sindrome,i
24,2010-019912-18,de,i
24,2010-019912-18,Sjögren,i
24,2010-019912-18,secundario,i
24,2010-019912-18,asociado,o
24,2010-019912-18,a,o
24,2010-019912-18,AR,i
24,2010-019912-18,Clase,o
24,2010-019912-18,funcional,o
24,2010-019912-18,IV,o
24,2010-019912-18,definida,o
24,2010-019912-18,de,o
24,2010-019912-18,acuerdo,o
24,2010-019912-18,con,o
24,2010-019912-18,la,o
24,2010-019912-18,Clasificacion,o
24,2010-019912-18,del,o
24,2010-019912-18,ACR,o
24,2010-019912-18,del,o
24,2010-019912-18,Estado,o
24,2010-019912-18,Funcional,o
24,2010-019912-18,en,o
24,2010-019912-18,Artritis,i
24,2010-019912-18,Reumatoide,i
24,2010-019912-18,Artritis,i
24,2010-019912-18,idiopatica,i
24,2010-019912-18,juvenil,i
24,2010-019912-18,AIJ,i
24,2010-019912-18,o,o
24,2010-019912-18,artritis,i
24,2010-019912-18,reumatoide,i
24,2010-019912-18,juvenil,i
24,2010-019912-18,ARJ,i
24,2010-019912-18,yo,o
24,2010-019912-18,AR,i
24,2010-019912-18,diagnosticadas,i
24,2010-019912-18,antes,o
24,2010-019912-18,de,o
24,2010-019912-18,los,o
24,2010-019912-18,16,o
24,2010-019912-18,años,o
24,2010-019912-18,de,o
24,2010-019912-18,edad,o
24,2010-019912-18,Enfermedad,i
24,2010-019912-18,articular,i
24,2010-019912-18,inflamatoria,i
24,2010-019912-18,distinta,o
24,2010-019912-18,de,o
24,2010-019912-18,AR,i
24,2010-019912-18,en,o
24,2010-019912-18,el,o
24,2010-019912-18,pasado,o
24,2010-019912-18,o,o
24,2010-019912-18,en,o
24,2010-019912-18,la,o
24,2010-019912-18,actualidad,o
25,2010-019912-18,EudraCT,o
25,2010-019912-18,Nº,o
25,2010-019912-18,201001991218,o
25,2010-019912-18,Titulo,o
25,2010-019912-18,cientifico,o
25,2010-019912-18,Estudio,o
25,2010-019912-18,randomizado,o
25,2010-019912-18,doble,o
25,2010-019912-18,ciego,o
25,2010-019912-18,con,o
25,2010-019912-18,grupos,o
25,2010-019912-18,de,o
25,2010-019912-18,tratamiento,i
25,2010-019912-18,paralelos,o
25,2010-019912-18,para,o
25,2010-019912-18,evaluar,i
25,2010-019912-18,la,i
25,2010-019912-18,seguridad,i
25,2010-019912-18,y,o
25,2010-019912-18,el,o
25,2010-019912-18,efecto,o
25,2010-019912-18,sobre,o
25,2010-019912-18,el,o
25,2010-019912-18,resultado,o
25,2010-019912-18,clinico,o
25,2010-019912-18,de,o
25,2010-019912-18,tocilizumab,i
25,2010-019912-18,SC,o
25,2010-019912-18,frente,o
25,2010-019912-18,a,o
25,2010-019912-18,placebo,i
25,2010-019912-18,SC,o
25,2010-019912-18,en,o
25,2010-019912-18,combinacion,o
25,2010-019912-18,con,o
25,2010-019912-18,farmacos,i
25,2010-019912-18,antirreumaticos,i
25,2010-019912-18,modificadores,i
25,2010-019912-18,de,i
25,2010-019912-18,la,i
25,2010-019912-18,enfermedad,i
25,2010-019912-18,FAMEs,i
25,2010-019912-18,tradicionales,o
25,2010-019912-18,en,o
25,2010-019912-18,pacientes,o
25,2010-019912-18,con,o
25,2010-019912-18,artritis,i
25,2010-019912-18,reumatoide,i
25,2010-019912-18,activa,o
25,2010-019912-18,moderada,o
25,2010-019912-18,a,o
25,2010-019912-18,severa,o
25,2010-019912-18,Indicacion,o
25,2010-019912-18,cientifica,o
25,2010-019912-18,Artritis,i
25,2010-019912-18,Reumatoide,i
25,2010-019912-18,AR,i
25,2010-019912-18,Criterios,o
25,2010-019912-18,de,o
25,2010-019912-18,inclusion,o
25,2010-019912-18,Presentar,o
25,2010-019912-18,artritis,i
25,2010-019912-18,reumatoide,i
25,2010-019912-18,de,o
25,2010-019912-18,mayor,o
25,2010-019912-18,o,o
25,2010-019912-18,igual,o
25,2010-019912-18,a,o
25,2010-019912-18,6,o
25,2010-019912-18,meses,o
25,2010-019912-18,de,o
25,2010-019912-18,duracion,o
25,2010-019912-18,Recibir,o
25,2010-019912-18,tratamiento,i
25,2010-019912-18,de,i
25,2010-019912-18,forma,i
25,2010-019912-18,ambulatoria,i
25,2010-019912-18,Presentar,o
25,2010-019912-18,un,o
25,2010-019912-18,recuento,o
25,2010-019912-18,de,o
25,2010-019912-18,articulaciones,i
25,2010-019912-18,inflamadas,i
25,2010-019912-18,RAI,o
25,2010-019912-18,mayor,o
25,2010-019912-18,o,o
25,2010-019912-18,igual,o
25,2010-019912-18,a,o
25,2010-019912-18,6,o
25,2010-019912-18,recuento,o
25,2010-019912-18,de,o
25,2010-019912-18,66,o
25,2010-019912-18,articulaciones,i
25,2010-019912-18,y,o
25,2010-019912-18,de,o
25,2010-019912-18,articulaciones,i
25,2010-019912-18,dolorosas,i
25,2010-019912-18,RAD,o
25,2010-019912-18,mayor,o
25,2010-019912-18,o,o
25,2010-019912-18,igual,o
25,2010-019912-18,a,o
25,2010-019912-18,8,o
25,2010-019912-18,recuento,o
25,2010-019912-18,de,o
25,2010-019912-18,68,o
25,2010-019912-18,articulaciones,i
25,2010-019912-18,en,o
25,2010-019912-18,las,o
25,2010-019912-18,visitas,o
25,2010-019912-18,de,o
25,2010-019912-18,seleccion,o
25,2010-019912-18,y,o
25,2010-019912-18,basal,o
25,2010-019912-18,Los,o
25,2010-019912-18,pacientes,o
25,2010-019912-18,deben,o
25,2010-019912-18,estar,o
25,2010-019912-18,recibiendo,o
25,2010-019912-18,tratamiento,i
25,2010-019912-18,con,o
25,2010-019912-18,una,o
25,2010-019912-18,dosis,o
25,2010-019912-18,estable,o
25,2010-019912-18,de,o
25,2010-019912-18,los,o
25,2010-019912-18,FAMEs,i
25,2010-019912-18,permitidos,o
25,2010-019912-18,como,o
25,2010-019912-18,minimo,o
25,2010-019912-18,8,o
25,2010-019912-18,semanas,o
25,2010-019912-18,antes,o
25,2010-019912-18,de,o
25,2010-019912-18,la,o
25,2010-019912-18,visita,o
25,2010-019912-18,basal,o
25,2010-019912-18,Criterios,o
25,2010-019912-18,de,o
25,2010-019912-18,exclusion,o
25,2010-019912-18,Pacientes,o
25,2010-019912-18,sometidos,o
25,2010-019912-18,a,o
25,2010-019912-18,intervenciones,i
25,2010-019912-18,de,i
25,2010-019912-18,cirugia,i
25,2010-019912-18,mayor,i
25,2010-019912-18,incluyendo,o
25,2010-019912-18,cirugia,i
25,2010-019912-18,articular,i
25,2010-019912-18,en,o
25,2010-019912-18,las,o
25,2010-019912-18,8,o
25,2010-019912-18,semanas,o
25,2010-019912-18,previas,o
25,2010-019912-18,a,o
25,2010-019912-18,la,o
25,2010-019912-18,visita,o
25,2010-019912-18,de,o
25,2010-019912-18,seleccion,o
25,2010-019912-18,o,o
25,2010-019912-18,que,o
25,2010-019912-18,tengan,o
25,2010-019912-18,previsto,o
25,2010-019912-18,someterse,o
25,2010-019912-18,a,o
25,2010-019912-18,una,o
25,2010-019912-18,intervencion,i
25,2010-019912-18,de,o
25,2010-019912-18,este,o
25,2010-019912-18,tipo,o
25,2010-019912-18,en,o
25,2010-019912-18,los,o
25,2010-019912-18,6,o
25,2010-019912-18,meses,o
25,2010-019912-18,siguientes,o
25,2010-019912-18,a,o
25,2010-019912-18,la,o
25,2010-019912-18,randomizacion,i
25,2010-019912-18,Enfermedad,i
25,2010-019912-18,reumatica,i
25,2010-019912-18,autoinmune,i
25,2010-019912-18,distinta,o
25,2010-019912-18,de,o
25,2010-019912-18,AR,i
25,2010-019912-18,Se,o
25,2010-019912-18,permite,o
25,2010-019912-18,la,o
25,2010-019912-18,inclusion,o
25,2010-019912-18,de,o
25,2010-019912-18,pacientes,o
25,2010-019912-18,con,o
25,2010-019912-18,sindrome,i
25,2010-019912-18,de,i
25,2010-019912-18,Sjögren,i
25,2010-019912-18,secundario,i
25,2010-019912-18,asociado,o
25,2010-019912-18,a,o
25,2010-019912-18,AR,i
25,2010-019912-18,Clase,o
25,2010-019912-18,funcional,o
25,2010-019912-18,IV,o
25,2010-019912-18,definida,o
25,2010-019912-18,de,o
25,2010-019912-18,acuerdo,o
25,2010-019912-18,con,o
25,2010-019912-18,la,o
25,2010-019912-18,Clasificacion,o
25,2010-019912-18,del,o
25,2010-019912-18,ACR,o
25,2010-019912-18,del,o
25,2010-019912-18,Estado,o
25,2010-019912-18,Funcional,o
25,2010-019912-18,en,o
25,2010-019912-18,Artritis,i
25,2010-019912-18,Reumatoide,i
25,2010-019912-18,Artritis,i
25,2010-019912-18,idiopatica,i
25,2010-019912-18,juvenil,i
25,2010-019912-18,AIJ,i
25,2010-019912-18,o,o
25,2010-019912-18,artritis,i
25,2010-019912-18,reumatoide,i
25,2010-019912-18,juvenil,i
25,2010-019912-18,ARJ,i
25,2010-019912-18,yo,o
25,2010-019912-18,AR,i
25,2010-019912-18,diagnosticadas,i
25,2010-019912-18,antes,o
25,2010-019912-18,de,o
25,2010-019912-18,los,o
25,2010-019912-18,16,o
25,2010-019912-18,años,o
25,2010-019912-18,de,o
25,2010-019912-18,edad,o
25,2010-019912-18,Enfermedad,i
25,2010-019912-18,articular,i
25,2010-019912-18,inflamatoria,i
25,2010-019912-18,distinta,o
25,2010-019912-18,de,o
25,2010-019912-18,AR,i
25,2010-019912-18,en,o
25,2010-019912-18,el,o
25,2010-019912-18,pasado,o
25,2010-019912-18,o,o
25,2010-019912-18,en,o
25,2010-019912-18,la,o
25,2010-019912-18,actualidad,o
26,2010-019912-18,EudraCT,o
26,2010-019912-18,Nº,o
26,2010-019912-18,201001991218,o
26,2010-019912-18,Titulo,o
26,2010-019912-18,cientifico,o
26,2010-019912-18,Estudio,o
26,2010-019912-18,randomizado,o
26,2010-019912-18,doble,o
26,2010-019912-18,ciego,o
26,2010-019912-18,con,o
26,2010-019912-18,grupos,o
26,2010-019912-18,de,o
26,2010-019912-18,tratamiento,i
26,2010-019912-18,paralelos,o
26,2010-019912-18,para,o
26,2010-019912-18,evaluar,i
26,2010-019912-18,la,i
26,2010-019912-18,seguridad,i
26,2010-019912-18,y,o
26,2010-019912-18,el,o
26,2010-019912-18,efecto,o
26,2010-019912-18,sobre,o
26,2010-019912-18,el,o
26,2010-019912-18,resultado,o
26,2010-019912-18,clinico,o
26,2010-019912-18,de,o
26,2010-019912-18,tocilizumab,i
26,2010-019912-18,SC,o
26,2010-019912-18,frente,o
26,2010-019912-18,a,o
26,2010-019912-18,placebo,i
26,2010-019912-18,SC,o
26,2010-019912-18,en,o
26,2010-019912-18,combinacion,o
26,2010-019912-18,con,o
26,2010-019912-18,farmacos,i
26,2010-019912-18,antirreumaticos,i
26,2010-019912-18,modificadores,i
26,2010-019912-18,de,i
26,2010-019912-18,la,i
26,2010-019912-18,enfermedad,i
26,2010-019912-18,FAMEs,i
26,2010-019912-18,tradicionales,o
26,2010-019912-18,en,o
26,2010-019912-18,pacientes,o
26,2010-019912-18,con,o
26,2010-019912-18,artritis,i
26,2010-019912-18,reumatoide,i
26,2010-019912-18,activa,o
26,2010-019912-18,moderada,o
26,2010-019912-18,a,o
26,2010-019912-18,severa,o
26,2010-019912-18,Indicacion,o
26,2010-019912-18,cientifica,o
26,2010-019912-18,Artritis,i
26,2010-019912-18,Reumatoide,i
26,2010-019912-18,AR,i
26,2010-019912-18,Criterios,o
26,2010-019912-18,de,o
26,2010-019912-18,inclusion,o
26,2010-019912-18,Presentar,o
26,2010-019912-18,artritis,i
26,2010-019912-18,reumatoide,i
26,2010-019912-18,de,o
26,2010-019912-18,mayor,o
26,2010-019912-18,o,o
26,2010-019912-18,igual,o
26,2010-019912-18,a,o
26,2010-019912-18,6,o
26,2010-019912-18,meses,o
26,2010-019912-18,de,o
26,2010-019912-18,duracion,o
26,2010-019912-18,Recibir,o
26,2010-019912-18,tratamiento,i
26,2010-019912-18,de,i
26,2010-019912-18,forma,i
26,2010-019912-18,ambulatoria,i
26,2010-019912-18,Presentar,o
26,2010-019912-18,un,o
26,2010-019912-18,recuento,o
26,2010-019912-18,de,o
26,2010-019912-18,articulaciones,i
26,2010-019912-18,inflamadas,i
26,2010-019912-18,RAI,o
26,2010-019912-18,mayor,o
26,2010-019912-18,o,o
26,2010-019912-18,igual,o
26,2010-019912-18,a,o
26,2010-019912-18,6,o
26,2010-019912-18,recuento,o
26,2010-019912-18,de,o
26,2010-019912-18,66,o
26,2010-019912-18,articulaciones,i
26,2010-019912-18,y,o
26,2010-019912-18,de,o
26,2010-019912-18,articulaciones,i
26,2010-019912-18,dolorosas,i
26,2010-019912-18,RAD,o
26,2010-019912-18,mayor,o
26,2010-019912-18,o,o
26,2010-019912-18,igual,o
26,2010-019912-18,a,o
26,2010-019912-18,8,o
26,2010-019912-18,recuento,o
26,2010-019912-18,de,o
26,2010-019912-18,68,o
26,2010-019912-18,articulaciones,i
26,2010-019912-18,en,o
26,2010-019912-18,las,o
26,2010-019912-18,visitas,o
26,2010-019912-18,de,o
26,2010-019912-18,seleccion,o
26,2010-019912-18,y,o
26,2010-019912-18,basal,o
26,2010-019912-18,Los,o
26,2010-019912-18,pacientes,o
26,2010-019912-18,deben,o
26,2010-019912-18,estar,o
26,2010-019912-18,recibiendo,o
26,2010-019912-18,tratamiento,i
26,2010-019912-18,con,o
26,2010-019912-18,una,o
26,2010-019912-18,dosis,o
26,2010-019912-18,estable,o
26,2010-019912-18,de,o
26,2010-019912-18,los,o
26,2010-019912-18,FAMEs,i
26,2010-019912-18,permitidos,o
26,2010-019912-18,como,o
26,2010-019912-18,minimo,o
26,2010-019912-18,8,o
26,2010-019912-18,semanas,o
26,2010-019912-18,antes,o
26,2010-019912-18,de,o
26,2010-019912-18,la,o
26,2010-019912-18,visita,o
26,2010-019912-18,basal,o
26,2010-019912-18,Criterios,o
26,2010-019912-18,de,o
26,2010-019912-18,exclusion,o
26,2010-019912-18,Pacientes,o
26,2010-019912-18,sometidos,o
26,2010-019912-18,a,o
26,2010-019912-18,intervenciones,i
26,2010-019912-18,de,i
26,2010-019912-18,cirugia,i
26,2010-019912-18,mayor,i
26,2010-019912-18,incluyendo,o
26,2010-019912-18,cirugia,i
26,2010-019912-18,articular,i
26,2010-019912-18,en,o
26,2010-019912-18,las,o
26,2010-019912-18,8,o
26,2010-019912-18,semanas,o
26,2010-019912-18,previas,o
26,2010-019912-18,a,o
26,2010-019912-18,la,o
26,2010-019912-18,visita,o
26,2010-019912-18,de,o
26,2010-019912-18,seleccion,o
26,2010-019912-18,o,o
26,2010-019912-18,que,o
26,2010-019912-18,tengan,o
26,2010-019912-18,previsto,o
26,2010-019912-18,someterse,o
26,2010-019912-18,a,o
26,2010-019912-18,una,o
26,2010-019912-18,intervencion,i
26,2010-019912-18,de,o
26,2010-019912-18,este,o
26,2010-019912-18,tipo,o
26,2010-019912-18,en,o
26,2010-019912-18,los,o
26,2010-019912-18,6,o
26,2010-019912-18,meses,o
26,2010-019912-18,siguientes,o
26,2010-019912-18,a,o
26,2010-019912-18,la,o
26,2010-019912-18,randomizacion,i
26,2010-019912-18,Enfermedad,i
26,2010-019912-18,reumatica,i
26,2010-019912-18,autoinmune,i
26,2010-019912-18,distinta,o
26,2010-019912-18,de,o
26,2010-019912-18,AR,i
26,2010-019912-18,Se,o
26,2010-019912-18,permite,o
26,2010-019912-18,la,o
26,2010-019912-18,inclusion,o
26,2010-019912-18,de,o
26,2010-019912-18,pacientes,o
26,2010-019912-18,con,o
26,2010-019912-18,sindrome,i
26,2010-019912-18,de,i
26,2010-019912-18,Sjögren,i
26,2010-019912-18,secundario,i
26,2010-019912-18,asociado,o
26,2010-019912-18,a,o
26,2010-019912-18,AR,i
26,2010-019912-18,Clase,o
26,2010-019912-18,funcional,o
26,2010-019912-18,IV,o
26,2010-019912-18,definida,o
26,2010-019912-18,de,o
26,2010-019912-18,acuerdo,o
26,2010-019912-18,con,o
26,2010-019912-18,la,o
26,2010-019912-18,Clasificacion,o
26,2010-019912-18,del,o
26,2010-019912-18,ACR,o
26,2010-019912-18,del,o
26,2010-019912-18,Estado,o
26,2010-019912-18,Funcional,o
26,2010-019912-18,en,o
26,2010-019912-18,Artritis,i
26,2010-019912-18,Reumatoide,i
26,2010-019912-18,Artritis,i
26,2010-019912-18,idiopatica,i
26,2010-019912-18,juvenil,i
26,2010-019912-18,AIJ,i
26,2010-019912-18,o,o
26,2010-019912-18,artritis,i
26,2010-019912-18,reumatoide,i
26,2010-019912-18,juvenil,i
26,2010-019912-18,ARJ,i
26,2010-019912-18,yo,o
26,2010-019912-18,AR,i
26,2010-019912-18,diagnosticadas,i
26,2010-019912-18,antes,o
26,2010-019912-18,de,o
26,2010-019912-18,los,o
26,2010-019912-18,16,o
26,2010-019912-18,años,o
26,2010-019912-18,de,o
26,2010-019912-18,edad,o
26,2010-019912-18,Enfermedad,i
26,2010-019912-18,articular,i
26,2010-019912-18,inflamatoria,i
26,2010-019912-18,distinta,o
26,2010-019912-18,de,o
26,2010-019912-18,AR,i
26,2010-019912-18,en,o
26,2010-019912-18,el,o
26,2010-019912-18,pasado,o
26,2010-019912-18,o,o
26,2010-019912-18,en,o
26,2010-019912-18,la,o
26,2010-019912-18,actualidad,o
27,2010-019912-18,EudraCT,o
27,2010-019912-18,Nº,o
27,2010-019912-18,201001991218,o
27,2010-019912-18,Titulo,o
27,2010-019912-18,cientifico,o
27,2010-019912-18,Estudio,o
27,2010-019912-18,randomizado,o
27,2010-019912-18,doble,o
27,2010-019912-18,ciego,o
27,2010-019912-18,con,o
27,2010-019912-18,grupos,o
27,2010-019912-18,de,o
27,2010-019912-18,tratamiento,i
27,2010-019912-18,paralelos,o
27,2010-019912-18,para,o
27,2010-019912-18,evaluar,i
27,2010-019912-18,la,i
27,2010-019912-18,seguridad,i
27,2010-019912-18,y,o
27,2010-019912-18,el,o
27,2010-019912-18,efecto,o
27,2010-019912-18,sobre,o
27,2010-019912-18,el,o
27,2010-019912-18,resultado,o
27,2010-019912-18,clinico,o
27,2010-019912-18,de,o
27,2010-019912-18,tocilizumab,i
27,2010-019912-18,SC,o
27,2010-019912-18,frente,o
27,2010-019912-18,a,o
27,2010-019912-18,placebo,i
27,2010-019912-18,SC,o
27,2010-019912-18,en,o
27,2010-019912-18,combinacion,o
27,2010-019912-18,con,o
27,2010-019912-18,farmacos,i
27,2010-019912-18,antirreumaticos,i
27,2010-019912-18,modificadores,i
27,2010-019912-18,de,i
27,2010-019912-18,la,i
27,2010-019912-18,enfermedad,i
27,2010-019912-18,FAMEs,i
27,2010-019912-18,tradicionales,o
27,2010-019912-18,en,o
27,2010-019912-18,pacientes,o
27,2010-019912-18,con,o
27,2010-019912-18,artritis,i
27,2010-019912-18,reumatoide,i
27,2010-019912-18,activa,o
27,2010-019912-18,moderada,o
27,2010-019912-18,a,o
27,2010-019912-18,severa,o
27,2010-019912-18,Indicacion,o
27,2010-019912-18,cientifica,o
27,2010-019912-18,Artritis,i
27,2010-019912-18,Reumatoide,i
27,2010-019912-18,AR,i
27,2010-019912-18,Criterios,o
27,2010-019912-18,de,o
27,2010-019912-18,inclusion,o
27,2010-019912-18,Presentar,o
27,2010-019912-18,artritis,i
27,2010-019912-18,reumatoide,i
27,2010-019912-18,de,o
27,2010-019912-18,mayor,o
27,2010-019912-18,o,o
27,2010-019912-18,igual,o
27,2010-019912-18,a,o
27,2010-019912-18,6,o
27,2010-019912-18,meses,o
27,2010-019912-18,de,o
27,2010-019912-18,duracion,o
27,2010-019912-18,Recibir,o
27,2010-019912-18,tratamiento,i
27,2010-019912-18,de,i
27,2010-019912-18,forma,i
27,2010-019912-18,ambulatoria,i
27,2010-019912-18,Presentar,o
27,2010-019912-18,un,o
27,2010-019912-18,recuento,o
27,2010-019912-18,de,o
27,2010-019912-18,articulaciones,i
27,2010-019912-18,inflamadas,i
27,2010-019912-18,RAI,o
27,2010-019912-18,mayor,o
27,2010-019912-18,o,o
27,2010-019912-18,igual,o
27,2010-019912-18,a,o
27,2010-019912-18,6,o
27,2010-019912-18,recuento,o
27,2010-019912-18,de,o
27,2010-019912-18,66,o
27,2010-019912-18,articulaciones,i
27,2010-019912-18,y,o
27,2010-019912-18,de,o
27,2010-019912-18,articulaciones,i
27,2010-019912-18,dolorosas,i
27,2010-019912-18,RAD,o
27,2010-019912-18,mayor,o
27,2010-019912-18,o,o
27,2010-019912-18,igual,o
27,2010-019912-18,a,o
27,2010-019912-18,8,o
27,2010-019912-18,recuento,o
27,2010-019912-18,de,o
27,2010-019912-18,68,o
27,2010-019912-18,articulaciones,i
27,2010-019912-18,en,o
27,2010-019912-18,las,o
27,2010-019912-18,visitas,o
27,2010-019912-18,de,o
27,2010-019912-18,seleccion,o
27,2010-019912-18,y,o
27,2010-019912-18,basal,o
27,2010-019912-18,Los,o
27,2010-019912-18,pacientes,o
27,2010-019912-18,deben,o
27,2010-019912-18,estar,o
27,2010-019912-18,recibiendo,o
27,2010-019912-18,tratamiento,i
27,2010-019912-18,con,o
27,2010-019912-18,una,o
27,2010-019912-18,dosis,o
27,2010-019912-18,estable,o
27,2010-019912-18,de,o
27,2010-019912-18,los,o
27,2010-019912-18,FAMEs,i
27,2010-019912-18,permitidos,o
27,2010-019912-18,como,o
27,2010-019912-18,minimo,o
27,2010-019912-18,8,o
27,2010-019912-18,semanas,o
27,2010-019912-18,antes,o
27,2010-019912-18,de,o
27,2010-019912-18,la,o
27,2010-019912-18,visita,o
27,2010-019912-18,basal,o
27,2010-019912-18,Criterios,o
27,2010-019912-18,de,o
27,2010-019912-18,exclusion,o
27,2010-019912-18,Pacientes,o
27,2010-019912-18,sometidos,o
27,2010-019912-18,a,o
27,2010-019912-18,intervenciones,i
27,2010-019912-18,de,i
27,2010-019912-18,cirugia,i
27,2010-019912-18,mayor,i
27,2010-019912-18,incluyendo,o
27,2010-019912-18,cirugia,i
27,2010-019912-18,articular,i
27,2010-019912-18,en,o
27,2010-019912-18,las,o
27,2010-019912-18,8,o
27,2010-019912-18,semanas,o
27,2010-019912-18,previas,o
27,2010-019912-18,a,o
27,2010-019912-18,la,o
27,2010-019912-18,visita,o
27,2010-019912-18,de,o
27,2010-019912-18,seleccion,o
27,2010-019912-18,o,o
27,2010-019912-18,que,o
27,2010-019912-18,tengan,o
27,2010-019912-18,previsto,o
27,2010-019912-18,someterse,o
27,2010-019912-18,a,o
27,2010-019912-18,una,o
27,2010-019912-18,intervencion,i
27,2010-019912-18,de,o
27,2010-019912-18,este,o
27,2010-019912-18,tipo,o
27,2010-019912-18,en,o
27,2010-019912-18,los,o
27,2010-019912-18,6,o
27,2010-019912-18,meses,o
27,2010-019912-18,siguientes,o
27,2010-019912-18,a,o
27,2010-019912-18,la,o
27,2010-019912-18,randomizacion,i
27,2010-019912-18,Enfermedad,i
27,2010-019912-18,reumatica,i
27,2010-019912-18,autoinmune,i
27,2010-019912-18,distinta,o
27,2010-019912-18,de,o
27,2010-019912-18,AR,i
27,2010-019912-18,Se,o
27,2010-019912-18,permite,o
27,2010-019912-18,la,o
27,2010-019912-18,inclusion,o
27,2010-019912-18,de,o
27,2010-019912-18,pacientes,o
27,2010-019912-18,con,o
27,2010-019912-18,sindrome,i
27,2010-019912-18,de,i
27,2010-019912-18,Sjögren,i
27,2010-019912-18,secundario,i
27,2010-019912-18,asociado,o
27,2010-019912-18,a,o
27,2010-019912-18,AR,i
27,2010-019912-18,Clase,o
27,2010-019912-18,funcional,o
27,2010-019912-18,IV,o
27,2010-019912-18,definida,o
27,2010-019912-18,de,o
27,2010-019912-18,acuerdo,o
27,2010-019912-18,con,o
27,2010-019912-18,la,o
27,2010-019912-18,Clasificacion,o
27,2010-019912-18,del,o
27,2010-019912-18,ACR,o
27,2010-019912-18,del,o
27,2010-019912-18,Estado,o
27,2010-019912-18,Funcional,o
27,2010-019912-18,en,o
27,2010-019912-18,Artritis,i
27,2010-019912-18,Reumatoide,i
27,2010-019912-18,Artritis,i
27,2010-019912-18,idiopatica,i
27,2010-019912-18,juvenil,i
27,2010-019912-18,AIJ,i
27,2010-019912-18,o,o
27,2010-019912-18,artritis,i
27,2010-019912-18,reumatoide,i
27,2010-019912-18,juvenil,i
27,2010-019912-18,ARJ,i
27,2010-019912-18,yo,o
27,2010-019912-18,AR,i
27,2010-019912-18,diagnosticadas,i
27,2010-019912-18,antes,o
27,2010-019912-18,de,o
27,2010-019912-18,los,o
27,2010-019912-18,16,o
27,2010-019912-18,años,o
27,2010-019912-18,de,o
27,2010-019912-18,edad,o
27,2010-019912-18,Enfermedad,i
27,2010-019912-18,articular,i
27,2010-019912-18,inflamatoria,i
27,2010-019912-18,distinta,o
27,2010-019912-18,de,o
27,2010-019912-18,AR,i
27,2010-019912-18,en,o
27,2010-019912-18,el,o
27,2010-019912-18,pasado,o
27,2010-019912-18,o,o
27,2010-019912-18,en,o
27,2010-019912-18,la,o
27,2010-019912-18,actualidad,o
28,2010-019912-18,EudraCT,o
28,2010-019912-18,Nº,o
28,2010-019912-18,201001991218,o
28,2010-019912-18,Titulo,o
28,2010-019912-18,cientifico,o
28,2010-019912-18,Estudio,o
28,2010-019912-18,randomizado,o
28,2010-019912-18,doble,o
28,2010-019912-18,ciego,o
28,2010-019912-18,con,o
28,2010-019912-18,grupos,o
28,2010-019912-18,de,o
28,2010-019912-18,tratamiento,i
28,2010-019912-18,paralelos,o
28,2010-019912-18,para,o
28,2010-019912-18,evaluar,i
28,2010-019912-18,la,i
28,2010-019912-18,seguridad,i
28,2010-019912-18,y,o
28,2010-019912-18,el,o
28,2010-019912-18,efecto,o
28,2010-019912-18,sobre,o
28,2010-019912-18,el,o
28,2010-019912-18,resultado,o
28,2010-019912-18,clinico,o
28,2010-019912-18,de,o
28,2010-019912-18,tocilizumab,i
28,2010-019912-18,SC,o
28,2010-019912-18,frente,o
28,2010-019912-18,a,o
28,2010-019912-18,placebo,i
28,2010-019912-18,SC,o
28,2010-019912-18,en,o
28,2010-019912-18,combinacion,o
28,2010-019912-18,con,o
28,2010-019912-18,farmacos,i
28,2010-019912-18,antirreumaticos,i
28,2010-019912-18,modificadores,i
28,2010-019912-18,de,i
28,2010-019912-18,la,i
28,2010-019912-18,enfermedad,i
28,2010-019912-18,FAMEs,i
28,2010-019912-18,tradicionales,o
28,2010-019912-18,en,o
28,2010-019912-18,pacientes,o
28,2010-019912-18,con,o
28,2010-019912-18,artritis,i
28,2010-019912-18,reumatoide,i
28,2010-019912-18,activa,o
28,2010-019912-18,moderada,o
28,2010-019912-18,a,o
28,2010-019912-18,severa,o
28,2010-019912-18,Indicacion,o
28,2010-019912-18,cientifica,o
28,2010-019912-18,Artritis,i
28,2010-019912-18,Reumatoide,i
28,2010-019912-18,AR,i
28,2010-019912-18,Criterios,o
28,2010-019912-18,de,o
28,2010-019912-18,inclusion,o
28,2010-019912-18,Presentar,o
28,2010-019912-18,artritis,i
28,2010-019912-18,reumatoide,i
28,2010-019912-18,de,o
28,2010-019912-18,mayor,o
28,2010-019912-18,o,o
28,2010-019912-18,igual,o
28,2010-019912-18,a,o
28,2010-019912-18,6,o
28,2010-019912-18,meses,o
28,2010-019912-18,de,o
28,2010-019912-18,duracion,o
28,2010-019912-18,Recibir,o
28,2010-019912-18,tratamiento,i
28,2010-019912-18,de,i
28,2010-019912-18,forma,i
28,2010-019912-18,ambulatoria,i
28,2010-019912-18,Presentar,o
28,2010-019912-18,un,o
28,2010-019912-18,recuento,o
28,2010-019912-18,de,o
28,2010-019912-18,articulaciones,i
28,2010-019912-18,inflamadas,i
28,2010-019912-18,RAI,o
28,2010-019912-18,mayor,o
28,2010-019912-18,o,o
28,2010-019912-18,igual,o
28,2010-019912-18,a,o
28,2010-019912-18,6,o
28,2010-019912-18,recuento,o
28,2010-019912-18,de,o
28,2010-019912-18,66,o
28,2010-019912-18,articulaciones,i
28,2010-019912-18,y,o
28,2010-019912-18,de,o
28,2010-019912-18,articulaciones,i
28,2010-019912-18,dolorosas,i
28,2010-019912-18,RAD,o
28,2010-019912-18,mayor,o
28,2010-019912-18,o,o
28,2010-019912-18,igual,o
28,2010-019912-18,a,o
28,2010-019912-18,8,o
28,2010-019912-18,recuento,o
28,2010-019912-18,de,o
28,2010-019912-18,68,o
28,2010-019912-18,articulaciones,i
28,2010-019912-18,en,o
28,2010-019912-18,las,o
28,2010-019912-18,visitas,o
28,2010-019912-18,de,o
28,2010-019912-18,seleccion,o
28,2010-019912-18,y,o
28,2010-019912-18,basal,o
28,2010-019912-18,Los,o
28,2010-019912-18,pacientes,o
28,2010-019912-18,deben,o
28,2010-019912-18,estar,o
28,2010-019912-18,recibiendo,o
28,2010-019912-18,tratamiento,i
28,2010-019912-18,con,o
28,2010-019912-18,una,o
28,2010-019912-18,dosis,o
28,2010-019912-18,estable,o
28,2010-019912-18,de,o
28,2010-019912-18,los,o
28,2010-019912-18,FAMEs,i
28,2010-019912-18,permitidos,o
28,2010-019912-18,como,o
28,2010-019912-18,minimo,o
28,2010-019912-18,8,o
28,2010-019912-18,semanas,o
28,2010-019912-18,antes,o
28,2010-019912-18,de,o
28,2010-019912-18,la,o
28,2010-019912-18,visita,o
28,2010-019912-18,basal,o
28,2010-019912-18,Criterios,o
28,2010-019912-18,de,o
28,2010-019912-18,exclusion,o
28,2010-019912-18,Pacientes,o
28,2010-019912-18,sometidos,o
28,2010-019912-18,a,o
28,2010-019912-18,intervenciones,i
28,2010-019912-18,de,i
28,2010-019912-18,cirugia,i
28,2010-019912-18,mayor,i
28,2010-019912-18,incluyendo,o
28,2010-019912-18,cirugia,i
28,2010-019912-18,articular,i
28,2010-019912-18,en,o
28,2010-019912-18,las,o
28,2010-019912-18,8,o
28,2010-019912-18,semanas,o
28,2010-019912-18,previas,o
28,2010-019912-18,a,o
28,2010-019912-18,la,o
28,2010-019912-18,visita,o
28,2010-019912-18,de,o
28,2010-019912-18,seleccion,o
28,2010-019912-18,o,o
28,2010-019912-18,que,o
28,2010-019912-18,tengan,o
28,2010-019912-18,previsto,o
28,2010-019912-18,someterse,o
28,2010-019912-18,a,o
28,2010-019912-18,una,o
28,2010-019912-18,intervencion,i
28,2010-019912-18,de,o
28,2010-019912-18,este,o
28,2010-019912-18,tipo,o
28,2010-019912-18,en,o
28,2010-019912-18,los,o
28,2010-019912-18,6,o
28,2010-019912-18,meses,o
28,2010-019912-18,siguientes,o
28,2010-019912-18,a,o
28,2010-019912-18,la,o
28,2010-019912-18,randomizacion,i
28,2010-019912-18,Enfermedad,i
28,2010-019912-18,reumatica,i
28,2010-019912-18,autoinmune,i
28,2010-019912-18,distinta,o
28,2010-019912-18,de,o
28,2010-019912-18,AR,i
28,2010-019912-18,Se,o
28,2010-019912-18,permite,o
28,2010-019912-18,la,o
28,2010-019912-18,inclusion,o
28,2010-019912-18,de,o
28,2010-019912-18,pacientes,o
28,2010-019912-18,con,o
28,2010-019912-18,sindrome,i
28,2010-019912-18,de,i
28,2010-019912-18,Sjögren,i
28,2010-019912-18,secundario,i
28,2010-019912-18,asociado,o
28,2010-019912-18,a,o
28,2010-019912-18,AR,i
28,2010-019912-18,Clase,o
28,2010-019912-18,funcional,o
28,2010-019912-18,IV,o
28,2010-019912-18,definida,o
28,2010-019912-18,de,o
28,2010-019912-18,acuerdo,o
28,2010-019912-18,con,o
28,2010-019912-18,la,o
28,2010-019912-18,Clasificacion,o
28,2010-019912-18,del,o
28,2010-019912-18,ACR,o
28,2010-019912-18,del,o
28,2010-019912-18,Estado,o
28,2010-019912-18,Funcional,o
28,2010-019912-18,en,o
28,2010-019912-18,Artritis,i
28,2010-019912-18,Reumatoide,i
28,2010-019912-18,Artritis,i
28,2010-019912-18,idiopatica,i
28,2010-019912-18,juvenil,i
28,2010-019912-18,AIJ,i
28,2010-019912-18,o,o
28,2010-019912-18,artritis,i
28,2010-019912-18,reumatoide,i
28,2010-019912-18,juvenil,i
28,2010-019912-18,ARJ,i
28,2010-019912-18,yo,o
28,2010-019912-18,AR,i
28,2010-019912-18,diagnosticadas,i
28,2010-019912-18,antes,o
28,2010-019912-18,de,o
28,2010-019912-18,los,o
28,2010-019912-18,16,o
28,2010-019912-18,años,o
28,2010-019912-18,de,o
28,2010-019912-18,edad,o
28,2010-019912-18,Enfermedad,i
28,2010-019912-18,articular,i
28,2010-019912-18,inflamatoria,i
28,2010-019912-18,distinta,o
28,2010-019912-18,de,o
28,2010-019912-18,AR,i
28,2010-019912-18,en,o
28,2010-019912-18,el,o
28,2010-019912-18,pasado,o
28,2010-019912-18,o,o
28,2010-019912-18,en,o
28,2010-019912-18,la,o
28,2010-019912-18,actualidad,o
29,2010-019912-18,EudraCT,o
29,2010-019912-18,Nº,o
29,2010-019912-18,201001991218,o
29,2010-019912-18,Titulo,o
29,2010-019912-18,cientifico,o
29,2010-019912-18,Estudio,o
29,2010-019912-18,randomizado,o
29,2010-019912-18,doble,o
29,2010-019912-18,ciego,o
29,2010-019912-18,con,o
29,2010-019912-18,grupos,o
29,2010-019912-18,de,o
29,2010-019912-18,tratamiento,i
29,2010-019912-18,paralelos,o
29,2010-019912-18,para,o
29,2010-019912-18,evaluar,i
29,2010-019912-18,la,i
29,2010-019912-18,seguridad,i
29,2010-019912-18,y,o
29,2010-019912-18,el,o
29,2010-019912-18,efecto,o
29,2010-019912-18,sobre,o
29,2010-019912-18,el,o
29,2010-019912-18,resultado,o
29,2010-019912-18,clinico,o
29,2010-019912-18,de,o
29,2010-019912-18,tocilizumab,i
29,2010-019912-18,SC,o
29,2010-019912-18,frente,o
29,2010-019912-18,a,o
29,2010-019912-18,placebo,i
29,2010-019912-18,SC,o
29,2010-019912-18,en,o
29,2010-019912-18,combinacion,o
29,2010-019912-18,con,o
29,2010-019912-18,farmacos,i
29,2010-019912-18,antirreumaticos,i
29,2010-019912-18,modificadores,i
29,2010-019912-18,de,i
29,2010-019912-18,la,i
29,2010-019912-18,enfermedad,i
29,2010-019912-18,FAMEs,i
29,2010-019912-18,tradicionales,o
29,2010-019912-18,en,o
29,2010-019912-18,pacientes,o
29,2010-019912-18,con,o
29,2010-019912-18,artritis,i
29,2010-019912-18,reumatoide,i
29,2010-019912-18,activa,o
29,2010-019912-18,moderada,o
29,2010-019912-18,a,o
29,2010-019912-18,severa,o
29,2010-019912-18,Indicacion,o
29,2010-019912-18,cientifica,o
29,2010-019912-18,Artritis,i
29,2010-019912-18,Reumatoide,i
29,2010-019912-18,AR,i
29,2010-019912-18,Criterios,o
29,2010-019912-18,de,o
29,2010-019912-18,inclusion,o
29,2010-019912-18,Presentar,o
29,2010-019912-18,artritis,i
29,2010-019912-18,reumatoide,i
29,2010-019912-18,de,o
29,2010-019912-18,mayor,o
29,2010-019912-18,o,o
29,2010-019912-18,igual,o
29,2010-019912-18,a,o
29,2010-019912-18,6,o
29,2010-019912-18,meses,o
29,2010-019912-18,de,o
29,2010-019912-18,duracion,o
29,2010-019912-18,Recibir,o
29,2010-019912-18,tratamiento,i
29,2010-019912-18,de,i
29,2010-019912-18,forma,i
29,2010-019912-18,ambulatoria,i
29,2010-019912-18,Presentar,o
29,2010-019912-18,un,o
29,2010-019912-18,recuento,o
29,2010-019912-18,de,o
29,2010-019912-18,articulaciones,i
29,2010-019912-18,inflamadas,i
29,2010-019912-18,RAI,o
29,2010-019912-18,mayor,o
29,2010-019912-18,o,o
29,2010-019912-18,igual,o
29,2010-019912-18,a,o
29,2010-019912-18,6,o
29,2010-019912-18,recuento,o
29,2010-019912-18,de,o
29,2010-019912-18,66,o
29,2010-019912-18,articulaciones,i
29,2010-019912-18,y,o
29,2010-019912-18,de,o
29,2010-019912-18,articulaciones,i
29,2010-019912-18,dolorosas,i
29,2010-019912-18,RAD,o
29,2010-019912-18,mayor,o
29,2010-019912-18,o,o
29,2010-019912-18,igual,o
29,2010-019912-18,a,o
29,2010-019912-18,8,o
29,2010-019912-18,recuento,o
29,2010-019912-18,de,o
29,2010-019912-18,68,o
29,2010-019912-18,articulaciones,i
29,2010-019912-18,en,o
29,2010-019912-18,las,o
29,2010-019912-18,visitas,o
29,2010-019912-18,de,o
29,2010-019912-18,seleccion,o
29,2010-019912-18,y,o
29,2010-019912-18,basal,o
29,2010-019912-18,Los,o
29,2010-019912-18,pacientes,o
29,2010-019912-18,deben,o
29,2010-019912-18,estar,o
29,2010-019912-18,recibiendo,o
29,2010-019912-18,tratamiento,i
29,2010-019912-18,con,o
29,2010-019912-18,una,o
29,2010-019912-18,dosis,o
29,2010-019912-18,estable,o
29,2010-019912-18,de,o
29,2010-019912-18,los,o
29,2010-019912-18,FAMEs,i
29,2010-019912-18,permitidos,o
29,2010-019912-18,como,o
29,2010-019912-18,minimo,o
29,2010-019912-18,8,o
29,2010-019912-18,semanas,o
29,2010-019912-18,antes,o
29,2010-019912-18,de,o
29,2010-019912-18,la,o
29,2010-019912-18,visita,o
29,2010-019912-18,basal,o
29,2010-019912-18,Criterios,o
29,2010-019912-18,de,o
29,2010-019912-18,exclusion,o
29,2010-019912-18,Pacientes,o
29,2010-019912-18,sometidos,o
29,2010-019912-18,a,o
29,2010-019912-18,intervenciones,i
29,2010-019912-18,de,i
29,2010-019912-18,cirugia,i
29,2010-019912-18,mayor,i
29,2010-019912-18,incluyendo,o
29,2010-019912-18,cirugia,i
29,2010-019912-18,articular,i
29,2010-019912-18,en,o
29,2010-019912-18,las,o
29,2010-019912-18,8,o
29,2010-019912-18,semanas,o
29,2010-019912-18,previas,o
29,2010-019912-18,a,o
29,2010-019912-18,la,o
29,2010-019912-18,visita,o
29,2010-019912-18,de,o
29,2010-019912-18,seleccion,o
29,2010-019912-18,o,o
29,2010-019912-18,que,o
29,2010-019912-18,tengan,o
29,2010-019912-18,previsto,o
29,2010-019912-18,someterse,o
29,2010-019912-18,a,o
29,2010-019912-18,una,o
29,2010-019912-18,intervencion,i
29,2010-019912-18,de,o
29,2010-019912-18,este,o
29,2010-019912-18,tipo,o
29,2010-019912-18,en,o
29,2010-019912-18,los,o
29,2010-019912-18,6,o
29,2010-019912-18,meses,o
29,2010-019912-18,siguientes,o
29,2010-019912-18,a,o
29,2010-019912-18,la,o
29,2010-019912-18,randomizacion,i
29,2010-019912-18,Enfermedad,i
29,2010-019912-18,reumatica,i
29,2010-019912-18,autoinmune,i
29,2010-019912-18,distinta,o
29,2010-019912-18,de,o
29,2010-019912-18,AR,i
29,2010-019912-18,Se,o
29,2010-019912-18,permite,o
29,2010-019912-18,la,o
29,2010-019912-18,inclusion,o
29,2010-019912-18,de,o
29,2010-019912-18,pacientes,o
29,2010-019912-18,con,o
29,2010-019912-18,sindrome,i
29,2010-019912-18,de,i
29,2010-019912-18,Sjögren,i
29,2010-019912-18,secundario,i
29,2010-019912-18,asociado,o
29,2010-019912-18,a,o
29,2010-019912-18,AR,i
29,2010-019912-18,Clase,o
29,2010-019912-18,funcional,o
29,2010-019912-18,IV,o
29,2010-019912-18,definida,o
29,2010-019912-18,de,o
29,2010-019912-18,acuerdo,o
29,2010-019912-18,con,o
29,2010-019912-18,la,o
29,2010-019912-18,Clasificacion,o
29,2010-019912-18,del,o
29,2010-019912-18,ACR,o
29,2010-019912-18,del,o
29,2010-019912-18,Estado,o
29,2010-019912-18,Funcional,o
29,2010-019912-18,en,o
29,2010-019912-18,Artritis,i
29,2010-019912-18,Reumatoide,i
29,2010-019912-18,Artritis,i
29,2010-019912-18,idiopatica,i
29,2010-019912-18,juvenil,i
29,2010-019912-18,AIJ,i
29,2010-019912-18,o,o
29,2010-019912-18,artritis,i
29,2010-019912-18,reumatoide,i
29,2010-019912-18,juvenil,i
29,2010-019912-18,ARJ,i
29,2010-019912-18,yo,o
29,2010-019912-18,AR,i
29,2010-019912-18,diagnosticadas,i
29,2010-019912-18,antes,o
29,2010-019912-18,de,o
29,2010-019912-18,los,o
29,2010-019912-18,16,o
29,2010-019912-18,años,o
29,2010-019912-18,de,o
29,2010-019912-18,edad,o
29,2010-019912-18,Enfermedad,i
29,2010-019912-18,articular,i
29,2010-019912-18,inflamatoria,i
29,2010-019912-18,distinta,o
29,2010-019912-18,de,o
29,2010-019912-18,AR,i
29,2010-019912-18,en,o
29,2010-019912-18,el,o
29,2010-019912-18,pasado,o
29,2010-019912-18,o,o
29,2010-019912-18,en,o
29,2010-019912-18,la,o
29,2010-019912-18,actualidad,o
30,2010-019912-18,EudraCT,o
30,2010-019912-18,Nº,o
30,2010-019912-18,201001991218,o
30,2010-019912-18,Titulo,o
30,2010-019912-18,cientifico,o
30,2010-019912-18,Estudio,o
30,2010-019912-18,randomizado,o
30,2010-019912-18,doble,o
30,2010-019912-18,ciego,o
30,2010-019912-18,con,o
30,2010-019912-18,grupos,o
30,2010-019912-18,de,o
30,2010-019912-18,tratamiento,i
30,2010-019912-18,paralelos,o
30,2010-019912-18,para,o
30,2010-019912-18,evaluar,i
30,2010-019912-18,la,i
30,2010-019912-18,seguridad,i
30,2010-019912-18,y,o
30,2010-019912-18,el,o
30,2010-019912-18,efecto,o
30,2010-019912-18,sobre,o
30,2010-019912-18,el,o
30,2010-019912-18,resultado,o
30,2010-019912-18,clinico,o
30,2010-019912-18,de,o
30,2010-019912-18,tocilizumab,i
30,2010-019912-18,SC,o
30,2010-019912-18,frente,o
30,2010-019912-18,a,o
30,2010-019912-18,placebo,i
30,2010-019912-18,SC,o
30,2010-019912-18,en,o
30,2010-019912-18,combinacion,o
30,2010-019912-18,con,o
30,2010-019912-18,farmacos,i
30,2010-019912-18,antirreumaticos,i
30,2010-019912-18,modificadores,i
30,2010-019912-18,de,i
30,2010-019912-18,la,i
30,2010-019912-18,enfermedad,i
30,2010-019912-18,FAMEs,i
30,2010-019912-18,tradicionales,o
30,2010-019912-18,en,o
30,2010-019912-18,pacientes,o
30,2010-019912-18,con,o
30,2010-019912-18,artritis,i
30,2010-019912-18,reumatoide,i
30,2010-019912-18,activa,o
30,2010-019912-18,moderada,o
30,2010-019912-18,a,o
30,2010-019912-18,severa,o
30,2010-019912-18,Indicacion,o
30,2010-019912-18,cientifica,o
30,2010-019912-18,Artritis,i
30,2010-019912-18,Reumatoide,i
30,2010-019912-18,AR,i
30,2010-019912-18,Criterios,o
30,2010-019912-18,de,o
30,2010-019912-18,inclusion,o
30,2010-019912-18,Presentar,o
30,2010-019912-18,artritis,i
30,2010-019912-18,reumatoide,i
30,2010-019912-18,de,o
30,2010-019912-18,mayor,o
30,2010-019912-18,o,o
30,2010-019912-18,igual,o
30,2010-019912-18,a,o
30,2010-019912-18,6,o
30,2010-019912-18,meses,o
30,2010-019912-18,de,o
30,2010-019912-18,duracion,o
30,2010-019912-18,Recibir,o
30,2010-019912-18,tratamiento,i
30,2010-019912-18,de,i
30,2010-019912-18,forma,i
30,2010-019912-18,ambulatoria,i
30,2010-019912-18,Presentar,o
30,2010-019912-18,un,o
30,2010-019912-18,recuento,o
30,2010-019912-18,de,o
30,2010-019912-18,articulaciones,i
30,2010-019912-18,inflamadas,i
30,2010-019912-18,RAI,o
30,2010-019912-18,mayor,o
30,2010-019912-18,o,o
30,2010-019912-18,igual,o
30,2010-019912-18,a,o
30,2010-019912-18,6,o
30,2010-019912-18,recuento,o
30,2010-019912-18,de,o
30,2010-019912-18,66,o
30,2010-019912-18,articulaciones,i
30,2010-019912-18,y,o
30,2010-019912-18,de,o
30,2010-019912-18,articulaciones,i
30,2010-019912-18,dolorosas,i
30,2010-019912-18,RAD,o
30,2010-019912-18,mayor,o
30,2010-019912-18,o,o
30,2010-019912-18,igual,o
30,2010-019912-18,a,o
30,2010-019912-18,8,o
30,2010-019912-18,recuento,o
30,2010-019912-18,de,o
30,2010-019912-18,68,o
30,2010-019912-18,articulaciones,i
30,2010-019912-18,en,o
30,2010-019912-18,las,o
30,2010-019912-18,visitas,o
30,2010-019912-18,de,o
30,2010-019912-18,seleccion,o
30,2010-019912-18,y,o
30,2010-019912-18,basal,o
30,2010-019912-18,Los,o
30,2010-019912-18,pacientes,o
30,2010-019912-18,deben,o
30,2010-019912-18,estar,o
30,2010-019912-18,recibiendo,o
30,2010-019912-18,tratamiento,i
30,2010-019912-18,con,o
30,2010-019912-18,una,o
30,2010-019912-18,dosis,o
30,2010-019912-18,estable,o
30,2010-019912-18,de,o
30,2010-019912-18,los,o
30,2010-019912-18,FAMEs,i
30,2010-019912-18,permitidos,o
30,2010-019912-18,como,o
30,2010-019912-18,minimo,o
30,2010-019912-18,8,o
30,2010-019912-18,semanas,o
30,2010-019912-18,antes,o
30,2010-019912-18,de,o
30,2010-019912-18,la,o
30,2010-019912-18,visita,o
30,2010-019912-18,basal,o
30,2010-019912-18,Criterios,o
30,2010-019912-18,de,o
30,2010-019912-18,exclusion,o
30,2010-019912-18,Pacientes,o
30,2010-019912-18,sometidos,o
30,2010-019912-18,a,o
30,2010-019912-18,intervenciones,i
30,2010-019912-18,de,i
30,2010-019912-18,cirugia,i
30,2010-019912-18,mayor,i
30,2010-019912-18,incluyendo,o
30,2010-019912-18,cirugia,i
30,2010-019912-18,articular,i
30,2010-019912-18,en,o
30,2010-019912-18,las,o
30,2010-019912-18,8,o
30,2010-019912-18,semanas,o
30,2010-019912-18,previas,o
30,2010-019912-18,a,o
30,2010-019912-18,la,o
30,2010-019912-18,visita,o
30,2010-019912-18,de,o
30,2010-019912-18,seleccion,o
30,2010-019912-18,o,o
30,2010-019912-18,que,o
30,2010-019912-18,tengan,o
30,2010-019912-18,previsto,o
30,2010-019912-18,someterse,o
30,2010-019912-18,a,o
30,2010-019912-18,una,o
30,2010-019912-18,intervencion,i
30,2010-019912-18,de,o
30,2010-019912-18,este,o
30,2010-019912-18,tipo,o
30,2010-019912-18,en,o
30,2010-019912-18,los,o
30,2010-019912-18,6,o
30,2010-019912-18,meses,o
30,2010-019912-18,siguientes,o
30,2010-019912-18,a,o
30,2010-019912-18,la,o
30,2010-019912-18,randomizacion,i
30,2010-019912-18,Enfermedad,i
30,2010-019912-18,reumatica,i
30,2010-019912-18,autoinmune,i
30,2010-019912-18,distinta,o
30,2010-019912-18,de,o
30,2010-019912-18,AR,i
30,2010-019912-18,Se,o
30,2010-019912-18,permite,o
30,2010-019912-18,la,o
30,2010-019912-18,inclusion,o
30,2010-019912-18,de,o
30,2010-019912-18,pacientes,o
30,2010-019912-18,con,o
30,2010-019912-18,sindrome,i
30,2010-019912-18,de,i
30,2010-019912-18,Sjögren,i
30,2010-019912-18,secundario,i
30,2010-019912-18,asociado,o
30,2010-019912-18,a,o
30,2010-019912-18,AR,i
30,2010-019912-18,Clase,o
30,2010-019912-18,funcional,o
30,2010-019912-18,IV,o
30,2010-019912-18,definida,o
30,2010-019912-18,de,o
30,2010-019912-18,acuerdo,o
30,2010-019912-18,con,o
30,2010-019912-18,la,o
30,2010-019912-18,Clasificacion,o
30,2010-019912-18,del,o
30,2010-019912-18,ACR,o
30,2010-019912-18,del,o
30,2010-019912-18,Estado,o
30,2010-019912-18,Funcional,o
30,2010-019912-18,en,o
30,2010-019912-18,Artritis,i
30,2010-019912-18,Reumatoide,i
30,2010-019912-18,Artritis,i
30,2010-019912-18,idiopatica,i
30,2010-019912-18,juvenil,i
30,2010-019912-18,AIJ,i
30,2010-019912-18,o,o
30,2010-019912-18,artritis,i
30,2010-019912-18,reumatoide,i
30,2010-019912-18,juvenil,i
30,2010-019912-18,ARJ,i
30,2010-019912-18,yo,o
30,2010-019912-18,AR,i
30,2010-019912-18,diagnosticadas,i
30,2010-019912-18,antes,o
30,2010-019912-18,de,o
30,2010-019912-18,los,o
30,2010-019912-18,16,o
30,2010-019912-18,años,o
30,2010-019912-18,de,o
30,2010-019912-18,edad,o
30,2010-019912-18,Enfermedad,i
30,2010-019912-18,articular,i
30,2010-019912-18,inflamatoria,i
30,2010-019912-18,distinta,o
30,2010-019912-18,de,o
30,2010-019912-18,AR,i
30,2010-019912-18,en,o
30,2010-019912-18,el,o
30,2010-019912-18,pasado,o
30,2010-019912-18,o,o
30,2010-019912-18,en,o
30,2010-019912-18,la,o
30,2010-019912-18,actualidad,o
31,2010-019912-18,EudraCT,o
31,2010-019912-18,Nº,o
31,2010-019912-18,201001991218,o
31,2010-019912-18,Titulo,o
31,2010-019912-18,cientifico,o
31,2010-019912-18,Estudio,o
31,2010-019912-18,randomizado,o
31,2010-019912-18,doble,o
31,2010-019912-18,ciego,o
31,2010-019912-18,con,o
31,2010-019912-18,grupos,o
31,2010-019912-18,de,o
31,2010-019912-18,tratamiento,i
31,2010-019912-18,paralelos,o
31,2010-019912-18,para,o
31,2010-019912-18,evaluar,i
31,2010-019912-18,la,i
31,2010-019912-18,seguridad,i
31,2010-019912-18,y,o
31,2010-019912-18,el,o
31,2010-019912-18,efecto,o
31,2010-019912-18,sobre,o
31,2010-019912-18,el,o
31,2010-019912-18,resultado,o
31,2010-019912-18,clinico,o
31,2010-019912-18,de,o
31,2010-019912-18,tocilizumab,i
31,2010-019912-18,SC,o
31,2010-019912-18,frente,o
31,2010-019912-18,a,o
31,2010-019912-18,placebo,i
31,2010-019912-18,SC,o
31,2010-019912-18,en,o
31,2010-019912-18,combinacion,o
31,2010-019912-18,con,o
31,2010-019912-18,farmacos,i
31,2010-019912-18,antirreumaticos,i
31,2010-019912-18,modificadores,i
31,2010-019912-18,de,i
31,2010-019912-18,la,i
31,2010-019912-18,enfermedad,i
31,2010-019912-18,FAMEs,i
31,2010-019912-18,tradicionales,o
31,2010-019912-18,en,o
31,2010-019912-18,pacientes,o
31,2010-019912-18,con,o
31,2010-019912-18,artritis,i
31,2010-019912-18,reumatoide,i
31,2010-019912-18,activa,o
31,2010-019912-18,moderada,o
31,2010-019912-18,a,o
31,2010-019912-18,severa,o
31,2010-019912-18,Indicacion,o
31,2010-019912-18,cientifica,o
31,2010-019912-18,Artritis,i
31,2010-019912-18,Reumatoide,i
31,2010-019912-18,AR,i
31,2010-019912-18,Criterios,o
31,2010-019912-18,de,o
31,2010-019912-18,inclusion,o
31,2010-019912-18,Presentar,o
31,2010-019912-18,artritis,i
31,2010-019912-18,reumatoide,i
31,2010-019912-18,de,o
31,2010-019912-18,mayor,o
31,2010-019912-18,o,o
31,2010-019912-18,igual,o
31,2010-019912-18,a,o
31,2010-019912-18,6,o
31,2010-019912-18,meses,o
31,2010-019912-18,de,o
31,2010-019912-18,duracion,o
31,2010-019912-18,Recibir,o
31,2010-019912-18,tratamiento,i
31,2010-019912-18,de,i
31,2010-019912-18,forma,i
31,2010-019912-18,ambulatoria,i
31,2010-019912-18,Presentar,o
31,2010-019912-18,un,o
31,2010-019912-18,recuento,o
31,2010-019912-18,de,o
31,2010-019912-18,articulaciones,i
31,2010-019912-18,inflamadas,i
31,2010-019912-18,RAI,o
31,2010-019912-18,mayor,o
31,2010-019912-18,o,o
31,2010-019912-18,igual,o
31,2010-019912-18,a,o
31,2010-019912-18,6,o
31,2010-019912-18,recuento,o
31,2010-019912-18,de,o
31,2010-019912-18,66,o
31,2010-019912-18,articulaciones,i
31,2010-019912-18,y,o
31,2010-019912-18,de,o
31,2010-019912-18,articulaciones,i
31,2010-019912-18,dolorosas,i
31,2010-019912-18,RAD,o
31,2010-019912-18,mayor,o
31,2010-019912-18,o,o
31,2010-019912-18,igual,o
31,2010-019912-18,a,o
31,2010-019912-18,8,o
31,2010-019912-18,recuento,o
31,2010-019912-18,de,o
31,2010-019912-18,68,o
31,2010-019912-18,articulaciones,i
31,2010-019912-18,en,o
31,2010-019912-18,las,o
31,2010-019912-18,visitas,o
31,2010-019912-18,de,o
31,2010-019912-18,seleccion,o
31,2010-019912-18,y,o
31,2010-019912-18,basal,o
31,2010-019912-18,Los,o
31,2010-019912-18,pacientes,o
31,2010-019912-18,deben,o
31,2010-019912-18,estar,o
31,2010-019912-18,recibiendo,o
31,2010-019912-18,tratamiento,i
31,2010-019912-18,con,o
31,2010-019912-18,una,o
31,2010-019912-18,dosis,o
31,2010-019912-18,estable,o
31,2010-019912-18,de,o
31,2010-019912-18,los,o
31,2010-019912-18,FAMEs,i
31,2010-019912-18,permitidos,o
31,2010-019912-18,como,o
31,2010-019912-18,minimo,o
31,2010-019912-18,8,o
31,2010-019912-18,semanas,o
31,2010-019912-18,antes,o
31,2010-019912-18,de,o
31,2010-019912-18,la,o
31,2010-019912-18,visita,o
31,2010-019912-18,basal,o
31,2010-019912-18,Criterios,o
31,2010-019912-18,de,o
31,2010-019912-18,exclusion,o
31,2010-019912-18,Pacientes,o
31,2010-019912-18,sometidos,o
31,2010-019912-18,a,o
31,2010-019912-18,intervenciones,i
31,2010-019912-18,de,i
31,2010-019912-18,cirugia,i
31,2010-019912-18,mayor,i
31,2010-019912-18,incluyendo,o
31,2010-019912-18,cirugia,i
31,2010-019912-18,articular,i
31,2010-019912-18,en,o
31,2010-019912-18,las,o
31,2010-019912-18,8,o
31,2010-019912-18,semanas,o
31,2010-019912-18,previas,o
31,2010-019912-18,a,o
31,2010-019912-18,la,o
31,2010-019912-18,visita,o
31,2010-019912-18,de,o
31,2010-019912-18,seleccion,o
31,2010-019912-18,o,o
31,2010-019912-18,que,o
31,2010-019912-18,tengan,o
31,2010-019912-18,previsto,o
31,2010-019912-18,someterse,o
31,2010-019912-18,a,o
31,2010-019912-18,una,o
31,2010-019912-18,intervencion,i
31,2010-019912-18,de,o
31,2010-019912-18,este,o
31,2010-019912-18,tipo,o
31,2010-019912-18,en,o
31,2010-019912-18,los,o
31,2010-019912-18,6,o
31,2010-019912-18,meses,o
31,2010-019912-18,siguientes,o
31,2010-019912-18,a,o
31,2010-019912-18,la,o
31,2010-019912-18,randomizacion,i
31,2010-019912-18,Enfermedad,i
31,2010-019912-18,reumatica,i
31,2010-019912-18,autoinmune,i
31,2010-019912-18,distinta,o
31,2010-019912-18,de,o
31,2010-019912-18,AR,i
31,2010-019912-18,Se,o
31,2010-019912-18,permite,o
31,2010-019912-18,la,o
31,2010-019912-18,inclusion,o
31,2010-019912-18,de,o
31,2010-019912-18,pacientes,o
31,2010-019912-18,con,o
31,2010-019912-18,sindrome,i
31,2010-019912-18,de,i
31,2010-019912-18,Sjögren,i
31,2010-019912-18,secundario,i
31,2010-019912-18,asociado,o
31,2010-019912-18,a,o
31,2010-019912-18,AR,i
31,2010-019912-18,Clase,o
31,2010-019912-18,funcional,o
31,2010-019912-18,IV,o
31,2010-019912-18,definida,o
31,2010-019912-18,de,o
31,2010-019912-18,acuerdo,o
31,2010-019912-18,con,o
31,2010-019912-18,la,o
31,2010-019912-18,Clasificacion,o
31,2010-019912-18,del,o
31,2010-019912-18,ACR,o
31,2010-019912-18,del,o
31,2010-019912-18,Estado,o
31,2010-019912-18,Funcional,o
31,2010-019912-18,en,o
31,2010-019912-18,Artritis,i
31,2010-019912-18,Reumatoide,i
31,2010-019912-18,Artritis,i
31,2010-019912-18,idiopatica,i
31,2010-019912-18,juvenil,i
31,2010-019912-18,AIJ,i
31,2010-019912-18,o,o
31,2010-019912-18,artritis,i
31,2010-019912-18,reumatoide,i
31,2010-019912-18,juvenil,i
31,2010-019912-18,ARJ,i
31,2010-019912-18,yo,o
31,2010-019912-18,AR,i
31,2010-019912-18,diagnosticadas,i
31,2010-019912-18,antes,o
31,2010-019912-18,de,o
31,2010-019912-18,los,o
31,2010-019912-18,16,o
31,2010-019912-18,años,o
31,2010-019912-18,de,o
31,2010-019912-18,edad,o
31,2010-019912-18,Enfermedad,i
31,2010-019912-18,articular,i
31,2010-019912-18,inflamatoria,i
31,2010-019912-18,distinta,o
31,2010-019912-18,de,o
31,2010-019912-18,AR,i
31,2010-019912-18,en,o
31,2010-019912-18,el,o
31,2010-019912-18,pasado,o
31,2010-019912-18,o,o
31,2010-019912-18,en,o
31,2010-019912-18,la,o
31,2010-019912-18,actualidad,o
32,2010-019912-18,EudraCT,o
32,2010-019912-18,Nº,o
32,2010-019912-18,201001991218,o
32,2010-019912-18,Titulo,o
32,2010-019912-18,cientifico,o
32,2010-019912-18,Estudio,o
32,2010-019912-18,randomizado,o
32,2010-019912-18,doble,o
32,2010-019912-18,ciego,o
32,2010-019912-18,con,o
32,2010-019912-18,grupos,o
32,2010-019912-18,de,o
32,2010-019912-18,tratamiento,i
32,2010-019912-18,paralelos,o
32,2010-019912-18,para,o
32,2010-019912-18,evaluar,i
32,2010-019912-18,la,i
32,2010-019912-18,seguridad,i
32,2010-019912-18,y,o
32,2010-019912-18,el,o
32,2010-019912-18,efecto,o
32,2010-019912-18,sobre,o
32,2010-019912-18,el,o
32,2010-019912-18,resultado,o
32,2010-019912-18,clinico,o
32,2010-019912-18,de,o
32,2010-019912-18,tocilizumab,i
32,2010-019912-18,SC,o
32,2010-019912-18,frente,o
32,2010-019912-18,a,o
32,2010-019912-18,placebo,i
32,2010-019912-18,SC,o
32,2010-019912-18,en,o
32,2010-019912-18,combinacion,o
32,2010-019912-18,con,o
32,2010-019912-18,farmacos,i
32,2010-019912-18,antirreumaticos,i
32,2010-019912-18,modificadores,i
32,2010-019912-18,de,i
32,2010-019912-18,la,i
32,2010-019912-18,enfermedad,i
32,2010-019912-18,FAMEs,i
32,2010-019912-18,tradicionales,o
32,2010-019912-18,en,o
32,2010-019912-18,pacientes,o
32,2010-019912-18,con,o
32,2010-019912-18,artritis,i
32,2010-019912-18,reumatoide,i
32,2010-019912-18,activa,o
32,2010-019912-18,moderada,o
32,2010-019912-18,a,o
32,2010-019912-18,severa,o
32,2010-019912-18,Indicacion,o
32,2010-019912-18,cientifica,o
32,2010-019912-18,Artritis,i
32,2010-019912-18,Reumatoide,i
32,2010-019912-18,AR,i
32,2010-019912-18,Criterios,o
32,2010-019912-18,de,o
32,2010-019912-18,inclusion,o
32,2010-019912-18,Presentar,o
32,2010-019912-18,artritis,i
32,2010-019912-18,reumatoide,i
32,2010-019912-18,de,o
32,2010-019912-18,mayor,o
32,2010-019912-18,o,o
32,2010-019912-18,igual,o
32,2010-019912-18,a,o
32,2010-019912-18,6,o
32,2010-019912-18,meses,o
32,2010-019912-18,de,o
32,2010-019912-18,duracion,o
32,2010-019912-18,Recibir,o
32,2010-019912-18,tratamiento,i
32,2010-019912-18,de,i
32,2010-019912-18,forma,i
32,2010-019912-18,ambulatoria,i
32,2010-019912-18,Presentar,o
32,2010-019912-18,un,o
32,2010-019912-18,recuento,o
32,2010-019912-18,de,o
32,2010-019912-18,articulaciones,i
32,2010-019912-18,inflamadas,i
32,2010-019912-18,RAI,o
32,2010-019912-18,mayor,o
32,2010-019912-18,o,o
32,2010-019912-18,igual,o
32,2010-019912-18,a,o
32,2010-019912-18,6,o
32,2010-019912-18,recuento,o
32,2010-019912-18,de,o
32,2010-019912-18,66,o
32,2010-019912-18,articulaciones,i
32,2010-019912-18,y,o
32,2010-019912-18,de,o
32,2010-019912-18,articulaciones,i
32,2010-019912-18,dolorosas,i
32,2010-019912-18,RAD,o
32,2010-019912-18,mayor,o
32,2010-019912-18,o,o
32,2010-019912-18,igual,o
32,2010-019912-18,a,o
32,2010-019912-18,8,o
32,2010-019912-18,recuento,o
32,2010-019912-18,de,o
32,2010-019912-18,68,o
32,2010-019912-18,articulaciones,i
32,2010-019912-18,en,o
32,2010-019912-18,las,o
32,2010-019912-18,visitas,o
32,2010-019912-18,de,o
32,2010-019912-18,seleccion,o
32,2010-019912-18,y,o
32,2010-019912-18,basal,o
32,2010-019912-18,Los,o
32,2010-019912-18,pacientes,o
32,2010-019912-18,deben,o
32,2010-019912-18,estar,o
32,2010-019912-18,recibiendo,o
32,2010-019912-18,tratamiento,i
32,2010-019912-18,con,o
32,2010-019912-18,una,o
32,2010-019912-18,dosis,o
32,2010-019912-18,estable,o
32,2010-019912-18,de,o
32,2010-019912-18,los,o
32,2010-019912-18,FAMEs,i
32,2010-019912-18,permitidos,o
32,2010-019912-18,como,o
32,2010-019912-18,minimo,o
32,2010-019912-18,8,o
32,2010-019912-18,semanas,o
32,2010-019912-18,antes,o
32,2010-019912-18,de,o
32,2010-019912-18,la,o
32,2010-019912-18,visita,o
32,2010-019912-18,basal,o
32,2010-019912-18,Criterios,o
32,2010-019912-18,de,o
32,2010-019912-18,exclusion,o
32,2010-019912-18,Pacientes,o
32,2010-019912-18,sometidos,o
32,2010-019912-18,a,o
32,2010-019912-18,intervenciones,i
32,2010-019912-18,de,i
32,2010-019912-18,cirugia,i
32,2010-019912-18,mayor,i
32,2010-019912-18,incluyendo,o
32,2010-019912-18,cirugia,i
32,2010-019912-18,articular,i
32,2010-019912-18,en,o
32,2010-019912-18,las,o
32,2010-019912-18,8,o
32,2010-019912-18,semanas,o
32,2010-019912-18,previas,o
32,2010-019912-18,a,o
32,2010-019912-18,la,o
32,2010-019912-18,visita,o
32,2010-019912-18,de,o
32,2010-019912-18,seleccion,o
32,2010-019912-18,o,o
32,2010-019912-18,que,o
32,2010-019912-18,tengan,o
32,2010-019912-18,previsto,o
32,2010-019912-18,someterse,o
32,2010-019912-18,a,o
32,2010-019912-18,una,o
32,2010-019912-18,intervencion,i
32,2010-019912-18,de,o
32,2010-019912-18,este,o
32,2010-019912-18,tipo,o
32,2010-019912-18,en,o
32,2010-019912-18,los,o
32,2010-019912-18,6,o
32,2010-019912-18,meses,o
32,2010-019912-18,siguientes,o
32,2010-019912-18,a,o
32,2010-019912-18,la,o
32,2010-019912-18,randomizacion,i
32,2010-019912-18,Enfermedad,i
32,2010-019912-18,reumatica,i
32,2010-019912-18,autoinmune,i
32,2010-019912-18,distinta,o
32,2010-019912-18,de,o
32,2010-019912-18,AR,i
32,2010-019912-18,Se,o
32,2010-019912-18,permite,o
32,2010-019912-18,la,o
32,2010-019912-18,inclusion,o
32,2010-019912-18,de,o
32,2010-019912-18,pacientes,o
32,2010-019912-18,con,o
32,2010-019912-18,sindrome,i
32,2010-019912-18,de,i
32,2010-019912-18,Sjögren,i
32,2010-019912-18,secundario,i
32,2010-019912-18,asociado,o
32,2010-019912-18,a,o
32,2010-019912-18,AR,i
32,2010-019912-18,Clase,o
32,2010-019912-18,funcional,o
32,2010-019912-18,IV,o
32,2010-019912-18,definida,o
32,2010-019912-18,de,o
32,2010-019912-18,acuerdo,o
32,2010-019912-18,con,o
32,2010-019912-18,la,o
32,2010-019912-18,Clasificacion,o
32,2010-019912-18,del,o
32,2010-019912-18,ACR,o
32,2010-019912-18,del,o
32,2010-019912-18,Estado,o
32,2010-019912-18,Funcional,o
32,2010-019912-18,en,o
32,2010-019912-18,Artritis,i
32,2010-019912-18,Reumatoide,i
32,2010-019912-18,Artritis,i
32,2010-019912-18,idiopatica,i
32,2010-019912-18,juvenil,i
32,2010-019912-18,AIJ,i
32,2010-019912-18,o,o
32,2010-019912-18,artritis,i
32,2010-019912-18,reumatoide,i
32,2010-019912-18,juvenil,i
32,2010-019912-18,ARJ,i
32,2010-019912-18,yo,o
32,2010-019912-18,AR,i
32,2010-019912-18,diagnosticadas,i
32,2010-019912-18,antes,o
32,2010-019912-18,de,o
32,2010-019912-18,los,o
32,2010-019912-18,16,o
32,2010-019912-18,años,o
32,2010-019912-18,de,o
32,2010-019912-18,edad,o
32,2010-019912-18,Enfermedad,i
32,2010-019912-18,articular,i
32,2010-019912-18,inflamatoria,i
32,2010-019912-18,distinta,o
32,2010-019912-18,de,o
32,2010-019912-18,AR,i
32,2010-019912-18,en,o
32,2010-019912-18,el,o
32,2010-019912-18,pasado,o
32,2010-019912-18,o,o
32,2010-019912-18,en,o
32,2010-019912-18,la,o
32,2010-019912-18,actualidad,o
33,2010-019912-18,EudraCT,o
33,2010-019912-18,Nº,o
33,2010-019912-18,201001991218,o
33,2010-019912-18,Titulo,o
33,2010-019912-18,cientifico,o
33,2010-019912-18,Estudio,o
33,2010-019912-18,randomizado,o
33,2010-019912-18,doble,o
33,2010-019912-18,ciego,o
33,2010-019912-18,con,o
33,2010-019912-18,grupos,o
33,2010-019912-18,de,o
33,2010-019912-18,tratamiento,i
33,2010-019912-18,paralelos,o
33,2010-019912-18,para,o
33,2010-019912-18,evaluar,i
33,2010-019912-18,la,i
33,2010-019912-18,seguridad,i
33,2010-019912-18,y,o
33,2010-019912-18,el,o
33,2010-019912-18,efecto,o
33,2010-019912-18,sobre,o
33,2010-019912-18,el,o
33,2010-019912-18,resultado,o
33,2010-019912-18,clinico,o
33,2010-019912-18,de,o
33,2010-019912-18,tocilizumab,i
33,2010-019912-18,SC,o
33,2010-019912-18,frente,o
33,2010-019912-18,a,o
33,2010-019912-18,placebo,i
33,2010-019912-18,SC,o
33,2010-019912-18,en,o
33,2010-019912-18,combinacion,o
33,2010-019912-18,con,o
33,2010-019912-18,farmacos,i
33,2010-019912-18,antirreumaticos,i
33,2010-019912-18,modificadores,i
33,2010-019912-18,de,i
33,2010-019912-18,la,i
33,2010-019912-18,enfermedad,i
33,2010-019912-18,FAMEs,i
33,2010-019912-18,tradicionales,o
33,2010-019912-18,en,o
33,2010-019912-18,pacientes,o
33,2010-019912-18,con,o
33,2010-019912-18,artritis,i
33,2010-019912-18,reumatoide,i
33,2010-019912-18,activa,o
33,2010-019912-18,moderada,o
33,2010-019912-18,a,o
33,2010-019912-18,severa,o
33,2010-019912-18,Indicacion,o
33,2010-019912-18,cientifica,o
33,2010-019912-18,Artritis,i
33,2010-019912-18,Reumatoide,i
33,2010-019912-18,AR,i
33,2010-019912-18,Criterios,o
33,2010-019912-18,de,o
33,2010-019912-18,inclusion,o
33,2010-019912-18,Presentar,o
33,2010-019912-18,artritis,i
33,2010-019912-18,reumatoide,i
33,2010-019912-18,de,o
33,2010-019912-18,mayor,o
33,2010-019912-18,o,o
33,2010-019912-18,igual,o
33,2010-019912-18,a,o
33,2010-019912-18,6,o
33,2010-019912-18,meses,o
33,2010-019912-18,de,o
33,2010-019912-18,duracion,o
33,2010-019912-18,Recibir,o
33,2010-019912-18,tratamiento,i
33,2010-019912-18,de,i
33,2010-019912-18,forma,i
33,2010-019912-18,ambulatoria,i
33,2010-019912-18,Presentar,o
33,2010-019912-18,un,o
33,2010-019912-18,recuento,o
33,2010-019912-18,de,o
33,2010-019912-18,articulaciones,i
33,2010-019912-18,inflamadas,i
33,2010-019912-18,RAI,o
33,2010-019912-18,mayor,o
33,2010-019912-18,o,o
33,2010-019912-18,igual,o
33,2010-019912-18,a,o
33,2010-019912-18,6,o
33,2010-019912-18,recuento,o
33,2010-019912-18,de,o
33,2010-019912-18,66,o
33,2010-019912-18,articulaciones,i
33,2010-019912-18,y,o
33,2010-019912-18,de,o
33,2010-019912-18,articulaciones,i
33,2010-019912-18,dolorosas,i
33,2010-019912-18,RAD,o
33,2010-019912-18,mayor,o
33,2010-019912-18,o,o
33,2010-019912-18,igual,o
33,2010-019912-18,a,o
33,2010-019912-18,8,o
33,2010-019912-18,recuento,o
33,2010-019912-18,de,o
33,2010-019912-18,68,o
33,2010-019912-18,articulaciones,i
33,2010-019912-18,en,o
33,2010-019912-18,las,o
33,2010-019912-18,visitas,o
33,2010-019912-18,de,o
33,2010-019912-18,seleccion,o
33,2010-019912-18,y,o
33,2010-019912-18,basal,o
33,2010-019912-18,Los,o
33,2010-019912-18,pacientes,o
33,2010-019912-18,deben,o
33,2010-019912-18,estar,o
33,2010-019912-18,recibiendo,o
33,2010-019912-18,tratamiento,i
33,2010-019912-18,con,o
33,2010-019912-18,una,o
33,2010-019912-18,dosis,o
33,2010-019912-18,estable,o
33,2010-019912-18,de,o
33,2010-019912-18,los,o
33,2010-019912-18,FAMEs,i
33,2010-019912-18,permitidos,o
33,2010-019912-18,como,o
33,2010-019912-18,minimo,o
33,2010-019912-18,8,o
33,2010-019912-18,semanas,o
33,2010-019912-18,antes,o
33,2010-019912-18,de,o
33,2010-019912-18,la,o
33,2010-019912-18,visita,o
33,2010-019912-18,basal,o
33,2010-019912-18,Criterios,o
33,2010-019912-18,de,o
33,2010-019912-18,exclusion,o
33,2010-019912-18,Pacientes,o
33,2010-019912-18,sometidos,o
33,2010-019912-18,a,o
33,2010-019912-18,intervenciones,i
33,2010-019912-18,de,i
33,2010-019912-18,cirugia,i
33,2010-019912-18,mayor,i
33,2010-019912-18,incluyendo,o
33,2010-019912-18,cirugia,i
33,2010-019912-18,articular,i
33,2010-019912-18,en,o
33,2010-019912-18,las,o
33,2010-019912-18,8,o
33,2010-019912-18,semanas,o
33,2010-019912-18,previas,o
33,2010-019912-18,a,o
33,2010-019912-18,la,o
33,2010-019912-18,visita,o
33,2010-019912-18,de,o
33,2010-019912-18,seleccion,o
33,2010-019912-18,o,o
33,2010-019912-18,que,o
33,2010-019912-18,tengan,o
33,2010-019912-18,previsto,o
33,2010-019912-18,someterse,o
33,2010-019912-18,a,o
33,2010-019912-18,una,o
33,2010-019912-18,intervencion,i
33,2010-019912-18,de,o
33,2010-019912-18,este,o
33,2010-019912-18,tipo,o
33,2010-019912-18,en,o
33,2010-019912-18,los,o
33,2010-019912-18,6,o
33,2010-019912-18,meses,o
33,2010-019912-18,siguientes,o
33,2010-019912-18,a,o
33,2010-019912-18,la,o
33,2010-019912-18,randomizacion,i
33,2010-019912-18,Enfermedad,i
33,2010-019912-18,reumatica,i
33,2010-019912-18,autoinmune,i
33,2010-019912-18,distinta,o
33,2010-019912-18,de,o
33,2010-019912-18,AR,i
33,2010-019912-18,Se,o
33,2010-019912-18,permite,o
33,2010-019912-18,la,o
33,2010-019912-18,inclusion,o
33,2010-019912-18,de,o
33,2010-019912-18,pacientes,o
33,2010-019912-18,con,o
33,2010-019912-18,sindrome,i
33,2010-019912-18,de,i
33,2010-019912-18,Sjögren,i
33,2010-019912-18,secundario,i
33,2010-019912-18,asociado,o
33,2010-019912-18,a,o
33,2010-019912-18,AR,i
33,2010-019912-18,Clase,o
33,2010-019912-18,funcional,o
33,2010-019912-18,IV,o
33,2010-019912-18,definida,o
33,2010-019912-18,de,o
33,2010-019912-18,acuerdo,o
33,2010-019912-18,con,o
33,2010-019912-18,la,o
33,2010-019912-18,Clasificacion,o
33,2010-019912-18,del,o
33,2010-019912-18,ACR,o
33,2010-019912-18,del,o
33,2010-019912-18,Estado,o
33,2010-019912-18,Funcional,o
33,2010-019912-18,en,o
33,2010-019912-18,Artritis,i
33,2010-019912-18,Reumatoide,i
33,2010-019912-18,Artritis,i
33,2010-019912-18,idiopatica,i
33,2010-019912-18,juvenil,i
33,2010-019912-18,AIJ,i
33,2010-019912-18,o,o
33,2010-019912-18,artritis,i
33,2010-019912-18,reumatoide,i
33,2010-019912-18,juvenil,i
33,2010-019912-18,ARJ,i
33,2010-019912-18,yo,o
33,2010-019912-18,AR,i
33,2010-019912-18,diagnosticadas,i
33,2010-019912-18,antes,o
33,2010-019912-18,de,o
33,2010-019912-18,los,o
33,2010-019912-18,16,o
33,2010-019912-18,años,o
33,2010-019912-18,de,o
33,2010-019912-18,edad,o
33,2010-019912-18,Enfermedad,i
33,2010-019912-18,articular,i
33,2010-019912-18,inflamatoria,i
33,2010-019912-18,distinta,o
33,2010-019912-18,de,o
33,2010-019912-18,AR,i
33,2010-019912-18,en,o
33,2010-019912-18,el,o
33,2010-019912-18,pasado,o
33,2010-019912-18,o,o
33,2010-019912-18,en,o
33,2010-019912-18,la,o
33,2010-019912-18,actualidad,o
34,2010-019912-18,EudraCT,o
34,2010-019912-18,Nº,o
34,2010-019912-18,201001991218,o
34,2010-019912-18,Titulo,o
34,2010-019912-18,cientifico,o
34,2010-019912-18,Estudio,o
34,2010-019912-18,randomizado,o
34,2010-019912-18,doble,o
34,2010-019912-18,ciego,o
34,2010-019912-18,con,o
34,2010-019912-18,grupos,o
34,2010-019912-18,de,o
34,2010-019912-18,tratamiento,i
34,2010-019912-18,paralelos,o
34,2010-019912-18,para,o
34,2010-019912-18,evaluar,i
34,2010-019912-18,la,i
34,2010-019912-18,seguridad,i
34,2010-019912-18,y,o
34,2010-019912-18,el,o
34,2010-019912-18,efecto,o
34,2010-019912-18,sobre,o
34,2010-019912-18,el,o
34,2010-019912-18,resultado,o
34,2010-019912-18,clinico,o
34,2010-019912-18,de,o
34,2010-019912-18,tocilizumab,i
34,2010-019912-18,SC,o
34,2010-019912-18,frente,o
34,2010-019912-18,a,o
34,2010-019912-18,placebo,i
34,2010-019912-18,SC,o
34,2010-019912-18,en,o
34,2010-019912-18,combinacion,o
34,2010-019912-18,con,o
34,2010-019912-18,farmacos,i
34,2010-019912-18,antirreumaticos,i
34,2010-019912-18,modificadores,i
34,2010-019912-18,de,i
34,2010-019912-18,la,i
34,2010-019912-18,enfermedad,i
34,2010-019912-18,FAMEs,i
34,2010-019912-18,tradicionales,o
34,2010-019912-18,en,o
34,2010-019912-18,pacientes,o
34,2010-019912-18,con,o
34,2010-019912-18,artritis,i
34,2010-019912-18,reumatoide,i
34,2010-019912-18,activa,o
34,2010-019912-18,moderada,o
34,2010-019912-18,a,o
34,2010-019912-18,severa,o
34,2010-019912-18,Indicacion,o
34,2010-019912-18,cientifica,o
34,2010-019912-18,Artritis,i
34,2010-019912-18,Reumatoide,i
34,2010-019912-18,AR,i
34,2010-019912-18,Criterios,o
34,2010-019912-18,de,o
34,2010-019912-18,inclusion,o
34,2010-019912-18,Presentar,o
34,2010-019912-18,artritis,i
34,2010-019912-18,reumatoide,i
34,2010-019912-18,de,o
34,2010-019912-18,mayor,o
34,2010-019912-18,o,o
34,2010-019912-18,igual,o
34,2010-019912-18,a,o
34,2010-019912-18,6,o
34,2010-019912-18,meses,o
34,2010-019912-18,de,o
34,2010-019912-18,duracion,o
34,2010-019912-18,Recibir,o
34,2010-019912-18,tratamiento,i
34,2010-019912-18,de,i
34,2010-019912-18,forma,i
34,2010-019912-18,ambulatoria,i
34,2010-019912-18,Presentar,o
34,2010-019912-18,un,o
34,2010-019912-18,recuento,o
34,2010-019912-18,de,o
34,2010-019912-18,articulaciones,i
34,2010-019912-18,inflamadas,i
34,2010-019912-18,RAI,o
34,2010-019912-18,mayor,o
34,2010-019912-18,o,o
34,2010-019912-18,igual,o
34,2010-019912-18,a,o
34,2010-019912-18,6,o
34,2010-019912-18,recuento,o
34,2010-019912-18,de,o
34,2010-019912-18,66,o
34,2010-019912-18,articulaciones,i
34,2010-019912-18,y,o
34,2010-019912-18,de,o
34,2010-019912-18,articulaciones,i
34,2010-019912-18,dolorosas,i
34,2010-019912-18,RAD,o
34,2010-019912-18,mayor,o
34,2010-019912-18,o,o
34,2010-019912-18,igual,o
34,2010-019912-18,a,o
34,2010-019912-18,8,o
34,2010-019912-18,recuento,o
34,2010-019912-18,de,o
34,2010-019912-18,68,o
34,2010-019912-18,articulaciones,i
34,2010-019912-18,en,o
34,2010-019912-18,las,o
34,2010-019912-18,visitas,o
34,2010-019912-18,de,o
34,2010-019912-18,seleccion,o
34,2010-019912-18,y,o
34,2010-019912-18,basal,o
34,2010-019912-18,Los,o
34,2010-019912-18,pacientes,o
34,2010-019912-18,deben,o
34,2010-019912-18,estar,o
34,2010-019912-18,recibiendo,o
34,2010-019912-18,tratamiento,i
34,2010-019912-18,con,o
34,2010-019912-18,una,o
34,2010-019912-18,dosis,o
34,2010-019912-18,estable,o
34,2010-019912-18,de,o
34,2010-019912-18,los,o
34,2010-019912-18,FAMEs,i
34,2010-019912-18,permitidos,o
34,2010-019912-18,como,o
34,2010-019912-18,minimo,o
34,2010-019912-18,8,o
34,2010-019912-18,semanas,o
34,2010-019912-18,antes,o
34,2010-019912-18,de,o
34,2010-019912-18,la,o
34,2010-019912-18,visita,o
34,2010-019912-18,basal,o
34,2010-019912-18,Criterios,o
34,2010-019912-18,de,o
34,2010-019912-18,exclusion,o
34,2010-019912-18,Pacientes,o
34,2010-019912-18,sometidos,o
34,2010-019912-18,a,o
34,2010-019912-18,intervenciones,i
34,2010-019912-18,de,i
34,2010-019912-18,cirugia,i
34,2010-019912-18,mayor,i
34,2010-019912-18,incluyendo,o
34,2010-019912-18,cirugia,i
34,2010-019912-18,articular,i
34,2010-019912-18,en,o
34,2010-019912-18,las,o
34,2010-019912-18,8,o
34,2010-019912-18,semanas,o
34,2010-019912-18,previas,o
34,2010-019912-18,a,o
34,2010-019912-18,la,o
34,2010-019912-18,visita,o
34,2010-019912-18,de,o
34,2010-019912-18,seleccion,o
34,2010-019912-18,o,o
34,2010-019912-18,que,o
34,2010-019912-18,tengan,o
34,2010-019912-18,previsto,o
34,2010-019912-18,someterse,o
34,2010-019912-18,a,o
34,2010-019912-18,una,o
34,2010-019912-18,intervencion,i
34,2010-019912-18,de,o
34,2010-019912-18,este,o
34,2010-019912-18,tipo,o
34,2010-019912-18,en,o
34,2010-019912-18,los,o
34,2010-019912-18,6,o
34,2010-019912-18,meses,o
34,2010-019912-18,siguientes,o
34,2010-019912-18,a,o
34,2010-019912-18,la,o
34,2010-019912-18,randomizacion,i
34,2010-019912-18,Enfermedad,i
34,2010-019912-18,reumatica,i
34,2010-019912-18,autoinmune,i
34,2010-019912-18,distinta,o
34,2010-019912-18,de,o
34,2010-019912-18,AR,i
34,2010-019912-18,Se,o
34,2010-019912-18,permite,o
34,2010-019912-18,la,o
34,2010-019912-18,inclusion,o
34,2010-019912-18,de,o
34,2010-019912-18,pacientes,o
34,2010-019912-18,con,o
34,2010-019912-18,sindrome,i
34,2010-019912-18,de,i
34,2010-019912-18,Sjögren,i
34,2010-019912-18,secundario,i
34,2010-019912-18,asociado,o
34,2010-019912-18,a,o
34,2010-019912-18,AR,i
34,2010-019912-18,Clase,o
34,2010-019912-18,funcional,o
34,2010-019912-18,IV,o
34,2010-019912-18,definida,o
34,2010-019912-18,de,o
34,2010-019912-18,acuerdo,o
34,2010-019912-18,con,o
34,2010-019912-18,la,o
34,2010-019912-18,Clasificacion,o
34,2010-019912-18,del,o
34,2010-019912-18,ACR,o
34,2010-019912-18,del,o
34,2010-019912-18,Estado,o
34,2010-019912-18,Funcional,o
34,2010-019912-18,en,o
34,2010-019912-18,Artritis,i
34,2010-019912-18,Reumatoide,i
34,2010-019912-18,Artritis,i
34,2010-019912-18,idiopatica,i
34,2010-019912-18,juvenil,i
34,2010-019912-18,AIJ,i
34,2010-019912-18,o,o
34,2010-019912-18,artritis,i
34,2010-019912-18,reumatoide,i
34,2010-019912-18,juvenil,i
34,2010-019912-18,ARJ,i
34,2010-019912-18,yo,o
34,2010-019912-18,AR,i
34,2010-019912-18,diagnosticadas,i
34,2010-019912-18,antes,o
34,2010-019912-18,de,o
34,2010-019912-18,los,o
34,2010-019912-18,16,o
34,2010-019912-18,años,o
34,2010-019912-18,de,o
34,2010-019912-18,edad,o
34,2010-019912-18,Enfermedad,i
34,2010-019912-18,articular,i
34,2010-019912-18,inflamatoria,i
34,2010-019912-18,distinta,o
34,2010-019912-18,de,o
34,2010-019912-18,AR,i
34,2010-019912-18,en,o
34,2010-019912-18,el,o
34,2010-019912-18,pasado,o
34,2010-019912-18,o,o
34,2010-019912-18,en,o
34,2010-019912-18,la,o
34,2010-019912-18,actualidad,o
35,2010-019912-18,EudraCT,o
35,2010-019912-18,Nº,o
35,2010-019912-18,201001991218,o
35,2010-019912-18,Titulo,o
35,2010-019912-18,cientifico,o
35,2010-019912-18,Estudio,o
35,2010-019912-18,randomizado,o
35,2010-019912-18,doble,o
35,2010-019912-18,ciego,o
35,2010-019912-18,con,o
35,2010-019912-18,grupos,o
35,2010-019912-18,de,o
35,2010-019912-18,tratamiento,i
35,2010-019912-18,paralelos,o
35,2010-019912-18,para,o
35,2010-019912-18,evaluar,i
35,2010-019912-18,la,i
35,2010-019912-18,seguridad,i
35,2010-019912-18,y,o
35,2010-019912-18,el,o
35,2010-019912-18,efecto,o
35,2010-019912-18,sobre,o
35,2010-019912-18,el,o
35,2010-019912-18,resultado,o
35,2010-019912-18,clinico,o
35,2010-019912-18,de,o
35,2010-019912-18,tocilizumab,i
35,2010-019912-18,SC,o
35,2010-019912-18,frente,o
35,2010-019912-18,a,o
35,2010-019912-18,placebo,i
35,2010-019912-18,SC,o
35,2010-019912-18,en,o
35,2010-019912-18,combinacion,o
35,2010-019912-18,con,o
35,2010-019912-18,farmacos,i
35,2010-019912-18,antirreumaticos,i
35,2010-019912-18,modificadores,i
35,2010-019912-18,de,i
35,2010-019912-18,la,i
35,2010-019912-18,enfermedad,i
35,2010-019912-18,FAMEs,i
35,2010-019912-18,tradicionales,o
35,2010-019912-18,en,o
35,2010-019912-18,pacientes,o
35,2010-019912-18,con,o
35,2010-019912-18,artritis,i
35,2010-019912-18,reumatoide,i
35,2010-019912-18,activa,o
35,2010-019912-18,moderada,o
35,2010-019912-18,a,o
35,2010-019912-18,severa,o
35,2010-019912-18,Indicacion,o
35,2010-019912-18,cientifica,o
35,2010-019912-18,Artritis,i
35,2010-019912-18,Reumatoide,i
35,2010-019912-18,AR,i
35,2010-019912-18,Criterios,o
35,2010-019912-18,de,o
35,2010-019912-18,inclusion,o
35,2010-019912-18,Presentar,o
35,2010-019912-18,artritis,i
35,2010-019912-18,reumatoide,i
35,2010-019912-18,de,o
35,2010-019912-18,mayor,o
35,2010-019912-18,o,o
35,2010-019912-18,igual,o
35,2010-019912-18,a,o
35,2010-019912-18,6,o
35,2010-019912-18,meses,o
35,2010-019912-18,de,o
35,2010-019912-18,duracion,o
35,2010-019912-18,Recibir,o
35,2010-019912-18,tratamiento,i
35,2010-019912-18,de,i
35,2010-019912-18,forma,i
35,2010-019912-18,ambulatoria,i
35,2010-019912-18,Presentar,o
35,2010-019912-18,un,o
35,2010-019912-18,recuento,o
35,2010-019912-18,de,o
35,2010-019912-18,articulaciones,i
35,2010-019912-18,inflamadas,i
35,2010-019912-18,RAI,o
35,2010-019912-18,mayor,o
35,2010-019912-18,o,o
35,2010-019912-18,igual,o
35,2010-019912-18,a,o
35,2010-019912-18,6,o
35,2010-019912-18,recuento,o
35,2010-019912-18,de,o
35,2010-019912-18,66,o
35,2010-019912-18,articulaciones,i
35,2010-019912-18,y,o
35,2010-019912-18,de,o
35,2010-019912-18,articulaciones,i
35,2010-019912-18,dolorosas,i
35,2010-019912-18,RAD,o
35,2010-019912-18,mayor,o
35,2010-019912-18,o,o
35,2010-019912-18,igual,o
35,2010-019912-18,a,o
35,2010-019912-18,8,o
35,2010-019912-18,recuento,o
35,2010-019912-18,de,o
35,2010-019912-18,68,o
35,2010-019912-18,articulaciones,i
35,2010-019912-18,en,o
35,2010-019912-18,las,o
35,2010-019912-18,visitas,o
35,2010-019912-18,de,o
35,2010-019912-18,seleccion,o
35,2010-019912-18,y,o
35,2010-019912-18,basal,o
35,2010-019912-18,Los,o
35,2010-019912-18,pacientes,o
35,2010-019912-18,deben,o
35,2010-019912-18,estar,o
35,2010-019912-18,recibiendo,o
35,2010-019912-18,tratamiento,i
35,2010-019912-18,con,o
35,2010-019912-18,una,o
35,2010-019912-18,dosis,o
35,2010-019912-18,estable,o
35,2010-019912-18,de,o
35,2010-019912-18,los,o
35,2010-019912-18,FAMEs,i
35,2010-019912-18,permitidos,o
35,2010-019912-18,como,o
35,2010-019912-18,minimo,o
35,2010-019912-18,8,o
35,2010-019912-18,semanas,o
35,2010-019912-18,antes,o
35,2010-019912-18,de,o
35,2010-019912-18,la,o
35,2010-019912-18,visita,o
35,2010-019912-18,basal,o
35,2010-019912-18,Criterios,o
35,2010-019912-18,de,o
35,2010-019912-18,exclusion,o
35,2010-019912-18,Pacientes,o
35,2010-019912-18,sometidos,o
35,2010-019912-18,a,o
35,2010-019912-18,intervenciones,i
35,2010-019912-18,de,i
35,2010-019912-18,cirugia,i
35,2010-019912-18,mayor,i
35,2010-019912-18,incluyendo,o
35,2010-019912-18,cirugia,i
35,2010-019912-18,articular,i
35,2010-019912-18,en,o
35,2010-019912-18,las,o
35,2010-019912-18,8,o
35,2010-019912-18,semanas,o
35,2010-019912-18,previas,o
35,2010-019912-18,a,o
35,2010-019912-18,la,o
35,2010-019912-18,visita,o
35,2010-019912-18,de,o
35,2010-019912-18,seleccion,o
35,2010-019912-18,o,o
35,2010-019912-18,que,o
35,2010-019912-18,tengan,o
35,2010-019912-18,previsto,o
35,2010-019912-18,someterse,o
35,2010-019912-18,a,o
35,2010-019912-18,una,o
35,2010-019912-18,intervencion,i
35,2010-019912-18,de,o
35,2010-019912-18,este,o
35,2010-019912-18,tipo,o
35,2010-019912-18,en,o
35,2010-019912-18,los,o
35,2010-019912-18,6,o
35,2010-019912-18,meses,o
35,2010-019912-18,siguientes,o
35,2010-019912-18,a,o
35,2010-019912-18,la,o
35,2010-019912-18,randomizacion,i
35,2010-019912-18,Enfermedad,i
35,2010-019912-18,reumatica,i
35,2010-019912-18,autoinmune,i
35,2010-019912-18,distinta,o
35,2010-019912-18,de,o
35,2010-019912-18,AR,i
35,2010-019912-18,Se,o
35,2010-019912-18,permite,o
35,2010-019912-18,la,o
35,2010-019912-18,inclusion,o
35,2010-019912-18,de,o
35,2010-019912-18,pacientes,o
35,2010-019912-18,con,o
35,2010-019912-18,sindrome,i
35,2010-019912-18,de,i
35,2010-019912-18,Sjögren,i
35,2010-019912-18,secundario,i
35,2010-019912-18,asociado,o
35,2010-019912-18,a,o
35,2010-019912-18,AR,i
35,2010-019912-18,Clase,o
35,2010-019912-18,funcional,o
35,2010-019912-18,IV,o
35,2010-019912-18,definida,o
35,2010-019912-18,de,o
35,2010-019912-18,acuerdo,o
35,2010-019912-18,con,o
35,2010-019912-18,la,o
35,2010-019912-18,Clasificacion,o
35,2010-019912-18,del,o
35,2010-019912-18,ACR,o
35,2010-019912-18,del,o
35,2010-019912-18,Estado,o
35,2010-019912-18,Funcional,o
35,2010-019912-18,en,o
35,2010-019912-18,Artritis,i
35,2010-019912-18,Reumatoide,i
35,2010-019912-18,Artritis,i
35,2010-019912-18,idiopatica,i
35,2010-019912-18,juvenil,i
35,2010-019912-18,AIJ,i
35,2010-019912-18,o,o
35,2010-019912-18,artritis,i
35,2010-019912-18,reumatoide,i
35,2010-019912-18,juvenil,i
35,2010-019912-18,ARJ,i
35,2010-019912-18,yo,o
35,2010-019912-18,AR,i
35,2010-019912-18,diagnosticadas,i
35,2010-019912-18,antes,o
35,2010-019912-18,de,o
35,2010-019912-18,los,o
35,2010-019912-18,16,o
35,2010-019912-18,años,o
35,2010-019912-18,de,o
35,2010-019912-18,edad,o
35,2010-019912-18,Enfermedad,i
35,2010-019912-18,articular,i
35,2010-019912-18,inflamatoria,i
35,2010-019912-18,distinta,o
35,2010-019912-18,de,o
35,2010-019912-18,AR,i
35,2010-019912-18,en,o
35,2010-019912-18,el,o
35,2010-019912-18,pasado,o
35,2010-019912-18,o,o
35,2010-019912-18,en,o
35,2010-019912-18,la,o
35,2010-019912-18,actualidad,o
36,2010-019912-18,EudraCT,o
36,2010-019912-18,Nº,o
36,2010-019912-18,201001991218,o
36,2010-019912-18,Titulo,o
36,2010-019912-18,cientifico,o
36,2010-019912-18,Estudio,o
36,2010-019912-18,randomizado,o
36,2010-019912-18,doble,o
36,2010-019912-18,ciego,o
36,2010-019912-18,con,o
36,2010-019912-18,grupos,o
36,2010-019912-18,de,o
36,2010-019912-18,tratamiento,i
36,2010-019912-18,paralelos,o
36,2010-019912-18,para,o
36,2010-019912-18,evaluar,i
36,2010-019912-18,la,i
36,2010-019912-18,seguridad,i
36,2010-019912-18,y,o
36,2010-019912-18,el,o
36,2010-019912-18,efecto,o
36,2010-019912-18,sobre,o
36,2010-019912-18,el,o
36,2010-019912-18,resultado,o
36,2010-019912-18,clinico,o
36,2010-019912-18,de,o
36,2010-019912-18,tocilizumab,i
36,2010-019912-18,SC,o
36,2010-019912-18,frente,o
36,2010-019912-18,a,o
36,2010-019912-18,placebo,i
36,2010-019912-18,SC,o
36,2010-019912-18,en,o
36,2010-019912-18,combinacion,o
36,2010-019912-18,con,o
36,2010-019912-18,farmacos,i
36,2010-019912-18,antirreumaticos,i
36,2010-019912-18,modificadores,i
36,2010-019912-18,de,i
36,2010-019912-18,la,i
36,2010-019912-18,enfermedad,i
36,2010-019912-18,FAMEs,i
36,2010-019912-18,tradicionales,o
36,2010-019912-18,en,o
36,2010-019912-18,pacientes,o
36,2010-019912-18,con,o
36,2010-019912-18,artritis,i
36,2010-019912-18,reumatoide,i
36,2010-019912-18,activa,o
36,2010-019912-18,moderada,o
36,2010-019912-18,a,o
36,2010-019912-18,severa,o
36,2010-019912-18,Indicacion,o
36,2010-019912-18,cientifica,o
36,2010-019912-18,Artritis,i
36,2010-019912-18,Reumatoide,i
36,2010-019912-18,AR,i
36,2010-019912-18,Criterios,o
36,2010-019912-18,de,o
36,2010-019912-18,inclusion,o
36,2010-019912-18,Presentar,o
36,2010-019912-18,artritis,i
36,2010-019912-18,reumatoide,i
36,2010-019912-18,de,o
36,2010-019912-18,mayor,o
36,2010-019912-18,o,o
36,2010-019912-18,igual,o
36,2010-019912-18,a,o
36,2010-019912-18,6,o
36,2010-019912-18,meses,o
36,2010-019912-18,de,o
36,2010-019912-18,duracion,o
36,2010-019912-18,Recibir,o
36,2010-019912-18,tratamiento,i
36,2010-019912-18,de,i
36,2010-019912-18,forma,i
36,2010-019912-18,ambulatoria,i
36,2010-019912-18,Presentar,o
36,2010-019912-18,un,o
36,2010-019912-18,recuento,o
36,2010-019912-18,de,o
36,2010-019912-18,articulaciones,i
36,2010-019912-18,inflamadas,i
36,2010-019912-18,RAI,o
36,2010-019912-18,mayor,o
36,2010-019912-18,o,o
36,2010-019912-18,igual,o
36,2010-019912-18,a,o
36,2010-019912-18,6,o
36,2010-019912-18,recuento,o
36,2010-019912-18,de,o
36,2010-019912-18,66,o
36,2010-019912-18,articulaciones,i
36,2010-019912-18,y,o
36,2010-019912-18,de,o
36,2010-019912-18,articulaciones,i
36,2010-019912-18,dolorosas,i
36,2010-019912-18,RAD,o
36,2010-019912-18,mayor,o
36,2010-019912-18,o,o
36,2010-019912-18,igual,o
36,2010-019912-18,a,o
36,2010-019912-18,8,o
36,2010-019912-18,recuento,o
36,2010-019912-18,de,o
36,2010-019912-18,68,o
36,2010-019912-18,articulaciones,i
36,2010-019912-18,en,o
36,2010-019912-18,las,o
36,2010-019912-18,visitas,o
36,2010-019912-18,de,o
36,2010-019912-18,seleccion,o
36,2010-019912-18,y,o
36,2010-019912-18,basal,o
36,2010-019912-18,Los,o
36,2010-019912-18,pacientes,o
36,2010-019912-18,deben,o
36,2010-019912-18,estar,o
36,2010-019912-18,recibiendo,o
36,2010-019912-18,tratamiento,i
36,2010-019912-18,con,o
36,2010-019912-18,una,o
36,2010-019912-18,dosis,o
36,2010-019912-18,estable,o
36,2010-019912-18,de,o
36,2010-019912-18,los,o
36,2010-019912-18,FAMEs,i
36,2010-019912-18,permitidos,o
36,2010-019912-18,como,o
36,2010-019912-18,minimo,o
36,2010-019912-18,8,o
36,2010-019912-18,semanas,o
36,2010-019912-18,antes,o
36,2010-019912-18,de,o
36,2010-019912-18,la,o
36,2010-019912-18,visita,o
36,2010-019912-18,basal,o
36,2010-019912-18,Criterios,o
36,2010-019912-18,de,o
36,2010-019912-18,exclusion,o
36,2010-019912-18,Pacientes,o
36,2010-019912-18,sometidos,o
36,2010-019912-18,a,o
36,2010-019912-18,intervenciones,i
36,2010-019912-18,de,i
36,2010-019912-18,cirugia,i
36,2010-019912-18,mayor,i
36,2010-019912-18,incluyendo,o
36,2010-019912-18,cirugia,i
36,2010-019912-18,articular,i
36,2010-019912-18,en,o
36,2010-019912-18,las,o
36,2010-019912-18,8,o
36,2010-019912-18,semanas,o
36,2010-019912-18,previas,o
36,2010-019912-18,a,o
36,2010-019912-18,la,o
36,2010-019912-18,visita,o
36,2010-019912-18,de,o
36,2010-019912-18,seleccion,o
36,2010-019912-18,o,o
36,2010-019912-18,que,o
36,2010-019912-18,tengan,o
36,2010-019912-18,previsto,o
36,2010-019912-18,someterse,o
36,2010-019912-18,a,o
36,2010-019912-18,una,o
36,2010-019912-18,intervencion,i
36,2010-019912-18,de,o
36,2010-019912-18,este,o
36,2010-019912-18,tipo,o
36,2010-019912-18,en,o
36,2010-019912-18,los,o
36,2010-019912-18,6,o
36,2010-019912-18,meses,o
36,2010-019912-18,siguientes,o
36,2010-019912-18,a,o
36,2010-019912-18,la,o
36,2010-019912-18,randomizacion,i
36,2010-019912-18,Enfermedad,i
36,2010-019912-18,reumatica,i
36,2010-019912-18,autoinmune,i
36,2010-019912-18,distinta,o
36,2010-019912-18,de,o
36,2010-019912-18,AR,i
36,2010-019912-18,Se,o
36,2010-019912-18,permite,o
36,2010-019912-18,la,o
36,2010-019912-18,inclusion,o
36,2010-019912-18,de,o
36,2010-019912-18,pacientes,o
36,2010-019912-18,con,o
36,2010-019912-18,sindrome,i
36,2010-019912-18,de,i
36,2010-019912-18,Sjögren,i
36,2010-019912-18,secundario,i
36,2010-019912-18,asociado,o
36,2010-019912-18,a,o
36,2010-019912-18,AR,i
36,2010-019912-18,Clase,o
36,2010-019912-18,funcional,o
36,2010-019912-18,IV,o
36,2010-019912-18,definida,o
36,2010-019912-18,de,o
36,2010-019912-18,acuerdo,o
36,2010-019912-18,con,o
36,2010-019912-18,la,o
36,2010-019912-18,Clasificacion,o
36,2010-019912-18,del,o
36,2010-019912-18,ACR,o
36,2010-019912-18,del,o
36,2010-019912-18,Estado,o
36,2010-019912-18,Funcional,o
36,2010-019912-18,en,o
36,2010-019912-18,Artritis,i
36,2010-019912-18,Reumatoide,i
36,2010-019912-18,Artritis,i
36,2010-019912-18,idiopatica,i
36,2010-019912-18,juvenil,i
36,2010-019912-18,AIJ,i
36,2010-019912-18,o,o
36,2010-019912-18,artritis,i
36,2010-019912-18,reumatoide,i
36,2010-019912-18,juvenil,i
36,2010-019912-18,ARJ,i
36,2010-019912-18,yo,o
36,2010-019912-18,AR,i
36,2010-019912-18,diagnosticadas,i
36,2010-019912-18,antes,o
36,2010-019912-18,de,o
36,2010-019912-18,los,o
36,2010-019912-18,16,o
36,2010-019912-18,años,o
36,2010-019912-18,de,o
36,2010-019912-18,edad,o
36,2010-019912-18,Enfermedad,i
36,2010-019912-18,articular,i
36,2010-019912-18,inflamatoria,i
36,2010-019912-18,distinta,o
36,2010-019912-18,de,o
36,2010-019912-18,AR,i
36,2010-019912-18,en,o
36,2010-019912-18,el,o
36,2010-019912-18,pasado,o
36,2010-019912-18,o,o
36,2010-019912-18,en,o
36,2010-019912-18,la,o
36,2010-019912-18,actualidad,o
37,2010-019912-18,EudraCT,o
37,2010-019912-18,Nº,o
37,2010-019912-18,201001991218,o
37,2010-019912-18,Titulo,o
37,2010-019912-18,cientifico,o
37,2010-019912-18,Estudio,o
37,2010-019912-18,randomizado,o
37,2010-019912-18,doble,o
37,2010-019912-18,ciego,o
37,2010-019912-18,con,o
37,2010-019912-18,grupos,o
37,2010-019912-18,de,o
37,2010-019912-18,tratamiento,i
37,2010-019912-18,paralelos,o
37,2010-019912-18,para,o
37,2010-019912-18,evaluar,i
37,2010-019912-18,la,i
37,2010-019912-18,seguridad,i
37,2010-019912-18,y,o
37,2010-019912-18,el,o
37,2010-019912-18,efecto,o
37,2010-019912-18,sobre,o
37,2010-019912-18,el,o
37,2010-019912-18,resultado,o
37,2010-019912-18,clinico,o
37,2010-019912-18,de,o
37,2010-019912-18,tocilizumab,i
37,2010-019912-18,SC,o
37,2010-019912-18,frente,o
37,2010-019912-18,a,o
37,2010-019912-18,placebo,i
37,2010-019912-18,SC,o
37,2010-019912-18,en,o
37,2010-019912-18,combinacion,o
37,2010-019912-18,con,o
37,2010-019912-18,farmacos,i
37,2010-019912-18,antirreumaticos,i
37,2010-019912-18,modificadores,i
37,2010-019912-18,de,i
37,2010-019912-18,la,i
37,2010-019912-18,enfermedad,i
37,2010-019912-18,FAMEs,i
37,2010-019912-18,tradicionales,o
37,2010-019912-18,en,o
37,2010-019912-18,pacientes,o
37,2010-019912-18,con,o
37,2010-019912-18,artritis,i
37,2010-019912-18,reumatoide,i
37,2010-019912-18,activa,o
37,2010-019912-18,moderada,o
37,2010-019912-18,a,o
37,2010-019912-18,severa,o
37,2010-019912-18,Indicacion,o
37,2010-019912-18,cientifica,o
37,2010-019912-18,Artritis,i
37,2010-019912-18,Reumatoide,i
37,2010-019912-18,AR,i
37,2010-019912-18,Criterios,o
37,2010-019912-18,de,o
37,2010-019912-18,inclusion,o
37,2010-019912-18,Presentar,o
37,2010-019912-18,artritis,i
37,2010-019912-18,reumatoide,i
37,2010-019912-18,de,o
37,2010-019912-18,mayor,o
37,2010-019912-18,o,o
37,2010-019912-18,igual,o
37,2010-019912-18,a,o
37,2010-019912-18,6,o
37,2010-019912-18,meses,o
37,2010-019912-18,de,o
37,2010-019912-18,duracion,o
37,2010-019912-18,Recibir,o
37,2010-019912-18,tratamiento,i
37,2010-019912-18,de,i
37,2010-019912-18,forma,i
37,2010-019912-18,ambulatoria,i
37,2010-019912-18,Presentar,o
37,2010-019912-18,un,o
37,2010-019912-18,recuento,o
37,2010-019912-18,de,o
37,2010-019912-18,articulaciones,i
37,2010-019912-18,inflamadas,i
37,2010-019912-18,RAI,o
37,2010-019912-18,mayor,o
37,2010-019912-18,o,o
37,2010-019912-18,igual,o
37,2010-019912-18,a,o
37,2010-019912-18,6,o
37,2010-019912-18,recuento,o
37,2010-019912-18,de,o
37,2010-019912-18,66,o
37,2010-019912-18,articulaciones,i
37,2010-019912-18,y,o
37,2010-019912-18,de,o
37,2010-019912-18,articulaciones,i
37,2010-019912-18,dolorosas,i
37,2010-019912-18,RAD,o
37,2010-019912-18,mayor,o
37,2010-019912-18,o,o
37,2010-019912-18,igual,o
37,2010-019912-18,a,o
37,2010-019912-18,8,o
37,2010-019912-18,recuento,o
37,2010-019912-18,de,o
37,2010-019912-18,68,o
37,2010-019912-18,articulaciones,i
37,2010-019912-18,en,o
37,2010-019912-18,las,o
37,2010-019912-18,visitas,o
37,2010-019912-18,de,o
37,2010-019912-18,seleccion,o
37,2010-019912-18,y,o
37,2010-019912-18,basal,o
37,2010-019912-18,Los,o
37,2010-019912-18,pacientes,o
37,2010-019912-18,deben,o
37,2010-019912-18,estar,o
37,2010-019912-18,recibiendo,o
37,2010-019912-18,tratamiento,i
37,2010-019912-18,con,o
37,2010-019912-18,una,o
37,2010-019912-18,dosis,o
37,2010-019912-18,estable,o
37,2010-019912-18,de,o
37,2010-019912-18,los,o
37,2010-019912-18,FAMEs,i
37,2010-019912-18,permitidos,o
37,2010-019912-18,como,o
37,2010-019912-18,minimo,o
37,2010-019912-18,8,o
37,2010-019912-18,semanas,o
37,2010-019912-18,antes,o
37,2010-019912-18,de,o
37,2010-019912-18,la,o
37,2010-019912-18,visita,o
37,2010-019912-18,basal,o
37,2010-019912-18,Criterios,o
37,2010-019912-18,de,o
37,2010-019912-18,exclusion,o
37,2010-019912-18,Pacientes,o
37,2010-019912-18,sometidos,o
37,2010-019912-18,a,o
37,2010-019912-18,intervenciones,i
37,2010-019912-18,de,i
37,2010-019912-18,cirugia,i
37,2010-019912-18,mayor,i
37,2010-019912-18,incluyendo,o
37,2010-019912-18,cirugia,i
37,2010-019912-18,articular,i
37,2010-019912-18,en,o
37,2010-019912-18,las,o
37,2010-019912-18,8,o
37,2010-019912-18,semanas,o
37,2010-019912-18,previas,o
37,2010-019912-18,a,o
37,2010-019912-18,la,o
37,2010-019912-18,visita,o
37,2010-019912-18,de,o
37,2010-019912-18,seleccion,o
37,2010-019912-18,o,o
37,2010-019912-18,que,o
37,2010-019912-18,tengan,o
37,2010-019912-18,previsto,o
37,2010-019912-18,someterse,o
37,2010-019912-18,a,o
37,2010-019912-18,una,o
37,2010-019912-18,intervencion,i
37,2010-019912-18,de,o
37,2010-019912-18,este,o
37,2010-019912-18,tipo,o
37,2010-019912-18,en,o
37,2010-019912-18,los,o
37,2010-019912-18,6,o
37,2010-019912-18,meses,o
37,2010-019912-18,siguientes,o
37,2010-019912-18,a,o
37,2010-019912-18,la,o
37,2010-019912-18,randomizacion,i
37,2010-019912-18,Enfermedad,i
37,2010-019912-18,reumatica,i
37,2010-019912-18,autoinmune,i
37,2010-019912-18,distinta,o
37,2010-019912-18,de,o
37,2010-019912-18,AR,i
37,2010-019912-18,Se,o
37,2010-019912-18,permite,o
37,2010-019912-18,la,o
37,2010-019912-18,inclusion,o
37,2010-019912-18,de,o
37,2010-019912-18,pacientes,o
37,2010-019912-18,con,o
37,2010-019912-18,sindrome,i
37,2010-019912-18,de,i
37,2010-019912-18,Sjögren,i
37,2010-019912-18,secundario,i
37,2010-019912-18,asociado,o
37,2010-019912-18,a,o
37,2010-019912-18,AR,i
37,2010-019912-18,Clase,o
37,2010-019912-18,funcional,o
37,2010-019912-18,IV,o
37,2010-019912-18,definida,o
37,2010-019912-18,de,o
37,2010-019912-18,acuerdo,o
37,2010-019912-18,con,o
37,2010-019912-18,la,o
37,2010-019912-18,Clasificacion,o
37,2010-019912-18,del,o
37,2010-019912-18,ACR,o
37,2010-019912-18,del,o
37,2010-019912-18,Estado,o
37,2010-019912-18,Funcional,o
37,2010-019912-18,en,o
37,2010-019912-18,Artritis,i
37,2010-019912-18,Reumatoide,i
37,2010-019912-18,Artritis,i
37,2010-019912-18,idiopatica,i
37,2010-019912-18,juvenil,i
37,2010-019912-18,AIJ,i
37,2010-019912-18,o,o
37,2010-019912-18,artritis,i
37,2010-019912-18,reumatoide,i
37,2010-019912-18,juvenil,i
37,2010-019912-18,ARJ,i
37,2010-019912-18,yo,o
37,2010-019912-18,AR,i
37,2010-019912-18,diagnosticadas,i
37,2010-019912-18,antes,o
37,2010-019912-18,de,o
37,2010-019912-18,los,o
37,2010-019912-18,16,o
37,2010-019912-18,años,o
37,2010-019912-18,de,o
37,2010-019912-18,edad,o
37,2010-019912-18,Enfermedad,i
37,2010-019912-18,articular,i
37,2010-019912-18,inflamatoria,i
37,2010-019912-18,distinta,o
37,2010-019912-18,de,o
37,2010-019912-18,AR,i
37,2010-019912-18,en,o
37,2010-019912-18,el,o
37,2010-019912-18,pasado,o
37,2010-019912-18,o,o
37,2010-019912-18,en,o
37,2010-019912-18,la,o
37,2010-019912-18,actualidad,o
38,2010-019912-18,EudraCT,o
38,2010-019912-18,Nº,o
38,2010-019912-18,201001991218,o
38,2010-019912-18,Titulo,o
38,2010-019912-18,cientifico,o
38,2010-019912-18,Estudio,o
38,2010-019912-18,randomizado,o
38,2010-019912-18,doble,o
38,2010-019912-18,ciego,o
38,2010-019912-18,con,o
38,2010-019912-18,grupos,o
38,2010-019912-18,de,o
38,2010-019912-18,tratamiento,i
38,2010-019912-18,paralelos,o
38,2010-019912-18,para,o
38,2010-019912-18,evaluar,i
38,2010-019912-18,la,i
38,2010-019912-18,seguridad,i
38,2010-019912-18,y,o
38,2010-019912-18,el,o
38,2010-019912-18,efecto,o
38,2010-019912-18,sobre,o
38,2010-019912-18,el,o
38,2010-019912-18,resultado,o
38,2010-019912-18,clinico,o
38,2010-019912-18,de,o
38,2010-019912-18,tocilizumab,i
38,2010-019912-18,SC,o
38,2010-019912-18,frente,o
38,2010-019912-18,a,o
38,2010-019912-18,placebo,i
38,2010-019912-18,SC,o
38,2010-019912-18,en,o
38,2010-019912-18,combinacion,o
38,2010-019912-18,con,o
38,2010-019912-18,farmacos,i
38,2010-019912-18,antirreumaticos,i
38,2010-019912-18,modificadores,i
38,2010-019912-18,de,i
38,2010-019912-18,la,i
38,2010-019912-18,enfermedad,i
38,2010-019912-18,FAMEs,i
38,2010-019912-18,tradicionales,o
38,2010-019912-18,en,o
38,2010-019912-18,pacientes,o
38,2010-019912-18,con,o
38,2010-019912-18,artritis,i
38,2010-019912-18,reumatoide,i
38,2010-019912-18,activa,o
38,2010-019912-18,moderada,o
38,2010-019912-18,a,o
38,2010-019912-18,severa,o
38,2010-019912-18,Indicacion,o
38,2010-019912-18,cientifica,o
38,2010-019912-18,Artritis,i
38,2010-019912-18,Reumatoide,i
38,2010-019912-18,AR,i
38,2010-019912-18,Criterios,o
38,2010-019912-18,de,o
38,2010-019912-18,inclusion,o
38,2010-019912-18,Presentar,o
38,2010-019912-18,artritis,i
38,2010-019912-18,reumatoide,i
38,2010-019912-18,de,o
38,2010-019912-18,mayor,o
38,2010-019912-18,o,o
38,2010-019912-18,igual,o
38,2010-019912-18,a,o
38,2010-019912-18,6,o
38,2010-019912-18,meses,o
38,2010-019912-18,de,o
38,2010-019912-18,duracion,o
38,2010-019912-18,Recibir,o
38,2010-019912-18,tratamiento,i
38,2010-019912-18,de,i
38,2010-019912-18,forma,i
38,2010-019912-18,ambulatoria,i
38,2010-019912-18,Presentar,o
38,2010-019912-18,un,o
38,2010-019912-18,recuento,o
38,2010-019912-18,de,o
38,2010-019912-18,articulaciones,i
38,2010-019912-18,inflamadas,i
38,2010-019912-18,RAI,o
38,2010-019912-18,mayor,o
38,2010-019912-18,o,o
38,2010-019912-18,igual,o
38,2010-019912-18,a,o
38,2010-019912-18,6,o
38,2010-019912-18,recuento,o
38,2010-019912-18,de,o
38,2010-019912-18,66,o
38,2010-019912-18,articulaciones,i
38,2010-019912-18,y,o
38,2010-019912-18,de,o
38,2010-019912-18,articulaciones,i
38,2010-019912-18,dolorosas,i
38,2010-019912-18,RAD,o
38,2010-019912-18,mayor,o
38,2010-019912-18,o,o
38,2010-019912-18,igual,o
38,2010-019912-18,a,o
38,2010-019912-18,8,o
38,2010-019912-18,recuento,o
38,2010-019912-18,de,o
38,2010-019912-18,68,o
38,2010-019912-18,articulaciones,i
38,2010-019912-18,en,o
38,2010-019912-18,las,o
38,2010-019912-18,visitas,o
38,2010-019912-18,de,o
38,2010-019912-18,seleccion,o
38,2010-019912-18,y,o
38,2010-019912-18,basal,o
38,2010-019912-18,Los,o
38,2010-019912-18,pacientes,o
38,2010-019912-18,deben,o
38,2010-019912-18,estar,o
38,2010-019912-18,recibiendo,o
38,2010-019912-18,tratamiento,i
38,2010-019912-18,con,o
38,2010-019912-18,una,o
38,2010-019912-18,dosis,o
38,2010-019912-18,estable,o
38,2010-019912-18,de,o
38,2010-019912-18,los,o
38,2010-019912-18,FAMEs,i
38,2010-019912-18,permitidos,o
38,2010-019912-18,como,o
38,2010-019912-18,minimo,o
38,2010-019912-18,8,o
38,2010-019912-18,semanas,o
38,2010-019912-18,antes,o
38,2010-019912-18,de,o
38,2010-019912-18,la,o
38,2010-019912-18,visita,o
38,2010-019912-18,basal,o
38,2010-019912-18,Criterios,o
38,2010-019912-18,de,o
38,2010-019912-18,exclusion,o
38,2010-019912-18,Pacientes,o
38,2010-019912-18,sometidos,o
38,2010-019912-18,a,o
38,2010-019912-18,intervenciones,i
38,2010-019912-18,de,i
38,2010-019912-18,cirugia,i
38,2010-019912-18,mayor,i
38,2010-019912-18,incluyendo,o
38,2010-019912-18,cirugia,i
38,2010-019912-18,articular,i
38,2010-019912-18,en,o
38,2010-019912-18,las,o
38,2010-019912-18,8,o
38,2010-019912-18,semanas,o
38,2010-019912-18,previas,o
38,2010-019912-18,a,o
38,2010-019912-18,la,o
38,2010-019912-18,visita,o
38,2010-019912-18,de,o
38,2010-019912-18,seleccion,o
38,2010-019912-18,o,o
38,2010-019912-18,que,o
38,2010-019912-18,tengan,o
38,2010-019912-18,previsto,o
38,2010-019912-18,someterse,o
38,2010-019912-18,a,o
38,2010-019912-18,una,o
38,2010-019912-18,intervencion,i
38,2010-019912-18,de,o
38,2010-019912-18,este,o
38,2010-019912-18,tipo,o
38,2010-019912-18,en,o
38,2010-019912-18,los,o
38,2010-019912-18,6,o
38,2010-019912-18,meses,o
38,2010-019912-18,siguientes,o
38,2010-019912-18,a,o
38,2010-019912-18,la,o
38,2010-019912-18,randomizacion,i
38,2010-019912-18,Enfermedad,i
38,2010-019912-18,reumatica,i
38,2010-019912-18,autoinmune,i
38,2010-019912-18,distinta,o
38,2010-019912-18,de,o
38,2010-019912-18,AR,i
38,2010-019912-18,Se,o
38,2010-019912-18,permite,o
38,2010-019912-18,la,o
38,2010-019912-18,inclusion,o
38,2010-019912-18,de,o
38,2010-019912-18,pacientes,o
38,2010-019912-18,con,o
38,2010-019912-18,sindrome,i
38,2010-019912-18,de,i
38,2010-019912-18,Sjögren,i
38,2010-019912-18,secundario,i
38,2010-019912-18,asociado,o
38,2010-019912-18,a,o
38,2010-019912-18,AR,i
38,2010-019912-18,Clase,o
38,2010-019912-18,funcional,o
38,2010-019912-18,IV,o
38,2010-019912-18,definida,o
38,2010-019912-18,de,o
38,2010-019912-18,acuerdo,o
38,2010-019912-18,con,o
38,2010-019912-18,la,o
38,2010-019912-18,Clasificacion,o
38,2010-019912-18,del,o
38,2010-019912-18,ACR,o
38,2010-019912-18,del,o
38,2010-019912-18,Estado,o
38,2010-019912-18,Funcional,o
38,2010-019912-18,en,o
38,2010-019912-18,Artritis,i
38,2010-019912-18,Reumatoide,i
38,2010-019912-18,Artritis,i
38,2010-019912-18,idiopatica,i
38,2010-019912-18,juvenil,i
38,2010-019912-18,AIJ,i
38,2010-019912-18,o,o
38,2010-019912-18,artritis,i
38,2010-019912-18,reumatoide,i
38,2010-019912-18,juvenil,i
38,2010-019912-18,ARJ,i
38,2010-019912-18,yo,o
38,2010-019912-18,AR,i
38,2010-019912-18,diagnosticadas,i
38,2010-019912-18,antes,o
38,2010-019912-18,de,o
38,2010-019912-18,los,o
38,2010-019912-18,16,o
38,2010-019912-18,años,o
38,2010-019912-18,de,o
38,2010-019912-18,edad,o
38,2010-019912-18,Enfermedad,i
38,2010-019912-18,articular,i
38,2010-019912-18,inflamatoria,i
38,2010-019912-18,distinta,o
38,2010-019912-18,de,o
38,2010-019912-18,AR,i
38,2010-019912-18,en,o
38,2010-019912-18,el,o
38,2010-019912-18,pasado,o
38,2010-019912-18,o,o
38,2010-019912-18,en,o
38,2010-019912-18,la,o
38,2010-019912-18,actualidad,o
39,2010-019912-18,EudraCT,o
39,2010-019912-18,Nº,o
39,2010-019912-18,201001991218,o
39,2010-019912-18,Titulo,o
39,2010-019912-18,cientifico,o
39,2010-019912-18,Estudio,o
39,2010-019912-18,randomizado,o
39,2010-019912-18,doble,o
39,2010-019912-18,ciego,o
39,2010-019912-18,con,o
39,2010-019912-18,grupos,o
39,2010-019912-18,de,o
39,2010-019912-18,tratamiento,i
39,2010-019912-18,paralelos,o
39,2010-019912-18,para,o
39,2010-019912-18,evaluar,i
39,2010-019912-18,la,i
39,2010-019912-18,seguridad,i
39,2010-019912-18,y,o
39,2010-019912-18,el,o
39,2010-019912-18,efecto,o
39,2010-019912-18,sobre,o
39,2010-019912-18,el,o
39,2010-019912-18,resultado,o
39,2010-019912-18,clinico,o
39,2010-019912-18,de,o
39,2010-019912-18,tocilizumab,i
39,2010-019912-18,SC,o
39,2010-019912-18,frente,o
39,2010-019912-18,a,o
39,2010-019912-18,placebo,i
39,2010-019912-18,SC,o
39,2010-019912-18,en,o
39,2010-019912-18,combinacion,o
39,2010-019912-18,con,o
39,2010-019912-18,farmacos,i
39,2010-019912-18,antirreumaticos,i
39,2010-019912-18,modificadores,i
39,2010-019912-18,de,i
39,2010-019912-18,la,i
39,2010-019912-18,enfermedad,i
39,2010-019912-18,FAMEs,i
39,2010-019912-18,tradicionales,o
39,2010-019912-18,en,o
39,2010-019912-18,pacientes,o
39,2010-019912-18,con,o
39,2010-019912-18,artritis,i
39,2010-019912-18,reumatoide,i
39,2010-019912-18,activa,o
39,2010-019912-18,moderada,o
39,2010-019912-18,a,o
39,2010-019912-18,severa,o
39,2010-019912-18,Indicacion,o
39,2010-019912-18,cientifica,o
39,2010-019912-18,Artritis,i
39,2010-019912-18,Reumatoide,i
39,2010-019912-18,AR,i
39,2010-019912-18,Criterios,o
39,2010-019912-18,de,o
39,2010-019912-18,inclusion,o
39,2010-019912-18,Presentar,o
39,2010-019912-18,artritis,i
39,2010-019912-18,reumatoide,i
39,2010-019912-18,de,o
39,2010-019912-18,mayor,o
39,2010-019912-18,o,o
39,2010-019912-18,igual,o
39,2010-019912-18,a,o
39,2010-019912-18,6,o
39,2010-019912-18,meses,o
39,2010-019912-18,de,o
39,2010-019912-18,duracion,o
39,2010-019912-18,Recibir,o
39,2010-019912-18,tratamiento,i
39,2010-019912-18,de,i
39,2010-019912-18,forma,i
39,2010-019912-18,ambulatoria,i
39,2010-019912-18,Presentar,o
39,2010-019912-18,un,o
39,2010-019912-18,recuento,o
39,2010-019912-18,de,o
39,2010-019912-18,articulaciones,i
39,2010-019912-18,inflamadas,i
39,2010-019912-18,RAI,o
39,2010-019912-18,mayor,o
39,2010-019912-18,o,o
39,2010-019912-18,igual,o
39,2010-019912-18,a,o
39,2010-019912-18,6,o
39,2010-019912-18,recuento,o
39,2010-019912-18,de,o
39,2010-019912-18,66,o
39,2010-019912-18,articulaciones,i
39,2010-019912-18,y,o
39,2010-019912-18,de,o
39,2010-019912-18,articulaciones,i
39,2010-019912-18,dolorosas,i
39,2010-019912-18,RAD,o
39,2010-019912-18,mayor,o
39,2010-019912-18,o,o
39,2010-019912-18,igual,o
39,2010-019912-18,a,o
39,2010-019912-18,8,o
39,2010-019912-18,recuento,o
39,2010-019912-18,de,o
39,2010-019912-18,68,o
39,2010-019912-18,articulaciones,i
39,2010-019912-18,en,o
39,2010-019912-18,las,o
39,2010-019912-18,visitas,o
39,2010-019912-18,de,o
39,2010-019912-18,seleccion,o
39,2010-019912-18,y,o
39,2010-019912-18,basal,o
39,2010-019912-18,Los,o
39,2010-019912-18,pacientes,o
39,2010-019912-18,deben,o
39,2010-019912-18,estar,o
39,2010-019912-18,recibiendo,o
39,2010-019912-18,tratamiento,i
39,2010-019912-18,con,o
39,2010-019912-18,una,o
39,2010-019912-18,dosis,o
39,2010-019912-18,estable,o
39,2010-019912-18,de,o
39,2010-019912-18,los,o
39,2010-019912-18,FAMEs,i
39,2010-019912-18,permitidos,o
39,2010-019912-18,como,o
39,2010-019912-18,minimo,o
39,2010-019912-18,8,o
39,2010-019912-18,semanas,o
39,2010-019912-18,antes,o
39,2010-019912-18,de,o
39,2010-019912-18,la,o
39,2010-019912-18,visita,o
39,2010-019912-18,basal,o
39,2010-019912-18,Criterios,o
39,2010-019912-18,de,o
39,2010-019912-18,exclusion,o
39,2010-019912-18,Pacientes,o
39,2010-019912-18,sometidos,o
39,2010-019912-18,a,o
39,2010-019912-18,intervenciones,i
39,2010-019912-18,de,i
39,2010-019912-18,cirugia,i
39,2010-019912-18,mayor,i
39,2010-019912-18,incluyendo,o
39,2010-019912-18,cirugia,i
39,2010-019912-18,articular,i
39,2010-019912-18,en,o
39,2010-019912-18,las,o
39,2010-019912-18,8,o
39,2010-019912-18,semanas,o
39,2010-019912-18,previas,o
39,2010-019912-18,a,o
39,2010-019912-18,la,o
39,2010-019912-18,visita,o
39,2010-019912-18,de,o
39,2010-019912-18,seleccion,o
39,2010-019912-18,o,o
39,2010-019912-18,que,o
39,2010-019912-18,tengan,o
39,2010-019912-18,previsto,o
39,2010-019912-18,someterse,o
39,2010-019912-18,a,o
39,2010-019912-18,una,o
39,2010-019912-18,intervencion,i
39,2010-019912-18,de,o
39,2010-019912-18,este,o
39,2010-019912-18,tipo,o
39,2010-019912-18,en,o
39,2010-019912-18,los,o
39,2010-019912-18,6,o
39,2010-019912-18,meses,o
39,2010-019912-18,siguientes,o
39,2010-019912-18,a,o
39,2010-019912-18,la,o
39,2010-019912-18,randomizacion,i
39,2010-019912-18,Enfermedad,i
39,2010-019912-18,reumatica,i
39,2010-019912-18,autoinmune,i
39,2010-019912-18,distinta,o
39,2010-019912-18,de,o
39,2010-019912-18,AR,i
39,2010-019912-18,Se,o
39,2010-019912-18,permite,o
39,2010-019912-18,la,o
39,2010-019912-18,inclusion,o
39,2010-019912-18,de,o
39,2010-019912-18,pacientes,o
39,2010-019912-18,con,o
39,2010-019912-18,sindrome,i
39,2010-019912-18,de,i
39,2010-019912-18,Sjögren,i
39,2010-019912-18,secundario,i
39,2010-019912-18,asociado,o
39,2010-019912-18,a,o
39,2010-019912-18,AR,i
39,2010-019912-18,Clase,o
39,2010-019912-18,funcional,o
39,2010-019912-18,IV,o
39,2010-019912-18,definida,o
39,2010-019912-18,de,o
39,2010-019912-18,acuerdo,o
39,2010-019912-18,con,o
39,2010-019912-18,la,o
39,2010-019912-18,Clasificacion,o
39,2010-019912-18,del,o
39,2010-019912-18,ACR,o
39,2010-019912-18,del,o
39,2010-019912-18,Estado,o
39,2010-019912-18,Funcional,o
39,2010-019912-18,en,o
39,2010-019912-18,Artritis,i
39,2010-019912-18,Reumatoide,i
39,2010-019912-18,Artritis,i
39,2010-019912-18,idiopatica,i
39,2010-019912-18,juvenil,i
39,2010-019912-18,AIJ,i
39,2010-019912-18,o,o
39,2010-019912-18,artritis,i
39,2010-019912-18,reumatoide,i
39,2010-019912-18,juvenil,i
39,2010-019912-18,ARJ,i
39,2010-019912-18,yo,o
39,2010-019912-18,AR,i
39,2010-019912-18,diagnosticadas,i
39,2010-019912-18,antes,o
39,2010-019912-18,de,o
39,2010-019912-18,los,o
39,2010-019912-18,16,o
39,2010-019912-18,años,o
39,2010-019912-18,de,o
39,2010-019912-18,edad,o
39,2010-019912-18,Enfermedad,i
39,2010-019912-18,articular,i
39,2010-019912-18,inflamatoria,i
39,2010-019912-18,distinta,o
39,2010-019912-18,de,o
39,2010-019912-18,AR,i
39,2010-019912-18,en,o
39,2010-019912-18,el,o
39,2010-019912-18,pasado,o
39,2010-019912-18,o,o
39,2010-019912-18,en,o
39,2010-019912-18,la,o
39,2010-019912-18,actualidad,o
40,2010-019912-18,EudraCT,o
40,2010-019912-18,Nº,o
40,2010-019912-18,201001991218,o
40,2010-019912-18,Titulo,o
40,2010-019912-18,cientifico,o
40,2010-019912-18,Estudio,o
40,2010-019912-18,randomizado,o
40,2010-019912-18,doble,o
40,2010-019912-18,ciego,o
40,2010-019912-18,con,o
40,2010-019912-18,grupos,o
40,2010-019912-18,de,o
40,2010-019912-18,tratamiento,i
40,2010-019912-18,paralelos,o
40,2010-019912-18,para,o
40,2010-019912-18,evaluar,i
40,2010-019912-18,la,i
40,2010-019912-18,seguridad,i
40,2010-019912-18,y,o
40,2010-019912-18,el,o
40,2010-019912-18,efecto,o
40,2010-019912-18,sobre,o
40,2010-019912-18,el,o
40,2010-019912-18,resultado,o
40,2010-019912-18,clinico,o
40,2010-019912-18,de,o
40,2010-019912-18,tocilizumab,i
40,2010-019912-18,SC,o
40,2010-019912-18,frente,o
40,2010-019912-18,a,o
40,2010-019912-18,placebo,i
40,2010-019912-18,SC,o
40,2010-019912-18,en,o
40,2010-019912-18,combinacion,o
40,2010-019912-18,con,o
40,2010-019912-18,farmacos,i
40,2010-019912-18,antirreumaticos,i
40,2010-019912-18,modificadores,i
40,2010-019912-18,de,i
40,2010-019912-18,la,i
40,2010-019912-18,enfermedad,i
40,2010-019912-18,FAMEs,i
40,2010-019912-18,tradicionales,o
40,2010-019912-18,en,o
40,2010-019912-18,pacientes,o
40,2010-019912-18,con,o
40,2010-019912-18,artritis,i
40,2010-019912-18,reumatoide,i
40,2010-019912-18,activa,o
40,2010-019912-18,moderada,o
40,2010-019912-18,a,o
40,2010-019912-18,severa,o
40,2010-019912-18,Indicacion,o
40,2010-019912-18,cientifica,o
40,2010-019912-18,Artritis,i
40,2010-019912-18,Reumatoide,i
40,2010-019912-18,AR,i
40,2010-019912-18,Criterios,o
40,2010-019912-18,de,o
40,2010-019912-18,inclusion,o
40,2010-019912-18,Presentar,o
40,2010-019912-18,artritis,i
40,2010-019912-18,reumatoide,i
40,2010-019912-18,de,o
40,2010-019912-18,mayor,o
40,2010-019912-18,o,o
40,2010-019912-18,igual,o
40,2010-019912-18,a,o
40,2010-019912-18,6,o
40,2010-019912-18,meses,o
40,2010-019912-18,de,o
40,2010-019912-18,duracion,o
40,2010-019912-18,Recibir,o
40,2010-019912-18,tratamiento,i
40,2010-019912-18,de,i
40,2010-019912-18,forma,i
40,2010-019912-18,ambulatoria,i
40,2010-019912-18,Presentar,o
40,2010-019912-18,un,o
40,2010-019912-18,recuento,o
40,2010-019912-18,de,o
40,2010-019912-18,articulaciones,i
40,2010-019912-18,inflamadas,i
40,2010-019912-18,RAI,o
40,2010-019912-18,mayor,o
40,2010-019912-18,o,o
40,2010-019912-18,igual,o
40,2010-019912-18,a,o
40,2010-019912-18,6,o
40,2010-019912-18,recuento,o
40,2010-019912-18,de,o
40,2010-019912-18,66,o
40,2010-019912-18,articulaciones,i
40,2010-019912-18,y,o
40,2010-019912-18,de,o
40,2010-019912-18,articulaciones,i
40,2010-019912-18,dolorosas,i
40,2010-019912-18,RAD,o
40,2010-019912-18,mayor,o
40,2010-019912-18,o,o
40,2010-019912-18,igual,o
40,2010-019912-18,a,o
40,2010-019912-18,8,o
40,2010-019912-18,recuento,o
40,2010-019912-18,de,o
40,2010-019912-18,68,o
40,2010-019912-18,articulaciones,i
40,2010-019912-18,en,o
40,2010-019912-18,las,o
40,2010-019912-18,visitas,o
40,2010-019912-18,de,o
40,2010-019912-18,seleccion,o
40,2010-019912-18,y,o
40,2010-019912-18,basal,o
40,2010-019912-18,Los,o
40,2010-019912-18,pacientes,o
40,2010-019912-18,deben,o
40,2010-019912-18,estar,o
40,2010-019912-18,recibiendo,o
40,2010-019912-18,tratamiento,i
40,2010-019912-18,con,o
40,2010-019912-18,una,o
40,2010-019912-18,dosis,o
40,2010-019912-18,estable,o
40,2010-019912-18,de,o
40,2010-019912-18,los,o
40,2010-019912-18,FAMEs,i
40,2010-019912-18,permitidos,o
40,2010-019912-18,como,o
40,2010-019912-18,minimo,o
40,2010-019912-18,8,o
40,2010-019912-18,semanas,o
40,2010-019912-18,antes,o
40,2010-019912-18,de,o
40,2010-019912-18,la,o
40,2010-019912-18,visita,o
40,2010-019912-18,basal,o
40,2010-019912-18,Criterios,o
40,2010-019912-18,de,o
40,2010-019912-18,exclusion,o
40,2010-019912-18,Pacientes,o
40,2010-019912-18,sometidos,o
40,2010-019912-18,a,o
40,2010-019912-18,intervenciones,i
40,2010-019912-18,de,i
40,2010-019912-18,cirugia,i
40,2010-019912-18,mayor,i
40,2010-019912-18,incluyendo,o
40,2010-019912-18,cirugia,i
40,2010-019912-18,articular,i
40,2010-019912-18,en,o
40,2010-019912-18,las,o
40,2010-019912-18,8,o
40,2010-019912-18,semanas,o
40,2010-019912-18,previas,o
40,2010-019912-18,a,o
40,2010-019912-18,la,o
40,2010-019912-18,visita,o
40,2010-019912-18,de,o
40,2010-019912-18,seleccion,o
40,2010-019912-18,o,o
40,2010-019912-18,que,o
40,2010-019912-18,tengan,o
40,2010-019912-18,previsto,o
40,2010-019912-18,someterse,o
40,2010-019912-18,a,o
40,2010-019912-18,una,o
40,2010-019912-18,intervencion,i
40,2010-019912-18,de,o
40,2010-019912-18,este,o
40,2010-019912-18,tipo,o
40,2010-019912-18,en,o
40,2010-019912-18,los,o
40,2010-019912-18,6,o
40,2010-019912-18,meses,o
40,2010-019912-18,siguientes,o
40,2010-019912-18,a,o
40,2010-019912-18,la,o
40,2010-019912-18,randomizacion,i
40,2010-019912-18,Enfermedad,i
40,2010-019912-18,reumatica,i
40,2010-019912-18,autoinmune,i
40,2010-019912-18,distinta,o
40,2010-019912-18,de,o
40,2010-019912-18,AR,i
40,2010-019912-18,Se,o
40,2010-019912-18,permite,o
40,2010-019912-18,la,o
40,2010-019912-18,inclusion,o
40,2010-019912-18,de,o
40,2010-019912-18,pacientes,o
40,2010-019912-18,con,o
40,2010-019912-18,sindrome,i
40,2010-019912-18,de,i
40,2010-019912-18,Sjögren,i
40,2010-019912-18,secundario,i
40,2010-019912-18,asociado,o
40,2010-019912-18,a,o
40,2010-019912-18,AR,i
40,2010-019912-18,Clase,o
40,2010-019912-18,funcional,o
40,2010-019912-18,IV,o
40,2010-019912-18,definida,o
40,2010-019912-18,de,o
40,2010-019912-18,acuerdo,o
40,2010-019912-18,con,o
40,2010-019912-18,la,o
40,2010-019912-18,Clasificacion,o
40,2010-019912-18,del,o
40,2010-019912-18,ACR,o
40,2010-019912-18,del,o
40,2010-019912-18,Estado,o
40,2010-019912-18,Funcional,o
40,2010-019912-18,en,o
40,2010-019912-18,Artritis,i
40,2010-019912-18,Reumatoide,i
40,2010-019912-18,Artritis,i
40,2010-019912-18,idiopatica,i
40,2010-019912-18,juvenil,i
40,2010-019912-18,AIJ,i
40,2010-019912-18,o,o
40,2010-019912-18,artritis,i
40,2010-019912-18,reumatoide,i
40,2010-019912-18,juvenil,i
40,2010-019912-18,ARJ,i
40,2010-019912-18,yo,o
40,2010-019912-18,AR,i
40,2010-019912-18,diagnosticadas,i
40,2010-019912-18,antes,o
40,2010-019912-18,de,o
40,2010-019912-18,los,o
40,2010-019912-18,16,o
40,2010-019912-18,años,o
40,2010-019912-18,de,o
40,2010-019912-18,edad,o
40,2010-019912-18,Enfermedad,i
40,2010-019912-18,articular,i
40,2010-019912-18,inflamatoria,i
40,2010-019912-18,distinta,o
40,2010-019912-18,de,o
40,2010-019912-18,AR,i
40,2010-019912-18,en,o
40,2010-019912-18,el,o
40,2010-019912-18,pasado,o
40,2010-019912-18,o,o
40,2010-019912-18,en,o
40,2010-019912-18,la,o
40,2010-019912-18,actualidad,o
41,2010-019912-18,EudraCT,o
41,2010-019912-18,Nº,o
41,2010-019912-18,201001991218,o
41,2010-019912-18,Titulo,o
41,2010-019912-18,cientifico,o
41,2010-019912-18,Estudio,o
41,2010-019912-18,randomizado,o
41,2010-019912-18,doble,o
41,2010-019912-18,ciego,o
41,2010-019912-18,con,o
41,2010-019912-18,grupos,o
41,2010-019912-18,de,o
41,2010-019912-18,tratamiento,i
41,2010-019912-18,paralelos,o
41,2010-019912-18,para,o
41,2010-019912-18,evaluar,i
41,2010-019912-18,la,i
41,2010-019912-18,seguridad,i
41,2010-019912-18,y,o
41,2010-019912-18,el,o
41,2010-019912-18,efecto,o
41,2010-019912-18,sobre,o
41,2010-019912-18,el,o
41,2010-019912-18,resultado,o
41,2010-019912-18,clinico,o
41,2010-019912-18,de,o
41,2010-019912-18,tocilizumab,i
41,2010-019912-18,SC,o
41,2010-019912-18,frente,o
41,2010-019912-18,a,o
41,2010-019912-18,placebo,i
41,2010-019912-18,SC,o
41,2010-019912-18,en,o
41,2010-019912-18,combinacion,o
41,2010-019912-18,con,o
41,2010-019912-18,farmacos,i
41,2010-019912-18,antirreumaticos,i
41,2010-019912-18,modificadores,i
41,2010-019912-18,de,i
41,2010-019912-18,la,i
41,2010-019912-18,enfermedad,i
41,2010-019912-18,FAMEs,i
41,2010-019912-18,tradicionales,o
41,2010-019912-18,en,o
41,2010-019912-18,pacientes,o
41,2010-019912-18,con,o
41,2010-019912-18,artritis,i
41,2010-019912-18,reumatoide,i
41,2010-019912-18,activa,o
41,2010-019912-18,moderada,o
41,2010-019912-18,a,o
41,2010-019912-18,severa,o
41,2010-019912-18,Indicacion,o
41,2010-019912-18,cientifica,o
41,2010-019912-18,Artritis,i
41,2010-019912-18,Reumatoide,i
41,2010-019912-18,AR,i
41,2010-019912-18,Criterios,o
41,2010-019912-18,de,o
41,2010-019912-18,inclusion,o
41,2010-019912-18,Presentar,o
41,2010-019912-18,artritis,i
41,2010-019912-18,reumatoide,i
41,2010-019912-18,de,o
41,2010-019912-18,mayor,o
41,2010-019912-18,o,o
41,2010-019912-18,igual,o
41,2010-019912-18,a,o
41,2010-019912-18,6,o
41,2010-019912-18,meses,o
41,2010-019912-18,de,o
41,2010-019912-18,duracion,o
41,2010-019912-18,Recibir,o
41,2010-019912-18,tratamiento,i
41,2010-019912-18,de,i
41,2010-019912-18,forma,i
41,2010-019912-18,ambulatoria,i
41,2010-019912-18,Presentar,o
41,2010-019912-18,un,o
41,2010-019912-18,recuento,o
41,2010-019912-18,de,o
41,2010-019912-18,articulaciones,i
41,2010-019912-18,inflamadas,i
41,2010-019912-18,RAI,o
41,2010-019912-18,mayor,o
41,2010-019912-18,o,o
41,2010-019912-18,igual,o
41,2010-019912-18,a,o
41,2010-019912-18,6,o
41,2010-019912-18,recuento,o
41,2010-019912-18,de,o
41,2010-019912-18,66,o
41,2010-019912-18,articulaciones,i
41,2010-019912-18,y,o
41,2010-019912-18,de,o
41,2010-019912-18,articulaciones,i
41,2010-019912-18,dolorosas,i
41,2010-019912-18,RAD,o
41,2010-019912-18,mayor,o
41,2010-019912-18,o,o
41,2010-019912-18,igual,o
41,2010-019912-18,a,o
41,2010-019912-18,8,o
41,2010-019912-18,recuento,o
41,2010-019912-18,de,o
41,2010-019912-18,68,o
41,2010-019912-18,articulaciones,i
41,2010-019912-18,en,o
41,2010-019912-18,las,o
41,2010-019912-18,visitas,o
41,2010-019912-18,de,o
41,2010-019912-18,seleccion,o
41,2010-019912-18,y,o
41,2010-019912-18,basal,o
41,2010-019912-18,Los,o
41,2010-019912-18,pacientes,o
41,2010-019912-18,deben,o
41,2010-019912-18,estar,o
41,2010-019912-18,recibiendo,o
41,2010-019912-18,tratamiento,i
41,2010-019912-18,con,o
41,2010-019912-18,una,o
41,2010-019912-18,dosis,o
41,2010-019912-18,estable,o
41,2010-019912-18,de,o
41,2010-019912-18,los,o
41,2010-019912-18,FAMEs,i
41,2010-019912-18,permitidos,o
41,2010-019912-18,como,o
41,2010-019912-18,minimo,o
41,2010-019912-18,8,o
41,2010-019912-18,semanas,o
41,2010-019912-18,antes,o
41,2010-019912-18,de,o
41,2010-019912-18,la,o
41,2010-019912-18,visita,o
41,2010-019912-18,basal,o
41,2010-019912-18,Criterios,o
41,2010-019912-18,de,o
41,2010-019912-18,exclusion,o
41,2010-019912-18,Pacientes,o
41,2010-019912-18,sometidos,o
41,2010-019912-18,a,o
41,2010-019912-18,intervenciones,i
41,2010-019912-18,de,i
41,2010-019912-18,cirugia,i
41,2010-019912-18,mayor,i
41,2010-019912-18,incluyendo,o
41,2010-019912-18,cirugia,i
41,2010-019912-18,articular,i
41,2010-019912-18,en,o
41,2010-019912-18,las,o
41,2010-019912-18,8,o
41,2010-019912-18,semanas,o
41,2010-019912-18,previas,o
41,2010-019912-18,a,o
41,2010-019912-18,la,o
41,2010-019912-18,visita,o
41,2010-019912-18,de,o
41,2010-019912-18,seleccion,o
41,2010-019912-18,o,o
41,2010-019912-18,que,o
41,2010-019912-18,tengan,o
41,2010-019912-18,previsto,o
41,2010-019912-18,someterse,o
41,2010-019912-18,a,o
41,2010-019912-18,una,o
41,2010-019912-18,intervencion,i
41,2010-019912-18,de,o
41,2010-019912-18,este,o
41,2010-019912-18,tipo,o
41,2010-019912-18,en,o
41,2010-019912-18,los,o
41,2010-019912-18,6,o
41,2010-019912-18,meses,o
41,2010-019912-18,siguientes,o
41,2010-019912-18,a,o
41,2010-019912-18,la,o
41,2010-019912-18,randomizacion,i
41,2010-019912-18,Enfermedad,i
41,2010-019912-18,reumatica,i
41,2010-019912-18,autoinmune,i
41,2010-019912-18,distinta,o
41,2010-019912-18,de,o
41,2010-019912-18,AR,i
41,2010-019912-18,Se,o
41,2010-019912-18,permite,o
41,2010-019912-18,la,o
41,2010-019912-18,inclusion,o
41,2010-019912-18,de,o
41,2010-019912-18,pacientes,o
41,2010-019912-18,con,o
41,2010-019912-18,sindrome,i
41,2010-019912-18,de,i
41,2010-019912-18,Sjögren,i
41,2010-019912-18,secundario,i
41,2010-019912-18,asociado,o
41,2010-019912-18,a,o
41,2010-019912-18,AR,i
41,2010-019912-18,Clase,o
41,2010-019912-18,funcional,o
41,2010-019912-18,IV,o
41,2010-019912-18,definida,o
41,2010-019912-18,de,o
41,2010-019912-18,acuerdo,o
41,2010-019912-18,con,o
41,2010-019912-18,la,o
41,2010-019912-18,Clasificacion,o
41,2010-019912-18,del,o
41,2010-019912-18,ACR,o
41,2010-019912-18,del,o
41,2010-019912-18,Estado,o
41,2010-019912-18,Funcional,o
41,2010-019912-18,en,o
41,2010-019912-18,Artritis,i
41,2010-019912-18,Reumatoide,i
41,2010-019912-18,Artritis,i
41,2010-019912-18,idiopatica,i
41,2010-019912-18,juvenil,i
41,2010-019912-18,AIJ,i
41,2010-019912-18,o,o
41,2010-019912-18,artritis,i
41,2010-019912-18,reumatoide,i
41,2010-019912-18,juvenil,i
41,2010-019912-18,ARJ,i
41,2010-019912-18,yo,o
41,2010-019912-18,AR,i
41,2010-019912-18,diagnosticadas,i
41,2010-019912-18,antes,o
41,2010-019912-18,de,o
41,2010-019912-18,los,o
41,2010-019912-18,16,o
41,2010-019912-18,años,o
41,2010-019912-18,de,o
41,2010-019912-18,edad,o
41,2010-019912-18,Enfermedad,i
41,2010-019912-18,articular,i
41,2010-019912-18,inflamatoria,i
41,2010-019912-18,distinta,o
41,2010-019912-18,de,o
41,2010-019912-18,AR,i
41,2010-019912-18,en,o
41,2010-019912-18,el,o
41,2010-019912-18,pasado,o
41,2010-019912-18,o,o
41,2010-019912-18,en,o
41,2010-019912-18,la,o
41,2010-019912-18,actualidad,o
42,2010-019912-18,EudraCT,o
42,2010-019912-18,Nº,o
42,2010-019912-18,201001991218,o
42,2010-019912-18,Titulo,o
42,2010-019912-18,cientifico,o
42,2010-019912-18,Estudio,o
42,2010-019912-18,randomizado,o
42,2010-019912-18,doble,o
42,2010-019912-18,ciego,o
42,2010-019912-18,con,o
42,2010-019912-18,grupos,o
42,2010-019912-18,de,o
42,2010-019912-18,tratamiento,i
42,2010-019912-18,paralelos,o
42,2010-019912-18,para,o
42,2010-019912-18,evaluar,i
42,2010-019912-18,la,i
42,2010-019912-18,seguridad,i
42,2010-019912-18,y,o
42,2010-019912-18,el,o
42,2010-019912-18,efecto,o
42,2010-019912-18,sobre,o
42,2010-019912-18,el,o
42,2010-019912-18,resultado,o
42,2010-019912-18,clinico,o
42,2010-019912-18,de,o
42,2010-019912-18,tocilizumab,i
42,2010-019912-18,SC,o
42,2010-019912-18,frente,o
42,2010-019912-18,a,o
42,2010-019912-18,placebo,i
42,2010-019912-18,SC,o
42,2010-019912-18,en,o
42,2010-019912-18,combinacion,o
42,2010-019912-18,con,o
42,2010-019912-18,farmacos,i
42,2010-019912-18,antirreumaticos,i
42,2010-019912-18,modificadores,i
42,2010-019912-18,de,i
42,2010-019912-18,la,i
42,2010-019912-18,enfermedad,i
42,2010-019912-18,FAMEs,i
42,2010-019912-18,tradicionales,o
42,2010-019912-18,en,o
42,2010-019912-18,pacientes,o
42,2010-019912-18,con,o
42,2010-019912-18,artritis,i
42,2010-019912-18,reumatoide,i
42,2010-019912-18,activa,o
42,2010-019912-18,moderada,o
42,2010-019912-18,a,o
42,2010-019912-18,severa,o
42,2010-019912-18,Indicacion,o
42,2010-019912-18,cientifica,o
42,2010-019912-18,Artritis,i
42,2010-019912-18,Reumatoide,i
42,2010-019912-18,AR,i
42,2010-019912-18,Criterios,o
42,2010-019912-18,de,o
42,2010-019912-18,inclusion,o
42,2010-019912-18,Presentar,o
42,2010-019912-18,artritis,i
42,2010-019912-18,reumatoide,i
42,2010-019912-18,de,o
42,2010-019912-18,mayor,o
42,2010-019912-18,o,o
42,2010-019912-18,igual,o
42,2010-019912-18,a,o
42,2010-019912-18,6,o
42,2010-019912-18,meses,o
42,2010-019912-18,de,o
42,2010-019912-18,duracion,o
42,2010-019912-18,Recibir,o
42,2010-019912-18,tratamiento,i
42,2010-019912-18,de,i
42,2010-019912-18,forma,i
42,2010-019912-18,ambulatoria,i
42,2010-019912-18,Presentar,o
42,2010-019912-18,un,o
42,2010-019912-18,recuento,o
42,2010-019912-18,de,o
42,2010-019912-18,articulaciones,i
42,2010-019912-18,inflamadas,i
42,2010-019912-18,RAI,o
42,2010-019912-18,mayor,o
42,2010-019912-18,o,o
42,2010-019912-18,igual,o
42,2010-019912-18,a,o
42,2010-019912-18,6,o
42,2010-019912-18,recuento,o
42,2010-019912-18,de,o
42,2010-019912-18,66,o
42,2010-019912-18,articulaciones,i
42,2010-019912-18,y,o
42,2010-019912-18,de,o
42,2010-019912-18,articulaciones,i
42,2010-019912-18,dolorosas,i
42,2010-019912-18,RAD,o
42,2010-019912-18,mayor,o
42,2010-019912-18,o,o
42,2010-019912-18,igual,o
42,2010-019912-18,a,o
42,2010-019912-18,8,o
42,2010-019912-18,recuento,o
42,2010-019912-18,de,o
42,2010-019912-18,68,o
42,2010-019912-18,articulaciones,i
42,2010-019912-18,en,o
42,2010-019912-18,las,o
42,2010-019912-18,visitas,o
42,2010-019912-18,de,o
42,2010-019912-18,seleccion,o
42,2010-019912-18,y,o
42,2010-019912-18,basal,o
42,2010-019912-18,Los,o
42,2010-019912-18,pacientes,o
42,2010-019912-18,deben,o
42,2010-019912-18,estar,o
42,2010-019912-18,recibiendo,o
42,2010-019912-18,tratamiento,i
42,2010-019912-18,con,o
42,2010-019912-18,una,o
42,2010-019912-18,dosis,o
42,2010-019912-18,estable,o
42,2010-019912-18,de,o
42,2010-019912-18,los,o
42,2010-019912-18,FAMEs,i
42,2010-019912-18,permitidos,o
42,2010-019912-18,como,o
42,2010-019912-18,minimo,o
42,2010-019912-18,8,o
42,2010-019912-18,semanas,o
42,2010-019912-18,antes,o
42,2010-019912-18,de,o
42,2010-019912-18,la,o
42,2010-019912-18,visita,o
42,2010-019912-18,basal,o
42,2010-019912-18,Criterios,o
42,2010-019912-18,de,o
42,2010-019912-18,exclusion,o
42,2010-019912-18,Pacientes,o
42,2010-019912-18,sometidos,o
42,2010-019912-18,a,o
42,2010-019912-18,intervenciones,i
42,2010-019912-18,de,i
42,2010-019912-18,cirugia,i
42,2010-019912-18,mayor,i
42,2010-019912-18,incluyendo,o
42,2010-019912-18,cirugia,i
42,2010-019912-18,articular,i
42,2010-019912-18,en,o
42,2010-019912-18,las,o
42,2010-019912-18,8,o
42,2010-019912-18,semanas,o
42,2010-019912-18,previas,o
42,2010-019912-18,a,o
42,2010-019912-18,la,o
42,2010-019912-18,visita,o
42,2010-019912-18,de,o
42,2010-019912-18,seleccion,o
42,2010-019912-18,o,o
42,2010-019912-18,que,o
42,2010-019912-18,tengan,o
42,2010-019912-18,previsto,o
42,2010-019912-18,someterse,o
42,2010-019912-18,a,o
42,2010-019912-18,una,o
42,2010-019912-18,intervencion,i
42,2010-019912-18,de,o
42,2010-019912-18,este,o
42,2010-019912-18,tipo,o
42,2010-019912-18,en,o
42,2010-019912-18,los,o
42,2010-019912-18,6,o
42,2010-019912-18,meses,o
42,2010-019912-18,siguientes,o
42,2010-019912-18,a,o
42,2010-019912-18,la,o
42,2010-019912-18,randomizacion,i
42,2010-019912-18,Enfermedad,i
42,2010-019912-18,reumatica,i
42,2010-019912-18,autoinmune,i
42,2010-019912-18,distinta,o
42,2010-019912-18,de,o
42,2010-019912-18,AR,i
42,2010-019912-18,Se,o
42,2010-019912-18,permite,o
42,2010-019912-18,la,o
42,2010-019912-18,inclusion,o
42,2010-019912-18,de,o
42,2010-019912-18,pacientes,o
42,2010-019912-18,con,o
42,2010-019912-18,sindrome,i
42,2010-019912-18,de,i
42,2010-019912-18,Sjögren,i
42,2010-019912-18,secundario,i
42,2010-019912-18,asociado,o
42,2010-019912-18,a,o
42,2010-019912-18,AR,i
42,2010-019912-18,Clase,o
42,2010-019912-18,funcional,o
42,2010-019912-18,IV,o
42,2010-019912-18,definida,o
42,2010-019912-18,de,o
42,2010-019912-18,acuerdo,o
42,2010-019912-18,con,o
42,2010-019912-18,la,o
42,2010-019912-18,Clasificacion,o
42,2010-019912-18,del,o
42,2010-019912-18,ACR,o
42,2010-019912-18,del,o
42,2010-019912-18,Estado,o
42,2010-019912-18,Funcional,o
42,2010-019912-18,en,o
42,2010-019912-18,Artritis,i
42,2010-019912-18,Reumatoide,i
42,2010-019912-18,Artritis,i
42,2010-019912-18,idiopatica,i
42,2010-019912-18,juvenil,i
42,2010-019912-18,AIJ,i
42,2010-019912-18,o,o
42,2010-019912-18,artritis,i
42,2010-019912-18,reumatoide,i
42,2010-019912-18,juvenil,i
42,2010-019912-18,ARJ,i
42,2010-019912-18,yo,o
42,2010-019912-18,AR,i
42,2010-019912-18,diagnosticadas,i
42,2010-019912-18,antes,o
42,2010-019912-18,de,o
42,2010-019912-18,los,o
42,2010-019912-18,16,o
42,2010-019912-18,años,o
42,2010-019912-18,de,o
42,2010-019912-18,edad,o
42,2010-019912-18,Enfermedad,i
42,2010-019912-18,articular,i
42,2010-019912-18,inflamatoria,i
42,2010-019912-18,distinta,o
42,2010-019912-18,de,o
42,2010-019912-18,AR,i
42,2010-019912-18,en,o
42,2010-019912-18,el,o
42,2010-019912-18,pasado,o
42,2010-019912-18,o,o
42,2010-019912-18,en,o
42,2010-019912-18,la,o
42,2010-019912-18,actualidad,o
43,2010-019912-18,EudraCT,o
43,2010-019912-18,Nº,o
43,2010-019912-18,201001991218,o
43,2010-019912-18,Titulo,o
43,2010-019912-18,cientifico,o
43,2010-019912-18,Estudio,o
43,2010-019912-18,randomizado,o
43,2010-019912-18,doble,o
43,2010-019912-18,ciego,o
43,2010-019912-18,con,o
43,2010-019912-18,grupos,o
43,2010-019912-18,de,o
43,2010-019912-18,tratamiento,i
43,2010-019912-18,paralelos,o
43,2010-019912-18,para,o
43,2010-019912-18,evaluar,i
43,2010-019912-18,la,i
43,2010-019912-18,seguridad,i
43,2010-019912-18,y,o
43,2010-019912-18,el,o
43,2010-019912-18,efecto,o
43,2010-019912-18,sobre,o
43,2010-019912-18,el,o
43,2010-019912-18,resultado,o
43,2010-019912-18,clinico,o
43,2010-019912-18,de,o
43,2010-019912-18,tocilizumab,i
43,2010-019912-18,SC,o
43,2010-019912-18,frente,o
43,2010-019912-18,a,o
43,2010-019912-18,placebo,i
43,2010-019912-18,SC,o
43,2010-019912-18,en,o
43,2010-019912-18,combinacion,o
43,2010-019912-18,con,o
43,2010-019912-18,farmacos,i
43,2010-019912-18,antirreumaticos,i
43,2010-019912-18,modificadores,i
43,2010-019912-18,de,i
43,2010-019912-18,la,i
43,2010-019912-18,enfermedad,i
43,2010-019912-18,FAMEs,i
43,2010-019912-18,tradicionales,o
43,2010-019912-18,en,o
43,2010-019912-18,pacientes,o
43,2010-019912-18,con,o
43,2010-019912-18,artritis,i
43,2010-019912-18,reumatoide,i
43,2010-019912-18,activa,o
43,2010-019912-18,moderada,o
43,2010-019912-18,a,o
43,2010-019912-18,severa,o
43,2010-019912-18,Indicacion,o
43,2010-019912-18,cientifica,o
43,2010-019912-18,Artritis,i
43,2010-019912-18,Reumatoide,i
43,2010-019912-18,AR,i
43,2010-019912-18,Criterios,o
43,2010-019912-18,de,o
43,2010-019912-18,inclusion,o
43,2010-019912-18,Presentar,o
43,2010-019912-18,artritis,i
43,2010-019912-18,reumatoide,i
43,2010-019912-18,de,o
43,2010-019912-18,mayor,o
43,2010-019912-18,o,o
43,2010-019912-18,igual,o
43,2010-019912-18,a,o
43,2010-019912-18,6,o
43,2010-019912-18,meses,o
43,2010-019912-18,de,o
43,2010-019912-18,duracion,o
43,2010-019912-18,Recibir,o
43,2010-019912-18,tratamiento,i
43,2010-019912-18,de,i
43,2010-019912-18,forma,i
43,2010-019912-18,ambulatoria,i
43,2010-019912-18,Presentar,o
43,2010-019912-18,un,o
43,2010-019912-18,recuento,o
43,2010-019912-18,de,o
43,2010-019912-18,articulaciones,i
43,2010-019912-18,inflamadas,i
43,2010-019912-18,RAI,o
43,2010-019912-18,mayor,o
43,2010-019912-18,o,o
43,2010-019912-18,igual,o
43,2010-019912-18,a,o
43,2010-019912-18,6,o
43,2010-019912-18,recuento,o
43,2010-019912-18,de,o
43,2010-019912-18,66,o
43,2010-019912-18,articulaciones,i
43,2010-019912-18,y,o
43,2010-019912-18,de,o
43,2010-019912-18,articulaciones,i
43,2010-019912-18,dolorosas,i
43,2010-019912-18,RAD,o
43,2010-019912-18,mayor,o
43,2010-019912-18,o,o
43,2010-019912-18,igual,o
43,2010-019912-18,a,o
43,2010-019912-18,8,o
43,2010-019912-18,recuento,o
43,2010-019912-18,de,o
43,2010-019912-18,68,o
43,2010-019912-18,articulaciones,i
43,2010-019912-18,en,o
43,2010-019912-18,las,o
43,2010-019912-18,visitas,o
43,2010-019912-18,de,o
43,2010-019912-18,seleccion,o
43,2010-019912-18,y,o
43,2010-019912-18,basal,o
43,2010-019912-18,Los,o
43,2010-019912-18,pacientes,o
43,2010-019912-18,deben,o
43,2010-019912-18,estar,o
43,2010-019912-18,recibiendo,o
43,2010-019912-18,tratamiento,i
43,2010-019912-18,con,o
43,2010-019912-18,una,o
43,2010-019912-18,dosis,o
43,2010-019912-18,estable,o
43,2010-019912-18,de,o
43,2010-019912-18,los,o
43,2010-019912-18,FAMEs,i
43,2010-019912-18,permitidos,o
43,2010-019912-18,como,o
43,2010-019912-18,minimo,o
43,2010-019912-18,8,o
43,2010-019912-18,semanas,o
43,2010-019912-18,antes,o
43,2010-019912-18,de,o
43,2010-019912-18,la,o
43,2010-019912-18,visita,o
43,2010-019912-18,basal,o
43,2010-019912-18,Criterios,o
43,2010-019912-18,de,o
43,2010-019912-18,exclusion,o
43,2010-019912-18,Pacientes,o
43,2010-019912-18,sometidos,o
43,2010-019912-18,a,o
43,2010-019912-18,intervenciones,i
43,2010-019912-18,de,i
43,2010-019912-18,cirugia,i
43,2010-019912-18,mayor,i
43,2010-019912-18,incluyendo,o
43,2010-019912-18,cirugia,i
43,2010-019912-18,articular,i
43,2010-019912-18,en,o
43,2010-019912-18,las,o
43,2010-019912-18,8,o
43,2010-019912-18,semanas,o
43,2010-019912-18,previas,o
43,2010-019912-18,a,o
43,2010-019912-18,la,o
43,2010-019912-18,visita,o
43,2010-019912-18,de,o
43,2010-019912-18,seleccion,o
43,2010-019912-18,o,o
43,2010-019912-18,que,o
43,2010-019912-18,tengan,o
43,2010-019912-18,previsto,o
43,2010-019912-18,someterse,o
43,2010-019912-18,a,o
43,2010-019912-18,una,o
43,2010-019912-18,intervencion,i
43,2010-019912-18,de,o
43,2010-019912-18,este,o
43,2010-019912-18,tipo,o
43,2010-019912-18,en,o
43,2010-019912-18,los,o
43,2010-019912-18,6,o
43,2010-019912-18,meses,o
43,2010-019912-18,siguientes,o
43,2010-019912-18,a,o
43,2010-019912-18,la,o
43,2010-019912-18,randomizacion,i
43,2010-019912-18,Enfermedad,i
43,2010-019912-18,reumatica,i
43,2010-019912-18,autoinmune,i
43,2010-019912-18,distinta,o
43,2010-019912-18,de,o
43,2010-019912-18,AR,i
43,2010-019912-18,Se,o
43,2010-019912-18,permite,o
43,2010-019912-18,la,o
43,2010-019912-18,inclusion,o
43,2010-019912-18,de,o
43,2010-019912-18,pacientes,o
43,2010-019912-18,con,o
43,2010-019912-18,sindrome,i
43,2010-019912-18,de,i
43,2010-019912-18,Sjögren,i
43,2010-019912-18,secundario,i
43,2010-019912-18,asociado,o
43,2010-019912-18,a,o
43,2010-019912-18,AR,i
43,2010-019912-18,Clase,o
43,2010-019912-18,funcional,o
43,2010-019912-18,IV,o
43,2010-019912-18,definida,o
43,2010-019912-18,de,o
43,2010-019912-18,acuerdo,o
43,2010-019912-18,con,o
43,2010-019912-18,la,o
43,2010-019912-18,Clasificacion,o
43,2010-019912-18,del,o
43,2010-019912-18,ACR,o
43,2010-019912-18,del,o
43,2010-019912-18,Estado,o
43,2010-019912-18,Funcional,o
43,2010-019912-18,en,o
43,2010-019912-18,Artritis,i
43,2010-019912-18,Reumatoide,i
43,2010-019912-18,Artritis,i
43,2010-019912-18,idiopatica,i
43,2010-019912-18,juvenil,i
43,2010-019912-18,AIJ,i
43,2010-019912-18,o,o
43,2010-019912-18,artritis,i
43,2010-019912-18,reumatoide,i
43,2010-019912-18,juvenil,i
43,2010-019912-18,ARJ,i
43,2010-019912-18,yo,o
43,2010-019912-18,AR,i
43,2010-019912-18,diagnosticadas,i
43,2010-019912-18,antes,o
43,2010-019912-18,de,o
43,2010-019912-18,los,o
43,2010-019912-18,16,o
43,2010-019912-18,años,o
43,2010-019912-18,de,o
43,2010-019912-18,edad,o
43,2010-019912-18,Enfermedad,i
43,2010-019912-18,articular,i
43,2010-019912-18,inflamatoria,i
43,2010-019912-18,distinta,o
43,2010-019912-18,de,o
43,2010-019912-18,AR,i
43,2010-019912-18,en,o
43,2010-019912-18,el,o
43,2010-019912-18,pasado,o
43,2010-019912-18,o,o
43,2010-019912-18,en,o
43,2010-019912-18,la,o
43,2010-019912-18,actualidad,o
44,2010-019912-18,EudraCT,o
44,2010-019912-18,Nº,o
44,2010-019912-18,201001991218,o
44,2010-019912-18,Titulo,o
44,2010-019912-18,cientifico,o
44,2010-019912-18,Estudio,o
44,2010-019912-18,randomizado,o
44,2010-019912-18,doble,o
44,2010-019912-18,ciego,o
44,2010-019912-18,con,o
44,2010-019912-18,grupos,o
44,2010-019912-18,de,o
44,2010-019912-18,tratamiento,i
44,2010-019912-18,paralelos,o
44,2010-019912-18,para,o
44,2010-019912-18,evaluar,i
44,2010-019912-18,la,i
44,2010-019912-18,seguridad,i
44,2010-019912-18,y,o
44,2010-019912-18,el,o
44,2010-019912-18,efecto,o
44,2010-019912-18,sobre,o
44,2010-019912-18,el,o
44,2010-019912-18,resultado,o
44,2010-019912-18,clinico,o
44,2010-019912-18,de,o
44,2010-019912-18,tocilizumab,i
44,2010-019912-18,SC,o
44,2010-019912-18,frente,o
44,2010-019912-18,a,o
44,2010-019912-18,placebo,i
44,2010-019912-18,SC,o
44,2010-019912-18,en,o
44,2010-019912-18,combinacion,o
44,2010-019912-18,con,o
44,2010-019912-18,farmacos,i
44,2010-019912-18,antirreumaticos,i
44,2010-019912-18,modificadores,i
44,2010-019912-18,de,i
44,2010-019912-18,la,i
44,2010-019912-18,enfermedad,i
44,2010-019912-18,FAMEs,i
44,2010-019912-18,tradicionales,o
44,2010-019912-18,en,o
44,2010-019912-18,pacientes,o
44,2010-019912-18,con,o
44,2010-019912-18,artritis,i
44,2010-019912-18,reumatoide,i
44,2010-019912-18,activa,o
44,2010-019912-18,moderada,o
44,2010-019912-18,a,o
44,2010-019912-18,severa,o
44,2010-019912-18,Indicacion,o
44,2010-019912-18,cientifica,o
44,2010-019912-18,Artritis,i
44,2010-019912-18,Reumatoide,i
44,2010-019912-18,AR,i
44,2010-019912-18,Criterios,o
44,2010-019912-18,de,o
44,2010-019912-18,inclusion,o
44,2010-019912-18,Presentar,o
44,2010-019912-18,artritis,i
44,2010-019912-18,reumatoide,i
44,2010-019912-18,de,o
44,2010-019912-18,mayor,o
44,2010-019912-18,o,o
44,2010-019912-18,igual,o
44,2010-019912-18,a,o
44,2010-019912-18,6,o
44,2010-019912-18,meses,o
44,2010-019912-18,de,o
44,2010-019912-18,duracion,o
44,2010-019912-18,Recibir,o
44,2010-019912-18,tratamiento,i
44,2010-019912-18,de,i
44,2010-019912-18,forma,i
44,2010-019912-18,ambulatoria,i
44,2010-019912-18,Presentar,o
44,2010-019912-18,un,o
44,2010-019912-18,recuento,o
44,2010-019912-18,de,o
44,2010-019912-18,articulaciones,i
44,2010-019912-18,inflamadas,i
44,2010-019912-18,RAI,o
44,2010-019912-18,mayor,o
44,2010-019912-18,o,o
44,2010-019912-18,igual,o
44,2010-019912-18,a,o
44,2010-019912-18,6,o
44,2010-019912-18,recuento,o
44,2010-019912-18,de,o
44,2010-019912-18,66,o
44,2010-019912-18,articulaciones,i
44,2010-019912-18,y,o
44,2010-019912-18,de,o
44,2010-019912-18,articulaciones,i
44,2010-019912-18,dolorosas,i
44,2010-019912-18,RAD,o
44,2010-019912-18,mayor,o
44,2010-019912-18,o,o
44,2010-019912-18,igual,o
44,2010-019912-18,a,o
44,2010-019912-18,8,o
44,2010-019912-18,recuento,o
44,2010-019912-18,de,o
44,2010-019912-18,68,o
44,2010-019912-18,articulaciones,i
44,2010-019912-18,en,o
44,2010-019912-18,las,o
44,2010-019912-18,visitas,o
44,2010-019912-18,de,o
44,2010-019912-18,seleccion,o
44,2010-019912-18,y,o
44,2010-019912-18,basal,o
44,2010-019912-18,Los,o
44,2010-019912-18,pacientes,o
44,2010-019912-18,deben,o
44,2010-019912-18,estar,o
44,2010-019912-18,recibiendo,o
44,2010-019912-18,tratamiento,i
44,2010-019912-18,con,o
44,2010-019912-18,una,o
44,2010-019912-18,dosis,o
44,2010-019912-18,estable,o
44,2010-019912-18,de,o
44,2010-019912-18,los,o
44,2010-019912-18,FAMEs,i
44,2010-019912-18,permitidos,o
44,2010-019912-18,como,o
44,2010-019912-18,minimo,o
44,2010-019912-18,8,o
44,2010-019912-18,semanas,o
44,2010-019912-18,antes,o
44,2010-019912-18,de,o
44,2010-019912-18,la,o
44,2010-019912-18,visita,o
44,2010-019912-18,basal,o
44,2010-019912-18,Criterios,o
44,2010-019912-18,de,o
44,2010-019912-18,exclusion,o
44,2010-019912-18,Pacientes,o
44,2010-019912-18,sometidos,o
44,2010-019912-18,a,o
44,2010-019912-18,intervenciones,i
44,2010-019912-18,de,i
44,2010-019912-18,cirugia,i
44,2010-019912-18,mayor,i
44,2010-019912-18,incluyendo,o
44,2010-019912-18,cirugia,i
44,2010-019912-18,articular,i
44,2010-019912-18,en,o
44,2010-019912-18,las,o
44,2010-019912-18,8,o
44,2010-019912-18,semanas,o
44,2010-019912-18,previas,o
44,2010-019912-18,a,o
44,2010-019912-18,la,o
44,2010-019912-18,visita,o
44,2010-019912-18,de,o
44,2010-019912-18,seleccion,o
44,2010-019912-18,o,o
44,2010-019912-18,que,o
44,2010-019912-18,tengan,o
44,2010-019912-18,previsto,o
44,2010-019912-18,someterse,o
44,2010-019912-18,a,o
44,2010-019912-18,una,o
44,2010-019912-18,intervencion,i
44,2010-019912-18,de,o
44,2010-019912-18,este,o
44,2010-019912-18,tipo,o
44,2010-019912-18,en,o
44,2010-019912-18,los,o
44,2010-019912-18,6,o
44,2010-019912-18,meses,o
44,2010-019912-18,siguientes,o
44,2010-019912-18,a,o
44,2010-019912-18,la,o
44,2010-019912-18,randomizacion,i
44,2010-019912-18,Enfermedad,i
44,2010-019912-18,reumatica,i
44,2010-019912-18,autoinmune,i
44,2010-019912-18,distinta,o
44,2010-019912-18,de,o
44,2010-019912-18,AR,i
44,2010-019912-18,Se,o
44,2010-019912-18,permite,o
44,2010-019912-18,la,o
44,2010-019912-18,inclusion,o
44,2010-019912-18,de,o
44,2010-019912-18,pacientes,o
44,2010-019912-18,con,o
44,2010-019912-18,sindrome,i
44,2010-019912-18,de,i
44,2010-019912-18,Sjögren,i
44,2010-019912-18,secundario,i
44,2010-019912-18,asociado,o
44,2010-019912-18,a,o
44,2010-019912-18,AR,i
44,2010-019912-18,Clase,o
44,2010-019912-18,funcional,o
44,2010-019912-18,IV,o
44,2010-019912-18,definida,o
44,2010-019912-18,de,o
44,2010-019912-18,acuerdo,o
44,2010-019912-18,con,o
44,2010-019912-18,la,o
44,2010-019912-18,Clasificacion,o
44,2010-019912-18,del,o
44,2010-019912-18,ACR,o
44,2010-019912-18,del,o
44,2010-019912-18,Estado,o
44,2010-019912-18,Funcional,o
44,2010-019912-18,en,o
44,2010-019912-18,Artritis,i
44,2010-019912-18,Reumatoide,i
44,2010-019912-18,Artritis,i
44,2010-019912-18,idiopatica,i
44,2010-019912-18,juvenil,i
44,2010-019912-18,AIJ,i
44,2010-019912-18,o,o
44,2010-019912-18,artritis,i
44,2010-019912-18,reumatoide,i
44,2010-019912-18,juvenil,i
44,2010-019912-18,ARJ,i
44,2010-019912-18,yo,o
44,2010-019912-18,AR,i
44,2010-019912-18,diagnosticadas,i
44,2010-019912-18,antes,o
44,2010-019912-18,de,o
44,2010-019912-18,los,o
44,2010-019912-18,16,o
44,2010-019912-18,años,o
44,2010-019912-18,de,o
44,2010-019912-18,edad,o
44,2010-019912-18,Enfermedad,i
44,2010-019912-18,articular,i
44,2010-019912-18,inflamatoria,i
44,2010-019912-18,distinta,o
44,2010-019912-18,de,o
44,2010-019912-18,AR,i
44,2010-019912-18,en,o
44,2010-019912-18,el,o
44,2010-019912-18,pasado,o
44,2010-019912-18,o,o
44,2010-019912-18,en,o
44,2010-019912-18,la,o
44,2010-019912-18,actualidad,o
45,2010-019912-18,EudraCT,o
45,2010-019912-18,Nº,o
45,2010-019912-18,201001991218,o
45,2010-019912-18,Titulo,o
45,2010-019912-18,cientifico,o
45,2010-019912-18,Estudio,o
45,2010-019912-18,randomizado,o
45,2010-019912-18,doble,o
45,2010-019912-18,ciego,o
45,2010-019912-18,con,o
45,2010-019912-18,grupos,o
45,2010-019912-18,de,o
45,2010-019912-18,tratamiento,i
45,2010-019912-18,paralelos,o
45,2010-019912-18,para,o
45,2010-019912-18,evaluar,i
45,2010-019912-18,la,i
45,2010-019912-18,seguridad,i
45,2010-019912-18,y,o
45,2010-019912-18,el,o
45,2010-019912-18,efecto,o
45,2010-019912-18,sobre,o
45,2010-019912-18,el,o
45,2010-019912-18,resultado,o
45,2010-019912-18,clinico,o
45,2010-019912-18,de,o
45,2010-019912-18,tocilizumab,i
45,2010-019912-18,SC,o
45,2010-019912-18,frente,o
45,2010-019912-18,a,o
45,2010-019912-18,placebo,i
45,2010-019912-18,SC,o
45,2010-019912-18,en,o
45,2010-019912-18,combinacion,o
45,2010-019912-18,con,o
45,2010-019912-18,farmacos,i
45,2010-019912-18,antirreumaticos,i
45,2010-019912-18,modificadores,i
45,2010-019912-18,de,i
45,2010-019912-18,la,i
45,2010-019912-18,enfermedad,i
45,2010-019912-18,FAMEs,i
45,2010-019912-18,tradicionales,o
45,2010-019912-18,en,o
45,2010-019912-18,pacientes,o
45,2010-019912-18,con,o
45,2010-019912-18,artritis,i
45,2010-019912-18,reumatoide,i
45,2010-019912-18,activa,o
45,2010-019912-18,moderada,o
45,2010-019912-18,a,o
45,2010-019912-18,severa,o
45,2010-019912-18,Indicacion,o
45,2010-019912-18,cientifica,o
45,2010-019912-18,Artritis,i
45,2010-019912-18,Reumatoide,i
45,2010-019912-18,AR,i
45,2010-019912-18,Criterios,o
45,2010-019912-18,de,o
45,2010-019912-18,inclusion,o
45,2010-019912-18,Presentar,o
45,2010-019912-18,artritis,i
45,2010-019912-18,reumatoide,i
45,2010-019912-18,de,o
45,2010-019912-18,mayor,o
45,2010-019912-18,o,o
45,2010-019912-18,igual,o
45,2010-019912-18,a,o
45,2010-019912-18,6,o
45,2010-019912-18,meses,o
45,2010-019912-18,de,o
45,2010-019912-18,duracion,o
45,2010-019912-18,Recibir,o
45,2010-019912-18,tratamiento,i
45,2010-019912-18,de,i
45,2010-019912-18,forma,i
45,2010-019912-18,ambulatoria,i
45,2010-019912-18,Presentar,o
45,2010-019912-18,un,o
45,2010-019912-18,recuento,o
45,2010-019912-18,de,o
45,2010-019912-18,articulaciones,i
45,2010-019912-18,inflamadas,i
45,2010-019912-18,RAI,o
45,2010-019912-18,mayor,o
45,2010-019912-18,o,o
45,2010-019912-18,igual,o
45,2010-019912-18,a,o
45,2010-019912-18,6,o
45,2010-019912-18,recuento,o
45,2010-019912-18,de,o
45,2010-019912-18,66,o
45,2010-019912-18,articulaciones,i
45,2010-019912-18,y,o
45,2010-019912-18,de,o
45,2010-019912-18,articulaciones,i
45,2010-019912-18,dolorosas,i
45,2010-019912-18,RAD,o
45,2010-019912-18,mayor,o
45,2010-019912-18,o,o
45,2010-019912-18,igual,o
45,2010-019912-18,a,o
45,2010-019912-18,8,o
45,2010-019912-18,recuento,o
45,2010-019912-18,de,o
45,2010-019912-18,68,o
45,2010-019912-18,articulaciones,i
45,2010-019912-18,en,o
45,2010-019912-18,las,o
45,2010-019912-18,visitas,o
45,2010-019912-18,de,o
45,2010-019912-18,seleccion,o
45,2010-019912-18,y,o
45,2010-019912-18,basal,o
45,2010-019912-18,Los,o
45,2010-019912-18,pacientes,o
45,2010-019912-18,deben,o
45,2010-019912-18,estar,o
45,2010-019912-18,recibiendo,o
45,2010-019912-18,tratamiento,i
45,2010-019912-18,con,o
45,2010-019912-18,una,o
45,2010-019912-18,dosis,o
45,2010-019912-18,estable,o
45,2010-019912-18,de,o
45,2010-019912-18,los,o
45,2010-019912-18,FAMEs,i
45,2010-019912-18,permitidos,o
45,2010-019912-18,como,o
45,2010-019912-18,minimo,o
45,2010-019912-18,8,o
45,2010-019912-18,semanas,o
45,2010-019912-18,antes,o
45,2010-019912-18,de,o
45,2010-019912-18,la,o
45,2010-019912-18,visita,o
45,2010-019912-18,basal,o
45,2010-019912-18,Criterios,o
45,2010-019912-18,de,o
45,2010-019912-18,exclusion,o
45,2010-019912-18,Pacientes,o
45,2010-019912-18,sometidos,o
45,2010-019912-18,a,o
45,2010-019912-18,intervenciones,i
45,2010-019912-18,de,i
45,2010-019912-18,cirugia,i
45,2010-019912-18,mayor,i
45,2010-019912-18,incluyendo,o
45,2010-019912-18,cirugia,i
45,2010-019912-18,articular,i
45,2010-019912-18,en,o
45,2010-019912-18,las,o
45,2010-019912-18,8,o
45,2010-019912-18,semanas,o
45,2010-019912-18,previas,o
45,2010-019912-18,a,o
45,2010-019912-18,la,o
45,2010-019912-18,visita,o
45,2010-019912-18,de,o
45,2010-019912-18,seleccion,o
45,2010-019912-18,o,o
45,2010-019912-18,que,o
45,2010-019912-18,tengan,o
45,2010-019912-18,previsto,o
45,2010-019912-18,someterse,o
45,2010-019912-18,a,o
45,2010-019912-18,una,o
45,2010-019912-18,intervencion,i
45,2010-019912-18,de,o
45,2010-019912-18,este,o
45,2010-019912-18,tipo,o
45,2010-019912-18,en,o
45,2010-019912-18,los,o
45,2010-019912-18,6,o
45,2010-019912-18,meses,o
45,2010-019912-18,siguientes,o
45,2010-019912-18,a,o
45,2010-019912-18,la,o
45,2010-019912-18,randomizacion,i
45,2010-019912-18,Enfermedad,i
45,2010-019912-18,reumatica,i
45,2010-019912-18,autoinmune,i
45,2010-019912-18,distinta,o
45,2010-019912-18,de,o
45,2010-019912-18,AR,i
45,2010-019912-18,Se,o
45,2010-019912-18,permite,o
45,2010-019912-18,la,o
45,2010-019912-18,inclusion,o
45,2010-019912-18,de,o
45,2010-019912-18,pacientes,o
45,2010-019912-18,con,o
45,2010-019912-18,sindrome,i
45,2010-019912-18,de,i
45,2010-019912-18,Sjögren,i
45,2010-019912-18,secundario,i
45,2010-019912-18,asociado,o
45,2010-019912-18,a,o
45,2010-019912-18,AR,i
45,2010-019912-18,Clase,o
45,2010-019912-18,funcional,o
45,2010-019912-18,IV,o
45,2010-019912-18,definida,o
45,2010-019912-18,de,o
45,2010-019912-18,acuerdo,o
45,2010-019912-18,con,o
45,2010-019912-18,la,o
45,2010-019912-18,Clasificacion,o
45,2010-019912-18,del,o
45,2010-019912-18,ACR,o
45,2010-019912-18,del,o
45,2010-019912-18,Estado,o
45,2010-019912-18,Funcional,o
45,2010-019912-18,en,o
45,2010-019912-18,Artritis,i
45,2010-019912-18,Reumatoide,i
45,2010-019912-18,Artritis,i
45,2010-019912-18,idiopatica,i
45,2010-019912-18,juvenil,i
45,2010-019912-18,AIJ,i
45,2010-019912-18,o,o
45,2010-019912-18,artritis,i
45,2010-019912-18,reumatoide,i
45,2010-019912-18,juvenil,i
45,2010-019912-18,ARJ,i
45,2010-019912-18,yo,o
45,2010-019912-18,AR,i
45,2010-019912-18,diagnosticadas,i
45,2010-019912-18,antes,o
45,2010-019912-18,de,o
45,2010-019912-18,los,o
45,2010-019912-18,16,o
45,2010-019912-18,años,o
45,2010-019912-18,de,o
45,2010-019912-18,edad,o
45,2010-019912-18,Enfermedad,i
45,2010-019912-18,articular,i
45,2010-019912-18,inflamatoria,i
45,2010-019912-18,distinta,o
45,2010-019912-18,de,o
45,2010-019912-18,AR,i
45,2010-019912-18,en,o
45,2010-019912-18,el,o
45,2010-019912-18,pasado,o
45,2010-019912-18,o,o
45,2010-019912-18,en,o
45,2010-019912-18,la,o
45,2010-019912-18,actualidad,o
46,2010-019912-18,EudraCT,o
46,2010-019912-18,Nº,o
46,2010-019912-18,201001991218,o
46,2010-019912-18,Titulo,o
46,2010-019912-18,cientifico,o
46,2010-019912-18,Estudio,o
46,2010-019912-18,randomizado,o
46,2010-019912-18,doble,o
46,2010-019912-18,ciego,o
46,2010-019912-18,con,o
46,2010-019912-18,grupos,o
46,2010-019912-18,de,o
46,2010-019912-18,tratamiento,i
46,2010-019912-18,paralelos,o
46,2010-019912-18,para,o
46,2010-019912-18,evaluar,i
46,2010-019912-18,la,i
46,2010-019912-18,seguridad,i
46,2010-019912-18,y,o
46,2010-019912-18,el,o
46,2010-019912-18,efecto,o
46,2010-019912-18,sobre,o
46,2010-019912-18,el,o
46,2010-019912-18,resultado,o
46,2010-019912-18,clinico,o
46,2010-019912-18,de,o
46,2010-019912-18,tocilizumab,i
46,2010-019912-18,SC,o
46,2010-019912-18,frente,o
46,2010-019912-18,a,o
46,2010-019912-18,placebo,i
46,2010-019912-18,SC,o
46,2010-019912-18,en,o
46,2010-019912-18,combinacion,o
46,2010-019912-18,con,o
46,2010-019912-18,farmacos,i
46,2010-019912-18,antirreumaticos,i
46,2010-019912-18,modificadores,i
46,2010-019912-18,de,i
46,2010-019912-18,la,i
46,2010-019912-18,enfermedad,i
46,2010-019912-18,FAMEs,i
46,2010-019912-18,tradicionales,o
46,2010-019912-18,en,o
46,2010-019912-18,pacientes,o
46,2010-019912-18,con,o
46,2010-019912-18,artritis,i
46,2010-019912-18,reumatoide,i
46,2010-019912-18,activa,o
46,2010-019912-18,moderada,o
46,2010-019912-18,a,o
46,2010-019912-18,severa,o
46,2010-019912-18,Indicacion,o
46,2010-019912-18,cientifica,o
46,2010-019912-18,Artritis,i
46,2010-019912-18,Reumatoide,i
46,2010-019912-18,AR,i
46,2010-019912-18,Criterios,o
46,2010-019912-18,de,o
46,2010-019912-18,inclusion,o
46,2010-019912-18,Presentar,o
46,2010-019912-18,artritis,i
46,2010-019912-18,reumatoide,i
46,2010-019912-18,de,o
46,2010-019912-18,mayor,o
46,2010-019912-18,o,o
46,2010-019912-18,igual,o
46,2010-019912-18,a,o
46,2010-019912-18,6,o
46,2010-019912-18,meses,o
46,2010-019912-18,de,o
46,2010-019912-18,duracion,o
46,2010-019912-18,Recibir,o
46,2010-019912-18,tratamiento,i
46,2010-019912-18,de,i
46,2010-019912-18,forma,i
46,2010-019912-18,ambulatoria,i
46,2010-019912-18,Presentar,o
46,2010-019912-18,un,o
46,2010-019912-18,recuento,o
46,2010-019912-18,de,o
46,2010-019912-18,articulaciones,i
46,2010-019912-18,inflamadas,i
46,2010-019912-18,RAI,o
46,2010-019912-18,mayor,o
46,2010-019912-18,o,o
46,2010-019912-18,igual,o
46,2010-019912-18,a,o
46,2010-019912-18,6,o
46,2010-019912-18,recuento,o
46,2010-019912-18,de,o
46,2010-019912-18,66,o
46,2010-019912-18,articulaciones,i
46,2010-019912-18,y,o
46,2010-019912-18,de,o
46,2010-019912-18,articulaciones,i
46,2010-019912-18,dolorosas,i
46,2010-019912-18,RAD,o
46,2010-019912-18,mayor,o
46,2010-019912-18,o,o
46,2010-019912-18,igual,o
46,2010-019912-18,a,o
46,2010-019912-18,8,o
46,2010-019912-18,recuento,o
46,2010-019912-18,de,o
46,2010-019912-18,68,o
46,2010-019912-18,articulaciones,i
46,2010-019912-18,en,o
46,2010-019912-18,las,o
46,2010-019912-18,visitas,o
46,2010-019912-18,de,o
46,2010-019912-18,seleccion,o
46,2010-019912-18,y,o
46,2010-019912-18,basal,o
46,2010-019912-18,Los,o
46,2010-019912-18,pacientes,o
46,2010-019912-18,deben,o
46,2010-019912-18,estar,o
46,2010-019912-18,recibiendo,o
46,2010-019912-18,tratamiento,i
46,2010-019912-18,con,o
46,2010-019912-18,una,o
46,2010-019912-18,dosis,o
46,2010-019912-18,estable,o
46,2010-019912-18,de,o
46,2010-019912-18,los,o
46,2010-019912-18,FAMEs,i
46,2010-019912-18,permitidos,o
46,2010-019912-18,como,o
46,2010-019912-18,minimo,o
46,2010-019912-18,8,o
46,2010-019912-18,semanas,o
46,2010-019912-18,antes,o
46,2010-019912-18,de,o
46,2010-019912-18,la,o
46,2010-019912-18,visita,o
46,2010-019912-18,basal,o
46,2010-019912-18,Criterios,o
46,2010-019912-18,de,o
46,2010-019912-18,exclusion,o
46,2010-019912-18,Pacientes,o
46,2010-019912-18,sometidos,o
46,2010-019912-18,a,o
46,2010-019912-18,intervenciones,i
46,2010-019912-18,de,i
46,2010-019912-18,cirugia,i
46,2010-019912-18,mayor,i
46,2010-019912-18,incluyendo,o
46,2010-019912-18,cirugia,i
46,2010-019912-18,articular,i
46,2010-019912-18,en,o
46,2010-019912-18,las,o
46,2010-019912-18,8,o
46,2010-019912-18,semanas,o
46,2010-019912-18,previas,o
46,2010-019912-18,a,o
46,2010-019912-18,la,o
46,2010-019912-18,visita,o
46,2010-019912-18,de,o
46,2010-019912-18,seleccion,o
46,2010-019912-18,o,o
46,2010-019912-18,que,o
46,2010-019912-18,tengan,o
46,2010-019912-18,previsto,o
46,2010-019912-18,someterse,o
46,2010-019912-18,a,o
46,2010-019912-18,una,o
46,2010-019912-18,intervencion,i
46,2010-019912-18,de,o
46,2010-019912-18,este,o
46,2010-019912-18,tipo,o
46,2010-019912-18,en,o
46,2010-019912-18,los,o
46,2010-019912-18,6,o
46,2010-019912-18,meses,o
46,2010-019912-18,siguientes,o
46,2010-019912-18,a,o
46,2010-019912-18,la,o
46,2010-019912-18,randomizacion,i
46,2010-019912-18,Enfermedad,i
46,2010-019912-18,reumatica,i
46,2010-019912-18,autoinmune,i
46,2010-019912-18,distinta,o
46,2010-019912-18,de,o
46,2010-019912-18,AR,i
46,2010-019912-18,Se,o
46,2010-019912-18,permite,o
46,2010-019912-18,la,o
46,2010-019912-18,inclusion,o
46,2010-019912-18,de,o
46,2010-019912-18,pacientes,o
46,2010-019912-18,con,o
46,2010-019912-18,sindrome,i
46,2010-019912-18,de,i
46,2010-019912-18,Sjögren,i
46,2010-019912-18,secundario,i
46,2010-019912-18,asociado,o
46,2010-019912-18,a,o
46,2010-019912-18,AR,i
46,2010-019912-18,Clase,o
46,2010-019912-18,funcional,o
46,2010-019912-18,IV,o
46,2010-019912-18,definida,o
46,2010-019912-18,de,o
46,2010-019912-18,acuerdo,o
46,2010-019912-18,con,o
46,2010-019912-18,la,o
46,2010-019912-18,Clasificacion,o
46,2010-019912-18,del,o
46,2010-019912-18,ACR,o
46,2010-019912-18,del,o
46,2010-019912-18,Estado,o
46,2010-019912-18,Funcional,o
46,2010-019912-18,en,o
46,2010-019912-18,Artritis,i
46,2010-019912-18,Reumatoide,i
46,2010-019912-18,Artritis,i
46,2010-019912-18,idiopatica,i
46,2010-019912-18,juvenil,i
46,2010-019912-18,AIJ,i
46,2010-019912-18,o,o
46,2010-019912-18,artritis,i
46,2010-019912-18,reumatoide,i
46,2010-019912-18,juvenil,i
46,2010-019912-18,ARJ,i
46,2010-019912-18,yo,o
46,2010-019912-18,AR,i
46,2010-019912-18,diagnosticadas,i
46,2010-019912-18,antes,o
46,2010-019912-18,de,o
46,2010-019912-18,los,o
46,2010-019912-18,16,o
46,2010-019912-18,años,o
46,2010-019912-18,de,o
46,2010-019912-18,edad,o
46,2010-019912-18,Enfermedad,i
46,2010-019912-18,articular,i
46,2010-019912-18,inflamatoria,i
46,2010-019912-18,distinta,o
46,2010-019912-18,de,o
46,2010-019912-18,AR,i
46,2010-019912-18,en,o
46,2010-019912-18,el,o
46,2010-019912-18,pasado,o
46,2010-019912-18,o,o
46,2010-019912-18,en,o
46,2010-019912-18,la,o
46,2010-019912-18,actualidad,o
47,2010-019912-18,EudraCT,o
47,2010-019912-18,Nº,o
47,2010-019912-18,201001991218,o
47,2010-019912-18,Titulo,o
47,2010-019912-18,cientifico,o
47,2010-019912-18,Estudio,o
47,2010-019912-18,randomizado,o
47,2010-019912-18,doble,o
47,2010-019912-18,ciego,o
47,2010-019912-18,con,o
47,2010-019912-18,grupos,o
47,2010-019912-18,de,o
47,2010-019912-18,tratamiento,i
47,2010-019912-18,paralelos,o
47,2010-019912-18,para,o
47,2010-019912-18,evaluar,i
47,2010-019912-18,la,i
47,2010-019912-18,seguridad,i
47,2010-019912-18,y,o
47,2010-019912-18,el,o
47,2010-019912-18,efecto,o
47,2010-019912-18,sobre,o
47,2010-019912-18,el,o
47,2010-019912-18,resultado,o
47,2010-019912-18,clinico,o
47,2010-019912-18,de,o
47,2010-019912-18,tocilizumab,i
47,2010-019912-18,SC,o
47,2010-019912-18,frente,o
47,2010-019912-18,a,o
47,2010-019912-18,placebo,i
47,2010-019912-18,SC,o
47,2010-019912-18,en,o
47,2010-019912-18,combinacion,o
47,2010-019912-18,con,o
47,2010-019912-18,farmacos,i
47,2010-019912-18,antirreumaticos,i
47,2010-019912-18,modificadores,i
47,2010-019912-18,de,i
47,2010-019912-18,la,i
47,2010-019912-18,enfermedad,i
47,2010-019912-18,FAMEs,i
47,2010-019912-18,tradicionales,o
47,2010-019912-18,en,o
47,2010-019912-18,pacientes,o
47,2010-019912-18,con,o
47,2010-019912-18,artritis,i
47,2010-019912-18,reumatoide,i
47,2010-019912-18,activa,o
47,2010-019912-18,moderada,o
47,2010-019912-18,a,o
47,2010-019912-18,severa,o
47,2010-019912-18,Indicacion,o
47,2010-019912-18,cientifica,o
47,2010-019912-18,Artritis,i
47,2010-019912-18,Reumatoide,i
47,2010-019912-18,AR,i
47,2010-019912-18,Criterios,o
47,2010-019912-18,de,o
47,2010-019912-18,inclusion,o
47,2010-019912-18,Presentar,o
47,2010-019912-18,artritis,i
47,2010-019912-18,reumatoide,i
47,2010-019912-18,de,o
47,2010-019912-18,mayor,o
47,2010-019912-18,o,o
47,2010-019912-18,igual,o
47,2010-019912-18,a,o
47,2010-019912-18,6,o
47,2010-019912-18,meses,o
47,2010-019912-18,de,o
47,2010-019912-18,duracion,o
47,2010-019912-18,Recibir,o
47,2010-019912-18,tratamiento,i
47,2010-019912-18,de,i
47,2010-019912-18,forma,i
47,2010-019912-18,ambulatoria,i
47,2010-019912-18,Presentar,o
47,2010-019912-18,un,o
47,2010-019912-18,recuento,o
47,2010-019912-18,de,o
47,2010-019912-18,articulaciones,i
47,2010-019912-18,inflamadas,i
47,2010-019912-18,RAI,o
47,2010-019912-18,mayor,o
47,2010-019912-18,o,o
47,2010-019912-18,igual,o
47,2010-019912-18,a,o
47,2010-019912-18,6,o
47,2010-019912-18,recuento,o
47,2010-019912-18,de,o
47,2010-019912-18,66,o
47,2010-019912-18,articulaciones,i
47,2010-019912-18,y,o
47,2010-019912-18,de,o
47,2010-019912-18,articulaciones,i
47,2010-019912-18,dolorosas,i
47,2010-019912-18,RAD,o
47,2010-019912-18,mayor,o
47,2010-019912-18,o,o
47,2010-019912-18,igual,o
47,2010-019912-18,a,o
47,2010-019912-18,8,o
47,2010-019912-18,recuento,o
47,2010-019912-18,de,o
47,2010-019912-18,68,o
47,2010-019912-18,articulaciones,i
47,2010-019912-18,en,o
47,2010-019912-18,las,o
47,2010-019912-18,visitas,o
47,2010-019912-18,de,o
47,2010-019912-18,seleccion,o
47,2010-019912-18,y,o
47,2010-019912-18,basal,o
47,2010-019912-18,Los,o
47,2010-019912-18,pacientes,o
47,2010-019912-18,deben,o
47,2010-019912-18,estar,o
47,2010-019912-18,recibiendo,o
47,2010-019912-18,tratamiento,i
47,2010-019912-18,con,o
47,2010-019912-18,una,o
47,2010-019912-18,dosis,o
47,2010-019912-18,estable,o
47,2010-019912-18,de,o
47,2010-019912-18,los,o
47,2010-019912-18,FAMEs,i
47,2010-019912-18,permitidos,o
47,2010-019912-18,como,o
47,2010-019912-18,minimo,o
47,2010-019912-18,8,o
47,2010-019912-18,semanas,o
47,2010-019912-18,antes,o
47,2010-019912-18,de,o
47,2010-019912-18,la,o
47,2010-019912-18,visita,o
47,2010-019912-18,basal,o
47,2010-019912-18,Criterios,o
47,2010-019912-18,de,o
47,2010-019912-18,exclusion,o
47,2010-019912-18,Pacientes,o
47,2010-019912-18,sometidos,o
47,2010-019912-18,a,o
47,2010-019912-18,intervenciones,i
47,2010-019912-18,de,i
47,2010-019912-18,cirugia,i
47,2010-019912-18,mayor,i
47,2010-019912-18,incluyendo,o
47,2010-019912-18,cirugia,i
47,2010-019912-18,articular,i
47,2010-019912-18,en,o
47,2010-019912-18,las,o
47,2010-019912-18,8,o
47,2010-019912-18,semanas,o
47,2010-019912-18,previas,o
47,2010-019912-18,a,o
47,2010-019912-18,la,o
47,2010-019912-18,visita,o
47,2010-019912-18,de,o
47,2010-019912-18,seleccion,o
47,2010-019912-18,o,o
47,2010-019912-18,que,o
47,2010-019912-18,tengan,o
47,2010-019912-18,previsto,o
47,2010-019912-18,someterse,o
47,2010-019912-18,a,o
47,2010-019912-18,una,o
47,2010-019912-18,intervencion,i
47,2010-019912-18,de,o
47,2010-019912-18,este,o
47,2010-019912-18,tipo,o
47,2010-019912-18,en,o
47,2010-019912-18,los,o
47,2010-019912-18,6,o
47,2010-019912-18,meses,o
47,2010-019912-18,siguientes,o
47,2010-019912-18,a,o
47,2010-019912-18,la,o
47,2010-019912-18,randomizacion,i
47,2010-019912-18,Enfermedad,i
47,2010-019912-18,reumatica,i
47,2010-019912-18,autoinmune,i
47,2010-019912-18,distinta,o
47,2010-019912-18,de,o
47,2010-019912-18,AR,i
47,2010-019912-18,Se,o
47,2010-019912-18,permite,o
47,2010-019912-18,la,o
47,2010-019912-18,inclusion,o
47,2010-019912-18,de,o
47,2010-019912-18,pacientes,o
47,2010-019912-18,con,o
47,2010-019912-18,sindrome,i
47,2010-019912-18,de,i
47,2010-019912-18,Sjögren,i
47,2010-019912-18,secundario,i
47,2010-019912-18,asociado,o
47,2010-019912-18,a,o
47,2010-019912-18,AR,i
47,2010-019912-18,Clase,o
47,2010-019912-18,funcional,o
47,2010-019912-18,IV,o
47,2010-019912-18,definida,o
47,2010-019912-18,de,o
47,2010-019912-18,acuerdo,o
47,2010-019912-18,con,o
47,2010-019912-18,la,o
47,2010-019912-18,Clasificacion,o
47,2010-019912-18,del,o
47,2010-019912-18,ACR,o
47,2010-019912-18,del,o
47,2010-019912-18,Estado,o
47,2010-019912-18,Funcional,o
47,2010-019912-18,en,o
47,2010-019912-18,Artritis,i
47,2010-019912-18,Reumatoide,i
47,2010-019912-18,Artritis,i
47,2010-019912-18,idiopatica,i
47,2010-019912-18,juvenil,i
47,2010-019912-18,AIJ,i
47,2010-019912-18,o,o
47,2010-019912-18,artritis,i
47,2010-019912-18,reumatoide,i
47,2010-019912-18,juvenil,i
47,2010-019912-18,ARJ,i
47,2010-019912-18,yo,o
47,2010-019912-18,AR,i
47,2010-019912-18,diagnosticadas,i
47,2010-019912-18,antes,o
47,2010-019912-18,de,o
47,2010-019912-18,los,o
47,2010-019912-18,16,o
47,2010-019912-18,años,o
47,2010-019912-18,de,o
47,2010-019912-18,edad,o
47,2010-019912-18,Enfermedad,i
47,2010-019912-18,articular,i
47,2010-019912-18,inflamatoria,i
47,2010-019912-18,distinta,o
47,2010-019912-18,de,o
47,2010-019912-18,AR,i
47,2010-019912-18,en,o
47,2010-019912-18,el,o
47,2010-019912-18,pasado,o
47,2010-019912-18,o,o
47,2010-019912-18,en,o
47,2010-019912-18,la,o
47,2010-019912-18,actualidad,o
48,2010-019912-18,EudraCT,o
48,2010-019912-18,Nº,o
48,2010-019912-18,201001991218,o
48,2010-019912-18,Titulo,o
48,2010-019912-18,cientifico,o
48,2010-019912-18,Estudio,o
48,2010-019912-18,randomizado,o
48,2010-019912-18,doble,o
48,2010-019912-18,ciego,o
48,2010-019912-18,con,o
48,2010-019912-18,grupos,o
48,2010-019912-18,de,o
48,2010-019912-18,tratamiento,i
48,2010-019912-18,paralelos,o
48,2010-019912-18,para,o
48,2010-019912-18,evaluar,i
48,2010-019912-18,la,i
48,2010-019912-18,seguridad,i
48,2010-019912-18,y,o
48,2010-019912-18,el,o
48,2010-019912-18,efecto,o
48,2010-019912-18,sobre,o
48,2010-019912-18,el,o
48,2010-019912-18,resultado,o
48,2010-019912-18,clinico,o
48,2010-019912-18,de,o
48,2010-019912-18,tocilizumab,i
48,2010-019912-18,SC,o
48,2010-019912-18,frente,o
48,2010-019912-18,a,o
48,2010-019912-18,placebo,i
48,2010-019912-18,SC,o
48,2010-019912-18,en,o
48,2010-019912-18,combinacion,o
48,2010-019912-18,con,o
48,2010-019912-18,farmacos,i
48,2010-019912-18,antirreumaticos,i
48,2010-019912-18,modificadores,i
48,2010-019912-18,de,i
48,2010-019912-18,la,i
48,2010-019912-18,enfermedad,i
48,2010-019912-18,FAMEs,i
48,2010-019912-18,tradicionales,o
48,2010-019912-18,en,o
48,2010-019912-18,pacientes,o
48,2010-019912-18,con,o
48,2010-019912-18,artritis,i
48,2010-019912-18,reumatoide,i
48,2010-019912-18,activa,o
48,2010-019912-18,moderada,o
48,2010-019912-18,a,o
48,2010-019912-18,severa,o
48,2010-019912-18,Indicacion,o
48,2010-019912-18,cientifica,o
48,2010-019912-18,Artritis,i
48,2010-019912-18,Reumatoide,i
48,2010-019912-18,AR,i
48,2010-019912-18,Criterios,o
48,2010-019912-18,de,o
48,2010-019912-18,inclusion,o
48,2010-019912-18,Presentar,o
48,2010-019912-18,artritis,i
48,2010-019912-18,reumatoide,i
48,2010-019912-18,de,o
48,2010-019912-18,mayor,o
48,2010-019912-18,o,o
48,2010-019912-18,igual,o
48,2010-019912-18,a,o
48,2010-019912-18,6,o
48,2010-019912-18,meses,o
48,2010-019912-18,de,o
48,2010-019912-18,duracion,o
48,2010-019912-18,Recibir,o
48,2010-019912-18,tratamiento,i
48,2010-019912-18,de,i
48,2010-019912-18,forma,i
48,2010-019912-18,ambulatoria,i
48,2010-019912-18,Presentar,o
48,2010-019912-18,un,o
48,2010-019912-18,recuento,o
48,2010-019912-18,de,o
48,2010-019912-18,articulaciones,i
48,2010-019912-18,inflamadas,i
48,2010-019912-18,RAI,o
48,2010-019912-18,mayor,o
48,2010-019912-18,o,o
48,2010-019912-18,igual,o
48,2010-019912-18,a,o
48,2010-019912-18,6,o
48,2010-019912-18,recuento,o
48,2010-019912-18,de,o
48,2010-019912-18,66,o
48,2010-019912-18,articulaciones,i
48,2010-019912-18,y,o
48,2010-019912-18,de,o
48,2010-019912-18,articulaciones,i
48,2010-019912-18,dolorosas,i
48,2010-019912-18,RAD,o
48,2010-019912-18,mayor,o
48,2010-019912-18,o,o
48,2010-019912-18,igual,o
48,2010-019912-18,a,o
48,2010-019912-18,8,o
48,2010-019912-18,recuento,o
48,2010-019912-18,de,o
48,2010-019912-18,68,o
48,2010-019912-18,articulaciones,i
48,2010-019912-18,en,o
48,2010-019912-18,las,o
48,2010-019912-18,visitas,o
48,2010-019912-18,de,o
48,2010-019912-18,seleccion,o
48,2010-019912-18,y,o
48,2010-019912-18,basal,o
48,2010-019912-18,Los,o
48,2010-019912-18,pacientes,o
48,2010-019912-18,deben,o
48,2010-019912-18,estar,o
48,2010-019912-18,recibiendo,o
48,2010-019912-18,tratamiento,i
48,2010-019912-18,con,o
48,2010-019912-18,una,o
48,2010-019912-18,dosis,o
48,2010-019912-18,estable,o
48,2010-019912-18,de,o
48,2010-019912-18,los,o
48,2010-019912-18,FAMEs,i
48,2010-019912-18,permitidos,o
48,2010-019912-18,como,o
48,2010-019912-18,minimo,o
48,2010-019912-18,8,o
48,2010-019912-18,semanas,o
48,2010-019912-18,antes,o
48,2010-019912-18,de,o
48,2010-019912-18,la,o
48,2010-019912-18,visita,o
48,2010-019912-18,basal,o
48,2010-019912-18,Criterios,o
48,2010-019912-18,de,o
48,2010-019912-18,exclusion,o
48,2010-019912-18,Pacientes,o
48,2010-019912-18,sometidos,o
48,2010-019912-18,a,o
48,2010-019912-18,intervenciones,i
48,2010-019912-18,de,i
48,2010-019912-18,cirugia,i
48,2010-019912-18,mayor,i
48,2010-019912-18,incluyendo,o
48,2010-019912-18,cirugia,i
48,2010-019912-18,articular,i
48,2010-019912-18,en,o
48,2010-019912-18,las,o
48,2010-019912-18,8,o
48,2010-019912-18,semanas,o
48,2010-019912-18,previas,o
48,2010-019912-18,a,o
48,2010-019912-18,la,o
48,2010-019912-18,visita,o
48,2010-019912-18,de,o
48,2010-019912-18,seleccion,o
48,2010-019912-18,o,o
48,2010-019912-18,que,o
48,2010-019912-18,tengan,o
48,2010-019912-18,previsto,o
48,2010-019912-18,someterse,o
48,2010-019912-18,a,o
48,2010-019912-18,una,o
48,2010-019912-18,intervencion,i
48,2010-019912-18,de,o
48,2010-019912-18,este,o
48,2010-019912-18,tipo,o
48,2010-019912-18,en,o
48,2010-019912-18,los,o
48,2010-019912-18,6,o
48,2010-019912-18,meses,o
48,2010-019912-18,siguientes,o
48,2010-019912-18,a,o
48,2010-019912-18,la,o
48,2010-019912-18,randomizacion,i
48,2010-019912-18,Enfermedad,i
48,2010-019912-18,reumatica,i
48,2010-019912-18,autoinmune,i
48,2010-019912-18,distinta,o
48,2010-019912-18,de,o
48,2010-019912-18,AR,i
48,2010-019912-18,Se,o
48,2010-019912-18,permite,o
48,2010-019912-18,la,o
48,2010-019912-18,inclusion,o
48,2010-019912-18,de,o
48,2010-019912-18,pacientes,o
48,2010-019912-18,con,o
48,2010-019912-18,sindrome,i
48,2010-019912-18,de,i
48,2010-019912-18,Sjögren,i
48,2010-019912-18,secundario,i
48,2010-019912-18,asociado,o
48,2010-019912-18,a,o
48,2010-019912-18,AR,i
48,2010-019912-18,Clase,o
48,2010-019912-18,funcional,o
48,2010-019912-18,IV,o
48,2010-019912-18,definida,o
48,2010-019912-18,de,o
48,2010-019912-18,acuerdo,o
48,2010-019912-18,con,o
48,2010-019912-18,la,o
48,2010-019912-18,Clasificacion,o
48,2010-019912-18,del,o
48,2010-019912-18,ACR,o
48,2010-019912-18,del,o
48,2010-019912-18,Estado,o
48,2010-019912-18,Funcional,o
48,2010-019912-18,en,o
48,2010-019912-18,Artritis,i
48,2010-019912-18,Reumatoide,i
48,2010-019912-18,Artritis,i
48,2010-019912-18,idiopatica,i
48,2010-019912-18,juvenil,i
48,2010-019912-18,AIJ,i
48,2010-019912-18,o,o
48,2010-019912-18,artritis,i
48,2010-019912-18,reumatoide,i
48,2010-019912-18,juvenil,i
48,2010-019912-18,ARJ,i
48,2010-019912-18,yo,o
48,2010-019912-18,AR,i
48,2010-019912-18,diagnosticadas,i
48,2010-019912-18,antes,o
48,2010-019912-18,de,o
48,2010-019912-18,los,o
48,2010-019912-18,16,o
48,2010-019912-18,años,o
48,2010-019912-18,de,o
48,2010-019912-18,edad,o
48,2010-019912-18,Enfermedad,i
48,2010-019912-18,articular,i
48,2010-019912-18,inflamatoria,i
48,2010-019912-18,distinta,o
48,2010-019912-18,de,o
48,2010-019912-18,AR,i
48,2010-019912-18,en,o
48,2010-019912-18,el,o
48,2010-019912-18,pasado,o
48,2010-019912-18,o,o
48,2010-019912-18,en,o
48,2010-019912-18,la,o
48,2010-019912-18,actualidad,o
49,2010-019912-18,EudraCT,o
49,2010-019912-18,Nº,o
49,2010-019912-18,201001991218,o
49,2010-019912-18,Titulo,o
49,2010-019912-18,cientifico,o
49,2010-019912-18,Estudio,o
49,2010-019912-18,randomizado,o
49,2010-019912-18,doble,o
49,2010-019912-18,ciego,o
49,2010-019912-18,con,o
49,2010-019912-18,grupos,o
49,2010-019912-18,de,o
49,2010-019912-18,tratamiento,i
49,2010-019912-18,paralelos,o
49,2010-019912-18,para,o
49,2010-019912-18,evaluar,i
49,2010-019912-18,la,i
49,2010-019912-18,seguridad,i
49,2010-019912-18,y,o
49,2010-019912-18,el,o
49,2010-019912-18,efecto,o
49,2010-019912-18,sobre,o
49,2010-019912-18,el,o
49,2010-019912-18,resultado,o
49,2010-019912-18,clinico,o
49,2010-019912-18,de,o
49,2010-019912-18,tocilizumab,i
49,2010-019912-18,SC,o
49,2010-019912-18,frente,o
49,2010-019912-18,a,o
49,2010-019912-18,placebo,i
49,2010-019912-18,SC,o
49,2010-019912-18,en,o
49,2010-019912-18,combinacion,o
49,2010-019912-18,con,o
49,2010-019912-18,farmacos,i
49,2010-019912-18,antirreumaticos,i
49,2010-019912-18,modificadores,i
49,2010-019912-18,de,i
49,2010-019912-18,la,i
49,2010-019912-18,enfermedad,i
49,2010-019912-18,FAMEs,i
49,2010-019912-18,tradicionales,o
49,2010-019912-18,en,o
49,2010-019912-18,pacientes,o
49,2010-019912-18,con,o
49,2010-019912-18,artritis,i
49,2010-019912-18,reumatoide,i
49,2010-019912-18,activa,o
49,2010-019912-18,moderada,o
49,2010-019912-18,a,o
49,2010-019912-18,severa,o
49,2010-019912-18,Indicacion,o
49,2010-019912-18,cientifica,o
49,2010-019912-18,Artritis,i
49,2010-019912-18,Reumatoide,i
49,2010-019912-18,AR,i
49,2010-019912-18,Criterios,o
49,2010-019912-18,de,o
49,2010-019912-18,inclusion,o
49,2010-019912-18,Presentar,o
49,2010-019912-18,artritis,i
49,2010-019912-18,reumatoide,i
49,2010-019912-18,de,o
49,2010-019912-18,mayor,o
49,2010-019912-18,o,o
49,2010-019912-18,igual,o
49,2010-019912-18,a,o
49,2010-019912-18,6,o
49,2010-019912-18,meses,o
49,2010-019912-18,de,o
49,2010-019912-18,duracion,o
49,2010-019912-18,Recibir,o
49,2010-019912-18,tratamiento,i
49,2010-019912-18,de,i
49,2010-019912-18,forma,i
49,2010-019912-18,ambulatoria,i
49,2010-019912-18,Presentar,o
49,2010-019912-18,un,o
49,2010-019912-18,recuento,o
49,2010-019912-18,de,o
49,2010-019912-18,articulaciones,i
49,2010-019912-18,inflamadas,i
49,2010-019912-18,RAI,o
49,2010-019912-18,mayor,o
49,2010-019912-18,o,o
49,2010-019912-18,igual,o
49,2010-019912-18,a,o
49,2010-019912-18,6,o
49,2010-019912-18,recuento,o
49,2010-019912-18,de,o
49,2010-019912-18,66,o
49,2010-019912-18,articulaciones,i
49,2010-019912-18,y,o
49,2010-019912-18,de,o
49,2010-019912-18,articulaciones,i
49,2010-019912-18,dolorosas,i
49,2010-019912-18,RAD,o
49,2010-019912-18,mayor,o
49,2010-019912-18,o,o
49,2010-019912-18,igual,o
49,2010-019912-18,a,o
49,2010-019912-18,8,o
49,2010-019912-18,recuento,o
49,2010-019912-18,de,o
49,2010-019912-18,68,o
49,2010-019912-18,articulaciones,i
49,2010-019912-18,en,o
49,2010-019912-18,las,o
49,2010-019912-18,visitas,o
49,2010-019912-18,de,o
49,2010-019912-18,seleccion,o
49,2010-019912-18,y,o
49,2010-019912-18,basal,o
49,2010-019912-18,Los,o
49,2010-019912-18,pacientes,o
49,2010-019912-18,deben,o
49,2010-019912-18,estar,o
49,2010-019912-18,recibiendo,o
49,2010-019912-18,tratamiento,i
49,2010-019912-18,con,o
49,2010-019912-18,una,o
49,2010-019912-18,dosis,o
49,2010-019912-18,estable,o
49,2010-019912-18,de,o
49,2010-019912-18,los,o
49,2010-019912-18,FAMEs,i
49,2010-019912-18,permitidos,o
49,2010-019912-18,como,o
49,2010-019912-18,minimo,o
49,2010-019912-18,8,o
49,2010-019912-18,semanas,o
49,2010-019912-18,antes,o
49,2010-019912-18,de,o
49,2010-019912-18,la,o
49,2010-019912-18,visita,o
49,2010-019912-18,basal,o
49,2010-019912-18,Criterios,o
49,2010-019912-18,de,o
49,2010-019912-18,exclusion,o
49,2010-019912-18,Pacientes,o
49,2010-019912-18,sometidos,o
49,2010-019912-18,a,o
49,2010-019912-18,intervenciones,i
49,2010-019912-18,de,i
49,2010-019912-18,cirugia,i
49,2010-019912-18,mayor,i
49,2010-019912-18,incluyendo,o
49,2010-019912-18,cirugia,i
49,2010-019912-18,articular,i
49,2010-019912-18,en,o
49,2010-019912-18,las,o
49,2010-019912-18,8,o
49,2010-019912-18,semanas,o
49,2010-019912-18,previas,o
49,2010-019912-18,a,o
49,2010-019912-18,la,o
49,2010-019912-18,visita,o
49,2010-019912-18,de,o
49,2010-019912-18,seleccion,o
49,2010-019912-18,o,o
49,2010-019912-18,que,o
49,2010-019912-18,tengan,o
49,2010-019912-18,previsto,o
49,2010-019912-18,someterse,o
49,2010-019912-18,a,o
49,2010-019912-18,una,o
49,2010-019912-18,intervencion,i
49,2010-019912-18,de,o
49,2010-019912-18,este,o
49,2010-019912-18,tipo,o
49,2010-019912-18,en,o
49,2010-019912-18,los,o
49,2010-019912-18,6,o
49,2010-019912-18,meses,o
49,2010-019912-18,siguientes,o
49,2010-019912-18,a,o
49,2010-019912-18,la,o
49,2010-019912-18,randomizacion,i
49,2010-019912-18,Enfermedad,i
49,2010-019912-18,reumatica,i
49,2010-019912-18,autoinmune,i
49,2010-019912-18,distinta,o
49,2010-019912-18,de,o
49,2010-019912-18,AR,i
49,2010-019912-18,Se,o
49,2010-019912-18,permite,o
49,2010-019912-18,la,o
49,2010-019912-18,inclusion,o
49,2010-019912-18,de,o
49,2010-019912-18,pacientes,o
49,2010-019912-18,con,o
49,2010-019912-18,sindrome,i
49,2010-019912-18,de,i
49,2010-019912-18,Sjögren,i
49,2010-019912-18,secundario,i
49,2010-019912-18,asociado,o
49,2010-019912-18,a,o
49,2010-019912-18,AR,i
49,2010-019912-18,Clase,o
49,2010-019912-18,funcional,o
49,2010-019912-18,IV,o
49,2010-019912-18,definida,o
49,2010-019912-18,de,o
49,2010-019912-18,acuerdo,o
49,2010-019912-18,con,o
49,2010-019912-18,la,o
49,2010-019912-18,Clasificacion,o
49,2010-019912-18,del,o
49,2010-019912-18,ACR,o
49,2010-019912-18,del,o
49,2010-019912-18,Estado,o
49,2010-019912-18,Funcional,o
49,2010-019912-18,en,o
49,2010-019912-18,Artritis,i
49,2010-019912-18,Reumatoide,i
49,2010-019912-18,Artritis,i
49,2010-019912-18,idiopatica,i
49,2010-019912-18,juvenil,i
49,2010-019912-18,AIJ,i
49,2010-019912-18,o,o
49,2010-019912-18,artritis,i
49,2010-019912-18,reumatoide,i
49,2010-019912-18,juvenil,i
49,2010-019912-18,ARJ,i
49,2010-019912-18,yo,o
49,2010-019912-18,AR,i
49,2010-019912-18,diagnosticadas,i
49,2010-019912-18,antes,o
49,2010-019912-18,de,o
49,2010-019912-18,los,o
49,2010-019912-18,16,o
49,2010-019912-18,años,o
49,2010-019912-18,de,o
49,2010-019912-18,edad,o
49,2010-019912-18,Enfermedad,i
49,2010-019912-18,articular,i
49,2010-019912-18,inflamatoria,i
49,2010-019912-18,distinta,o
49,2010-019912-18,de,o
49,2010-019912-18,AR,i
49,2010-019912-18,en,o
49,2010-019912-18,el,o
49,2010-019912-18,pasado,o
49,2010-019912-18,o,o
49,2010-019912-18,en,o
49,2010-019912-18,la,o
49,2010-019912-18,actualidad,o
50,2010-019912-18,EudraCT,o
50,2010-019912-18,Nº,o
50,2010-019912-18,201001991218,o
50,2010-019912-18,Titulo,o
50,2010-019912-18,cientifico,o
50,2010-019912-18,Estudio,o
50,2010-019912-18,randomizado,o
50,2010-019912-18,doble,o
50,2010-019912-18,ciego,o
50,2010-019912-18,con,o
50,2010-019912-18,grupos,o
50,2010-019912-18,de,o
50,2010-019912-18,tratamiento,i
50,2010-019912-18,paralelos,o
50,2010-019912-18,para,o
50,2010-019912-18,evaluar,i
50,2010-019912-18,la,i
50,2010-019912-18,seguridad,i
50,2010-019912-18,y,o
50,2010-019912-18,el,o
50,2010-019912-18,efecto,o
50,2010-019912-18,sobre,o
50,2010-019912-18,el,o
50,2010-019912-18,resultado,o
50,2010-019912-18,clinico,o
50,2010-019912-18,de,o
50,2010-019912-18,tocilizumab,i
50,2010-019912-18,SC,o
50,2010-019912-18,frente,o
50,2010-019912-18,a,o
50,2010-019912-18,placebo,i
50,2010-019912-18,SC,o
50,2010-019912-18,en,o
50,2010-019912-18,combinacion,o
50,2010-019912-18,con,o
50,2010-019912-18,farmacos,i
50,2010-019912-18,antirreumaticos,i
50,2010-019912-18,modificadores,i
50,2010-019912-18,de,i
50,2010-019912-18,la,i
50,2010-019912-18,enfermedad,i
50,2010-019912-18,FAMEs,i
50,2010-019912-18,tradicionales,o
50,2010-019912-18,en,o
50,2010-019912-18,pacientes,o
50,2010-019912-18,con,o
50,2010-019912-18,artritis,i
50,2010-019912-18,reumatoide,i
50,2010-019912-18,activa,o
50,2010-019912-18,moderada,o
50,2010-019912-18,a,o
50,2010-019912-18,severa,o
50,2010-019912-18,Indicacion,o
50,2010-019912-18,cientifica,o
50,2010-019912-18,Artritis,i
50,2010-019912-18,Reumatoide,i
50,2010-019912-18,AR,i
50,2010-019912-18,Criterios,o
50,2010-019912-18,de,o
50,2010-019912-18,inclusion,o
50,2010-019912-18,Presentar,o
50,2010-019912-18,artritis,i
50,2010-019912-18,reumatoide,i
50,2010-019912-18,de,o
50,2010-019912-18,mayor,o
50,2010-019912-18,o,o
50,2010-019912-18,igual,o
50,2010-019912-18,a,o
50,2010-019912-18,6,o
50,2010-019912-18,meses,o
50,2010-019912-18,de,o
50,2010-019912-18,duracion,o
50,2010-019912-18,Recibir,o
50,2010-019912-18,tratamiento,i
50,2010-019912-18,de,i
50,2010-019912-18,forma,i
50,2010-019912-18,ambulatoria,i
50,2010-019912-18,Presentar,o
50,2010-019912-18,un,o
50,2010-019912-18,recuento,o
50,2010-019912-18,de,o
50,2010-019912-18,articulaciones,i
50,2010-019912-18,inflamadas,i
50,2010-019912-18,RAI,o
50,2010-019912-18,mayor,o
50,2010-019912-18,o,o
50,2010-019912-18,igual,o
50,2010-019912-18,a,o
50,2010-019912-18,6,o
50,2010-019912-18,recuento,o
50,2010-019912-18,de,o
50,2010-019912-18,66,o
50,2010-019912-18,articulaciones,i
50,2010-019912-18,y,o
50,2010-019912-18,de,o
50,2010-019912-18,articulaciones,i
50,2010-019912-18,dolorosas,i
50,2010-019912-18,RAD,o
50,2010-019912-18,mayor,o
50,2010-019912-18,o,o
50,2010-019912-18,igual,o
50,2010-019912-18,a,o
50,2010-019912-18,8,o
50,2010-019912-18,recuento,o
50,2010-019912-18,de,o
50,2010-019912-18,68,o
50,2010-019912-18,articulaciones,i
50,2010-019912-18,en,o
50,2010-019912-18,las,o
50,2010-019912-18,visitas,o
50,2010-019912-18,de,o
50,2010-019912-18,seleccion,o
50,2010-019912-18,y,o
50,2010-019912-18,basal,o
50,2010-019912-18,Los,o
50,2010-019912-18,pacientes,o
50,2010-019912-18,deben,o
50,2010-019912-18,estar,o
50,2010-019912-18,recibiendo,o
50,2010-019912-18,tratamiento,i
50,2010-019912-18,con,o
50,2010-019912-18,una,o
50,2010-019912-18,dosis,o
50,2010-019912-18,estable,o
50,2010-019912-18,de,o
50,2010-019912-18,los,o
50,2010-019912-18,FAMEs,i
50,2010-019912-18,permitidos,o
50,2010-019912-18,como,o
50,2010-019912-18,minimo,o
50,2010-019912-18,8,o
50,2010-019912-18,semanas,o
50,2010-019912-18,antes,o
50,2010-019912-18,de,o
50,2010-019912-18,la,o
50,2010-019912-18,visita,o
50,2010-019912-18,basal,o
50,2010-019912-18,Criterios,o
50,2010-019912-18,de,o
50,2010-019912-18,exclusion,o
50,2010-019912-18,Pacientes,o
50,2010-019912-18,sometidos,o
50,2010-019912-18,a,o
50,2010-019912-18,intervenciones,i
50,2010-019912-18,de,i
50,2010-019912-18,cirugia,i
50,2010-019912-18,mayor,i
50,2010-019912-18,incluyendo,o
50,2010-019912-18,cirugia,i
50,2010-019912-18,articular,i
50,2010-019912-18,en,o
50,2010-019912-18,las,o
50,2010-019912-18,8,o
50,2010-019912-18,semanas,o
50,2010-019912-18,previas,o
50,2010-019912-18,a,o
50,2010-019912-18,la,o
50,2010-019912-18,visita,o
50,2010-019912-18,de,o
50,2010-019912-18,seleccion,o
50,2010-019912-18,o,o
50,2010-019912-18,que,o
50,2010-019912-18,tengan,o
50,2010-019912-18,previsto,o
50,2010-019912-18,someterse,o
50,2010-019912-18,a,o
50,2010-019912-18,una,o
50,2010-019912-18,intervencion,i
50,2010-019912-18,de,o
50,2010-019912-18,este,o
50,2010-019912-18,tipo,o
50,2010-019912-18,en,o
50,2010-019912-18,los,o
50,2010-019912-18,6,o
50,2010-019912-18,meses,o
50,2010-019912-18,siguientes,o
50,2010-019912-18,a,o
50,2010-019912-18,la,o
50,2010-019912-18,randomizacion,i
50,2010-019912-18,Enfermedad,i
50,2010-019912-18,reumatica,i
50,2010-019912-18,autoinmune,i
50,2010-019912-18,distinta,o
50,2010-019912-18,de,o
50,2010-019912-18,AR,i
50,2010-019912-18,Se,o
50,2010-019912-18,permite,o
50,2010-019912-18,la,o
50,2010-019912-18,inclusion,o
50,2010-019912-18,de,o
50,2010-019912-18,pacientes,o
50,2010-019912-18,con,o
50,2010-019912-18,sindrome,i
50,2010-019912-18,de,i
50,2010-019912-18,Sjögren,i
50,2010-019912-18,secundario,i
50,2010-019912-18,asociado,o
50,2010-019912-18,a,o
50,2010-019912-18,AR,i
50,2010-019912-18,Clase,o
50,2010-019912-18,funcional,o
50,2010-019912-18,IV,o
50,2010-019912-18,definida,o
50,2010-019912-18,de,o
50,2010-019912-18,acuerdo,o
50,2010-019912-18,con,o
50,2010-019912-18,la,o
50,2010-019912-18,Clasificacion,o
50,2010-019912-18,del,o
50,2010-019912-18,ACR,o
50,2010-019912-18,del,o
50,2010-019912-18,Estado,o
50,2010-019912-18,Funcional,o
50,2010-019912-18,en,o
50,2010-019912-18,Artritis,i
50,2010-019912-18,Reumatoide,i
50,2010-019912-18,Artritis,i
50,2010-019912-18,idiopatica,i
50,2010-019912-18,juvenil,i
50,2010-019912-18,AIJ,i
50,2010-019912-18,o,o
50,2010-019912-18,artritis,i
50,2010-019912-18,reumatoide,i
50,2010-019912-18,juvenil,i
50,2010-019912-18,ARJ,i
50,2010-019912-18,yo,o
50,2010-019912-18,AR,i
50,2010-019912-18,diagnosticadas,i
50,2010-019912-18,antes,o
50,2010-019912-18,de,o
50,2010-019912-18,los,o
50,2010-019912-18,16,o
50,2010-019912-18,años,o
50,2010-019912-18,de,o
50,2010-019912-18,edad,o
50,2010-019912-18,Enfermedad,i
50,2010-019912-18,articular,i
50,2010-019912-18,inflamatoria,i
50,2010-019912-18,distinta,o
50,2010-019912-18,de,o
50,2010-019912-18,AR,i
50,2010-019912-18,en,o
50,2010-019912-18,el,o
50,2010-019912-18,pasado,o
50,2010-019912-18,o,o
50,2010-019912-18,en,o
50,2010-019912-18,la,o
50,2010-019912-18,actualidad,o
51,2010-019912-18,EudraCT,o
51,2010-019912-18,Nº,o
51,2010-019912-18,201001991218,o
51,2010-019912-18,Titulo,o
51,2010-019912-18,cientifico,o
51,2010-019912-18,Estudio,o
51,2010-019912-18,randomizado,o
51,2010-019912-18,doble,o
51,2010-019912-18,ciego,o
51,2010-019912-18,con,o
51,2010-019912-18,grupos,o
51,2010-019912-18,de,o
51,2010-019912-18,tratamiento,i
51,2010-019912-18,paralelos,o
51,2010-019912-18,para,o
51,2010-019912-18,evaluar,i
51,2010-019912-18,la,i
51,2010-019912-18,seguridad,i
51,2010-019912-18,y,o
51,2010-019912-18,el,o
51,2010-019912-18,efecto,o
51,2010-019912-18,sobre,o
51,2010-019912-18,el,o
51,2010-019912-18,resultado,o
51,2010-019912-18,clinico,o
51,2010-019912-18,de,o
51,2010-019912-18,tocilizumab,i
51,2010-019912-18,SC,o
51,2010-019912-18,frente,o
51,2010-019912-18,a,o
51,2010-019912-18,placebo,i
51,2010-019912-18,SC,o
51,2010-019912-18,en,o
51,2010-019912-18,combinacion,o
51,2010-019912-18,con,o
51,2010-019912-18,farmacos,i
51,2010-019912-18,antirreumaticos,i
51,2010-019912-18,modificadores,i
51,2010-019912-18,de,i
51,2010-019912-18,la,i
51,2010-019912-18,enfermedad,i
51,2010-019912-18,FAMEs,i
51,2010-019912-18,tradicionales,o
51,2010-019912-18,en,o
51,2010-019912-18,pacientes,o
51,2010-019912-18,con,o
51,2010-019912-18,artritis,i
51,2010-019912-18,reumatoide,i
51,2010-019912-18,activa,o
51,2010-019912-18,moderada,o
51,2010-019912-18,a,o
51,2010-019912-18,severa,o
51,2010-019912-18,Indicacion,o
51,2010-019912-18,cientifica,o
51,2010-019912-18,Artritis,i
51,2010-019912-18,Reumatoide,i
51,2010-019912-18,AR,i
51,2010-019912-18,Criterios,o
51,2010-019912-18,de,o
51,2010-019912-18,inclusion,o
51,2010-019912-18,Presentar,o
51,2010-019912-18,artritis,i
51,2010-019912-18,reumatoide,i
51,2010-019912-18,de,o
51,2010-019912-18,mayor,o
51,2010-019912-18,o,o
51,2010-019912-18,igual,o
51,2010-019912-18,a,o
51,2010-019912-18,6,o
51,2010-019912-18,meses,o
51,2010-019912-18,de,o
51,2010-019912-18,duracion,o
51,2010-019912-18,Recibir,o
51,2010-019912-18,tratamiento,i
51,2010-019912-18,de,i
51,2010-019912-18,forma,i
51,2010-019912-18,ambulatoria,i
51,2010-019912-18,Presentar,o
51,2010-019912-18,un,o
51,2010-019912-18,recuento,o
51,2010-019912-18,de,o
51,2010-019912-18,articulaciones,i
51,2010-019912-18,inflamadas,i
51,2010-019912-18,RAI,o
51,2010-019912-18,mayor,o
51,2010-019912-18,o,o
51,2010-019912-18,igual,o
51,2010-019912-18,a,o
51,2010-019912-18,6,o
51,2010-019912-18,recuento,o
51,2010-019912-18,de,o
51,2010-019912-18,66,o
51,2010-019912-18,articulaciones,i
51,2010-019912-18,y,o
51,2010-019912-18,de,o
51,2010-019912-18,articulaciones,i
51,2010-019912-18,dolorosas,i
51,2010-019912-18,RAD,o
51,2010-019912-18,mayor,o
51,2010-019912-18,o,o
51,2010-019912-18,igual,o
51,2010-019912-18,a,o
51,2010-019912-18,8,o
51,2010-019912-18,recuento,o
51,2010-019912-18,de,o
51,2010-019912-18,68,o
51,2010-019912-18,articulaciones,i
51,2010-019912-18,en,o
51,2010-019912-18,las,o
51,2010-019912-18,visitas,o
51,2010-019912-18,de,o
51,2010-019912-18,seleccion,o
51,2010-019912-18,y,o
51,2010-019912-18,basal,o
51,2010-019912-18,Los,o
51,2010-019912-18,pacientes,o
51,2010-019912-18,deben,o
51,2010-019912-18,estar,o
51,2010-019912-18,recibiendo,o
51,2010-019912-18,tratamiento,i
51,2010-019912-18,con,o
51,2010-019912-18,una,o
51,2010-019912-18,dosis,o
51,2010-019912-18,estable,o
51,2010-019912-18,de,o
51,2010-019912-18,los,o
51,2010-019912-18,FAMEs,i
51,2010-019912-18,permitidos,o
51,2010-019912-18,como,o
51,2010-019912-18,minimo,o
51,2010-019912-18,8,o
51,2010-019912-18,semanas,o
51,2010-019912-18,antes,o
51,2010-019912-18,de,o
51,2010-019912-18,la,o
51,2010-019912-18,visita,o
51,2010-019912-18,basal,o
51,2010-019912-18,Criterios,o
51,2010-019912-18,de,o
51,2010-019912-18,exclusion,o
51,2010-019912-18,Pacientes,o
51,2010-019912-18,sometidos,o
51,2010-019912-18,a,o
51,2010-019912-18,intervenciones,i
51,2010-019912-18,de,i
51,2010-019912-18,cirugia,i
51,2010-019912-18,mayor,i
51,2010-019912-18,incluyendo,o
51,2010-019912-18,cirugia,i
51,2010-019912-18,articular,i
51,2010-019912-18,en,o
51,2010-019912-18,las,o
51,2010-019912-18,8,o
51,2010-019912-18,semanas,o
51,2010-019912-18,previas,o
51,2010-019912-18,a,o
51,2010-019912-18,la,o
51,2010-019912-18,visita,o
51,2010-019912-18,de,o
51,2010-019912-18,seleccion,o
51,2010-019912-18,o,o
51,2010-019912-18,que,o
51,2010-019912-18,tengan,o
51,2010-019912-18,previsto,o
51,2010-019912-18,someterse,o
51,2010-019912-18,a,o
51,2010-019912-18,una,o
51,2010-019912-18,intervencion,i
51,2010-019912-18,de,o
51,2010-019912-18,este,o
51,2010-019912-18,tipo,o
51,2010-019912-18,en,o
51,2010-019912-18,los,o
51,2010-019912-18,6,o
51,2010-019912-18,meses,o
51,2010-019912-18,siguientes,o
51,2010-019912-18,a,o
51,2010-019912-18,la,o
51,2010-019912-18,randomizacion,i
51,2010-019912-18,Enfermedad,i
51,2010-019912-18,reumatica,i
51,2010-019912-18,autoinmune,i
51,2010-019912-18,distinta,o
51,2010-019912-18,de,o
51,2010-019912-18,AR,i
51,2010-019912-18,Se,o
51,2010-019912-18,permite,o
51,2010-019912-18,la,o
51,2010-019912-18,inclusion,o
51,2010-019912-18,de,o
51,2010-019912-18,pacientes,o
51,2010-019912-18,con,o
51,2010-019912-18,sindrome,i
51,2010-019912-18,de,i
51,2010-019912-18,Sjögren,i
51,2010-019912-18,secundario,i
51,2010-019912-18,asociado,o
51,2010-019912-18,a,o
51,2010-019912-18,AR,i
51,2010-019912-18,Clase,o
51,2010-019912-18,funcional,o
51,2010-019912-18,IV,o
51,2010-019912-18,definida,o
51,2010-019912-18,de,o
51,2010-019912-18,acuerdo,o
51,2010-019912-18,con,o
51,2010-019912-18,la,o
51,2010-019912-18,Clasificacion,o
51,2010-019912-18,del,o
51,2010-019912-18,ACR,o
51,2010-019912-18,del,o
51,2010-019912-18,Estado,o
51,2010-019912-18,Funcional,o
51,2010-019912-18,en,o
51,2010-019912-18,Artritis,i
51,2010-019912-18,Reumatoide,i
51,2010-019912-18,Artritis,i
51,2010-019912-18,idiopatica,i
51,2010-019912-18,juvenil,i
51,2010-019912-18,AIJ,i
51,2010-019912-18,o,o
51,2010-019912-18,artritis,i
51,2010-019912-18,reumatoide,i
51,2010-019912-18,juvenil,i
51,2010-019912-18,ARJ,i
51,2010-019912-18,yo,o
51,2010-019912-18,AR,i
51,2010-019912-18,diagnosticadas,i
51,2010-019912-18,antes,o
51,2010-019912-18,de,o
51,2010-019912-18,los,o
51,2010-019912-18,16,o
51,2010-019912-18,años,o
51,2010-019912-18,de,o
51,2010-019912-18,edad,o
51,2010-019912-18,Enfermedad,i
51,2010-019912-18,articular,i
51,2010-019912-18,inflamatoria,i
51,2010-019912-18,distinta,o
51,2010-019912-18,de,o
51,2010-019912-18,AR,i
51,2010-019912-18,en,o
51,2010-019912-18,el,o
51,2010-019912-18,pasado,o
51,2010-019912-18,o,o
51,2010-019912-18,en,o
51,2010-019912-18,la,o
51,2010-019912-18,actualidad,o
52,2010-019912-18,EudraCT,o
52,2010-019912-18,Nº,o
52,2010-019912-18,201001991218,o
52,2010-019912-18,Titulo,o
52,2010-019912-18,cientifico,o
52,2010-019912-18,Estudio,o
52,2010-019912-18,randomizado,o
52,2010-019912-18,doble,o
52,2010-019912-18,ciego,o
52,2010-019912-18,con,o
52,2010-019912-18,grupos,o
52,2010-019912-18,de,o
52,2010-019912-18,tratamiento,i
52,2010-019912-18,paralelos,o
52,2010-019912-18,para,o
52,2010-019912-18,evaluar,i
52,2010-019912-18,la,i
52,2010-019912-18,seguridad,i
52,2010-019912-18,y,o
52,2010-019912-18,el,o
52,2010-019912-18,efecto,o
52,2010-019912-18,sobre,o
52,2010-019912-18,el,o
52,2010-019912-18,resultado,o
52,2010-019912-18,clinico,o
52,2010-019912-18,de,o
52,2010-019912-18,tocilizumab,i
52,2010-019912-18,SC,o
52,2010-019912-18,frente,o
52,2010-019912-18,a,o
52,2010-019912-18,placebo,i
52,2010-019912-18,SC,o
52,2010-019912-18,en,o
52,2010-019912-18,combinacion,o
52,2010-019912-18,con,o
52,2010-019912-18,farmacos,i
52,2010-019912-18,antirreumaticos,i
52,2010-019912-18,modificadores,i
52,2010-019912-18,de,i
52,2010-019912-18,la,i
52,2010-019912-18,enfermedad,i
52,2010-019912-18,FAMEs,i
52,2010-019912-18,tradicionales,o
52,2010-019912-18,en,o
52,2010-019912-18,pacientes,o
52,2010-019912-18,con,o
52,2010-019912-18,artritis,i
52,2010-019912-18,reumatoide,i
52,2010-019912-18,activa,o
52,2010-019912-18,moderada,o
52,2010-019912-18,a,o
52,2010-019912-18,severa,o
52,2010-019912-18,Indicacion,o
52,2010-019912-18,cientifica,o
52,2010-019912-18,Artritis,i
52,2010-019912-18,Reumatoide,i
52,2010-019912-18,AR,i
52,2010-019912-18,Criterios,o
52,2010-019912-18,de,o
52,2010-019912-18,inclusion,o
52,2010-019912-18,Presentar,o
52,2010-019912-18,artritis,i
52,2010-019912-18,reumatoide,i
52,2010-019912-18,de,o
52,2010-019912-18,mayor,o
52,2010-019912-18,o,o
52,2010-019912-18,igual,o
52,2010-019912-18,a,o
52,2010-019912-18,6,o
52,2010-019912-18,meses,o
52,2010-019912-18,de,o
52,2010-019912-18,duracion,o
52,2010-019912-18,Recibir,o
52,2010-019912-18,tratamiento,i
52,2010-019912-18,de,i
52,2010-019912-18,forma,i
52,2010-019912-18,ambulatoria,i
52,2010-019912-18,Presentar,o
52,2010-019912-18,un,o
52,2010-019912-18,recuento,o
52,2010-019912-18,de,o
52,2010-019912-18,articulaciones,i
52,2010-019912-18,inflamadas,i
52,2010-019912-18,RAI,o
52,2010-019912-18,mayor,o
52,2010-019912-18,o,o
52,2010-019912-18,igual,o
52,2010-019912-18,a,o
52,2010-019912-18,6,o
52,2010-019912-18,recuento,o
52,2010-019912-18,de,o
52,2010-019912-18,66,o
52,2010-019912-18,articulaciones,i
52,2010-019912-18,y,o
52,2010-019912-18,de,o
52,2010-019912-18,articulaciones,i
52,2010-019912-18,dolorosas,i
52,2010-019912-18,RAD,o
52,2010-019912-18,mayor,o
52,2010-019912-18,o,o
52,2010-019912-18,igual,o
52,2010-019912-18,a,o
52,2010-019912-18,8,o
52,2010-019912-18,recuento,o
52,2010-019912-18,de,o
52,2010-019912-18,68,o
52,2010-019912-18,articulaciones,i
52,2010-019912-18,en,o
52,2010-019912-18,las,o
52,2010-019912-18,visitas,o
52,2010-019912-18,de,o
52,2010-019912-18,seleccion,o
52,2010-019912-18,y,o
52,2010-019912-18,basal,o
52,2010-019912-18,Los,o
52,2010-019912-18,pacientes,o
52,2010-019912-18,deben,o
52,2010-019912-18,estar,o
52,2010-019912-18,recibiendo,o
52,2010-019912-18,tratamiento,i
52,2010-019912-18,con,o
52,2010-019912-18,una,o
52,2010-019912-18,dosis,o
52,2010-019912-18,estable,o
52,2010-019912-18,de,o
52,2010-019912-18,los,o
52,2010-019912-18,FAMEs,i
52,2010-019912-18,permitidos,o
52,2010-019912-18,como,o
52,2010-019912-18,minimo,o
52,2010-019912-18,8,o
52,2010-019912-18,semanas,o
52,2010-019912-18,antes,o
52,2010-019912-18,de,o
52,2010-019912-18,la,o
52,2010-019912-18,visita,o
52,2010-019912-18,basal,o
52,2010-019912-18,Criterios,o
52,2010-019912-18,de,o
52,2010-019912-18,exclusion,o
52,2010-019912-18,Pacientes,o
52,2010-019912-18,sometidos,o
52,2010-019912-18,a,o
52,2010-019912-18,intervenciones,i
52,2010-019912-18,de,i
52,2010-019912-18,cirugia,i
52,2010-019912-18,mayor,i
52,2010-019912-18,incluyendo,o
52,2010-019912-18,cirugia,i
52,2010-019912-18,articular,i
52,2010-019912-18,en,o
52,2010-019912-18,las,o
52,2010-019912-18,8,o
52,2010-019912-18,semanas,o
52,2010-019912-18,previas,o
52,2010-019912-18,a,o
52,2010-019912-18,la,o
52,2010-019912-18,visita,o
52,2010-019912-18,de,o
52,2010-019912-18,seleccion,o
52,2010-019912-18,o,o
52,2010-019912-18,que,o
52,2010-019912-18,tengan,o
52,2010-019912-18,previsto,o
52,2010-019912-18,someterse,o
52,2010-019912-18,a,o
52,2010-019912-18,una,o
52,2010-019912-18,intervencion,i
52,2010-019912-18,de,o
52,2010-019912-18,este,o
52,2010-019912-18,tipo,o
52,2010-019912-18,en,o
52,2010-019912-18,los,o
52,2010-019912-18,6,o
52,2010-019912-18,meses,o
52,2010-019912-18,siguientes,o
52,2010-019912-18,a,o
52,2010-019912-18,la,o
52,2010-019912-18,randomizacion,i
52,2010-019912-18,Enfermedad,i
52,2010-019912-18,reumatica,i
52,2010-019912-18,autoinmune,i
52,2010-019912-18,distinta,o
52,2010-019912-18,de,o
52,2010-019912-18,AR,i
52,2010-019912-18,Se,o
52,2010-019912-18,permite,o
52,2010-019912-18,la,o
52,2010-019912-18,inclusion,o
52,2010-019912-18,de,o
52,2010-019912-18,pacientes,o
52,2010-019912-18,con,o
52,2010-019912-18,sindrome,i
52,2010-019912-18,de,i
52,2010-019912-18,Sjögren,i
52,2010-019912-18,secundario,i
52,2010-019912-18,asociado,o
52,2010-019912-18,a,o
52,2010-019912-18,AR,i
52,2010-019912-18,Clase,o
52,2010-019912-18,funcional,o
52,2010-019912-18,IV,o
52,2010-019912-18,definida,o
52,2010-019912-18,de,o
52,2010-019912-18,acuerdo,o
52,2010-019912-18,con,o
52,2010-019912-18,la,o
52,2010-019912-18,Clasificacion,o
52,2010-019912-18,del,o
52,2010-019912-18,ACR,o
52,2010-019912-18,del,o
52,2010-019912-18,Estado,o
52,2010-019912-18,Funcional,o
52,2010-019912-18,en,o
52,2010-019912-18,Artritis,i
52,2010-019912-18,Reumatoide,i
52,2010-019912-18,Artritis,i
52,2010-019912-18,idiopatica,i
52,2010-019912-18,juvenil,i
52,2010-019912-18,AIJ,i
52,2010-019912-18,o,o
52,2010-019912-18,artritis,i
52,2010-019912-18,reumatoide,i
52,2010-019912-18,juvenil,i
52,2010-019912-18,ARJ,i
52,2010-019912-18,yo,o
52,2010-019912-18,AR,i
52,2010-019912-18,diagnosticadas,i
52,2010-019912-18,antes,o
52,2010-019912-18,de,o
52,2010-019912-18,los,o
52,2010-019912-18,16,o
52,2010-019912-18,años,o
52,2010-019912-18,de,o
52,2010-019912-18,edad,o
52,2010-019912-18,Enfermedad,i
52,2010-019912-18,articular,i
52,2010-019912-18,inflamatoria,i
52,2010-019912-18,distinta,o
52,2010-019912-18,de,o
52,2010-019912-18,AR,i
52,2010-019912-18,en,o
52,2010-019912-18,el,o
52,2010-019912-18,pasado,o
52,2010-019912-18,o,o
52,2010-019912-18,en,o
52,2010-019912-18,la,o
52,2010-019912-18,actualidad,o
53,2010-019912-18,EudraCT,o
53,2010-019912-18,Nº,o
53,2010-019912-18,201001991218,o
53,2010-019912-18,Titulo,o
53,2010-019912-18,cientifico,o
53,2010-019912-18,Estudio,o
53,2010-019912-18,randomizado,o
53,2010-019912-18,doble,o
53,2010-019912-18,ciego,o
53,2010-019912-18,con,o
53,2010-019912-18,grupos,o
53,2010-019912-18,de,o
53,2010-019912-18,tratamiento,i
53,2010-019912-18,paralelos,o
53,2010-019912-18,para,o
53,2010-019912-18,evaluar,i
53,2010-019912-18,la,i
53,2010-019912-18,seguridad,i
53,2010-019912-18,y,o
53,2010-019912-18,el,o
53,2010-019912-18,efecto,o
53,2010-019912-18,sobre,o
53,2010-019912-18,el,o
53,2010-019912-18,resultado,o
53,2010-019912-18,clinico,o
53,2010-019912-18,de,o
53,2010-019912-18,tocilizumab,i
53,2010-019912-18,SC,o
53,2010-019912-18,frente,o
53,2010-019912-18,a,o
53,2010-019912-18,placebo,i
53,2010-019912-18,SC,o
53,2010-019912-18,en,o
53,2010-019912-18,combinacion,o
53,2010-019912-18,con,o
53,2010-019912-18,farmacos,i
53,2010-019912-18,antirreumaticos,i
53,2010-019912-18,modificadores,i
53,2010-019912-18,de,i
53,2010-019912-18,la,i
53,2010-019912-18,enfermedad,i
53,2010-019912-18,FAMEs,i
53,2010-019912-18,tradicionales,o
53,2010-019912-18,en,o
53,2010-019912-18,pacientes,o
53,2010-019912-18,con,o
53,2010-019912-18,artritis,i
53,2010-019912-18,reumatoide,i
53,2010-019912-18,activa,o
53,2010-019912-18,moderada,o
53,2010-019912-18,a,o
53,2010-019912-18,severa,o
53,2010-019912-18,Indicacion,o
53,2010-019912-18,cientifica,o
53,2010-019912-18,Artritis,i
53,2010-019912-18,Reumatoide,i
53,2010-019912-18,AR,i
53,2010-019912-18,Criterios,o
53,2010-019912-18,de,o
53,2010-019912-18,inclusion,o
53,2010-019912-18,Presentar,o
53,2010-019912-18,artritis,i
53,2010-019912-18,reumatoide,i
53,2010-019912-18,de,o
53,2010-019912-18,mayor,o
53,2010-019912-18,o,o
53,2010-019912-18,igual,o
53,2010-019912-18,a,o
53,2010-019912-18,6,o
53,2010-019912-18,meses,o
53,2010-019912-18,de,o
53,2010-019912-18,duracion,o
53,2010-019912-18,Recibir,o
53,2010-019912-18,tratamiento,i
53,2010-019912-18,de,i
53,2010-019912-18,forma,i
53,2010-019912-18,ambulatoria,i
53,2010-019912-18,Presentar,o
53,2010-019912-18,un,o
53,2010-019912-18,recuento,o
53,2010-019912-18,de,o
53,2010-019912-18,articulaciones,i
53,2010-019912-18,inflamadas,i
53,2010-019912-18,RAI,o
53,2010-019912-18,mayor,o
53,2010-019912-18,o,o
53,2010-019912-18,igual,o
53,2010-019912-18,a,o
53,2010-019912-18,6,o
53,2010-019912-18,recuento,o
53,2010-019912-18,de,o
53,2010-019912-18,66,o
53,2010-019912-18,articulaciones,i
53,2010-019912-18,y,o
53,2010-019912-18,de,o
53,2010-019912-18,articulaciones,i
53,2010-019912-18,dolorosas,i
53,2010-019912-18,RAD,o
53,2010-019912-18,mayor,o
53,2010-019912-18,o,o
53,2010-019912-18,igual,o
53,2010-019912-18,a,o
53,2010-019912-18,8,o
53,2010-019912-18,recuento,o
53,2010-019912-18,de,o
53,2010-019912-18,68,o
53,2010-019912-18,articulaciones,i
53,2010-019912-18,en,o
53,2010-019912-18,las,o
53,2010-019912-18,visitas,o
53,2010-019912-18,de,o
53,2010-019912-18,seleccion,o
53,2010-019912-18,y,o
53,2010-019912-18,basal,o
53,2010-019912-18,Los,o
53,2010-019912-18,pacientes,o
53,2010-019912-18,deben,o
53,2010-019912-18,estar,o
53,2010-019912-18,recibiendo,o
53,2010-019912-18,tratamiento,i
53,2010-019912-18,con,o
53,2010-019912-18,una,o
53,2010-019912-18,dosis,o
53,2010-019912-18,estable,o
53,2010-019912-18,de,o
53,2010-019912-18,los,o
53,2010-019912-18,FAMEs,i
53,2010-019912-18,permitidos,o
53,2010-019912-18,como,o
53,2010-019912-18,minimo,o
53,2010-019912-18,8,o
53,2010-019912-18,semanas,o
53,2010-019912-18,antes,o
53,2010-019912-18,de,o
53,2010-019912-18,la,o
53,2010-019912-18,visita,o
53,2010-019912-18,basal,o
53,2010-019912-18,Criterios,o
53,2010-019912-18,de,o
53,2010-019912-18,exclusion,o
53,2010-019912-18,Pacientes,o
53,2010-019912-18,sometidos,o
53,2010-019912-18,a,o
53,2010-019912-18,intervenciones,i
53,2010-019912-18,de,i
53,2010-019912-18,cirugia,i
53,2010-019912-18,mayor,i
53,2010-019912-18,incluyendo,o
53,2010-019912-18,cirugia,i
53,2010-019912-18,articular,i
53,2010-019912-18,en,o
53,2010-019912-18,las,o
53,2010-019912-18,8,o
53,2010-019912-18,semanas,o
53,2010-019912-18,previas,o
53,2010-019912-18,a,o
53,2010-019912-18,la,o
53,2010-019912-18,visita,o
53,2010-019912-18,de,o
53,2010-019912-18,seleccion,o
53,2010-019912-18,o,o
53,2010-019912-18,que,o
53,2010-019912-18,tengan,o
53,2010-019912-18,previsto,o
53,2010-019912-18,someterse,o
53,2010-019912-18,a,o
53,2010-019912-18,una,o
53,2010-019912-18,intervencion,i
53,2010-019912-18,de,o
53,2010-019912-18,este,o
53,2010-019912-18,tipo,o
53,2010-019912-18,en,o
53,2010-019912-18,los,o
53,2010-019912-18,6,o
53,2010-019912-18,meses,o
53,2010-019912-18,siguientes,o
53,2010-019912-18,a,o
53,2010-019912-18,la,o
53,2010-019912-18,randomizacion,i
53,2010-019912-18,Enfermedad,i
53,2010-019912-18,reumatica,i
53,2010-019912-18,autoinmune,i
53,2010-019912-18,distinta,o
53,2010-019912-18,de,o
53,2010-019912-18,AR,i
53,2010-019912-18,Se,o
53,2010-019912-18,permite,o
53,2010-019912-18,la,o
53,2010-019912-18,inclusion,o
53,2010-019912-18,de,o
53,2010-019912-18,pacientes,o
53,2010-019912-18,con,o
53,2010-019912-18,sindrome,i
53,2010-019912-18,de,i
53,2010-019912-18,Sjögren,i
53,2010-019912-18,secundario,i
53,2010-019912-18,asociado,o
53,2010-019912-18,a,o
53,2010-019912-18,AR,i
53,2010-019912-18,Clase,o
53,2010-019912-18,funcional,o
53,2010-019912-18,IV,o
53,2010-019912-18,definida,o
53,2010-019912-18,de,o
53,2010-019912-18,acuerdo,o
53,2010-019912-18,con,o
53,2010-019912-18,la,o
53,2010-019912-18,Clasificacion,o
53,2010-019912-18,del,o
53,2010-019912-18,ACR,o
53,2010-019912-18,del,o
53,2010-019912-18,Estado,o
53,2010-019912-18,Funcional,o
53,2010-019912-18,en,o
53,2010-019912-18,Artritis,i
53,2010-019912-18,Reumatoide,i
53,2010-019912-18,Artritis,i
53,2010-019912-18,idiopatica,i
53,2010-019912-18,juvenil,i
53,2010-019912-18,AIJ,i
53,2010-019912-18,o,o
53,2010-019912-18,artritis,i
53,2010-019912-18,reumatoide,i
53,2010-019912-18,juvenil,i
53,2010-019912-18,ARJ,i
53,2010-019912-18,yo,o
53,2010-019912-18,AR,i
53,2010-019912-18,diagnosticadas,i
53,2010-019912-18,antes,o
53,2010-019912-18,de,o
53,2010-019912-18,los,o
53,2010-019912-18,16,o
53,2010-019912-18,años,o
53,2010-019912-18,de,o
53,2010-019912-18,edad,o
53,2010-019912-18,Enfermedad,i
53,2010-019912-18,articular,i
53,2010-019912-18,inflamatoria,i
53,2010-019912-18,distinta,o
53,2010-019912-18,de,o
53,2010-019912-18,AR,i
53,2010-019912-18,en,o
53,2010-019912-18,el,o
53,2010-019912-18,pasado,o
53,2010-019912-18,o,o
53,2010-019912-18,en,o
53,2010-019912-18,la,o
53,2010-019912-18,actualidad,o
54,2010-019912-18,EudraCT,o
54,2010-019912-18,Nº,o
54,2010-019912-18,201001991218,o
54,2010-019912-18,Titulo,o
54,2010-019912-18,cientifico,o
54,2010-019912-18,Estudio,o
54,2010-019912-18,randomizado,o
54,2010-019912-18,doble,o
54,2010-019912-18,ciego,o
54,2010-019912-18,con,o
54,2010-019912-18,grupos,o
54,2010-019912-18,de,o
54,2010-019912-18,tratamiento,i
54,2010-019912-18,paralelos,o
54,2010-019912-18,para,o
54,2010-019912-18,evaluar,i
54,2010-019912-18,la,i
54,2010-019912-18,seguridad,i
54,2010-019912-18,y,o
54,2010-019912-18,el,o
54,2010-019912-18,efecto,o
54,2010-019912-18,sobre,o
54,2010-019912-18,el,o
54,2010-019912-18,resultado,o
54,2010-019912-18,clinico,o
54,2010-019912-18,de,o
54,2010-019912-18,tocilizumab,i
54,2010-019912-18,SC,o
54,2010-019912-18,frente,o
54,2010-019912-18,a,o
54,2010-019912-18,placebo,i
54,2010-019912-18,SC,o
54,2010-019912-18,en,o
54,2010-019912-18,combinacion,o
54,2010-019912-18,con,o
54,2010-019912-18,farmacos,i
54,2010-019912-18,antirreumaticos,i
54,2010-019912-18,modificadores,i
54,2010-019912-18,de,i
54,2010-019912-18,la,i
54,2010-019912-18,enfermedad,i
54,2010-019912-18,FAMEs,i
54,2010-019912-18,tradicionales,o
54,2010-019912-18,en,o
54,2010-019912-18,pacientes,o
54,2010-019912-18,con,o
54,2010-019912-18,artritis,i
54,2010-019912-18,reumatoide,i
54,2010-019912-18,activa,o
54,2010-019912-18,moderada,o
54,2010-019912-18,a,o
54,2010-019912-18,severa,o
54,2010-019912-18,Indicacion,o
54,2010-019912-18,cientifica,o
54,2010-019912-18,Artritis,i
54,2010-019912-18,Reumatoide,i
54,2010-019912-18,AR,i
54,2010-019912-18,Criterios,o
54,2010-019912-18,de,o
54,2010-019912-18,inclusion,o
54,2010-019912-18,Presentar,o
54,2010-019912-18,artritis,i
54,2010-019912-18,reumatoide,i
54,2010-019912-18,de,o
54,2010-019912-18,mayor,o
54,2010-019912-18,o,o
54,2010-019912-18,igual,o
54,2010-019912-18,a,o
54,2010-019912-18,6,o
54,2010-019912-18,meses,o
54,2010-019912-18,de,o
54,2010-019912-18,duracion,o
54,2010-019912-18,Recibir,o
54,2010-019912-18,tratamiento,i
54,2010-019912-18,de,i
54,2010-019912-18,forma,i
54,2010-019912-18,ambulatoria,i
54,2010-019912-18,Presentar,o
54,2010-019912-18,un,o
54,2010-019912-18,recuento,o
54,2010-019912-18,de,o
54,2010-019912-18,articulaciones,i
54,2010-019912-18,inflamadas,i
54,2010-019912-18,RAI,o
54,2010-019912-18,mayor,o
54,2010-019912-18,o,o
54,2010-019912-18,igual,o
54,2010-019912-18,a,o
54,2010-019912-18,6,o
54,2010-019912-18,recuento,o
54,2010-019912-18,de,o
54,2010-019912-18,66,o
54,2010-019912-18,articulaciones,i
54,2010-019912-18,y,o
54,2010-019912-18,de,o
54,2010-019912-18,articulaciones,i
54,2010-019912-18,dolorosas,i
54,2010-019912-18,RAD,o
54,2010-019912-18,mayor,o
54,2010-019912-18,o,o
54,2010-019912-18,igual,o
54,2010-019912-18,a,o
54,2010-019912-18,8,o
54,2010-019912-18,recuento,o
54,2010-019912-18,de,o
54,2010-019912-18,68,o
54,2010-019912-18,articulaciones,i
54,2010-019912-18,en,o
54,2010-019912-18,las,o
54,2010-019912-18,visitas,o
54,2010-019912-18,de,o
54,2010-019912-18,seleccion,o
54,2010-019912-18,y,o
54,2010-019912-18,basal,o
54,2010-019912-18,Los,o
54,2010-019912-18,pacientes,o
54,2010-019912-18,deben,o
54,2010-019912-18,estar,o
54,2010-019912-18,recibiendo,o
54,2010-019912-18,tratamiento,i
54,2010-019912-18,con,o
54,2010-019912-18,una,o
54,2010-019912-18,dosis,o
54,2010-019912-18,estable,o
54,2010-019912-18,de,o
54,2010-019912-18,los,o
54,2010-019912-18,FAMEs,i
54,2010-019912-18,permitidos,o
54,2010-019912-18,como,o
54,2010-019912-18,minimo,o
54,2010-019912-18,8,o
54,2010-019912-18,semanas,o
54,2010-019912-18,antes,o
54,2010-019912-18,de,o
54,2010-019912-18,la,o
54,2010-019912-18,visita,o
54,2010-019912-18,basal,o
54,2010-019912-18,Criterios,o
54,2010-019912-18,de,o
54,2010-019912-18,exclusion,o
54,2010-019912-18,Pacientes,o
54,2010-019912-18,sometidos,o
54,2010-019912-18,a,o
54,2010-019912-18,intervenciones,i
54,2010-019912-18,de,i
54,2010-019912-18,cirugia,i
54,2010-019912-18,mayor,i
54,2010-019912-18,incluyendo,o
54,2010-019912-18,cirugia,i
54,2010-019912-18,articular,i
54,2010-019912-18,en,o
54,2010-019912-18,las,o
54,2010-019912-18,8,o
54,2010-019912-18,semanas,o
54,2010-019912-18,previas,o
54,2010-019912-18,a,o
54,2010-019912-18,la,o
54,2010-019912-18,visita,o
54,2010-019912-18,de,o
54,2010-019912-18,seleccion,o
54,2010-019912-18,o,o
54,2010-019912-18,que,o
54,2010-019912-18,tengan,o
54,2010-019912-18,previsto,o
54,2010-019912-18,someterse,o
54,2010-019912-18,a,o
54,2010-019912-18,una,o
54,2010-019912-18,intervencion,i
54,2010-019912-18,de,o
54,2010-019912-18,este,o
54,2010-019912-18,tipo,o
54,2010-019912-18,en,o
54,2010-019912-18,los,o
54,2010-019912-18,6,o
54,2010-019912-18,meses,o
54,2010-019912-18,siguientes,o
54,2010-019912-18,a,o
54,2010-019912-18,la,o
54,2010-019912-18,randomizacion,i
54,2010-019912-18,Enfermedad,i
54,2010-019912-18,reumatica,i
54,2010-019912-18,autoinmune,i
54,2010-019912-18,distinta,o
54,2010-019912-18,de,o
54,2010-019912-18,AR,i
54,2010-019912-18,Se,o
54,2010-019912-18,permite,o
54,2010-019912-18,la,o
54,2010-019912-18,inclusion,o
54,2010-019912-18,de,o
54,2010-019912-18,pacientes,o
54,2010-019912-18,con,o
54,2010-019912-18,sindrome,i
54,2010-019912-18,de,i
54,2010-019912-18,Sjögren,i
54,2010-019912-18,secundario,i
54,2010-019912-18,asociado,o
54,2010-019912-18,a,o
54,2010-019912-18,AR,i
54,2010-019912-18,Clase,o
54,2010-019912-18,funcional,o
54,2010-019912-18,IV,o
54,2010-019912-18,definida,o
54,2010-019912-18,de,o
54,2010-019912-18,acuerdo,o
54,2010-019912-18,con,o
54,2010-019912-18,la,o
54,2010-019912-18,Clasificacion,o
54,2010-019912-18,del,o
54,2010-019912-18,ACR,o
54,2010-019912-18,del,o
54,2010-019912-18,Estado,o
54,2010-019912-18,Funcional,o
54,2010-019912-18,en,o
54,2010-019912-18,Artritis,i
54,2010-019912-18,Reumatoide,i
54,2010-019912-18,Artritis,i
54,2010-019912-18,idiopatica,i
54,2010-019912-18,juvenil,i
54,2010-019912-18,AIJ,i
54,2010-019912-18,o,o
54,2010-019912-18,artritis,i
54,2010-019912-18,reumatoide,i
54,2010-019912-18,juvenil,i
54,2010-019912-18,ARJ,i
54,2010-019912-18,yo,o
54,2010-019912-18,AR,i
54,2010-019912-18,diagnosticadas,i
54,2010-019912-18,antes,o
54,2010-019912-18,de,o
54,2010-019912-18,los,o
54,2010-019912-18,16,o
54,2010-019912-18,años,o
54,2010-019912-18,de,o
54,2010-019912-18,edad,o
54,2010-019912-18,Enfermedad,i
54,2010-019912-18,articular,i
54,2010-019912-18,inflamatoria,i
54,2010-019912-18,distinta,o
54,2010-019912-18,de,o
54,2010-019912-18,AR,i
54,2010-019912-18,en,o
54,2010-019912-18,el,o
54,2010-019912-18,pasado,o
54,2010-019912-18,o,o
54,2010-019912-18,en,o
54,2010-019912-18,la,o
54,2010-019912-18,actualidad,o
55,2010-019912-18,EudraCT,o
55,2010-019912-18,Nº,o
55,2010-019912-18,201001991218,o
55,2010-019912-18,Titulo,o
55,2010-019912-18,cientifico,o
55,2010-019912-18,Estudio,o
55,2010-019912-18,randomizado,o
55,2010-019912-18,doble,o
55,2010-019912-18,ciego,o
55,2010-019912-18,con,o
55,2010-019912-18,grupos,o
55,2010-019912-18,de,o
55,2010-019912-18,tratamiento,i
55,2010-019912-18,paralelos,o
55,2010-019912-18,para,o
55,2010-019912-18,evaluar,i
55,2010-019912-18,la,i
55,2010-019912-18,seguridad,i
55,2010-019912-18,y,o
55,2010-019912-18,el,o
55,2010-019912-18,efecto,o
55,2010-019912-18,sobre,o
55,2010-019912-18,el,o
55,2010-019912-18,resultado,o
55,2010-019912-18,clinico,o
55,2010-019912-18,de,o
55,2010-019912-18,tocilizumab,i
55,2010-019912-18,SC,o
55,2010-019912-18,frente,o
55,2010-019912-18,a,o
55,2010-019912-18,placebo,i
55,2010-019912-18,SC,o
55,2010-019912-18,en,o
55,2010-019912-18,combinacion,o
55,2010-019912-18,con,o
55,2010-019912-18,farmacos,i
55,2010-019912-18,antirreumaticos,i
55,2010-019912-18,modificadores,i
55,2010-019912-18,de,i
55,2010-019912-18,la,i
55,2010-019912-18,enfermedad,i
55,2010-019912-18,FAMEs,i
55,2010-019912-18,tradicionales,o
55,2010-019912-18,en,o
55,2010-019912-18,pacientes,o
55,2010-019912-18,con,o
55,2010-019912-18,artritis,i
55,2010-019912-18,reumatoide,i
55,2010-019912-18,activa,o
55,2010-019912-18,moderada,o
55,2010-019912-18,a,o
55,2010-019912-18,severa,o
55,2010-019912-18,Indicacion,o
55,2010-019912-18,cientifica,o
55,2010-019912-18,Artritis,i
55,2010-019912-18,Reumatoide,i
55,2010-019912-18,AR,i
55,2010-019912-18,Criterios,o
55,2010-019912-18,de,o
55,2010-019912-18,inclusion,o
55,2010-019912-18,Presentar,o
55,2010-019912-18,artritis,i
55,2010-019912-18,reumatoide,i
55,2010-019912-18,de,o
55,2010-019912-18,mayor,o
55,2010-019912-18,o,o
55,2010-019912-18,igual,o
55,2010-019912-18,a,o
55,2010-019912-18,6,o
55,2010-019912-18,meses,o
55,2010-019912-18,de,o
55,2010-019912-18,duracion,o
55,2010-019912-18,Recibir,o
55,2010-019912-18,tratamiento,i
55,2010-019912-18,de,i
55,2010-019912-18,forma,i
55,2010-019912-18,ambulatoria,i
55,2010-019912-18,Presentar,o
55,2010-019912-18,un,o
55,2010-019912-18,recuento,o
55,2010-019912-18,de,o
55,2010-019912-18,articulaciones,i
55,2010-019912-18,inflamadas,i
55,2010-019912-18,RAI,o
55,2010-019912-18,mayor,o
55,2010-019912-18,o,o
55,2010-019912-18,igual,o
55,2010-019912-18,a,o
55,2010-019912-18,6,o
55,2010-019912-18,recuento,o
55,2010-019912-18,de,o
55,2010-019912-18,66,o
55,2010-019912-18,articulaciones,i
55,2010-019912-18,y,o
55,2010-019912-18,de,o
55,2010-019912-18,articulaciones,i
55,2010-019912-18,dolorosas,i
55,2010-019912-18,RAD,o
55,2010-019912-18,mayor,o
55,2010-019912-18,o,o
55,2010-019912-18,igual,o
55,2010-019912-18,a,o
55,2010-019912-18,8,o
55,2010-019912-18,recuento,o
55,2010-019912-18,de,o
55,2010-019912-18,68,o
55,2010-019912-18,articulaciones,i
55,2010-019912-18,en,o
55,2010-019912-18,las,o
55,2010-019912-18,visitas,o
55,2010-019912-18,de,o
55,2010-019912-18,seleccion,o
55,2010-019912-18,y,o
55,2010-019912-18,basal,o
55,2010-019912-18,Los,o
55,2010-019912-18,pacientes,o
55,2010-019912-18,deben,o
55,2010-019912-18,estar,o
55,2010-019912-18,recibiendo,o
55,2010-019912-18,tratamiento,i
55,2010-019912-18,con,o
55,2010-019912-18,una,o
55,2010-019912-18,dosis,o
55,2010-019912-18,estable,o
55,2010-019912-18,de,o
55,2010-019912-18,los,o
55,2010-019912-18,FAMEs,i
55,2010-019912-18,permitidos,o
55,2010-019912-18,como,o
55,2010-019912-18,minimo,o
55,2010-019912-18,8,o
55,2010-019912-18,semanas,o
55,2010-019912-18,antes,o
55,2010-019912-18,de,o
55,2010-019912-18,la,o
55,2010-019912-18,visita,o
55,2010-019912-18,basal,o
55,2010-019912-18,Criterios,o
55,2010-019912-18,de,o
55,2010-019912-18,exclusion,o
55,2010-019912-18,Pacientes,o
55,2010-019912-18,sometidos,o
55,2010-019912-18,a,o
55,2010-019912-18,intervenciones,i
55,2010-019912-18,de,i
55,2010-019912-18,cirugia,i
55,2010-019912-18,mayor,i
55,2010-019912-18,incluyendo,o
55,2010-019912-18,cirugia,i
55,2010-019912-18,articular,i
55,2010-019912-18,en,o
55,2010-019912-18,las,o
55,2010-019912-18,8,o
55,2010-019912-18,semanas,o
55,2010-019912-18,previas,o
55,2010-019912-18,a,o
55,2010-019912-18,la,o
55,2010-019912-18,visita,o
55,2010-019912-18,de,o
55,2010-019912-18,seleccion,o
55,2010-019912-18,o,o
55,2010-019912-18,que,o
55,2010-019912-18,tengan,o
55,2010-019912-18,previsto,o
55,2010-019912-18,someterse,o
55,2010-019912-18,a,o
55,2010-019912-18,una,o
55,2010-019912-18,intervencion,i
55,2010-019912-18,de,o
55,2010-019912-18,este,o
55,2010-019912-18,tipo,o
55,2010-019912-18,en,o
55,2010-019912-18,los,o
55,2010-019912-18,6,o
55,2010-019912-18,meses,o
55,2010-019912-18,siguientes,o
55,2010-019912-18,a,o
55,2010-019912-18,la,o
55,2010-019912-18,randomizacion,i
55,2010-019912-18,Enfermedad,i
55,2010-019912-18,reumatica,i
55,2010-019912-18,autoinmune,i
55,2010-019912-18,distinta,o
55,2010-019912-18,de,o
55,2010-019912-18,AR,i
55,2010-019912-18,Se,o
55,2010-019912-18,permite,o
55,2010-019912-18,la,o
55,2010-019912-18,inclusion,o
55,2010-019912-18,de,o
55,2010-019912-18,pacientes,o
55,2010-019912-18,con,o
55,2010-019912-18,sindrome,i
55,2010-019912-18,de,i
55,2010-019912-18,Sjögren,i
55,2010-019912-18,secundario,i
55,2010-019912-18,asociado,o
55,2010-019912-18,a,o
55,2010-019912-18,AR,i
55,2010-019912-18,Clase,o
55,2010-019912-18,funcional,o
55,2010-019912-18,IV,o
55,2010-019912-18,definida,o
55,2010-019912-18,de,o
55,2010-019912-18,acuerdo,o
55,2010-019912-18,con,o
55,2010-019912-18,la,o
55,2010-019912-18,Clasificacion,o
55,2010-019912-18,del,o
55,2010-019912-18,ACR,o
55,2010-019912-18,del,o
55,2010-019912-18,Estado,o
55,2010-019912-18,Funcional,o
55,2010-019912-18,en,o
55,2010-019912-18,Artritis,i
55,2010-019912-18,Reumatoide,i
55,2010-019912-18,Artritis,i
55,2010-019912-18,idiopatica,i
55,2010-019912-18,juvenil,i
55,2010-019912-18,AIJ,i
55,2010-019912-18,o,o
55,2010-019912-18,artritis,i
55,2010-019912-18,reumatoide,i
55,2010-019912-18,juvenil,i
55,2010-019912-18,ARJ,i
55,2010-019912-18,yo,o
55,2010-019912-18,AR,i
55,2010-019912-18,diagnosticadas,i
55,2010-019912-18,antes,o
55,2010-019912-18,de,o
55,2010-019912-18,los,o
55,2010-019912-18,16,o
55,2010-019912-18,años,o
55,2010-019912-18,de,o
55,2010-019912-18,edad,o
55,2010-019912-18,Enfermedad,i
55,2010-019912-18,articular,i
55,2010-019912-18,inflamatoria,i
55,2010-019912-18,distinta,o
55,2010-019912-18,de,o
55,2010-019912-18,AR,i
55,2010-019912-18,en,o
55,2010-019912-18,el,o
55,2010-019912-18,pasado,o
55,2010-019912-18,o,o
55,2010-019912-18,en,o
55,2010-019912-18,la,o
55,2010-019912-18,actualidad,o
56,2010-019912-18,EudraCT,o
56,2010-019912-18,Nº,o
56,2010-019912-18,201001991218,o
56,2010-019912-18,Titulo,o
56,2010-019912-18,cientifico,o
56,2010-019912-18,Estudio,o
56,2010-019912-18,randomizado,o
56,2010-019912-18,doble,o
56,2010-019912-18,ciego,o
56,2010-019912-18,con,o
56,2010-019912-18,grupos,o
56,2010-019912-18,de,o
56,2010-019912-18,tratamiento,i
56,2010-019912-18,paralelos,o
56,2010-019912-18,para,o
56,2010-019912-18,evaluar,i
56,2010-019912-18,la,i
56,2010-019912-18,seguridad,i
56,2010-019912-18,y,o
56,2010-019912-18,el,o
56,2010-019912-18,efecto,o
56,2010-019912-18,sobre,o
56,2010-019912-18,el,o
56,2010-019912-18,resultado,o
56,2010-019912-18,clinico,o
56,2010-019912-18,de,o
56,2010-019912-18,tocilizumab,i
56,2010-019912-18,SC,o
56,2010-019912-18,frente,o
56,2010-019912-18,a,o
56,2010-019912-18,placebo,i
56,2010-019912-18,SC,o
56,2010-019912-18,en,o
56,2010-019912-18,combinacion,o
56,2010-019912-18,con,o
56,2010-019912-18,farmacos,i
56,2010-019912-18,antirreumaticos,i
56,2010-019912-18,modificadores,i
56,2010-019912-18,de,i
56,2010-019912-18,la,i
56,2010-019912-18,enfermedad,i
56,2010-019912-18,FAMEs,i
56,2010-019912-18,tradicionales,o
56,2010-019912-18,en,o
56,2010-019912-18,pacientes,o
56,2010-019912-18,con,o
56,2010-019912-18,artritis,i
56,2010-019912-18,reumatoide,i
56,2010-019912-18,activa,o
56,2010-019912-18,moderada,o
56,2010-019912-18,a,o
56,2010-019912-18,severa,o
56,2010-019912-18,Indicacion,o
56,2010-019912-18,cientifica,o
56,2010-019912-18,Artritis,i
56,2010-019912-18,Reumatoide,i
56,2010-019912-18,AR,i
56,2010-019912-18,Criterios,o
56,2010-019912-18,de,o
56,2010-019912-18,inclusion,o
56,2010-019912-18,Presentar,o
56,2010-019912-18,artritis,i
56,2010-019912-18,reumatoide,i
56,2010-019912-18,de,o
56,2010-019912-18,mayor,o
56,2010-019912-18,o,o
56,2010-019912-18,igual,o
56,2010-019912-18,a,o
56,2010-019912-18,6,o
56,2010-019912-18,meses,o
56,2010-019912-18,de,o
56,2010-019912-18,duracion,o
56,2010-019912-18,Recibir,o
56,2010-019912-18,tratamiento,i
56,2010-019912-18,de,i
56,2010-019912-18,forma,i
56,2010-019912-18,ambulatoria,i
56,2010-019912-18,Presentar,o
56,2010-019912-18,un,o
56,2010-019912-18,recuento,o
56,2010-019912-18,de,o
56,2010-019912-18,articulaciones,i
56,2010-019912-18,inflamadas,i
56,2010-019912-18,RAI,o
56,2010-019912-18,mayor,o
56,2010-019912-18,o,o
56,2010-019912-18,igual,o
56,2010-019912-18,a,o
56,2010-019912-18,6,o
56,2010-019912-18,recuento,o
56,2010-019912-18,de,o
56,2010-019912-18,66,o
56,2010-019912-18,articulaciones,i
56,2010-019912-18,y,o
56,2010-019912-18,de,o
56,2010-019912-18,articulaciones,i
56,2010-019912-18,dolorosas,i
56,2010-019912-18,RAD,o
56,2010-019912-18,mayor,o
56,2010-019912-18,o,o
56,2010-019912-18,igual,o
56,2010-019912-18,a,o
56,2010-019912-18,8,o
56,2010-019912-18,recuento,o
56,2010-019912-18,de,o
56,2010-019912-18,68,o
56,2010-019912-18,articulaciones,i
56,2010-019912-18,en,o
56,2010-019912-18,las,o
56,2010-019912-18,visitas,o
56,2010-019912-18,de,o
56,2010-019912-18,seleccion,o
56,2010-019912-18,y,o
56,2010-019912-18,basal,o
56,2010-019912-18,Los,o
56,2010-019912-18,pacientes,o
56,2010-019912-18,deben,o
56,2010-019912-18,estar,o
56,2010-019912-18,recibiendo,o
56,2010-019912-18,tratamiento,i
56,2010-019912-18,con,o
56,2010-019912-18,una,o
56,2010-019912-18,dosis,o
56,2010-019912-18,estable,o
56,2010-019912-18,de,o
56,2010-019912-18,los,o
56,2010-019912-18,FAMEs,i
56,2010-019912-18,permitidos,o
56,2010-019912-18,como,o
56,2010-019912-18,minimo,o
56,2010-019912-18,8,o
56,2010-019912-18,semanas,o
56,2010-019912-18,antes,o
56,2010-019912-18,de,o
56,2010-019912-18,la,o
56,2010-019912-18,visita,o
56,2010-019912-18,basal,o
56,2010-019912-18,Criterios,o
56,2010-019912-18,de,o
56,2010-019912-18,exclusion,o
56,2010-019912-18,Pacientes,o
56,2010-019912-18,sometidos,o
56,2010-019912-18,a,o
56,2010-019912-18,intervenciones,i
56,2010-019912-18,de,i
56,2010-019912-18,cirugia,i
56,2010-019912-18,mayor,i
56,2010-019912-18,incluyendo,o
56,2010-019912-18,cirugia,i
56,2010-019912-18,articular,i
56,2010-019912-18,en,o
56,2010-019912-18,las,o
56,2010-019912-18,8,o
56,2010-019912-18,semanas,o
56,2010-019912-18,previas,o
56,2010-019912-18,a,o
56,2010-019912-18,la,o
56,2010-019912-18,visita,o
56,2010-019912-18,de,o
56,2010-019912-18,seleccion,o
56,2010-019912-18,o,o
56,2010-019912-18,que,o
56,2010-019912-18,tengan,o
56,2010-019912-18,previsto,o
56,2010-019912-18,someterse,o
56,2010-019912-18,a,o
56,2010-019912-18,una,o
56,2010-019912-18,intervencion,i
56,2010-019912-18,de,o
56,2010-019912-18,este,o
56,2010-019912-18,tipo,o
56,2010-019912-18,en,o
56,2010-019912-18,los,o
56,2010-019912-18,6,o
56,2010-019912-18,meses,o
56,2010-019912-18,siguientes,o
56,2010-019912-18,a,o
56,2010-019912-18,la,o
56,2010-019912-18,randomizacion,i
56,2010-019912-18,Enfermedad,i
56,2010-019912-18,reumatica,i
56,2010-019912-18,autoinmune,i
56,2010-019912-18,distinta,o
56,2010-019912-18,de,o
56,2010-019912-18,AR,i
56,2010-019912-18,Se,o
56,2010-019912-18,permite,o
56,2010-019912-18,la,o
56,2010-019912-18,inclusion,o
56,2010-019912-18,de,o
56,2010-019912-18,pacientes,o
56,2010-019912-18,con,o
56,2010-019912-18,sindrome,i
56,2010-019912-18,de,i
56,2010-019912-18,Sjögren,i
56,2010-019912-18,secundario,i
56,2010-019912-18,asociado,o
56,2010-019912-18,a,o
56,2010-019912-18,AR,i
56,2010-019912-18,Clase,o
56,2010-019912-18,funcional,o
56,2010-019912-18,IV,o
56,2010-019912-18,definida,o
56,2010-019912-18,de,o
56,2010-019912-18,acuerdo,o
56,2010-019912-18,con,o
56,2010-019912-18,la,o
56,2010-019912-18,Clasificacion,o
56,2010-019912-18,del,o
56,2010-019912-18,ACR,o
56,2010-019912-18,del,o
56,2010-019912-18,Estado,o
56,2010-019912-18,Funcional,o
56,2010-019912-18,en,o
56,2010-019912-18,Artritis,i
56,2010-019912-18,Reumatoide,i
56,2010-019912-18,Artritis,i
56,2010-019912-18,idiopatica,i
56,2010-019912-18,juvenil,i
56,2010-019912-18,AIJ,i
56,2010-019912-18,o,o
56,2010-019912-18,artritis,i
56,2010-019912-18,reumatoide,i
56,2010-019912-18,juvenil,i
56,2010-019912-18,ARJ,i
56,2010-019912-18,yo,o
56,2010-019912-18,AR,i
56,2010-019912-18,diagnosticadas,i
56,2010-019912-18,antes,o
56,2010-019912-18,de,o
56,2010-019912-18,los,o
56,2010-019912-18,16,o
56,2010-019912-18,años,o
56,2010-019912-18,de,o
56,2010-019912-18,edad,o
56,2010-019912-18,Enfermedad,i
56,2010-019912-18,articular,i
56,2010-019912-18,inflamatoria,i
56,2010-019912-18,distinta,o
56,2010-019912-18,de,o
56,2010-019912-18,AR,i
56,2010-019912-18,en,o
56,2010-019912-18,el,o
56,2010-019912-18,pasado,o
56,2010-019912-18,o,o
56,2010-019912-18,en,o
56,2010-019912-18,la,o
56,2010-019912-18,actualidad,o
57,2010-019912-18,EudraCT,o
57,2010-019912-18,Nº,o
57,2010-019912-18,201001991218,o
57,2010-019912-18,Titulo,o
57,2010-019912-18,cientifico,o
57,2010-019912-18,Estudio,o
57,2010-019912-18,randomizado,o
57,2010-019912-18,doble,o
57,2010-019912-18,ciego,o
57,2010-019912-18,con,o
57,2010-019912-18,grupos,o
57,2010-019912-18,de,o
57,2010-019912-18,tratamiento,i
57,2010-019912-18,paralelos,o
57,2010-019912-18,para,o
57,2010-019912-18,evaluar,i
57,2010-019912-18,la,i
57,2010-019912-18,seguridad,i
57,2010-019912-18,y,o
57,2010-019912-18,el,o
57,2010-019912-18,efecto,o
57,2010-019912-18,sobre,o
57,2010-019912-18,el,o
57,2010-019912-18,resultado,o
57,2010-019912-18,clinico,o
57,2010-019912-18,de,o
57,2010-019912-18,tocilizumab,i
57,2010-019912-18,SC,o
57,2010-019912-18,frente,o
57,2010-019912-18,a,o
57,2010-019912-18,placebo,i
57,2010-019912-18,SC,o
57,2010-019912-18,en,o
57,2010-019912-18,combinacion,o
57,2010-019912-18,con,o
57,2010-019912-18,farmacos,i
57,2010-019912-18,antirreumaticos,i
57,2010-019912-18,modificadores,i
57,2010-019912-18,de,i
57,2010-019912-18,la,i
57,2010-019912-18,enfermedad,i
57,2010-019912-18,FAMEs,i
57,2010-019912-18,tradicionales,o
57,2010-019912-18,en,o
57,2010-019912-18,pacientes,o
57,2010-019912-18,con,o
57,2010-019912-18,artritis,i
57,2010-019912-18,reumatoide,i
57,2010-019912-18,activa,o
57,2010-019912-18,moderada,o
57,2010-019912-18,a,o
57,2010-019912-18,severa,o
57,2010-019912-18,Indicacion,o
57,2010-019912-18,cientifica,o
57,2010-019912-18,Artritis,i
57,2010-019912-18,Reumatoide,i
57,2010-019912-18,AR,i
57,2010-019912-18,Criterios,o
57,2010-019912-18,de,o
57,2010-019912-18,inclusion,o
57,2010-019912-18,Presentar,o
57,2010-019912-18,artritis,i
57,2010-019912-18,reumatoide,i
57,2010-019912-18,de,o
57,2010-019912-18,mayor,o
57,2010-019912-18,o,o
57,2010-019912-18,igual,o
57,2010-019912-18,a,o
57,2010-019912-18,6,o
57,2010-019912-18,meses,o
57,2010-019912-18,de,o
57,2010-019912-18,duracion,o
57,2010-019912-18,Recibir,o
57,2010-019912-18,tratamiento,i
57,2010-019912-18,de,i
57,2010-019912-18,forma,i
57,2010-019912-18,ambulatoria,i
57,2010-019912-18,Presentar,o
57,2010-019912-18,un,o
57,2010-019912-18,recuento,o
57,2010-019912-18,de,o
57,2010-019912-18,articulaciones,i
57,2010-019912-18,inflamadas,i
57,2010-019912-18,RAI,o
57,2010-019912-18,mayor,o
57,2010-019912-18,o,o
57,2010-019912-18,igual,o
57,2010-019912-18,a,o
57,2010-019912-18,6,o
57,2010-019912-18,recuento,o
57,2010-019912-18,de,o
57,2010-019912-18,66,o
57,2010-019912-18,articulaciones,i
57,2010-019912-18,y,o
57,2010-019912-18,de,o
57,2010-019912-18,articulaciones,i
57,2010-019912-18,dolorosas,i
57,2010-019912-18,RAD,o
57,2010-019912-18,mayor,o
57,2010-019912-18,o,o
57,2010-019912-18,igual,o
57,2010-019912-18,a,o
57,2010-019912-18,8,o
57,2010-019912-18,recuento,o
57,2010-019912-18,de,o
57,2010-019912-18,68,o
57,2010-019912-18,articulaciones,i
57,2010-019912-18,en,o
57,2010-019912-18,las,o
57,2010-019912-18,visitas,o
57,2010-019912-18,de,o
57,2010-019912-18,seleccion,o
57,2010-019912-18,y,o
57,2010-019912-18,basal,o
57,2010-019912-18,Los,o
57,2010-019912-18,pacientes,o
57,2010-019912-18,deben,o
57,2010-019912-18,estar,o
57,2010-019912-18,recibiendo,o
57,2010-019912-18,tratamiento,i
57,2010-019912-18,con,o
57,2010-019912-18,una,o
57,2010-019912-18,dosis,o
57,2010-019912-18,estable,o
57,2010-019912-18,de,o
57,2010-019912-18,los,o
57,2010-019912-18,FAMEs,i
57,2010-019912-18,permitidos,o
57,2010-019912-18,como,o
57,2010-019912-18,minimo,o
57,2010-019912-18,8,o
57,2010-019912-18,semanas,o
57,2010-019912-18,antes,o
57,2010-019912-18,de,o
57,2010-019912-18,la,o
57,2010-019912-18,visita,o
57,2010-019912-18,basal,o
57,2010-019912-18,Criterios,o
57,2010-019912-18,de,o
57,2010-019912-18,exclusion,o
57,2010-019912-18,Pacientes,o
57,2010-019912-18,sometidos,o
57,2010-019912-18,a,o
57,2010-019912-18,intervenciones,i
57,2010-019912-18,de,i
57,2010-019912-18,cirugia,i
57,2010-019912-18,mayor,i
57,2010-019912-18,incluyendo,o
57,2010-019912-18,cirugia,i
57,2010-019912-18,articular,i
57,2010-019912-18,en,o
57,2010-019912-18,las,o
57,2010-019912-18,8,o
57,2010-019912-18,semanas,o
57,2010-019912-18,previas,o
57,2010-019912-18,a,o
57,2010-019912-18,la,o
57,2010-019912-18,visita,o
57,2010-019912-18,de,o
57,2010-019912-18,seleccion,o
57,2010-019912-18,o,o
57,2010-019912-18,que,o
57,2010-019912-18,tengan,o
57,2010-019912-18,previsto,o
57,2010-019912-18,someterse,o
57,2010-019912-18,a,o
57,2010-019912-18,una,o
57,2010-019912-18,intervencion,i
57,2010-019912-18,de,o
57,2010-019912-18,este,o
57,2010-019912-18,tipo,o
57,2010-019912-18,en,o
57,2010-019912-18,los,o
57,2010-019912-18,6,o
57,2010-019912-18,meses,o
57,2010-019912-18,siguientes,o
57,2010-019912-18,a,o
57,2010-019912-18,la,o
57,2010-019912-18,randomizacion,i
57,2010-019912-18,Enfermedad,i
57,2010-019912-18,reumatica,i
57,2010-019912-18,autoinmune,i
57,2010-019912-18,distinta,o
57,2010-019912-18,de,o
57,2010-019912-18,AR,i
57,2010-019912-18,Se,o
57,2010-019912-18,permite,o
57,2010-019912-18,la,o
57,2010-019912-18,inclusion,o
57,2010-019912-18,de,o
57,2010-019912-18,pacientes,o
57,2010-019912-18,con,o
57,2010-019912-18,sindrome,i
57,2010-019912-18,de,i
57,2010-019912-18,Sjögren,i
57,2010-019912-18,secundario,i
57,2010-019912-18,asociado,o
57,2010-019912-18,a,o
57,2010-019912-18,AR,i
57,2010-019912-18,Clase,o
57,2010-019912-18,funcional,o
57,2010-019912-18,IV,o
57,2010-019912-18,definida,o
57,2010-019912-18,de,o
57,2010-019912-18,acuerdo,o
57,2010-019912-18,con,o
57,2010-019912-18,la,o
57,2010-019912-18,Clasificacion,o
57,2010-019912-18,del,o
57,2010-019912-18,ACR,o
57,2010-019912-18,del,o
57,2010-019912-18,Estado,o
57,2010-019912-18,Funcional,o
57,2010-019912-18,en,o
57,2010-019912-18,Artritis,i
57,2010-019912-18,Reumatoide,i
57,2010-019912-18,Artritis,i
57,2010-019912-18,idiopatica,i
57,2010-019912-18,juvenil,i
57,2010-019912-18,AIJ,i
57,2010-019912-18,o,o
57,2010-019912-18,artritis,i
57,2010-019912-18,reumatoide,i
57,2010-019912-18,juvenil,i
57,2010-019912-18,ARJ,i
57,2010-019912-18,yo,o
57,2010-019912-18,AR,i
57,2010-019912-18,diagnosticadas,i
57,2010-019912-18,antes,o
57,2010-019912-18,de,o
57,2010-019912-18,los,o
57,2010-019912-18,16,o
57,2010-019912-18,años,o
57,2010-019912-18,de,o
57,2010-019912-18,edad,o
57,2010-019912-18,Enfermedad,i
57,2010-019912-18,articular,i
57,2010-019912-18,inflamatoria,i
57,2010-019912-18,distinta,o
57,2010-019912-18,de,o
57,2010-019912-18,AR,i
57,2010-019912-18,en,o
57,2010-019912-18,el,o
57,2010-019912-18,pasado,o
57,2010-019912-18,o,o
57,2010-019912-18,en,o
57,2010-019912-18,la,o
57,2010-019912-18,actualidad,o
58,2010-019912-18,EudraCT,o
58,2010-019912-18,Nº,o
58,2010-019912-18,201001991218,o
58,2010-019912-18,Titulo,o
58,2010-019912-18,cientifico,o
58,2010-019912-18,Estudio,o
58,2010-019912-18,randomizado,o
58,2010-019912-18,doble,o
58,2010-019912-18,ciego,o
58,2010-019912-18,con,o
58,2010-019912-18,grupos,o
58,2010-019912-18,de,o
58,2010-019912-18,tratamiento,i
58,2010-019912-18,paralelos,o
58,2010-019912-18,para,o
58,2010-019912-18,evaluar,i
58,2010-019912-18,la,i
58,2010-019912-18,seguridad,i
58,2010-019912-18,y,o
58,2010-019912-18,el,o
58,2010-019912-18,efecto,o
58,2010-019912-18,sobre,o
58,2010-019912-18,el,o
58,2010-019912-18,resultado,o
58,2010-019912-18,clinico,o
58,2010-019912-18,de,o
58,2010-019912-18,tocilizumab,i
58,2010-019912-18,SC,o
58,2010-019912-18,frente,o
58,2010-019912-18,a,o
58,2010-019912-18,placebo,i
58,2010-019912-18,SC,o
58,2010-019912-18,en,o
58,2010-019912-18,combinacion,o
58,2010-019912-18,con,o
58,2010-019912-18,farmacos,i
58,2010-019912-18,antirreumaticos,i
58,2010-019912-18,modificadores,i
58,2010-019912-18,de,i
58,2010-019912-18,la,i
58,2010-019912-18,enfermedad,i
58,2010-019912-18,FAMEs,i
58,2010-019912-18,tradicionales,o
58,2010-019912-18,en,o
58,2010-019912-18,pacientes,o
58,2010-019912-18,con,o
58,2010-019912-18,artritis,i
58,2010-019912-18,reumatoide,i
58,2010-019912-18,activa,o
58,2010-019912-18,moderada,o
58,2010-019912-18,a,o
58,2010-019912-18,severa,o
58,2010-019912-18,Indicacion,o
58,2010-019912-18,cientifica,o
58,2010-019912-18,Artritis,i
58,2010-019912-18,Reumatoide,i
58,2010-019912-18,AR,i
58,2010-019912-18,Criterios,o
58,2010-019912-18,de,o
58,2010-019912-18,inclusion,o
58,2010-019912-18,Presentar,o
58,2010-019912-18,artritis,i
58,2010-019912-18,reumatoide,i
58,2010-019912-18,de,o
58,2010-019912-18,mayor,o
58,2010-019912-18,o,o
58,2010-019912-18,igual,o
58,2010-019912-18,a,o
58,2010-019912-18,6,o
58,2010-019912-18,meses,o
58,2010-019912-18,de,o
58,2010-019912-18,duracion,o
58,2010-019912-18,Recibir,o
58,2010-019912-18,tratamiento,i
58,2010-019912-18,de,i
58,2010-019912-18,forma,i
58,2010-019912-18,ambulatoria,i
58,2010-019912-18,Presentar,o
58,2010-019912-18,un,o
58,2010-019912-18,recuento,o
58,2010-019912-18,de,o
58,2010-019912-18,articulaciones,i
58,2010-019912-18,inflamadas,i
58,2010-019912-18,RAI,o
58,2010-019912-18,mayor,o
58,2010-019912-18,o,o
58,2010-019912-18,igual,o
58,2010-019912-18,a,o
58,2010-019912-18,6,o
58,2010-019912-18,recuento,o
58,2010-019912-18,de,o
58,2010-019912-18,66,o
58,2010-019912-18,articulaciones,i
58,2010-019912-18,y,o
58,2010-019912-18,de,o
58,2010-019912-18,articulaciones,i
58,2010-019912-18,dolorosas,i
58,2010-019912-18,RAD,o
58,2010-019912-18,mayor,o
58,2010-019912-18,o,o
58,2010-019912-18,igual,o
58,2010-019912-18,a,o
58,2010-019912-18,8,o
58,2010-019912-18,recuento,o
58,2010-019912-18,de,o
58,2010-019912-18,68,o
58,2010-019912-18,articulaciones,i
58,2010-019912-18,en,o
58,2010-019912-18,las,o
58,2010-019912-18,visitas,o
58,2010-019912-18,de,o
58,2010-019912-18,seleccion,o
58,2010-019912-18,y,o
58,2010-019912-18,basal,o
58,2010-019912-18,Los,o
58,2010-019912-18,pacientes,o
58,2010-019912-18,deben,o
58,2010-019912-18,estar,o
58,2010-019912-18,recibiendo,o
58,2010-019912-18,tratamiento,i
58,2010-019912-18,con,o
58,2010-019912-18,una,o
58,2010-019912-18,dosis,o
58,2010-019912-18,estable,o
58,2010-019912-18,de,o
58,2010-019912-18,los,o
58,2010-019912-18,FAMEs,i
58,2010-019912-18,permitidos,o
58,2010-019912-18,como,o
58,2010-019912-18,minimo,o
58,2010-019912-18,8,o
58,2010-019912-18,semanas,o
58,2010-019912-18,antes,o
58,2010-019912-18,de,o
58,2010-019912-18,la,o
58,2010-019912-18,visita,o
58,2010-019912-18,basal,o
58,2010-019912-18,Criterios,o
58,2010-019912-18,de,o
58,2010-019912-18,exclusion,o
58,2010-019912-18,Pacientes,o
58,2010-019912-18,sometidos,o
58,2010-019912-18,a,o
58,2010-019912-18,intervenciones,i
58,2010-019912-18,de,i
58,2010-019912-18,cirugia,i
58,2010-019912-18,mayor,i
58,2010-019912-18,incluyendo,o
58,2010-019912-18,cirugia,i
58,2010-019912-18,articular,i
58,2010-019912-18,en,o
58,2010-019912-18,las,o
58,2010-019912-18,8,o
58,2010-019912-18,semanas,o
58,2010-019912-18,previas,o
58,2010-019912-18,a,o
58,2010-019912-18,la,o
58,2010-019912-18,visita,o
58,2010-019912-18,de,o
58,2010-019912-18,seleccion,o
58,2010-019912-18,o,o
58,2010-019912-18,que,o
58,2010-019912-18,tengan,o
58,2010-019912-18,previsto,o
58,2010-019912-18,someterse,o
58,2010-019912-18,a,o
58,2010-019912-18,una,o
58,2010-019912-18,intervencion,i
58,2010-019912-18,de,o
58,2010-019912-18,este,o
58,2010-019912-18,tipo,o
58,2010-019912-18,en,o
58,2010-019912-18,los,o
58,2010-019912-18,6,o
58,2010-019912-18,meses,o
58,2010-019912-18,siguientes,o
58,2010-019912-18,a,o
58,2010-019912-18,la,o
58,2010-019912-18,randomizacion,i
58,2010-019912-18,Enfermedad,i
58,2010-019912-18,reumatica,i
58,2010-019912-18,autoinmune,i
58,2010-019912-18,distinta,o
58,2010-019912-18,de,o
58,2010-019912-18,AR,i
58,2010-019912-18,Se,o
58,2010-019912-18,permite,o
58,2010-019912-18,la,o
58,2010-019912-18,inclusion,o
58,2010-019912-18,de,o
58,2010-019912-18,pacientes,o
58,2010-019912-18,con,o
58,2010-019912-18,sindrome,i
58,2010-019912-18,de,i
58,2010-019912-18,Sjögren,i
58,2010-019912-18,secundario,i
58,2010-019912-18,asociado,o
58,2010-019912-18,a,o
58,2010-019912-18,AR,i
58,2010-019912-18,Clase,o
58,2010-019912-18,funcional,o
58,2010-019912-18,IV,o
58,2010-019912-18,definida,o
58,2010-019912-18,de,o
58,2010-019912-18,acuerdo,o
58,2010-019912-18,con,o
58,2010-019912-18,la,o
58,2010-019912-18,Clasificacion,o
58,2010-019912-18,del,o
58,2010-019912-18,ACR,o
58,2010-019912-18,del,o
58,2010-019912-18,Estado,o
58,2010-019912-18,Funcional,o
58,2010-019912-18,en,o
58,2010-019912-18,Artritis,i
58,2010-019912-18,Reumatoide,i
58,2010-019912-18,Artritis,i
58,2010-019912-18,idiopatica,i
58,2010-019912-18,juvenil,i
58,2010-019912-18,AIJ,i
58,2010-019912-18,o,o
58,2010-019912-18,artritis,i
58,2010-019912-18,reumatoide,i
58,2010-019912-18,juvenil,i
58,2010-019912-18,ARJ,i
58,2010-019912-18,yo,o
58,2010-019912-18,AR,i
58,2010-019912-18,diagnosticadas,i
58,2010-019912-18,antes,o
58,2010-019912-18,de,o
58,2010-019912-18,los,o
58,2010-019912-18,16,o
58,2010-019912-18,años,o
58,2010-019912-18,de,o
58,2010-019912-18,edad,o
58,2010-019912-18,Enfermedad,i
58,2010-019912-18,articular,i
58,2010-019912-18,inflamatoria,i
58,2010-019912-18,distinta,o
58,2010-019912-18,de,o
58,2010-019912-18,AR,i
58,2010-019912-18,en,o
58,2010-019912-18,el,o
58,2010-019912-18,pasado,o
58,2010-019912-18,o,o
58,2010-019912-18,en,o
58,2010-019912-18,la,o
58,2010-019912-18,actualidad,o
59,2010-019912-18,EudraCT,o
59,2010-019912-18,Nº,o
59,2010-019912-18,201001991218,o
59,2010-019912-18,Titulo,o
59,2010-019912-18,cientifico,o
59,2010-019912-18,Estudio,o
59,2010-019912-18,randomizado,o
59,2010-019912-18,doble,o
59,2010-019912-18,ciego,o
59,2010-019912-18,con,o
59,2010-019912-18,grupos,o
59,2010-019912-18,de,o
59,2010-019912-18,tratamiento,i
59,2010-019912-18,paralelos,o
59,2010-019912-18,para,o
59,2010-019912-18,evaluar,i
59,2010-019912-18,la,i
59,2010-019912-18,seguridad,i
59,2010-019912-18,y,o
59,2010-019912-18,el,o
59,2010-019912-18,efecto,o
59,2010-019912-18,sobre,o
59,2010-019912-18,el,o
59,2010-019912-18,resultado,o
59,2010-019912-18,clinico,o
59,2010-019912-18,de,o
59,2010-019912-18,tocilizumab,i
59,2010-019912-18,SC,o
59,2010-019912-18,frente,o
59,2010-019912-18,a,o
59,2010-019912-18,placebo,i
59,2010-019912-18,SC,o
59,2010-019912-18,en,o
59,2010-019912-18,combinacion,o
59,2010-019912-18,con,o
59,2010-019912-18,farmacos,i
59,2010-019912-18,antirreumaticos,i
59,2010-019912-18,modificadores,i
59,2010-019912-18,de,i
59,2010-019912-18,la,i
59,2010-019912-18,enfermedad,i
59,2010-019912-18,FAMEs,i
59,2010-019912-18,tradicionales,o
59,2010-019912-18,en,o
59,2010-019912-18,pacientes,o
59,2010-019912-18,con,o
59,2010-019912-18,artritis,i
59,2010-019912-18,reumatoide,i
59,2010-019912-18,activa,o
59,2010-019912-18,moderada,o
59,2010-019912-18,a,o
59,2010-019912-18,severa,o
59,2010-019912-18,Indicacion,o
59,2010-019912-18,cientifica,o
59,2010-019912-18,Artritis,i
59,2010-019912-18,Reumatoide,i
59,2010-019912-18,AR,i
59,2010-019912-18,Criterios,o
59,2010-019912-18,de,o
59,2010-019912-18,inclusion,o
59,2010-019912-18,Presentar,o
59,2010-019912-18,artritis,i
59,2010-019912-18,reumatoide,i
59,2010-019912-18,de,o
59,2010-019912-18,mayor,o
59,2010-019912-18,o,o
59,2010-019912-18,igual,o
59,2010-019912-18,a,o
59,2010-019912-18,6,o
59,2010-019912-18,meses,o
59,2010-019912-18,de,o
59,2010-019912-18,duracion,o
59,2010-019912-18,Recibir,o
59,2010-019912-18,tratamiento,i
59,2010-019912-18,de,i
59,2010-019912-18,forma,i
59,2010-019912-18,ambulatoria,i
59,2010-019912-18,Presentar,o
59,2010-019912-18,un,o
59,2010-019912-18,recuento,o
59,2010-019912-18,de,o
59,2010-019912-18,articulaciones,i
59,2010-019912-18,inflamadas,i
59,2010-019912-18,RAI,o
59,2010-019912-18,mayor,o
59,2010-019912-18,o,o
59,2010-019912-18,igual,o
59,2010-019912-18,a,o
59,2010-019912-18,6,o
59,2010-019912-18,recuento,o
59,2010-019912-18,de,o
59,2010-019912-18,66,o
59,2010-019912-18,articulaciones,i
59,2010-019912-18,y,o
59,2010-019912-18,de,o
59,2010-019912-18,articulaciones,i
59,2010-019912-18,dolorosas,i
59,2010-019912-18,RAD,o
59,2010-019912-18,mayor,o
59,2010-019912-18,o,o
59,2010-019912-18,igual,o
59,2010-019912-18,a,o
59,2010-019912-18,8,o
59,2010-019912-18,recuento,o
59,2010-019912-18,de,o
59,2010-019912-18,68,o
59,2010-019912-18,articulaciones,i
59,2010-019912-18,en,o
59,2010-019912-18,las,o
59,2010-019912-18,visitas,o
59,2010-019912-18,de,o
59,2010-019912-18,seleccion,o
59,2010-019912-18,y,o
59,2010-019912-18,basal,o
59,2010-019912-18,Los,o
59,2010-019912-18,pacientes,o
59,2010-019912-18,deben,o
59,2010-019912-18,estar,o
59,2010-019912-18,recibiendo,o
59,2010-019912-18,tratamiento,i
59,2010-019912-18,con,o
59,2010-019912-18,una,o
59,2010-019912-18,dosis,o
59,2010-019912-18,estable,o
59,2010-019912-18,de,o
59,2010-019912-18,los,o
59,2010-019912-18,FAMEs,i
59,2010-019912-18,permitidos,o
59,2010-019912-18,como,o
59,2010-019912-18,minimo,o
59,2010-019912-18,8,o
59,2010-019912-18,semanas,o
59,2010-019912-18,antes,o
59,2010-019912-18,de,o
59,2010-019912-18,la,o
59,2010-019912-18,visita,o
59,2010-019912-18,basal,o
59,2010-019912-18,Criterios,o
59,2010-019912-18,de,o
59,2010-019912-18,exclusion,o
59,2010-019912-18,Pacientes,o
59,2010-019912-18,sometidos,o
59,2010-019912-18,a,o
59,2010-019912-18,intervenciones,i
59,2010-019912-18,de,i
59,2010-019912-18,cirugia,i
59,2010-019912-18,mayor,i
59,2010-019912-18,incluyendo,o
59,2010-019912-18,cirugia,i
59,2010-019912-18,articular,i
59,2010-019912-18,en,o
59,2010-019912-18,las,o
59,2010-019912-18,8,o
59,2010-019912-18,semanas,o
59,2010-019912-18,previas,o
59,2010-019912-18,a,o
59,2010-019912-18,la,o
59,2010-019912-18,visita,o
59,2010-019912-18,de,o
59,2010-019912-18,seleccion,o
59,2010-019912-18,o,o
59,2010-019912-18,que,o
59,2010-019912-18,tengan,o
59,2010-019912-18,previsto,o
59,2010-019912-18,someterse,o
59,2010-019912-18,a,o
59,2010-019912-18,una,o
59,2010-019912-18,intervencion,i
59,2010-019912-18,de,o
59,2010-019912-18,este,o
59,2010-019912-18,tipo,o
59,2010-019912-18,en,o
59,2010-019912-18,los,o
59,2010-019912-18,6,o
59,2010-019912-18,meses,o
59,2010-019912-18,siguientes,o
59,2010-019912-18,a,o
59,2010-019912-18,la,o
59,2010-019912-18,randomizacion,i
59,2010-019912-18,Enfermedad,i
59,2010-019912-18,reumatica,i
59,2010-019912-18,autoinmune,i
59,2010-019912-18,distinta,o
59,2010-019912-18,de,o
59,2010-019912-18,AR,i
59,2010-019912-18,Se,o
59,2010-019912-18,permite,o
59,2010-019912-18,la,o
59,2010-019912-18,inclusion,o
59,2010-019912-18,de,o
59,2010-019912-18,pacientes,o
59,2010-019912-18,con,o
59,2010-019912-18,sindrome,i
59,2010-019912-18,de,i
59,2010-019912-18,Sjögren,i
59,2010-019912-18,secundario,i
59,2010-019912-18,asociado,o
59,2010-019912-18,a,o
59,2010-019912-18,AR,i
59,2010-019912-18,Clase,o
59,2010-019912-18,funcional,o
59,2010-019912-18,IV,o
59,2010-019912-18,definida,o
59,2010-019912-18,de,o
59,2010-019912-18,acuerdo,o
59,2010-019912-18,con,o
59,2010-019912-18,la,o
59,2010-019912-18,Clasificacion,o
59,2010-019912-18,del,o
59,2010-019912-18,ACR,o
59,2010-019912-18,del,o
59,2010-019912-18,Estado,o
59,2010-019912-18,Funcional,o
59,2010-019912-18,en,o
59,2010-019912-18,Artritis,i
59,2010-019912-18,Reumatoide,i
59,2010-019912-18,Artritis,i
59,2010-019912-18,idiopatica,i
59,2010-019912-18,juvenil,i
59,2010-019912-18,AIJ,i
59,2010-019912-18,o,o
59,2010-019912-18,artritis,i
59,2010-019912-18,reumatoide,i
59,2010-019912-18,juvenil,i
59,2010-019912-18,ARJ,i
59,2010-019912-18,yo,o
59,2010-019912-18,AR,i
59,2010-019912-18,diagnosticadas,i
59,2010-019912-18,antes,o
59,2010-019912-18,de,o
59,2010-019912-18,los,o
59,2010-019912-18,16,o
59,2010-019912-18,años,o
59,2010-019912-18,de,o
59,2010-019912-18,edad,o
59,2010-019912-18,Enfermedad,i
59,2010-019912-18,articular,i
59,2010-019912-18,inflamatoria,i
59,2010-019912-18,distinta,o
59,2010-019912-18,de,o
59,2010-019912-18,AR,i
59,2010-019912-18,en,o
59,2010-019912-18,el,o
59,2010-019912-18,pasado,o
59,2010-019912-18,o,o
59,2010-019912-18,en,o
59,2010-019912-18,la,o
59,2010-019912-18,actualidad,o
60,2010-019912-18,EudraCT,o
60,2010-019912-18,Nº,o
60,2010-019912-18,201001991218,o
60,2010-019912-18,Titulo,o
60,2010-019912-18,cientifico,o
60,2010-019912-18,Estudio,o
60,2010-019912-18,randomizado,o
60,2010-019912-18,doble,o
60,2010-019912-18,ciego,o
60,2010-019912-18,con,o
60,2010-019912-18,grupos,o
60,2010-019912-18,de,o
60,2010-019912-18,tratamiento,i
60,2010-019912-18,paralelos,o
60,2010-019912-18,para,o
60,2010-019912-18,evaluar,i
60,2010-019912-18,la,i
60,2010-019912-18,seguridad,i
60,2010-019912-18,y,o
60,2010-019912-18,el,o
60,2010-019912-18,efecto,o
60,2010-019912-18,sobre,o
60,2010-019912-18,el,o
60,2010-019912-18,resultado,o
60,2010-019912-18,clinico,o
60,2010-019912-18,de,o
60,2010-019912-18,tocilizumab,i
60,2010-019912-18,SC,o
60,2010-019912-18,frente,o
60,2010-019912-18,a,o
60,2010-019912-18,placebo,i
60,2010-019912-18,SC,o
60,2010-019912-18,en,o
60,2010-019912-18,combinacion,o
60,2010-019912-18,con,o
60,2010-019912-18,farmacos,i
60,2010-019912-18,antirreumaticos,i
60,2010-019912-18,modificadores,i
60,2010-019912-18,de,i
60,2010-019912-18,la,i
60,2010-019912-18,enfermedad,i
60,2010-019912-18,FAMEs,i
60,2010-019912-18,tradicionales,o
60,2010-019912-18,en,o
60,2010-019912-18,pacientes,o
60,2010-019912-18,con,o
60,2010-019912-18,artritis,i
60,2010-019912-18,reumatoide,i
60,2010-019912-18,activa,o
60,2010-019912-18,moderada,o
60,2010-019912-18,a,o
60,2010-019912-18,severa,o
60,2010-019912-18,Indicacion,o
60,2010-019912-18,cientifica,o
60,2010-019912-18,Artritis,i
60,2010-019912-18,Reumatoide,i
60,2010-019912-18,AR,i
60,2010-019912-18,Criterios,o
60,2010-019912-18,de,o
60,2010-019912-18,inclusion,o
60,2010-019912-18,Presentar,o
60,2010-019912-18,artritis,i
60,2010-019912-18,reumatoide,i
60,2010-019912-18,de,o
60,2010-019912-18,mayor,o
60,2010-019912-18,o,o
60,2010-019912-18,igual,o
60,2010-019912-18,a,o
60,2010-019912-18,6,o
60,2010-019912-18,meses,o
60,2010-019912-18,de,o
60,2010-019912-18,duracion,o
60,2010-019912-18,Recibir,o
60,2010-019912-18,tratamiento,i
60,2010-019912-18,de,i
60,2010-019912-18,forma,i
60,2010-019912-18,ambulatoria,i
60,2010-019912-18,Presentar,o
60,2010-019912-18,un,o
60,2010-019912-18,recuento,o
60,2010-019912-18,de,o
60,2010-019912-18,articulaciones,i
60,2010-019912-18,inflamadas,i
60,2010-019912-18,RAI,o
60,2010-019912-18,mayor,o
60,2010-019912-18,o,o
60,2010-019912-18,igual,o
60,2010-019912-18,a,o
60,2010-019912-18,6,o
60,2010-019912-18,recuento,o
60,2010-019912-18,de,o
60,2010-019912-18,66,o
60,2010-019912-18,articulaciones,i
60,2010-019912-18,y,o
60,2010-019912-18,de,o
60,2010-019912-18,articulaciones,i
60,2010-019912-18,dolorosas,i
60,2010-019912-18,RAD,o
60,2010-019912-18,mayor,o
60,2010-019912-18,o,o
60,2010-019912-18,igual,o
60,2010-019912-18,a,o
60,2010-019912-18,8,o
60,2010-019912-18,recuento,o
60,2010-019912-18,de,o
60,2010-019912-18,68,o
60,2010-019912-18,articulaciones,i
60,2010-019912-18,en,o
60,2010-019912-18,las,o
60,2010-019912-18,visitas,o
60,2010-019912-18,de,o
60,2010-019912-18,seleccion,o
60,2010-019912-18,y,o
60,2010-019912-18,basal,o
60,2010-019912-18,Los,o
60,2010-019912-18,pacientes,o
60,2010-019912-18,deben,o
60,2010-019912-18,estar,o
60,2010-019912-18,recibiendo,o
60,2010-019912-18,tratamiento,i
60,2010-019912-18,con,o
60,2010-019912-18,una,o
60,2010-019912-18,dosis,o
60,2010-019912-18,estable,o
60,2010-019912-18,de,o
60,2010-019912-18,los,o
60,2010-019912-18,FAMEs,i
60,2010-019912-18,permitidos,o
60,2010-019912-18,como,o
60,2010-019912-18,minimo,o
60,2010-019912-18,8,o
60,2010-019912-18,semanas,o
60,2010-019912-18,antes,o
60,2010-019912-18,de,o
60,2010-019912-18,la,o
60,2010-019912-18,visita,o
60,2010-019912-18,basal,o
60,2010-019912-18,Criterios,o
60,2010-019912-18,de,o
60,2010-019912-18,exclusion,o
60,2010-019912-18,Pacientes,o
60,2010-019912-18,sometidos,o
60,2010-019912-18,a,o
60,2010-019912-18,intervenciones,i
60,2010-019912-18,de,i
60,2010-019912-18,cirugia,i
60,2010-019912-18,mayor,i
60,2010-019912-18,incluyendo,o
60,2010-019912-18,cirugia,i
60,2010-019912-18,articular,i
60,2010-019912-18,en,o
60,2010-019912-18,las,o
60,2010-019912-18,8,o
60,2010-019912-18,semanas,o
60,2010-019912-18,previas,o
60,2010-019912-18,a,o
60,2010-019912-18,la,o
60,2010-019912-18,visita,o
60,2010-019912-18,de,o
60,2010-019912-18,seleccion,o
60,2010-019912-18,o,o
60,2010-019912-18,que,o
60,2010-019912-18,tengan,o
60,2010-019912-18,previsto,o
60,2010-019912-18,someterse,o
60,2010-019912-18,a,o
60,2010-019912-18,una,o
60,2010-019912-18,intervencion,i
60,2010-019912-18,de,o
60,2010-019912-18,este,o
60,2010-019912-18,tipo,o
60,2010-019912-18,en,o
60,2010-019912-18,los,o
60,2010-019912-18,6,o
60,2010-019912-18,meses,o
60,2010-019912-18,siguientes,o
60,2010-019912-18,a,o
60,2010-019912-18,la,o
60,2010-019912-18,randomizacion,i
60,2010-019912-18,Enfermedad,i
60,2010-019912-18,reumatica,i
60,2010-019912-18,autoinmune,i
60,2010-019912-18,distinta,o
60,2010-019912-18,de,o
60,2010-019912-18,AR,i
60,2010-019912-18,Se,o
60,2010-019912-18,permite,o
60,2010-019912-18,la,o
60,2010-019912-18,inclusion,o
60,2010-019912-18,de,o
60,2010-019912-18,pacientes,o
60,2010-019912-18,con,o
60,2010-019912-18,sindrome,i
60,2010-019912-18,de,i
60,2010-019912-18,Sjögren,i
60,2010-019912-18,secundario,i
60,2010-019912-18,asociado,o
60,2010-019912-18,a,o
60,2010-019912-18,AR,i
60,2010-019912-18,Clase,o
60,2010-019912-18,funcional,o
60,2010-019912-18,IV,o
60,2010-019912-18,definida,o
60,2010-019912-18,de,o
60,2010-019912-18,acuerdo,o
60,2010-019912-18,con,o
60,2010-019912-18,la,o
60,2010-019912-18,Clasificacion,o
60,2010-019912-18,del,o
60,2010-019912-18,ACR,o
60,2010-019912-18,del,o
60,2010-019912-18,Estado,o
60,2010-019912-18,Funcional,o
60,2010-019912-18,en,o
60,2010-019912-18,Artritis,i
60,2010-019912-18,Reumatoide,i
60,2010-019912-18,Artritis,i
60,2010-019912-18,idiopatica,i
60,2010-019912-18,juvenil,i
60,2010-019912-18,AIJ,i
60,2010-019912-18,o,o
60,2010-019912-18,artritis,i
60,2010-019912-18,reumatoide,i
60,2010-019912-18,juvenil,i
60,2010-019912-18,ARJ,i
60,2010-019912-18,yo,o
60,2010-019912-18,AR,i
60,2010-019912-18,diagnosticadas,i
60,2010-019912-18,antes,o
60,2010-019912-18,de,o
60,2010-019912-18,los,o
60,2010-019912-18,16,o
60,2010-019912-18,años,o
60,2010-019912-18,de,o
60,2010-019912-18,edad,o
60,2010-019912-18,Enfermedad,i
60,2010-019912-18,articular,i
60,2010-019912-18,inflamatoria,i
60,2010-019912-18,distinta,o
60,2010-019912-18,de,o
60,2010-019912-18,AR,i
60,2010-019912-18,en,o
60,2010-019912-18,el,o
60,2010-019912-18,pasado,o
60,2010-019912-18,o,o
60,2010-019912-18,en,o
60,2010-019912-18,la,o
60,2010-019912-18,actualidad,o
61,2010-019912-18,EudraCT,o
61,2010-019912-18,Nº,o
61,2010-019912-18,201001991218,o
61,2010-019912-18,Titulo,o
61,2010-019912-18,cientifico,o
61,2010-019912-18,Estudio,o
61,2010-019912-18,randomizado,o
61,2010-019912-18,doble,o
61,2010-019912-18,ciego,o
61,2010-019912-18,con,o
61,2010-019912-18,grupos,o
61,2010-019912-18,de,o
61,2010-019912-18,tratamiento,i
61,2010-019912-18,paralelos,o
61,2010-019912-18,para,o
61,2010-019912-18,evaluar,i
61,2010-019912-18,la,i
61,2010-019912-18,seguridad,i
61,2010-019912-18,y,o
61,2010-019912-18,el,o
61,2010-019912-18,efecto,o
61,2010-019912-18,sobre,o
61,2010-019912-18,el,o
61,2010-019912-18,resultado,o
61,2010-019912-18,clinico,o
61,2010-019912-18,de,o
61,2010-019912-18,tocilizumab,i
61,2010-019912-18,SC,o
61,2010-019912-18,frente,o
61,2010-019912-18,a,o
61,2010-019912-18,placebo,i
61,2010-019912-18,SC,o
61,2010-019912-18,en,o
61,2010-019912-18,combinacion,o
61,2010-019912-18,con,o
61,2010-019912-18,farmacos,i
61,2010-019912-18,antirreumaticos,i
61,2010-019912-18,modificadores,i
61,2010-019912-18,de,i
61,2010-019912-18,la,i
61,2010-019912-18,enfermedad,i
61,2010-019912-18,FAMEs,i
61,2010-019912-18,tradicionales,o
61,2010-019912-18,en,o
61,2010-019912-18,pacientes,o
61,2010-019912-18,con,o
61,2010-019912-18,artritis,i
61,2010-019912-18,reumatoide,i
61,2010-019912-18,activa,o
61,2010-019912-18,moderada,o
61,2010-019912-18,a,o
61,2010-019912-18,severa,o
61,2010-019912-18,Indicacion,o
61,2010-019912-18,cientifica,o
61,2010-019912-18,Artritis,i
61,2010-019912-18,Reumatoide,i
61,2010-019912-18,AR,i
61,2010-019912-18,Criterios,o
61,2010-019912-18,de,o
61,2010-019912-18,inclusion,o
61,2010-019912-18,Presentar,o
61,2010-019912-18,artritis,i
61,2010-019912-18,reumatoide,i
61,2010-019912-18,de,o
61,2010-019912-18,mayor,o
61,2010-019912-18,o,o
61,2010-019912-18,igual,o
61,2010-019912-18,a,o
61,2010-019912-18,6,o
61,2010-019912-18,meses,o
61,2010-019912-18,de,o
61,2010-019912-18,duracion,o
61,2010-019912-18,Recibir,o
61,2010-019912-18,tratamiento,i
61,2010-019912-18,de,i
61,2010-019912-18,forma,i
61,2010-019912-18,ambulatoria,i
61,2010-019912-18,Presentar,o
61,2010-019912-18,un,o
61,2010-019912-18,recuento,o
61,2010-019912-18,de,o
61,2010-019912-18,articulaciones,i
61,2010-019912-18,inflamadas,i
61,2010-019912-18,RAI,o
61,2010-019912-18,mayor,o
61,2010-019912-18,o,o
61,2010-019912-18,igual,o
61,2010-019912-18,a,o
61,2010-019912-18,6,o
61,2010-019912-18,recuento,o
61,2010-019912-18,de,o
61,2010-019912-18,66,o
61,2010-019912-18,articulaciones,i
61,2010-019912-18,y,o
61,2010-019912-18,de,o
61,2010-019912-18,articulaciones,i
61,2010-019912-18,dolorosas,i
61,2010-019912-18,RAD,o
61,2010-019912-18,mayor,o
61,2010-019912-18,o,o
61,2010-019912-18,igual,o
61,2010-019912-18,a,o
61,2010-019912-18,8,o
61,2010-019912-18,recuento,o
61,2010-019912-18,de,o
61,2010-019912-18,68,o
61,2010-019912-18,articulaciones,i
61,2010-019912-18,en,o
61,2010-019912-18,las,o
61,2010-019912-18,visitas,o
61,2010-019912-18,de,o
61,2010-019912-18,seleccion,o
61,2010-019912-18,y,o
61,2010-019912-18,basal,o
61,2010-019912-18,Los,o
61,2010-019912-18,pacientes,o
61,2010-019912-18,deben,o
61,2010-019912-18,estar,o
61,2010-019912-18,recibiendo,o
61,2010-019912-18,tratamiento,i
61,2010-019912-18,con,o
61,2010-019912-18,una,o
61,2010-019912-18,dosis,o
61,2010-019912-18,estable,o
61,2010-019912-18,de,o
61,2010-019912-18,los,o
61,2010-019912-18,FAMEs,i
61,2010-019912-18,permitidos,o
61,2010-019912-18,como,o
61,2010-019912-18,minimo,o
61,2010-019912-18,8,o
61,2010-019912-18,semanas,o
61,2010-019912-18,antes,o
61,2010-019912-18,de,o
61,2010-019912-18,la,o
61,2010-019912-18,visita,o
61,2010-019912-18,basal,o
61,2010-019912-18,Criterios,o
61,2010-019912-18,de,o
61,2010-019912-18,exclusion,o
61,2010-019912-18,Pacientes,o
61,2010-019912-18,sometidos,o
61,2010-019912-18,a,o
61,2010-019912-18,intervenciones,i
61,2010-019912-18,de,i
61,2010-019912-18,cirugia,i
61,2010-019912-18,mayor,i
61,2010-019912-18,incluyendo,o
61,2010-019912-18,cirugia,i
61,2010-019912-18,articular,i
61,2010-019912-18,en,o
61,2010-019912-18,las,o
61,2010-019912-18,8,o
61,2010-019912-18,semanas,o
61,2010-019912-18,previas,o
61,2010-019912-18,a,o
61,2010-019912-18,la,o
61,2010-019912-18,visita,o
61,2010-019912-18,de,o
61,2010-019912-18,seleccion,o
61,2010-019912-18,o,o
61,2010-019912-18,que,o
61,2010-019912-18,tengan,o
61,2010-019912-18,previsto,o
61,2010-019912-18,someterse,o
61,2010-019912-18,a,o
61,2010-019912-18,una,o
61,2010-019912-18,intervencion,i
61,2010-019912-18,de,o
61,2010-019912-18,este,o
61,2010-019912-18,tipo,o
61,2010-019912-18,en,o
61,2010-019912-18,los,o
61,2010-019912-18,6,o
61,2010-019912-18,meses,o
61,2010-019912-18,siguientes,o
61,2010-019912-18,a,o
61,2010-019912-18,la,o
61,2010-019912-18,randomizacion,i
61,2010-019912-18,Enfermedad,i
61,2010-019912-18,reumatica,i
61,2010-019912-18,autoinmune,i
61,2010-019912-18,distinta,o
61,2010-019912-18,de,o
61,2010-019912-18,AR,i
61,2010-019912-18,Se,o
61,2010-019912-18,permite,o
61,2010-019912-18,la,o
61,2010-019912-18,inclusion,o
61,2010-019912-18,de,o
61,2010-019912-18,pacientes,o
61,2010-019912-18,con,o
61,2010-019912-18,sindrome,i
61,2010-019912-18,de,i
61,2010-019912-18,Sjögren,i
61,2010-019912-18,secundario,i
61,2010-019912-18,asociado,o
61,2010-019912-18,a,o
61,2010-019912-18,AR,i
61,2010-019912-18,Clase,o
61,2010-019912-18,funcional,o
61,2010-019912-18,IV,o
61,2010-019912-18,definida,o
61,2010-019912-18,de,o
61,2010-019912-18,acuerdo,o
61,2010-019912-18,con,o
61,2010-019912-18,la,o
61,2010-019912-18,Clasificacion,o
61,2010-019912-18,del,o
61,2010-019912-18,ACR,o
61,2010-019912-18,del,o
61,2010-019912-18,Estado,o
61,2010-019912-18,Funcional,o
61,2010-019912-18,en,o
61,2010-019912-18,Artritis,i
61,2010-019912-18,Reumatoide,i
61,2010-019912-18,Artritis,i
61,2010-019912-18,idiopatica,i
61,2010-019912-18,juvenil,i
61,2010-019912-18,AIJ,i
61,2010-019912-18,o,o
61,2010-019912-18,artritis,i
61,2010-019912-18,reumatoide,i
61,2010-019912-18,juvenil,i
61,2010-019912-18,ARJ,i
61,2010-019912-18,yo,o
61,2010-019912-18,AR,i
61,2010-019912-18,diagnosticadas,i
61,2010-019912-18,antes,o
61,2010-019912-18,de,o
61,2010-019912-18,los,o
61,2010-019912-18,16,o
61,2010-019912-18,años,o
61,2010-019912-18,de,o
61,2010-019912-18,edad,o
61,2010-019912-18,Enfermedad,i
61,2010-019912-18,articular,i
61,2010-019912-18,inflamatoria,i
61,2010-019912-18,distinta,o
61,2010-019912-18,de,o
61,2010-019912-18,AR,i
61,2010-019912-18,en,o
61,2010-019912-18,el,o
61,2010-019912-18,pasado,o
61,2010-019912-18,o,o
61,2010-019912-18,en,o
61,2010-019912-18,la,o
61,2010-019912-18,actualidad,o
62,2010-019912-18,EudraCT,o
62,2010-019912-18,Nº,o
62,2010-019912-18,201001991218,o
62,2010-019912-18,Titulo,o
62,2010-019912-18,cientifico,o
62,2010-019912-18,Estudio,o
62,2010-019912-18,randomizado,o
62,2010-019912-18,doble,o
62,2010-019912-18,ciego,o
62,2010-019912-18,con,o
62,2010-019912-18,grupos,o
62,2010-019912-18,de,o
62,2010-019912-18,tratamiento,i
62,2010-019912-18,paralelos,o
62,2010-019912-18,para,o
62,2010-019912-18,evaluar,i
62,2010-019912-18,la,i
62,2010-019912-18,seguridad,i
62,2010-019912-18,y,o
62,2010-019912-18,el,o
62,2010-019912-18,efecto,o
62,2010-019912-18,sobre,o
62,2010-019912-18,el,o
62,2010-019912-18,resultado,o
62,2010-019912-18,clinico,o
62,2010-019912-18,de,o
62,2010-019912-18,tocilizumab,i
62,2010-019912-18,SC,o
62,2010-019912-18,frente,o
62,2010-019912-18,a,o
62,2010-019912-18,placebo,i
62,2010-019912-18,SC,o
62,2010-019912-18,en,o
62,2010-019912-18,combinacion,o
62,2010-019912-18,con,o
62,2010-019912-18,farmacos,i
62,2010-019912-18,antirreumaticos,i
62,2010-019912-18,modificadores,i
62,2010-019912-18,de,i
62,2010-019912-18,la,i
62,2010-019912-18,enfermedad,i
62,2010-019912-18,FAMEs,i
62,2010-019912-18,tradicionales,o
62,2010-019912-18,en,o
62,2010-019912-18,pacientes,o
62,2010-019912-18,con,o
62,2010-019912-18,artritis,i
62,2010-019912-18,reumatoide,i
62,2010-019912-18,activa,o
62,2010-019912-18,moderada,o
62,2010-019912-18,a,o
62,2010-019912-18,severa,o
62,2010-019912-18,Indicacion,o
62,2010-019912-18,cientifica,o
62,2010-019912-18,Artritis,i
62,2010-019912-18,Reumatoide,i
62,2010-019912-18,AR,i
62,2010-019912-18,Criterios,o
62,2010-019912-18,de,o
62,2010-019912-18,inclusion,o
62,2010-019912-18,Presentar,o
62,2010-019912-18,artritis,i
62,2010-019912-18,reumatoide,i
62,2010-019912-18,de,o
62,2010-019912-18,mayor,o
62,2010-019912-18,o,o
62,2010-019912-18,igual,o
62,2010-019912-18,a,o
62,2010-019912-18,6,o
62,2010-019912-18,meses,o
62,2010-019912-18,de,o
62,2010-019912-18,duracion,o
62,2010-019912-18,Recibir,o
62,2010-019912-18,tratamiento,i
62,2010-019912-18,de,i
62,2010-019912-18,forma,i
62,2010-019912-18,ambulatoria,i
62,2010-019912-18,Presentar,o
62,2010-019912-18,un,o
62,2010-019912-18,recuento,o
62,2010-019912-18,de,o
62,2010-019912-18,articulaciones,i
62,2010-019912-18,inflamadas,i
62,2010-019912-18,RAI,o
62,2010-019912-18,mayor,o
62,2010-019912-18,o,o
62,2010-019912-18,igual,o
62,2010-019912-18,a,o
62,2010-019912-18,6,o
62,2010-019912-18,recuento,o
62,2010-019912-18,de,o
62,2010-019912-18,66,o
62,2010-019912-18,articulaciones,i
62,2010-019912-18,y,o
62,2010-019912-18,de,o
62,2010-019912-18,articulaciones,i
62,2010-019912-18,dolorosas,i
62,2010-019912-18,RAD,o
62,2010-019912-18,mayor,o
62,2010-019912-18,o,o
62,2010-019912-18,igual,o
62,2010-019912-18,a,o
62,2010-019912-18,8,o
62,2010-019912-18,recuento,o
62,2010-019912-18,de,o
62,2010-019912-18,68,o
62,2010-019912-18,articulaciones,i
62,2010-019912-18,en,o
62,2010-019912-18,las,o
62,2010-019912-18,visitas,o
62,2010-019912-18,de,o
62,2010-019912-18,seleccion,o
62,2010-019912-18,y,o
62,2010-019912-18,basal,o
62,2010-019912-18,Los,o
62,2010-019912-18,pacientes,o
62,2010-019912-18,deben,o
62,2010-019912-18,estar,o
62,2010-019912-18,recibiendo,o
62,2010-019912-18,tratamiento,i
62,2010-019912-18,con,o
62,2010-019912-18,una,o
62,2010-019912-18,dosis,o
62,2010-019912-18,estable,o
62,2010-019912-18,de,o
62,2010-019912-18,los,o
62,2010-019912-18,FAMEs,i
62,2010-019912-18,permitidos,o
62,2010-019912-18,como,o
62,2010-019912-18,minimo,o
62,2010-019912-18,8,o
62,2010-019912-18,semanas,o
62,2010-019912-18,antes,o
62,2010-019912-18,de,o
62,2010-019912-18,la,o
62,2010-019912-18,visita,o
62,2010-019912-18,basal,o
62,2010-019912-18,Criterios,o
62,2010-019912-18,de,o
62,2010-019912-18,exclusion,o
62,2010-019912-18,Pacientes,o
62,2010-019912-18,sometidos,o
62,2010-019912-18,a,o
62,2010-019912-18,intervenciones,i
62,2010-019912-18,de,i
62,2010-019912-18,cirugia,i
62,2010-019912-18,mayor,i
62,2010-019912-18,incluyendo,o
62,2010-019912-18,cirugia,i
62,2010-019912-18,articular,i
62,2010-019912-18,en,o
62,2010-019912-18,las,o
62,2010-019912-18,8,o
62,2010-019912-18,semanas,o
62,2010-019912-18,previas,o
62,2010-019912-18,a,o
62,2010-019912-18,la,o
62,2010-019912-18,visita,o
62,2010-019912-18,de,o
62,2010-019912-18,seleccion,o
62,2010-019912-18,o,o
62,2010-019912-18,que,o
62,2010-019912-18,tengan,o
62,2010-019912-18,previsto,o
62,2010-019912-18,someterse,o
62,2010-019912-18,a,o
62,2010-019912-18,una,o
62,2010-019912-18,intervencion,i
62,2010-019912-18,de,o
62,2010-019912-18,este,o
62,2010-019912-18,tipo,o
62,2010-019912-18,en,o
62,2010-019912-18,los,o
62,2010-019912-18,6,o
62,2010-019912-18,meses,o
62,2010-019912-18,siguientes,o
62,2010-019912-18,a,o
62,2010-019912-18,la,o
62,2010-019912-18,randomizacion,i
62,2010-019912-18,Enfermedad,i
62,2010-019912-18,reumatica,i
62,2010-019912-18,autoinmune,i
62,2010-019912-18,distinta,o
62,2010-019912-18,de,o
62,2010-019912-18,AR,i
62,2010-019912-18,Se,o
62,2010-019912-18,permite,o
62,2010-019912-18,la,o
62,2010-019912-18,inclusion,o
62,2010-019912-18,de,o
62,2010-019912-18,pacientes,o
62,2010-019912-18,con,o
62,2010-019912-18,sindrome,i
62,2010-019912-18,de,i
62,2010-019912-18,Sjögren,i
62,2010-019912-18,secundario,i
62,2010-019912-18,asociado,o
62,2010-019912-18,a,o
62,2010-019912-18,AR,i
62,2010-019912-18,Clase,o
62,2010-019912-18,funcional,o
62,2010-019912-18,IV,o
62,2010-019912-18,definida,o
62,2010-019912-18,de,o
62,2010-019912-18,acuerdo,o
62,2010-019912-18,con,o
62,2010-019912-18,la,o
62,2010-019912-18,Clasificacion,o
62,2010-019912-18,del,o
62,2010-019912-18,ACR,o
62,2010-019912-18,del,o
62,2010-019912-18,Estado,o
62,2010-019912-18,Funcional,o
62,2010-019912-18,en,o
62,2010-019912-18,Artritis,i
62,2010-019912-18,Reumatoide,i
62,2010-019912-18,Artritis,i
62,2010-019912-18,idiopatica,i
62,2010-019912-18,juvenil,i
62,2010-019912-18,AIJ,i
62,2010-019912-18,o,o
62,2010-019912-18,artritis,i
62,2010-019912-18,reumatoide,i
62,2010-019912-18,juvenil,i
62,2010-019912-18,ARJ,i
62,2010-019912-18,yo,o
62,2010-019912-18,AR,i
62,2010-019912-18,diagnosticadas,i
62,2010-019912-18,antes,o
62,2010-019912-18,de,o
62,2010-019912-18,los,o
62,2010-019912-18,16,o
62,2010-019912-18,años,o
62,2010-019912-18,de,o
62,2010-019912-18,edad,o
62,2010-019912-18,Enfermedad,i
62,2010-019912-18,articular,i
62,2010-019912-18,inflamatoria,i
62,2010-019912-18,distinta,o
62,2010-019912-18,de,o
62,2010-019912-18,AR,i
62,2010-019912-18,en,o
62,2010-019912-18,el,o
62,2010-019912-18,pasado,o
62,2010-019912-18,o,o
62,2010-019912-18,en,o
62,2010-019912-18,la,o
62,2010-019912-18,actualidad,o
63,2010-019912-18,EudraCT,o
63,2010-019912-18,Nº,o
63,2010-019912-18,201001991218,o
63,2010-019912-18,Titulo,o
63,2010-019912-18,cientifico,o
63,2010-019912-18,Estudio,o
63,2010-019912-18,randomizado,o
63,2010-019912-18,doble,o
63,2010-019912-18,ciego,o
63,2010-019912-18,con,o
63,2010-019912-18,grupos,o
63,2010-019912-18,de,o
63,2010-019912-18,tratamiento,i
63,2010-019912-18,paralelos,o
63,2010-019912-18,para,o
63,2010-019912-18,evaluar,i
63,2010-019912-18,la,i
63,2010-019912-18,seguridad,i
63,2010-019912-18,y,o
63,2010-019912-18,el,o
63,2010-019912-18,efecto,o
63,2010-019912-18,sobre,o
63,2010-019912-18,el,o
63,2010-019912-18,resultado,o
63,2010-019912-18,clinico,o
63,2010-019912-18,de,o
63,2010-019912-18,tocilizumab,i
63,2010-019912-18,SC,o
63,2010-019912-18,frente,o
63,2010-019912-18,a,o
63,2010-019912-18,placebo,i
63,2010-019912-18,SC,o
63,2010-019912-18,en,o
63,2010-019912-18,combinacion,o
63,2010-019912-18,con,o
63,2010-019912-18,farmacos,i
63,2010-019912-18,antirreumaticos,i
63,2010-019912-18,modificadores,i
63,2010-019912-18,de,i
63,2010-019912-18,la,i
63,2010-019912-18,enfermedad,i
63,2010-019912-18,FAMEs,i
63,2010-019912-18,tradicionales,o
63,2010-019912-18,en,o
63,2010-019912-18,pacientes,o
63,2010-019912-18,con,o
63,2010-019912-18,artritis,i
63,2010-019912-18,reumatoide,i
63,2010-019912-18,activa,o
63,2010-019912-18,moderada,o
63,2010-019912-18,a,o
63,2010-019912-18,severa,o
63,2010-019912-18,Indicacion,o
63,2010-019912-18,cientifica,o
63,2010-019912-18,Artritis,i
63,2010-019912-18,Reumatoide,i
63,2010-019912-18,AR,i
63,2010-019912-18,Criterios,o
63,2010-019912-18,de,o
63,2010-019912-18,inclusion,o
63,2010-019912-18,Presentar,o
63,2010-019912-18,artritis,i
63,2010-019912-18,reumatoide,i
63,2010-019912-18,de,o
63,2010-019912-18,mayor,o
63,2010-019912-18,o,o
63,2010-019912-18,igual,o
63,2010-019912-18,a,o
63,2010-019912-18,6,o
63,2010-019912-18,meses,o
63,2010-019912-18,de,o
63,2010-019912-18,duracion,o
63,2010-019912-18,Recibir,o
63,2010-019912-18,tratamiento,i
63,2010-019912-18,de,i
63,2010-019912-18,forma,i
63,2010-019912-18,ambulatoria,i
63,2010-019912-18,Presentar,o
63,2010-019912-18,un,o
63,2010-019912-18,recuento,o
63,2010-019912-18,de,o
63,2010-019912-18,articulaciones,i
63,2010-019912-18,inflamadas,i
63,2010-019912-18,RAI,o
63,2010-019912-18,mayor,o
63,2010-019912-18,o,o
63,2010-019912-18,igual,o
63,2010-019912-18,a,o
63,2010-019912-18,6,o
63,2010-019912-18,recuento,o
63,2010-019912-18,de,o
63,2010-019912-18,66,o
63,2010-019912-18,articulaciones,i
63,2010-019912-18,y,o
63,2010-019912-18,de,o
63,2010-019912-18,articulaciones,i
63,2010-019912-18,dolorosas,i
63,2010-019912-18,RAD,o
63,2010-019912-18,mayor,o
63,2010-019912-18,o,o
63,2010-019912-18,igual,o
63,2010-019912-18,a,o
63,2010-019912-18,8,o
63,2010-019912-18,recuento,o
63,2010-019912-18,de,o
63,2010-019912-18,68,o
63,2010-019912-18,articulaciones,i
63,2010-019912-18,en,o
63,2010-019912-18,las,o
63,2010-019912-18,visitas,o
63,2010-019912-18,de,o
63,2010-019912-18,seleccion,o
63,2010-019912-18,y,o
63,2010-019912-18,basal,o
63,2010-019912-18,Los,o
63,2010-019912-18,pacientes,o
63,2010-019912-18,deben,o
63,2010-019912-18,estar,o
63,2010-019912-18,recibiendo,o
63,2010-019912-18,tratamiento,i
63,2010-019912-18,con,o
63,2010-019912-18,una,o
63,2010-019912-18,dosis,o
63,2010-019912-18,estable,o
63,2010-019912-18,de,o
63,2010-019912-18,los,o
63,2010-019912-18,FAMEs,i
63,2010-019912-18,permitidos,o
63,2010-019912-18,como,o
63,2010-019912-18,minimo,o
63,2010-019912-18,8,o
63,2010-019912-18,semanas,o
63,2010-019912-18,antes,o
63,2010-019912-18,de,o
63,2010-019912-18,la,o
63,2010-019912-18,visita,o
63,2010-019912-18,basal,o
63,2010-019912-18,Criterios,o
63,2010-019912-18,de,o
63,2010-019912-18,exclusion,o
63,2010-019912-18,Pacientes,o
63,2010-019912-18,sometidos,o
63,2010-019912-18,a,o
63,2010-019912-18,intervenciones,i
63,2010-019912-18,de,i
63,2010-019912-18,cirugia,i
63,2010-019912-18,mayor,i
63,2010-019912-18,incluyendo,o
63,2010-019912-18,cirugia,i
63,2010-019912-18,articular,i
63,2010-019912-18,en,o
63,2010-019912-18,las,o
63,2010-019912-18,8,o
63,2010-019912-18,semanas,o
63,2010-019912-18,previas,o
63,2010-019912-18,a,o
63,2010-019912-18,la,o
63,2010-019912-18,visita,o
63,2010-019912-18,de,o
63,2010-019912-18,seleccion,o
63,2010-019912-18,o,o
63,2010-019912-18,que,o
63,2010-019912-18,tengan,o
63,2010-019912-18,previsto,o
63,2010-019912-18,someterse,o
63,2010-019912-18,a,o
63,2010-019912-18,una,o
63,2010-019912-18,intervencion,i
63,2010-019912-18,de,o
63,2010-019912-18,este,o
63,2010-019912-18,tipo,o
63,2010-019912-18,en,o
63,2010-019912-18,los,o
63,2010-019912-18,6,o
63,2010-019912-18,meses,o
63,2010-019912-18,siguientes,o
63,2010-019912-18,a,o
63,2010-019912-18,la,o
63,2010-019912-18,randomizacion,i
63,2010-019912-18,Enfermedad,i
63,2010-019912-18,reumatica,i
63,2010-019912-18,autoinmune,i
63,2010-019912-18,distinta,o
63,2010-019912-18,de,o
63,2010-019912-18,AR,i
63,2010-019912-18,Se,o
63,2010-019912-18,permite,o
63,2010-019912-18,la,o
63,2010-019912-18,inclusion,o
63,2010-019912-18,de,o
63,2010-019912-18,pacientes,o
63,2010-019912-18,con,o
63,2010-019912-18,sindrome,i
63,2010-019912-18,de,i
63,2010-019912-18,Sjögren,i
63,2010-019912-18,secundario,i
63,2010-019912-18,asociado,o
63,2010-019912-18,a,o
63,2010-019912-18,AR,i
63,2010-019912-18,Clase,o
63,2010-019912-18,funcional,o
63,2010-019912-18,IV,o
63,2010-019912-18,definida,o
63,2010-019912-18,de,o
63,2010-019912-18,acuerdo,o
63,2010-019912-18,con,o
63,2010-019912-18,la,o
63,2010-019912-18,Clasificacion,o
63,2010-019912-18,del,o
63,2010-019912-18,ACR,o
63,2010-019912-18,del,o
63,2010-019912-18,Estado,o
63,2010-019912-18,Funcional,o
63,2010-019912-18,en,o
63,2010-019912-18,Artritis,i
63,2010-019912-18,Reumatoide,i
63,2010-019912-18,Artritis,i
63,2010-019912-18,idiopatica,i
63,2010-019912-18,juvenil,i
63,2010-019912-18,AIJ,i
63,2010-019912-18,o,o
63,2010-019912-18,artritis,i
63,2010-019912-18,reumatoide,i
63,2010-019912-18,juvenil,i
63,2010-019912-18,ARJ,i
63,2010-019912-18,yo,o
63,2010-019912-18,AR,i
63,2010-019912-18,diagnosticadas,i
63,2010-019912-18,antes,o
63,2010-019912-18,de,o
63,2010-019912-18,los,o
63,2010-019912-18,16,o
63,2010-019912-18,años,o
63,2010-019912-18,de,o
63,2010-019912-18,edad,o
63,2010-019912-18,Enfermedad,i
63,2010-019912-18,articular,i
63,2010-019912-18,inflamatoria,i
63,2010-019912-18,distinta,o
63,2010-019912-18,de,o
63,2010-019912-18,AR,i
63,2010-019912-18,en,o
63,2010-019912-18,el,o
63,2010-019912-18,pasado,o
63,2010-019912-18,o,o
63,2010-019912-18,en,o
63,2010-019912-18,la,o
63,2010-019912-18,actualidad,o
64,2010-019912-18,EudraCT,o
64,2010-019912-18,Nº,o
64,2010-019912-18,201001991218,o
64,2010-019912-18,Titulo,o
64,2010-019912-18,cientifico,o
64,2010-019912-18,Estudio,o
64,2010-019912-18,randomizado,o
64,2010-019912-18,doble,o
64,2010-019912-18,ciego,o
64,2010-019912-18,con,o
64,2010-019912-18,grupos,o
64,2010-019912-18,de,o
64,2010-019912-18,tratamiento,i
64,2010-019912-18,paralelos,o
64,2010-019912-18,para,o
64,2010-019912-18,evaluar,i
64,2010-019912-18,la,i
64,2010-019912-18,seguridad,i
64,2010-019912-18,y,o
64,2010-019912-18,el,o
64,2010-019912-18,efecto,o
64,2010-019912-18,sobre,o
64,2010-019912-18,el,o
64,2010-019912-18,resultado,o
64,2010-019912-18,clinico,o
64,2010-019912-18,de,o
64,2010-019912-18,tocilizumab,i
64,2010-019912-18,SC,o
64,2010-019912-18,frente,o
64,2010-019912-18,a,o
64,2010-019912-18,placebo,i
64,2010-019912-18,SC,o
64,2010-019912-18,en,o
64,2010-019912-18,combinacion,o
64,2010-019912-18,con,o
64,2010-019912-18,farmacos,i
64,2010-019912-18,antirreumaticos,i
64,2010-019912-18,modificadores,i
64,2010-019912-18,de,i
64,2010-019912-18,la,i
64,2010-019912-18,enfermedad,i
64,2010-019912-18,FAMEs,i
64,2010-019912-18,tradicionales,o
64,2010-019912-18,en,o
64,2010-019912-18,pacientes,o
64,2010-019912-18,con,o
64,2010-019912-18,artritis,i
64,2010-019912-18,reumatoide,i
64,2010-019912-18,activa,o
64,2010-019912-18,moderada,o
64,2010-019912-18,a,o
64,2010-019912-18,severa,o
64,2010-019912-18,Indicacion,o
64,2010-019912-18,cientifica,o
64,2010-019912-18,Artritis,i
64,2010-019912-18,Reumatoide,i
64,2010-019912-18,AR,i
64,2010-019912-18,Criterios,o
64,2010-019912-18,de,o
64,2010-019912-18,inclusion,o
64,2010-019912-18,Presentar,o
64,2010-019912-18,artritis,i
64,2010-019912-18,reumatoide,i
64,2010-019912-18,de,o
64,2010-019912-18,mayor,o
64,2010-019912-18,o,o
64,2010-019912-18,igual,o
64,2010-019912-18,a,o
64,2010-019912-18,6,o
64,2010-019912-18,meses,o
64,2010-019912-18,de,o
64,2010-019912-18,duracion,o
64,2010-019912-18,Recibir,o
64,2010-019912-18,tratamiento,i
64,2010-019912-18,de,i
64,2010-019912-18,forma,i
64,2010-019912-18,ambulatoria,i
64,2010-019912-18,Presentar,o
64,2010-019912-18,un,o
64,2010-019912-18,recuento,o
64,2010-019912-18,de,o
64,2010-019912-18,articulaciones,i
64,2010-019912-18,inflamadas,i
64,2010-019912-18,RAI,o
64,2010-019912-18,mayor,o
64,2010-019912-18,o,o
64,2010-019912-18,igual,o
64,2010-019912-18,a,o
64,2010-019912-18,6,o
64,2010-019912-18,recuento,o
64,2010-019912-18,de,o
64,2010-019912-18,66,o
64,2010-019912-18,articulaciones,i
64,2010-019912-18,y,o
64,2010-019912-18,de,o
64,2010-019912-18,articulaciones,i
64,2010-019912-18,dolorosas,i
64,2010-019912-18,RAD,o
64,2010-019912-18,mayor,o
64,2010-019912-18,o,o
64,2010-019912-18,igual,o
64,2010-019912-18,a,o
64,2010-019912-18,8,o
64,2010-019912-18,recuento,o
64,2010-019912-18,de,o
64,2010-019912-18,68,o
64,2010-019912-18,articulaciones,i
64,2010-019912-18,en,o
64,2010-019912-18,las,o
64,2010-019912-18,visitas,o
64,2010-019912-18,de,o
64,2010-019912-18,seleccion,o
64,2010-019912-18,y,o
64,2010-019912-18,basal,o
64,2010-019912-18,Los,o
64,2010-019912-18,pacientes,o
64,2010-019912-18,deben,o
64,2010-019912-18,estar,o
64,2010-019912-18,recibiendo,o
64,2010-019912-18,tratamiento,i
64,2010-019912-18,con,o
64,2010-019912-18,una,o
64,2010-019912-18,dosis,o
64,2010-019912-18,estable,o
64,2010-019912-18,de,o
64,2010-019912-18,los,o
64,2010-019912-18,FAMEs,i
64,2010-019912-18,permitidos,o
64,2010-019912-18,como,o
64,2010-019912-18,minimo,o
64,2010-019912-18,8,o
64,2010-019912-18,semanas,o
64,2010-019912-18,antes,o
64,2010-019912-18,de,o
64,2010-019912-18,la,o
64,2010-019912-18,visita,o
64,2010-019912-18,basal,o
64,2010-019912-18,Criterios,o
64,2010-019912-18,de,o
64,2010-019912-18,exclusion,o
64,2010-019912-18,Pacientes,o
64,2010-019912-18,sometidos,o
64,2010-019912-18,a,o
64,2010-019912-18,intervenciones,i
64,2010-019912-18,de,i
64,2010-019912-18,cirugia,i
64,2010-019912-18,mayor,i
64,2010-019912-18,incluyendo,o
64,2010-019912-18,cirugia,i
64,2010-019912-18,articular,i
64,2010-019912-18,en,o
64,2010-019912-18,las,o
64,2010-019912-18,8,o
64,2010-019912-18,semanas,o
64,2010-019912-18,previas,o
64,2010-019912-18,a,o
64,2010-019912-18,la,o
64,2010-019912-18,visita,o
64,2010-019912-18,de,o
64,2010-019912-18,seleccion,o
64,2010-019912-18,o,o
64,2010-019912-18,que,o
64,2010-019912-18,tengan,o
64,2010-019912-18,previsto,o
64,2010-019912-18,someterse,o
64,2010-019912-18,a,o
64,2010-019912-18,una,o
64,2010-019912-18,intervencion,i
64,2010-019912-18,de,o
64,2010-019912-18,este,o
64,2010-019912-18,tipo,o
64,2010-019912-18,en,o
64,2010-019912-18,los,o
64,2010-019912-18,6,o
64,2010-019912-18,meses,o
64,2010-019912-18,siguientes,o
64,2010-019912-18,a,o
64,2010-019912-18,la,o
64,2010-019912-18,randomizacion,i
64,2010-019912-18,Enfermedad,i
64,2010-019912-18,reumatica,i
64,2010-019912-18,autoinmune,i
64,2010-019912-18,distinta,o
64,2010-019912-18,de,o
64,2010-019912-18,AR,i
64,2010-019912-18,Se,o
64,2010-019912-18,permite,o
64,2010-019912-18,la,o
64,2010-019912-18,inclusion,o
64,2010-019912-18,de,o
64,2010-019912-18,pacientes,o
64,2010-019912-18,con,o
64,2010-019912-18,sindrome,i
64,2010-019912-18,de,i
64,2010-019912-18,Sjögren,i
64,2010-019912-18,secundario,i
64,2010-019912-18,asociado,o
64,2010-019912-18,a,o
64,2010-019912-18,AR,i
64,2010-019912-18,Clase,o
64,2010-019912-18,funcional,o
64,2010-019912-18,IV,o
64,2010-019912-18,definida,o
64,2010-019912-18,de,o
64,2010-019912-18,acuerdo,o
64,2010-019912-18,con,o
64,2010-019912-18,la,o
64,2010-019912-18,Clasificacion,o
64,2010-019912-18,del,o
64,2010-019912-18,ACR,o
64,2010-019912-18,del,o
64,2010-019912-18,Estado,o
64,2010-019912-18,Funcional,o
64,2010-019912-18,en,o
64,2010-019912-18,Artritis,i
64,2010-019912-18,Reumatoide,i
64,2010-019912-18,Artritis,i
64,2010-019912-18,idiopatica,i
64,2010-019912-18,juvenil,i
64,2010-019912-18,AIJ,i
64,2010-019912-18,o,o
64,2010-019912-18,artritis,i
64,2010-019912-18,reumatoide,i
64,2010-019912-18,juvenil,i
64,2010-019912-18,ARJ,i
64,2010-019912-18,yo,o
64,2010-019912-18,AR,i
64,2010-019912-18,diagnosticadas,i
64,2010-019912-18,antes,o
64,2010-019912-18,de,o
64,2010-019912-18,los,o
64,2010-019912-18,16,o
64,2010-019912-18,años,o
64,2010-019912-18,de,o
64,2010-019912-18,edad,o
64,2010-019912-18,Enfermedad,i
64,2010-019912-18,articular,i
64,2010-019912-18,inflamatoria,i
64,2010-019912-18,distinta,o
64,2010-019912-18,de,o
64,2010-019912-18,AR,i
64,2010-019912-18,en,o
64,2010-019912-18,el,o
64,2010-019912-18,pasado,o
64,2010-019912-18,o,o
64,2010-019912-18,en,o
64,2010-019912-18,la,o
64,2010-019912-18,actualidad,o
65,2010-019912-18,EudraCT,o
65,2010-019912-18,Nº,o
65,2010-019912-18,201001991218,o
65,2010-019912-18,Titulo,o
65,2010-019912-18,cientifico,o
65,2010-019912-18,Estudio,o
65,2010-019912-18,randomizado,o
65,2010-019912-18,doble,o
65,2010-019912-18,ciego,o
65,2010-019912-18,con,o
65,2010-019912-18,grupos,o
65,2010-019912-18,de,o
65,2010-019912-18,tratamiento,i
65,2010-019912-18,paralelos,o
65,2010-019912-18,para,o
65,2010-019912-18,evaluar,i
65,2010-019912-18,la,i
65,2010-019912-18,seguridad,i
65,2010-019912-18,y,o
65,2010-019912-18,el,o
65,2010-019912-18,efecto,o
65,2010-019912-18,sobre,o
65,2010-019912-18,el,o
65,2010-019912-18,resultado,o
65,2010-019912-18,clinico,o
65,2010-019912-18,de,o
65,2010-019912-18,tocilizumab,i
65,2010-019912-18,SC,o
65,2010-019912-18,frente,o
65,2010-019912-18,a,o
65,2010-019912-18,placebo,i
65,2010-019912-18,SC,o
65,2010-019912-18,en,o
65,2010-019912-18,combinacion,o
65,2010-019912-18,con,o
65,2010-019912-18,farmacos,i
65,2010-019912-18,antirreumaticos,i
65,2010-019912-18,modificadores,i
65,2010-019912-18,de,i
65,2010-019912-18,la,i
65,2010-019912-18,enfermedad,i
65,2010-019912-18,FAMEs,i
65,2010-019912-18,tradicionales,o
65,2010-019912-18,en,o
65,2010-019912-18,pacientes,o
65,2010-019912-18,con,o
65,2010-019912-18,artritis,i
65,2010-019912-18,reumatoide,i
65,2010-019912-18,activa,o
65,2010-019912-18,moderada,o
65,2010-019912-18,a,o
65,2010-019912-18,severa,o
65,2010-019912-18,Indicacion,o
65,2010-019912-18,cientifica,o
65,2010-019912-18,Artritis,i
65,2010-019912-18,Reumatoide,i
65,2010-019912-18,AR,i
65,2010-019912-18,Criterios,o
65,2010-019912-18,de,o
65,2010-019912-18,inclusion,o
65,2010-019912-18,Presentar,o
65,2010-019912-18,artritis,i
65,2010-019912-18,reumatoide,i
65,2010-019912-18,de,o
65,2010-019912-18,mayor,o
65,2010-019912-18,o,o
65,2010-019912-18,igual,o
65,2010-019912-18,a,o
65,2010-019912-18,6,o
65,2010-019912-18,meses,o
65,2010-019912-18,de,o
65,2010-019912-18,duracion,o
65,2010-019912-18,Recibir,o
65,2010-019912-18,tratamiento,i
65,2010-019912-18,de,i
65,2010-019912-18,forma,i
65,2010-019912-18,ambulatoria,i
65,2010-019912-18,Presentar,o
65,2010-019912-18,un,o
65,2010-019912-18,recuento,o
65,2010-019912-18,de,o
65,2010-019912-18,articulaciones,i
65,2010-019912-18,inflamadas,i
65,2010-019912-18,RAI,o
65,2010-019912-18,mayor,o
65,2010-019912-18,o,o
65,2010-019912-18,igual,o
65,2010-019912-18,a,o
65,2010-019912-18,6,o
65,2010-019912-18,recuento,o
65,2010-019912-18,de,o
65,2010-019912-18,66,o
65,2010-019912-18,articulaciones,i
65,2010-019912-18,y,o
65,2010-019912-18,de,o
65,2010-019912-18,articulaciones,i
65,2010-019912-18,dolorosas,i
65,2010-019912-18,RAD,o
65,2010-019912-18,mayor,o
65,2010-019912-18,o,o
65,2010-019912-18,igual,o
65,2010-019912-18,a,o
65,2010-019912-18,8,o
65,2010-019912-18,recuento,o
65,2010-019912-18,de,o
65,2010-019912-18,68,o
65,2010-019912-18,articulaciones,i
65,2010-019912-18,en,o
65,2010-019912-18,las,o
65,2010-019912-18,visitas,o
65,2010-019912-18,de,o
65,2010-019912-18,seleccion,o
65,2010-019912-18,y,o
65,2010-019912-18,basal,o
65,2010-019912-18,Los,o
65,2010-019912-18,pacientes,o
65,2010-019912-18,deben,o
65,2010-019912-18,estar,o
65,2010-019912-18,recibiendo,o
65,2010-019912-18,tratamiento,i
65,2010-019912-18,con,o
65,2010-019912-18,una,o
65,2010-019912-18,dosis,o
65,2010-019912-18,estable,o
65,2010-019912-18,de,o
65,2010-019912-18,los,o
65,2010-019912-18,FAMEs,i
65,2010-019912-18,permitidos,o
65,2010-019912-18,como,o
65,2010-019912-18,minimo,o
65,2010-019912-18,8,o
65,2010-019912-18,semanas,o
65,2010-019912-18,antes,o
65,2010-019912-18,de,o
65,2010-019912-18,la,o
65,2010-019912-18,visita,o
65,2010-019912-18,basal,o
65,2010-019912-18,Criterios,o
65,2010-019912-18,de,o
65,2010-019912-18,exclusion,o
65,2010-019912-18,Pacientes,o
65,2010-019912-18,sometidos,o
65,2010-019912-18,a,o
65,2010-019912-18,intervenciones,i
65,2010-019912-18,de,i
65,2010-019912-18,cirugia,i
65,2010-019912-18,mayor,i
65,2010-019912-18,incluyendo,o
65,2010-019912-18,cirugia,i
65,2010-019912-18,articular,i
65,2010-019912-18,en,o
65,2010-019912-18,las,o
65,2010-019912-18,8,o
65,2010-019912-18,semanas,o
65,2010-019912-18,previas,o
65,2010-019912-18,a,o
65,2010-019912-18,la,o
65,2010-019912-18,visita,o
65,2010-019912-18,de,o
65,2010-019912-18,seleccion,o
65,2010-019912-18,o,o
65,2010-019912-18,que,o
65,2010-019912-18,tengan,o
65,2010-019912-18,previsto,o
65,2010-019912-18,someterse,o
65,2010-019912-18,a,o
65,2010-019912-18,una,o
65,2010-019912-18,intervencion,i
65,2010-019912-18,de,o
65,2010-019912-18,este,o
65,2010-019912-18,tipo,o
65,2010-019912-18,en,o
65,2010-019912-18,los,o
65,2010-019912-18,6,o
65,2010-019912-18,meses,o
65,2010-019912-18,siguientes,o
65,2010-019912-18,a,o
65,2010-019912-18,la,o
65,2010-019912-18,randomizacion,i
65,2010-019912-18,Enfermedad,i
65,2010-019912-18,reumatica,i
65,2010-019912-18,autoinmune,i
65,2010-019912-18,distinta,o
65,2010-019912-18,de,o
65,2010-019912-18,AR,i
65,2010-019912-18,Se,o
65,2010-019912-18,permite,o
65,2010-019912-18,la,o
65,2010-019912-18,inclusion,o
65,2010-019912-18,de,o
65,2010-019912-18,pacientes,o
65,2010-019912-18,con,o
65,2010-019912-18,sindrome,i
65,2010-019912-18,de,i
65,2010-019912-18,Sjögren,i
65,2010-019912-18,secundario,i
65,2010-019912-18,asociado,o
65,2010-019912-18,a,o
65,2010-019912-18,AR,i
65,2010-019912-18,Clase,o
65,2010-019912-18,funcional,o
65,2010-019912-18,IV,o
65,2010-019912-18,definida,o
65,2010-019912-18,de,o
65,2010-019912-18,acuerdo,o
65,2010-019912-18,con,o
65,2010-019912-18,la,o
65,2010-019912-18,Clasificacion,o
65,2010-019912-18,del,o
65,2010-019912-18,ACR,o
65,2010-019912-18,del,o
65,2010-019912-18,Estado,o
65,2010-019912-18,Funcional,o
65,2010-019912-18,en,o
65,2010-019912-18,Artritis,i
65,2010-019912-18,Reumatoide,i
65,2010-019912-18,Artritis,i
65,2010-019912-18,idiopatica,i
65,2010-019912-18,juvenil,i
65,2010-019912-18,AIJ,i
65,2010-019912-18,o,o
65,2010-019912-18,artritis,i
65,2010-019912-18,reumatoide,i
65,2010-019912-18,juvenil,i
65,2010-019912-18,ARJ,i
65,2010-019912-18,yo,o
65,2010-019912-18,AR,i
65,2010-019912-18,diagnosticadas,i
65,2010-019912-18,antes,o
65,2010-019912-18,de,o
65,2010-019912-18,los,o
65,2010-019912-18,16,o
65,2010-019912-18,años,o
65,2010-019912-18,de,o
65,2010-019912-18,edad,o
65,2010-019912-18,Enfermedad,i
65,2010-019912-18,articular,i
65,2010-019912-18,inflamatoria,i
65,2010-019912-18,distinta,o
65,2010-019912-18,de,o
65,2010-019912-18,AR,i
65,2010-019912-18,en,o
65,2010-019912-18,el,o
65,2010-019912-18,pasado,o
65,2010-019912-18,o,o
65,2010-019912-18,en,o
65,2010-019912-18,la,o
65,2010-019912-18,actualidad,o
66,2010-019912-18,EudraCT,o
66,2010-019912-18,Nº,o
66,2010-019912-18,201001991218,o
66,2010-019912-18,Titulo,o
66,2010-019912-18,cientifico,o
66,2010-019912-18,Estudio,o
66,2010-019912-18,randomizado,o
66,2010-019912-18,doble,o
66,2010-019912-18,ciego,o
66,2010-019912-18,con,o
66,2010-019912-18,grupos,o
66,2010-019912-18,de,o
66,2010-019912-18,tratamiento,i
66,2010-019912-18,paralelos,o
66,2010-019912-18,para,o
66,2010-019912-18,evaluar,i
66,2010-019912-18,la,i
66,2010-019912-18,seguridad,i
66,2010-019912-18,y,o
66,2010-019912-18,el,o
66,2010-019912-18,efecto,o
66,2010-019912-18,sobre,o
66,2010-019912-18,el,o
66,2010-019912-18,resultado,o
66,2010-019912-18,clinico,o
66,2010-019912-18,de,o
66,2010-019912-18,tocilizumab,i
66,2010-019912-18,SC,o
66,2010-019912-18,frente,o
66,2010-019912-18,a,o
66,2010-019912-18,placebo,i
66,2010-019912-18,SC,o
66,2010-019912-18,en,o
66,2010-019912-18,combinacion,o
66,2010-019912-18,con,o
66,2010-019912-18,farmacos,i
66,2010-019912-18,antirreumaticos,i
66,2010-019912-18,modificadores,i
66,2010-019912-18,de,i
66,2010-019912-18,la,i
66,2010-019912-18,enfermedad,i
66,2010-019912-18,FAMEs,i
66,2010-019912-18,tradicionales,o
66,2010-019912-18,en,o
66,2010-019912-18,pacientes,o
66,2010-019912-18,con,o
66,2010-019912-18,artritis,i
66,2010-019912-18,reumatoide,i
66,2010-019912-18,activa,o
66,2010-019912-18,moderada,o
66,2010-019912-18,a,o
66,2010-019912-18,severa,o
66,2010-019912-18,Indicacion,o
66,2010-019912-18,cientifica,o
66,2010-019912-18,Artritis,i
66,2010-019912-18,Reumatoide,i
66,2010-019912-18,AR,i
66,2010-019912-18,Criterios,o
66,2010-019912-18,de,o
66,2010-019912-18,inclusion,o
66,2010-019912-18,Presentar,o
66,2010-019912-18,artritis,i
66,2010-019912-18,reumatoide,i
66,2010-019912-18,de,o
66,2010-019912-18,mayor,o
66,2010-019912-18,o,o
66,2010-019912-18,igual,o
66,2010-019912-18,a,o
66,2010-019912-18,6,o
66,2010-019912-18,meses,o
66,2010-019912-18,de,o
66,2010-019912-18,duracion,o
66,2010-019912-18,Recibir,o
66,2010-019912-18,tratamiento,i
66,2010-019912-18,de,i
66,2010-019912-18,forma,i
66,2010-019912-18,ambulatoria,i
66,2010-019912-18,Presentar,o
66,2010-019912-18,un,o
66,2010-019912-18,recuento,o
66,2010-019912-18,de,o
66,2010-019912-18,articulaciones,i
66,2010-019912-18,inflamadas,i
66,2010-019912-18,RAI,o
66,2010-019912-18,mayor,o
66,2010-019912-18,o,o
66,2010-019912-18,igual,o
66,2010-019912-18,a,o
66,2010-019912-18,6,o
66,2010-019912-18,recuento,o
66,2010-019912-18,de,o
66,2010-019912-18,66,o
66,2010-019912-18,articulaciones,i
66,2010-019912-18,y,o
66,2010-019912-18,de,o
66,2010-019912-18,articulaciones,i
66,2010-019912-18,dolorosas,i
66,2010-019912-18,RAD,o
66,2010-019912-18,mayor,o
66,2010-019912-18,o,o
66,2010-019912-18,igual,o
66,2010-019912-18,a,o
66,2010-019912-18,8,o
66,2010-019912-18,recuento,o
66,2010-019912-18,de,o
66,2010-019912-18,68,o
66,2010-019912-18,articulaciones,i
66,2010-019912-18,en,o
66,2010-019912-18,las,o
66,2010-019912-18,visitas,o
66,2010-019912-18,de,o
66,2010-019912-18,seleccion,o
66,2010-019912-18,y,o
66,2010-019912-18,basal,o
66,2010-019912-18,Los,o
66,2010-019912-18,pacientes,o
66,2010-019912-18,deben,o
66,2010-019912-18,estar,o
66,2010-019912-18,recibiendo,o
66,2010-019912-18,tratamiento,i
66,2010-019912-18,con,o
66,2010-019912-18,una,o
66,2010-019912-18,dosis,o
66,2010-019912-18,estable,o
66,2010-019912-18,de,o
66,2010-019912-18,los,o
66,2010-019912-18,FAMEs,i
66,2010-019912-18,permitidos,o
66,2010-019912-18,como,o
66,2010-019912-18,minimo,o
66,2010-019912-18,8,o
66,2010-019912-18,semanas,o
66,2010-019912-18,antes,o
66,2010-019912-18,de,o
66,2010-019912-18,la,o
66,2010-019912-18,visita,o
66,2010-019912-18,basal,o
66,2010-019912-18,Criterios,o
66,2010-019912-18,de,o
66,2010-019912-18,exclusion,o
66,2010-019912-18,Pacientes,o
66,2010-019912-18,sometidos,o
66,2010-019912-18,a,o
66,2010-019912-18,intervenciones,i
66,2010-019912-18,de,i
66,2010-019912-18,cirugia,i
66,2010-019912-18,mayor,i
66,2010-019912-18,incluyendo,o
66,2010-019912-18,cirugia,i
66,2010-019912-18,articular,i
66,2010-019912-18,en,o
66,2010-019912-18,las,o
66,2010-019912-18,8,o
66,2010-019912-18,semanas,o
66,2010-019912-18,previas,o
66,2010-019912-18,a,o
66,2010-019912-18,la,o
66,2010-019912-18,visita,o
66,2010-019912-18,de,o
66,2010-019912-18,seleccion,o
66,2010-019912-18,o,o
66,2010-019912-18,que,o
66,2010-019912-18,tengan,o
66,2010-019912-18,previsto,o
66,2010-019912-18,someterse,o
66,2010-019912-18,a,o
66,2010-019912-18,una,o
66,2010-019912-18,intervencion,i
66,2010-019912-18,de,o
66,2010-019912-18,este,o
66,2010-019912-18,tipo,o
66,2010-019912-18,en,o
66,2010-019912-18,los,o
66,2010-019912-18,6,o
66,2010-019912-18,meses,o
66,2010-019912-18,siguientes,o
66,2010-019912-18,a,o
66,2010-019912-18,la,o
66,2010-019912-18,randomizacion,i
66,2010-019912-18,Enfermedad,i
66,2010-019912-18,reumatica,i
66,2010-019912-18,autoinmune,i
66,2010-019912-18,distinta,o
66,2010-019912-18,de,o
66,2010-019912-18,AR,i
66,2010-019912-18,Se,o
66,2010-019912-18,permite,o
66,2010-019912-18,la,o
66,2010-019912-18,inclusion,o
66,2010-019912-18,de,o
66,2010-019912-18,pacientes,o
66,2010-019912-18,con,o
66,2010-019912-18,sindrome,i
66,2010-019912-18,de,i
66,2010-019912-18,Sjögren,i
66,2010-019912-18,secundario,i
66,2010-019912-18,asociado,o
66,2010-019912-18,a,o
66,2010-019912-18,AR,i
66,2010-019912-18,Clase,o
66,2010-019912-18,funcional,o
66,2010-019912-18,IV,o
66,2010-019912-18,definida,o
66,2010-019912-18,de,o
66,2010-019912-18,acuerdo,o
66,2010-019912-18,con,o
66,2010-019912-18,la,o
66,2010-019912-18,Clasificacion,o
66,2010-019912-18,del,o
66,2010-019912-18,ACR,o
66,2010-019912-18,del,o
66,2010-019912-18,Estado,o
66,2010-019912-18,Funcional,o
66,2010-019912-18,en,o
66,2010-019912-18,Artritis,i
66,2010-019912-18,Reumatoide,i
66,2010-019912-18,Artritis,i
66,2010-019912-18,idiopatica,i
66,2010-019912-18,juvenil,i
66,2010-019912-18,AIJ,i
66,2010-019912-18,o,o
66,2010-019912-18,artritis,i
66,2010-019912-18,reumatoide,i
66,2010-019912-18,juvenil,i
66,2010-019912-18,ARJ,i
66,2010-019912-18,yo,o
66,2010-019912-18,AR,i
66,2010-019912-18,diagnosticadas,i
66,2010-019912-18,antes,o
66,2010-019912-18,de,o
66,2010-019912-18,los,o
66,2010-019912-18,16,o
66,2010-019912-18,años,o
66,2010-019912-18,de,o
66,2010-019912-18,edad,o
66,2010-019912-18,Enfermedad,i
66,2010-019912-18,articular,i
66,2010-019912-18,inflamatoria,i
66,2010-019912-18,distinta,o
66,2010-019912-18,de,o
66,2010-019912-18,AR,i
66,2010-019912-18,en,o
66,2010-019912-18,el,o
66,2010-019912-18,pasado,o
66,2010-019912-18,o,o
66,2010-019912-18,en,o
66,2010-019912-18,la,o
66,2010-019912-18,actualidad,o
67,2010-019912-18,EudraCT,o
67,2010-019912-18,Nº,o
67,2010-019912-18,201001991218,o
67,2010-019912-18,Titulo,o
67,2010-019912-18,cientifico,o
67,2010-019912-18,Estudio,o
67,2010-019912-18,randomizado,o
67,2010-019912-18,doble,o
67,2010-019912-18,ciego,o
67,2010-019912-18,con,o
67,2010-019912-18,grupos,o
67,2010-019912-18,de,o
67,2010-019912-18,tratamiento,i
67,2010-019912-18,paralelos,o
67,2010-019912-18,para,o
67,2010-019912-18,evaluar,i
67,2010-019912-18,la,i
67,2010-019912-18,seguridad,i
67,2010-019912-18,y,o
67,2010-019912-18,el,o
67,2010-019912-18,efecto,o
67,2010-019912-18,sobre,o
67,2010-019912-18,el,o
67,2010-019912-18,resultado,o
67,2010-019912-18,clinico,o
67,2010-019912-18,de,o
67,2010-019912-18,tocilizumab,i
67,2010-019912-18,SC,o
67,2010-019912-18,frente,o
67,2010-019912-18,a,o
67,2010-019912-18,placebo,i
67,2010-019912-18,SC,o
67,2010-019912-18,en,o
67,2010-019912-18,combinacion,o
67,2010-019912-18,con,o
67,2010-019912-18,farmacos,i
67,2010-019912-18,antirreumaticos,i
67,2010-019912-18,modificadores,i
67,2010-019912-18,de,i
67,2010-019912-18,la,i
67,2010-019912-18,enfermedad,i
67,2010-019912-18,FAMEs,i
67,2010-019912-18,tradicionales,o
67,2010-019912-18,en,o
67,2010-019912-18,pacientes,o
67,2010-019912-18,con,o
67,2010-019912-18,artritis,i
67,2010-019912-18,reumatoide,i
67,2010-019912-18,activa,o
67,2010-019912-18,moderada,o
67,2010-019912-18,a,o
67,2010-019912-18,severa,o
67,2010-019912-18,Indicacion,o
67,2010-019912-18,cientifica,o
67,2010-019912-18,Artritis,i
67,2010-019912-18,Reumatoide,i
67,2010-019912-18,AR,i
67,2010-019912-18,Criterios,o
67,2010-019912-18,de,o
67,2010-019912-18,inclusion,o
67,2010-019912-18,Presentar,o
67,2010-019912-18,artritis,i
67,2010-019912-18,reumatoide,i
67,2010-019912-18,de,o
67,2010-019912-18,mayor,o
67,2010-019912-18,o,o
67,2010-019912-18,igual,o
67,2010-019912-18,a,o
67,2010-019912-18,6,o
67,2010-019912-18,meses,o
67,2010-019912-18,de,o
67,2010-019912-18,duracion,o
67,2010-019912-18,Recibir,o
67,2010-019912-18,tratamiento,i
67,2010-019912-18,de,i
67,2010-019912-18,forma,i
67,2010-019912-18,ambulatoria,i
67,2010-019912-18,Presentar,o
67,2010-019912-18,un,o
67,2010-019912-18,recuento,o
67,2010-019912-18,de,o
67,2010-019912-18,articulaciones,i
67,2010-019912-18,inflamadas,i
67,2010-019912-18,RAI,o
67,2010-019912-18,mayor,o
67,2010-019912-18,o,o
67,2010-019912-18,igual,o
67,2010-019912-18,a,o
67,2010-019912-18,6,o
67,2010-019912-18,recuento,o
67,2010-019912-18,de,o
67,2010-019912-18,66,o
67,2010-019912-18,articulaciones,i
67,2010-019912-18,y,o
67,2010-019912-18,de,o
67,2010-019912-18,articulaciones,i
67,2010-019912-18,dolorosas,i
67,2010-019912-18,RAD,o
67,2010-019912-18,mayor,o
67,2010-019912-18,o,o
67,2010-019912-18,igual,o
67,2010-019912-18,a,o
67,2010-019912-18,8,o
67,2010-019912-18,recuento,o
67,2010-019912-18,de,o
67,2010-019912-18,68,o
67,2010-019912-18,articulaciones,i
67,2010-019912-18,en,o
67,2010-019912-18,las,o
67,2010-019912-18,visitas,o
67,2010-019912-18,de,o
67,2010-019912-18,seleccion,o
67,2010-019912-18,y,o
67,2010-019912-18,basal,o
67,2010-019912-18,Los,o
67,2010-019912-18,pacientes,o
67,2010-019912-18,deben,o
67,2010-019912-18,estar,o
67,2010-019912-18,recibiendo,o
67,2010-019912-18,tratamiento,i
67,2010-019912-18,con,o
67,2010-019912-18,una,o
67,2010-019912-18,dosis,o
67,2010-019912-18,estable,o
67,2010-019912-18,de,o
67,2010-019912-18,los,o
67,2010-019912-18,FAMEs,i
67,2010-019912-18,permitidos,o
67,2010-019912-18,como,o
67,2010-019912-18,minimo,o
67,2010-019912-18,8,o
67,2010-019912-18,semanas,o
67,2010-019912-18,antes,o
67,2010-019912-18,de,o
67,2010-019912-18,la,o
67,2010-019912-18,visita,o
67,2010-019912-18,basal,o
67,2010-019912-18,Criterios,o
67,2010-019912-18,de,o
67,2010-019912-18,exclusion,o
67,2010-019912-18,Pacientes,o
67,2010-019912-18,sometidos,o
67,2010-019912-18,a,o
67,2010-019912-18,intervenciones,i
67,2010-019912-18,de,i
67,2010-019912-18,cirugia,i
67,2010-019912-18,mayor,i
67,2010-019912-18,incluyendo,o
67,2010-019912-18,cirugia,i
67,2010-019912-18,articular,i
67,2010-019912-18,en,o
67,2010-019912-18,las,o
67,2010-019912-18,8,o
67,2010-019912-18,semanas,o
67,2010-019912-18,previas,o
67,2010-019912-18,a,o
67,2010-019912-18,la,o
67,2010-019912-18,visita,o
67,2010-019912-18,de,o
67,2010-019912-18,seleccion,o
67,2010-019912-18,o,o
67,2010-019912-18,que,o
67,2010-019912-18,tengan,o
67,2010-019912-18,previsto,o
67,2010-019912-18,someterse,o
67,2010-019912-18,a,o
67,2010-019912-18,una,o
67,2010-019912-18,intervencion,i
67,2010-019912-18,de,o
67,2010-019912-18,este,o
67,2010-019912-18,tipo,o
67,2010-019912-18,en,o
67,2010-019912-18,los,o
67,2010-019912-18,6,o
67,2010-019912-18,meses,o
67,2010-019912-18,siguientes,o
67,2010-019912-18,a,o
67,2010-019912-18,la,o
67,2010-019912-18,randomizacion,i
67,2010-019912-18,Enfermedad,i
67,2010-019912-18,reumatica,i
67,2010-019912-18,autoinmune,i
67,2010-019912-18,distinta,o
67,2010-019912-18,de,o
67,2010-019912-18,AR,i
67,2010-019912-18,Se,o
67,2010-019912-18,permite,o
67,2010-019912-18,la,o
67,2010-019912-18,inclusion,o
67,2010-019912-18,de,o
67,2010-019912-18,pacientes,o
67,2010-019912-18,con,o
67,2010-019912-18,sindrome,i
67,2010-019912-18,de,i
67,2010-019912-18,Sjögren,i
67,2010-019912-18,secundario,i
67,2010-019912-18,asociado,o
67,2010-019912-18,a,o
67,2010-019912-18,AR,i
67,2010-019912-18,Clase,o
67,2010-019912-18,funcional,o
67,2010-019912-18,IV,o
67,2010-019912-18,definida,o
67,2010-019912-18,de,o
67,2010-019912-18,acuerdo,o
67,2010-019912-18,con,o
67,2010-019912-18,la,o
67,2010-019912-18,Clasificacion,o
67,2010-019912-18,del,o
67,2010-019912-18,ACR,o
67,2010-019912-18,del,o
67,2010-019912-18,Estado,o
67,2010-019912-18,Funcional,o
67,2010-019912-18,en,o
67,2010-019912-18,Artritis,i
67,2010-019912-18,Reumatoide,i
67,2010-019912-18,Artritis,i
67,2010-019912-18,idiopatica,i
67,2010-019912-18,juvenil,i
67,2010-019912-18,AIJ,i
67,2010-019912-18,o,o
67,2010-019912-18,artritis,i
67,2010-019912-18,reumatoide,i
67,2010-019912-18,juvenil,i
67,2010-019912-18,ARJ,i
67,2010-019912-18,yo,o
67,2010-019912-18,AR,i
67,2010-019912-18,diagnosticadas,i
67,2010-019912-18,antes,o
67,2010-019912-18,de,o
67,2010-019912-18,los,o
67,2010-019912-18,16,o
67,2010-019912-18,años,o
67,2010-019912-18,de,o
67,2010-019912-18,edad,o
67,2010-019912-18,Enfermedad,i
67,2010-019912-18,articular,i
67,2010-019912-18,inflamatoria,i
67,2010-019912-18,distinta,o
67,2010-019912-18,de,o
67,2010-019912-18,AR,i
67,2010-019912-18,en,o
67,2010-019912-18,el,o
67,2010-019912-18,pasado,o
67,2010-019912-18,o,o
67,2010-019912-18,en,o
67,2010-019912-18,la,o
67,2010-019912-18,actualidad,o
68,2010-019912-18,EudraCT,o
68,2010-019912-18,Nº,o
68,2010-019912-18,201001991218,o
68,2010-019912-18,Titulo,o
68,2010-019912-18,cientifico,o
68,2010-019912-18,Estudio,o
68,2010-019912-18,randomizado,o
68,2010-019912-18,doble,o
68,2010-019912-18,ciego,o
68,2010-019912-18,con,o
68,2010-019912-18,grupos,o
68,2010-019912-18,de,o
68,2010-019912-18,tratamiento,i
68,2010-019912-18,paralelos,o
68,2010-019912-18,para,o
68,2010-019912-18,evaluar,i
68,2010-019912-18,la,i
68,2010-019912-18,seguridad,i
68,2010-019912-18,y,o
68,2010-019912-18,el,o
68,2010-019912-18,efecto,o
68,2010-019912-18,sobre,o
68,2010-019912-18,el,o
68,2010-019912-18,resultado,o
68,2010-019912-18,clinico,o
68,2010-019912-18,de,o
68,2010-019912-18,tocilizumab,i
68,2010-019912-18,SC,o
68,2010-019912-18,frente,o
68,2010-019912-18,a,o
68,2010-019912-18,placebo,i
68,2010-019912-18,SC,o
68,2010-019912-18,en,o
68,2010-019912-18,combinacion,o
68,2010-019912-18,con,o
68,2010-019912-18,farmacos,i
68,2010-019912-18,antirreumaticos,i
68,2010-019912-18,modificadores,i
68,2010-019912-18,de,i
68,2010-019912-18,la,i
68,2010-019912-18,enfermedad,i
68,2010-019912-18,FAMEs,i
68,2010-019912-18,tradicionales,o
68,2010-019912-18,en,o
68,2010-019912-18,pacientes,o
68,2010-019912-18,con,o
68,2010-019912-18,artritis,i
68,2010-019912-18,reumatoide,i
68,2010-019912-18,activa,o
68,2010-019912-18,moderada,o
68,2010-019912-18,a,o
68,2010-019912-18,severa,o
68,2010-019912-18,Indicacion,o
68,2010-019912-18,cientifica,o
68,2010-019912-18,Artritis,i
68,2010-019912-18,Reumatoide,i
68,2010-019912-18,AR,i
68,2010-019912-18,Criterios,o
68,2010-019912-18,de,o
68,2010-019912-18,inclusion,o
68,2010-019912-18,Presentar,o
68,2010-019912-18,artritis,i
68,2010-019912-18,reumatoide,i
68,2010-019912-18,de,o
68,2010-019912-18,mayor,o
68,2010-019912-18,o,o
68,2010-019912-18,igual,o
68,2010-019912-18,a,o
68,2010-019912-18,6,o
68,2010-019912-18,meses,o
68,2010-019912-18,de,o
68,2010-019912-18,duracion,o
68,2010-019912-18,Recibir,o
68,2010-019912-18,tratamiento,i
68,2010-019912-18,de,i
68,2010-019912-18,forma,i
68,2010-019912-18,ambulatoria,i
68,2010-019912-18,Presentar,o
68,2010-019912-18,un,o
68,2010-019912-18,recuento,o
68,2010-019912-18,de,o
68,2010-019912-18,articulaciones,i
68,2010-019912-18,inflamadas,i
68,2010-019912-18,RAI,o
68,2010-019912-18,mayor,o
68,2010-019912-18,o,o
68,2010-019912-18,igual,o
68,2010-019912-18,a,o
68,2010-019912-18,6,o
68,2010-019912-18,recuento,o
68,2010-019912-18,de,o
68,2010-019912-18,66,o
68,2010-019912-18,articulaciones,i
68,2010-019912-18,y,o
68,2010-019912-18,de,o
68,2010-019912-18,articulaciones,i
68,2010-019912-18,dolorosas,i
68,2010-019912-18,RAD,o
68,2010-019912-18,mayor,o
68,2010-019912-18,o,o
68,2010-019912-18,igual,o
68,2010-019912-18,a,o
68,2010-019912-18,8,o
68,2010-019912-18,recuento,o
68,2010-019912-18,de,o
68,2010-019912-18,68,o
68,2010-019912-18,articulaciones,i
68,2010-019912-18,en,o
68,2010-019912-18,las,o
68,2010-019912-18,visitas,o
68,2010-019912-18,de,o
68,2010-019912-18,seleccion,o
68,2010-019912-18,y,o
68,2010-019912-18,basal,o
68,2010-019912-18,Los,o
68,2010-019912-18,pacientes,o
68,2010-019912-18,deben,o
68,2010-019912-18,estar,o
68,2010-019912-18,recibiendo,o
68,2010-019912-18,tratamiento,i
68,2010-019912-18,con,o
68,2010-019912-18,una,o
68,2010-019912-18,dosis,o
68,2010-019912-18,estable,o
68,2010-019912-18,de,o
68,2010-019912-18,los,o
68,2010-019912-18,FAMEs,i
68,2010-019912-18,permitidos,o
68,2010-019912-18,como,o
68,2010-019912-18,minimo,o
68,2010-019912-18,8,o
68,2010-019912-18,semanas,o
68,2010-019912-18,antes,o
68,2010-019912-18,de,o
68,2010-019912-18,la,o
68,2010-019912-18,visita,o
68,2010-019912-18,basal,o
68,2010-019912-18,Criterios,o
68,2010-019912-18,de,o
68,2010-019912-18,exclusion,o
68,2010-019912-18,Pacientes,o
68,2010-019912-18,sometidos,o
68,2010-019912-18,a,o
68,2010-019912-18,intervenciones,i
68,2010-019912-18,de,i
68,2010-019912-18,cirugia,i
68,2010-019912-18,mayor,i
68,2010-019912-18,incluyendo,o
68,2010-019912-18,cirugia,i
68,2010-019912-18,articular,i
68,2010-019912-18,en,o
68,2010-019912-18,las,o
68,2010-019912-18,8,o
68,2010-019912-18,semanas,o
68,2010-019912-18,previas,o
68,2010-019912-18,a,o
68,2010-019912-18,la,o
68,2010-019912-18,visita,o
68,2010-019912-18,de,o
68,2010-019912-18,seleccion,o
68,2010-019912-18,o,o
68,2010-019912-18,que,o
68,2010-019912-18,tengan,o
68,2010-019912-18,previsto,o
68,2010-019912-18,someterse,o
68,2010-019912-18,a,o
68,2010-019912-18,una,o
68,2010-019912-18,intervencion,i
68,2010-019912-18,de,o
68,2010-019912-18,este,o
68,2010-019912-18,tipo,o
68,2010-019912-18,en,o
68,2010-019912-18,los,o
68,2010-019912-18,6,o
68,2010-019912-18,meses,o
68,2010-019912-18,siguientes,o
68,2010-019912-18,a,o
68,2010-019912-18,la,o
68,2010-019912-18,randomizacion,i
68,2010-019912-18,Enfermedad,i
68,2010-019912-18,reumatica,i
68,2010-019912-18,autoinmune,i
68,2010-019912-18,distinta,o
68,2010-019912-18,de,o
68,2010-019912-18,AR,i
68,2010-019912-18,Se,o
68,2010-019912-18,permite,o
68,2010-019912-18,la,o
68,2010-019912-18,inclusion,o
68,2010-019912-18,de,o
68,2010-019912-18,pacientes,o
68,2010-019912-18,con,o
68,2010-019912-18,sindrome,i
68,2010-019912-18,de,i
68,2010-019912-18,Sjögren,i
68,2010-019912-18,secundario,i
68,2010-019912-18,asociado,o
68,2010-019912-18,a,o
68,2010-019912-18,AR,i
68,2010-019912-18,Clase,o
68,2010-019912-18,funcional,o
68,2010-019912-18,IV,o
68,2010-019912-18,definida,o
68,2010-019912-18,de,o
68,2010-019912-18,acuerdo,o
68,2010-019912-18,con,o
68,2010-019912-18,la,o
68,2010-019912-18,Clasificacion,o
68,2010-019912-18,del,o
68,2010-019912-18,ACR,o
68,2010-019912-18,del,o
68,2010-019912-18,Estado,o
68,2010-019912-18,Funcional,o
68,2010-019912-18,en,o
68,2010-019912-18,Artritis,i
68,2010-019912-18,Reumatoide,i
68,2010-019912-18,Artritis,i
68,2010-019912-18,idiopatica,i
68,2010-019912-18,juvenil,i
68,2010-019912-18,AIJ,i
68,2010-019912-18,o,o
68,2010-019912-18,artritis,i
68,2010-019912-18,reumatoide,i
68,2010-019912-18,juvenil,i
68,2010-019912-18,ARJ,i
68,2010-019912-18,yo,o
68,2010-019912-18,AR,i
68,2010-019912-18,diagnosticadas,i
68,2010-019912-18,antes,o
68,2010-019912-18,de,o
68,2010-019912-18,los,o
68,2010-019912-18,16,o
68,2010-019912-18,años,o
68,2010-019912-18,de,o
68,2010-019912-18,edad,o
68,2010-019912-18,Enfermedad,i
68,2010-019912-18,articular,i
68,2010-019912-18,inflamatoria,i
68,2010-019912-18,distinta,o
68,2010-019912-18,de,o
68,2010-019912-18,AR,i
68,2010-019912-18,en,o
68,2010-019912-18,el,o
68,2010-019912-18,pasado,o
68,2010-019912-18,o,o
68,2010-019912-18,en,o
68,2010-019912-18,la,o
68,2010-019912-18,actualidad,o
69,2010-019912-18,EudraCT,o
69,2010-019912-18,Nº,o
69,2010-019912-18,201001991218,o
69,2010-019912-18,Titulo,o
69,2010-019912-18,cientifico,o
69,2010-019912-18,Estudio,o
69,2010-019912-18,randomizado,o
69,2010-019912-18,doble,o
69,2010-019912-18,ciego,o
69,2010-019912-18,con,o
69,2010-019912-18,grupos,o
69,2010-019912-18,de,o
69,2010-019912-18,tratamiento,i
69,2010-019912-18,paralelos,o
69,2010-019912-18,para,o
69,2010-019912-18,evaluar,i
69,2010-019912-18,la,i
69,2010-019912-18,seguridad,i
69,2010-019912-18,y,o
69,2010-019912-18,el,o
69,2010-019912-18,efecto,o
69,2010-019912-18,sobre,o
69,2010-019912-18,el,o
69,2010-019912-18,resultado,o
69,2010-019912-18,clinico,o
69,2010-019912-18,de,o
69,2010-019912-18,tocilizumab,i
69,2010-019912-18,SC,o
69,2010-019912-18,frente,o
69,2010-019912-18,a,o
69,2010-019912-18,placebo,i
69,2010-019912-18,SC,o
69,2010-019912-18,en,o
69,2010-019912-18,combinacion,o
69,2010-019912-18,con,o
69,2010-019912-18,farmacos,i
69,2010-019912-18,antirreumaticos,i
69,2010-019912-18,modificadores,i
69,2010-019912-18,de,i
69,2010-019912-18,la,i
69,2010-019912-18,enfermedad,i
69,2010-019912-18,FAMEs,i
69,2010-019912-18,tradicionales,o
69,2010-019912-18,en,o
69,2010-019912-18,pacientes,o
69,2010-019912-18,con,o
69,2010-019912-18,artritis,i
69,2010-019912-18,reumatoide,i
69,2010-019912-18,activa,o
69,2010-019912-18,moderada,o
69,2010-019912-18,a,o
69,2010-019912-18,severa,o
69,2010-019912-18,Indicacion,o
69,2010-019912-18,cientifica,o
69,2010-019912-18,Artritis,i
69,2010-019912-18,Reumatoide,i
69,2010-019912-18,AR,i
69,2010-019912-18,Criterios,o
69,2010-019912-18,de,o
69,2010-019912-18,inclusion,o
69,2010-019912-18,Presentar,o
69,2010-019912-18,artritis,i
69,2010-019912-18,reumatoide,i
69,2010-019912-18,de,o
69,2010-019912-18,mayor,o
69,2010-019912-18,o,o
69,2010-019912-18,igual,o
69,2010-019912-18,a,o
69,2010-019912-18,6,o
69,2010-019912-18,meses,o
69,2010-019912-18,de,o
69,2010-019912-18,duracion,o
69,2010-019912-18,Recibir,o
69,2010-019912-18,tratamiento,i
69,2010-019912-18,de,i
69,2010-019912-18,forma,i
69,2010-019912-18,ambulatoria,i
69,2010-019912-18,Presentar,o
69,2010-019912-18,un,o
69,2010-019912-18,recuento,o
69,2010-019912-18,de,o
69,2010-019912-18,articulaciones,i
69,2010-019912-18,inflamadas,i
69,2010-019912-18,RAI,o
69,2010-019912-18,mayor,o
69,2010-019912-18,o,o
69,2010-019912-18,igual,o
69,2010-019912-18,a,o
69,2010-019912-18,6,o
69,2010-019912-18,recuento,o
69,2010-019912-18,de,o
69,2010-019912-18,66,o
69,2010-019912-18,articulaciones,i
69,2010-019912-18,y,o
69,2010-019912-18,de,o
69,2010-019912-18,articulaciones,i
69,2010-019912-18,dolorosas,i
69,2010-019912-18,RAD,o
69,2010-019912-18,mayor,o
69,2010-019912-18,o,o
69,2010-019912-18,igual,o
69,2010-019912-18,a,o
69,2010-019912-18,8,o
69,2010-019912-18,recuento,o
69,2010-019912-18,de,o
69,2010-019912-18,68,o
69,2010-019912-18,articulaciones,i
69,2010-019912-18,en,o
69,2010-019912-18,las,o
69,2010-019912-18,visitas,o
69,2010-019912-18,de,o
69,2010-019912-18,seleccion,o
69,2010-019912-18,y,o
69,2010-019912-18,basal,o
69,2010-019912-18,Los,o
69,2010-019912-18,pacientes,o
69,2010-019912-18,deben,o
69,2010-019912-18,estar,o
69,2010-019912-18,recibiendo,o
69,2010-019912-18,tratamiento,i
69,2010-019912-18,con,o
69,2010-019912-18,una,o
69,2010-019912-18,dosis,o
69,2010-019912-18,estable,o
69,2010-019912-18,de,o
69,2010-019912-18,los,o
69,2010-019912-18,FAMEs,i
69,2010-019912-18,permitidos,o
69,2010-019912-18,como,o
69,2010-019912-18,minimo,o
69,2010-019912-18,8,o
69,2010-019912-18,semanas,o
69,2010-019912-18,antes,o
69,2010-019912-18,de,o
69,2010-019912-18,la,o
69,2010-019912-18,visita,o
69,2010-019912-18,basal,o
69,2010-019912-18,Criterios,o
69,2010-019912-18,de,o
69,2010-019912-18,exclusion,o
69,2010-019912-18,Pacientes,o
69,2010-019912-18,sometidos,o
69,2010-019912-18,a,o
69,2010-019912-18,intervenciones,i
69,2010-019912-18,de,i
69,2010-019912-18,cirugia,i
69,2010-019912-18,mayor,i
69,2010-019912-18,incluyendo,o
69,2010-019912-18,cirugia,i
69,2010-019912-18,articular,i
69,2010-019912-18,en,o
69,2010-019912-18,las,o
69,2010-019912-18,8,o
69,2010-019912-18,semanas,o
69,2010-019912-18,previas,o
69,2010-019912-18,a,o
69,2010-019912-18,la,o
69,2010-019912-18,visita,o
69,2010-019912-18,de,o
69,2010-019912-18,seleccion,o
69,2010-019912-18,o,o
69,2010-019912-18,que,o
69,2010-019912-18,tengan,o
69,2010-019912-18,previsto,o
69,2010-019912-18,someterse,o
69,2010-019912-18,a,o
69,2010-019912-18,una,o
69,2010-019912-18,intervencion,i
69,2010-019912-18,de,o
69,2010-019912-18,este,o
69,2010-019912-18,tipo,o
69,2010-019912-18,en,o
69,2010-019912-18,los,o
69,2010-019912-18,6,o
69,2010-019912-18,meses,o
69,2010-019912-18,siguientes,o
69,2010-019912-18,a,o
69,2010-019912-18,la,o
69,2010-019912-18,randomizacion,i
69,2010-019912-18,Enfermedad,i
69,2010-019912-18,reumatica,i
69,2010-019912-18,autoinmune,i
69,2010-019912-18,distinta,o
69,2010-019912-18,de,o
69,2010-019912-18,AR,i
69,2010-019912-18,Se,o
69,2010-019912-18,permite,o
69,2010-019912-18,la,o
69,2010-019912-18,inclusion,o
69,2010-019912-18,de,o
69,2010-019912-18,pacientes,o
69,2010-019912-18,con,o
69,2010-019912-18,sindrome,i
69,2010-019912-18,de,i
69,2010-019912-18,Sjögren,i
69,2010-019912-18,secundario,i
69,2010-019912-18,asociado,o
69,2010-019912-18,a,o
69,2010-019912-18,AR,i
69,2010-019912-18,Clase,o
69,2010-019912-18,funcional,o
69,2010-019912-18,IV,o
69,2010-019912-18,definida,o
69,2010-019912-18,de,o
69,2010-019912-18,acuerdo,o
69,2010-019912-18,con,o
69,2010-019912-18,la,o
69,2010-019912-18,Clasificacion,o
69,2010-019912-18,del,o
69,2010-019912-18,ACR,o
69,2010-019912-18,del,o
69,2010-019912-18,Estado,o
69,2010-019912-18,Funcional,o
69,2010-019912-18,en,o
69,2010-019912-18,Artritis,i
69,2010-019912-18,Reumatoide,i
69,2010-019912-18,Artritis,i
69,2010-019912-18,idiopatica,i
69,2010-019912-18,juvenil,i
69,2010-019912-18,AIJ,i
69,2010-019912-18,o,o
69,2010-019912-18,artritis,i
69,2010-019912-18,reumatoide,i
69,2010-019912-18,juvenil,i
69,2010-019912-18,ARJ,i
69,2010-019912-18,yo,o
69,2010-019912-18,AR,i
69,2010-019912-18,diagnosticadas,i
69,2010-019912-18,antes,o
69,2010-019912-18,de,o
69,2010-019912-18,los,o
69,2010-019912-18,16,o
69,2010-019912-18,años,o
69,2010-019912-18,de,o
69,2010-019912-18,edad,o
69,2010-019912-18,Enfermedad,i
69,2010-019912-18,articular,i
69,2010-019912-18,inflamatoria,i
69,2010-019912-18,distinta,o
69,2010-019912-18,de,o
69,2010-019912-18,AR,i
69,2010-019912-18,en,o
69,2010-019912-18,el,o
69,2010-019912-18,pasado,o
69,2010-019912-18,o,o
69,2010-019912-18,en,o
69,2010-019912-18,la,o
69,2010-019912-18,actualidad,o
70,2010-019912-18,EudraCT,o
70,2010-019912-18,Nº,o
70,2010-019912-18,201001991218,o
70,2010-019912-18,Titulo,o
70,2010-019912-18,cientifico,o
70,2010-019912-18,Estudio,o
70,2010-019912-18,randomizado,o
70,2010-019912-18,doble,o
70,2010-019912-18,ciego,o
70,2010-019912-18,con,o
70,2010-019912-18,grupos,o
70,2010-019912-18,de,o
70,2010-019912-18,tratamiento,i
70,2010-019912-18,paralelos,o
70,2010-019912-18,para,o
70,2010-019912-18,evaluar,i
70,2010-019912-18,la,i
70,2010-019912-18,seguridad,i
70,2010-019912-18,y,o
70,2010-019912-18,el,o
70,2010-019912-18,efecto,o
70,2010-019912-18,sobre,o
70,2010-019912-18,el,o
70,2010-019912-18,resultado,o
70,2010-019912-18,clinico,o
70,2010-019912-18,de,o
70,2010-019912-18,tocilizumab,i
70,2010-019912-18,SC,o
70,2010-019912-18,frente,o
70,2010-019912-18,a,o
70,2010-019912-18,placebo,i
70,2010-019912-18,SC,o
70,2010-019912-18,en,o
70,2010-019912-18,combinacion,o
70,2010-019912-18,con,o
70,2010-019912-18,farmacos,i
70,2010-019912-18,antirreumaticos,i
70,2010-019912-18,modificadores,i
70,2010-019912-18,de,i
70,2010-019912-18,la,i
70,2010-019912-18,enfermedad,i
70,2010-019912-18,FAMEs,i
70,2010-019912-18,tradicionales,o
70,2010-019912-18,en,o
70,2010-019912-18,pacientes,o
70,2010-019912-18,con,o
70,2010-019912-18,artritis,i
70,2010-019912-18,reumatoide,i
70,2010-019912-18,activa,o
70,2010-019912-18,moderada,o
70,2010-019912-18,a,o
70,2010-019912-18,severa,o
70,2010-019912-18,Indicacion,o
70,2010-019912-18,cientifica,o
70,2010-019912-18,Artritis,i
70,2010-019912-18,Reumatoide,i
70,2010-019912-18,AR,i
70,2010-019912-18,Criterios,o
70,2010-019912-18,de,o
70,2010-019912-18,inclusion,o
70,2010-019912-18,Presentar,o
70,2010-019912-18,artritis,i
70,2010-019912-18,reumatoide,i
70,2010-019912-18,de,o
70,2010-019912-18,mayor,o
70,2010-019912-18,o,o
70,2010-019912-18,igual,o
70,2010-019912-18,a,o
70,2010-019912-18,6,o
70,2010-019912-18,meses,o
70,2010-019912-18,de,o
70,2010-019912-18,duracion,o
70,2010-019912-18,Recibir,o
70,2010-019912-18,tratamiento,i
70,2010-019912-18,de,i
70,2010-019912-18,forma,i
70,2010-019912-18,ambulatoria,i
70,2010-019912-18,Presentar,o
70,2010-019912-18,un,o
70,2010-019912-18,recuento,o
70,2010-019912-18,de,o
70,2010-019912-18,articulaciones,i
70,2010-019912-18,inflamadas,i
70,2010-019912-18,RAI,o
70,2010-019912-18,mayor,o
70,2010-019912-18,o,o
70,2010-019912-18,igual,o
70,2010-019912-18,a,o
70,2010-019912-18,6,o
70,2010-019912-18,recuento,o
70,2010-019912-18,de,o
70,2010-019912-18,66,o
70,2010-019912-18,articulaciones,i
70,2010-019912-18,y,o
70,2010-019912-18,de,o
70,2010-019912-18,articulaciones,i
70,2010-019912-18,dolorosas,i
70,2010-019912-18,RAD,o
70,2010-019912-18,mayor,o
70,2010-019912-18,o,o
70,2010-019912-18,igual,o
70,2010-019912-18,a,o
70,2010-019912-18,8,o
70,2010-019912-18,recuento,o
70,2010-019912-18,de,o
70,2010-019912-18,68,o
70,2010-019912-18,articulaciones,i
70,2010-019912-18,en,o
70,2010-019912-18,las,o
70,2010-019912-18,visitas,o
70,2010-019912-18,de,o
70,2010-019912-18,seleccion,o
70,2010-019912-18,y,o
70,2010-019912-18,basal,o
70,2010-019912-18,Los,o
70,2010-019912-18,pacientes,o
70,2010-019912-18,deben,o
70,2010-019912-18,estar,o
70,2010-019912-18,recibiendo,o
70,2010-019912-18,tratamiento,i
70,2010-019912-18,con,o
70,2010-019912-18,una,o
70,2010-019912-18,dosis,o
70,2010-019912-18,estable,o
70,2010-019912-18,de,o
70,2010-019912-18,los,o
70,2010-019912-18,FAMEs,i
70,2010-019912-18,permitidos,o
70,2010-019912-18,como,o
70,2010-019912-18,minimo,o
70,2010-019912-18,8,o
70,2010-019912-18,semanas,o
70,2010-019912-18,antes,o
70,2010-019912-18,de,o
70,2010-019912-18,la,o
70,2010-019912-18,visita,o
70,2010-019912-18,basal,o
70,2010-019912-18,Criterios,o
70,2010-019912-18,de,o
70,2010-019912-18,exclusion,o
70,2010-019912-18,Pacientes,o
70,2010-019912-18,sometidos,o
70,2010-019912-18,a,o
70,2010-019912-18,intervenciones,i
70,2010-019912-18,de,i
70,2010-019912-18,cirugia,i
70,2010-019912-18,mayor,i
70,2010-019912-18,incluyendo,o
70,2010-019912-18,cirugia,i
70,2010-019912-18,articular,i
70,2010-019912-18,en,o
70,2010-019912-18,las,o
70,2010-019912-18,8,o
70,2010-019912-18,semanas,o
70,2010-019912-18,previas,o
70,2010-019912-18,a,o
70,2010-019912-18,la,o
70,2010-019912-18,visita,o
70,2010-019912-18,de,o
70,2010-019912-18,seleccion,o
70,2010-019912-18,o,o
70,2010-019912-18,que,o
70,2010-019912-18,tengan,o
70,2010-019912-18,previsto,o
70,2010-019912-18,someterse,o
70,2010-019912-18,a,o
70,2010-019912-18,una,o
70,2010-019912-18,intervencion,i
70,2010-019912-18,de,o
70,2010-019912-18,este,o
70,2010-019912-18,tipo,o
70,2010-019912-18,en,o
70,2010-019912-18,los,o
70,2010-019912-18,6,o
70,2010-019912-18,meses,o
70,2010-019912-18,siguientes,o
70,2010-019912-18,a,o
70,2010-019912-18,la,o
70,2010-019912-18,randomizacion,i
70,2010-019912-18,Enfermedad,i
70,2010-019912-18,reumatica,i
70,2010-019912-18,autoinmune,i
70,2010-019912-18,distinta,o
70,2010-019912-18,de,o
70,2010-019912-18,AR,i
70,2010-019912-18,Se,o
70,2010-019912-18,permite,o
70,2010-019912-18,la,o
70,2010-019912-18,inclusion,o
70,2010-019912-18,de,o
70,2010-019912-18,pacientes,o
70,2010-019912-18,con,o
70,2010-019912-18,sindrome,i
70,2010-019912-18,de,i
70,2010-019912-18,Sjögren,i
70,2010-019912-18,secundario,i
70,2010-019912-18,asociado,o
70,2010-019912-18,a,o
70,2010-019912-18,AR,i
70,2010-019912-18,Clase,o
70,2010-019912-18,funcional,o
70,2010-019912-18,IV,o
70,2010-019912-18,definida,o
70,2010-019912-18,de,o
70,2010-019912-18,acuerdo,o
70,2010-019912-18,con,o
70,2010-019912-18,la,o
70,2010-019912-18,Clasificacion,o
70,2010-019912-18,del,o
70,2010-019912-18,ACR,o
70,2010-019912-18,del,o
70,2010-019912-18,Estado,o
70,2010-019912-18,Funcional,o
70,2010-019912-18,en,o
70,2010-019912-18,Artritis,i
70,2010-019912-18,Reumatoide,i
70,2010-019912-18,Artritis,i
70,2010-019912-18,idiopatica,i
70,2010-019912-18,juvenil,i
70,2010-019912-18,AIJ,i
70,2010-019912-18,o,o
70,2010-019912-18,artritis,i
70,2010-019912-18,reumatoide,i
70,2010-019912-18,juvenil,i
70,2010-019912-18,ARJ,i
70,2010-019912-18,yo,o
70,2010-019912-18,AR,i
70,2010-019912-18,diagnosticadas,i
70,2010-019912-18,antes,o
70,2010-019912-18,de,o
70,2010-019912-18,los,o
70,2010-019912-18,16,o
70,2010-019912-18,años,o
70,2010-019912-18,de,o
70,2010-019912-18,edad,o
70,2010-019912-18,Enfermedad,i
70,2010-019912-18,articular,i
70,2010-019912-18,inflamatoria,i
70,2010-019912-18,distinta,o
70,2010-019912-18,de,o
70,2010-019912-18,AR,i
70,2010-019912-18,en,o
70,2010-019912-18,el,o
70,2010-019912-18,pasado,o
70,2010-019912-18,o,o
70,2010-019912-18,en,o
70,2010-019912-18,la,o
70,2010-019912-18,actualidad,o
71,2010-019912-18,EudraCT,o
71,2010-019912-18,Nº,o
71,2010-019912-18,201001991218,o
71,2010-019912-18,Titulo,o
71,2010-019912-18,cientifico,o
71,2010-019912-18,Estudio,o
71,2010-019912-18,randomizado,o
71,2010-019912-18,doble,o
71,2010-019912-18,ciego,o
71,2010-019912-18,con,o
71,2010-019912-18,grupos,o
71,2010-019912-18,de,o
71,2010-019912-18,tratamiento,i
71,2010-019912-18,paralelos,o
71,2010-019912-18,para,o
71,2010-019912-18,evaluar,i
71,2010-019912-18,la,i
71,2010-019912-18,seguridad,i
71,2010-019912-18,y,o
71,2010-019912-18,el,o
71,2010-019912-18,efecto,o
71,2010-019912-18,sobre,o
71,2010-019912-18,el,o
71,2010-019912-18,resultado,o
71,2010-019912-18,clinico,o
71,2010-019912-18,de,o
71,2010-019912-18,tocilizumab,i
71,2010-019912-18,SC,o
71,2010-019912-18,frente,o
71,2010-019912-18,a,o
71,2010-019912-18,placebo,i
71,2010-019912-18,SC,o
71,2010-019912-18,en,o
71,2010-019912-18,combinacion,o
71,2010-019912-18,con,o
71,2010-019912-18,farmacos,i
71,2010-019912-18,antirreumaticos,i
71,2010-019912-18,modificadores,i
71,2010-019912-18,de,i
71,2010-019912-18,la,i
71,2010-019912-18,enfermedad,i
71,2010-019912-18,FAMEs,i
71,2010-019912-18,tradicionales,o
71,2010-019912-18,en,o
71,2010-019912-18,pacientes,o
71,2010-019912-18,con,o
71,2010-019912-18,artritis,i
71,2010-019912-18,reumatoide,i
71,2010-019912-18,activa,o
71,2010-019912-18,moderada,o
71,2010-019912-18,a,o
71,2010-019912-18,severa,o
71,2010-019912-18,Indicacion,o
71,2010-019912-18,cientifica,o
71,2010-019912-18,Artritis,i
71,2010-019912-18,Reumatoide,i
71,2010-019912-18,AR,i
71,2010-019912-18,Criterios,o
71,2010-019912-18,de,o
71,2010-019912-18,inclusion,o
71,2010-019912-18,Presentar,o
71,2010-019912-18,artritis,i
71,2010-019912-18,reumatoide,i
71,2010-019912-18,de,o
71,2010-019912-18,mayor,o
71,2010-019912-18,o,o
71,2010-019912-18,igual,o
71,2010-019912-18,a,o
71,2010-019912-18,6,o
71,2010-019912-18,meses,o
71,2010-019912-18,de,o
71,2010-019912-18,duracion,o
71,2010-019912-18,Recibir,o
71,2010-019912-18,tratamiento,i
71,2010-019912-18,de,i
71,2010-019912-18,forma,i
71,2010-019912-18,ambulatoria,i
71,2010-019912-18,Presentar,o
71,2010-019912-18,un,o
71,2010-019912-18,recuento,o
71,2010-019912-18,de,o
71,2010-019912-18,articulaciones,i
71,2010-019912-18,inflamadas,i
71,2010-019912-18,RAI,o
71,2010-019912-18,mayor,o
71,2010-019912-18,o,o
71,2010-019912-18,igual,o
71,2010-019912-18,a,o
71,2010-019912-18,6,o
71,2010-019912-18,recuento,o
71,2010-019912-18,de,o
71,2010-019912-18,66,o
71,2010-019912-18,articulaciones,i
71,2010-019912-18,y,o
71,2010-019912-18,de,o
71,2010-019912-18,articulaciones,i
71,2010-019912-18,dolorosas,i
71,2010-019912-18,RAD,o
71,2010-019912-18,mayor,o
71,2010-019912-18,o,o
71,2010-019912-18,igual,o
71,2010-019912-18,a,o
71,2010-019912-18,8,o
71,2010-019912-18,recuento,o
71,2010-019912-18,de,o
71,2010-019912-18,68,o
71,2010-019912-18,articulaciones,i
71,2010-019912-18,en,o
71,2010-019912-18,las,o
71,2010-019912-18,visitas,o
71,2010-019912-18,de,o
71,2010-019912-18,seleccion,o
71,2010-019912-18,y,o
71,2010-019912-18,basal,o
71,2010-019912-18,Los,o
71,2010-019912-18,pacientes,o
71,2010-019912-18,deben,o
71,2010-019912-18,estar,o
71,2010-019912-18,recibiendo,o
71,2010-019912-18,tratamiento,i
71,2010-019912-18,con,o
71,2010-019912-18,una,o
71,2010-019912-18,dosis,o
71,2010-019912-18,estable,o
71,2010-019912-18,de,o
71,2010-019912-18,los,o
71,2010-019912-18,FAMEs,i
71,2010-019912-18,permitidos,o
71,2010-019912-18,como,o
71,2010-019912-18,minimo,o
71,2010-019912-18,8,o
71,2010-019912-18,semanas,o
71,2010-019912-18,antes,o
71,2010-019912-18,de,o
71,2010-019912-18,la,o
71,2010-019912-18,visita,o
71,2010-019912-18,basal,o
71,2010-019912-18,Criterios,o
71,2010-019912-18,de,o
71,2010-019912-18,exclusion,o
71,2010-019912-18,Pacientes,o
71,2010-019912-18,sometidos,o
71,2010-019912-18,a,o
71,2010-019912-18,intervenciones,i
71,2010-019912-18,de,i
71,2010-019912-18,cirugia,i
71,2010-019912-18,mayor,i
71,2010-019912-18,incluyendo,o
71,2010-019912-18,cirugia,i
71,2010-019912-18,articular,i
71,2010-019912-18,en,o
71,2010-019912-18,las,o
71,2010-019912-18,8,o
71,2010-019912-18,semanas,o
71,2010-019912-18,previas,o
71,2010-019912-18,a,o
71,2010-019912-18,la,o
71,2010-019912-18,visita,o
71,2010-019912-18,de,o
71,2010-019912-18,seleccion,o
71,2010-019912-18,o,o
71,2010-019912-18,que,o
71,2010-019912-18,tengan,o
71,2010-019912-18,previsto,o
71,2010-019912-18,someterse,o
71,2010-019912-18,a,o
71,2010-019912-18,una,o
71,2010-019912-18,intervencion,i
71,2010-019912-18,de,o
71,2010-019912-18,este,o
71,2010-019912-18,tipo,o
71,2010-019912-18,en,o
71,2010-019912-18,los,o
71,2010-019912-18,6,o
71,2010-019912-18,meses,o
71,2010-019912-18,siguientes,o
71,2010-019912-18,a,o
71,2010-019912-18,la,o
71,2010-019912-18,randomizacion,i
71,2010-019912-18,Enfermedad,i
71,2010-019912-18,reumatica,i
71,2010-019912-18,autoinmune,i
71,2010-019912-18,distinta,o
71,2010-019912-18,de,o
71,2010-019912-18,AR,i
71,2010-019912-18,Se,o
71,2010-019912-18,permite,o
71,2010-019912-18,la,o
71,2010-019912-18,inclusion,o
71,2010-019912-18,de,o
71,2010-019912-18,pacientes,o
71,2010-019912-18,con,o
71,2010-019912-18,sindrome,i
71,2010-019912-18,de,i
71,2010-019912-18,Sjögren,i
71,2010-019912-18,secundario,i
71,2010-019912-18,asociado,o
71,2010-019912-18,a,o
71,2010-019912-18,AR,i
71,2010-019912-18,Clase,o
71,2010-019912-18,funcional,o
71,2010-019912-18,IV,o
71,2010-019912-18,definida,o
71,2010-019912-18,de,o
71,2010-019912-18,acuerdo,o
71,2010-019912-18,con,o
71,2010-019912-18,la,o
71,2010-019912-18,Clasificacion,o
71,2010-019912-18,del,o
71,2010-019912-18,ACR,o
71,2010-019912-18,del,o
71,2010-019912-18,Estado,o
71,2010-019912-18,Funcional,o
71,2010-019912-18,en,o
71,2010-019912-18,Artritis,i
71,2010-019912-18,Reumatoide,i
71,2010-019912-18,Artritis,i
71,2010-019912-18,idiopatica,i
71,2010-019912-18,juvenil,i
71,2010-019912-18,AIJ,i
71,2010-019912-18,o,o
71,2010-019912-18,artritis,i
71,2010-019912-18,reumatoide,i
71,2010-019912-18,juvenil,i
71,2010-019912-18,ARJ,i
71,2010-019912-18,yo,o
71,2010-019912-18,AR,i
71,2010-019912-18,diagnosticadas,i
71,2010-019912-18,antes,o
71,2010-019912-18,de,o
71,2010-019912-18,los,o
71,2010-019912-18,16,o
71,2010-019912-18,años,o
71,2010-019912-18,de,o
71,2010-019912-18,edad,o
71,2010-019912-18,Enfermedad,i
71,2010-019912-18,articular,i
71,2010-019912-18,inflamatoria,i
71,2010-019912-18,distinta,o
71,2010-019912-18,de,o
71,2010-019912-18,AR,i
71,2010-019912-18,en,o
71,2010-019912-18,el,o
71,2010-019912-18,pasado,o
71,2010-019912-18,o,o
71,2010-019912-18,en,o
71,2010-019912-18,la,o
71,2010-019912-18,actualidad,o
72,2010-019912-18,EudraCT,o
72,2010-019912-18,Nº,o
72,2010-019912-18,201001991218,o
72,2010-019912-18,Titulo,o
72,2010-019912-18,cientifico,o
72,2010-019912-18,Estudio,o
72,2010-019912-18,randomizado,o
72,2010-019912-18,doble,o
72,2010-019912-18,ciego,o
72,2010-019912-18,con,o
72,2010-019912-18,grupos,o
72,2010-019912-18,de,o
72,2010-019912-18,tratamiento,i
72,2010-019912-18,paralelos,o
72,2010-019912-18,para,o
72,2010-019912-18,evaluar,i
72,2010-019912-18,la,i
72,2010-019912-18,seguridad,i
72,2010-019912-18,y,o
72,2010-019912-18,el,o
72,2010-019912-18,efecto,o
72,2010-019912-18,sobre,o
72,2010-019912-18,el,o
72,2010-019912-18,resultado,o
72,2010-019912-18,clinico,o
72,2010-019912-18,de,o
72,2010-019912-18,tocilizumab,i
72,2010-019912-18,SC,o
72,2010-019912-18,frente,o
72,2010-019912-18,a,o
72,2010-019912-18,placebo,i
72,2010-019912-18,SC,o
72,2010-019912-18,en,o
72,2010-019912-18,combinacion,o
72,2010-019912-18,con,o
72,2010-019912-18,farmacos,i
72,2010-019912-18,antirreumaticos,i
72,2010-019912-18,modificadores,i
72,2010-019912-18,de,i
72,2010-019912-18,la,i
72,2010-019912-18,enfermedad,i
72,2010-019912-18,FAMEs,i
72,2010-019912-18,tradicionales,o
72,2010-019912-18,en,o
72,2010-019912-18,pacientes,o
72,2010-019912-18,con,o
72,2010-019912-18,artritis,i
72,2010-019912-18,reumatoide,i
72,2010-019912-18,activa,o
72,2010-019912-18,moderada,o
72,2010-019912-18,a,o
72,2010-019912-18,severa,o
72,2010-019912-18,Indicacion,o
72,2010-019912-18,cientifica,o
72,2010-019912-18,Artritis,i
72,2010-019912-18,Reumatoide,i
72,2010-019912-18,AR,i
72,2010-019912-18,Criterios,o
72,2010-019912-18,de,o
72,2010-019912-18,inclusion,o
72,2010-019912-18,Presentar,o
72,2010-019912-18,artritis,i
72,2010-019912-18,reumatoide,i
72,2010-019912-18,de,o
72,2010-019912-18,mayor,o
72,2010-019912-18,o,o
72,2010-019912-18,igual,o
72,2010-019912-18,a,o
72,2010-019912-18,6,o
72,2010-019912-18,meses,o
72,2010-019912-18,de,o
72,2010-019912-18,duracion,o
72,2010-019912-18,Recibir,o
72,2010-019912-18,tratamiento,i
72,2010-019912-18,de,i
72,2010-019912-18,forma,i
72,2010-019912-18,ambulatoria,i
72,2010-019912-18,Presentar,o
72,2010-019912-18,un,o
72,2010-019912-18,recuento,o
72,2010-019912-18,de,o
72,2010-019912-18,articulaciones,i
72,2010-019912-18,inflamadas,i
72,2010-019912-18,RAI,o
72,2010-019912-18,mayor,o
72,2010-019912-18,o,o
72,2010-019912-18,igual,o
72,2010-019912-18,a,o
72,2010-019912-18,6,o
72,2010-019912-18,recuento,o
72,2010-019912-18,de,o
72,2010-019912-18,66,o
72,2010-019912-18,articulaciones,i
72,2010-019912-18,y,o
72,2010-019912-18,de,o
72,2010-019912-18,articulaciones,i
72,2010-019912-18,dolorosas,i
72,2010-019912-18,RAD,o
72,2010-019912-18,mayor,o
72,2010-019912-18,o,o
72,2010-019912-18,igual,o
72,2010-019912-18,a,o
72,2010-019912-18,8,o
72,2010-019912-18,recuento,o
72,2010-019912-18,de,o
72,2010-019912-18,68,o
72,2010-019912-18,articulaciones,i
72,2010-019912-18,en,o
72,2010-019912-18,las,o
72,2010-019912-18,visitas,o
72,2010-019912-18,de,o
72,2010-019912-18,seleccion,o
72,2010-019912-18,y,o
72,2010-019912-18,basal,o
72,2010-019912-18,Los,o
72,2010-019912-18,pacientes,o
72,2010-019912-18,deben,o
72,2010-019912-18,estar,o
72,2010-019912-18,recibiendo,o
72,2010-019912-18,tratamiento,i
72,2010-019912-18,con,o
72,2010-019912-18,una,o
72,2010-019912-18,dosis,o
72,2010-019912-18,estable,o
72,2010-019912-18,de,o
72,2010-019912-18,los,o
72,2010-019912-18,FAMEs,i
72,2010-019912-18,permitidos,o
72,2010-019912-18,como,o
72,2010-019912-18,minimo,o
72,2010-019912-18,8,o
72,2010-019912-18,semanas,o
72,2010-019912-18,antes,o
72,2010-019912-18,de,o
72,2010-019912-18,la,o
72,2010-019912-18,visita,o
72,2010-019912-18,basal,o
72,2010-019912-18,Criterios,o
72,2010-019912-18,de,o
72,2010-019912-18,exclusion,o
72,2010-019912-18,Pacientes,o
72,2010-019912-18,sometidos,o
72,2010-019912-18,a,o
72,2010-019912-18,intervenciones,i
72,2010-019912-18,de,i
72,2010-019912-18,cirugia,i
72,2010-019912-18,mayor,i
72,2010-019912-18,incluyendo,o
72,2010-019912-18,cirugia,i
72,2010-019912-18,articular,i
72,2010-019912-18,en,o
72,2010-019912-18,las,o
72,2010-019912-18,8,o
72,2010-019912-18,semanas,o
72,2010-019912-18,previas,o
72,2010-019912-18,a,o
72,2010-019912-18,la,o
72,2010-019912-18,visita,o
72,2010-019912-18,de,o
72,2010-019912-18,seleccion,o
72,2010-019912-18,o,o
72,2010-019912-18,que,o
72,2010-019912-18,tengan,o
72,2010-019912-18,previsto,o
72,2010-019912-18,someterse,o
72,2010-019912-18,a,o
72,2010-019912-18,una,o
72,2010-019912-18,intervencion,i
72,2010-019912-18,de,o
72,2010-019912-18,este,o
72,2010-019912-18,tipo,o
72,2010-019912-18,en,o
72,2010-019912-18,los,o
72,2010-019912-18,6,o
72,2010-019912-18,meses,o
72,2010-019912-18,siguientes,o
72,2010-019912-18,a,o
72,2010-019912-18,la,o
72,2010-019912-18,randomizacion,i
72,2010-019912-18,Enfermedad,i
72,2010-019912-18,reumatica,i
72,2010-019912-18,autoinmune,i
72,2010-019912-18,distinta,o
72,2010-019912-18,de,o
72,2010-019912-18,AR,i
72,2010-019912-18,Se,o
72,2010-019912-18,permite,o
72,2010-019912-18,la,o
72,2010-019912-18,inclusion,o
72,2010-019912-18,de,o
72,2010-019912-18,pacientes,o
72,2010-019912-18,con,o
72,2010-019912-18,sindrome,i
72,2010-019912-18,de,i
72,2010-019912-18,Sjögren,i
72,2010-019912-18,secundario,i
72,2010-019912-18,asociado,o
72,2010-019912-18,a,o
72,2010-019912-18,AR,i
72,2010-019912-18,Clase,o
72,2010-019912-18,funcional,o
72,2010-019912-18,IV,o
72,2010-019912-18,definida,o
72,2010-019912-18,de,o
72,2010-019912-18,acuerdo,o
72,2010-019912-18,con,o
72,2010-019912-18,la,o
72,2010-019912-18,Clasificacion,o
72,2010-019912-18,del,o
72,2010-019912-18,ACR,o
72,2010-019912-18,del,o
72,2010-019912-18,Estado,o
72,2010-019912-18,Funcional,o
72,2010-019912-18,en,o
72,2010-019912-18,Artritis,i
72,2010-019912-18,Reumatoide,i
72,2010-019912-18,Artritis,i
72,2010-019912-18,idiopatica,i
72,2010-019912-18,juvenil,i
72,2010-019912-18,AIJ,i
72,2010-019912-18,o,o
72,2010-019912-18,artritis,i
72,2010-019912-18,reumatoide,i
72,2010-019912-18,juvenil,i
72,2010-019912-18,ARJ,i
72,2010-019912-18,yo,o
72,2010-019912-18,AR,i
72,2010-019912-18,diagnosticadas,i
72,2010-019912-18,antes,o
72,2010-019912-18,de,o
72,2010-019912-18,los,o
72,2010-019912-18,16,o
72,2010-019912-18,años,o
72,2010-019912-18,de,o
72,2010-019912-18,edad,o
72,2010-019912-18,Enfermedad,i
72,2010-019912-18,articular,i
72,2010-019912-18,inflamatoria,i
72,2010-019912-18,distinta,o
72,2010-019912-18,de,o
72,2010-019912-18,AR,i
72,2010-019912-18,en,o
72,2010-019912-18,el,o
72,2010-019912-18,pasado,o
72,2010-019912-18,o,o
72,2010-019912-18,en,o
72,2010-019912-18,la,o
72,2010-019912-18,actualidad,o
73,2010-019912-18,EudraCT,o
73,2010-019912-18,Nº,o
73,2010-019912-18,201001991218,o
73,2010-019912-18,Titulo,o
73,2010-019912-18,cientifico,o
73,2010-019912-18,Estudio,o
73,2010-019912-18,randomizado,o
73,2010-019912-18,doble,o
73,2010-019912-18,ciego,o
73,2010-019912-18,con,o
73,2010-019912-18,grupos,o
73,2010-019912-18,de,o
73,2010-019912-18,tratamiento,i
73,2010-019912-18,paralelos,o
73,2010-019912-18,para,o
73,2010-019912-18,evaluar,i
73,2010-019912-18,la,i
73,2010-019912-18,seguridad,i
73,2010-019912-18,y,o
73,2010-019912-18,el,o
73,2010-019912-18,efecto,o
73,2010-019912-18,sobre,o
73,2010-019912-18,el,o
73,2010-019912-18,resultado,o
73,2010-019912-18,clinico,o
73,2010-019912-18,de,o
73,2010-019912-18,tocilizumab,i
73,2010-019912-18,SC,o
73,2010-019912-18,frente,o
73,2010-019912-18,a,o
73,2010-019912-18,placebo,i
73,2010-019912-18,SC,o
73,2010-019912-18,en,o
73,2010-019912-18,combinacion,o
73,2010-019912-18,con,o
73,2010-019912-18,farmacos,i
73,2010-019912-18,antirreumaticos,i
73,2010-019912-18,modificadores,i
73,2010-019912-18,de,i
73,2010-019912-18,la,i
73,2010-019912-18,enfermedad,i
73,2010-019912-18,FAMEs,i
73,2010-019912-18,tradicionales,o
73,2010-019912-18,en,o
73,2010-019912-18,pacientes,o
73,2010-019912-18,con,o
73,2010-019912-18,artritis,i
73,2010-019912-18,reumatoide,i
73,2010-019912-18,activa,o
73,2010-019912-18,moderada,o
73,2010-019912-18,a,o
73,2010-019912-18,severa,o
73,2010-019912-18,Indicacion,o
73,2010-019912-18,cientifica,o
73,2010-019912-18,Artritis,i
73,2010-019912-18,Reumatoide,i
73,2010-019912-18,AR,i
73,2010-019912-18,Criterios,o
73,2010-019912-18,de,o
73,2010-019912-18,inclusion,o
73,2010-019912-18,Presentar,o
73,2010-019912-18,artritis,i
73,2010-019912-18,reumatoide,i
73,2010-019912-18,de,o
73,2010-019912-18,mayor,o
73,2010-019912-18,o,o
73,2010-019912-18,igual,o
73,2010-019912-18,a,o
73,2010-019912-18,6,o
73,2010-019912-18,meses,o
73,2010-019912-18,de,o
73,2010-019912-18,duracion,o
73,2010-019912-18,Recibir,o
73,2010-019912-18,tratamiento,i
73,2010-019912-18,de,i
73,2010-019912-18,forma,i
73,2010-019912-18,ambulatoria,i
73,2010-019912-18,Presentar,o
73,2010-019912-18,un,o
73,2010-019912-18,recuento,o
73,2010-019912-18,de,o
73,2010-019912-18,articulaciones,i
73,2010-019912-18,inflamadas,i
73,2010-019912-18,RAI,o
73,2010-019912-18,mayor,o
73,2010-019912-18,o,o
73,2010-019912-18,igual,o
73,2010-019912-18,a,o
73,2010-019912-18,6,o
73,2010-019912-18,recuento,o
73,2010-019912-18,de,o
73,2010-019912-18,66,o
73,2010-019912-18,articulaciones,i
73,2010-019912-18,y,o
73,2010-019912-18,de,o
73,2010-019912-18,articulaciones,i
73,2010-019912-18,dolorosas,i
73,2010-019912-18,RAD,o
73,2010-019912-18,mayor,o
73,2010-019912-18,o,o
73,2010-019912-18,igual,o
73,2010-019912-18,a,o
73,2010-019912-18,8,o
73,2010-019912-18,recuento,o
73,2010-019912-18,de,o
73,2010-019912-18,68,o
73,2010-019912-18,articulaciones,i
73,2010-019912-18,en,o
73,2010-019912-18,las,o
73,2010-019912-18,visitas,o
73,2010-019912-18,de,o
73,2010-019912-18,seleccion,o
73,2010-019912-18,y,o
73,2010-019912-18,basal,o
73,2010-019912-18,Los,o
73,2010-019912-18,pacientes,o
73,2010-019912-18,deben,o
73,2010-019912-18,estar,o
73,2010-019912-18,recibiendo,o
73,2010-019912-18,tratamiento,i
73,2010-019912-18,con,o
73,2010-019912-18,una,o
73,2010-019912-18,dosis,o
73,2010-019912-18,estable,o
73,2010-019912-18,de,o
73,2010-019912-18,los,o
73,2010-019912-18,FAMEs,i
73,2010-019912-18,permitidos,o
73,2010-019912-18,como,o
73,2010-019912-18,minimo,o
73,2010-019912-18,8,o
73,2010-019912-18,semanas,o
73,2010-019912-18,antes,o
73,2010-019912-18,de,o
73,2010-019912-18,la,o
73,2010-019912-18,visita,o
73,2010-019912-18,basal,o
73,2010-019912-18,Criterios,o
73,2010-019912-18,de,o
73,2010-019912-18,exclusion,o
73,2010-019912-18,Pacientes,o
73,2010-019912-18,sometidos,o
73,2010-019912-18,a,o
73,2010-019912-18,intervenciones,i
73,2010-019912-18,de,i
73,2010-019912-18,cirugia,i
73,2010-019912-18,mayor,i
73,2010-019912-18,incluyendo,o
73,2010-019912-18,cirugia,i
73,2010-019912-18,articular,i
73,2010-019912-18,en,o
73,2010-019912-18,las,o
73,2010-019912-18,8,o
73,2010-019912-18,semanas,o
73,2010-019912-18,previas,o
73,2010-019912-18,a,o
73,2010-019912-18,la,o
73,2010-019912-18,visita,o
73,2010-019912-18,de,o
73,2010-019912-18,seleccion,o
73,2010-019912-18,o,o
73,2010-019912-18,que,o
73,2010-019912-18,tengan,o
73,2010-019912-18,previsto,o
73,2010-019912-18,someterse,o
73,2010-019912-18,a,o
73,2010-019912-18,una,o
73,2010-019912-18,intervencion,i
73,2010-019912-18,de,o
73,2010-019912-18,este,o
73,2010-019912-18,tipo,o
73,2010-019912-18,en,o
73,2010-019912-18,los,o
73,2010-019912-18,6,o
73,2010-019912-18,meses,o
73,2010-019912-18,siguientes,o
73,2010-019912-18,a,o
73,2010-019912-18,la,o
73,2010-019912-18,randomizacion,i
73,2010-019912-18,Enfermedad,i
73,2010-019912-18,reumatica,i
73,2010-019912-18,autoinmune,i
73,2010-019912-18,distinta,o
73,2010-019912-18,de,o
73,2010-019912-18,AR,i
73,2010-019912-18,Se,o
73,2010-019912-18,permite,o
73,2010-019912-18,la,o
73,2010-019912-18,inclusion,o
73,2010-019912-18,de,o
73,2010-019912-18,pacientes,o
73,2010-019912-18,con,o
73,2010-019912-18,sindrome,i
73,2010-019912-18,de,i
73,2010-019912-18,Sjögren,i
73,2010-019912-18,secundario,i
73,2010-019912-18,asociado,o
73,2010-019912-18,a,o
73,2010-019912-18,AR,i
73,2010-019912-18,Clase,o
73,2010-019912-18,funcional,o
73,2010-019912-18,IV,o
73,2010-019912-18,definida,o
73,2010-019912-18,de,o
73,2010-019912-18,acuerdo,o
73,2010-019912-18,con,o
73,2010-019912-18,la,o
73,2010-019912-18,Clasificacion,o
73,2010-019912-18,del,o
73,2010-019912-18,ACR,o
73,2010-019912-18,del,o
73,2010-019912-18,Estado,o
73,2010-019912-18,Funcional,o
73,2010-019912-18,en,o
73,2010-019912-18,Artritis,i
73,2010-019912-18,Reumatoide,i
73,2010-019912-18,Artritis,i
73,2010-019912-18,idiopatica,i
73,2010-019912-18,juvenil,i
73,2010-019912-18,AIJ,i
73,2010-019912-18,o,o
73,2010-019912-18,artritis,i
73,2010-019912-18,reumatoide,i
73,2010-019912-18,juvenil,i
73,2010-019912-18,ARJ,i
73,2010-019912-18,yo,o
73,2010-019912-18,AR,i
73,2010-019912-18,diagnosticadas,i
73,2010-019912-18,antes,o
73,2010-019912-18,de,o
73,2010-019912-18,los,o
73,2010-019912-18,16,o
73,2010-019912-18,años,o
73,2010-019912-18,de,o
73,2010-019912-18,edad,o
73,2010-019912-18,Enfermedad,i
73,2010-019912-18,articular,i
73,2010-019912-18,inflamatoria,i
73,2010-019912-18,distinta,o
73,2010-019912-18,de,o
73,2010-019912-18,AR,i
73,2010-019912-18,en,o
73,2010-019912-18,el,o
73,2010-019912-18,pasado,o
73,2010-019912-18,o,o
73,2010-019912-18,en,o
73,2010-019912-18,la,o
73,2010-019912-18,actualidad,o
74,2010-019912-18,EudraCT,o
74,2010-019912-18,Nº,o
74,2010-019912-18,201001991218,o
74,2010-019912-18,Titulo,o
74,2010-019912-18,cientifico,o
74,2010-019912-18,Estudio,o
74,2010-019912-18,randomizado,o
74,2010-019912-18,doble,o
74,2010-019912-18,ciego,o
74,2010-019912-18,con,o
74,2010-019912-18,grupos,o
74,2010-019912-18,de,o
74,2010-019912-18,tratamiento,i
74,2010-019912-18,paralelos,o
74,2010-019912-18,para,o
74,2010-019912-18,evaluar,i
74,2010-019912-18,la,i
74,2010-019912-18,seguridad,i
74,2010-019912-18,y,o
74,2010-019912-18,el,o
74,2010-019912-18,efecto,o
74,2010-019912-18,sobre,o
74,2010-019912-18,el,o
74,2010-019912-18,resultado,o
74,2010-019912-18,clinico,o
74,2010-019912-18,de,o
74,2010-019912-18,tocilizumab,i
74,2010-019912-18,SC,o
74,2010-019912-18,frente,o
74,2010-019912-18,a,o
74,2010-019912-18,placebo,i
74,2010-019912-18,SC,o
74,2010-019912-18,en,o
74,2010-019912-18,combinacion,o
74,2010-019912-18,con,o
74,2010-019912-18,farmacos,i
74,2010-019912-18,antirreumaticos,i
74,2010-019912-18,modificadores,i
74,2010-019912-18,de,i
74,2010-019912-18,la,i
74,2010-019912-18,enfermedad,i
74,2010-019912-18,FAMEs,i
74,2010-019912-18,tradicionales,o
74,2010-019912-18,en,o
74,2010-019912-18,pacientes,o
74,2010-019912-18,con,o
74,2010-019912-18,artritis,i
74,2010-019912-18,reumatoide,i
74,2010-019912-18,activa,o
74,2010-019912-18,moderada,o
74,2010-019912-18,a,o
74,2010-019912-18,severa,o
74,2010-019912-18,Indicacion,o
74,2010-019912-18,cientifica,o
74,2010-019912-18,Artritis,i
74,2010-019912-18,Reumatoide,i
74,2010-019912-18,AR,i
74,2010-019912-18,Criterios,o
74,2010-019912-18,de,o
74,2010-019912-18,inclusion,o
74,2010-019912-18,Presentar,o
74,2010-019912-18,artritis,i
74,2010-019912-18,reumatoide,i
74,2010-019912-18,de,o
74,2010-019912-18,mayor,o
74,2010-019912-18,o,o
74,2010-019912-18,igual,o
74,2010-019912-18,a,o
74,2010-019912-18,6,o
74,2010-019912-18,meses,o
74,2010-019912-18,de,o
74,2010-019912-18,duracion,o
74,2010-019912-18,Recibir,o
74,2010-019912-18,tratamiento,i
74,2010-019912-18,de,i
74,2010-019912-18,forma,i
74,2010-019912-18,ambulatoria,i
74,2010-019912-18,Presentar,o
74,2010-019912-18,un,o
74,2010-019912-18,recuento,o
74,2010-019912-18,de,o
74,2010-019912-18,articulaciones,i
74,2010-019912-18,inflamadas,i
74,2010-019912-18,RAI,o
74,2010-019912-18,mayor,o
74,2010-019912-18,o,o
74,2010-019912-18,igual,o
74,2010-019912-18,a,o
74,2010-019912-18,6,o
74,2010-019912-18,recuento,o
74,2010-019912-18,de,o
74,2010-019912-18,66,o
74,2010-019912-18,articulaciones,i
74,2010-019912-18,y,o
74,2010-019912-18,de,o
74,2010-019912-18,articulaciones,i
74,2010-019912-18,dolorosas,i
74,2010-019912-18,RAD,o
74,2010-019912-18,mayor,o
74,2010-019912-18,o,o
74,2010-019912-18,igual,o
74,2010-019912-18,a,o
74,2010-019912-18,8,o
74,2010-019912-18,recuento,o
74,2010-019912-18,de,o
74,2010-019912-18,68,o
74,2010-019912-18,articulaciones,i
74,2010-019912-18,en,o
74,2010-019912-18,las,o
74,2010-019912-18,visitas,o
74,2010-019912-18,de,o
74,2010-019912-18,seleccion,o
74,2010-019912-18,y,o
74,2010-019912-18,basal,o
74,2010-019912-18,Los,o
74,2010-019912-18,pacientes,o
74,2010-019912-18,deben,o
74,2010-019912-18,estar,o
74,2010-019912-18,recibiendo,o
74,2010-019912-18,tratamiento,i
74,2010-019912-18,con,o
74,2010-019912-18,una,o
74,2010-019912-18,dosis,o
74,2010-019912-18,estable,o
74,2010-019912-18,de,o
74,2010-019912-18,los,o
74,2010-019912-18,FAMEs,i
74,2010-019912-18,permitidos,o
74,2010-019912-18,como,o
74,2010-019912-18,minimo,o
74,2010-019912-18,8,o
74,2010-019912-18,semanas,o
74,2010-019912-18,antes,o
74,2010-019912-18,de,o
74,2010-019912-18,la,o
74,2010-019912-18,visita,o
74,2010-019912-18,basal,o
74,2010-019912-18,Criterios,o
74,2010-019912-18,de,o
74,2010-019912-18,exclusion,o
74,2010-019912-18,Pacientes,o
74,2010-019912-18,sometidos,o
74,2010-019912-18,a,o
74,2010-019912-18,intervenciones,i
74,2010-019912-18,de,i
74,2010-019912-18,cirugia,i
74,2010-019912-18,mayor,i
74,2010-019912-18,incluyendo,o
74,2010-019912-18,cirugia,i
74,2010-019912-18,articular,i
74,2010-019912-18,en,o
74,2010-019912-18,las,o
74,2010-019912-18,8,o
74,2010-019912-18,semanas,o
74,2010-019912-18,previas,o
74,2010-019912-18,a,o
74,2010-019912-18,la,o
74,2010-019912-18,visita,o
74,2010-019912-18,de,o
74,2010-019912-18,seleccion,o
74,2010-019912-18,o,o
74,2010-019912-18,que,o
74,2010-019912-18,tengan,o
74,2010-019912-18,previsto,o
74,2010-019912-18,someterse,o
74,2010-019912-18,a,o
74,2010-019912-18,una,o
74,2010-019912-18,intervencion,i
74,2010-019912-18,de,o
74,2010-019912-18,este,o
74,2010-019912-18,tipo,o
74,2010-019912-18,en,o
74,2010-019912-18,los,o
74,2010-019912-18,6,o
74,2010-019912-18,meses,o
74,2010-019912-18,siguientes,o
74,2010-019912-18,a,o
74,2010-019912-18,la,o
74,2010-019912-18,randomizacion,i
74,2010-019912-18,Enfermedad,i
74,2010-019912-18,reumatica,i
74,2010-019912-18,autoinmune,i
74,2010-019912-18,distinta,o
74,2010-019912-18,de,o
74,2010-019912-18,AR,i
74,2010-019912-18,Se,o
74,2010-019912-18,permite,o
74,2010-019912-18,la,o
74,2010-019912-18,inclusion,o
74,2010-019912-18,de,o
74,2010-019912-18,pacientes,o
74,2010-019912-18,con,o
74,2010-019912-18,sindrome,i
74,2010-019912-18,de,i
74,2010-019912-18,Sjögren,i
74,2010-019912-18,secundario,i
74,2010-019912-18,asociado,o
74,2010-019912-18,a,o
74,2010-019912-18,AR,i
74,2010-019912-18,Clase,o
74,2010-019912-18,funcional,o
74,2010-019912-18,IV,o
74,2010-019912-18,definida,o
74,2010-019912-18,de,o
74,2010-019912-18,acuerdo,o
74,2010-019912-18,con,o
74,2010-019912-18,la,o
74,2010-019912-18,Clasificacion,o
74,2010-019912-18,del,o
74,2010-019912-18,ACR,o
74,2010-019912-18,del,o
74,2010-019912-18,Estado,o
74,2010-019912-18,Funcional,o
74,2010-019912-18,en,o
74,2010-019912-18,Artritis,i
74,2010-019912-18,Reumatoide,i
74,2010-019912-18,Artritis,i
74,2010-019912-18,idiopatica,i
74,2010-019912-18,juvenil,i
74,2010-019912-18,AIJ,i
74,2010-019912-18,o,o
74,2010-019912-18,artritis,i
74,2010-019912-18,reumatoide,i
74,2010-019912-18,juvenil,i
74,2010-019912-18,ARJ,i
74,2010-019912-18,yo,o
74,2010-019912-18,AR,i
74,2010-019912-18,diagnosticadas,i
74,2010-019912-18,antes,o
74,2010-019912-18,de,o
74,2010-019912-18,los,o
74,2010-019912-18,16,o
74,2010-019912-18,años,o
74,2010-019912-18,de,o
74,2010-019912-18,edad,o
74,2010-019912-18,Enfermedad,i
74,2010-019912-18,articular,i
74,2010-019912-18,inflamatoria,i
74,2010-019912-18,distinta,o
74,2010-019912-18,de,o
74,2010-019912-18,AR,i
74,2010-019912-18,en,o
74,2010-019912-18,el,o
74,2010-019912-18,pasado,o
74,2010-019912-18,o,o
74,2010-019912-18,en,o
74,2010-019912-18,la,o
74,2010-019912-18,actualidad,o
75,2010-019912-18,EudraCT,o
75,2010-019912-18,Nº,o
75,2010-019912-18,201001991218,o
75,2010-019912-18,Titulo,o
75,2010-019912-18,cientifico,o
75,2010-019912-18,Estudio,o
75,2010-019912-18,randomizado,o
75,2010-019912-18,doble,o
75,2010-019912-18,ciego,o
75,2010-019912-18,con,o
75,2010-019912-18,grupos,o
75,2010-019912-18,de,o
75,2010-019912-18,tratamiento,i
75,2010-019912-18,paralelos,o
75,2010-019912-18,para,o
75,2010-019912-18,evaluar,i
75,2010-019912-18,la,i
75,2010-019912-18,seguridad,i
75,2010-019912-18,y,o
75,2010-019912-18,el,o
75,2010-019912-18,efecto,o
75,2010-019912-18,sobre,o
75,2010-019912-18,el,o
75,2010-019912-18,resultado,o
75,2010-019912-18,clinico,o
75,2010-019912-18,de,o
75,2010-019912-18,tocilizumab,i
75,2010-019912-18,SC,o
75,2010-019912-18,frente,o
75,2010-019912-18,a,o
75,2010-019912-18,placebo,i
75,2010-019912-18,SC,o
75,2010-019912-18,en,o
75,2010-019912-18,combinacion,o
75,2010-019912-18,con,o
75,2010-019912-18,farmacos,i
75,2010-019912-18,antirreumaticos,i
75,2010-019912-18,modificadores,i
75,2010-019912-18,de,i
75,2010-019912-18,la,i
75,2010-019912-18,enfermedad,i
75,2010-019912-18,FAMEs,i
75,2010-019912-18,tradicionales,o
75,2010-019912-18,en,o
75,2010-019912-18,pacientes,o
75,2010-019912-18,con,o
75,2010-019912-18,artritis,i
75,2010-019912-18,reumatoide,i
75,2010-019912-18,activa,o
75,2010-019912-18,moderada,o
75,2010-019912-18,a,o
75,2010-019912-18,severa,o
75,2010-019912-18,Indicacion,o
75,2010-019912-18,cientifica,o
75,2010-019912-18,Artritis,i
75,2010-019912-18,Reumatoide,i
75,2010-019912-18,AR,i
75,2010-019912-18,Criterios,o
75,2010-019912-18,de,o
75,2010-019912-18,inclusion,o
75,2010-019912-18,Presentar,o
75,2010-019912-18,artritis,i
75,2010-019912-18,reumatoide,i
75,2010-019912-18,de,o
75,2010-019912-18,mayor,o
75,2010-019912-18,o,o
75,2010-019912-18,igual,o
75,2010-019912-18,a,o
75,2010-019912-18,6,o
75,2010-019912-18,meses,o
75,2010-019912-18,de,o
75,2010-019912-18,duracion,o
75,2010-019912-18,Recibir,o
75,2010-019912-18,tratamiento,i
75,2010-019912-18,de,i
75,2010-019912-18,forma,i
75,2010-019912-18,ambulatoria,i
75,2010-019912-18,Presentar,o
75,2010-019912-18,un,o
75,2010-019912-18,recuento,o
75,2010-019912-18,de,o
75,2010-019912-18,articulaciones,i
75,2010-019912-18,inflamadas,i
75,2010-019912-18,RAI,o
75,2010-019912-18,mayor,o
75,2010-019912-18,o,o
75,2010-019912-18,igual,o
75,2010-019912-18,a,o
75,2010-019912-18,6,o
75,2010-019912-18,recuento,o
75,2010-019912-18,de,o
75,2010-019912-18,66,o
75,2010-019912-18,articulaciones,i
75,2010-019912-18,y,o
75,2010-019912-18,de,o
75,2010-019912-18,articulaciones,i
75,2010-019912-18,dolorosas,i
75,2010-019912-18,RAD,o
75,2010-019912-18,mayor,o
75,2010-019912-18,o,o
75,2010-019912-18,igual,o
75,2010-019912-18,a,o
75,2010-019912-18,8,o
75,2010-019912-18,recuento,o
75,2010-019912-18,de,o
75,2010-019912-18,68,o
75,2010-019912-18,articulaciones,i
75,2010-019912-18,en,o
75,2010-019912-18,las,o
75,2010-019912-18,visitas,o
75,2010-019912-18,de,o
75,2010-019912-18,seleccion,o
75,2010-019912-18,y,o
75,2010-019912-18,basal,o
75,2010-019912-18,Los,o
75,2010-019912-18,pacientes,o
75,2010-019912-18,deben,o
75,2010-019912-18,estar,o
75,2010-019912-18,recibiendo,o
75,2010-019912-18,tratamiento,i
75,2010-019912-18,con,o
75,2010-019912-18,una,o
75,2010-019912-18,dosis,o
75,2010-019912-18,estable,o
75,2010-019912-18,de,o
75,2010-019912-18,los,o
75,2010-019912-18,FAMEs,i
75,2010-019912-18,permitidos,o
75,2010-019912-18,como,o
75,2010-019912-18,minimo,o
75,2010-019912-18,8,o
75,2010-019912-18,semanas,o
75,2010-019912-18,antes,o
75,2010-019912-18,de,o
75,2010-019912-18,la,o
75,2010-019912-18,visita,o
75,2010-019912-18,basal,o
75,2010-019912-18,Criterios,o
75,2010-019912-18,de,o
75,2010-019912-18,exclusion,o
75,2010-019912-18,Pacientes,o
75,2010-019912-18,sometidos,o
75,2010-019912-18,a,o
75,2010-019912-18,intervenciones,i
75,2010-019912-18,de,i
75,2010-019912-18,cirugia,i
75,2010-019912-18,mayor,i
75,2010-019912-18,incluyendo,o
75,2010-019912-18,cirugia,i
75,2010-019912-18,articular,i
75,2010-019912-18,en,o
75,2010-019912-18,las,o
75,2010-019912-18,8,o
75,2010-019912-18,semanas,o
75,2010-019912-18,previas,o
75,2010-019912-18,a,o
75,2010-019912-18,la,o
75,2010-019912-18,visita,o
75,2010-019912-18,de,o
75,2010-019912-18,seleccion,o
75,2010-019912-18,o,o
75,2010-019912-18,que,o
75,2010-019912-18,tengan,o
75,2010-019912-18,previsto,o
75,2010-019912-18,someterse,o
75,2010-019912-18,a,o
75,2010-019912-18,una,o
75,2010-019912-18,intervencion,i
75,2010-019912-18,de,o
75,2010-019912-18,este,o
75,2010-019912-18,tipo,o
75,2010-019912-18,en,o
75,2010-019912-18,los,o
75,2010-019912-18,6,o
75,2010-019912-18,meses,o
75,2010-019912-18,siguientes,o
75,2010-019912-18,a,o
75,2010-019912-18,la,o
75,2010-019912-18,randomizacion,i
75,2010-019912-18,Enfermedad,i
75,2010-019912-18,reumatica,i
75,2010-019912-18,autoinmune,i
75,2010-019912-18,distinta,o
75,2010-019912-18,de,o
75,2010-019912-18,AR,i
75,2010-019912-18,Se,o
75,2010-019912-18,permite,o
75,2010-019912-18,la,o
75,2010-019912-18,inclusion,o
75,2010-019912-18,de,o
75,2010-019912-18,pacientes,o
75,2010-019912-18,con,o
75,2010-019912-18,sindrome,i
75,2010-019912-18,de,i
75,2010-019912-18,Sjögren,i
75,2010-019912-18,secundario,i
75,2010-019912-18,asociado,o
75,2010-019912-18,a,o
75,2010-019912-18,AR,i
75,2010-019912-18,Clase,o
75,2010-019912-18,funcional,o
75,2010-019912-18,IV,o
75,2010-019912-18,definida,o
75,2010-019912-18,de,o
75,2010-019912-18,acuerdo,o
75,2010-019912-18,con,o
75,2010-019912-18,la,o
75,2010-019912-18,Clasificacion,o
75,2010-019912-18,del,o
75,2010-019912-18,ACR,o
75,2010-019912-18,del,o
75,2010-019912-18,Estado,o
75,2010-019912-18,Funcional,o
75,2010-019912-18,en,o
75,2010-019912-18,Artritis,i
75,2010-019912-18,Reumatoide,i
75,2010-019912-18,Artritis,i
75,2010-019912-18,idiopatica,i
75,2010-019912-18,juvenil,i
75,2010-019912-18,AIJ,i
75,2010-019912-18,o,o
75,2010-019912-18,artritis,i
75,2010-019912-18,reumatoide,i
75,2010-019912-18,juvenil,i
75,2010-019912-18,ARJ,i
75,2010-019912-18,yo,o
75,2010-019912-18,AR,i
75,2010-019912-18,diagnosticadas,i
75,2010-019912-18,antes,o
75,2010-019912-18,de,o
75,2010-019912-18,los,o
75,2010-019912-18,16,o
75,2010-019912-18,años,o
75,2010-019912-18,de,o
75,2010-019912-18,edad,o
75,2010-019912-18,Enfermedad,i
75,2010-019912-18,articular,i
75,2010-019912-18,inflamatoria,i
75,2010-019912-18,distinta,o
75,2010-019912-18,de,o
75,2010-019912-18,AR,i
75,2010-019912-18,en,o
75,2010-019912-18,el,o
75,2010-019912-18,pasado,o
75,2010-019912-18,o,o
75,2010-019912-18,en,o
75,2010-019912-18,la,o
75,2010-019912-18,actualidad,o
76,2010-019912-18,EudraCT,o
76,2010-019912-18,Nº,o
76,2010-019912-18,201001991218,o
76,2010-019912-18,Titulo,o
76,2010-019912-18,cientifico,o
76,2010-019912-18,Estudio,o
76,2010-019912-18,randomizado,o
76,2010-019912-18,doble,o
76,2010-019912-18,ciego,o
76,2010-019912-18,con,o
76,2010-019912-18,grupos,o
76,2010-019912-18,de,o
76,2010-019912-18,tratamiento,i
76,2010-019912-18,paralelos,o
76,2010-019912-18,para,o
76,2010-019912-18,evaluar,i
76,2010-019912-18,la,i
76,2010-019912-18,seguridad,i
76,2010-019912-18,y,o
76,2010-019912-18,el,o
76,2010-019912-18,efecto,o
76,2010-019912-18,sobre,o
76,2010-019912-18,el,o
76,2010-019912-18,resultado,o
76,2010-019912-18,clinico,o
76,2010-019912-18,de,o
76,2010-019912-18,tocilizumab,i
76,2010-019912-18,SC,o
76,2010-019912-18,frente,o
76,2010-019912-18,a,o
76,2010-019912-18,placebo,i
76,2010-019912-18,SC,o
76,2010-019912-18,en,o
76,2010-019912-18,combinacion,o
76,2010-019912-18,con,o
76,2010-019912-18,farmacos,i
76,2010-019912-18,antirreumaticos,i
76,2010-019912-18,modificadores,i
76,2010-019912-18,de,i
76,2010-019912-18,la,i
76,2010-019912-18,enfermedad,i
76,2010-019912-18,FAMEs,i
76,2010-019912-18,tradicionales,o
76,2010-019912-18,en,o
76,2010-019912-18,pacientes,o
76,2010-019912-18,con,o
76,2010-019912-18,artritis,i
76,2010-019912-18,reumatoide,i
76,2010-019912-18,activa,o
76,2010-019912-18,moderada,o
76,2010-019912-18,a,o
76,2010-019912-18,severa,o
76,2010-019912-18,Indicacion,o
76,2010-019912-18,cientifica,o
76,2010-019912-18,Artritis,i
76,2010-019912-18,Reumatoide,i
76,2010-019912-18,AR,i
76,2010-019912-18,Criterios,o
76,2010-019912-18,de,o
76,2010-019912-18,inclusion,o
76,2010-019912-18,Presentar,o
76,2010-019912-18,artritis,i
76,2010-019912-18,reumatoide,i
76,2010-019912-18,de,o
76,2010-019912-18,mayor,o
76,2010-019912-18,o,o
76,2010-019912-18,igual,o
76,2010-019912-18,a,o
76,2010-019912-18,6,o
76,2010-019912-18,meses,o
76,2010-019912-18,de,o
76,2010-019912-18,duracion,o
76,2010-019912-18,Recibir,o
76,2010-019912-18,tratamiento,i
76,2010-019912-18,de,i
76,2010-019912-18,forma,i
76,2010-019912-18,ambulatoria,i
76,2010-019912-18,Presentar,o
76,2010-019912-18,un,o
76,2010-019912-18,recuento,o
76,2010-019912-18,de,o
76,2010-019912-18,articulaciones,i
76,2010-019912-18,inflamadas,i
76,2010-019912-18,RAI,o
76,2010-019912-18,mayor,o
76,2010-019912-18,o,o
76,2010-019912-18,igual,o
76,2010-019912-18,a,o
76,2010-019912-18,6,o
76,2010-019912-18,recuento,o
76,2010-019912-18,de,o
76,2010-019912-18,66,o
76,2010-019912-18,articulaciones,i
76,2010-019912-18,y,o
76,2010-019912-18,de,o
76,2010-019912-18,articulaciones,i
76,2010-019912-18,dolorosas,i
76,2010-019912-18,RAD,o
76,2010-019912-18,mayor,o
76,2010-019912-18,o,o
76,2010-019912-18,igual,o
76,2010-019912-18,a,o
76,2010-019912-18,8,o
76,2010-019912-18,recuento,o
76,2010-019912-18,de,o
76,2010-019912-18,68,o
76,2010-019912-18,articulaciones,i
76,2010-019912-18,en,o
76,2010-019912-18,las,o
76,2010-019912-18,visitas,o
76,2010-019912-18,de,o
76,2010-019912-18,seleccion,o
76,2010-019912-18,y,o
76,2010-019912-18,basal,o
76,2010-019912-18,Los,o
76,2010-019912-18,pacientes,o
76,2010-019912-18,deben,o
76,2010-019912-18,estar,o
76,2010-019912-18,recibiendo,o
76,2010-019912-18,tratamiento,i
76,2010-019912-18,con,o
76,2010-019912-18,una,o
76,2010-019912-18,dosis,o
76,2010-019912-18,estable,o
76,2010-019912-18,de,o
76,2010-019912-18,los,o
76,2010-019912-18,FAMEs,i
76,2010-019912-18,permitidos,o
76,2010-019912-18,como,o
76,2010-019912-18,minimo,o
76,2010-019912-18,8,o
76,2010-019912-18,semanas,o
76,2010-019912-18,antes,o
76,2010-019912-18,de,o
76,2010-019912-18,la,o
76,2010-019912-18,visita,o
76,2010-019912-18,basal,o
76,2010-019912-18,Criterios,o
76,2010-019912-18,de,o
76,2010-019912-18,exclusion,o
76,2010-019912-18,Pacientes,o
76,2010-019912-18,sometidos,o
76,2010-019912-18,a,o
76,2010-019912-18,intervenciones,i
76,2010-019912-18,de,i
76,2010-019912-18,cirugia,i
76,2010-019912-18,mayor,i
76,2010-019912-18,incluyendo,o
76,2010-019912-18,cirugia,i
76,2010-019912-18,articular,i
76,2010-019912-18,en,o
76,2010-019912-18,las,o
76,2010-019912-18,8,o
76,2010-019912-18,semanas,o
76,2010-019912-18,previas,o
76,2010-019912-18,a,o
76,2010-019912-18,la,o
76,2010-019912-18,visita,o
76,2010-019912-18,de,o
76,2010-019912-18,seleccion,o
76,2010-019912-18,o,o
76,2010-019912-18,que,o
76,2010-019912-18,tengan,o
76,2010-019912-18,previsto,o
76,2010-019912-18,someterse,o
76,2010-019912-18,a,o
76,2010-019912-18,una,o
76,2010-019912-18,intervencion,i
76,2010-019912-18,de,o
76,2010-019912-18,este,o
76,2010-019912-18,tipo,o
76,2010-019912-18,en,o
76,2010-019912-18,los,o
76,2010-019912-18,6,o
76,2010-019912-18,meses,o
76,2010-019912-18,siguientes,o
76,2010-019912-18,a,o
76,2010-019912-18,la,o
76,2010-019912-18,randomizacion,i
76,2010-019912-18,Enfermedad,i
76,2010-019912-18,reumatica,i
76,2010-019912-18,autoinmune,i
76,2010-019912-18,distinta,o
76,2010-019912-18,de,o
76,2010-019912-18,AR,i
76,2010-019912-18,Se,o
76,2010-019912-18,permite,o
76,2010-019912-18,la,o
76,2010-019912-18,inclusion,o
76,2010-019912-18,de,o
76,2010-019912-18,pacientes,o
76,2010-019912-18,con,o
76,2010-019912-18,sindrome,i
76,2010-019912-18,de,i
76,2010-019912-18,Sjögren,i
76,2010-019912-18,secundario,i
76,2010-019912-18,asociado,o
76,2010-019912-18,a,o
76,2010-019912-18,AR,i
76,2010-019912-18,Clase,o
76,2010-019912-18,funcional,o
76,2010-019912-18,IV,o
76,2010-019912-18,definida,o
76,2010-019912-18,de,o
76,2010-019912-18,acuerdo,o
76,2010-019912-18,con,o
76,2010-019912-18,la,o
76,2010-019912-18,Clasificacion,o
76,2010-019912-18,del,o
76,2010-019912-18,ACR,o
76,2010-019912-18,del,o
76,2010-019912-18,Estado,o
76,2010-019912-18,Funcional,o
76,2010-019912-18,en,o
76,2010-019912-18,Artritis,i
76,2010-019912-18,Reumatoide,i
76,2010-019912-18,Artritis,i
76,2010-019912-18,idiopatica,i
76,2010-019912-18,juvenil,i
76,2010-019912-18,AIJ,i
76,2010-019912-18,o,o
76,2010-019912-18,artritis,i
76,2010-019912-18,reumatoide,i
76,2010-019912-18,juvenil,i
76,2010-019912-18,ARJ,i
76,2010-019912-18,yo,o
76,2010-019912-18,AR,i
76,2010-019912-18,diagnosticadas,i
76,2010-019912-18,antes,o
76,2010-019912-18,de,o
76,2010-019912-18,los,o
76,2010-019912-18,16,o
76,2010-019912-18,años,o
76,2010-019912-18,de,o
76,2010-019912-18,edad,o
76,2010-019912-18,Enfermedad,i
76,2010-019912-18,articular,i
76,2010-019912-18,inflamatoria,i
76,2010-019912-18,distinta,o
76,2010-019912-18,de,o
76,2010-019912-18,AR,i
76,2010-019912-18,en,o
76,2010-019912-18,el,o
76,2010-019912-18,pasado,o
76,2010-019912-18,o,o
76,2010-019912-18,en,o
76,2010-019912-18,la,o
76,2010-019912-18,actualidad,o
77,2010-019912-18,EudraCT,o
77,2010-019912-18,Nº,o
77,2010-019912-18,201001991218,o
77,2010-019912-18,Titulo,o
77,2010-019912-18,cientifico,o
77,2010-019912-18,Estudio,o
77,2010-019912-18,randomizado,o
77,2010-019912-18,doble,o
77,2010-019912-18,ciego,o
77,2010-019912-18,con,o
77,2010-019912-18,grupos,o
77,2010-019912-18,de,o
77,2010-019912-18,tratamiento,i
77,2010-019912-18,paralelos,o
77,2010-019912-18,para,o
77,2010-019912-18,evaluar,i
77,2010-019912-18,la,i
77,2010-019912-18,seguridad,i
77,2010-019912-18,y,o
77,2010-019912-18,el,o
77,2010-019912-18,efecto,o
77,2010-019912-18,sobre,o
77,2010-019912-18,el,o
77,2010-019912-18,resultado,o
77,2010-019912-18,clinico,o
77,2010-019912-18,de,o
77,2010-019912-18,tocilizumab,i
77,2010-019912-18,SC,o
77,2010-019912-18,frente,o
77,2010-019912-18,a,o
77,2010-019912-18,placebo,i
77,2010-019912-18,SC,o
77,2010-019912-18,en,o
77,2010-019912-18,combinacion,o
77,2010-019912-18,con,o
77,2010-019912-18,farmacos,i
77,2010-019912-18,antirreumaticos,i
77,2010-019912-18,modificadores,i
77,2010-019912-18,de,i
77,2010-019912-18,la,i
77,2010-019912-18,enfermedad,i
77,2010-019912-18,FAMEs,i
77,2010-019912-18,tradicionales,o
77,2010-019912-18,en,o
77,2010-019912-18,pacientes,o
77,2010-019912-18,con,o
77,2010-019912-18,artritis,i
77,2010-019912-18,reumatoide,i
77,2010-019912-18,activa,o
77,2010-019912-18,moderada,o
77,2010-019912-18,a,o
77,2010-019912-18,severa,o
77,2010-019912-18,Indicacion,o
77,2010-019912-18,cientifica,o
77,2010-019912-18,Artritis,i
77,2010-019912-18,Reumatoide,i
77,2010-019912-18,AR,i
77,2010-019912-18,Criterios,o
77,2010-019912-18,de,o
77,2010-019912-18,inclusion,o
77,2010-019912-18,Presentar,o
77,2010-019912-18,artritis,i
77,2010-019912-18,reumatoide,i
77,2010-019912-18,de,o
77,2010-019912-18,mayor,o
77,2010-019912-18,o,o
77,2010-019912-18,igual,o
77,2010-019912-18,a,o
77,2010-019912-18,6,o
77,2010-019912-18,meses,o
77,2010-019912-18,de,o
77,2010-019912-18,duracion,o
77,2010-019912-18,Recibir,o
77,2010-019912-18,tratamiento,i
77,2010-019912-18,de,i
77,2010-019912-18,forma,i
77,2010-019912-18,ambulatoria,i
77,2010-019912-18,Presentar,o
77,2010-019912-18,un,o
77,2010-019912-18,recuento,o
77,2010-019912-18,de,o
77,2010-019912-18,articulaciones,i
77,2010-019912-18,inflamadas,i
77,2010-019912-18,RAI,o
77,2010-019912-18,mayor,o
77,2010-019912-18,o,o
77,2010-019912-18,igual,o
77,2010-019912-18,a,o
77,2010-019912-18,6,o
77,2010-019912-18,recuento,o
77,2010-019912-18,de,o
77,2010-019912-18,66,o
77,2010-019912-18,articulaciones,i
77,2010-019912-18,y,o
77,2010-019912-18,de,o
77,2010-019912-18,articulaciones,i
77,2010-019912-18,dolorosas,i
77,2010-019912-18,RAD,o
77,2010-019912-18,mayor,o
77,2010-019912-18,o,o
77,2010-019912-18,igual,o
77,2010-019912-18,a,o
77,2010-019912-18,8,o
77,2010-019912-18,recuento,o
77,2010-019912-18,de,o
77,2010-019912-18,68,o
77,2010-019912-18,articulaciones,i
77,2010-019912-18,en,o
77,2010-019912-18,las,o
77,2010-019912-18,visitas,o
77,2010-019912-18,de,o
77,2010-019912-18,seleccion,o
77,2010-019912-18,y,o
77,2010-019912-18,basal,o
77,2010-019912-18,Los,o
77,2010-019912-18,pacientes,o
77,2010-019912-18,deben,o
77,2010-019912-18,estar,o
77,2010-019912-18,recibiendo,o
77,2010-019912-18,tratamiento,i
77,2010-019912-18,con,o
77,2010-019912-18,una,o
77,2010-019912-18,dosis,o
77,2010-019912-18,estable,o
77,2010-019912-18,de,o
77,2010-019912-18,los,o
77,2010-019912-18,FAMEs,i
77,2010-019912-18,permitidos,o
77,2010-019912-18,como,o
77,2010-019912-18,minimo,o
77,2010-019912-18,8,o
77,2010-019912-18,semanas,o
77,2010-019912-18,antes,o
77,2010-019912-18,de,o
77,2010-019912-18,la,o
77,2010-019912-18,visita,o
77,2010-019912-18,basal,o
77,2010-019912-18,Criterios,o
77,2010-019912-18,de,o
77,2010-019912-18,exclusion,o
77,2010-019912-18,Pacientes,o
77,2010-019912-18,sometidos,o
77,2010-019912-18,a,o
77,2010-019912-18,intervenciones,i
77,2010-019912-18,de,i
77,2010-019912-18,cirugia,i
77,2010-019912-18,mayor,i
77,2010-019912-18,incluyendo,o
77,2010-019912-18,cirugia,i
77,2010-019912-18,articular,i
77,2010-019912-18,en,o
77,2010-019912-18,las,o
77,2010-019912-18,8,o
77,2010-019912-18,semanas,o
77,2010-019912-18,previas,o
77,2010-019912-18,a,o
77,2010-019912-18,la,o
77,2010-019912-18,visita,o
77,2010-019912-18,de,o
77,2010-019912-18,seleccion,o
77,2010-019912-18,o,o
77,2010-019912-18,que,o
77,2010-019912-18,tengan,o
77,2010-019912-18,previsto,o
77,2010-019912-18,someterse,o
77,2010-019912-18,a,o
77,2010-019912-18,una,o
77,2010-019912-18,intervencion,i
77,2010-019912-18,de,o
77,2010-019912-18,este,o
77,2010-019912-18,tipo,o
77,2010-019912-18,en,o
77,2010-019912-18,los,o
77,2010-019912-18,6,o
77,2010-019912-18,meses,o
77,2010-019912-18,siguientes,o
77,2010-019912-18,a,o
77,2010-019912-18,la,o
77,2010-019912-18,randomizacion,i
77,2010-019912-18,Enfermedad,i
77,2010-019912-18,reumatica,i
77,2010-019912-18,autoinmune,i
77,2010-019912-18,distinta,o
77,2010-019912-18,de,o
77,2010-019912-18,AR,i
77,2010-019912-18,Se,o
77,2010-019912-18,permite,o
77,2010-019912-18,la,o
77,2010-019912-18,inclusion,o
77,2010-019912-18,de,o
77,2010-019912-18,pacientes,o
77,2010-019912-18,con,o
77,2010-019912-18,sindrome,i
77,2010-019912-18,de,i
77,2010-019912-18,Sjögren,i
77,2010-019912-18,secundario,i
77,2010-019912-18,asociado,o
77,2010-019912-18,a,o
77,2010-019912-18,AR,i
77,2010-019912-18,Clase,o
77,2010-019912-18,funcional,o
77,2010-019912-18,IV,o
77,2010-019912-18,definida,o
77,2010-019912-18,de,o
77,2010-019912-18,acuerdo,o
77,2010-019912-18,con,o
77,2010-019912-18,la,o
77,2010-019912-18,Clasificacion,o
77,2010-019912-18,del,o
77,2010-019912-18,ACR,o
77,2010-019912-18,del,o
77,2010-019912-18,Estado,o
77,2010-019912-18,Funcional,o
77,2010-019912-18,en,o
77,2010-019912-18,Artritis,i
77,2010-019912-18,Reumatoide,i
77,2010-019912-18,Artritis,i
77,2010-019912-18,idiopatica,i
77,2010-019912-18,juvenil,i
77,2010-019912-18,AIJ,i
77,2010-019912-18,o,o
77,2010-019912-18,artritis,i
77,2010-019912-18,reumatoide,i
77,2010-019912-18,juvenil,i
77,2010-019912-18,ARJ,i
77,2010-019912-18,yo,o
77,2010-019912-18,AR,i
77,2010-019912-18,diagnosticadas,i
77,2010-019912-18,antes,o
77,2010-019912-18,de,o
77,2010-019912-18,los,o
77,2010-019912-18,16,o
77,2010-019912-18,años,o
77,2010-019912-18,de,o
77,2010-019912-18,edad,o
77,2010-019912-18,Enfermedad,i
77,2010-019912-18,articular,i
77,2010-019912-18,inflamatoria,i
77,2010-019912-18,distinta,o
77,2010-019912-18,de,o
77,2010-019912-18,AR,i
77,2010-019912-18,en,o
77,2010-019912-18,el,o
77,2010-019912-18,pasado,o
77,2010-019912-18,o,o
77,2010-019912-18,en,o
77,2010-019912-18,la,o
77,2010-019912-18,actualidad,o
78,2010-019912-18,EudraCT,o
78,2010-019912-18,Nº,o
78,2010-019912-18,201001991218,o
78,2010-019912-18,Titulo,o
78,2010-019912-18,cientifico,o
78,2010-019912-18,Estudio,o
78,2010-019912-18,randomizado,o
78,2010-019912-18,doble,o
78,2010-019912-18,ciego,o
78,2010-019912-18,con,o
78,2010-019912-18,grupos,o
78,2010-019912-18,de,o
78,2010-019912-18,tratamiento,i
78,2010-019912-18,paralelos,o
78,2010-019912-18,para,o
78,2010-019912-18,evaluar,i
78,2010-019912-18,la,i
78,2010-019912-18,seguridad,i
78,2010-019912-18,y,o
78,2010-019912-18,el,o
78,2010-019912-18,efecto,o
78,2010-019912-18,sobre,o
78,2010-019912-18,el,o
78,2010-019912-18,resultado,o
78,2010-019912-18,clinico,o
78,2010-019912-18,de,o
78,2010-019912-18,tocilizumab,i
78,2010-019912-18,SC,o
78,2010-019912-18,frente,o
78,2010-019912-18,a,o
78,2010-019912-18,placebo,i
78,2010-019912-18,SC,o
78,2010-019912-18,en,o
78,2010-019912-18,combinacion,o
78,2010-019912-18,con,o
78,2010-019912-18,farmacos,i
78,2010-019912-18,antirreumaticos,i
78,2010-019912-18,modificadores,i
78,2010-019912-18,de,i
78,2010-019912-18,la,i
78,2010-019912-18,enfermedad,i
78,2010-019912-18,FAMEs,i
78,2010-019912-18,tradicionales,o
78,2010-019912-18,en,o
78,2010-019912-18,pacientes,o
78,2010-019912-18,con,o
78,2010-019912-18,artritis,i
78,2010-019912-18,reumatoide,i
78,2010-019912-18,activa,o
78,2010-019912-18,moderada,o
78,2010-019912-18,a,o
78,2010-019912-18,severa,o
78,2010-019912-18,Indicacion,o
78,2010-019912-18,cientifica,o
78,2010-019912-18,Artritis,i
78,2010-019912-18,Reumatoide,i
78,2010-019912-18,AR,i
78,2010-019912-18,Criterios,o
78,2010-019912-18,de,o
78,2010-019912-18,inclusion,o
78,2010-019912-18,Presentar,o
78,2010-019912-18,artritis,i
78,2010-019912-18,reumatoide,i
78,2010-019912-18,de,o
78,2010-019912-18,mayor,o
78,2010-019912-18,o,o
78,2010-019912-18,igual,o
78,2010-019912-18,a,o
78,2010-019912-18,6,o
78,2010-019912-18,meses,o
78,2010-019912-18,de,o
78,2010-019912-18,duracion,o
78,2010-019912-18,Recibir,o
78,2010-019912-18,tratamiento,i
78,2010-019912-18,de,i
78,2010-019912-18,forma,i
78,2010-019912-18,ambulatoria,i
78,2010-019912-18,Presentar,o
78,2010-019912-18,un,o
78,2010-019912-18,recuento,o
78,2010-019912-18,de,o
78,2010-019912-18,articulaciones,i
78,2010-019912-18,inflamadas,i
78,2010-019912-18,RAI,o
78,2010-019912-18,mayor,o
78,2010-019912-18,o,o
78,2010-019912-18,igual,o
78,2010-019912-18,a,o
78,2010-019912-18,6,o
78,2010-019912-18,recuento,o
78,2010-019912-18,de,o
78,2010-019912-18,66,o
78,2010-019912-18,articulaciones,i
78,2010-019912-18,y,o
78,2010-019912-18,de,o
78,2010-019912-18,articulaciones,i
78,2010-019912-18,dolorosas,i
78,2010-019912-18,RAD,o
78,2010-019912-18,mayor,o
78,2010-019912-18,o,o
78,2010-019912-18,igual,o
78,2010-019912-18,a,o
78,2010-019912-18,8,o
78,2010-019912-18,recuento,o
78,2010-019912-18,de,o
78,2010-019912-18,68,o
78,2010-019912-18,articulaciones,i
78,2010-019912-18,en,o
78,2010-019912-18,las,o
78,2010-019912-18,visitas,o
78,2010-019912-18,de,o
78,2010-019912-18,seleccion,o
78,2010-019912-18,y,o
78,2010-019912-18,basal,o
78,2010-019912-18,Los,o
78,2010-019912-18,pacientes,o
78,2010-019912-18,deben,o
78,2010-019912-18,estar,o
78,2010-019912-18,recibiendo,o
78,2010-019912-18,tratamiento,i
78,2010-019912-18,con,o
78,2010-019912-18,una,o
78,2010-019912-18,dosis,o
78,2010-019912-18,estable,o
78,2010-019912-18,de,o
78,2010-019912-18,los,o
78,2010-019912-18,FAMEs,i
78,2010-019912-18,permitidos,o
78,2010-019912-18,como,o
78,2010-019912-18,minimo,o
78,2010-019912-18,8,o
78,2010-019912-18,semanas,o
78,2010-019912-18,antes,o
78,2010-019912-18,de,o
78,2010-019912-18,la,o
78,2010-019912-18,visita,o
78,2010-019912-18,basal,o
78,2010-019912-18,Criterios,o
78,2010-019912-18,de,o
78,2010-019912-18,exclusion,o
78,2010-019912-18,Pacientes,o
78,2010-019912-18,sometidos,o
78,2010-019912-18,a,o
78,2010-019912-18,intervenciones,i
78,2010-019912-18,de,i
78,2010-019912-18,cirugia,i
78,2010-019912-18,mayor,i
78,2010-019912-18,incluyendo,o
78,2010-019912-18,cirugia,i
78,2010-019912-18,articular,i
78,2010-019912-18,en,o
78,2010-019912-18,las,o
78,2010-019912-18,8,o
78,2010-019912-18,semanas,o
78,2010-019912-18,previas,o
78,2010-019912-18,a,o
78,2010-019912-18,la,o
78,2010-019912-18,visita,o
78,2010-019912-18,de,o
78,2010-019912-18,seleccion,o
78,2010-019912-18,o,o
78,2010-019912-18,que,o
78,2010-019912-18,tengan,o
78,2010-019912-18,previsto,o
78,2010-019912-18,someterse,o
78,2010-019912-18,a,o
78,2010-019912-18,una,o
78,2010-019912-18,intervencion,i
78,2010-019912-18,de,o
78,2010-019912-18,este,o
78,2010-019912-18,tipo,o
78,2010-019912-18,en,o
78,2010-019912-18,los,o
78,2010-019912-18,6,o
78,2010-019912-18,meses,o
78,2010-019912-18,siguientes,o
78,2010-019912-18,a,o
78,2010-019912-18,la,o
78,2010-019912-18,randomizacion,i
78,2010-019912-18,Enfermedad,i
78,2010-019912-18,reumatica,i
78,2010-019912-18,autoinmune,i
78,2010-019912-18,distinta,o
78,2010-019912-18,de,o
78,2010-019912-18,AR,i
78,2010-019912-18,Se,o
78,2010-019912-18,permite,o
78,2010-019912-18,la,o
78,2010-019912-18,inclusion,o
78,2010-019912-18,de,o
78,2010-019912-18,pacientes,o
78,2010-019912-18,con,o
78,2010-019912-18,sindrome,i
78,2010-019912-18,de,i
78,2010-019912-18,Sjögren,i
78,2010-019912-18,secundario,i
78,2010-019912-18,asociado,o
78,2010-019912-18,a,o
78,2010-019912-18,AR,i
78,2010-019912-18,Clase,o
78,2010-019912-18,funcional,o
78,2010-019912-18,IV,o
78,2010-019912-18,definida,o
78,2010-019912-18,de,o
78,2010-019912-18,acuerdo,o
78,2010-019912-18,con,o
78,2010-019912-18,la,o
78,2010-019912-18,Clasificacion,o
78,2010-019912-18,del,o
78,2010-019912-18,ACR,o
78,2010-019912-18,del,o
78,2010-019912-18,Estado,o
78,2010-019912-18,Funcional,o
78,2010-019912-18,en,o
78,2010-019912-18,Artritis,i
78,2010-019912-18,Reumatoide,i
78,2010-019912-18,Artritis,i
78,2010-019912-18,idiopatica,i
78,2010-019912-18,juvenil,i
78,2010-019912-18,AIJ,i
78,2010-019912-18,o,o
78,2010-019912-18,artritis,i
78,2010-019912-18,reumatoide,i
78,2010-019912-18,juvenil,i
78,2010-019912-18,ARJ,i
78,2010-019912-18,yo,o
78,2010-019912-18,AR,i
78,2010-019912-18,diagnosticadas,i
78,2010-019912-18,antes,o
78,2010-019912-18,de,o
78,2010-019912-18,los,o
78,2010-019912-18,16,o
78,2010-019912-18,años,o
78,2010-019912-18,de,o
78,2010-019912-18,edad,o
78,2010-019912-18,Enfermedad,i
78,2010-019912-18,articular,i
78,2010-019912-18,inflamatoria,i
78,2010-019912-18,distinta,o
78,2010-019912-18,de,o
78,2010-019912-18,AR,i
78,2010-019912-18,en,o
78,2010-019912-18,el,o
78,2010-019912-18,pasado,o
78,2010-019912-18,o,o
78,2010-019912-18,en,o
78,2010-019912-18,la,o
78,2010-019912-18,actualidad,o
79,2010-019912-18,EudraCT,o
79,2010-019912-18,Nº,o
79,2010-019912-18,201001991218,o
79,2010-019912-18,Titulo,o
79,2010-019912-18,cientifico,o
79,2010-019912-18,Estudio,o
79,2010-019912-18,randomizado,o
79,2010-019912-18,doble,o
79,2010-019912-18,ciego,o
79,2010-019912-18,con,o
79,2010-019912-18,grupos,o
79,2010-019912-18,de,o
79,2010-019912-18,tratamiento,i
79,2010-019912-18,paralelos,o
79,2010-019912-18,para,o
79,2010-019912-18,evaluar,i
79,2010-019912-18,la,i
79,2010-019912-18,seguridad,i
79,2010-019912-18,y,o
79,2010-019912-18,el,o
79,2010-019912-18,efecto,o
79,2010-019912-18,sobre,o
79,2010-019912-18,el,o
79,2010-019912-18,resultado,o
79,2010-019912-18,clinico,o
79,2010-019912-18,de,o
79,2010-019912-18,tocilizumab,i
79,2010-019912-18,SC,o
79,2010-019912-18,frente,o
79,2010-019912-18,a,o
79,2010-019912-18,placebo,i
79,2010-019912-18,SC,o
79,2010-019912-18,en,o
79,2010-019912-18,combinacion,o
79,2010-019912-18,con,o
79,2010-019912-18,farmacos,i
79,2010-019912-18,antirreumaticos,i
79,2010-019912-18,modificadores,i
79,2010-019912-18,de,i
79,2010-019912-18,la,i
79,2010-019912-18,enfermedad,i
79,2010-019912-18,FAMEs,i
79,2010-019912-18,tradicionales,o
79,2010-019912-18,en,o
79,2010-019912-18,pacientes,o
79,2010-019912-18,con,o
79,2010-019912-18,artritis,i
79,2010-019912-18,reumatoide,i
79,2010-019912-18,activa,o
79,2010-019912-18,moderada,o
79,2010-019912-18,a,o
79,2010-019912-18,severa,o
79,2010-019912-18,Indicacion,o
79,2010-019912-18,cientifica,o
79,2010-019912-18,Artritis,i
79,2010-019912-18,Reumatoide,i
79,2010-019912-18,AR,i
79,2010-019912-18,Criterios,o
79,2010-019912-18,de,o
79,2010-019912-18,inclusion,o
79,2010-019912-18,Presentar,o
79,2010-019912-18,artritis,i
79,2010-019912-18,reumatoide,i
79,2010-019912-18,de,o
79,2010-019912-18,mayor,o
79,2010-019912-18,o,o
79,2010-019912-18,igual,o
79,2010-019912-18,a,o
79,2010-019912-18,6,o
79,2010-019912-18,meses,o
79,2010-019912-18,de,o
79,2010-019912-18,duracion,o
79,2010-019912-18,Recibir,o
79,2010-019912-18,tratamiento,i
79,2010-019912-18,de,i
79,2010-019912-18,forma,i
79,2010-019912-18,ambulatoria,i
79,2010-019912-18,Presentar,o
79,2010-019912-18,un,o
79,2010-019912-18,recuento,o
79,2010-019912-18,de,o
79,2010-019912-18,articulaciones,i
79,2010-019912-18,inflamadas,i
79,2010-019912-18,RAI,o
79,2010-019912-18,mayor,o
79,2010-019912-18,o,o
79,2010-019912-18,igual,o
79,2010-019912-18,a,o
79,2010-019912-18,6,o
79,2010-019912-18,recuento,o
79,2010-019912-18,de,o
79,2010-019912-18,66,o
79,2010-019912-18,articulaciones,i
79,2010-019912-18,y,o
79,2010-019912-18,de,o
79,2010-019912-18,articulaciones,i
79,2010-019912-18,dolorosas,i
79,2010-019912-18,RAD,o
79,2010-019912-18,mayor,o
79,2010-019912-18,o,o
79,2010-019912-18,igual,o
79,2010-019912-18,a,o
79,2010-019912-18,8,o
79,2010-019912-18,recuento,o
79,2010-019912-18,de,o
79,2010-019912-18,68,o
79,2010-019912-18,articulaciones,i
79,2010-019912-18,en,o
79,2010-019912-18,las,o
79,2010-019912-18,visitas,o
79,2010-019912-18,de,o
79,2010-019912-18,seleccion,o
79,2010-019912-18,y,o
79,2010-019912-18,basal,o
79,2010-019912-18,Los,o
79,2010-019912-18,pacientes,o
79,2010-019912-18,deben,o
79,2010-019912-18,estar,o
79,2010-019912-18,recibiendo,o
79,2010-019912-18,tratamiento,i
79,2010-019912-18,con,o
79,2010-019912-18,una,o
79,2010-019912-18,dosis,o
79,2010-019912-18,estable,o
79,2010-019912-18,de,o
79,2010-019912-18,los,o
79,2010-019912-18,FAMEs,i
79,2010-019912-18,permitidos,o
79,2010-019912-18,como,o
79,2010-019912-18,minimo,o
79,2010-019912-18,8,o
79,2010-019912-18,semanas,o
79,2010-019912-18,antes,o
79,2010-019912-18,de,o
79,2010-019912-18,la,o
79,2010-019912-18,visita,o
79,2010-019912-18,basal,o
79,2010-019912-18,Criterios,o
79,2010-019912-18,de,o
79,2010-019912-18,exclusion,o
79,2010-019912-18,Pacientes,o
79,2010-019912-18,sometidos,o
79,2010-019912-18,a,o
79,2010-019912-18,intervenciones,i
79,2010-019912-18,de,i
79,2010-019912-18,cirugia,i
79,2010-019912-18,mayor,i
79,2010-019912-18,incluyendo,o
79,2010-019912-18,cirugia,i
79,2010-019912-18,articular,i
79,2010-019912-18,en,o
79,2010-019912-18,las,o
79,2010-019912-18,8,o
79,2010-019912-18,semanas,o
79,2010-019912-18,previas,o
79,2010-019912-18,a,o
79,2010-019912-18,la,o
79,2010-019912-18,visita,o
79,2010-019912-18,de,o
79,2010-019912-18,seleccion,o
79,2010-019912-18,o,o
79,2010-019912-18,que,o
79,2010-019912-18,tengan,o
79,2010-019912-18,previsto,o
79,2010-019912-18,someterse,o
79,2010-019912-18,a,o
79,2010-019912-18,una,o
79,2010-019912-18,intervencion,i
79,2010-019912-18,de,o
79,2010-019912-18,este,o
79,2010-019912-18,tipo,o
79,2010-019912-18,en,o
79,2010-019912-18,los,o
79,2010-019912-18,6,o
79,2010-019912-18,meses,o
79,2010-019912-18,siguientes,o
79,2010-019912-18,a,o
79,2010-019912-18,la,o
79,2010-019912-18,randomizacion,i
79,2010-019912-18,Enfermedad,i
79,2010-019912-18,reumatica,i
79,2010-019912-18,autoinmune,i
79,2010-019912-18,distinta,o
79,2010-019912-18,de,o
79,2010-019912-18,AR,i
79,2010-019912-18,Se,o
79,2010-019912-18,permite,o
79,2010-019912-18,la,o
79,2010-019912-18,inclusion,o
79,2010-019912-18,de,o
79,2010-019912-18,pacientes,o
79,2010-019912-18,con,o
79,2010-019912-18,sindrome,i
79,2010-019912-18,de,i
79,2010-019912-18,Sjögren,i
79,2010-019912-18,secundario,i
79,2010-019912-18,asociado,o
79,2010-019912-18,a,o
79,2010-019912-18,AR,i
79,2010-019912-18,Clase,o
79,2010-019912-18,funcional,o
79,2010-019912-18,IV,o
79,2010-019912-18,definida,o
79,2010-019912-18,de,o
79,2010-019912-18,acuerdo,o
79,2010-019912-18,con,o
79,2010-019912-18,la,o
79,2010-019912-18,Clasificacion,o
79,2010-019912-18,del,o
79,2010-019912-18,ACR,o
79,2010-019912-18,del,o
79,2010-019912-18,Estado,o
79,2010-019912-18,Funcional,o
79,2010-019912-18,en,o
79,2010-019912-18,Artritis,i
79,2010-019912-18,Reumatoide,i
79,2010-019912-18,Artritis,i
79,2010-019912-18,idiopatica,i
79,2010-019912-18,juvenil,i
79,2010-019912-18,AIJ,i
79,2010-019912-18,o,o
79,2010-019912-18,artritis,i
79,2010-019912-18,reumatoide,i
79,2010-019912-18,juvenil,i
79,2010-019912-18,ARJ,i
79,2010-019912-18,yo,o
79,2010-019912-18,AR,i
79,2010-019912-18,diagnosticadas,i
79,2010-019912-18,antes,o
79,2010-019912-18,de,o
79,2010-019912-18,los,o
79,2010-019912-18,16,o
79,2010-019912-18,años,o
79,2010-019912-18,de,o
79,2010-019912-18,edad,o
79,2010-019912-18,Enfermedad,i
79,2010-019912-18,articular,i
79,2010-019912-18,inflamatoria,i
79,2010-019912-18,distinta,o
79,2010-019912-18,de,o
79,2010-019912-18,AR,i
79,2010-019912-18,en,o
79,2010-019912-18,el,o
79,2010-019912-18,pasado,o
79,2010-019912-18,o,o
79,2010-019912-18,en,o
79,2010-019912-18,la,o
79,2010-019912-18,actualidad,o
80,2010-019912-18,EudraCT,o
80,2010-019912-18,Nº,o
80,2010-019912-18,201001991218,o
80,2010-019912-18,Titulo,o
80,2010-019912-18,cientifico,o
80,2010-019912-18,Estudio,o
80,2010-019912-18,randomizado,o
80,2010-019912-18,doble,o
80,2010-019912-18,ciego,o
80,2010-019912-18,con,o
80,2010-019912-18,grupos,o
80,2010-019912-18,de,o
80,2010-019912-18,tratamiento,i
80,2010-019912-18,paralelos,o
80,2010-019912-18,para,o
80,2010-019912-18,evaluar,i
80,2010-019912-18,la,i
80,2010-019912-18,seguridad,i
80,2010-019912-18,y,o
80,2010-019912-18,el,o
80,2010-019912-18,efecto,o
80,2010-019912-18,sobre,o
80,2010-019912-18,el,o
80,2010-019912-18,resultado,o
80,2010-019912-18,clinico,o
80,2010-019912-18,de,o
80,2010-019912-18,tocilizumab,i
80,2010-019912-18,SC,o
80,2010-019912-18,frente,o
80,2010-019912-18,a,o
80,2010-019912-18,placebo,i
80,2010-019912-18,SC,o
80,2010-019912-18,en,o
80,2010-019912-18,combinacion,o
80,2010-019912-18,con,o
80,2010-019912-18,farmacos,i
80,2010-019912-18,antirreumaticos,i
80,2010-019912-18,modificadores,i
80,2010-019912-18,de,i
80,2010-019912-18,la,i
80,2010-019912-18,enfermedad,i
80,2010-019912-18,FAMEs,i
80,2010-019912-18,tradicionales,o
80,2010-019912-18,en,o
80,2010-019912-18,pacientes,o
80,2010-019912-18,con,o
80,2010-019912-18,artritis,i
80,2010-019912-18,reumatoide,i
80,2010-019912-18,activa,o
80,2010-019912-18,moderada,o
80,2010-019912-18,a,o
80,2010-019912-18,severa,o
80,2010-019912-18,Indicacion,o
80,2010-019912-18,cientifica,o
80,2010-019912-18,Artritis,i
80,2010-019912-18,Reumatoide,i
80,2010-019912-18,AR,i
80,2010-019912-18,Criterios,o
80,2010-019912-18,de,o
80,2010-019912-18,inclusion,o
80,2010-019912-18,Presentar,o
80,2010-019912-18,artritis,i
80,2010-019912-18,reumatoide,i
80,2010-019912-18,de,o
80,2010-019912-18,mayor,o
80,2010-019912-18,o,o
80,2010-019912-18,igual,o
80,2010-019912-18,a,o
80,2010-019912-18,6,o
80,2010-019912-18,meses,o
80,2010-019912-18,de,o
80,2010-019912-18,duracion,o
80,2010-019912-18,Recibir,o
80,2010-019912-18,tratamiento,i
80,2010-019912-18,de,i
80,2010-019912-18,forma,i
80,2010-019912-18,ambulatoria,i
80,2010-019912-18,Presentar,o
80,2010-019912-18,un,o
80,2010-019912-18,recuento,o
80,2010-019912-18,de,o
80,2010-019912-18,articulaciones,i
80,2010-019912-18,inflamadas,i
80,2010-019912-18,RAI,o
80,2010-019912-18,mayor,o
80,2010-019912-18,o,o
80,2010-019912-18,igual,o
80,2010-019912-18,a,o
80,2010-019912-18,6,o
80,2010-019912-18,recuento,o
80,2010-019912-18,de,o
80,2010-019912-18,66,o
80,2010-019912-18,articulaciones,i
80,2010-019912-18,y,o
80,2010-019912-18,de,o
80,2010-019912-18,articulaciones,i
80,2010-019912-18,dolorosas,i
80,2010-019912-18,RAD,o
80,2010-019912-18,mayor,o
80,2010-019912-18,o,o
80,2010-019912-18,igual,o
80,2010-019912-18,a,o
80,2010-019912-18,8,o
80,2010-019912-18,recuento,o
80,2010-019912-18,de,o
80,2010-019912-18,68,o
80,2010-019912-18,articulaciones,i
80,2010-019912-18,en,o
80,2010-019912-18,las,o
80,2010-019912-18,visitas,o
80,2010-019912-18,de,o
80,2010-019912-18,seleccion,o
80,2010-019912-18,y,o
80,2010-019912-18,basal,o
80,2010-019912-18,Los,o
80,2010-019912-18,pacientes,o
80,2010-019912-18,deben,o
80,2010-019912-18,estar,o
80,2010-019912-18,recibiendo,o
80,2010-019912-18,tratamiento,i
80,2010-019912-18,con,o
80,2010-019912-18,una,o
80,2010-019912-18,dosis,o
80,2010-019912-18,estable,o
80,2010-019912-18,de,o
80,2010-019912-18,los,o
80,2010-019912-18,FAMEs,i
80,2010-019912-18,permitidos,o
80,2010-019912-18,como,o
80,2010-019912-18,minimo,o
80,2010-019912-18,8,o
80,2010-019912-18,semanas,o
80,2010-019912-18,antes,o
80,2010-019912-18,de,o
80,2010-019912-18,la,o
80,2010-019912-18,visita,o
80,2010-019912-18,basal,o
80,2010-019912-18,Criterios,o
80,2010-019912-18,de,o
80,2010-019912-18,exclusion,o
80,2010-019912-18,Pacientes,o
80,2010-019912-18,sometidos,o
80,2010-019912-18,a,o
80,2010-019912-18,intervenciones,i
80,2010-019912-18,de,i
80,2010-019912-18,cirugia,i
80,2010-019912-18,mayor,i
80,2010-019912-18,incluyendo,o
80,2010-019912-18,cirugia,i
80,2010-019912-18,articular,i
80,2010-019912-18,en,o
80,2010-019912-18,las,o
80,2010-019912-18,8,o
80,2010-019912-18,semanas,o
80,2010-019912-18,previas,o
80,2010-019912-18,a,o
80,2010-019912-18,la,o
80,2010-019912-18,visita,o
80,2010-019912-18,de,o
80,2010-019912-18,seleccion,o
80,2010-019912-18,o,o
80,2010-019912-18,que,o
80,2010-019912-18,tengan,o
80,2010-019912-18,previsto,o
80,2010-019912-18,someterse,o
80,2010-019912-18,a,o
80,2010-019912-18,una,o
80,2010-019912-18,intervencion,i
80,2010-019912-18,de,o
80,2010-019912-18,este,o
80,2010-019912-18,tipo,o
80,2010-019912-18,en,o
80,2010-019912-18,los,o
80,2010-019912-18,6,o
80,2010-019912-18,meses,o
80,2010-019912-18,siguientes,o
80,2010-019912-18,a,o
80,2010-019912-18,la,o
80,2010-019912-18,randomizacion,i
80,2010-019912-18,Enfermedad,i
80,2010-019912-18,reumatica,i
80,2010-019912-18,autoinmune,i
80,2010-019912-18,distinta,o
80,2010-019912-18,de,o
80,2010-019912-18,AR,i
80,2010-019912-18,Se,o
80,2010-019912-18,permite,o
80,2010-019912-18,la,o
80,2010-019912-18,inclusion,o
80,2010-019912-18,de,o
80,2010-019912-18,pacientes,o
80,2010-019912-18,con,o
80,2010-019912-18,sindrome,i
80,2010-019912-18,de,i
80,2010-019912-18,Sjögren,i
80,2010-019912-18,secundario,i
80,2010-019912-18,asociado,o
80,2010-019912-18,a,o
80,2010-019912-18,AR,i
80,2010-019912-18,Clase,o
80,2010-019912-18,funcional,o
80,2010-019912-18,IV,o
80,2010-019912-18,definida,o
80,2010-019912-18,de,o
80,2010-019912-18,acuerdo,o
80,2010-019912-18,con,o
80,2010-019912-18,la,o
80,2010-019912-18,Clasificacion,o
80,2010-019912-18,del,o
80,2010-019912-18,ACR,o
80,2010-019912-18,del,o
80,2010-019912-18,Estado,o
80,2010-019912-18,Funcional,o
80,2010-019912-18,en,o
80,2010-019912-18,Artritis,i
80,2010-019912-18,Reumatoide,i
80,2010-019912-18,Artritis,i
80,2010-019912-18,idiopatica,i
80,2010-019912-18,juvenil,i
80,2010-019912-18,AIJ,i
80,2010-019912-18,o,o
80,2010-019912-18,artritis,i
80,2010-019912-18,reumatoide,i
80,2010-019912-18,juvenil,i
80,2010-019912-18,ARJ,i
80,2010-019912-18,yo,o
80,2010-019912-18,AR,i
80,2010-019912-18,diagnosticadas,i
80,2010-019912-18,antes,o
80,2010-019912-18,de,o
80,2010-019912-18,los,o
80,2010-019912-18,16,o
80,2010-019912-18,años,o
80,2010-019912-18,de,o
80,2010-019912-18,edad,o
80,2010-019912-18,Enfermedad,i
80,2010-019912-18,articular,i
80,2010-019912-18,inflamatoria,i
80,2010-019912-18,distinta,o
80,2010-019912-18,de,o
80,2010-019912-18,AR,i
80,2010-019912-18,en,o
80,2010-019912-18,el,o
80,2010-019912-18,pasado,o
80,2010-019912-18,o,o
80,2010-019912-18,en,o
80,2010-019912-18,la,o
80,2010-019912-18,actualidad,o
81,2010-019912-18,EudraCT,o
81,2010-019912-18,Nº,o
81,2010-019912-18,201001991218,o
81,2010-019912-18,Titulo,o
81,2010-019912-18,cientifico,o
81,2010-019912-18,Estudio,o
81,2010-019912-18,randomizado,o
81,2010-019912-18,doble,o
81,2010-019912-18,ciego,o
81,2010-019912-18,con,o
81,2010-019912-18,grupos,o
81,2010-019912-18,de,o
81,2010-019912-18,tratamiento,i
81,2010-019912-18,paralelos,o
81,2010-019912-18,para,o
81,2010-019912-18,evaluar,i
81,2010-019912-18,la,i
81,2010-019912-18,seguridad,i
81,2010-019912-18,y,o
81,2010-019912-18,el,o
81,2010-019912-18,efecto,o
81,2010-019912-18,sobre,o
81,2010-019912-18,el,o
81,2010-019912-18,resultado,o
81,2010-019912-18,clinico,o
81,2010-019912-18,de,o
81,2010-019912-18,tocilizumab,i
81,2010-019912-18,SC,o
81,2010-019912-18,frente,o
81,2010-019912-18,a,o
81,2010-019912-18,placebo,i
81,2010-019912-18,SC,o
81,2010-019912-18,en,o
81,2010-019912-18,combinacion,o
81,2010-019912-18,con,o
81,2010-019912-18,farmacos,i
81,2010-019912-18,antirreumaticos,i
81,2010-019912-18,modificadores,i
81,2010-019912-18,de,i
81,2010-019912-18,la,i
81,2010-019912-18,enfermedad,i
81,2010-019912-18,FAMEs,i
81,2010-019912-18,tradicionales,o
81,2010-019912-18,en,o
81,2010-019912-18,pacientes,o
81,2010-019912-18,con,o
81,2010-019912-18,artritis,i
81,2010-019912-18,reumatoide,i
81,2010-019912-18,activa,o
81,2010-019912-18,moderada,o
81,2010-019912-18,a,o
81,2010-019912-18,severa,o
81,2010-019912-18,Indicacion,o
81,2010-019912-18,cientifica,o
81,2010-019912-18,Artritis,i
81,2010-019912-18,Reumatoide,i
81,2010-019912-18,AR,i
81,2010-019912-18,Criterios,o
81,2010-019912-18,de,o
81,2010-019912-18,inclusion,o
81,2010-019912-18,Presentar,o
81,2010-019912-18,artritis,i
81,2010-019912-18,reumatoide,i
81,2010-019912-18,de,o
81,2010-019912-18,mayor,o
81,2010-019912-18,o,o
81,2010-019912-18,igual,o
81,2010-019912-18,a,o
81,2010-019912-18,6,o
81,2010-019912-18,meses,o
81,2010-019912-18,de,o
81,2010-019912-18,duracion,o
81,2010-019912-18,Recibir,o
81,2010-019912-18,tratamiento,i
81,2010-019912-18,de,i
81,2010-019912-18,forma,i
81,2010-019912-18,ambulatoria,i
81,2010-019912-18,Presentar,o
81,2010-019912-18,un,o
81,2010-019912-18,recuento,o
81,2010-019912-18,de,o
81,2010-019912-18,articulaciones,i
81,2010-019912-18,inflamadas,i
81,2010-019912-18,RAI,o
81,2010-019912-18,mayor,o
81,2010-019912-18,o,o
81,2010-019912-18,igual,o
81,2010-019912-18,a,o
81,2010-019912-18,6,o
81,2010-019912-18,recuento,o
81,2010-019912-18,de,o
81,2010-019912-18,66,o
81,2010-019912-18,articulaciones,i
81,2010-019912-18,y,o
81,2010-019912-18,de,o
81,2010-019912-18,articulaciones,i
81,2010-019912-18,dolorosas,i
81,2010-019912-18,RAD,o
81,2010-019912-18,mayor,o
81,2010-019912-18,o,o
81,2010-019912-18,igual,o
81,2010-019912-18,a,o
81,2010-019912-18,8,o
81,2010-019912-18,recuento,o
81,2010-019912-18,de,o
81,2010-019912-18,68,o
81,2010-019912-18,articulaciones,i
81,2010-019912-18,en,o
81,2010-019912-18,las,o
81,2010-019912-18,visitas,o
81,2010-019912-18,de,o
81,2010-019912-18,seleccion,o
81,2010-019912-18,y,o
81,2010-019912-18,basal,o
81,2010-019912-18,Los,o
81,2010-019912-18,pacientes,o
81,2010-019912-18,deben,o
81,2010-019912-18,estar,o
81,2010-019912-18,recibiendo,o
81,2010-019912-18,tratamiento,i
81,2010-019912-18,con,o
81,2010-019912-18,una,o
81,2010-019912-18,dosis,o
81,2010-019912-18,estable,o
81,2010-019912-18,de,o
81,2010-019912-18,los,o
81,2010-019912-18,FAMEs,i
81,2010-019912-18,permitidos,o
81,2010-019912-18,como,o
81,2010-019912-18,minimo,o
81,2010-019912-18,8,o
81,2010-019912-18,semanas,o
81,2010-019912-18,antes,o
81,2010-019912-18,de,o
81,2010-019912-18,la,o
81,2010-019912-18,visita,o
81,2010-019912-18,basal,o
81,2010-019912-18,Criterios,o
81,2010-019912-18,de,o
81,2010-019912-18,exclusion,o
81,2010-019912-18,Pacientes,o
81,2010-019912-18,sometidos,o
81,2010-019912-18,a,o
81,2010-019912-18,intervenciones,i
81,2010-019912-18,de,i
81,2010-019912-18,cirugia,i
81,2010-019912-18,mayor,i
81,2010-019912-18,incluyendo,o
81,2010-019912-18,cirugia,i
81,2010-019912-18,articular,i
81,2010-019912-18,en,o
81,2010-019912-18,las,o
81,2010-019912-18,8,o
81,2010-019912-18,semanas,o
81,2010-019912-18,previas,o
81,2010-019912-18,a,o
81,2010-019912-18,la,o
81,2010-019912-18,visita,o
81,2010-019912-18,de,o
81,2010-019912-18,seleccion,o
81,2010-019912-18,o,o
81,2010-019912-18,que,o
81,2010-019912-18,tengan,o
81,2010-019912-18,previsto,o
81,2010-019912-18,someterse,o
81,2010-019912-18,a,o
81,2010-019912-18,una,o
81,2010-019912-18,intervencion,i
81,2010-019912-18,de,o
81,2010-019912-18,este,o
81,2010-019912-18,tipo,o
81,2010-019912-18,en,o
81,2010-019912-18,los,o
81,2010-019912-18,6,o
81,2010-019912-18,meses,o
81,2010-019912-18,siguientes,o
81,2010-019912-18,a,o
81,2010-019912-18,la,o
81,2010-019912-18,randomizacion,i
81,2010-019912-18,Enfermedad,i
81,2010-019912-18,reumatica,i
81,2010-019912-18,autoinmune,i
81,2010-019912-18,distinta,o
81,2010-019912-18,de,o
81,2010-019912-18,AR,i
81,2010-019912-18,Se,o
81,2010-019912-18,permite,o
81,2010-019912-18,la,o
81,2010-019912-18,inclusion,o
81,2010-019912-18,de,o
81,2010-019912-18,pacientes,o
81,2010-019912-18,con,o
81,2010-019912-18,sindrome,i
81,2010-019912-18,de,i
81,2010-019912-18,Sjögren,i
81,2010-019912-18,secundario,i
81,2010-019912-18,asociado,o
81,2010-019912-18,a,o
81,2010-019912-18,AR,i
81,2010-019912-18,Clase,o
81,2010-019912-18,funcional,o
81,2010-019912-18,IV,o
81,2010-019912-18,definida,o
81,2010-019912-18,de,o
81,2010-019912-18,acuerdo,o
81,2010-019912-18,con,o
81,2010-019912-18,la,o
81,2010-019912-18,Clasificacion,o
81,2010-019912-18,del,o
81,2010-019912-18,ACR,o
81,2010-019912-18,del,o
81,2010-019912-18,Estado,o
81,2010-019912-18,Funcional,o
81,2010-019912-18,en,o
81,2010-019912-18,Artritis,i
81,2010-019912-18,Reumatoide,i
81,2010-019912-18,Artritis,i
81,2010-019912-18,idiopatica,i
81,2010-019912-18,juvenil,i
81,2010-019912-18,AIJ,i
81,2010-019912-18,o,o
81,2010-019912-18,artritis,i
81,2010-019912-18,reumatoide,i
81,2010-019912-18,juvenil,i
81,2010-019912-18,ARJ,i
81,2010-019912-18,yo,o
81,2010-019912-18,AR,i
81,2010-019912-18,diagnosticadas,i
81,2010-019912-18,antes,o
81,2010-019912-18,de,o
81,2010-019912-18,los,o
81,2010-019912-18,16,o
81,2010-019912-18,años,o
81,2010-019912-18,de,o
81,2010-019912-18,edad,o
81,2010-019912-18,Enfermedad,i
81,2010-019912-18,articular,i
81,2010-019912-18,inflamatoria,i
81,2010-019912-18,distinta,o
81,2010-019912-18,de,o
81,2010-019912-18,AR,i
81,2010-019912-18,en,o
81,2010-019912-18,el,o
81,2010-019912-18,pasado,o
81,2010-019912-18,o,o
81,2010-019912-18,en,o
81,2010-019912-18,la,o
81,2010-019912-18,actualidad,o
82,2010-019912-18,EudraCT,o
82,2010-019912-18,Nº,o
82,2010-019912-18,201001991218,o
82,2010-019912-18,Titulo,o
82,2010-019912-18,cientifico,o
82,2010-019912-18,Estudio,o
82,2010-019912-18,randomizado,o
82,2010-019912-18,doble,o
82,2010-019912-18,ciego,o
82,2010-019912-18,con,o
82,2010-019912-18,grupos,o
82,2010-019912-18,de,o
82,2010-019912-18,tratamiento,i
82,2010-019912-18,paralelos,o
82,2010-019912-18,para,o
82,2010-019912-18,evaluar,i
82,2010-019912-18,la,i
82,2010-019912-18,seguridad,i
82,2010-019912-18,y,o
82,2010-019912-18,el,o
82,2010-019912-18,efecto,o
82,2010-019912-18,sobre,o
82,2010-019912-18,el,o
82,2010-019912-18,resultado,o
82,2010-019912-18,clinico,o
82,2010-019912-18,de,o
82,2010-019912-18,tocilizumab,i
82,2010-019912-18,SC,o
82,2010-019912-18,frente,o
82,2010-019912-18,a,o
82,2010-019912-18,placebo,i
82,2010-019912-18,SC,o
82,2010-019912-18,en,o
82,2010-019912-18,combinacion,o
82,2010-019912-18,con,o
82,2010-019912-18,farmacos,i
82,2010-019912-18,antirreumaticos,i
82,2010-019912-18,modificadores,i
82,2010-019912-18,de,i
82,2010-019912-18,la,i
82,2010-019912-18,enfermedad,i
82,2010-019912-18,FAMEs,i
82,2010-019912-18,tradicionales,o
82,2010-019912-18,en,o
82,2010-019912-18,pacientes,o
82,2010-019912-18,con,o
82,2010-019912-18,artritis,i
82,2010-019912-18,reumatoide,i
82,2010-019912-18,activa,o
82,2010-019912-18,moderada,o
82,2010-019912-18,a,o
82,2010-019912-18,severa,o
82,2010-019912-18,Indicacion,o
82,2010-019912-18,cientifica,o
82,2010-019912-18,Artritis,i
82,2010-019912-18,Reumatoide,i
82,2010-019912-18,AR,i
82,2010-019912-18,Criterios,o
82,2010-019912-18,de,o
82,2010-019912-18,inclusion,o
82,2010-019912-18,Presentar,o
82,2010-019912-18,artritis,i
82,2010-019912-18,reumatoide,i
82,2010-019912-18,de,o
82,2010-019912-18,mayor,o
82,2010-019912-18,o,o
82,2010-019912-18,igual,o
82,2010-019912-18,a,o
82,2010-019912-18,6,o
82,2010-019912-18,meses,o
82,2010-019912-18,de,o
82,2010-019912-18,duracion,o
82,2010-019912-18,Recibir,o
82,2010-019912-18,tratamiento,i
82,2010-019912-18,de,i
82,2010-019912-18,forma,i
82,2010-019912-18,ambulatoria,i
82,2010-019912-18,Presentar,o
82,2010-019912-18,un,o
82,2010-019912-18,recuento,o
82,2010-019912-18,de,o
82,2010-019912-18,articulaciones,i
82,2010-019912-18,inflamadas,i
82,2010-019912-18,RAI,o
82,2010-019912-18,mayor,o
82,2010-019912-18,o,o
82,2010-019912-18,igual,o
82,2010-019912-18,a,o
82,2010-019912-18,6,o
82,2010-019912-18,recuento,o
82,2010-019912-18,de,o
82,2010-019912-18,66,o
82,2010-019912-18,articulaciones,i
82,2010-019912-18,y,o
82,2010-019912-18,de,o
82,2010-019912-18,articulaciones,i
82,2010-019912-18,dolorosas,i
82,2010-019912-18,RAD,o
82,2010-019912-18,mayor,o
82,2010-019912-18,o,o
82,2010-019912-18,igual,o
82,2010-019912-18,a,o
82,2010-019912-18,8,o
82,2010-019912-18,recuento,o
82,2010-019912-18,de,o
82,2010-019912-18,68,o
82,2010-019912-18,articulaciones,i
82,2010-019912-18,en,o
82,2010-019912-18,las,o
82,2010-019912-18,visitas,o
82,2010-019912-18,de,o
82,2010-019912-18,seleccion,o
82,2010-019912-18,y,o
82,2010-019912-18,basal,o
82,2010-019912-18,Los,o
82,2010-019912-18,pacientes,o
82,2010-019912-18,deben,o
82,2010-019912-18,estar,o
82,2010-019912-18,recibiendo,o
82,2010-019912-18,tratamiento,i
82,2010-019912-18,con,o
82,2010-019912-18,una,o
82,2010-019912-18,dosis,o
82,2010-019912-18,estable,o
82,2010-019912-18,de,o
82,2010-019912-18,los,o
82,2010-019912-18,FAMEs,i
82,2010-019912-18,permitidos,o
82,2010-019912-18,como,o
82,2010-019912-18,minimo,o
82,2010-019912-18,8,o
82,2010-019912-18,semanas,o
82,2010-019912-18,antes,o
82,2010-019912-18,de,o
82,2010-019912-18,la,o
82,2010-019912-18,visita,o
82,2010-019912-18,basal,o
82,2010-019912-18,Criterios,o
82,2010-019912-18,de,o
82,2010-019912-18,exclusion,o
82,2010-019912-18,Pacientes,o
82,2010-019912-18,sometidos,o
82,2010-019912-18,a,o
82,2010-019912-18,intervenciones,i
82,2010-019912-18,de,i
82,2010-019912-18,cirugia,i
82,2010-019912-18,mayor,i
82,2010-019912-18,incluyendo,o
82,2010-019912-18,cirugia,i
82,2010-019912-18,articular,i
82,2010-019912-18,en,o
82,2010-019912-18,las,o
82,2010-019912-18,8,o
82,2010-019912-18,semanas,o
82,2010-019912-18,previas,o
82,2010-019912-18,a,o
82,2010-019912-18,la,o
82,2010-019912-18,visita,o
82,2010-019912-18,de,o
82,2010-019912-18,seleccion,o
82,2010-019912-18,o,o
82,2010-019912-18,que,o
82,2010-019912-18,tengan,o
82,2010-019912-18,previsto,o
82,2010-019912-18,someterse,o
82,2010-019912-18,a,o
82,2010-019912-18,una,o
82,2010-019912-18,intervencion,i
82,2010-019912-18,de,o
82,2010-019912-18,este,o
82,2010-019912-18,tipo,o
82,2010-019912-18,en,o
82,2010-019912-18,los,o
82,2010-019912-18,6,o
82,2010-019912-18,meses,o
82,2010-019912-18,siguientes,o
82,2010-019912-18,a,o
82,2010-019912-18,la,o
82,2010-019912-18,randomizacion,i
82,2010-019912-18,Enfermedad,i
82,2010-019912-18,reumatica,i
82,2010-019912-18,autoinmune,i
82,2010-019912-18,distinta,o
82,2010-019912-18,de,o
82,2010-019912-18,AR,i
82,2010-019912-18,Se,o
82,2010-019912-18,permite,o
82,2010-019912-18,la,o
82,2010-019912-18,inclusion,o
82,2010-019912-18,de,o
82,2010-019912-18,pacientes,o
82,2010-019912-18,con,o
82,2010-019912-18,sindrome,i
82,2010-019912-18,de,i
82,2010-019912-18,Sjögren,i
82,2010-019912-18,secundario,i
82,2010-019912-18,asociado,o
82,2010-019912-18,a,o
82,2010-019912-18,AR,i
82,2010-019912-18,Clase,o
82,2010-019912-18,funcional,o
82,2010-019912-18,IV,o
82,2010-019912-18,definida,o
82,2010-019912-18,de,o
82,2010-019912-18,acuerdo,o
82,2010-019912-18,con,o
82,2010-019912-18,la,o
82,2010-019912-18,Clasificacion,o
82,2010-019912-18,del,o
82,2010-019912-18,ACR,o
82,2010-019912-18,del,o
82,2010-019912-18,Estado,o
82,2010-019912-18,Funcional,o
82,2010-019912-18,en,o
82,2010-019912-18,Artritis,i
82,2010-019912-18,Reumatoide,i
82,2010-019912-18,Artritis,i
82,2010-019912-18,idiopatica,i
82,2010-019912-18,juvenil,i
82,2010-019912-18,AIJ,i
82,2010-019912-18,o,o
82,2010-019912-18,artritis,i
82,2010-019912-18,reumatoide,i
82,2010-019912-18,juvenil,i
82,2010-019912-18,ARJ,i
82,2010-019912-18,yo,o
82,2010-019912-18,AR,i
82,2010-019912-18,diagnosticadas,i
82,2010-019912-18,antes,o
82,2010-019912-18,de,o
82,2010-019912-18,los,o
82,2010-019912-18,16,o
82,2010-019912-18,años,o
82,2010-019912-18,de,o
82,2010-019912-18,edad,o
82,2010-019912-18,Enfermedad,i
82,2010-019912-18,articular,i
82,2010-019912-18,inflamatoria,i
82,2010-019912-18,distinta,o
82,2010-019912-18,de,o
82,2010-019912-18,AR,i
82,2010-019912-18,en,o
82,2010-019912-18,el,o
82,2010-019912-18,pasado,o
82,2010-019912-18,o,o
82,2010-019912-18,en,o
82,2010-019912-18,la,o
82,2010-019912-18,actualidad,o
83,2010-019912-18,EudraCT,o
83,2010-019912-18,Nº,o
83,2010-019912-18,201001991218,o
83,2010-019912-18,Titulo,o
83,2010-019912-18,cientifico,o
83,2010-019912-18,Estudio,o
83,2010-019912-18,randomizado,o
83,2010-019912-18,doble,o
83,2010-019912-18,ciego,o
83,2010-019912-18,con,o
83,2010-019912-18,grupos,o
83,2010-019912-18,de,o
83,2010-019912-18,tratamiento,i
83,2010-019912-18,paralelos,o
83,2010-019912-18,para,o
83,2010-019912-18,evaluar,i
83,2010-019912-18,la,i
83,2010-019912-18,seguridad,i
83,2010-019912-18,y,o
83,2010-019912-18,el,o
83,2010-019912-18,efecto,o
83,2010-019912-18,sobre,o
83,2010-019912-18,el,o
83,2010-019912-18,resultado,o
83,2010-019912-18,clinico,o
83,2010-019912-18,de,o
83,2010-019912-18,tocilizumab,i
83,2010-019912-18,SC,o
83,2010-019912-18,frente,o
83,2010-019912-18,a,o
83,2010-019912-18,placebo,i
83,2010-019912-18,SC,o
83,2010-019912-18,en,o
83,2010-019912-18,combinacion,o
83,2010-019912-18,con,o
83,2010-019912-18,farmacos,i
83,2010-019912-18,antirreumaticos,i
83,2010-019912-18,modificadores,i
83,2010-019912-18,de,i
83,2010-019912-18,la,i
83,2010-019912-18,enfermedad,i
83,2010-019912-18,FAMEs,i
83,2010-019912-18,tradicionales,o
83,2010-019912-18,en,o
83,2010-019912-18,pacientes,o
83,2010-019912-18,con,o
83,2010-019912-18,artritis,i
83,2010-019912-18,reumatoide,i
83,2010-019912-18,activa,o
83,2010-019912-18,moderada,o
83,2010-019912-18,a,o
83,2010-019912-18,severa,o
83,2010-019912-18,Indicacion,o
83,2010-019912-18,cientifica,o
83,2010-019912-18,Artritis,i
83,2010-019912-18,Reumatoide,i
83,2010-019912-18,AR,i
83,2010-019912-18,Criterios,o
83,2010-019912-18,de,o
83,2010-019912-18,inclusion,o
83,2010-019912-18,Presentar,o
83,2010-019912-18,artritis,i
83,2010-019912-18,reumatoide,i
83,2010-019912-18,de,o
83,2010-019912-18,mayor,o
83,2010-019912-18,o,o
83,2010-019912-18,igual,o
83,2010-019912-18,a,o
83,2010-019912-18,6,o
83,2010-019912-18,meses,o
83,2010-019912-18,de,o
83,2010-019912-18,duracion,o
83,2010-019912-18,Recibir,o
83,2010-019912-18,tratamiento,i
83,2010-019912-18,de,i
83,2010-019912-18,forma,i
83,2010-019912-18,ambulatoria,i
83,2010-019912-18,Presentar,o
83,2010-019912-18,un,o
83,2010-019912-18,recuento,o
83,2010-019912-18,de,o
83,2010-019912-18,articulaciones,i
83,2010-019912-18,inflamadas,i
83,2010-019912-18,RAI,o
83,2010-019912-18,mayor,o
83,2010-019912-18,o,o
83,2010-019912-18,igual,o
83,2010-019912-18,a,o
83,2010-019912-18,6,o
83,2010-019912-18,recuento,o
83,2010-019912-18,de,o
83,2010-019912-18,66,o
83,2010-019912-18,articulaciones,i
83,2010-019912-18,y,o
83,2010-019912-18,de,o
83,2010-019912-18,articulaciones,i
83,2010-019912-18,dolorosas,i
83,2010-019912-18,RAD,o
83,2010-019912-18,mayor,o
83,2010-019912-18,o,o
83,2010-019912-18,igual,o
83,2010-019912-18,a,o
83,2010-019912-18,8,o
83,2010-019912-18,recuento,o
83,2010-019912-18,de,o
83,2010-019912-18,68,o
83,2010-019912-18,articulaciones,i
83,2010-019912-18,en,o
83,2010-019912-18,las,o
83,2010-019912-18,visitas,o
83,2010-019912-18,de,o
83,2010-019912-18,seleccion,o
83,2010-019912-18,y,o
83,2010-019912-18,basal,o
83,2010-019912-18,Los,o
83,2010-019912-18,pacientes,o
83,2010-019912-18,deben,o
83,2010-019912-18,estar,o
83,2010-019912-18,recibiendo,o
83,2010-019912-18,tratamiento,i
83,2010-019912-18,con,o
83,2010-019912-18,una,o
83,2010-019912-18,dosis,o
83,2010-019912-18,estable,o
83,2010-019912-18,de,o
83,2010-019912-18,los,o
83,2010-019912-18,FAMEs,i
83,2010-019912-18,permitidos,o
83,2010-019912-18,como,o
83,2010-019912-18,minimo,o
83,2010-019912-18,8,o
83,2010-019912-18,semanas,o
83,2010-019912-18,antes,o
83,2010-019912-18,de,o
83,2010-019912-18,la,o
83,2010-019912-18,visita,o
83,2010-019912-18,basal,o
83,2010-019912-18,Criterios,o
83,2010-019912-18,de,o
83,2010-019912-18,exclusion,o
83,2010-019912-18,Pacientes,o
83,2010-019912-18,sometidos,o
83,2010-019912-18,a,o
83,2010-019912-18,intervenciones,i
83,2010-019912-18,de,i
83,2010-019912-18,cirugia,i
83,2010-019912-18,mayor,i
83,2010-019912-18,incluyendo,o
83,2010-019912-18,cirugia,i
83,2010-019912-18,articular,i
83,2010-019912-18,en,o
83,2010-019912-18,las,o
83,2010-019912-18,8,o
83,2010-019912-18,semanas,o
83,2010-019912-18,previas,o
83,2010-019912-18,a,o
83,2010-019912-18,la,o
83,2010-019912-18,visita,o
83,2010-019912-18,de,o
83,2010-019912-18,seleccion,o
83,2010-019912-18,o,o
83,2010-019912-18,que,o
83,2010-019912-18,tengan,o
83,2010-019912-18,previsto,o
83,2010-019912-18,someterse,o
83,2010-019912-18,a,o
83,2010-019912-18,una,o
83,2010-019912-18,intervencion,i
83,2010-019912-18,de,o
83,2010-019912-18,este,o
83,2010-019912-18,tipo,o
83,2010-019912-18,en,o
83,2010-019912-18,los,o
83,2010-019912-18,6,o
83,2010-019912-18,meses,o
83,2010-019912-18,siguientes,o
83,2010-019912-18,a,o
83,2010-019912-18,la,o
83,2010-019912-18,randomizacion,i
83,2010-019912-18,Enfermedad,i
83,2010-019912-18,reumatica,i
83,2010-019912-18,autoinmune,i
83,2010-019912-18,distinta,o
83,2010-019912-18,de,o
83,2010-019912-18,AR,i
83,2010-019912-18,Se,o
83,2010-019912-18,permite,o
83,2010-019912-18,la,o
83,2010-019912-18,inclusion,o
83,2010-019912-18,de,o
83,2010-019912-18,pacientes,o
83,2010-019912-18,con,o
83,2010-019912-18,sindrome,i
83,2010-019912-18,de,i
83,2010-019912-18,Sjögren,i
83,2010-019912-18,secundario,i
83,2010-019912-18,asociado,o
83,2010-019912-18,a,o
83,2010-019912-18,AR,i
83,2010-019912-18,Clase,o
83,2010-019912-18,funcional,o
83,2010-019912-18,IV,o
83,2010-019912-18,definida,o
83,2010-019912-18,de,o
83,2010-019912-18,acuerdo,o
83,2010-019912-18,con,o
83,2010-019912-18,la,o
83,2010-019912-18,Clasificacion,o
83,2010-019912-18,del,o
83,2010-019912-18,ACR,o
83,2010-019912-18,del,o
83,2010-019912-18,Estado,o
83,2010-019912-18,Funcional,o
83,2010-019912-18,en,o
83,2010-019912-18,Artritis,i
83,2010-019912-18,Reumatoide,i
83,2010-019912-18,Artritis,i
83,2010-019912-18,idiopatica,i
83,2010-019912-18,juvenil,i
83,2010-019912-18,AIJ,i
83,2010-019912-18,o,o
83,2010-019912-18,artritis,i
83,2010-019912-18,reumatoide,i
83,2010-019912-18,juvenil,i
83,2010-019912-18,ARJ,i
83,2010-019912-18,yo,o
83,2010-019912-18,AR,i
83,2010-019912-18,diagnosticadas,i
83,2010-019912-18,antes,o
83,2010-019912-18,de,o
83,2010-019912-18,los,o
83,2010-019912-18,16,o
83,2010-019912-18,años,o
83,2010-019912-18,de,o
83,2010-019912-18,edad,o
83,2010-019912-18,Enfermedad,i
83,2010-019912-18,articular,i
83,2010-019912-18,inflamatoria,i
83,2010-019912-18,distinta,o
83,2010-019912-18,de,o
83,2010-019912-18,AR,i
83,2010-019912-18,en,o
83,2010-019912-18,el,o
83,2010-019912-18,pasado,o
83,2010-019912-18,o,o
83,2010-019912-18,en,o
83,2010-019912-18,la,o
83,2010-019912-18,actualidad,o
84,2010-019912-18,EudraCT,o
84,2010-019912-18,Nº,o
84,2010-019912-18,201001991218,o
84,2010-019912-18,Titulo,o
84,2010-019912-18,cientifico,o
84,2010-019912-18,Estudio,o
84,2010-019912-18,randomizado,o
84,2010-019912-18,doble,o
84,2010-019912-18,ciego,o
84,2010-019912-18,con,o
84,2010-019912-18,grupos,o
84,2010-019912-18,de,o
84,2010-019912-18,tratamiento,i
84,2010-019912-18,paralelos,o
84,2010-019912-18,para,o
84,2010-019912-18,evaluar,i
84,2010-019912-18,la,i
84,2010-019912-18,seguridad,i
84,2010-019912-18,y,o
84,2010-019912-18,el,o
84,2010-019912-18,efecto,o
84,2010-019912-18,sobre,o
84,2010-019912-18,el,o
84,2010-019912-18,resultado,o
84,2010-019912-18,clinico,o
84,2010-019912-18,de,o
84,2010-019912-18,tocilizumab,i
84,2010-019912-18,SC,o
84,2010-019912-18,frente,o
84,2010-019912-18,a,o
84,2010-019912-18,placebo,i
84,2010-019912-18,SC,o
84,2010-019912-18,en,o
84,2010-019912-18,combinacion,o
84,2010-019912-18,con,o
84,2010-019912-18,farmacos,i
84,2010-019912-18,antirreumaticos,i
84,2010-019912-18,modificadores,i
84,2010-019912-18,de,i
84,2010-019912-18,la,i
84,2010-019912-18,enfermedad,i
84,2010-019912-18,FAMEs,i
84,2010-019912-18,tradicionales,o
84,2010-019912-18,en,o
84,2010-019912-18,pacientes,o
84,2010-019912-18,con,o
84,2010-019912-18,artritis,i
84,2010-019912-18,reumatoide,i
84,2010-019912-18,activa,o
84,2010-019912-18,moderada,o
84,2010-019912-18,a,o
84,2010-019912-18,severa,o
84,2010-019912-18,Indicacion,o
84,2010-019912-18,cientifica,o
84,2010-019912-18,Artritis,i
84,2010-019912-18,Reumatoide,i
84,2010-019912-18,AR,i
84,2010-019912-18,Criterios,o
84,2010-019912-18,de,o
84,2010-019912-18,inclusion,o
84,2010-019912-18,Presentar,o
84,2010-019912-18,artritis,i
84,2010-019912-18,reumatoide,i
84,2010-019912-18,de,o
84,2010-019912-18,mayor,o
84,2010-019912-18,o,o
84,2010-019912-18,igual,o
84,2010-019912-18,a,o
84,2010-019912-18,6,o
84,2010-019912-18,meses,o
84,2010-019912-18,de,o
84,2010-019912-18,duracion,o
84,2010-019912-18,Recibir,o
84,2010-019912-18,tratamiento,i
84,2010-019912-18,de,i
84,2010-019912-18,forma,i
84,2010-019912-18,ambulatoria,i
84,2010-019912-18,Presentar,o
84,2010-019912-18,un,o
84,2010-019912-18,recuento,o
84,2010-019912-18,de,o
84,2010-019912-18,articulaciones,i
84,2010-019912-18,inflamadas,i
84,2010-019912-18,RAI,o
84,2010-019912-18,mayor,o
84,2010-019912-18,o,o
84,2010-019912-18,igual,o
84,2010-019912-18,a,o
84,2010-019912-18,6,o
84,2010-019912-18,recuento,o
84,2010-019912-18,de,o
84,2010-019912-18,66,o
84,2010-019912-18,articulaciones,i
84,2010-019912-18,y,o
84,2010-019912-18,de,o
84,2010-019912-18,articulaciones,i
84,2010-019912-18,dolorosas,i
84,2010-019912-18,RAD,o
84,2010-019912-18,mayor,o
84,2010-019912-18,o,o
84,2010-019912-18,igual,o
84,2010-019912-18,a,o
84,2010-019912-18,8,o
84,2010-019912-18,recuento,o
84,2010-019912-18,de,o
84,2010-019912-18,68,o
84,2010-019912-18,articulaciones,i
84,2010-019912-18,en,o
84,2010-019912-18,las,o
84,2010-019912-18,visitas,o
84,2010-019912-18,de,o
84,2010-019912-18,seleccion,o
84,2010-019912-18,y,o
84,2010-019912-18,basal,o
84,2010-019912-18,Los,o
84,2010-019912-18,pacientes,o
84,2010-019912-18,deben,o
84,2010-019912-18,estar,o
84,2010-019912-18,recibiendo,o
84,2010-019912-18,tratamiento,i
84,2010-019912-18,con,o
84,2010-019912-18,una,o
84,2010-019912-18,dosis,o
84,2010-019912-18,estable,o
84,2010-019912-18,de,o
84,2010-019912-18,los,o
84,2010-019912-18,FAMEs,i
84,2010-019912-18,permitidos,o
84,2010-019912-18,como,o
84,2010-019912-18,minimo,o
84,2010-019912-18,8,o
84,2010-019912-18,semanas,o
84,2010-019912-18,antes,o
84,2010-019912-18,de,o
84,2010-019912-18,la,o
84,2010-019912-18,visita,o
84,2010-019912-18,basal,o
84,2010-019912-18,Criterios,o
84,2010-019912-18,de,o
84,2010-019912-18,exclusion,o
84,2010-019912-18,Pacientes,o
84,2010-019912-18,sometidos,o
84,2010-019912-18,a,o
84,2010-019912-18,intervenciones,i
84,2010-019912-18,de,i
84,2010-019912-18,cirugia,i
84,2010-019912-18,mayor,i
84,2010-019912-18,incluyendo,o
84,2010-019912-18,cirugia,i
84,2010-019912-18,articular,i
84,2010-019912-18,en,o
84,2010-019912-18,las,o
84,2010-019912-18,8,o
84,2010-019912-18,semanas,o
84,2010-019912-18,previas,o
84,2010-019912-18,a,o
84,2010-019912-18,la,o
84,2010-019912-18,visita,o
84,2010-019912-18,de,o
84,2010-019912-18,seleccion,o
84,2010-019912-18,o,o
84,2010-019912-18,que,o
84,2010-019912-18,tengan,o
84,2010-019912-18,previsto,o
84,2010-019912-18,someterse,o
84,2010-019912-18,a,o
84,2010-019912-18,una,o
84,2010-019912-18,intervencion,i
84,2010-019912-18,de,o
84,2010-019912-18,este,o
84,2010-019912-18,tipo,o
84,2010-019912-18,en,o
84,2010-019912-18,los,o
84,2010-019912-18,6,o
84,2010-019912-18,meses,o
84,2010-019912-18,siguientes,o
84,2010-019912-18,a,o
84,2010-019912-18,la,o
84,2010-019912-18,randomizacion,i
84,2010-019912-18,Enfermedad,i
84,2010-019912-18,reumatica,i
84,2010-019912-18,autoinmune,i
84,2010-019912-18,distinta,o
84,2010-019912-18,de,o
84,2010-019912-18,AR,i
84,2010-019912-18,Se,o
84,2010-019912-18,permite,o
84,2010-019912-18,la,o
84,2010-019912-18,inclusion,o
84,2010-019912-18,de,o
84,2010-019912-18,pacientes,o
84,2010-019912-18,con,o
84,2010-019912-18,sindrome,i
84,2010-019912-18,de,i
84,2010-019912-18,Sjögren,i
84,2010-019912-18,secundario,i
84,2010-019912-18,asociado,o
84,2010-019912-18,a,o
84,2010-019912-18,AR,i
84,2010-019912-18,Clase,o
84,2010-019912-18,funcional,o
84,2010-019912-18,IV,o
84,2010-019912-18,definida,o
84,2010-019912-18,de,o
84,2010-019912-18,acuerdo,o
84,2010-019912-18,con,o
84,2010-019912-18,la,o
84,2010-019912-18,Clasificacion,o
84,2010-019912-18,del,o
84,2010-019912-18,ACR,o
84,2010-019912-18,del,o
84,2010-019912-18,Estado,o
84,2010-019912-18,Funcional,o
84,2010-019912-18,en,o
84,2010-019912-18,Artritis,i
84,2010-019912-18,Reumatoide,i
84,2010-019912-18,Artritis,i
84,2010-019912-18,idiopatica,i
84,2010-019912-18,juvenil,i
84,2010-019912-18,AIJ,i
84,2010-019912-18,o,o
84,2010-019912-18,artritis,i
84,2010-019912-18,reumatoide,i
84,2010-019912-18,juvenil,i
84,2010-019912-18,ARJ,i
84,2010-019912-18,yo,o
84,2010-019912-18,AR,i
84,2010-019912-18,diagnosticadas,i
84,2010-019912-18,antes,o
84,2010-019912-18,de,o
84,2010-019912-18,los,o
84,2010-019912-18,16,o
84,2010-019912-18,años,o
84,2010-019912-18,de,o
84,2010-019912-18,edad,o
84,2010-019912-18,Enfermedad,i
84,2010-019912-18,articular,i
84,2010-019912-18,inflamatoria,i
84,2010-019912-18,distinta,o
84,2010-019912-18,de,o
84,2010-019912-18,AR,i
84,2010-019912-18,en,o
84,2010-019912-18,el,o
84,2010-019912-18,pasado,o
84,2010-019912-18,o,o
84,2010-019912-18,en,o
84,2010-019912-18,la,o
84,2010-019912-18,actualidad,o
85,2010-019912-18,EudraCT,o
85,2010-019912-18,Nº,o
85,2010-019912-18,201001991218,o
85,2010-019912-18,Titulo,o
85,2010-019912-18,cientifico,o
85,2010-019912-18,Estudio,o
85,2010-019912-18,randomizado,o
85,2010-019912-18,doble,o
85,2010-019912-18,ciego,o
85,2010-019912-18,con,o
85,2010-019912-18,grupos,o
85,2010-019912-18,de,o
85,2010-019912-18,tratamiento,i
85,2010-019912-18,paralelos,o
85,2010-019912-18,para,o
85,2010-019912-18,evaluar,i
85,2010-019912-18,la,i
85,2010-019912-18,seguridad,i
85,2010-019912-18,y,o
85,2010-019912-18,el,o
85,2010-019912-18,efecto,o
85,2010-019912-18,sobre,o
85,2010-019912-18,el,o
85,2010-019912-18,resultado,o
85,2010-019912-18,clinico,o
85,2010-019912-18,de,o
85,2010-019912-18,tocilizumab,i
85,2010-019912-18,SC,o
85,2010-019912-18,frente,o
85,2010-019912-18,a,o
85,2010-019912-18,placebo,i
85,2010-019912-18,SC,o
85,2010-019912-18,en,o
85,2010-019912-18,combinacion,o
85,2010-019912-18,con,o
85,2010-019912-18,farmacos,i
85,2010-019912-18,antirreumaticos,i
85,2010-019912-18,modificadores,i
85,2010-019912-18,de,i
85,2010-019912-18,la,i
85,2010-019912-18,enfermedad,i
85,2010-019912-18,FAMEs,i
85,2010-019912-18,tradicionales,o
85,2010-019912-18,en,o
85,2010-019912-18,pacientes,o
85,2010-019912-18,con,o
85,2010-019912-18,artritis,i
85,2010-019912-18,reumatoide,i
85,2010-019912-18,activa,o
85,2010-019912-18,moderada,o
85,2010-019912-18,a,o
85,2010-019912-18,severa,o
85,2010-019912-18,Indicacion,o
85,2010-019912-18,cientifica,o
85,2010-019912-18,Artritis,i
85,2010-019912-18,Reumatoide,i
85,2010-019912-18,AR,i
85,2010-019912-18,Criterios,o
85,2010-019912-18,de,o
85,2010-019912-18,inclusion,o
85,2010-019912-18,Presentar,o
85,2010-019912-18,artritis,i
85,2010-019912-18,reumatoide,i
85,2010-019912-18,de,o
85,2010-019912-18,mayor,o
85,2010-019912-18,o,o
85,2010-019912-18,igual,o
85,2010-019912-18,a,o
85,2010-019912-18,6,o
85,2010-019912-18,meses,o
85,2010-019912-18,de,o
85,2010-019912-18,duracion,o
85,2010-019912-18,Recibir,o
85,2010-019912-18,tratamiento,i
85,2010-019912-18,de,i
85,2010-019912-18,forma,i
85,2010-019912-18,ambulatoria,i
85,2010-019912-18,Presentar,o
85,2010-019912-18,un,o
85,2010-019912-18,recuento,o
85,2010-019912-18,de,o
85,2010-019912-18,articulaciones,i
85,2010-019912-18,inflamadas,i
85,2010-019912-18,RAI,o
85,2010-019912-18,mayor,o
85,2010-019912-18,o,o
85,2010-019912-18,igual,o
85,2010-019912-18,a,o
85,2010-019912-18,6,o
85,2010-019912-18,recuento,o
85,2010-019912-18,de,o
85,2010-019912-18,66,o
85,2010-019912-18,articulaciones,i
85,2010-019912-18,y,o
85,2010-019912-18,de,o
85,2010-019912-18,articulaciones,i
85,2010-019912-18,dolorosas,i
85,2010-019912-18,RAD,o
85,2010-019912-18,mayor,o
85,2010-019912-18,o,o
85,2010-019912-18,igual,o
85,2010-019912-18,a,o
85,2010-019912-18,8,o
85,2010-019912-18,recuento,o
85,2010-019912-18,de,o
85,2010-019912-18,68,o
85,2010-019912-18,articulaciones,i
85,2010-019912-18,en,o
85,2010-019912-18,las,o
85,2010-019912-18,visitas,o
85,2010-019912-18,de,o
85,2010-019912-18,seleccion,o
85,2010-019912-18,y,o
85,2010-019912-18,basal,o
85,2010-019912-18,Los,o
85,2010-019912-18,pacientes,o
85,2010-019912-18,deben,o
85,2010-019912-18,estar,o
85,2010-019912-18,recibiendo,o
85,2010-019912-18,tratamiento,i
85,2010-019912-18,con,o
85,2010-019912-18,una,o
85,2010-019912-18,dosis,o
85,2010-019912-18,estable,o
85,2010-019912-18,de,o
85,2010-019912-18,los,o
85,2010-019912-18,FAMEs,i
85,2010-019912-18,permitidos,o
85,2010-019912-18,como,o
85,2010-019912-18,minimo,o
85,2010-019912-18,8,o
85,2010-019912-18,semanas,o
85,2010-019912-18,antes,o
85,2010-019912-18,de,o
85,2010-019912-18,la,o
85,2010-019912-18,visita,o
85,2010-019912-18,basal,o
85,2010-019912-18,Criterios,o
85,2010-019912-18,de,o
85,2010-019912-18,exclusion,o
85,2010-019912-18,Pacientes,o
85,2010-019912-18,sometidos,o
85,2010-019912-18,a,o
85,2010-019912-18,intervenciones,i
85,2010-019912-18,de,i
85,2010-019912-18,cirugia,i
85,2010-019912-18,mayor,i
85,2010-019912-18,incluyendo,o
85,2010-019912-18,cirugia,i
85,2010-019912-18,articular,i
85,2010-019912-18,en,o
85,2010-019912-18,las,o
85,2010-019912-18,8,o
85,2010-019912-18,semanas,o
85,2010-019912-18,previas,o
85,2010-019912-18,a,o
85,2010-019912-18,la,o
85,2010-019912-18,visita,o
85,2010-019912-18,de,o
85,2010-019912-18,seleccion,o
85,2010-019912-18,o,o
85,2010-019912-18,que,o
85,2010-019912-18,tengan,o
85,2010-019912-18,previsto,o
85,2010-019912-18,someterse,o
85,2010-019912-18,a,o
85,2010-019912-18,una,o
85,2010-019912-18,intervencion,i
85,2010-019912-18,de,o
85,2010-019912-18,este,o
85,2010-019912-18,tipo,o
85,2010-019912-18,en,o
85,2010-019912-18,los,o
85,2010-019912-18,6,o
85,2010-019912-18,meses,o
85,2010-019912-18,siguientes,o
85,2010-019912-18,a,o
85,2010-019912-18,la,o
85,2010-019912-18,randomizacion,i
85,2010-019912-18,Enfermedad,i
85,2010-019912-18,reumatica,i
85,2010-019912-18,autoinmune,i
85,2010-019912-18,distinta,o
85,2010-019912-18,de,o
85,2010-019912-18,AR,i
85,2010-019912-18,Se,o
85,2010-019912-18,permite,o
85,2010-019912-18,la,o
85,2010-019912-18,inclusion,o
85,2010-019912-18,de,o
85,2010-019912-18,pacientes,o
85,2010-019912-18,con,o
85,2010-019912-18,sindrome,i
85,2010-019912-18,de,i
85,2010-019912-18,Sjögren,i
85,2010-019912-18,secundario,i
85,2010-019912-18,asociado,o
85,2010-019912-18,a,o
85,2010-019912-18,AR,i
85,2010-019912-18,Clase,o
85,2010-019912-18,funcional,o
85,2010-019912-18,IV,o
85,2010-019912-18,definida,o
85,2010-019912-18,de,o
85,2010-019912-18,acuerdo,o
85,2010-019912-18,con,o
85,2010-019912-18,la,o
85,2010-019912-18,Clasificacion,o
85,2010-019912-18,del,o
85,2010-019912-18,ACR,o
85,2010-019912-18,del,o
85,2010-019912-18,Estado,o
85,2010-019912-18,Funcional,o
85,2010-019912-18,en,o
85,2010-019912-18,Artritis,i
85,2010-019912-18,Reumatoide,i
85,2010-019912-18,Artritis,i
85,2010-019912-18,idiopatica,i
85,2010-019912-18,juvenil,i
85,2010-019912-18,AIJ,i
85,2010-019912-18,o,o
85,2010-019912-18,artritis,i
85,2010-019912-18,reumatoide,i
85,2010-019912-18,juvenil,i
85,2010-019912-18,ARJ,i
85,2010-019912-18,yo,o
85,2010-019912-18,AR,i
85,2010-019912-18,diagnosticadas,i
85,2010-019912-18,antes,o
85,2010-019912-18,de,o
85,2010-019912-18,los,o
85,2010-019912-18,16,o
85,2010-019912-18,años,o
85,2010-019912-18,de,o
85,2010-019912-18,edad,o
85,2010-019912-18,Enfermedad,i
85,2010-019912-18,articular,i
85,2010-019912-18,inflamatoria,i
85,2010-019912-18,distinta,o
85,2010-019912-18,de,o
85,2010-019912-18,AR,i
85,2010-019912-18,en,o
85,2010-019912-18,el,o
85,2010-019912-18,pasado,o
85,2010-019912-18,o,o
85,2010-019912-18,en,o
85,2010-019912-18,la,o
85,2010-019912-18,actualidad,o
86,2010-019912-18,EudraCT,o
86,2010-019912-18,Nº,o
86,2010-019912-18,201001991218,o
86,2010-019912-18,Titulo,o
86,2010-019912-18,cientifico,o
86,2010-019912-18,Estudio,o
86,2010-019912-18,randomizado,o
86,2010-019912-18,doble,o
86,2010-019912-18,ciego,o
86,2010-019912-18,con,o
86,2010-019912-18,grupos,o
86,2010-019912-18,de,o
86,2010-019912-18,tratamiento,i
86,2010-019912-18,paralelos,o
86,2010-019912-18,para,o
86,2010-019912-18,evaluar,i
86,2010-019912-18,la,i
86,2010-019912-18,seguridad,i
86,2010-019912-18,y,o
86,2010-019912-18,el,o
86,2010-019912-18,efecto,o
86,2010-019912-18,sobre,o
86,2010-019912-18,el,o
86,2010-019912-18,resultado,o
86,2010-019912-18,clinico,o
86,2010-019912-18,de,o
86,2010-019912-18,tocilizumab,i
86,2010-019912-18,SC,o
86,2010-019912-18,frente,o
86,2010-019912-18,a,o
86,2010-019912-18,placebo,i
86,2010-019912-18,SC,o
86,2010-019912-18,en,o
86,2010-019912-18,combinacion,o
86,2010-019912-18,con,o
86,2010-019912-18,farmacos,i
86,2010-019912-18,antirreumaticos,i
86,2010-019912-18,modificadores,i
86,2010-019912-18,de,i
86,2010-019912-18,la,i
86,2010-019912-18,enfermedad,i
86,2010-019912-18,FAMEs,i
86,2010-019912-18,tradicionales,o
86,2010-019912-18,en,o
86,2010-019912-18,pacientes,o
86,2010-019912-18,con,o
86,2010-019912-18,artritis,i
86,2010-019912-18,reumatoide,i
86,2010-019912-18,activa,o
86,2010-019912-18,moderada,o
86,2010-019912-18,a,o
86,2010-019912-18,severa,o
86,2010-019912-18,Indicacion,o
86,2010-019912-18,cientifica,o
86,2010-019912-18,Artritis,i
86,2010-019912-18,Reumatoide,i
86,2010-019912-18,AR,i
86,2010-019912-18,Criterios,o
86,2010-019912-18,de,o
86,2010-019912-18,inclusion,o
86,2010-019912-18,Presentar,o
86,2010-019912-18,artritis,i
86,2010-019912-18,reumatoide,i
86,2010-019912-18,de,o
86,2010-019912-18,mayor,o
86,2010-019912-18,o,o
86,2010-019912-18,igual,o
86,2010-019912-18,a,o
86,2010-019912-18,6,o
86,2010-019912-18,meses,o
86,2010-019912-18,de,o
86,2010-019912-18,duracion,o
86,2010-019912-18,Recibir,o
86,2010-019912-18,tratamiento,i
86,2010-019912-18,de,i
86,2010-019912-18,forma,i
86,2010-019912-18,ambulatoria,i
86,2010-019912-18,Presentar,o
86,2010-019912-18,un,o
86,2010-019912-18,recuento,o
86,2010-019912-18,de,o
86,2010-019912-18,articulaciones,i
86,2010-019912-18,inflamadas,i
86,2010-019912-18,RAI,o
86,2010-019912-18,mayor,o
86,2010-019912-18,o,o
86,2010-019912-18,igual,o
86,2010-019912-18,a,o
86,2010-019912-18,6,o
86,2010-019912-18,recuento,o
86,2010-019912-18,de,o
86,2010-019912-18,66,o
86,2010-019912-18,articulaciones,i
86,2010-019912-18,y,o
86,2010-019912-18,de,o
86,2010-019912-18,articulaciones,i
86,2010-019912-18,dolorosas,i
86,2010-019912-18,RAD,o
86,2010-019912-18,mayor,o
86,2010-019912-18,o,o
86,2010-019912-18,igual,o
86,2010-019912-18,a,o
86,2010-019912-18,8,o
86,2010-019912-18,recuento,o
86,2010-019912-18,de,o
86,2010-019912-18,68,o
86,2010-019912-18,articulaciones,i
86,2010-019912-18,en,o
86,2010-019912-18,las,o
86,2010-019912-18,visitas,o
86,2010-019912-18,de,o
86,2010-019912-18,seleccion,o
86,2010-019912-18,y,o
86,2010-019912-18,basal,o
86,2010-019912-18,Los,o
86,2010-019912-18,pacientes,o
86,2010-019912-18,deben,o
86,2010-019912-18,estar,o
86,2010-019912-18,recibiendo,o
86,2010-019912-18,tratamiento,i
86,2010-019912-18,con,o
86,2010-019912-18,una,o
86,2010-019912-18,dosis,o
86,2010-019912-18,estable,o
86,2010-019912-18,de,o
86,2010-019912-18,los,o
86,2010-019912-18,FAMEs,i
86,2010-019912-18,permitidos,o
86,2010-019912-18,como,o
86,2010-019912-18,minimo,o
86,2010-019912-18,8,o
86,2010-019912-18,semanas,o
86,2010-019912-18,antes,o
86,2010-019912-18,de,o
86,2010-019912-18,la,o
86,2010-019912-18,visita,o
86,2010-019912-18,basal,o
86,2010-019912-18,Criterios,o
86,2010-019912-18,de,o
86,2010-019912-18,exclusion,o
86,2010-019912-18,Pacientes,o
86,2010-019912-18,sometidos,o
86,2010-019912-18,a,o
86,2010-019912-18,intervenciones,i
86,2010-019912-18,de,i
86,2010-019912-18,cirugia,i
86,2010-019912-18,mayor,i
86,2010-019912-18,incluyendo,o
86,2010-019912-18,cirugia,i
86,2010-019912-18,articular,i
86,2010-019912-18,en,o
86,2010-019912-18,las,o
86,2010-019912-18,8,o
86,2010-019912-18,semanas,o
86,2010-019912-18,previas,o
86,2010-019912-18,a,o
86,2010-019912-18,la,o
86,2010-019912-18,visita,o
86,2010-019912-18,de,o
86,2010-019912-18,seleccion,o
86,2010-019912-18,o,o
86,2010-019912-18,que,o
86,2010-019912-18,tengan,o
86,2010-019912-18,previsto,o
86,2010-019912-18,someterse,o
86,2010-019912-18,a,o
86,2010-019912-18,una,o
86,2010-019912-18,intervencion,i
86,2010-019912-18,de,o
86,2010-019912-18,este,o
86,2010-019912-18,tipo,o
86,2010-019912-18,en,o
86,2010-019912-18,los,o
86,2010-019912-18,6,o
86,2010-019912-18,meses,o
86,2010-019912-18,siguientes,o
86,2010-019912-18,a,o
86,2010-019912-18,la,o
86,2010-019912-18,randomizacion,i
86,2010-019912-18,Enfermedad,i
86,2010-019912-18,reumatica,i
86,2010-019912-18,autoinmune,i
86,2010-019912-18,distinta,o
86,2010-019912-18,de,o
86,2010-019912-18,AR,i
86,2010-019912-18,Se,o
86,2010-019912-18,permite,o
86,2010-019912-18,la,o
86,2010-019912-18,inclusion,o
86,2010-019912-18,de,o
86,2010-019912-18,pacientes,o
86,2010-019912-18,con,o
86,2010-019912-18,sindrome,i
86,2010-019912-18,de,i
86,2010-019912-18,Sjögren,i
86,2010-019912-18,secundario,i
86,2010-019912-18,asociado,o
86,2010-019912-18,a,o
86,2010-019912-18,AR,i
86,2010-019912-18,Clase,o
86,2010-019912-18,funcional,o
86,2010-019912-18,IV,o
86,2010-019912-18,definida,o
86,2010-019912-18,de,o
86,2010-019912-18,acuerdo,o
86,2010-019912-18,con,o
86,2010-019912-18,la,o
86,2010-019912-18,Clasificacion,o
86,2010-019912-18,del,o
86,2010-019912-18,ACR,o
86,2010-019912-18,del,o
86,2010-019912-18,Estado,o
86,2010-019912-18,Funcional,o
86,2010-019912-18,en,o
86,2010-019912-18,Artritis,i
86,2010-019912-18,Reumatoide,i
86,2010-019912-18,Artritis,i
86,2010-019912-18,idiopatica,i
86,2010-019912-18,juvenil,i
86,2010-019912-18,AIJ,i
86,2010-019912-18,o,o
86,2010-019912-18,artritis,i
86,2010-019912-18,reumatoide,i
86,2010-019912-18,juvenil,i
86,2010-019912-18,ARJ,i
86,2010-019912-18,yo,o
86,2010-019912-18,AR,i
86,2010-019912-18,diagnosticadas,i
86,2010-019912-18,antes,o
86,2010-019912-18,de,o
86,2010-019912-18,los,o
86,2010-019912-18,16,o
86,2010-019912-18,años,o
86,2010-019912-18,de,o
86,2010-019912-18,edad,o
86,2010-019912-18,Enfermedad,i
86,2010-019912-18,articular,i
86,2010-019912-18,inflamatoria,i
86,2010-019912-18,distinta,o
86,2010-019912-18,de,o
86,2010-019912-18,AR,i
86,2010-019912-18,en,o
86,2010-019912-18,el,o
86,2010-019912-18,pasado,o
86,2010-019912-18,o,o
86,2010-019912-18,en,o
86,2010-019912-18,la,o
86,2010-019912-18,actualidad,o
87,2010-019912-18,EudraCT,o
87,2010-019912-18,Nº,o
87,2010-019912-18,201001991218,o
87,2010-019912-18,Titulo,o
87,2010-019912-18,cientifico,o
87,2010-019912-18,Estudio,o
87,2010-019912-18,randomizado,o
87,2010-019912-18,doble,o
87,2010-019912-18,ciego,o
87,2010-019912-18,con,o
87,2010-019912-18,grupos,o
87,2010-019912-18,de,o
87,2010-019912-18,tratamiento,i
87,2010-019912-18,paralelos,o
87,2010-019912-18,para,o
87,2010-019912-18,evaluar,i
87,2010-019912-18,la,i
87,2010-019912-18,seguridad,i
87,2010-019912-18,y,o
87,2010-019912-18,el,o
87,2010-019912-18,efecto,o
87,2010-019912-18,sobre,o
87,2010-019912-18,el,o
87,2010-019912-18,resultado,o
87,2010-019912-18,clinico,o
87,2010-019912-18,de,o
87,2010-019912-18,tocilizumab,i
87,2010-019912-18,SC,o
87,2010-019912-18,frente,o
87,2010-019912-18,a,o
87,2010-019912-18,placebo,i
87,2010-019912-18,SC,o
87,2010-019912-18,en,o
87,2010-019912-18,combinacion,o
87,2010-019912-18,con,o
87,2010-019912-18,farmacos,i
87,2010-019912-18,antirreumaticos,i
87,2010-019912-18,modificadores,i
87,2010-019912-18,de,i
87,2010-019912-18,la,i
87,2010-019912-18,enfermedad,i
87,2010-019912-18,FAMEs,i
87,2010-019912-18,tradicionales,o
87,2010-019912-18,en,o
87,2010-019912-18,pacientes,o
87,2010-019912-18,con,o
87,2010-019912-18,artritis,i
87,2010-019912-18,reumatoide,i
87,2010-019912-18,activa,o
87,2010-019912-18,moderada,o
87,2010-019912-18,a,o
87,2010-019912-18,severa,o
87,2010-019912-18,Indicacion,o
87,2010-019912-18,cientifica,o
87,2010-019912-18,Artritis,i
87,2010-019912-18,Reumatoide,i
87,2010-019912-18,AR,i
87,2010-019912-18,Criterios,o
87,2010-019912-18,de,o
87,2010-019912-18,inclusion,o
87,2010-019912-18,Presentar,o
87,2010-019912-18,artritis,i
87,2010-019912-18,reumatoide,i
87,2010-019912-18,de,o
87,2010-019912-18,mayor,o
87,2010-019912-18,o,o
87,2010-019912-18,igual,o
87,2010-019912-18,a,o
87,2010-019912-18,6,o
87,2010-019912-18,meses,o
87,2010-019912-18,de,o
87,2010-019912-18,duracion,o
87,2010-019912-18,Recibir,o
87,2010-019912-18,tratamiento,i
87,2010-019912-18,de,i
87,2010-019912-18,forma,i
87,2010-019912-18,ambulatoria,i
87,2010-019912-18,Presentar,o
87,2010-019912-18,un,o
87,2010-019912-18,recuento,o
87,2010-019912-18,de,o
87,2010-019912-18,articulaciones,i
87,2010-019912-18,inflamadas,i
87,2010-019912-18,RAI,o
87,2010-019912-18,mayor,o
87,2010-019912-18,o,o
87,2010-019912-18,igual,o
87,2010-019912-18,a,o
87,2010-019912-18,6,o
87,2010-019912-18,recuento,o
87,2010-019912-18,de,o
87,2010-019912-18,66,o
87,2010-019912-18,articulaciones,i
87,2010-019912-18,y,o
87,2010-019912-18,de,o
87,2010-019912-18,articulaciones,i
87,2010-019912-18,dolorosas,i
87,2010-019912-18,RAD,o
87,2010-019912-18,mayor,o
87,2010-019912-18,o,o
87,2010-019912-18,igual,o
87,2010-019912-18,a,o
87,2010-019912-18,8,o
87,2010-019912-18,recuento,o
87,2010-019912-18,de,o
87,2010-019912-18,68,o
87,2010-019912-18,articulaciones,i
87,2010-019912-18,en,o
87,2010-019912-18,las,o
87,2010-019912-18,visitas,o
87,2010-019912-18,de,o
87,2010-019912-18,seleccion,o
87,2010-019912-18,y,o
87,2010-019912-18,basal,o
87,2010-019912-18,Los,o
87,2010-019912-18,pacientes,o
87,2010-019912-18,deben,o
87,2010-019912-18,estar,o
87,2010-019912-18,recibiendo,o
87,2010-019912-18,tratamiento,i
87,2010-019912-18,con,o
87,2010-019912-18,una,o
87,2010-019912-18,dosis,o
87,2010-019912-18,estable,o
87,2010-019912-18,de,o
87,2010-019912-18,los,o
87,2010-019912-18,FAMEs,i
87,2010-019912-18,permitidos,o
87,2010-019912-18,como,o
87,2010-019912-18,minimo,o
87,2010-019912-18,8,o
87,2010-019912-18,semanas,o
87,2010-019912-18,antes,o
87,2010-019912-18,de,o
87,2010-019912-18,la,o
87,2010-019912-18,visita,o
87,2010-019912-18,basal,o
87,2010-019912-18,Criterios,o
87,2010-019912-18,de,o
87,2010-019912-18,exclusion,o
87,2010-019912-18,Pacientes,o
87,2010-019912-18,sometidos,o
87,2010-019912-18,a,o
87,2010-019912-18,intervenciones,i
87,2010-019912-18,de,i
87,2010-019912-18,cirugia,i
87,2010-019912-18,mayor,i
87,2010-019912-18,incluyendo,o
87,2010-019912-18,cirugia,i
87,2010-019912-18,articular,i
87,2010-019912-18,en,o
87,2010-019912-18,las,o
87,2010-019912-18,8,o
87,2010-019912-18,semanas,o
87,2010-019912-18,previas,o
87,2010-019912-18,a,o
87,2010-019912-18,la,o
87,2010-019912-18,visita,o
87,2010-019912-18,de,o
87,2010-019912-18,seleccion,o
87,2010-019912-18,o,o
87,2010-019912-18,que,o
87,2010-019912-18,tengan,o
87,2010-019912-18,previsto,o
87,2010-019912-18,someterse,o
87,2010-019912-18,a,o
87,2010-019912-18,una,o
87,2010-019912-18,intervencion,i
87,2010-019912-18,de,o
87,2010-019912-18,este,o
87,2010-019912-18,tipo,o
87,2010-019912-18,en,o
87,2010-019912-18,los,o
87,2010-019912-18,6,o
87,2010-019912-18,meses,o
87,2010-019912-18,siguientes,o
87,2010-019912-18,a,o
87,2010-019912-18,la,o
87,2010-019912-18,randomizacion,i
87,2010-019912-18,Enfermedad,i
87,2010-019912-18,reumatica,i
87,2010-019912-18,autoinmune,i
87,2010-019912-18,distinta,o
87,2010-019912-18,de,o
87,2010-019912-18,AR,i
87,2010-019912-18,Se,o
87,2010-019912-18,permite,o
87,2010-019912-18,la,o
87,2010-019912-18,inclusion,o
87,2010-019912-18,de,o
87,2010-019912-18,pacientes,o
87,2010-019912-18,con,o
87,2010-019912-18,sindrome,i
87,2010-019912-18,de,i
87,2010-019912-18,Sjögren,i
87,2010-019912-18,secundario,i
87,2010-019912-18,asociado,o
87,2010-019912-18,a,o
87,2010-019912-18,AR,i
87,2010-019912-18,Clase,o
87,2010-019912-18,funcional,o
87,2010-019912-18,IV,o
87,2010-019912-18,definida,o
87,2010-019912-18,de,o
87,2010-019912-18,acuerdo,o
87,2010-019912-18,con,o
87,2010-019912-18,la,o
87,2010-019912-18,Clasificacion,o
87,2010-019912-18,del,o
87,2010-019912-18,ACR,o
87,2010-019912-18,del,o
87,2010-019912-18,Estado,o
87,2010-019912-18,Funcional,o
87,2010-019912-18,en,o
87,2010-019912-18,Artritis,i
87,2010-019912-18,Reumatoide,i
87,2010-019912-18,Artritis,i
87,2010-019912-18,idiopatica,i
87,2010-019912-18,juvenil,i
87,2010-019912-18,AIJ,i
87,2010-019912-18,o,o
87,2010-019912-18,artritis,i
87,2010-019912-18,reumatoide,i
87,2010-019912-18,juvenil,i
87,2010-019912-18,ARJ,i
87,2010-019912-18,yo,o
87,2010-019912-18,AR,i
87,2010-019912-18,diagnosticadas,i
87,2010-019912-18,antes,o
87,2010-019912-18,de,o
87,2010-019912-18,los,o
87,2010-019912-18,16,o
87,2010-019912-18,años,o
87,2010-019912-18,de,o
87,2010-019912-18,edad,o
87,2010-019912-18,Enfermedad,i
87,2010-019912-18,articular,i
87,2010-019912-18,inflamatoria,i
87,2010-019912-18,distinta,o
87,2010-019912-18,de,o
87,2010-019912-18,AR,i
87,2010-019912-18,en,o
87,2010-019912-18,el,o
87,2010-019912-18,pasado,o
87,2010-019912-18,o,o
87,2010-019912-18,en,o
87,2010-019912-18,la,o
87,2010-019912-18,actualidad,o
88,2010-019912-18,EudraCT,o
88,2010-019912-18,Nº,o
88,2010-019912-18,201001991218,o
88,2010-019912-18,Titulo,o
88,2010-019912-18,cientifico,o
88,2010-019912-18,Estudio,o
88,2010-019912-18,randomizado,o
88,2010-019912-18,doble,o
88,2010-019912-18,ciego,o
88,2010-019912-18,con,o
88,2010-019912-18,grupos,o
88,2010-019912-18,de,o
88,2010-019912-18,tratamiento,i
88,2010-019912-18,paralelos,o
88,2010-019912-18,para,o
88,2010-019912-18,evaluar,i
88,2010-019912-18,la,i
88,2010-019912-18,seguridad,i
88,2010-019912-18,y,o
88,2010-019912-18,el,o
88,2010-019912-18,efecto,o
88,2010-019912-18,sobre,o
88,2010-019912-18,el,o
88,2010-019912-18,resultado,o
88,2010-019912-18,clinico,o
88,2010-019912-18,de,o
88,2010-019912-18,tocilizumab,i
88,2010-019912-18,SC,o
88,2010-019912-18,frente,o
88,2010-019912-18,a,o
88,2010-019912-18,placebo,i
88,2010-019912-18,SC,o
88,2010-019912-18,en,o
88,2010-019912-18,combinacion,o
88,2010-019912-18,con,o
88,2010-019912-18,farmacos,i
88,2010-019912-18,antirreumaticos,i
88,2010-019912-18,modificadores,i
88,2010-019912-18,de,i
88,2010-019912-18,la,i
88,2010-019912-18,enfermedad,i
88,2010-019912-18,FAMEs,i
88,2010-019912-18,tradicionales,o
88,2010-019912-18,en,o
88,2010-019912-18,pacientes,o
88,2010-019912-18,con,o
88,2010-019912-18,artritis,i
88,2010-019912-18,reumatoide,i
88,2010-019912-18,activa,o
88,2010-019912-18,moderada,o
88,2010-019912-18,a,o
88,2010-019912-18,severa,o
88,2010-019912-18,Indicacion,o
88,2010-019912-18,cientifica,o
88,2010-019912-18,Artritis,i
88,2010-019912-18,Reumatoide,i
88,2010-019912-18,AR,i
88,2010-019912-18,Criterios,o
88,2010-019912-18,de,o
88,2010-019912-18,inclusion,o
88,2010-019912-18,Presentar,o
88,2010-019912-18,artritis,i
88,2010-019912-18,reumatoide,i
88,2010-019912-18,de,o
88,2010-019912-18,mayor,o
88,2010-019912-18,o,o
88,2010-019912-18,igual,o
88,2010-019912-18,a,o
88,2010-019912-18,6,o
88,2010-019912-18,meses,o
88,2010-019912-18,de,o
88,2010-019912-18,duracion,o
88,2010-019912-18,Recibir,o
88,2010-019912-18,tratamiento,i
88,2010-019912-18,de,i
88,2010-019912-18,forma,i
88,2010-019912-18,ambulatoria,i
88,2010-019912-18,Presentar,o
88,2010-019912-18,un,o
88,2010-019912-18,recuento,o
88,2010-019912-18,de,o
88,2010-019912-18,articulaciones,i
88,2010-019912-18,inflamadas,i
88,2010-019912-18,RAI,o
88,2010-019912-18,mayor,o
88,2010-019912-18,o,o
88,2010-019912-18,igual,o
88,2010-019912-18,a,o
88,2010-019912-18,6,o
88,2010-019912-18,recuento,o
88,2010-019912-18,de,o
88,2010-019912-18,66,o
88,2010-019912-18,articulaciones,i
88,2010-019912-18,y,o
88,2010-019912-18,de,o
88,2010-019912-18,articulaciones,i
88,2010-019912-18,dolorosas,i
88,2010-019912-18,RAD,o
88,2010-019912-18,mayor,o
88,2010-019912-18,o,o
88,2010-019912-18,igual,o
88,2010-019912-18,a,o
88,2010-019912-18,8,o
88,2010-019912-18,recuento,o
88,2010-019912-18,de,o
88,2010-019912-18,68,o
88,2010-019912-18,articulaciones,i
88,2010-019912-18,en,o
88,2010-019912-18,las,o
88,2010-019912-18,visitas,o
88,2010-019912-18,de,o
88,2010-019912-18,seleccion,o
88,2010-019912-18,y,o
88,2010-019912-18,basal,o
88,2010-019912-18,Los,o
88,2010-019912-18,pacientes,o
88,2010-019912-18,deben,o
88,2010-019912-18,estar,o
88,2010-019912-18,recibiendo,o
88,2010-019912-18,tratamiento,i
88,2010-019912-18,con,o
88,2010-019912-18,una,o
88,2010-019912-18,dosis,o
88,2010-019912-18,estable,o
88,2010-019912-18,de,o
88,2010-019912-18,los,o
88,2010-019912-18,FAMEs,i
88,2010-019912-18,permitidos,o
88,2010-019912-18,como,o
88,2010-019912-18,minimo,o
88,2010-019912-18,8,o
88,2010-019912-18,semanas,o
88,2010-019912-18,antes,o
88,2010-019912-18,de,o
88,2010-019912-18,la,o
88,2010-019912-18,visita,o
88,2010-019912-18,basal,o
88,2010-019912-18,Criterios,o
88,2010-019912-18,de,o
88,2010-019912-18,exclusion,o
88,2010-019912-18,Pacientes,o
88,2010-019912-18,sometidos,o
88,2010-019912-18,a,o
88,2010-019912-18,intervenciones,i
88,2010-019912-18,de,i
88,2010-019912-18,cirugia,i
88,2010-019912-18,mayor,i
88,2010-019912-18,incluyendo,o
88,2010-019912-18,cirugia,i
88,2010-019912-18,articular,i
88,2010-019912-18,en,o
88,2010-019912-18,las,o
88,2010-019912-18,8,o
88,2010-019912-18,semanas,o
88,2010-019912-18,previas,o
88,2010-019912-18,a,o
88,2010-019912-18,la,o
88,2010-019912-18,visita,o
88,2010-019912-18,de,o
88,2010-019912-18,seleccion,o
88,2010-019912-18,o,o
88,2010-019912-18,que,o
88,2010-019912-18,tengan,o
88,2010-019912-18,previsto,o
88,2010-019912-18,someterse,o
88,2010-019912-18,a,o
88,2010-019912-18,una,o
88,2010-019912-18,intervencion,i
88,2010-019912-18,de,o
88,2010-019912-18,este,o
88,2010-019912-18,tipo,o
88,2010-019912-18,en,o
88,2010-019912-18,los,o
88,2010-019912-18,6,o
88,2010-019912-18,meses,o
88,2010-019912-18,siguientes,o
88,2010-019912-18,a,o
88,2010-019912-18,la,o
88,2010-019912-18,randomizacion,i
88,2010-019912-18,Enfermedad,i
88,2010-019912-18,reumatica,i
88,2010-019912-18,autoinmune,i
88,2010-019912-18,distinta,o
88,2010-019912-18,de,o
88,2010-019912-18,AR,i
88,2010-019912-18,Se,o
88,2010-019912-18,permite,o
88,2010-019912-18,la,o
88,2010-019912-18,inclusion,o
88,2010-019912-18,de,o
88,2010-019912-18,pacientes,o
88,2010-019912-18,con,o
88,2010-019912-18,sindrome,i
88,2010-019912-18,de,i
88,2010-019912-18,Sjögren,i
88,2010-019912-18,secundario,i
88,2010-019912-18,asociado,o
88,2010-019912-18,a,o
88,2010-019912-18,AR,i
88,2010-019912-18,Clase,o
88,2010-019912-18,funcional,o
88,2010-019912-18,IV,o
88,2010-019912-18,definida,o
88,2010-019912-18,de,o
88,2010-019912-18,acuerdo,o
88,2010-019912-18,con,o
88,2010-019912-18,la,o
88,2010-019912-18,Clasificacion,o
88,2010-019912-18,del,o
88,2010-019912-18,ACR,o
88,2010-019912-18,del,o
88,2010-019912-18,Estado,o
88,2010-019912-18,Funcional,o
88,2010-019912-18,en,o
88,2010-019912-18,Artritis,i
88,2010-019912-18,Reumatoide,i
88,2010-019912-18,Artritis,i
88,2010-019912-18,idiopatica,i
88,2010-019912-18,juvenil,i
88,2010-019912-18,AIJ,i
88,2010-019912-18,o,o
88,2010-019912-18,artritis,i
88,2010-019912-18,reumatoide,i
88,2010-019912-18,juvenil,i
88,2010-019912-18,ARJ,i
88,2010-019912-18,yo,o
88,2010-019912-18,AR,i
88,2010-019912-18,diagnosticadas,i
88,2010-019912-18,antes,o
88,2010-019912-18,de,o
88,2010-019912-18,los,o
88,2010-019912-18,16,o
88,2010-019912-18,años,o
88,2010-019912-18,de,o
88,2010-019912-18,edad,o
88,2010-019912-18,Enfermedad,i
88,2010-019912-18,articular,i
88,2010-019912-18,inflamatoria,i
88,2010-019912-18,distinta,o
88,2010-019912-18,de,o
88,2010-019912-18,AR,i
88,2010-019912-18,en,o
88,2010-019912-18,el,o
88,2010-019912-18,pasado,o
88,2010-019912-18,o,o
88,2010-019912-18,en,o
88,2010-019912-18,la,o
88,2010-019912-18,actualidad,o
89,2010-019912-18,EudraCT,o
89,2010-019912-18,Nº,o
89,2010-019912-18,201001991218,o
89,2010-019912-18,Titulo,o
89,2010-019912-18,cientifico,o
89,2010-019912-18,Estudio,o
89,2010-019912-18,randomizado,o
89,2010-019912-18,doble,o
89,2010-019912-18,ciego,o
89,2010-019912-18,con,o
89,2010-019912-18,grupos,o
89,2010-019912-18,de,o
89,2010-019912-18,tratamiento,i
89,2010-019912-18,paralelos,o
89,2010-019912-18,para,o
89,2010-019912-18,evaluar,i
89,2010-019912-18,la,i
89,2010-019912-18,seguridad,i
89,2010-019912-18,y,o
89,2010-019912-18,el,o
89,2010-019912-18,efecto,o
89,2010-019912-18,sobre,o
89,2010-019912-18,el,o
89,2010-019912-18,resultado,o
89,2010-019912-18,clinico,o
89,2010-019912-18,de,o
89,2010-019912-18,tocilizumab,i
89,2010-019912-18,SC,o
89,2010-019912-18,frente,o
89,2010-019912-18,a,o
89,2010-019912-18,placebo,i
89,2010-019912-18,SC,o
89,2010-019912-18,en,o
89,2010-019912-18,combinacion,o
89,2010-019912-18,con,o
89,2010-019912-18,farmacos,i
89,2010-019912-18,antirreumaticos,i
89,2010-019912-18,modificadores,i
89,2010-019912-18,de,i
89,2010-019912-18,la,i
89,2010-019912-18,enfermedad,i
89,2010-019912-18,FAMEs,i
89,2010-019912-18,tradicionales,o
89,2010-019912-18,en,o
89,2010-019912-18,pacientes,o
89,2010-019912-18,con,o
89,2010-019912-18,artritis,i
89,2010-019912-18,reumatoide,i
89,2010-019912-18,activa,o
89,2010-019912-18,moderada,o
89,2010-019912-18,a,o
89,2010-019912-18,severa,o
89,2010-019912-18,Indicacion,o
89,2010-019912-18,cientifica,o
89,2010-019912-18,Artritis,i
89,2010-019912-18,Reumatoide,i
89,2010-019912-18,AR,i
89,2010-019912-18,Criterios,o
89,2010-019912-18,de,o
89,2010-019912-18,inclusion,o
89,2010-019912-18,Presentar,o
89,2010-019912-18,artritis,i
89,2010-019912-18,reumatoide,i
89,2010-019912-18,de,o
89,2010-019912-18,mayor,o
89,2010-019912-18,o,o
89,2010-019912-18,igual,o
89,2010-019912-18,a,o
89,2010-019912-18,6,o
89,2010-019912-18,meses,o
89,2010-019912-18,de,o
89,2010-019912-18,duracion,o
89,2010-019912-18,Recibir,o
89,2010-019912-18,tratamiento,i
89,2010-019912-18,de,i
89,2010-019912-18,forma,i
89,2010-019912-18,ambulatoria,i
89,2010-019912-18,Presentar,o
89,2010-019912-18,un,o
89,2010-019912-18,recuento,o
89,2010-019912-18,de,o
89,2010-019912-18,articulaciones,i
89,2010-019912-18,inflamadas,i
89,2010-019912-18,RAI,o
89,2010-019912-18,mayor,o
89,2010-019912-18,o,o
89,2010-019912-18,igual,o
89,2010-019912-18,a,o
89,2010-019912-18,6,o
89,2010-019912-18,recuento,o
89,2010-019912-18,de,o
89,2010-019912-18,66,o
89,2010-019912-18,articulaciones,i
89,2010-019912-18,y,o
89,2010-019912-18,de,o
89,2010-019912-18,articulaciones,i
89,2010-019912-18,dolorosas,i
89,2010-019912-18,RAD,o
89,2010-019912-18,mayor,o
89,2010-019912-18,o,o
89,2010-019912-18,igual,o
89,2010-019912-18,a,o
89,2010-019912-18,8,o
89,2010-019912-18,recuento,o
89,2010-019912-18,de,o
89,2010-019912-18,68,o
89,2010-019912-18,articulaciones,i
89,2010-019912-18,en,o
89,2010-019912-18,las,o
89,2010-019912-18,visitas,o
89,2010-019912-18,de,o
89,2010-019912-18,seleccion,o
89,2010-019912-18,y,o
89,2010-019912-18,basal,o
89,2010-019912-18,Los,o
89,2010-019912-18,pacientes,o
89,2010-019912-18,deben,o
89,2010-019912-18,estar,o
89,2010-019912-18,recibiendo,o
89,2010-019912-18,tratamiento,i
89,2010-019912-18,con,o
89,2010-019912-18,una,o
89,2010-019912-18,dosis,o
89,2010-019912-18,estable,o
89,2010-019912-18,de,o
89,2010-019912-18,los,o
89,2010-019912-18,FAMEs,i
89,2010-019912-18,permitidos,o
89,2010-019912-18,como,o
89,2010-019912-18,minimo,o
89,2010-019912-18,8,o
89,2010-019912-18,semanas,o
89,2010-019912-18,antes,o
89,2010-019912-18,de,o
89,2010-019912-18,la,o
89,2010-019912-18,visita,o
89,2010-019912-18,basal,o
89,2010-019912-18,Criterios,o
89,2010-019912-18,de,o
89,2010-019912-18,exclusion,o
89,2010-019912-18,Pacientes,o
89,2010-019912-18,sometidos,o
89,2010-019912-18,a,o
89,2010-019912-18,intervenciones,i
89,2010-019912-18,de,i
89,2010-019912-18,cirugia,i
89,2010-019912-18,mayor,i
89,2010-019912-18,incluyendo,o
89,2010-019912-18,cirugia,i
89,2010-019912-18,articular,i
89,2010-019912-18,en,o
89,2010-019912-18,las,o
89,2010-019912-18,8,o
89,2010-019912-18,semanas,o
89,2010-019912-18,previas,o
89,2010-019912-18,a,o
89,2010-019912-18,la,o
89,2010-019912-18,visita,o
89,2010-019912-18,de,o
89,2010-019912-18,seleccion,o
89,2010-019912-18,o,o
89,2010-019912-18,que,o
89,2010-019912-18,tengan,o
89,2010-019912-18,previsto,o
89,2010-019912-18,someterse,o
89,2010-019912-18,a,o
89,2010-019912-18,una,o
89,2010-019912-18,intervencion,i
89,2010-019912-18,de,o
89,2010-019912-18,este,o
89,2010-019912-18,tipo,o
89,2010-019912-18,en,o
89,2010-019912-18,los,o
89,2010-019912-18,6,o
89,2010-019912-18,meses,o
89,2010-019912-18,siguientes,o
89,2010-019912-18,a,o
89,2010-019912-18,la,o
89,2010-019912-18,randomizacion,i
89,2010-019912-18,Enfermedad,i
89,2010-019912-18,reumatica,i
89,2010-019912-18,autoinmune,i
89,2010-019912-18,distinta,o
89,2010-019912-18,de,o
89,2010-019912-18,AR,i
89,2010-019912-18,Se,o
89,2010-019912-18,permite,o
89,2010-019912-18,la,o
89,2010-019912-18,inclusion,o
89,2010-019912-18,de,o
89,2010-019912-18,pacientes,o
89,2010-019912-18,con,o
89,2010-019912-18,sindrome,i
89,2010-019912-18,de,i
89,2010-019912-18,Sjögren,i
89,2010-019912-18,secundario,i
89,2010-019912-18,asociado,o
89,2010-019912-18,a,o
89,2010-019912-18,AR,i
89,2010-019912-18,Clase,o
89,2010-019912-18,funcional,o
89,2010-019912-18,IV,o
89,2010-019912-18,definida,o
89,2010-019912-18,de,o
89,2010-019912-18,acuerdo,o
89,2010-019912-18,con,o
89,2010-019912-18,la,o
89,2010-019912-18,Clasificacion,o
89,2010-019912-18,del,o
89,2010-019912-18,ACR,o
89,2010-019912-18,del,o
89,2010-019912-18,Estado,o
89,2010-019912-18,Funcional,o
89,2010-019912-18,en,o
89,2010-019912-18,Artritis,i
89,2010-019912-18,Reumatoide,i
89,2010-019912-18,Artritis,i
89,2010-019912-18,idiopatica,i
89,2010-019912-18,juvenil,i
89,2010-019912-18,AIJ,i
89,2010-019912-18,o,o
89,2010-019912-18,artritis,i
89,2010-019912-18,reumatoide,i
89,2010-019912-18,juvenil,i
89,2010-019912-18,ARJ,i
89,2010-019912-18,yo,o
89,2010-019912-18,AR,i
89,2010-019912-18,diagnosticadas,i
89,2010-019912-18,antes,o
89,2010-019912-18,de,o
89,2010-019912-18,los,o
89,2010-019912-18,16,o
89,2010-019912-18,años,o
89,2010-019912-18,de,o
89,2010-019912-18,edad,o
89,2010-019912-18,Enfermedad,i
89,2010-019912-18,articular,i
89,2010-019912-18,inflamatoria,i
89,2010-019912-18,distinta,o
89,2010-019912-18,de,o
89,2010-019912-18,AR,i
89,2010-019912-18,en,o
89,2010-019912-18,el,o
89,2010-019912-18,pasado,o
89,2010-019912-18,o,o
89,2010-019912-18,en,o
89,2010-019912-18,la,o
89,2010-019912-18,actualidad,o
90,2010-019912-18,EudraCT,o
90,2010-019912-18,Nº,o
90,2010-019912-18,201001991218,o
90,2010-019912-18,Titulo,o
90,2010-019912-18,cientifico,o
90,2010-019912-18,Estudio,o
90,2010-019912-18,randomizado,o
90,2010-019912-18,doble,o
90,2010-019912-18,ciego,o
90,2010-019912-18,con,o
90,2010-019912-18,grupos,o
90,2010-019912-18,de,o
90,2010-019912-18,tratamiento,i
90,2010-019912-18,paralelos,o
90,2010-019912-18,para,o
90,2010-019912-18,evaluar,i
90,2010-019912-18,la,i
90,2010-019912-18,seguridad,i
90,2010-019912-18,y,o
90,2010-019912-18,el,o
90,2010-019912-18,efecto,o
90,2010-019912-18,sobre,o
90,2010-019912-18,el,o
90,2010-019912-18,resultado,o
90,2010-019912-18,clinico,o
90,2010-019912-18,de,o
90,2010-019912-18,tocilizumab,i
90,2010-019912-18,SC,o
90,2010-019912-18,frente,o
90,2010-019912-18,a,o
90,2010-019912-18,placebo,i
90,2010-019912-18,SC,o
90,2010-019912-18,en,o
90,2010-019912-18,combinacion,o
90,2010-019912-18,con,o
90,2010-019912-18,farmacos,i
90,2010-019912-18,antirreumaticos,i
90,2010-019912-18,modificadores,i
90,2010-019912-18,de,i
90,2010-019912-18,la,i
90,2010-019912-18,enfermedad,i
90,2010-019912-18,FAMEs,i
90,2010-019912-18,tradicionales,o
90,2010-019912-18,en,o
90,2010-019912-18,pacientes,o
90,2010-019912-18,con,o
90,2010-019912-18,artritis,i
90,2010-019912-18,reumatoide,i
90,2010-019912-18,activa,o
90,2010-019912-18,moderada,o
90,2010-019912-18,a,o
90,2010-019912-18,severa,o
90,2010-019912-18,Indicacion,o
90,2010-019912-18,cientifica,o
90,2010-019912-18,Artritis,i
90,2010-019912-18,Reumatoide,i
90,2010-019912-18,AR,i
90,2010-019912-18,Criterios,o
90,2010-019912-18,de,o
90,2010-019912-18,inclusion,o
90,2010-019912-18,Presentar,o
90,2010-019912-18,artritis,i
90,2010-019912-18,reumatoide,i
90,2010-019912-18,de,o
90,2010-019912-18,mayor,o
90,2010-019912-18,o,o
90,2010-019912-18,igual,o
90,2010-019912-18,a,o
90,2010-019912-18,6,o
90,2010-019912-18,meses,o
90,2010-019912-18,de,o
90,2010-019912-18,duracion,o
90,2010-019912-18,Recibir,o
90,2010-019912-18,tratamiento,i
90,2010-019912-18,de,i
90,2010-019912-18,forma,i
90,2010-019912-18,ambulatoria,i
90,2010-019912-18,Presentar,o
90,2010-019912-18,un,o
90,2010-019912-18,recuento,o
90,2010-019912-18,de,o
90,2010-019912-18,articulaciones,i
90,2010-019912-18,inflamadas,i
90,2010-019912-18,RAI,o
90,2010-019912-18,mayor,o
90,2010-019912-18,o,o
90,2010-019912-18,igual,o
90,2010-019912-18,a,o
90,2010-019912-18,6,o
90,2010-019912-18,recuento,o
90,2010-019912-18,de,o
90,2010-019912-18,66,o
90,2010-019912-18,articulaciones,i
90,2010-019912-18,y,o
90,2010-019912-18,de,o
90,2010-019912-18,articulaciones,i
90,2010-019912-18,dolorosas,i
90,2010-019912-18,RAD,o
90,2010-019912-18,mayor,o
90,2010-019912-18,o,o
90,2010-019912-18,igual,o
90,2010-019912-18,a,o
90,2010-019912-18,8,o
90,2010-019912-18,recuento,o
90,2010-019912-18,de,o
90,2010-019912-18,68,o
90,2010-019912-18,articulaciones,i
90,2010-019912-18,en,o
90,2010-019912-18,las,o
90,2010-019912-18,visitas,o
90,2010-019912-18,de,o
90,2010-019912-18,seleccion,o
90,2010-019912-18,y,o
90,2010-019912-18,basal,o
90,2010-019912-18,Los,o
90,2010-019912-18,pacientes,o
90,2010-019912-18,deben,o
90,2010-019912-18,estar,o
90,2010-019912-18,recibiendo,o
90,2010-019912-18,tratamiento,i
90,2010-019912-18,con,o
90,2010-019912-18,una,o
90,2010-019912-18,dosis,o
90,2010-019912-18,estable,o
90,2010-019912-18,de,o
90,2010-019912-18,los,o
90,2010-019912-18,FAMEs,i
90,2010-019912-18,permitidos,o
90,2010-019912-18,como,o
90,2010-019912-18,minimo,o
90,2010-019912-18,8,o
90,2010-019912-18,semanas,o
90,2010-019912-18,antes,o
90,2010-019912-18,de,o
90,2010-019912-18,la,o
90,2010-019912-18,visita,o
90,2010-019912-18,basal,o
90,2010-019912-18,Criterios,o
90,2010-019912-18,de,o
90,2010-019912-18,exclusion,o
90,2010-019912-18,Pacientes,o
90,2010-019912-18,sometidos,o
90,2010-019912-18,a,o
90,2010-019912-18,intervenciones,i
90,2010-019912-18,de,i
90,2010-019912-18,cirugia,i
90,2010-019912-18,mayor,i
90,2010-019912-18,incluyendo,o
90,2010-019912-18,cirugia,i
90,2010-019912-18,articular,i
90,2010-019912-18,en,o
90,2010-019912-18,las,o
90,2010-019912-18,8,o
90,2010-019912-18,semanas,o
90,2010-019912-18,previas,o
90,2010-019912-18,a,o
90,2010-019912-18,la,o
90,2010-019912-18,visita,o
90,2010-019912-18,de,o
90,2010-019912-18,seleccion,o
90,2010-019912-18,o,o
90,2010-019912-18,que,o
90,2010-019912-18,tengan,o
90,2010-019912-18,previsto,o
90,2010-019912-18,someterse,o
90,2010-019912-18,a,o
90,2010-019912-18,una,o
90,2010-019912-18,intervencion,i
90,2010-019912-18,de,o
90,2010-019912-18,este,o
90,2010-019912-18,tipo,o
90,2010-019912-18,en,o
90,2010-019912-18,los,o
90,2010-019912-18,6,o
90,2010-019912-18,meses,o
90,2010-019912-18,siguientes,o
90,2010-019912-18,a,o
90,2010-019912-18,la,o
90,2010-019912-18,randomizacion,i
90,2010-019912-18,Enfermedad,i
90,2010-019912-18,reumatica,i
90,2010-019912-18,autoinmune,i
90,2010-019912-18,distinta,o
90,2010-019912-18,de,o
90,2010-019912-18,AR,i
90,2010-019912-18,Se,o
90,2010-019912-18,permite,o
90,2010-019912-18,la,o
90,2010-019912-18,inclusion,o
90,2010-019912-18,de,o
90,2010-019912-18,pacientes,o
90,2010-019912-18,con,o
90,2010-019912-18,sindrome,i
90,2010-019912-18,de,i
90,2010-019912-18,Sjögren,i
90,2010-019912-18,secundario,i
90,2010-019912-18,asociado,o
90,2010-019912-18,a,o
90,2010-019912-18,AR,i
90,2010-019912-18,Clase,o
90,2010-019912-18,funcional,o
90,2010-019912-18,IV,o
90,2010-019912-18,definida,o
90,2010-019912-18,de,o
90,2010-019912-18,acuerdo,o
90,2010-019912-18,con,o
90,2010-019912-18,la,o
90,2010-019912-18,Clasificacion,o
90,2010-019912-18,del,o
90,2010-019912-18,ACR,o
90,2010-019912-18,del,o
90,2010-019912-18,Estado,o
90,2010-019912-18,Funcional,o
90,2010-019912-18,en,o
90,2010-019912-18,Artritis,i
90,2010-019912-18,Reumatoide,i
90,2010-019912-18,Artritis,i
90,2010-019912-18,idiopatica,i
90,2010-019912-18,juvenil,i
90,2010-019912-18,AIJ,i
90,2010-019912-18,o,o
90,2010-019912-18,artritis,i
90,2010-019912-18,reumatoide,i
90,2010-019912-18,juvenil,i
90,2010-019912-18,ARJ,i
90,2010-019912-18,yo,o
90,2010-019912-18,AR,i
90,2010-019912-18,diagnosticadas,i
90,2010-019912-18,antes,o
90,2010-019912-18,de,o
90,2010-019912-18,los,o
90,2010-019912-18,16,o
90,2010-019912-18,años,o
90,2010-019912-18,de,o
90,2010-019912-18,edad,o
90,2010-019912-18,Enfermedad,i
90,2010-019912-18,articular,i
90,2010-019912-18,inflamatoria,i
90,2010-019912-18,distinta,o
90,2010-019912-18,de,o
90,2010-019912-18,AR,i
90,2010-019912-18,en,o
90,2010-019912-18,el,o
90,2010-019912-18,pasado,o
90,2010-019912-18,o,o
90,2010-019912-18,en,o
90,2010-019912-18,la,o
90,2010-019912-18,actualidad,o
91,2010-019912-18,EudraCT,o
91,2010-019912-18,Nº,o
91,2010-019912-18,201001991218,o
91,2010-019912-18,Titulo,o
91,2010-019912-18,cientifico,o
91,2010-019912-18,Estudio,o
91,2010-019912-18,randomizado,o
91,2010-019912-18,doble,o
91,2010-019912-18,ciego,o
91,2010-019912-18,con,o
91,2010-019912-18,grupos,o
91,2010-019912-18,de,o
91,2010-019912-18,tratamiento,i
91,2010-019912-18,paralelos,o
91,2010-019912-18,para,o
91,2010-019912-18,evaluar,i
91,2010-019912-18,la,i
91,2010-019912-18,seguridad,i
91,2010-019912-18,y,o
91,2010-019912-18,el,o
91,2010-019912-18,efecto,o
91,2010-019912-18,sobre,o
91,2010-019912-18,el,o
91,2010-019912-18,resultado,o
91,2010-019912-18,clinico,o
91,2010-019912-18,de,o
91,2010-019912-18,tocilizumab,i
91,2010-019912-18,SC,o
91,2010-019912-18,frente,o
91,2010-019912-18,a,o
91,2010-019912-18,placebo,i
91,2010-019912-18,SC,o
91,2010-019912-18,en,o
91,2010-019912-18,combinacion,o
91,2010-019912-18,con,o
91,2010-019912-18,farmacos,i
91,2010-019912-18,antirreumaticos,i
91,2010-019912-18,modificadores,i
91,2010-019912-18,de,i
91,2010-019912-18,la,i
91,2010-019912-18,enfermedad,i
91,2010-019912-18,FAMEs,i
91,2010-019912-18,tradicionales,o
91,2010-019912-18,en,o
91,2010-019912-18,pacientes,o
91,2010-019912-18,con,o
91,2010-019912-18,artritis,i
91,2010-019912-18,reumatoide,i
91,2010-019912-18,activa,o
91,2010-019912-18,moderada,o
91,2010-019912-18,a,o
91,2010-019912-18,severa,o
91,2010-019912-18,Indicacion,o
91,2010-019912-18,cientifica,o
91,2010-019912-18,Artritis,i
91,2010-019912-18,Reumatoide,i
91,2010-019912-18,AR,i
91,2010-019912-18,Criterios,o
91,2010-019912-18,de,o
91,2010-019912-18,inclusion,o
91,2010-019912-18,Presentar,o
91,2010-019912-18,artritis,i
91,2010-019912-18,reumatoide,i
91,2010-019912-18,de,o
91,2010-019912-18,mayor,o
91,2010-019912-18,o,o
91,2010-019912-18,igual,o
91,2010-019912-18,a,o
91,2010-019912-18,6,o
91,2010-019912-18,meses,o
91,2010-019912-18,de,o
91,2010-019912-18,duracion,o
91,2010-019912-18,Recibir,o
91,2010-019912-18,tratamiento,i
91,2010-019912-18,de,i
91,2010-019912-18,forma,i
91,2010-019912-18,ambulatoria,i
91,2010-019912-18,Presentar,o
91,2010-019912-18,un,o
91,2010-019912-18,recuento,o
91,2010-019912-18,de,o
91,2010-019912-18,articulaciones,i
91,2010-019912-18,inflamadas,i
91,2010-019912-18,RAI,o
91,2010-019912-18,mayor,o
91,2010-019912-18,o,o
91,2010-019912-18,igual,o
91,2010-019912-18,a,o
91,2010-019912-18,6,o
91,2010-019912-18,recuento,o
91,2010-019912-18,de,o
91,2010-019912-18,66,o
91,2010-019912-18,articulaciones,i
91,2010-019912-18,y,o
91,2010-019912-18,de,o
91,2010-019912-18,articulaciones,i
91,2010-019912-18,dolorosas,i
91,2010-019912-18,RAD,o
91,2010-019912-18,mayor,o
91,2010-019912-18,o,o
91,2010-019912-18,igual,o
91,2010-019912-18,a,o
91,2010-019912-18,8,o
91,2010-019912-18,recuento,o
91,2010-019912-18,de,o
91,2010-019912-18,68,o
91,2010-019912-18,articulaciones,i
91,2010-019912-18,en,o
91,2010-019912-18,las,o
91,2010-019912-18,visitas,o
91,2010-019912-18,de,o
91,2010-019912-18,seleccion,o
91,2010-019912-18,y,o
91,2010-019912-18,basal,o
91,2010-019912-18,Los,o
91,2010-019912-18,pacientes,o
91,2010-019912-18,deben,o
91,2010-019912-18,estar,o
91,2010-019912-18,recibiendo,o
91,2010-019912-18,tratamiento,i
91,2010-019912-18,con,o
91,2010-019912-18,una,o
91,2010-019912-18,dosis,o
91,2010-019912-18,estable,o
91,2010-019912-18,de,o
91,2010-019912-18,los,o
91,2010-019912-18,FAMEs,i
91,2010-019912-18,permitidos,o
91,2010-019912-18,como,o
91,2010-019912-18,minimo,o
91,2010-019912-18,8,o
91,2010-019912-18,semanas,o
91,2010-019912-18,antes,o
91,2010-019912-18,de,o
91,2010-019912-18,la,o
91,2010-019912-18,visita,o
91,2010-019912-18,basal,o
91,2010-019912-18,Criterios,o
91,2010-019912-18,de,o
91,2010-019912-18,exclusion,o
91,2010-019912-18,Pacientes,o
91,2010-019912-18,sometidos,o
91,2010-019912-18,a,o
91,2010-019912-18,intervenciones,i
91,2010-019912-18,de,i
91,2010-019912-18,cirugia,i
91,2010-019912-18,mayor,i
91,2010-019912-18,incluyendo,o
91,2010-019912-18,cirugia,i
91,2010-019912-18,articular,i
91,2010-019912-18,en,o
91,2010-019912-18,las,o
91,2010-019912-18,8,o
91,2010-019912-18,semanas,o
91,2010-019912-18,previas,o
91,2010-019912-18,a,o
91,2010-019912-18,la,o
91,2010-019912-18,visita,o
91,2010-019912-18,de,o
91,2010-019912-18,seleccion,o
91,2010-019912-18,o,o
91,2010-019912-18,que,o
91,2010-019912-18,tengan,o
91,2010-019912-18,previsto,o
91,2010-019912-18,someterse,o
91,2010-019912-18,a,o
91,2010-019912-18,una,o
91,2010-019912-18,intervencion,i
91,2010-019912-18,de,o
91,2010-019912-18,este,o
91,2010-019912-18,tipo,o
91,2010-019912-18,en,o
91,2010-019912-18,los,o
91,2010-019912-18,6,o
91,2010-019912-18,meses,o
91,2010-019912-18,siguientes,o
91,2010-019912-18,a,o
91,2010-019912-18,la,o
91,2010-019912-18,randomizacion,i
91,2010-019912-18,Enfermedad,i
91,2010-019912-18,reumatica,i
91,2010-019912-18,autoinmune,i
91,2010-019912-18,distinta,o
91,2010-019912-18,de,o
91,2010-019912-18,AR,i
91,2010-019912-18,Se,o
91,2010-019912-18,permite,o
91,2010-019912-18,la,o
91,2010-019912-18,inclusion,o
91,2010-019912-18,de,o
91,2010-019912-18,pacientes,o
91,2010-019912-18,con,o
91,2010-019912-18,sindrome,i
91,2010-019912-18,de,i
91,2010-019912-18,Sjögren,i
91,2010-019912-18,secundario,i
91,2010-019912-18,asociado,o
91,2010-019912-18,a,o
91,2010-019912-18,AR,i
91,2010-019912-18,Clase,o
91,2010-019912-18,funcional,o
91,2010-019912-18,IV,o
91,2010-019912-18,definida,o
91,2010-019912-18,de,o
91,2010-019912-18,acuerdo,o
91,2010-019912-18,con,o
91,2010-019912-18,la,o
91,2010-019912-18,Clasificacion,o
91,2010-019912-18,del,o
91,2010-019912-18,ACR,o
91,2010-019912-18,del,o
91,2010-019912-18,Estado,o
91,2010-019912-18,Funcional,o
91,2010-019912-18,en,o
91,2010-019912-18,Artritis,i
91,2010-019912-18,Reumatoide,i
91,2010-019912-18,Artritis,i
91,2010-019912-18,idiopatica,i
91,2010-019912-18,juvenil,i
91,2010-019912-18,AIJ,i
91,2010-019912-18,o,o
91,2010-019912-18,artritis,i
91,2010-019912-18,reumatoide,i
91,2010-019912-18,juvenil,i
91,2010-019912-18,ARJ,i
91,2010-019912-18,yo,o
91,2010-019912-18,AR,i
91,2010-019912-18,diagnosticadas,i
91,2010-019912-18,antes,o
91,2010-019912-18,de,o
91,2010-019912-18,los,o
91,2010-019912-18,16,o
91,2010-019912-18,años,o
91,2010-019912-18,de,o
91,2010-019912-18,edad,o
91,2010-019912-18,Enfermedad,i
91,2010-019912-18,articular,i
91,2010-019912-18,inflamatoria,i
91,2010-019912-18,distinta,o
91,2010-019912-18,de,o
91,2010-019912-18,AR,i
91,2010-019912-18,en,o
91,2010-019912-18,el,o
91,2010-019912-18,pasado,o
91,2010-019912-18,o,o
91,2010-019912-18,en,o
91,2010-019912-18,la,o
91,2010-019912-18,actualidad,o
92,2010-019912-18,EudraCT,o
92,2010-019912-18,Nº,o
92,2010-019912-18,201001991218,o
92,2010-019912-18,Titulo,o
92,2010-019912-18,cientifico,o
92,2010-019912-18,Estudio,o
92,2010-019912-18,randomizado,o
92,2010-019912-18,doble,o
92,2010-019912-18,ciego,o
92,2010-019912-18,con,o
92,2010-019912-18,grupos,o
92,2010-019912-18,de,o
92,2010-019912-18,tratamiento,i
92,2010-019912-18,paralelos,o
92,2010-019912-18,para,o
92,2010-019912-18,evaluar,i
92,2010-019912-18,la,i
92,2010-019912-18,seguridad,i
92,2010-019912-18,y,o
92,2010-019912-18,el,o
92,2010-019912-18,efecto,o
92,2010-019912-18,sobre,o
92,2010-019912-18,el,o
92,2010-019912-18,resultado,o
92,2010-019912-18,clinico,o
92,2010-019912-18,de,o
92,2010-019912-18,tocilizumab,i
92,2010-019912-18,SC,o
92,2010-019912-18,frente,o
92,2010-019912-18,a,o
92,2010-019912-18,placebo,i
92,2010-019912-18,SC,o
92,2010-019912-18,en,o
92,2010-019912-18,combinacion,o
92,2010-019912-18,con,o
92,2010-019912-18,farmacos,i
92,2010-019912-18,antirreumaticos,i
92,2010-019912-18,modificadores,i
92,2010-019912-18,de,i
92,2010-019912-18,la,i
92,2010-019912-18,enfermedad,i
92,2010-019912-18,FAMEs,i
92,2010-019912-18,tradicionales,o
92,2010-019912-18,en,o
92,2010-019912-18,pacientes,o
92,2010-019912-18,con,o
92,2010-019912-18,artritis,i
92,2010-019912-18,reumatoide,i
92,2010-019912-18,activa,o
92,2010-019912-18,moderada,o
92,2010-019912-18,a,o
92,2010-019912-18,severa,o
92,2010-019912-18,Indicacion,o
92,2010-019912-18,cientifica,o
92,2010-019912-18,Artritis,i
92,2010-019912-18,Reumatoide,i
92,2010-019912-18,AR,i
92,2010-019912-18,Criterios,o
92,2010-019912-18,de,o
92,2010-019912-18,inclusion,o
92,2010-019912-18,Presentar,o
92,2010-019912-18,artritis,i
92,2010-019912-18,reumatoide,i
92,2010-019912-18,de,o
92,2010-019912-18,mayor,o
92,2010-019912-18,o,o
92,2010-019912-18,igual,o
92,2010-019912-18,a,o
92,2010-019912-18,6,o
92,2010-019912-18,meses,o
92,2010-019912-18,de,o
92,2010-019912-18,duracion,o
92,2010-019912-18,Recibir,o
92,2010-019912-18,tratamiento,i
92,2010-019912-18,de,i
92,2010-019912-18,forma,i
92,2010-019912-18,ambulatoria,i
92,2010-019912-18,Presentar,o
92,2010-019912-18,un,o
92,2010-019912-18,recuento,o
92,2010-019912-18,de,o
92,2010-019912-18,articulaciones,i
92,2010-019912-18,inflamadas,i
92,2010-019912-18,RAI,o
92,2010-019912-18,mayor,o
92,2010-019912-18,o,o
92,2010-019912-18,igual,o
92,2010-019912-18,a,o
92,2010-019912-18,6,o
92,2010-019912-18,recuento,o
92,2010-019912-18,de,o
92,2010-019912-18,66,o
92,2010-019912-18,articulaciones,i
92,2010-019912-18,y,o
92,2010-019912-18,de,o
92,2010-019912-18,articulaciones,i
92,2010-019912-18,dolorosas,i
92,2010-019912-18,RAD,o
92,2010-019912-18,mayor,o
92,2010-019912-18,o,o
92,2010-019912-18,igual,o
92,2010-019912-18,a,o
92,2010-019912-18,8,o
92,2010-019912-18,recuento,o
92,2010-019912-18,de,o
92,2010-019912-18,68,o
92,2010-019912-18,articulaciones,i
92,2010-019912-18,en,o
92,2010-019912-18,las,o
92,2010-019912-18,visitas,o
92,2010-019912-18,de,o
92,2010-019912-18,seleccion,o
92,2010-019912-18,y,o
92,2010-019912-18,basal,o
92,2010-019912-18,Los,o
92,2010-019912-18,pacientes,o
92,2010-019912-18,deben,o
92,2010-019912-18,estar,o
92,2010-019912-18,recibiendo,o
92,2010-019912-18,tratamiento,i
92,2010-019912-18,con,o
92,2010-019912-18,una,o
92,2010-019912-18,dosis,o
92,2010-019912-18,estable,o
92,2010-019912-18,de,o
92,2010-019912-18,los,o
92,2010-019912-18,FAMEs,i
92,2010-019912-18,permitidos,o
92,2010-019912-18,como,o
92,2010-019912-18,minimo,o
92,2010-019912-18,8,o
92,2010-019912-18,semanas,o
92,2010-019912-18,antes,o
92,2010-019912-18,de,o
92,2010-019912-18,la,o
92,2010-019912-18,visita,o
92,2010-019912-18,basal,o
92,2010-019912-18,Criterios,o
92,2010-019912-18,de,o
92,2010-019912-18,exclusion,o
92,2010-019912-18,Pacientes,o
92,2010-019912-18,sometidos,o
92,2010-019912-18,a,o
92,2010-019912-18,intervenciones,i
92,2010-019912-18,de,i
92,2010-019912-18,cirugia,i
92,2010-019912-18,mayor,i
92,2010-019912-18,incluyendo,o
92,2010-019912-18,cirugia,i
92,2010-019912-18,articular,i
92,2010-019912-18,en,o
92,2010-019912-18,las,o
92,2010-019912-18,8,o
92,2010-019912-18,semanas,o
92,2010-019912-18,previas,o
92,2010-019912-18,a,o
92,2010-019912-18,la,o
92,2010-019912-18,visita,o
92,2010-019912-18,de,o
92,2010-019912-18,seleccion,o
92,2010-019912-18,o,o
92,2010-019912-18,que,o
92,2010-019912-18,tengan,o
92,2010-019912-18,previsto,o
92,2010-019912-18,someterse,o
92,2010-019912-18,a,o
92,2010-019912-18,una,o
92,2010-019912-18,intervencion,i
92,2010-019912-18,de,o
92,2010-019912-18,este,o
92,2010-019912-18,tipo,o
92,2010-019912-18,en,o
92,2010-019912-18,los,o
92,2010-019912-18,6,o
92,2010-019912-18,meses,o
92,2010-019912-18,siguientes,o
92,2010-019912-18,a,o
92,2010-019912-18,la,o
92,2010-019912-18,randomizacion,i
92,2010-019912-18,Enfermedad,i
92,2010-019912-18,reumatica,i
92,2010-019912-18,autoinmune,i
92,2010-019912-18,distinta,o
92,2010-019912-18,de,o
92,2010-019912-18,AR,i
92,2010-019912-18,Se,o
92,2010-019912-18,permite,o
92,2010-019912-18,la,o
92,2010-019912-18,inclusion,o
92,2010-019912-18,de,o
92,2010-019912-18,pacientes,o
92,2010-019912-18,con,o
92,2010-019912-18,sindrome,i
92,2010-019912-18,de,i
92,2010-019912-18,Sjögren,i
92,2010-019912-18,secundario,i
92,2010-019912-18,asociado,o
92,2010-019912-18,a,o
92,2010-019912-18,AR,i
92,2010-019912-18,Clase,o
92,2010-019912-18,funcional,o
92,2010-019912-18,IV,o
92,2010-019912-18,definida,o
92,2010-019912-18,de,o
92,2010-019912-18,acuerdo,o
92,2010-019912-18,con,o
92,2010-019912-18,la,o
92,2010-019912-18,Clasificacion,o
92,2010-019912-18,del,o
92,2010-019912-18,ACR,o
92,2010-019912-18,del,o
92,2010-019912-18,Estado,o
92,2010-019912-18,Funcional,o
92,2010-019912-18,en,o
92,2010-019912-18,Artritis,i
92,2010-019912-18,Reumatoide,i
92,2010-019912-18,Artritis,i
92,2010-019912-18,idiopatica,i
92,2010-019912-18,juvenil,i
92,2010-019912-18,AIJ,i
92,2010-019912-18,o,o
92,2010-019912-18,artritis,i
92,2010-019912-18,reumatoide,i
92,2010-019912-18,juvenil,i
92,2010-019912-18,ARJ,i
92,2010-019912-18,yo,o
92,2010-019912-18,AR,i
92,2010-019912-18,diagnosticadas,i
92,2010-019912-18,antes,o
92,2010-019912-18,de,o
92,2010-019912-18,los,o
92,2010-019912-18,16,o
92,2010-019912-18,años,o
92,2010-019912-18,de,o
92,2010-019912-18,edad,o
92,2010-019912-18,Enfermedad,i
92,2010-019912-18,articular,i
92,2010-019912-18,inflamatoria,i
92,2010-019912-18,distinta,o
92,2010-019912-18,de,o
92,2010-019912-18,AR,i
92,2010-019912-18,en,o
92,2010-019912-18,el,o
92,2010-019912-18,pasado,o
92,2010-019912-18,o,o
92,2010-019912-18,en,o
92,2010-019912-18,la,o
92,2010-019912-18,actualidad,o
93,2010-019912-18,EudraCT,o
93,2010-019912-18,Nº,o
93,2010-019912-18,201001991218,o
93,2010-019912-18,Titulo,o
93,2010-019912-18,cientifico,o
93,2010-019912-18,Estudio,o
93,2010-019912-18,randomizado,o
93,2010-019912-18,doble,o
93,2010-019912-18,ciego,o
93,2010-019912-18,con,o
93,2010-019912-18,grupos,o
93,2010-019912-18,de,o
93,2010-019912-18,tratamiento,i
93,2010-019912-18,paralelos,o
93,2010-019912-18,para,o
93,2010-019912-18,evaluar,i
93,2010-019912-18,la,i
93,2010-019912-18,seguridad,i
93,2010-019912-18,y,o
93,2010-019912-18,el,o
93,2010-019912-18,efecto,o
93,2010-019912-18,sobre,o
93,2010-019912-18,el,o
93,2010-019912-18,resultado,o
93,2010-019912-18,clinico,o
93,2010-019912-18,de,o
93,2010-019912-18,tocilizumab,i
93,2010-019912-18,SC,o
93,2010-019912-18,frente,o
93,2010-019912-18,a,o
93,2010-019912-18,placebo,i
93,2010-019912-18,SC,o
93,2010-019912-18,en,o
93,2010-019912-18,combinacion,o
93,2010-019912-18,con,o
93,2010-019912-18,farmacos,i
93,2010-019912-18,antirreumaticos,i
93,2010-019912-18,modificadores,i
93,2010-019912-18,de,i
93,2010-019912-18,la,i
93,2010-019912-18,enfermedad,i
93,2010-019912-18,FAMEs,i
93,2010-019912-18,tradicionales,o
93,2010-019912-18,en,o
93,2010-019912-18,pacientes,o
93,2010-019912-18,con,o
93,2010-019912-18,artritis,i
93,2010-019912-18,reumatoide,i
93,2010-019912-18,activa,o
93,2010-019912-18,moderada,o
93,2010-019912-18,a,o
93,2010-019912-18,severa,o
93,2010-019912-18,Indicacion,o
93,2010-019912-18,cientifica,o
93,2010-019912-18,Artritis,i
93,2010-019912-18,Reumatoide,i
93,2010-019912-18,AR,i
93,2010-019912-18,Criterios,o
93,2010-019912-18,de,o
93,2010-019912-18,inclusion,o
93,2010-019912-18,Presentar,o
93,2010-019912-18,artritis,i
93,2010-019912-18,reumatoide,i
93,2010-019912-18,de,o
93,2010-019912-18,mayor,o
93,2010-019912-18,o,o
93,2010-019912-18,igual,o
93,2010-019912-18,a,o
93,2010-019912-18,6,o
93,2010-019912-18,meses,o
93,2010-019912-18,de,o
93,2010-019912-18,duracion,o
93,2010-019912-18,Recibir,o
93,2010-019912-18,tratamiento,i
93,2010-019912-18,de,i
93,2010-019912-18,forma,i
93,2010-019912-18,ambulatoria,i
93,2010-019912-18,Presentar,o
93,2010-019912-18,un,o
93,2010-019912-18,recuento,o
93,2010-019912-18,de,o
93,2010-019912-18,articulaciones,i
93,2010-019912-18,inflamadas,i
93,2010-019912-18,RAI,o
93,2010-019912-18,mayor,o
93,2010-019912-18,o,o
93,2010-019912-18,igual,o
93,2010-019912-18,a,o
93,2010-019912-18,6,o
93,2010-019912-18,recuento,o
93,2010-019912-18,de,o
93,2010-019912-18,66,o
93,2010-019912-18,articulaciones,i
93,2010-019912-18,y,o
93,2010-019912-18,de,o
93,2010-019912-18,articulaciones,i
93,2010-019912-18,dolorosas,i
93,2010-019912-18,RAD,o
93,2010-019912-18,mayor,o
93,2010-019912-18,o,o
93,2010-019912-18,igual,o
93,2010-019912-18,a,o
93,2010-019912-18,8,o
93,2010-019912-18,recuento,o
93,2010-019912-18,de,o
93,2010-019912-18,68,o
93,2010-019912-18,articulaciones,i
93,2010-019912-18,en,o
93,2010-019912-18,las,o
93,2010-019912-18,visitas,o
93,2010-019912-18,de,o
93,2010-019912-18,seleccion,o
93,2010-019912-18,y,o
93,2010-019912-18,basal,o
93,2010-019912-18,Los,o
93,2010-019912-18,pacientes,o
93,2010-019912-18,deben,o
93,2010-019912-18,estar,o
93,2010-019912-18,recibiendo,o
93,2010-019912-18,tratamiento,i
93,2010-019912-18,con,o
93,2010-019912-18,una,o
93,2010-019912-18,dosis,o
93,2010-019912-18,estable,o
93,2010-019912-18,de,o
93,2010-019912-18,los,o
93,2010-019912-18,FAMEs,i
93,2010-019912-18,permitidos,o
93,2010-019912-18,como,o
93,2010-019912-18,minimo,o
93,2010-019912-18,8,o
93,2010-019912-18,semanas,o
93,2010-019912-18,antes,o
93,2010-019912-18,de,o
93,2010-019912-18,la,o
93,2010-019912-18,visita,o
93,2010-019912-18,basal,o
93,2010-019912-18,Criterios,o
93,2010-019912-18,de,o
93,2010-019912-18,exclusion,o
93,2010-019912-18,Pacientes,o
93,2010-019912-18,sometidos,o
93,2010-019912-18,a,o
93,2010-019912-18,intervenciones,i
93,2010-019912-18,de,i
93,2010-019912-18,cirugia,i
93,2010-019912-18,mayor,i
93,2010-019912-18,incluyendo,o
93,2010-019912-18,cirugia,i
93,2010-019912-18,articular,i
93,2010-019912-18,en,o
93,2010-019912-18,las,o
93,2010-019912-18,8,o
93,2010-019912-18,semanas,o
93,2010-019912-18,previas,o
93,2010-019912-18,a,o
93,2010-019912-18,la,o
93,2010-019912-18,visita,o
93,2010-019912-18,de,o
93,2010-019912-18,seleccion,o
93,2010-019912-18,o,o
93,2010-019912-18,que,o
93,2010-019912-18,tengan,o
93,2010-019912-18,previsto,o
93,2010-019912-18,someterse,o
93,2010-019912-18,a,o
93,2010-019912-18,una,o
93,2010-019912-18,intervencion,i
93,2010-019912-18,de,o
93,2010-019912-18,este,o
93,2010-019912-18,tipo,o
93,2010-019912-18,en,o
93,2010-019912-18,los,o
93,2010-019912-18,6,o
93,2010-019912-18,meses,o
93,2010-019912-18,siguientes,o
93,2010-019912-18,a,o
93,2010-019912-18,la,o
93,2010-019912-18,randomizacion,i
93,2010-019912-18,Enfermedad,i
93,2010-019912-18,reumatica,i
93,2010-019912-18,autoinmune,i
93,2010-019912-18,distinta,o
93,2010-019912-18,de,o
93,2010-019912-18,AR,i
93,2010-019912-18,Se,o
93,2010-019912-18,permite,o
93,2010-019912-18,la,o
93,2010-019912-18,inclusion,o
93,2010-019912-18,de,o
93,2010-019912-18,pacientes,o
93,2010-019912-18,con,o
93,2010-019912-18,sindrome,i
93,2010-019912-18,de,i
93,2010-019912-18,Sjögren,i
93,2010-019912-18,secundario,i
93,2010-019912-18,asociado,o
93,2010-019912-18,a,o
93,2010-019912-18,AR,i
93,2010-019912-18,Clase,o
93,2010-019912-18,funcional,o
93,2010-019912-18,IV,o
93,2010-019912-18,definida,o
93,2010-019912-18,de,o
93,2010-019912-18,acuerdo,o
93,2010-019912-18,con,o
93,2010-019912-18,la,o
93,2010-019912-18,Clasificacion,o
93,2010-019912-18,del,o
93,2010-019912-18,ACR,o
93,2010-019912-18,del,o
93,2010-019912-18,Estado,o
93,2010-019912-18,Funcional,o
93,2010-019912-18,en,o
93,2010-019912-18,Artritis,i
93,2010-019912-18,Reumatoide,i
93,2010-019912-18,Artritis,i
93,2010-019912-18,idiopatica,i
93,2010-019912-18,juvenil,i
93,2010-019912-18,AIJ,i
93,2010-019912-18,o,o
93,2010-019912-18,artritis,i
93,2010-019912-18,reumatoide,i
93,2010-019912-18,juvenil,i
93,2010-019912-18,ARJ,i
93,2010-019912-18,yo,o
93,2010-019912-18,AR,i
93,2010-019912-18,diagnosticadas,i
93,2010-019912-18,antes,o
93,2010-019912-18,de,o
93,2010-019912-18,los,o
93,2010-019912-18,16,o
93,2010-019912-18,años,o
93,2010-019912-18,de,o
93,2010-019912-18,edad,o
93,2010-019912-18,Enfermedad,i
93,2010-019912-18,articular,i
93,2010-019912-18,inflamatoria,i
93,2010-019912-18,distinta,o
93,2010-019912-18,de,o
93,2010-019912-18,AR,i
93,2010-019912-18,en,o
93,2010-019912-18,el,o
93,2010-019912-18,pasado,o
93,2010-019912-18,o,o
93,2010-019912-18,en,o
93,2010-019912-18,la,o
93,2010-019912-18,actualidad,o
94,2010-019912-18,EudraCT,o
94,2010-019912-18,Nº,o
94,2010-019912-18,201001991218,o
94,2010-019912-18,Titulo,o
94,2010-019912-18,cientifico,o
94,2010-019912-18,Estudio,o
94,2010-019912-18,randomizado,o
94,2010-019912-18,doble,o
94,2010-019912-18,ciego,o
94,2010-019912-18,con,o
94,2010-019912-18,grupos,o
94,2010-019912-18,de,o
94,2010-019912-18,tratamiento,i
94,2010-019912-18,paralelos,o
94,2010-019912-18,para,o
94,2010-019912-18,evaluar,i
94,2010-019912-18,la,i
94,2010-019912-18,seguridad,i
94,2010-019912-18,y,o
94,2010-019912-18,el,o
94,2010-019912-18,efecto,o
94,2010-019912-18,sobre,o
94,2010-019912-18,el,o
94,2010-019912-18,resultado,o
94,2010-019912-18,clinico,o
94,2010-019912-18,de,o
94,2010-019912-18,tocilizumab,i
94,2010-019912-18,SC,o
94,2010-019912-18,frente,o
94,2010-019912-18,a,o
94,2010-019912-18,placebo,i
94,2010-019912-18,SC,o
94,2010-019912-18,en,o
94,2010-019912-18,combinacion,o
94,2010-019912-18,con,o
94,2010-019912-18,farmacos,i
94,2010-019912-18,antirreumaticos,i
94,2010-019912-18,modificadores,i
94,2010-019912-18,de,i
94,2010-019912-18,la,i
94,2010-019912-18,enfermedad,i
94,2010-019912-18,FAMEs,i
94,2010-019912-18,tradicionales,o
94,2010-019912-18,en,o
94,2010-019912-18,pacientes,o
94,2010-019912-18,con,o
94,2010-019912-18,artritis,i
94,2010-019912-18,reumatoide,i
94,2010-019912-18,activa,o
94,2010-019912-18,moderada,o
94,2010-019912-18,a,o
94,2010-019912-18,severa,o
94,2010-019912-18,Indicacion,o
94,2010-019912-18,cientifica,o
94,2010-019912-18,Artritis,i
94,2010-019912-18,Reumatoide,i
94,2010-019912-18,AR,i
94,2010-019912-18,Criterios,o
94,2010-019912-18,de,o
94,2010-019912-18,inclusion,o
94,2010-019912-18,Presentar,o
94,2010-019912-18,artritis,i
94,2010-019912-18,reumatoide,i
94,2010-019912-18,de,o
94,2010-019912-18,mayor,o
94,2010-019912-18,o,o
94,2010-019912-18,igual,o
94,2010-019912-18,a,o
94,2010-019912-18,6,o
94,2010-019912-18,meses,o
94,2010-019912-18,de,o
94,2010-019912-18,duracion,o
94,2010-019912-18,Recibir,o
94,2010-019912-18,tratamiento,i
94,2010-019912-18,de,i
94,2010-019912-18,forma,i
94,2010-019912-18,ambulatoria,i
94,2010-019912-18,Presentar,o
94,2010-019912-18,un,o
94,2010-019912-18,recuento,o
94,2010-019912-18,de,o
94,2010-019912-18,articulaciones,i
94,2010-019912-18,inflamadas,i
94,2010-019912-18,RAI,o
94,2010-019912-18,mayor,o
94,2010-019912-18,o,o
94,2010-019912-18,igual,o
94,2010-019912-18,a,o
94,2010-019912-18,6,o
94,2010-019912-18,recuento,o
94,2010-019912-18,de,o
94,2010-019912-18,66,o
94,2010-019912-18,articulaciones,i
94,2010-019912-18,y,o
94,2010-019912-18,de,o
94,2010-019912-18,articulaciones,i
94,2010-019912-18,dolorosas,i
94,2010-019912-18,RAD,o
94,2010-019912-18,mayor,o
94,2010-019912-18,o,o
94,2010-019912-18,igual,o
94,2010-019912-18,a,o
94,2010-019912-18,8,o
94,2010-019912-18,recuento,o
94,2010-019912-18,de,o
94,2010-019912-18,68,o
94,2010-019912-18,articulaciones,i
94,2010-019912-18,en,o
94,2010-019912-18,las,o
94,2010-019912-18,visitas,o
94,2010-019912-18,de,o
94,2010-019912-18,seleccion,o
94,2010-019912-18,y,o
94,2010-019912-18,basal,o
94,2010-019912-18,Los,o
94,2010-019912-18,pacientes,o
94,2010-019912-18,deben,o
94,2010-019912-18,estar,o
94,2010-019912-18,recibiendo,o
94,2010-019912-18,tratamiento,i
94,2010-019912-18,con,o
94,2010-019912-18,una,o
94,2010-019912-18,dosis,o
94,2010-019912-18,estable,o
94,2010-019912-18,de,o
94,2010-019912-18,los,o
94,2010-019912-18,FAMEs,i
94,2010-019912-18,permitidos,o
94,2010-019912-18,como,o
94,2010-019912-18,minimo,o
94,2010-019912-18,8,o
94,2010-019912-18,semanas,o
94,2010-019912-18,antes,o
94,2010-019912-18,de,o
94,2010-019912-18,la,o
94,2010-019912-18,visita,o
94,2010-019912-18,basal,o
94,2010-019912-18,Criterios,o
94,2010-019912-18,de,o
94,2010-019912-18,exclusion,o
94,2010-019912-18,Pacientes,o
94,2010-019912-18,sometidos,o
94,2010-019912-18,a,o
94,2010-019912-18,intervenciones,i
94,2010-019912-18,de,i
94,2010-019912-18,cirugia,i
94,2010-019912-18,mayor,i
94,2010-019912-18,incluyendo,o
94,2010-019912-18,cirugia,i
94,2010-019912-18,articular,i
94,2010-019912-18,en,o
94,2010-019912-18,las,o
94,2010-019912-18,8,o
94,2010-019912-18,semanas,o
94,2010-019912-18,previas,o
94,2010-019912-18,a,o
94,2010-019912-18,la,o
94,2010-019912-18,visita,o
94,2010-019912-18,de,o
94,2010-019912-18,seleccion,o
94,2010-019912-18,o,o
94,2010-019912-18,que,o
94,2010-019912-18,tengan,o
94,2010-019912-18,previsto,o
94,2010-019912-18,someterse,o
94,2010-019912-18,a,o
94,2010-019912-18,una,o
94,2010-019912-18,intervencion,i
94,2010-019912-18,de,o
94,2010-019912-18,este,o
94,2010-019912-18,tipo,o
94,2010-019912-18,en,o
94,2010-019912-18,los,o
94,2010-019912-18,6,o
94,2010-019912-18,meses,o
94,2010-019912-18,siguientes,o
94,2010-019912-18,a,o
94,2010-019912-18,la,o
94,2010-019912-18,randomizacion,i
94,2010-019912-18,Enfermedad,i
94,2010-019912-18,reumatica,i
94,2010-019912-18,autoinmune,i
94,2010-019912-18,distinta,o
94,2010-019912-18,de,o
94,2010-019912-18,AR,i
94,2010-019912-18,Se,o
94,2010-019912-18,permite,o
94,2010-019912-18,la,o
94,2010-019912-18,inclusion,o
94,2010-019912-18,de,o
94,2010-019912-18,pacientes,o
94,2010-019912-18,con,o
94,2010-019912-18,sindrome,i
94,2010-019912-18,de,i
94,2010-019912-18,Sjögren,i
94,2010-019912-18,secundario,i
94,2010-019912-18,asociado,o
94,2010-019912-18,a,o
94,2010-019912-18,AR,i
94,2010-019912-18,Clase,o
94,2010-019912-18,funcional,o
94,2010-019912-18,IV,o
94,2010-019912-18,definida,o
94,2010-019912-18,de,o
94,2010-019912-18,acuerdo,o
94,2010-019912-18,con,o
94,2010-019912-18,la,o
94,2010-019912-18,Clasificacion,o
94,2010-019912-18,del,o
94,2010-019912-18,ACR,o
94,2010-019912-18,del,o
94,2010-019912-18,Estado,o
94,2010-019912-18,Funcional,o
94,2010-019912-18,en,o
94,2010-019912-18,Artritis,i
94,2010-019912-18,Reumatoide,i
94,2010-019912-18,Artritis,i
94,2010-019912-18,idiopatica,i
94,2010-019912-18,juvenil,i
94,2010-019912-18,AIJ,i
94,2010-019912-18,o,o
94,2010-019912-18,artritis,i
94,2010-019912-18,reumatoide,i
94,2010-019912-18,juvenil,i
94,2010-019912-18,ARJ,i
94,2010-019912-18,yo,o
94,2010-019912-18,AR,i
94,2010-019912-18,diagnosticadas,i
94,2010-019912-18,antes,o
94,2010-019912-18,de,o
94,2010-019912-18,los,o
94,2010-019912-18,16,o
94,2010-019912-18,años,o
94,2010-019912-18,de,o
94,2010-019912-18,edad,o
94,2010-019912-18,Enfermedad,i
94,2010-019912-18,articular,i
94,2010-019912-18,inflamatoria,i
94,2010-019912-18,distinta,o
94,2010-019912-18,de,o
94,2010-019912-18,AR,i
94,2010-019912-18,en,o
94,2010-019912-18,el,o
94,2010-019912-18,pasado,o
94,2010-019912-18,o,o
94,2010-019912-18,en,o
94,2010-019912-18,la,o
94,2010-019912-18,actualidad,o
95,2010-019912-18,EudraCT,o
95,2010-019912-18,Nº,o
95,2010-019912-18,201001991218,o
95,2010-019912-18,Titulo,o
95,2010-019912-18,cientifico,o
95,2010-019912-18,Estudio,o
95,2010-019912-18,randomizado,o
95,2010-019912-18,doble,o
95,2010-019912-18,ciego,o
95,2010-019912-18,con,o
95,2010-019912-18,grupos,o
95,2010-019912-18,de,o
95,2010-019912-18,tratamiento,i
95,2010-019912-18,paralelos,o
95,2010-019912-18,para,o
95,2010-019912-18,evaluar,i
95,2010-019912-18,la,i
95,2010-019912-18,seguridad,i
95,2010-019912-18,y,o
95,2010-019912-18,el,o
95,2010-019912-18,efecto,o
95,2010-019912-18,sobre,o
95,2010-019912-18,el,o
95,2010-019912-18,resultado,o
95,2010-019912-18,clinico,o
95,2010-019912-18,de,o
95,2010-019912-18,tocilizumab,i
95,2010-019912-18,SC,o
95,2010-019912-18,frente,o
95,2010-019912-18,a,o
95,2010-019912-18,placebo,i
95,2010-019912-18,SC,o
95,2010-019912-18,en,o
95,2010-019912-18,combinacion,o
95,2010-019912-18,con,o
95,2010-019912-18,farmacos,i
95,2010-019912-18,antirreumaticos,i
95,2010-019912-18,modificadores,i
95,2010-019912-18,de,i
95,2010-019912-18,la,i
95,2010-019912-18,enfermedad,i
95,2010-019912-18,FAMEs,i
95,2010-019912-18,tradicionales,o
95,2010-019912-18,en,o
95,2010-019912-18,pacientes,o
95,2010-019912-18,con,o
95,2010-019912-18,artritis,i
95,2010-019912-18,reumatoide,i
95,2010-019912-18,activa,o
95,2010-019912-18,moderada,o
95,2010-019912-18,a,o
95,2010-019912-18,severa,o
95,2010-019912-18,Indicacion,o
95,2010-019912-18,cientifica,o
95,2010-019912-18,Artritis,i
95,2010-019912-18,Reumatoide,i
95,2010-019912-18,AR,i
95,2010-019912-18,Criterios,o
95,2010-019912-18,de,o
95,2010-019912-18,inclusion,o
95,2010-019912-18,Presentar,o
95,2010-019912-18,artritis,i
95,2010-019912-18,reumatoide,i
95,2010-019912-18,de,o
95,2010-019912-18,mayor,o
95,2010-019912-18,o,o
95,2010-019912-18,igual,o
95,2010-019912-18,a,o
95,2010-019912-18,6,o
95,2010-019912-18,meses,o
95,2010-019912-18,de,o
95,2010-019912-18,duracion,o
95,2010-019912-18,Recibir,o
95,2010-019912-18,tratamiento,i
95,2010-019912-18,de,i
95,2010-019912-18,forma,i
95,2010-019912-18,ambulatoria,i
95,2010-019912-18,Presentar,o
95,2010-019912-18,un,o
95,2010-019912-18,recuento,o
95,2010-019912-18,de,o
95,2010-019912-18,articulaciones,i
95,2010-019912-18,inflamadas,i
95,2010-019912-18,RAI,o
95,2010-019912-18,mayor,o
95,2010-019912-18,o,o
95,2010-019912-18,igual,o
95,2010-019912-18,a,o
95,2010-019912-18,6,o
95,2010-019912-18,recuento,o
95,2010-019912-18,de,o
95,2010-019912-18,66,o
95,2010-019912-18,articulaciones,i
95,2010-019912-18,y,o
95,2010-019912-18,de,o
95,2010-019912-18,articulaciones,i
95,2010-019912-18,dolorosas,i
95,2010-019912-18,RAD,o
95,2010-019912-18,mayor,o
95,2010-019912-18,o,o
95,2010-019912-18,igual,o
95,2010-019912-18,a,o
95,2010-019912-18,8,o
95,2010-019912-18,recuento,o
95,2010-019912-18,de,o
95,2010-019912-18,68,o
95,2010-019912-18,articulaciones,i
95,2010-019912-18,en,o
95,2010-019912-18,las,o
95,2010-019912-18,visitas,o
95,2010-019912-18,de,o
95,2010-019912-18,seleccion,o
95,2010-019912-18,y,o
95,2010-019912-18,basal,o
95,2010-019912-18,Los,o
95,2010-019912-18,pacientes,o
95,2010-019912-18,deben,o
95,2010-019912-18,estar,o
95,2010-019912-18,recibiendo,o
95,2010-019912-18,tratamiento,i
95,2010-019912-18,con,o
95,2010-019912-18,una,o
95,2010-019912-18,dosis,o
95,2010-019912-18,estable,o
95,2010-019912-18,de,o
95,2010-019912-18,los,o
95,2010-019912-18,FAMEs,i
95,2010-019912-18,permitidos,o
95,2010-019912-18,como,o
95,2010-019912-18,minimo,o
95,2010-019912-18,8,o
95,2010-019912-18,semanas,o
95,2010-019912-18,antes,o
95,2010-019912-18,de,o
95,2010-019912-18,la,o
95,2010-019912-18,visita,o
95,2010-019912-18,basal,o
95,2010-019912-18,Criterios,o
95,2010-019912-18,de,o
95,2010-019912-18,exclusion,o
95,2010-019912-18,Pacientes,o
95,2010-019912-18,sometidos,o
95,2010-019912-18,a,o
95,2010-019912-18,intervenciones,i
95,2010-019912-18,de,i
95,2010-019912-18,cirugia,i
95,2010-019912-18,mayor,i
95,2010-019912-18,incluyendo,o
95,2010-019912-18,cirugia,i
95,2010-019912-18,articular,i
95,2010-019912-18,en,o
95,2010-019912-18,las,o
95,2010-019912-18,8,o
95,2010-019912-18,semanas,o
95,2010-019912-18,previas,o
95,2010-019912-18,a,o
95,2010-019912-18,la,o
95,2010-019912-18,visita,o
95,2010-019912-18,de,o
95,2010-019912-18,seleccion,o
95,2010-019912-18,o,o
95,2010-019912-18,que,o
95,2010-019912-18,tengan,o
95,2010-019912-18,previsto,o
95,2010-019912-18,someterse,o
95,2010-019912-18,a,o
95,2010-019912-18,una,o
95,2010-019912-18,intervencion,i
95,2010-019912-18,de,o
95,2010-019912-18,este,o
95,2010-019912-18,tipo,o
95,2010-019912-18,en,o
95,2010-019912-18,los,o
95,2010-019912-18,6,o
95,2010-019912-18,meses,o
95,2010-019912-18,siguientes,o
95,2010-019912-18,a,o
95,2010-019912-18,la,o
95,2010-019912-18,randomizacion,i
95,2010-019912-18,Enfermedad,i
95,2010-019912-18,reumatica,i
95,2010-019912-18,autoinmune,i
95,2010-019912-18,distinta,o
95,2010-019912-18,de,o
95,2010-019912-18,AR,i
95,2010-019912-18,Se,o
95,2010-019912-18,permite,o
95,2010-019912-18,la,o
95,2010-019912-18,inclusion,o
95,2010-019912-18,de,o
95,2010-019912-18,pacientes,o
95,2010-019912-18,con,o
95,2010-019912-18,sindrome,i
95,2010-019912-18,de,i
95,2010-019912-18,Sjögren,i
95,2010-019912-18,secundario,i
95,2010-019912-18,asociado,o
95,2010-019912-18,a,o
95,2010-019912-18,AR,i
95,2010-019912-18,Clase,o
95,2010-019912-18,funcional,o
95,2010-019912-18,IV,o
95,2010-019912-18,definida,o
95,2010-019912-18,de,o
95,2010-019912-18,acuerdo,o
95,2010-019912-18,con,o
95,2010-019912-18,la,o
95,2010-019912-18,Clasificacion,o
95,2010-019912-18,del,o
95,2010-019912-18,ACR,o
95,2010-019912-18,del,o
95,2010-019912-18,Estado,o
95,2010-019912-18,Funcional,o
95,2010-019912-18,en,o
95,2010-019912-18,Artritis,i
95,2010-019912-18,Reumatoide,i
95,2010-019912-18,Artritis,i
95,2010-019912-18,idiopatica,i
95,2010-019912-18,juvenil,i
95,2010-019912-18,AIJ,i
95,2010-019912-18,o,o
95,2010-019912-18,artritis,i
95,2010-019912-18,reumatoide,i
95,2010-019912-18,juvenil,i
95,2010-019912-18,ARJ,i
95,2010-019912-18,yo,o
95,2010-019912-18,AR,i
95,2010-019912-18,diagnosticadas,i
95,2010-019912-18,antes,o
95,2010-019912-18,de,o
95,2010-019912-18,los,o
95,2010-019912-18,16,o
95,2010-019912-18,años,o
95,2010-019912-18,de,o
95,2010-019912-18,edad,o
95,2010-019912-18,Enfermedad,i
95,2010-019912-18,articular,i
95,2010-019912-18,inflamatoria,i
95,2010-019912-18,distinta,o
95,2010-019912-18,de,o
95,2010-019912-18,AR,i
95,2010-019912-18,en,o
95,2010-019912-18,el,o
95,2010-019912-18,pasado,o
95,2010-019912-18,o,o
95,2010-019912-18,en,o
95,2010-019912-18,la,o
95,2010-019912-18,actualidad,o
96,2010-019912-18,EudraCT,o
96,2010-019912-18,Nº,o
96,2010-019912-18,201001991218,o
96,2010-019912-18,Titulo,o
96,2010-019912-18,cientifico,o
96,2010-019912-18,Estudio,o
96,2010-019912-18,randomizado,o
96,2010-019912-18,doble,o
96,2010-019912-18,ciego,o
96,2010-019912-18,con,o
96,2010-019912-18,grupos,o
96,2010-019912-18,de,o
96,2010-019912-18,tratamiento,i
96,2010-019912-18,paralelos,o
96,2010-019912-18,para,o
96,2010-019912-18,evaluar,i
96,2010-019912-18,la,i
96,2010-019912-18,seguridad,i
96,2010-019912-18,y,o
96,2010-019912-18,el,o
96,2010-019912-18,efecto,o
96,2010-019912-18,sobre,o
96,2010-019912-18,el,o
96,2010-019912-18,resultado,o
96,2010-019912-18,clinico,o
96,2010-019912-18,de,o
96,2010-019912-18,tocilizumab,i
96,2010-019912-18,SC,o
96,2010-019912-18,frente,o
96,2010-019912-18,a,o
96,2010-019912-18,placebo,i
96,2010-019912-18,SC,o
96,2010-019912-18,en,o
96,2010-019912-18,combinacion,o
96,2010-019912-18,con,o
96,2010-019912-18,farmacos,i
96,2010-019912-18,antirreumaticos,i
96,2010-019912-18,modificadores,i
96,2010-019912-18,de,i
96,2010-019912-18,la,i
96,2010-019912-18,enfermedad,i
96,2010-019912-18,FAMEs,i
96,2010-019912-18,tradicionales,o
96,2010-019912-18,en,o
96,2010-019912-18,pacientes,o
96,2010-019912-18,con,o
96,2010-019912-18,artritis,i
96,2010-019912-18,reumatoide,i
96,2010-019912-18,activa,o
96,2010-019912-18,moderada,o
96,2010-019912-18,a,o
96,2010-019912-18,severa,o
96,2010-019912-18,Indicacion,o
96,2010-019912-18,cientifica,o
96,2010-019912-18,Artritis,i
96,2010-019912-18,Reumatoide,i
96,2010-019912-18,AR,i
96,2010-019912-18,Criterios,o
96,2010-019912-18,de,o
96,2010-019912-18,inclusion,o
96,2010-019912-18,Presentar,o
96,2010-019912-18,artritis,i
96,2010-019912-18,reumatoide,i
96,2010-019912-18,de,o
96,2010-019912-18,mayor,o
96,2010-019912-18,o,o
96,2010-019912-18,igual,o
96,2010-019912-18,a,o
96,2010-019912-18,6,o
96,2010-019912-18,meses,o
96,2010-019912-18,de,o
96,2010-019912-18,duracion,o
96,2010-019912-18,Recibir,o
96,2010-019912-18,tratamiento,i
96,2010-019912-18,de,i
96,2010-019912-18,forma,i
96,2010-019912-18,ambulatoria,i
96,2010-019912-18,Presentar,o
96,2010-019912-18,un,o
96,2010-019912-18,recuento,o
96,2010-019912-18,de,o
96,2010-019912-18,articulaciones,i
96,2010-019912-18,inflamadas,i
96,2010-019912-18,RAI,o
96,2010-019912-18,mayor,o
96,2010-019912-18,o,o
96,2010-019912-18,igual,o
96,2010-019912-18,a,o
96,2010-019912-18,6,o
96,2010-019912-18,recuento,o
96,2010-019912-18,de,o
96,2010-019912-18,66,o
96,2010-019912-18,articulaciones,i
96,2010-019912-18,y,o
96,2010-019912-18,de,o
96,2010-019912-18,articulaciones,i
96,2010-019912-18,dolorosas,i
96,2010-019912-18,RAD,o
96,2010-019912-18,mayor,o
96,2010-019912-18,o,o
96,2010-019912-18,igual,o
96,2010-019912-18,a,o
96,2010-019912-18,8,o
96,2010-019912-18,recuento,o
96,2010-019912-18,de,o
96,2010-019912-18,68,o
96,2010-019912-18,articulaciones,i
96,2010-019912-18,en,o
96,2010-019912-18,las,o
96,2010-019912-18,visitas,o
96,2010-019912-18,de,o
96,2010-019912-18,seleccion,o
96,2010-019912-18,y,o
96,2010-019912-18,basal,o
96,2010-019912-18,Los,o
96,2010-019912-18,pacientes,o
96,2010-019912-18,deben,o
96,2010-019912-18,estar,o
96,2010-019912-18,recibiendo,o
96,2010-019912-18,tratamiento,i
96,2010-019912-18,con,o
96,2010-019912-18,una,o
96,2010-019912-18,dosis,o
96,2010-019912-18,estable,o
96,2010-019912-18,de,o
96,2010-019912-18,los,o
96,2010-019912-18,FAMEs,i
96,2010-019912-18,permitidos,o
96,2010-019912-18,como,o
96,2010-019912-18,minimo,o
96,2010-019912-18,8,o
96,2010-019912-18,semanas,o
96,2010-019912-18,antes,o
96,2010-019912-18,de,o
96,2010-019912-18,la,o
96,2010-019912-18,visita,o
96,2010-019912-18,basal,o
96,2010-019912-18,Criterios,o
96,2010-019912-18,de,o
96,2010-019912-18,exclusion,o
96,2010-019912-18,Pacientes,o
96,2010-019912-18,sometidos,o
96,2010-019912-18,a,o
96,2010-019912-18,intervenciones,i
96,2010-019912-18,de,i
96,2010-019912-18,cirugia,i
96,2010-019912-18,mayor,i
96,2010-019912-18,incluyendo,o
96,2010-019912-18,cirugia,i
96,2010-019912-18,articular,i
96,2010-019912-18,en,o
96,2010-019912-18,las,o
96,2010-019912-18,8,o
96,2010-019912-18,semanas,o
96,2010-019912-18,previas,o
96,2010-019912-18,a,o
96,2010-019912-18,la,o
96,2010-019912-18,visita,o
96,2010-019912-18,de,o
96,2010-019912-18,seleccion,o
96,2010-019912-18,o,o
96,2010-019912-18,que,o
96,2010-019912-18,tengan,o
96,2010-019912-18,previsto,o
96,2010-019912-18,someterse,o
96,2010-019912-18,a,o
96,2010-019912-18,una,o
96,2010-019912-18,intervencion,i
96,2010-019912-18,de,o
96,2010-019912-18,este,o
96,2010-019912-18,tipo,o
96,2010-019912-18,en,o
96,2010-019912-18,los,o
96,2010-019912-18,6,o
96,2010-019912-18,meses,o
96,2010-019912-18,siguientes,o
96,2010-019912-18,a,o
96,2010-019912-18,la,o
96,2010-019912-18,randomizacion,i
96,2010-019912-18,Enfermedad,i
96,2010-019912-18,reumatica,i
96,2010-019912-18,autoinmune,i
96,2010-019912-18,distinta,o
96,2010-019912-18,de,o
96,2010-019912-18,AR,i
96,2010-019912-18,Se,o
96,2010-019912-18,permite,o
96,2010-019912-18,la,o
96,2010-019912-18,inclusion,o
96,2010-019912-18,de,o
96,2010-019912-18,pacientes,o
96,2010-019912-18,con,o
96,2010-019912-18,sindrome,i
96,2010-019912-18,de,i
96,2010-019912-18,Sjögren,i
96,2010-019912-18,secundario,i
96,2010-019912-18,asociado,o
96,2010-019912-18,a,o
96,2010-019912-18,AR,i
96,2010-019912-18,Clase,o
96,2010-019912-18,funcional,o
96,2010-019912-18,IV,o
96,2010-019912-18,definida,o
96,2010-019912-18,de,o
96,2010-019912-18,acuerdo,o
96,2010-019912-18,con,o
96,2010-019912-18,la,o
96,2010-019912-18,Clasificacion,o
96,2010-019912-18,del,o
96,2010-019912-18,ACR,o
96,2010-019912-18,del,o
96,2010-019912-18,Estado,o
96,2010-019912-18,Funcional,o
96,2010-019912-18,en,o
96,2010-019912-18,Artritis,i
96,2010-019912-18,Reumatoide,i
96,2010-019912-18,Artritis,i
96,2010-019912-18,idiopatica,i
96,2010-019912-18,juvenil,i
96,2010-019912-18,AIJ,i
96,2010-019912-18,o,o
96,2010-019912-18,artritis,i
96,2010-019912-18,reumatoide,i
96,2010-019912-18,juvenil,i
96,2010-019912-18,ARJ,i
96,2010-019912-18,yo,o
96,2010-019912-18,AR,i
96,2010-019912-18,diagnosticadas,i
96,2010-019912-18,antes,o
96,2010-019912-18,de,o
96,2010-019912-18,los,o
96,2010-019912-18,16,o
96,2010-019912-18,años,o
96,2010-019912-18,de,o
96,2010-019912-18,edad,o
96,2010-019912-18,Enfermedad,i
96,2010-019912-18,articular,i
96,2010-019912-18,inflamatoria,i
96,2010-019912-18,distinta,o
96,2010-019912-18,de,o
96,2010-019912-18,AR,i
96,2010-019912-18,en,o
96,2010-019912-18,el,o
96,2010-019912-18,pasado,o
96,2010-019912-18,o,o
96,2010-019912-18,en,o
96,2010-019912-18,la,o
96,2010-019912-18,actualidad,o
97,2010-019912-18,EudraCT,o
97,2010-019912-18,Nº,o
97,2010-019912-18,201001991218,o
97,2010-019912-18,Titulo,o
97,2010-019912-18,cientifico,o
97,2010-019912-18,Estudio,o
97,2010-019912-18,randomizado,o
97,2010-019912-18,doble,o
97,2010-019912-18,ciego,o
97,2010-019912-18,con,o
97,2010-019912-18,grupos,o
97,2010-019912-18,de,o
97,2010-019912-18,tratamiento,i
97,2010-019912-18,paralelos,o
97,2010-019912-18,para,o
97,2010-019912-18,evaluar,i
97,2010-019912-18,la,i
97,2010-019912-18,seguridad,i
97,2010-019912-18,y,o
97,2010-019912-18,el,o
97,2010-019912-18,efecto,o
97,2010-019912-18,sobre,o
97,2010-019912-18,el,o
97,2010-019912-18,resultado,o
97,2010-019912-18,clinico,o
97,2010-019912-18,de,o
97,2010-019912-18,tocilizumab,i
97,2010-019912-18,SC,o
97,2010-019912-18,frente,o
97,2010-019912-18,a,o
97,2010-019912-18,placebo,i
97,2010-019912-18,SC,o
97,2010-019912-18,en,o
97,2010-019912-18,combinacion,o
97,2010-019912-18,con,o
97,2010-019912-18,farmacos,i
97,2010-019912-18,antirreumaticos,i
97,2010-019912-18,modificadores,i
97,2010-019912-18,de,i
97,2010-019912-18,la,i
97,2010-019912-18,enfermedad,i
97,2010-019912-18,FAMEs,i
97,2010-019912-18,tradicionales,o
97,2010-019912-18,en,o
97,2010-019912-18,pacientes,o
97,2010-019912-18,con,o
97,2010-019912-18,artritis,i
97,2010-019912-18,reumatoide,i
97,2010-019912-18,activa,o
97,2010-019912-18,moderada,o
97,2010-019912-18,a,o
97,2010-019912-18,severa,o
97,2010-019912-18,Indicacion,o
97,2010-019912-18,cientifica,o
97,2010-019912-18,Artritis,i
97,2010-019912-18,Reumatoide,i
97,2010-019912-18,AR,i
97,2010-019912-18,Criterios,o
97,2010-019912-18,de,o
97,2010-019912-18,inclusion,o
97,2010-019912-18,Presentar,o
97,2010-019912-18,artritis,i
97,2010-019912-18,reumatoide,i
97,2010-019912-18,de,o
97,2010-019912-18,mayor,o
97,2010-019912-18,o,o
97,2010-019912-18,igual,o
97,2010-019912-18,a,o
97,2010-019912-18,6,o
97,2010-019912-18,meses,o
97,2010-019912-18,de,o
97,2010-019912-18,duracion,o
97,2010-019912-18,Recibir,o
97,2010-019912-18,tratamiento,i
97,2010-019912-18,de,i
97,2010-019912-18,forma,i
97,2010-019912-18,ambulatoria,i
97,2010-019912-18,Presentar,o
97,2010-019912-18,un,o
97,2010-019912-18,recuento,o
97,2010-019912-18,de,o
97,2010-019912-18,articulaciones,i
97,2010-019912-18,inflamadas,i
97,2010-019912-18,RAI,o
97,2010-019912-18,mayor,o
97,2010-019912-18,o,o
97,2010-019912-18,igual,o
97,2010-019912-18,a,o
97,2010-019912-18,6,o
97,2010-019912-18,recuento,o
97,2010-019912-18,de,o
97,2010-019912-18,66,o
97,2010-019912-18,articulaciones,i
97,2010-019912-18,y,o
97,2010-019912-18,de,o
97,2010-019912-18,articulaciones,i
97,2010-019912-18,dolorosas,i
97,2010-019912-18,RAD,o
97,2010-019912-18,mayor,o
97,2010-019912-18,o,o
97,2010-019912-18,igual,o
97,2010-019912-18,a,o
97,2010-019912-18,8,o
97,2010-019912-18,recuento,o
97,2010-019912-18,de,o
97,2010-019912-18,68,o
97,2010-019912-18,articulaciones,i
97,2010-019912-18,en,o
97,2010-019912-18,las,o
97,2010-019912-18,visitas,o
97,2010-019912-18,de,o
97,2010-019912-18,seleccion,o
97,2010-019912-18,y,o
97,2010-019912-18,basal,o
97,2010-019912-18,Los,o
97,2010-019912-18,pacientes,o
97,2010-019912-18,deben,o
97,2010-019912-18,estar,o
97,2010-019912-18,recibiendo,o
97,2010-019912-18,tratamiento,i
97,2010-019912-18,con,o
97,2010-019912-18,una,o
97,2010-019912-18,dosis,o
97,2010-019912-18,estable,o
97,2010-019912-18,de,o
97,2010-019912-18,los,o
97,2010-019912-18,FAMEs,i
97,2010-019912-18,permitidos,o
97,2010-019912-18,como,o
97,2010-019912-18,minimo,o
97,2010-019912-18,8,o
97,2010-019912-18,semanas,o
97,2010-019912-18,antes,o
97,2010-019912-18,de,o
97,2010-019912-18,la,o
97,2010-019912-18,visita,o
97,2010-019912-18,basal,o
97,2010-019912-18,Criterios,o
97,2010-019912-18,de,o
97,2010-019912-18,exclusion,o
97,2010-019912-18,Pacientes,o
97,2010-019912-18,sometidos,o
97,2010-019912-18,a,o
97,2010-019912-18,intervenciones,i
97,2010-019912-18,de,i
97,2010-019912-18,cirugia,i
97,2010-019912-18,mayor,i
97,2010-019912-18,incluyendo,o
97,2010-019912-18,cirugia,i
97,2010-019912-18,articular,i
97,2010-019912-18,en,o
97,2010-019912-18,las,o
97,2010-019912-18,8,o
97,2010-019912-18,semanas,o
97,2010-019912-18,previas,o
97,2010-019912-18,a,o
97,2010-019912-18,la,o
97,2010-019912-18,visita,o
97,2010-019912-18,de,o
97,2010-019912-18,seleccion,o
97,2010-019912-18,o,o
97,2010-019912-18,que,o
97,2010-019912-18,tengan,o
97,2010-019912-18,previsto,o
97,2010-019912-18,someterse,o
97,2010-019912-18,a,o
97,2010-019912-18,una,o
97,2010-019912-18,intervencion,i
97,2010-019912-18,de,o
97,2010-019912-18,este,o
97,2010-019912-18,tipo,o
97,2010-019912-18,en,o
97,2010-019912-18,los,o
97,2010-019912-18,6,o
97,2010-019912-18,meses,o
97,2010-019912-18,siguientes,o
97,2010-019912-18,a,o
97,2010-019912-18,la,o
97,2010-019912-18,randomizacion,i
97,2010-019912-18,Enfermedad,i
97,2010-019912-18,reumatica,i
97,2010-019912-18,autoinmune,i
97,2010-019912-18,distinta,o
97,2010-019912-18,de,o
97,2010-019912-18,AR,i
97,2010-019912-18,Se,o
97,2010-019912-18,permite,o
97,2010-019912-18,la,o
97,2010-019912-18,inclusion,o
97,2010-019912-18,de,o
97,2010-019912-18,pacientes,o
97,2010-019912-18,con,o
97,2010-019912-18,sindrome,i
97,2010-019912-18,de,i
97,2010-019912-18,Sjögren,i
97,2010-019912-18,secundario,i
97,2010-019912-18,asociado,o
97,2010-019912-18,a,o
97,2010-019912-18,AR,i
97,2010-019912-18,Clase,o
97,2010-019912-18,funcional,o
97,2010-019912-18,IV,o
97,2010-019912-18,definida,o
97,2010-019912-18,de,o
97,2010-019912-18,acuerdo,o
97,2010-019912-18,con,o
97,2010-019912-18,la,o
97,2010-019912-18,Clasificacion,o
97,2010-019912-18,del,o
97,2010-019912-18,ACR,o
97,2010-019912-18,del,o
97,2010-019912-18,Estado,o
97,2010-019912-18,Funcional,o
97,2010-019912-18,en,o
97,2010-019912-18,Artritis,i
97,2010-019912-18,Reumatoide,i
97,2010-019912-18,Artritis,i
97,2010-019912-18,idiopatica,i
97,2010-019912-18,juvenil,i
97,2010-019912-18,AIJ,i
97,2010-019912-18,o,o
97,2010-019912-18,artritis,i
97,2010-019912-18,reumatoide,i
97,2010-019912-18,juvenil,i
97,2010-019912-18,ARJ,i
97,2010-019912-18,yo,o
97,2010-019912-18,AR,i
97,2010-019912-18,diagnosticadas,i
97,2010-019912-18,antes,o
97,2010-019912-18,de,o
97,2010-019912-18,los,o
97,2010-019912-18,16,o
97,2010-019912-18,años,o
97,2010-019912-18,de,o
97,2010-019912-18,edad,o
97,2010-019912-18,Enfermedad,i
97,2010-019912-18,articular,i
97,2010-019912-18,inflamatoria,i
97,2010-019912-18,distinta,o
97,2010-019912-18,de,o
97,2010-019912-18,AR,i
97,2010-019912-18,en,o
97,2010-019912-18,el,o
97,2010-019912-18,pasado,o
97,2010-019912-18,o,o
97,2010-019912-18,en,o
97,2010-019912-18,la,o
97,2010-019912-18,actualidad,o
98,2010-019912-18,EudraCT,o
98,2010-019912-18,Nº,o
98,2010-019912-18,201001991218,o
98,2010-019912-18,Titulo,o
98,2010-019912-18,cientifico,o
98,2010-019912-18,Estudio,o
98,2010-019912-18,randomizado,o
98,2010-019912-18,doble,o
98,2010-019912-18,ciego,o
98,2010-019912-18,con,o
98,2010-019912-18,grupos,o
98,2010-019912-18,de,o
98,2010-019912-18,tratamiento,i
98,2010-019912-18,paralelos,o
98,2010-019912-18,para,o
98,2010-019912-18,evaluar,i
98,2010-019912-18,la,i
98,2010-019912-18,seguridad,i
98,2010-019912-18,y,o
98,2010-019912-18,el,o
98,2010-019912-18,efecto,o
98,2010-019912-18,sobre,o
98,2010-019912-18,el,o
98,2010-019912-18,resultado,o
98,2010-019912-18,clinico,o
98,2010-019912-18,de,o
98,2010-019912-18,tocilizumab,i
98,2010-019912-18,SC,o
98,2010-019912-18,frente,o
98,2010-019912-18,a,o
98,2010-019912-18,placebo,i
98,2010-019912-18,SC,o
98,2010-019912-18,en,o
98,2010-019912-18,combinacion,o
98,2010-019912-18,con,o
98,2010-019912-18,farmacos,i
98,2010-019912-18,antirreumaticos,i
98,2010-019912-18,modificadores,i
98,2010-019912-18,de,i
98,2010-019912-18,la,i
98,2010-019912-18,enfermedad,i
98,2010-019912-18,FAMEs,i
98,2010-019912-18,tradicionales,o
98,2010-019912-18,en,o
98,2010-019912-18,pacientes,o
98,2010-019912-18,con,o
98,2010-019912-18,artritis,i
98,2010-019912-18,reumatoide,i
98,2010-019912-18,activa,o
98,2010-019912-18,moderada,o
98,2010-019912-18,a,o
98,2010-019912-18,severa,o
98,2010-019912-18,Indicacion,o
98,2010-019912-18,cientifica,o
98,2010-019912-18,Artritis,i
98,2010-019912-18,Reumatoide,i
98,2010-019912-18,AR,i
98,2010-019912-18,Criterios,o
98,2010-019912-18,de,o
98,2010-019912-18,inclusion,o
98,2010-019912-18,Presentar,o
98,2010-019912-18,artritis,i
98,2010-019912-18,reumatoide,i
98,2010-019912-18,de,o
98,2010-019912-18,mayor,o
98,2010-019912-18,o,o
98,2010-019912-18,igual,o
98,2010-019912-18,a,o
98,2010-019912-18,6,o
98,2010-019912-18,meses,o
98,2010-019912-18,de,o
98,2010-019912-18,duracion,o
98,2010-019912-18,Recibir,o
98,2010-019912-18,tratamiento,i
98,2010-019912-18,de,i
98,2010-019912-18,forma,i
98,2010-019912-18,ambulatoria,i
98,2010-019912-18,Presentar,o
98,2010-019912-18,un,o
98,2010-019912-18,recuento,o
98,2010-019912-18,de,o
98,2010-019912-18,articulaciones,i
98,2010-019912-18,inflamadas,i
98,2010-019912-18,RAI,o
98,2010-019912-18,mayor,o
98,2010-019912-18,o,o
98,2010-019912-18,igual,o
98,2010-019912-18,a,o
98,2010-019912-18,6,o
98,2010-019912-18,recuento,o
98,2010-019912-18,de,o
98,2010-019912-18,66,o
98,2010-019912-18,articulaciones,i
98,2010-019912-18,y,o
98,2010-019912-18,de,o
98,2010-019912-18,articulaciones,i
98,2010-019912-18,dolorosas,i
98,2010-019912-18,RAD,o
98,2010-019912-18,mayor,o
98,2010-019912-18,o,o
98,2010-019912-18,igual,o
98,2010-019912-18,a,o
98,2010-019912-18,8,o
98,2010-019912-18,recuento,o
98,2010-019912-18,de,o
98,2010-019912-18,68,o
98,2010-019912-18,articulaciones,i
98,2010-019912-18,en,o
98,2010-019912-18,las,o
98,2010-019912-18,visitas,o
98,2010-019912-18,de,o
98,2010-019912-18,seleccion,o
98,2010-019912-18,y,o
98,2010-019912-18,basal,o
98,2010-019912-18,Los,o
98,2010-019912-18,pacientes,o
98,2010-019912-18,deben,o
98,2010-019912-18,estar,o
98,2010-019912-18,recibiendo,o
98,2010-019912-18,tratamiento,i
98,2010-019912-18,con,o
98,2010-019912-18,una,o
98,2010-019912-18,dosis,o
98,2010-019912-18,estable,o
98,2010-019912-18,de,o
98,2010-019912-18,los,o
98,2010-019912-18,FAMEs,i
98,2010-019912-18,permitidos,o
98,2010-019912-18,como,o
98,2010-019912-18,minimo,o
98,2010-019912-18,8,o
98,2010-019912-18,semanas,o
98,2010-019912-18,antes,o
98,2010-019912-18,de,o
98,2010-019912-18,la,o
98,2010-019912-18,visita,o
98,2010-019912-18,basal,o
98,2010-019912-18,Criterios,o
98,2010-019912-18,de,o
98,2010-019912-18,exclusion,o
98,2010-019912-18,Pacientes,o
98,2010-019912-18,sometidos,o
98,2010-019912-18,a,o
98,2010-019912-18,intervenciones,i
98,2010-019912-18,de,i
98,2010-019912-18,cirugia,i
98,2010-019912-18,mayor,i
98,2010-019912-18,incluyendo,o
98,2010-019912-18,cirugia,i
98,2010-019912-18,articular,i
98,2010-019912-18,en,o
98,2010-019912-18,las,o
98,2010-019912-18,8,o
98,2010-019912-18,semanas,o
98,2010-019912-18,previas,o
98,2010-019912-18,a,o
98,2010-019912-18,la,o
98,2010-019912-18,visita,o
98,2010-019912-18,de,o
98,2010-019912-18,seleccion,o
98,2010-019912-18,o,o
98,2010-019912-18,que,o
98,2010-019912-18,tengan,o
98,2010-019912-18,previsto,o
98,2010-019912-18,someterse,o
98,2010-019912-18,a,o
98,2010-019912-18,una,o
98,2010-019912-18,intervencion,i
98,2010-019912-18,de,o
98,2010-019912-18,este,o
98,2010-019912-18,tipo,o
98,2010-019912-18,en,o
98,2010-019912-18,los,o
98,2010-019912-18,6,o
98,2010-019912-18,meses,o
98,2010-019912-18,siguientes,o
98,2010-019912-18,a,o
98,2010-019912-18,la,o
98,2010-019912-18,randomizacion,i
98,2010-019912-18,Enfermedad,i
98,2010-019912-18,reumatica,i
98,2010-019912-18,autoinmune,i
98,2010-019912-18,distinta,o
98,2010-019912-18,de,o
98,2010-019912-18,AR,i
98,2010-019912-18,Se,o
98,2010-019912-18,permite,o
98,2010-019912-18,la,o
98,2010-019912-18,inclusion,o
98,2010-019912-18,de,o
98,2010-019912-18,pacientes,o
98,2010-019912-18,con,o
98,2010-019912-18,sindrome,i
98,2010-019912-18,de,i
98,2010-019912-18,Sjögren,i
98,2010-019912-18,secundario,i
98,2010-019912-18,asociado,o
98,2010-019912-18,a,o
98,2010-019912-18,AR,i
98,2010-019912-18,Clase,o
98,2010-019912-18,funcional,o
98,2010-019912-18,IV,o
98,2010-019912-18,definida,o
98,2010-019912-18,de,o
98,2010-019912-18,acuerdo,o
98,2010-019912-18,con,o
98,2010-019912-18,la,o
98,2010-019912-18,Clasificacion,o
98,2010-019912-18,del,o
98,2010-019912-18,ACR,o
98,2010-019912-18,del,o
98,2010-019912-18,Estado,o
98,2010-019912-18,Funcional,o
98,2010-019912-18,en,o
98,2010-019912-18,Artritis,i
98,2010-019912-18,Reumatoide,i
98,2010-019912-18,Artritis,i
98,2010-019912-18,idiopatica,i
98,2010-019912-18,juvenil,i
98,2010-019912-18,AIJ,i
98,2010-019912-18,o,o
98,2010-019912-18,artritis,i
98,2010-019912-18,reumatoide,i
98,2010-019912-18,juvenil,i
98,2010-019912-18,ARJ,i
98,2010-019912-18,yo,o
98,2010-019912-18,AR,i
98,2010-019912-18,diagnosticadas,i
98,2010-019912-18,antes,o
98,2010-019912-18,de,o
98,2010-019912-18,los,o
98,2010-019912-18,16,o
98,2010-019912-18,años,o
98,2010-019912-18,de,o
98,2010-019912-18,edad,o
98,2010-019912-18,Enfermedad,i
98,2010-019912-18,articular,i
98,2010-019912-18,inflamatoria,i
98,2010-019912-18,distinta,o
98,2010-019912-18,de,o
98,2010-019912-18,AR,i
98,2010-019912-18,en,o
98,2010-019912-18,el,o
98,2010-019912-18,pasado,o
98,2010-019912-18,o,o
98,2010-019912-18,en,o
98,2010-019912-18,la,o
98,2010-019912-18,actualidad,o
99,2010-019912-18,EudraCT,o
99,2010-019912-18,Nº,o
99,2010-019912-18,201001991218,o
99,2010-019912-18,Titulo,o
99,2010-019912-18,cientifico,o
99,2010-019912-18,Estudio,o
99,2010-019912-18,randomizado,o
99,2010-019912-18,doble,o
99,2010-019912-18,ciego,o
99,2010-019912-18,con,o
99,2010-019912-18,grupos,o
99,2010-019912-18,de,o
99,2010-019912-18,tratamiento,i
99,2010-019912-18,paralelos,o
99,2010-019912-18,para,o
99,2010-019912-18,evaluar,i
99,2010-019912-18,la,i
99,2010-019912-18,seguridad,i
99,2010-019912-18,y,o
99,2010-019912-18,el,o
99,2010-019912-18,efecto,o
99,2010-019912-18,sobre,o
99,2010-019912-18,el,o
99,2010-019912-18,resultado,o
99,2010-019912-18,clinico,o
99,2010-019912-18,de,o
99,2010-019912-18,tocilizumab,i
99,2010-019912-18,SC,o
99,2010-019912-18,frente,o
99,2010-019912-18,a,o
99,2010-019912-18,placebo,i
99,2010-019912-18,SC,o
99,2010-019912-18,en,o
99,2010-019912-18,combinacion,o
99,2010-019912-18,con,o
99,2010-019912-18,farmacos,i
99,2010-019912-18,antirreumaticos,i
99,2010-019912-18,modificadores,i
99,2010-019912-18,de,i
99,2010-019912-18,la,i
99,2010-019912-18,enfermedad,i
99,2010-019912-18,FAMEs,i
99,2010-019912-18,tradicionales,o
99,2010-019912-18,en,o
99,2010-019912-18,pacientes,o
99,2010-019912-18,con,o
99,2010-019912-18,artritis,i
99,2010-019912-18,reumatoide,i
99,2010-019912-18,activa,o
99,2010-019912-18,moderada,o
99,2010-019912-18,a,o
99,2010-019912-18,severa,o
99,2010-019912-18,Indicacion,o
99,2010-019912-18,cientifica,o
99,2010-019912-18,Artritis,i
99,2010-019912-18,Reumatoide,i
99,2010-019912-18,AR,i
99,2010-019912-18,Criterios,o
99,2010-019912-18,de,o
99,2010-019912-18,inclusion,o
99,2010-019912-18,Presentar,o
99,2010-019912-18,artritis,i
99,2010-019912-18,reumatoide,i
99,2010-019912-18,de,o
99,2010-019912-18,mayor,o
99,2010-019912-18,o,o
99,2010-019912-18,igual,o
99,2010-019912-18,a,o
99,2010-019912-18,6,o
99,2010-019912-18,meses,o
99,2010-019912-18,de,o
99,2010-019912-18,duracion,o
99,2010-019912-18,Recibir,o
99,2010-019912-18,tratamiento,i
99,2010-019912-18,de,i
99,2010-019912-18,forma,i
99,2010-019912-18,ambulatoria,i
99,2010-019912-18,Presentar,o
99,2010-019912-18,un,o
99,2010-019912-18,recuento,o
99,2010-019912-18,de,o
99,2010-019912-18,articulaciones,i
99,2010-019912-18,inflamadas,i
99,2010-019912-18,RAI,o
99,2010-019912-18,mayor,o
99,2010-019912-18,o,o
99,2010-019912-18,igual,o
99,2010-019912-18,a,o
99,2010-019912-18,6,o
99,2010-019912-18,recuento,o
99,2010-019912-18,de,o
99,2010-019912-18,66,o
99,2010-019912-18,articulaciones,i
99,2010-019912-18,y,o
99,2010-019912-18,de,o
99,2010-019912-18,articulaciones,i
99,2010-019912-18,dolorosas,i
99,2010-019912-18,RAD,o
99,2010-019912-18,mayor,o
99,2010-019912-18,o,o
99,2010-019912-18,igual,o
99,2010-019912-18,a,o
99,2010-019912-18,8,o
99,2010-019912-18,recuento,o
99,2010-019912-18,de,o
99,2010-019912-18,68,o
99,2010-019912-18,articulaciones,i
99,2010-019912-18,en,o
99,2010-019912-18,las,o
99,2010-019912-18,visitas,o
99,2010-019912-18,de,o
99,2010-019912-18,seleccion,o
99,2010-019912-18,y,o
99,2010-019912-18,basal,o
99,2010-019912-18,Los,o
99,2010-019912-18,pacientes,o
99,2010-019912-18,deben,o
99,2010-019912-18,estar,o
99,2010-019912-18,recibiendo,o
99,2010-019912-18,tratamiento,i
99,2010-019912-18,con,o
99,2010-019912-18,una,o
99,2010-019912-18,dosis,o
99,2010-019912-18,estable,o
99,2010-019912-18,de,o
99,2010-019912-18,los,o
99,2010-019912-18,FAMEs,i
99,2010-019912-18,permitidos,o
99,2010-019912-18,como,o
99,2010-019912-18,minimo,o
99,2010-019912-18,8,o
99,2010-019912-18,semanas,o
99,2010-019912-18,antes,o
99,2010-019912-18,de,o
99,2010-019912-18,la,o
99,2010-019912-18,visita,o
99,2010-019912-18,basal,o
99,2010-019912-18,Criterios,o
99,2010-019912-18,de,o
99,2010-019912-18,exclusion,o
99,2010-019912-18,Pacientes,o
99,2010-019912-18,sometidos,o
99,2010-019912-18,a,o
99,2010-019912-18,intervenciones,i
99,2010-019912-18,de,i
99,2010-019912-18,cirugia,i
99,2010-019912-18,mayor,i
99,2010-019912-18,incluyendo,o
99,2010-019912-18,cirugia,i
99,2010-019912-18,articular,i
99,2010-019912-18,en,o
99,2010-019912-18,las,o
99,2010-019912-18,8,o
99,2010-019912-18,semanas,o
99,2010-019912-18,previas,o
99,2010-019912-18,a,o
99,2010-019912-18,la,o
99,2010-019912-18,visita,o
99,2010-019912-18,de,o
99,2010-019912-18,seleccion,o
99,2010-019912-18,o,o
99,2010-019912-18,que,o
99,2010-019912-18,tengan,o
99,2010-019912-18,previsto,o
99,2010-019912-18,someterse,o
99,2010-019912-18,a,o
99,2010-019912-18,una,o
99,2010-019912-18,intervencion,i
99,2010-019912-18,de,o
99,2010-019912-18,este,o
99,2010-019912-18,tipo,o
99,2010-019912-18,en,o
99,2010-019912-18,los,o
99,2010-019912-18,6,o
99,2010-019912-18,meses,o
99,2010-019912-18,siguientes,o
99,2010-019912-18,a,o
99,2010-019912-18,la,o
99,2010-019912-18,randomizacion,i
99,2010-019912-18,Enfermedad,i
99,2010-019912-18,reumatica,i
99,2010-019912-18,autoinmune,i
99,2010-019912-18,distinta,o
99,2010-019912-18,de,o
99,2010-019912-18,AR,i
99,2010-019912-18,Se,o
99,2010-019912-18,permite,o
99,2010-019912-18,la,o
99,2010-019912-18,inclusion,o
99,2010-019912-18,de,o
99,2010-019912-18,pacientes,o
99,2010-019912-18,con,o
99,2010-019912-18,sindrome,i
99,2010-019912-18,de,i
99,2010-019912-18,Sjögren,i
99,2010-019912-18,secundario,i
99,2010-019912-18,asociado,o
99,2010-019912-18,a,o
99,2010-019912-18,AR,i
99,2010-019912-18,Clase,o
99,2010-019912-18,funcional,o
99,2010-019912-18,IV,o
99,2010-019912-18,definida,o
99,2010-019912-18,de,o
99,2010-019912-18,acuerdo,o
99,2010-019912-18,con,o
99,2010-019912-18,la,o
99,2010-019912-18,Clasificacion,o
99,2010-019912-18,del,o
99,2010-019912-18,ACR,o
99,2010-019912-18,del,o
99,2010-019912-18,Estado,o
99,2010-019912-18,Funcional,o
99,2010-019912-18,en,o
99,2010-019912-18,Artritis,i
99,2010-019912-18,Reumatoide,i
99,2010-019912-18,Artritis,i
99,2010-019912-18,idiopatica,i
99,2010-019912-18,juvenil,i
99,2010-019912-18,AIJ,i
99,2010-019912-18,o,o
99,2010-019912-18,artritis,i
99,2010-019912-18,reumatoide,i
99,2010-019912-18,juvenil,i
99,2010-019912-18,ARJ,i
99,2010-019912-18,yo,o
99,2010-019912-18,AR,i
99,2010-019912-18,diagnosticadas,i
99,2010-019912-18,antes,o
99,2010-019912-18,de,o
99,2010-019912-18,los,o
99,2010-019912-18,16,o
99,2010-019912-18,años,o
99,2010-019912-18,de,o
99,2010-019912-18,edad,o
99,2010-019912-18,Enfermedad,i
99,2010-019912-18,articular,i
99,2010-019912-18,inflamatoria,i
99,2010-019912-18,distinta,o
99,2010-019912-18,de,o
99,2010-019912-18,AR,i
99,2010-019912-18,en,o
99,2010-019912-18,el,o
99,2010-019912-18,pasado,o
99,2010-019912-18,o,o
99,2010-019912-18,en,o
99,2010-019912-18,la,o
99,2010-019912-18,actualidad,o
100,2010-019912-18,EudraCT,o
100,2010-019912-18,Nº,o
100,2010-019912-18,201001991218,o
100,2010-019912-18,Titulo,o
100,2010-019912-18,cientifico,o
100,2010-019912-18,Estudio,o
100,2010-019912-18,randomizado,o
100,2010-019912-18,doble,o
100,2010-019912-18,ciego,o
100,2010-019912-18,con,o
100,2010-019912-18,grupos,o
100,2010-019912-18,de,o
100,2010-019912-18,tratamiento,i
100,2010-019912-18,paralelos,o
100,2010-019912-18,para,o
100,2010-019912-18,evaluar,i
100,2010-019912-18,la,i
100,2010-019912-18,seguridad,i
100,2010-019912-18,y,o
100,2010-019912-18,el,o
100,2010-019912-18,efecto,o
100,2010-019912-18,sobre,o
100,2010-019912-18,el,o
100,2010-019912-18,resultado,o
100,2010-019912-18,clinico,o
100,2010-019912-18,de,o
100,2010-019912-18,tocilizumab,i
100,2010-019912-18,SC,o
100,2010-019912-18,frente,o
100,2010-019912-18,a,o
100,2010-019912-18,placebo,i
100,2010-019912-18,SC,o
100,2010-019912-18,en,o
100,2010-019912-18,combinacion,o
100,2010-019912-18,con,o
100,2010-019912-18,farmacos,i
100,2010-019912-18,antirreumaticos,i
100,2010-019912-18,modificadores,i
100,2010-019912-18,de,i
100,2010-019912-18,la,i
100,2010-019912-18,enfermedad,i
100,2010-019912-18,FAMEs,i
100,2010-019912-18,tradicionales,o
100,2010-019912-18,en,o
100,2010-019912-18,pacientes,o
100,2010-019912-18,con,o
100,2010-019912-18,artritis,i
100,2010-019912-18,reumatoide,i
100,2010-019912-18,activa,o
100,2010-019912-18,moderada,o
100,2010-019912-18,a,o
100,2010-019912-18,severa,o
100,2010-019912-18,Indicacion,o
100,2010-019912-18,cientifica,o
100,2010-019912-18,Artritis,i
100,2010-019912-18,Reumatoide,i
100,2010-019912-18,AR,i
100,2010-019912-18,Criterios,o
100,2010-019912-18,de,o
100,2010-019912-18,inclusion,o
100,2010-019912-18,Presentar,o
100,2010-019912-18,artritis,i
100,2010-019912-18,reumatoide,i
100,2010-019912-18,de,o
100,2010-019912-18,mayor,o
100,2010-019912-18,o,o
100,2010-019912-18,igual,o
100,2010-019912-18,a,o
100,2010-019912-18,6,o
100,2010-019912-18,meses,o
100,2010-019912-18,de,o
100,2010-019912-18,duracion,o
100,2010-019912-18,Recibir,o
100,2010-019912-18,tratamiento,i
100,2010-019912-18,de,i
100,2010-019912-18,forma,i
100,2010-019912-18,ambulatoria,i
100,2010-019912-18,Presentar,o
100,2010-019912-18,un,o
100,2010-019912-18,recuento,o
100,2010-019912-18,de,o
100,2010-019912-18,articulaciones,i
100,2010-019912-18,inflamadas,i
100,2010-019912-18,RAI,o
100,2010-019912-18,mayor,o
100,2010-019912-18,o,o
100,2010-019912-18,igual,o
100,2010-019912-18,a,o
100,2010-019912-18,6,o
100,2010-019912-18,recuento,o
100,2010-019912-18,de,o
100,2010-019912-18,66,o
100,2010-019912-18,articulaciones,i
100,2010-019912-18,y,o
100,2010-019912-18,de,o
100,2010-019912-18,articulaciones,i
100,2010-019912-18,dolorosas,i
100,2010-019912-18,RAD,o
100,2010-019912-18,mayor,o
100,2010-019912-18,o,o
100,2010-019912-18,igual,o
100,2010-019912-18,a,o
100,2010-019912-18,8,o
100,2010-019912-18,recuento,o
100,2010-019912-18,de,o
100,2010-019912-18,68,o
100,2010-019912-18,articulaciones,i
100,2010-019912-18,en,o
100,2010-019912-18,las,o
100,2010-019912-18,visitas,o
100,2010-019912-18,de,o
100,2010-019912-18,seleccion,o
100,2010-019912-18,y,o
100,2010-019912-18,basal,o
100,2010-019912-18,Los,o
100,2010-019912-18,pacientes,o
100,2010-019912-18,deben,o
100,2010-019912-18,estar,o
100,2010-019912-18,recibiendo,o
100,2010-019912-18,tratamiento,i
100,2010-019912-18,con,o
100,2010-019912-18,una,o
100,2010-019912-18,dosis,o
100,2010-019912-18,estable,o
100,2010-019912-18,de,o
100,2010-019912-18,los,o
100,2010-019912-18,FAMEs,i
100,2010-019912-18,permitidos,o
100,2010-019912-18,como,o
100,2010-019912-18,minimo,o
100,2010-019912-18,8,o
100,2010-019912-18,semanas,o
100,2010-019912-18,antes,o
100,2010-019912-18,de,o
100,2010-019912-18,la,o
100,2010-019912-18,visita,o
100,2010-019912-18,basal,o
100,2010-019912-18,Criterios,o
100,2010-019912-18,de,o
100,2010-019912-18,exclusion,o
100,2010-019912-18,Pacientes,o
100,2010-019912-18,sometidos,o
100,2010-019912-18,a,o
100,2010-019912-18,intervenciones,i
100,2010-019912-18,de,i
100,2010-019912-18,cirugia,i
100,2010-019912-18,mayor,i
100,2010-019912-18,incluyendo,o
100,2010-019912-18,cirugia,i
100,2010-019912-18,articular,i
100,2010-019912-18,en,o
100,2010-019912-18,las,o
100,2010-019912-18,8,o
100,2010-019912-18,semanas,o
100,2010-019912-18,previas,o
100,2010-019912-18,a,o
100,2010-019912-18,la,o
100,2010-019912-18,visita,o
100,2010-019912-18,de,o
100,2010-019912-18,seleccion,o
100,2010-019912-18,o,o
100,2010-019912-18,que,o
100,2010-019912-18,tengan,o
100,2010-019912-18,previsto,o
100,2010-019912-18,someterse,o
100,2010-019912-18,a,o
100,2010-019912-18,una,o
100,2010-019912-18,intervencion,i
100,2010-019912-18,de,o
100,2010-019912-18,este,o
100,2010-019912-18,tipo,o
100,2010-019912-18,en,o
100,2010-019912-18,los,o
100,2010-019912-18,6,o
100,2010-019912-18,meses,o
100,2010-019912-18,siguientes,o
100,2010-019912-18,a,o
100,2010-019912-18,la,o
100,2010-019912-18,randomizacion,i
100,2010-019912-18,Enfermedad,i
100,2010-019912-18,reumatica,i
100,2010-019912-18,autoinmune,i
100,2010-019912-18,distinta,o
100,2010-019912-18,de,o
100,2010-019912-18,AR,i
100,2010-019912-18,Se,o
100,2010-019912-18,permite,o
100,2010-019912-18,la,o
100,2010-019912-18,inclusion,o
100,2010-019912-18,de,o
100,2010-019912-18,pacientes,o
100,2010-019912-18,con,o
100,2010-019912-18,sindrome,i
100,2010-019912-18,de,i
100,2010-019912-18,Sjögren,i
100,2010-019912-18,secundario,i
100,2010-019912-18,asociado,o
100,2010-019912-18,a,o
100,2010-019912-18,AR,i
100,2010-019912-18,Clase,o
100,2010-019912-18,funcional,o
100,2010-019912-18,IV,o
100,2010-019912-18,definida,o
100,2010-019912-18,de,o
100,2010-019912-18,acuerdo,o
100,2010-019912-18,con,o
100,2010-019912-18,la,o
100,2010-019912-18,Clasificacion,o
100,2010-019912-18,del,o
100,2010-019912-18,ACR,o
100,2010-019912-18,del,o
100,2010-019912-18,Estado,o
100,2010-019912-18,Funcional,o
100,2010-019912-18,en,o
100,2010-019912-18,Artritis,i
100,2010-019912-18,Reumatoide,i
100,2010-019912-18,Artritis,i
100,2010-019912-18,idiopatica,i
100,2010-019912-18,juvenil,i
100,2010-019912-18,AIJ,i
100,2010-019912-18,o,o
100,2010-019912-18,artritis,i
100,2010-019912-18,reumatoide,i
100,2010-019912-18,juvenil,i
100,2010-019912-18,ARJ,i
100,2010-019912-18,yo,o
100,2010-019912-18,AR,i
100,2010-019912-18,diagnosticadas,i
100,2010-019912-18,antes,o
100,2010-019912-18,de,o
100,2010-019912-18,los,o
100,2010-019912-18,16,o
100,2010-019912-18,años,o
100,2010-019912-18,de,o
100,2010-019912-18,edad,o
100,2010-019912-18,Enfermedad,i
100,2010-019912-18,articular,i
100,2010-019912-18,inflamatoria,i
100,2010-019912-18,distinta,o
100,2010-019912-18,de,o
100,2010-019912-18,AR,i
100,2010-019912-18,en,o
100,2010-019912-18,el,o
100,2010-019912-18,pasado,o
100,2010-019912-18,o,o
100,2010-019912-18,en,o
100,2010-019912-18,la,o
100,2010-019912-18,actualidad,o
101,2010-019912-18,EudraCT,o
101,2010-019912-18,Nº,o
101,2010-019912-18,201001991218,o
101,2010-019912-18,Titulo,o
101,2010-019912-18,cientifico,o
101,2010-019912-18,Estudio,o
101,2010-019912-18,randomizado,o
101,2010-019912-18,doble,o
101,2010-019912-18,ciego,o
101,2010-019912-18,con,o
101,2010-019912-18,grupos,o
101,2010-019912-18,de,o
101,2010-019912-18,tratamiento,i
101,2010-019912-18,paralelos,o
101,2010-019912-18,para,o
101,2010-019912-18,evaluar,i
101,2010-019912-18,la,i
101,2010-019912-18,seguridad,i
101,2010-019912-18,y,o
101,2010-019912-18,el,o
101,2010-019912-18,efecto,o
101,2010-019912-18,sobre,o
101,2010-019912-18,el,o
101,2010-019912-18,resultado,o
101,2010-019912-18,clinico,o
101,2010-019912-18,de,o
101,2010-019912-18,tocilizumab,i
101,2010-019912-18,SC,o
101,2010-019912-18,frente,o
101,2010-019912-18,a,o
101,2010-019912-18,placebo,i
101,2010-019912-18,SC,o
101,2010-019912-18,en,o
101,2010-019912-18,combinacion,o
101,2010-019912-18,con,o
101,2010-019912-18,farmacos,i
101,2010-019912-18,antirreumaticos,i
101,2010-019912-18,modificadores,i
101,2010-019912-18,de,i
101,2010-019912-18,la,i
101,2010-019912-18,enfermedad,i
101,2010-019912-18,FAMEs,i
101,2010-019912-18,tradicionales,o
101,2010-019912-18,en,o
101,2010-019912-18,pacientes,o
101,2010-019912-18,con,o
101,2010-019912-18,artritis,i
101,2010-019912-18,reumatoide,i
101,2010-019912-18,activa,o
101,2010-019912-18,moderada,o
101,2010-019912-18,a,o
101,2010-019912-18,severa,o
101,2010-019912-18,Indicacion,o
101,2010-019912-18,cientifica,o
101,2010-019912-18,Artritis,i
101,2010-019912-18,Reumatoide,i
101,2010-019912-18,AR,i
101,2010-019912-18,Criterios,o
101,2010-019912-18,de,o
101,2010-019912-18,inclusion,o
101,2010-019912-18,Presentar,o
101,2010-019912-18,artritis,i
101,2010-019912-18,reumatoide,i
101,2010-019912-18,de,o
101,2010-019912-18,mayor,o
101,2010-019912-18,o,o
101,2010-019912-18,igual,o
101,2010-019912-18,a,o
101,2010-019912-18,6,o
101,2010-019912-18,meses,o
101,2010-019912-18,de,o
101,2010-019912-18,duracion,o
101,2010-019912-18,Recibir,o
101,2010-019912-18,tratamiento,i
101,2010-019912-18,de,i
101,2010-019912-18,forma,i
101,2010-019912-18,ambulatoria,i
101,2010-019912-18,Presentar,o
101,2010-019912-18,un,o
101,2010-019912-18,recuento,o
101,2010-019912-18,de,o
101,2010-019912-18,articulaciones,i
101,2010-019912-18,inflamadas,i
101,2010-019912-18,RAI,o
101,2010-019912-18,mayor,o
101,2010-019912-18,o,o
101,2010-019912-18,igual,o
101,2010-019912-18,a,o
101,2010-019912-18,6,o
101,2010-019912-18,recuento,o
101,2010-019912-18,de,o
101,2010-019912-18,66,o
101,2010-019912-18,articulaciones,i
101,2010-019912-18,y,o
101,2010-019912-18,de,o
101,2010-019912-18,articulaciones,i
101,2010-019912-18,dolorosas,i
101,2010-019912-18,RAD,o
101,2010-019912-18,mayor,o
101,2010-019912-18,o,o
101,2010-019912-18,igual,o
101,2010-019912-18,a,o
101,2010-019912-18,8,o
101,2010-019912-18,recuento,o
101,2010-019912-18,de,o
101,2010-019912-18,68,o
101,2010-019912-18,articulaciones,i
101,2010-019912-18,en,o
101,2010-019912-18,las,o
101,2010-019912-18,visitas,o
101,2010-019912-18,de,o
101,2010-019912-18,seleccion,o
101,2010-019912-18,y,o
101,2010-019912-18,basal,o
101,2010-019912-18,Los,o
101,2010-019912-18,pacientes,o
101,2010-019912-18,deben,o
101,2010-019912-18,estar,o
101,2010-019912-18,recibiendo,o
101,2010-019912-18,tratamiento,i
101,2010-019912-18,con,o
101,2010-019912-18,una,o
101,2010-019912-18,dosis,o
101,2010-019912-18,estable,o
101,2010-019912-18,de,o
101,2010-019912-18,los,o
101,2010-019912-18,FAMEs,i
101,2010-019912-18,permitidos,o
101,2010-019912-18,como,o
101,2010-019912-18,minimo,o
101,2010-019912-18,8,o
101,2010-019912-18,semanas,o
101,2010-019912-18,antes,o
101,2010-019912-18,de,o
101,2010-019912-18,la,o
101,2010-019912-18,visita,o
101,2010-019912-18,basal,o
101,2010-019912-18,Criterios,o
101,2010-019912-18,de,o
101,2010-019912-18,exclusion,o
101,2010-019912-18,Pacientes,o
101,2010-019912-18,sometidos,o
101,2010-019912-18,a,o
101,2010-019912-18,intervenciones,i
101,2010-019912-18,de,i
101,2010-019912-18,cirugia,i
101,2010-019912-18,mayor,i
101,2010-019912-18,incluyendo,o
101,2010-019912-18,cirugia,i
101,2010-019912-18,articular,i
101,2010-019912-18,en,o
101,2010-019912-18,las,o
101,2010-019912-18,8,o
101,2010-019912-18,semanas,o
101,2010-019912-18,previas,o
101,2010-019912-18,a,o
101,2010-019912-18,la,o
101,2010-019912-18,visita,o
101,2010-019912-18,de,o
101,2010-019912-18,seleccion,o
101,2010-019912-18,o,o
101,2010-019912-18,que,o
101,2010-019912-18,tengan,o
101,2010-019912-18,previsto,o
101,2010-019912-18,someterse,o
101,2010-019912-18,a,o
101,2010-019912-18,una,o
101,2010-019912-18,intervencion,i
101,2010-019912-18,de,o
101,2010-019912-18,este,o
101,2010-019912-18,tipo,o
101,2010-019912-18,en,o
101,2010-019912-18,los,o
101,2010-019912-18,6,o
101,2010-019912-18,meses,o
101,2010-019912-18,siguientes,o
101,2010-019912-18,a,o
101,2010-019912-18,la,o
101,2010-019912-18,randomizacion,i
101,2010-019912-18,Enfermedad,i
101,2010-019912-18,reumatica,i
101,2010-019912-18,autoinmune,i
101,2010-019912-18,distinta,o
101,2010-019912-18,de,o
101,2010-019912-18,AR,i
101,2010-019912-18,Se,o
101,2010-019912-18,permite,o
101,2010-019912-18,la,o
101,2010-019912-18,inclusion,o
101,2010-019912-18,de,o
101,2010-019912-18,pacientes,o
101,2010-019912-18,con,o
101,2010-019912-18,sindrome,i
101,2010-019912-18,de,i
101,2010-019912-18,Sjögren,i
101,2010-019912-18,secundario,i
101,2010-019912-18,asociado,o
101,2010-019912-18,a,o
101,2010-019912-18,AR,i
101,2010-019912-18,Clase,o
101,2010-019912-18,funcional,o
101,2010-019912-18,IV,o
101,2010-019912-18,definida,o
101,2010-019912-18,de,o
101,2010-019912-18,acuerdo,o
101,2010-019912-18,con,o
101,2010-019912-18,la,o
101,2010-019912-18,Clasificacion,o
101,2010-019912-18,del,o
101,2010-019912-18,ACR,o
101,2010-019912-18,del,o
101,2010-019912-18,Estado,o
101,2010-019912-18,Funcional,o
101,2010-019912-18,en,o
101,2010-019912-18,Artritis,i
101,2010-019912-18,Reumatoide,i
101,2010-019912-18,Artritis,i
101,2010-019912-18,idiopatica,i
101,2010-019912-18,juvenil,i
101,2010-019912-18,AIJ,i
101,2010-019912-18,o,o
101,2010-019912-18,artritis,i
101,2010-019912-18,reumatoide,i
101,2010-019912-18,juvenil,i
101,2010-019912-18,ARJ,i
101,2010-019912-18,yo,o
101,2010-019912-18,AR,i
101,2010-019912-18,diagnosticadas,i
101,2010-019912-18,antes,o
101,2010-019912-18,de,o
101,2010-019912-18,los,o
101,2010-019912-18,16,o
101,2010-019912-18,años,o
101,2010-019912-18,de,o
101,2010-019912-18,edad,o
101,2010-019912-18,Enfermedad,i
101,2010-019912-18,articular,i
101,2010-019912-18,inflamatoria,i
101,2010-019912-18,distinta,o
101,2010-019912-18,de,o
101,2010-019912-18,AR,i
101,2010-019912-18,en,o
101,2010-019912-18,el,o
101,2010-019912-18,pasado,o
101,2010-019912-18,o,o
101,2010-019912-18,en,o
101,2010-019912-18,la,o
101,2010-019912-18,actualidad,o
102,2010-019912-18,EudraCT,o
102,2010-019912-18,Nº,o
102,2010-019912-18,201001991218,o
102,2010-019912-18,Titulo,o
102,2010-019912-18,cientifico,o
102,2010-019912-18,Estudio,o
102,2010-019912-18,randomizado,o
102,2010-019912-18,doble,o
102,2010-019912-18,ciego,o
102,2010-019912-18,con,o
102,2010-019912-18,grupos,o
102,2010-019912-18,de,o
102,2010-019912-18,tratamiento,i
102,2010-019912-18,paralelos,o
102,2010-019912-18,para,o
102,2010-019912-18,evaluar,i
102,2010-019912-18,la,i
102,2010-019912-18,seguridad,i
102,2010-019912-18,y,o
102,2010-019912-18,el,o
102,2010-019912-18,efecto,o
102,2010-019912-18,sobre,o
102,2010-019912-18,el,o
102,2010-019912-18,resultado,o
102,2010-019912-18,clinico,o
102,2010-019912-18,de,o
102,2010-019912-18,tocilizumab,i
102,2010-019912-18,SC,o
102,2010-019912-18,frente,o
102,2010-019912-18,a,o
102,2010-019912-18,placebo,i
102,2010-019912-18,SC,o
102,2010-019912-18,en,o
102,2010-019912-18,combinacion,o
102,2010-019912-18,con,o
102,2010-019912-18,farmacos,i
102,2010-019912-18,antirreumaticos,i
102,2010-019912-18,modificadores,i
102,2010-019912-18,de,i
102,2010-019912-18,la,i
102,2010-019912-18,enfermedad,i
102,2010-019912-18,FAMEs,i
102,2010-019912-18,tradicionales,o
102,2010-019912-18,en,o
102,2010-019912-18,pacientes,o
102,2010-019912-18,con,o
102,2010-019912-18,artritis,i
102,2010-019912-18,reumatoide,i
102,2010-019912-18,activa,o
102,2010-019912-18,moderada,o
102,2010-019912-18,a,o
102,2010-019912-18,severa,o
102,2010-019912-18,Indicacion,o
102,2010-019912-18,cientifica,o
102,2010-019912-18,Artritis,i
102,2010-019912-18,Reumatoide,i
102,2010-019912-18,AR,i
102,2010-019912-18,Criterios,o
102,2010-019912-18,de,o
102,2010-019912-18,inclusion,o
102,2010-019912-18,Presentar,o
102,2010-019912-18,artritis,i
102,2010-019912-18,reumatoide,i
102,2010-019912-18,de,o
102,2010-019912-18,mayor,o
102,2010-019912-18,o,o
102,2010-019912-18,igual,o
102,2010-019912-18,a,o
102,2010-019912-18,6,o
102,2010-019912-18,meses,o
102,2010-019912-18,de,o
102,2010-019912-18,duracion,o
102,2010-019912-18,Recibir,o
102,2010-019912-18,tratamiento,i
102,2010-019912-18,de,i
102,2010-019912-18,forma,i
102,2010-019912-18,ambulatoria,i
102,2010-019912-18,Presentar,o
102,2010-019912-18,un,o
102,2010-019912-18,recuento,o
102,2010-019912-18,de,o
102,2010-019912-18,articulaciones,i
102,2010-019912-18,inflamadas,i
102,2010-019912-18,RAI,o
102,2010-019912-18,mayor,o
102,2010-019912-18,o,o
102,2010-019912-18,igual,o
102,2010-019912-18,a,o
102,2010-019912-18,6,o
102,2010-019912-18,recuento,o
102,2010-019912-18,de,o
102,2010-019912-18,66,o
102,2010-019912-18,articulaciones,i
102,2010-019912-18,y,o
102,2010-019912-18,de,o
102,2010-019912-18,articulaciones,i
102,2010-019912-18,dolorosas,i
102,2010-019912-18,RAD,o
102,2010-019912-18,mayor,o
102,2010-019912-18,o,o
102,2010-019912-18,igual,o
102,2010-019912-18,a,o
102,2010-019912-18,8,o
102,2010-019912-18,recuento,o
102,2010-019912-18,de,o
102,2010-019912-18,68,o
102,2010-019912-18,articulaciones,i
102,2010-019912-18,en,o
102,2010-019912-18,las,o
102,2010-019912-18,visitas,o
102,2010-019912-18,de,o
102,2010-019912-18,seleccion,o
102,2010-019912-18,y,o
102,2010-019912-18,basal,o
102,2010-019912-18,Los,o
102,2010-019912-18,pacientes,o
102,2010-019912-18,deben,o
102,2010-019912-18,estar,o
102,2010-019912-18,recibiendo,o
102,2010-019912-18,tratamiento,i
102,2010-019912-18,con,o
102,2010-019912-18,una,o
102,2010-019912-18,dosis,o
102,2010-019912-18,estable,o
102,2010-019912-18,de,o
102,2010-019912-18,los,o
102,2010-019912-18,FAMEs,i
102,2010-019912-18,permitidos,o
102,2010-019912-18,como,o
102,2010-019912-18,minimo,o
102,2010-019912-18,8,o
102,2010-019912-18,semanas,o
102,2010-019912-18,antes,o
102,2010-019912-18,de,o
102,2010-019912-18,la,o
102,2010-019912-18,visita,o
102,2010-019912-18,basal,o
102,2010-019912-18,Criterios,o
102,2010-019912-18,de,o
102,2010-019912-18,exclusion,o
102,2010-019912-18,Pacientes,o
102,2010-019912-18,sometidos,o
102,2010-019912-18,a,o
102,2010-019912-18,intervenciones,i
102,2010-019912-18,de,i
102,2010-019912-18,cirugia,i
102,2010-019912-18,mayor,i
102,2010-019912-18,incluyendo,o
102,2010-019912-18,cirugia,i
102,2010-019912-18,articular,i
102,2010-019912-18,en,o
102,2010-019912-18,las,o
102,2010-019912-18,8,o
102,2010-019912-18,semanas,o
102,2010-019912-18,previas,o
102,2010-019912-18,a,o
102,2010-019912-18,la,o
102,2010-019912-18,visita,o
102,2010-019912-18,de,o
102,2010-019912-18,seleccion,o
102,2010-019912-18,o,o
102,2010-019912-18,que,o
102,2010-019912-18,tengan,o
102,2010-019912-18,previsto,o
102,2010-019912-18,someterse,o
102,2010-019912-18,a,o
102,2010-019912-18,una,o
102,2010-019912-18,intervencion,i
102,2010-019912-18,de,o
102,2010-019912-18,este,o
102,2010-019912-18,tipo,o
102,2010-019912-18,en,o
102,2010-019912-18,los,o
102,2010-019912-18,6,o
102,2010-019912-18,meses,o
102,2010-019912-18,siguientes,o
102,2010-019912-18,a,o
102,2010-019912-18,la,o
102,2010-019912-18,randomizacion,i
102,2010-019912-18,Enfermedad,i
102,2010-019912-18,reumatica,i
102,2010-019912-18,autoinmune,i
102,2010-019912-18,distinta,o
102,2010-019912-18,de,o
102,2010-019912-18,AR,i
102,2010-019912-18,Se,o
102,2010-019912-18,permite,o
102,2010-019912-18,la,o
102,2010-019912-18,inclusion,o
102,2010-019912-18,de,o
102,2010-019912-18,pacientes,o
102,2010-019912-18,con,o
102,2010-019912-18,sindrome,i
102,2010-019912-18,de,i
102,2010-019912-18,Sjögren,i
102,2010-019912-18,secundario,i
102,2010-019912-18,asociado,o
102,2010-019912-18,a,o
102,2010-019912-18,AR,i
102,2010-019912-18,Clase,o
102,2010-019912-18,funcional,o
102,2010-019912-18,IV,o
102,2010-019912-18,definida,o
102,2010-019912-18,de,o
102,2010-019912-18,acuerdo,o
102,2010-019912-18,con,o
102,2010-019912-18,la,o
102,2010-019912-18,Clasificacion,o
102,2010-019912-18,del,o
102,2010-019912-18,ACR,o
102,2010-019912-18,del,o
102,2010-019912-18,Estado,o
102,2010-019912-18,Funcional,o
102,2010-019912-18,en,o
102,2010-019912-18,Artritis,i
102,2010-019912-18,Reumatoide,i
102,2010-019912-18,Artritis,i
102,2010-019912-18,idiopatica,i
102,2010-019912-18,juvenil,i
102,2010-019912-18,AIJ,i
102,2010-019912-18,o,o
102,2010-019912-18,artritis,i
102,2010-019912-18,reumatoide,i
102,2010-019912-18,juvenil,i
102,2010-019912-18,ARJ,i
102,2010-019912-18,yo,o
102,2010-019912-18,AR,i
102,2010-019912-18,diagnosticadas,i
102,2010-019912-18,antes,o
102,2010-019912-18,de,o
102,2010-019912-18,los,o
102,2010-019912-18,16,o
102,2010-019912-18,años,o
102,2010-019912-18,de,o
102,2010-019912-18,edad,o
102,2010-019912-18,Enfermedad,i
102,2010-019912-18,articular,i
102,2010-019912-18,inflamatoria,i
102,2010-019912-18,distinta,o
102,2010-019912-18,de,o
102,2010-019912-18,AR,i
102,2010-019912-18,en,o
102,2010-019912-18,el,o
102,2010-019912-18,pasado,o
102,2010-019912-18,o,o
102,2010-019912-18,en,o
102,2010-019912-18,la,o
102,2010-019912-18,actualidad,o
103,2010-019912-18,EudraCT,o
103,2010-019912-18,Nº,o
103,2010-019912-18,201001991218,o
103,2010-019912-18,Titulo,o
103,2010-019912-18,cientifico,o
103,2010-019912-18,Estudio,o
103,2010-019912-18,randomizado,o
103,2010-019912-18,doble,o
103,2010-019912-18,ciego,o
103,2010-019912-18,con,o
103,2010-019912-18,grupos,o
103,2010-019912-18,de,o
103,2010-019912-18,tratamiento,i
103,2010-019912-18,paralelos,o
103,2010-019912-18,para,o
103,2010-019912-18,evaluar,i
103,2010-019912-18,la,i
103,2010-019912-18,seguridad,i
103,2010-019912-18,y,o
103,2010-019912-18,el,o
103,2010-019912-18,efecto,o
103,2010-019912-18,sobre,o
103,2010-019912-18,el,o
103,2010-019912-18,resultado,o
103,2010-019912-18,clinico,o
103,2010-019912-18,de,o
103,2010-019912-18,tocilizumab,i
103,2010-019912-18,SC,o
103,2010-019912-18,frente,o
103,2010-019912-18,a,o
103,2010-019912-18,placebo,i
103,2010-019912-18,SC,o
103,2010-019912-18,en,o
103,2010-019912-18,combinacion,o
103,2010-019912-18,con,o
103,2010-019912-18,farmacos,i
103,2010-019912-18,antirreumaticos,i
103,2010-019912-18,modificadores,i
103,2010-019912-18,de,i
103,2010-019912-18,la,i
103,2010-019912-18,enfermedad,i
103,2010-019912-18,FAMEs,i
103,2010-019912-18,tradicionales,o
103,2010-019912-18,en,o
103,2010-019912-18,pacientes,o
103,2010-019912-18,con,o
103,2010-019912-18,artritis,i
103,2010-019912-18,reumatoide,i
103,2010-019912-18,activa,o
103,2010-019912-18,moderada,o
103,2010-019912-18,a,o
103,2010-019912-18,severa,o
103,2010-019912-18,Indicacion,o
103,2010-019912-18,cientifica,o
103,2010-019912-18,Artritis,i
103,2010-019912-18,Reumatoide,i
103,2010-019912-18,AR,i
103,2010-019912-18,Criterios,o
103,2010-019912-18,de,o
103,2010-019912-18,inclusion,o
103,2010-019912-18,Presentar,o
103,2010-019912-18,artritis,i
103,2010-019912-18,reumatoide,i
103,2010-019912-18,de,o
103,2010-019912-18,mayor,o
103,2010-019912-18,o,o
103,2010-019912-18,igual,o
103,2010-019912-18,a,o
103,2010-019912-18,6,o
103,2010-019912-18,meses,o
103,2010-019912-18,de,o
103,2010-019912-18,duracion,o
103,2010-019912-18,Recibir,o
103,2010-019912-18,tratamiento,i
103,2010-019912-18,de,i
103,2010-019912-18,forma,i
103,2010-019912-18,ambulatoria,i
103,2010-019912-18,Presentar,o
103,2010-019912-18,un,o
103,2010-019912-18,recuento,o
103,2010-019912-18,de,o
103,2010-019912-18,articulaciones,i
103,2010-019912-18,inflamadas,i
103,2010-019912-18,RAI,o
103,2010-019912-18,mayor,o
103,2010-019912-18,o,o
103,2010-019912-18,igual,o
103,2010-019912-18,a,o
103,2010-019912-18,6,o
103,2010-019912-18,recuento,o
103,2010-019912-18,de,o
103,2010-019912-18,66,o
103,2010-019912-18,articulaciones,i
103,2010-019912-18,y,o
103,2010-019912-18,de,o
103,2010-019912-18,articulaciones,i
103,2010-019912-18,dolorosas,i
103,2010-019912-18,RAD,o
103,2010-019912-18,mayor,o
103,2010-019912-18,o,o
103,2010-019912-18,igual,o
103,2010-019912-18,a,o
103,2010-019912-18,8,o
103,2010-019912-18,recuento,o
103,2010-019912-18,de,o
103,2010-019912-18,68,o
103,2010-019912-18,articulaciones,i
103,2010-019912-18,en,o
103,2010-019912-18,las,o
103,2010-019912-18,visitas,o
103,2010-019912-18,de,o
103,2010-019912-18,seleccion,o
103,2010-019912-18,y,o
103,2010-019912-18,basal,o
103,2010-019912-18,Los,o
103,2010-019912-18,pacientes,o
103,2010-019912-18,deben,o
103,2010-019912-18,estar,o
103,2010-019912-18,recibiendo,o
103,2010-019912-18,tratamiento,i
103,2010-019912-18,con,o
103,2010-019912-18,una,o
103,2010-019912-18,dosis,o
103,2010-019912-18,estable,o
103,2010-019912-18,de,o
103,2010-019912-18,los,o
103,2010-019912-18,FAMEs,i
103,2010-019912-18,permitidos,o
103,2010-019912-18,como,o
103,2010-019912-18,minimo,o
103,2010-019912-18,8,o
103,2010-019912-18,semanas,o
103,2010-019912-18,antes,o
103,2010-019912-18,de,o
103,2010-019912-18,la,o
103,2010-019912-18,visita,o
103,2010-019912-18,basal,o
103,2010-019912-18,Criterios,o
103,2010-019912-18,de,o
103,2010-019912-18,exclusion,o
103,2010-019912-18,Pacientes,o
103,2010-019912-18,sometidos,o
103,2010-019912-18,a,o
103,2010-019912-18,intervenciones,i
103,2010-019912-18,de,i
103,2010-019912-18,cirugia,i
103,2010-019912-18,mayor,i
103,2010-019912-18,incluyendo,o
103,2010-019912-18,cirugia,i
103,2010-019912-18,articular,i
103,2010-019912-18,en,o
103,2010-019912-18,las,o
103,2010-019912-18,8,o
103,2010-019912-18,semanas,o
103,2010-019912-18,previas,o
103,2010-019912-18,a,o
103,2010-019912-18,la,o
103,2010-019912-18,visita,o
103,2010-019912-18,de,o
103,2010-019912-18,seleccion,o
103,2010-019912-18,o,o
103,2010-019912-18,que,o
103,2010-019912-18,tengan,o
103,2010-019912-18,previsto,o
103,2010-019912-18,someterse,o
103,2010-019912-18,a,o
103,2010-019912-18,una,o
103,2010-019912-18,intervencion,i
103,2010-019912-18,de,o
103,2010-019912-18,este,o
103,2010-019912-18,tipo,o
103,2010-019912-18,en,o
103,2010-019912-18,los,o
103,2010-019912-18,6,o
103,2010-019912-18,meses,o
103,2010-019912-18,siguientes,o
103,2010-019912-18,a,o
103,2010-019912-18,la,o
103,2010-019912-18,randomizacion,i
103,2010-019912-18,Enfermedad,i
103,2010-019912-18,reumatica,i
103,2010-019912-18,autoinmune,i
103,2010-019912-18,distinta,o
103,2010-019912-18,de,o
103,2010-019912-18,AR,i
103,2010-019912-18,Se,o
103,2010-019912-18,permite,o
103,2010-019912-18,la,o
103,2010-019912-18,inclusion,o
103,2010-019912-18,de,o
103,2010-019912-18,pacientes,o
103,2010-019912-18,con,o
103,2010-019912-18,sindrome,i
103,2010-019912-18,de,i
103,2010-019912-18,Sjögren,i
103,2010-019912-18,secundario,i
103,2010-019912-18,asociado,o
103,2010-019912-18,a,o
103,2010-019912-18,AR,i
103,2010-019912-18,Clase,o
103,2010-019912-18,funcional,o
103,2010-019912-18,IV,o
103,2010-019912-18,definida,o
103,2010-019912-18,de,o
103,2010-019912-18,acuerdo,o
103,2010-019912-18,con,o
103,2010-019912-18,la,o
103,2010-019912-18,Clasificacion,o
103,2010-019912-18,del,o
103,2010-019912-18,ACR,o
103,2010-019912-18,del,o
103,2010-019912-18,Estado,o
103,2010-019912-18,Funcional,o
103,2010-019912-18,en,o
103,2010-019912-18,Artritis,i
103,2010-019912-18,Reumatoide,i
103,2010-019912-18,Artritis,i
103,2010-019912-18,idiopatica,i
103,2010-019912-18,juvenil,i
103,2010-019912-18,AIJ,i
103,2010-019912-18,o,o
103,2010-019912-18,artritis,i
103,2010-019912-18,reumatoide,i
103,2010-019912-18,juvenil,i
103,2010-019912-18,ARJ,i
103,2010-019912-18,yo,o
103,2010-019912-18,AR,i
103,2010-019912-18,diagnosticadas,i
103,2010-019912-18,antes,o
103,2010-019912-18,de,o
103,2010-019912-18,los,o
103,2010-019912-18,16,o
103,2010-019912-18,años,o
103,2010-019912-18,de,o
103,2010-019912-18,edad,o
103,2010-019912-18,Enfermedad,i
103,2010-019912-18,articular,i
103,2010-019912-18,inflamatoria,i
103,2010-019912-18,distinta,o
103,2010-019912-18,de,o
103,2010-019912-18,AR,i
103,2010-019912-18,en,o
103,2010-019912-18,el,o
103,2010-019912-18,pasado,o
103,2010-019912-18,o,o
103,2010-019912-18,en,o
103,2010-019912-18,la,o
103,2010-019912-18,actualidad,o
104,2010-019912-18,EudraCT,o
104,2010-019912-18,Nº,o
104,2010-019912-18,201001991218,o
104,2010-019912-18,Titulo,o
104,2010-019912-18,cientifico,o
104,2010-019912-18,Estudio,o
104,2010-019912-18,randomizado,o
104,2010-019912-18,doble,o
104,2010-019912-18,ciego,o
104,2010-019912-18,con,o
104,2010-019912-18,grupos,o
104,2010-019912-18,de,o
104,2010-019912-18,tratamiento,i
104,2010-019912-18,paralelos,o
104,2010-019912-18,para,o
104,2010-019912-18,evaluar,i
104,2010-019912-18,la,i
104,2010-019912-18,seguridad,i
104,2010-019912-18,y,o
104,2010-019912-18,el,o
104,2010-019912-18,efecto,o
104,2010-019912-18,sobre,o
104,2010-019912-18,el,o
104,2010-019912-18,resultado,o
104,2010-019912-18,clinico,o
104,2010-019912-18,de,o
104,2010-019912-18,tocilizumab,i
104,2010-019912-18,SC,o
104,2010-019912-18,frente,o
104,2010-019912-18,a,o
104,2010-019912-18,placebo,i
104,2010-019912-18,SC,o
104,2010-019912-18,en,o
104,2010-019912-18,combinacion,o
104,2010-019912-18,con,o
104,2010-019912-18,farmacos,i
104,2010-019912-18,antirreumaticos,i
104,2010-019912-18,modificadores,i
104,2010-019912-18,de,i
104,2010-019912-18,la,i
104,2010-019912-18,enfermedad,i
104,2010-019912-18,FAMEs,i
104,2010-019912-18,tradicionales,o
104,2010-019912-18,en,o
104,2010-019912-18,pacientes,o
104,2010-019912-18,con,o
104,2010-019912-18,artritis,i
104,2010-019912-18,reumatoide,i
104,2010-019912-18,activa,o
104,2010-019912-18,moderada,o
104,2010-019912-18,a,o
104,2010-019912-18,severa,o
104,2010-019912-18,Indicacion,o
104,2010-019912-18,cientifica,o
104,2010-019912-18,Artritis,i
104,2010-019912-18,Reumatoide,i
104,2010-019912-18,AR,i
104,2010-019912-18,Criterios,o
104,2010-019912-18,de,o
104,2010-019912-18,inclusion,o
104,2010-019912-18,Presentar,o
104,2010-019912-18,artritis,i
104,2010-019912-18,reumatoide,i
104,2010-019912-18,de,o
104,2010-019912-18,mayor,o
104,2010-019912-18,o,o
104,2010-019912-18,igual,o
104,2010-019912-18,a,o
104,2010-019912-18,6,o
104,2010-019912-18,meses,o
104,2010-019912-18,de,o
104,2010-019912-18,duracion,o
104,2010-019912-18,Recibir,o
104,2010-019912-18,tratamiento,i
104,2010-019912-18,de,i
104,2010-019912-18,forma,i
104,2010-019912-18,ambulatoria,i
104,2010-019912-18,Presentar,o
104,2010-019912-18,un,o
104,2010-019912-18,recuento,o
104,2010-019912-18,de,o
104,2010-019912-18,articulaciones,i
104,2010-019912-18,inflamadas,i
104,2010-019912-18,RAI,o
104,2010-019912-18,mayor,o
104,2010-019912-18,o,o
104,2010-019912-18,igual,o
104,2010-019912-18,a,o
104,2010-019912-18,6,o
104,2010-019912-18,recuento,o
104,2010-019912-18,de,o
104,2010-019912-18,66,o
104,2010-019912-18,articulaciones,i
104,2010-019912-18,y,o
104,2010-019912-18,de,o
104,2010-019912-18,articulaciones,i
104,2010-019912-18,dolorosas,i
104,2010-019912-18,RAD,o
104,2010-019912-18,mayor,o
104,2010-019912-18,o,o
104,2010-019912-18,igual,o
104,2010-019912-18,a,o
104,2010-019912-18,8,o
104,2010-019912-18,recuento,o
104,2010-019912-18,de,o
104,2010-019912-18,68,o
104,2010-019912-18,articulaciones,i
104,2010-019912-18,en,o
104,2010-019912-18,las,o
104,2010-019912-18,visitas,o
104,2010-019912-18,de,o
104,2010-019912-18,seleccion,o
104,2010-019912-18,y,o
104,2010-019912-18,basal,o
104,2010-019912-18,Los,o
104,2010-019912-18,pacientes,o
104,2010-019912-18,deben,o
104,2010-019912-18,estar,o
104,2010-019912-18,recibiendo,o
104,2010-019912-18,tratamiento,i
104,2010-019912-18,con,o
104,2010-019912-18,una,o
104,2010-019912-18,dosis,o
104,2010-019912-18,estable,o
104,2010-019912-18,de,o
104,2010-019912-18,los,o
104,2010-019912-18,FAMEs,i
104,2010-019912-18,permitidos,o
104,2010-019912-18,como,o
104,2010-019912-18,minimo,o
104,2010-019912-18,8,o
104,2010-019912-18,semanas,o
104,2010-019912-18,antes,o
104,2010-019912-18,de,o
104,2010-019912-18,la,o
104,2010-019912-18,visita,o
104,2010-019912-18,basal,o
104,2010-019912-18,Criterios,o
104,2010-019912-18,de,o
104,2010-019912-18,exclusion,o
104,2010-019912-18,Pacientes,o
104,2010-019912-18,sometidos,o
104,2010-019912-18,a,o
104,2010-019912-18,intervenciones,i
104,2010-019912-18,de,i
104,2010-019912-18,cirugia,i
104,2010-019912-18,mayor,i
104,2010-019912-18,incluyendo,o
104,2010-019912-18,cirugia,i
104,2010-019912-18,articular,i
104,2010-019912-18,en,o
104,2010-019912-18,las,o
104,2010-019912-18,8,o
104,2010-019912-18,semanas,o
104,2010-019912-18,previas,o
104,2010-019912-18,a,o
104,2010-019912-18,la,o
104,2010-019912-18,visita,o
104,2010-019912-18,de,o
104,2010-019912-18,seleccion,o
104,2010-019912-18,o,o
104,2010-019912-18,que,o
104,2010-019912-18,tengan,o
104,2010-019912-18,previsto,o
104,2010-019912-18,someterse,o
104,2010-019912-18,a,o
104,2010-019912-18,una,o
104,2010-019912-18,intervencion,i
104,2010-019912-18,de,o
104,2010-019912-18,este,o
104,2010-019912-18,tipo,o
104,2010-019912-18,en,o
104,2010-019912-18,los,o
104,2010-019912-18,6,o
104,2010-019912-18,meses,o
104,2010-019912-18,siguientes,o
104,2010-019912-18,a,o
104,2010-019912-18,la,o
104,2010-019912-18,randomizacion,i
104,2010-019912-18,Enfermedad,i
104,2010-019912-18,reumatica,i
104,2010-019912-18,autoinmune,i
104,2010-019912-18,distinta,o
104,2010-019912-18,de,o
104,2010-019912-18,AR,i
104,2010-019912-18,Se,o
104,2010-019912-18,permite,o
104,2010-019912-18,la,o
104,2010-019912-18,inclusion,o
104,2010-019912-18,de,o
104,2010-019912-18,pacientes,o
104,2010-019912-18,con,o
104,2010-019912-18,sindrome,i
104,2010-019912-18,de,i
104,2010-019912-18,Sjögren,i
104,2010-019912-18,secundario,i
104,2010-019912-18,asociado,o
104,2010-019912-18,a,o
104,2010-019912-18,AR,i
104,2010-019912-18,Clase,o
104,2010-019912-18,funcional,o
104,2010-019912-18,IV,o
104,2010-019912-18,definida,o
104,2010-019912-18,de,o
104,2010-019912-18,acuerdo,o
104,2010-019912-18,con,o
104,2010-019912-18,la,o
104,2010-019912-18,Clasificacion,o
104,2010-019912-18,del,o
104,2010-019912-18,ACR,o
104,2010-019912-18,del,o
104,2010-019912-18,Estado,o
104,2010-019912-18,Funcional,o
104,2010-019912-18,en,o
104,2010-019912-18,Artritis,i
104,2010-019912-18,Reumatoide,i
104,2010-019912-18,Artritis,i
104,2010-019912-18,idiopatica,i
104,2010-019912-18,juvenil,i
104,2010-019912-18,AIJ,i
104,2010-019912-18,o,o
104,2010-019912-18,artritis,i
104,2010-019912-18,reumatoide,i
104,2010-019912-18,juvenil,i
104,2010-019912-18,ARJ,i
104,2010-019912-18,yo,o
104,2010-019912-18,AR,i
104,2010-019912-18,diagnosticadas,i
104,2010-019912-18,antes,o
104,2010-019912-18,de,o
104,2010-019912-18,los,o
104,2010-019912-18,16,o
104,2010-019912-18,años,o
104,2010-019912-18,de,o
104,2010-019912-18,edad,o
104,2010-019912-18,Enfermedad,i
104,2010-019912-18,articular,i
104,2010-019912-18,inflamatoria,i
104,2010-019912-18,distinta,o
104,2010-019912-18,de,o
104,2010-019912-18,AR,i
104,2010-019912-18,en,o
104,2010-019912-18,el,o
104,2010-019912-18,pasado,o
104,2010-019912-18,o,o
104,2010-019912-18,en,o
104,2010-019912-18,la,o
104,2010-019912-18,actualidad,o
105,2010-019912-18,EudraCT,o
105,2010-019912-18,Nº,o
105,2010-019912-18,201001991218,o
105,2010-019912-18,Titulo,o
105,2010-019912-18,cientifico,o
105,2010-019912-18,Estudio,o
105,2010-019912-18,randomizado,o
105,2010-019912-18,doble,o
105,2010-019912-18,ciego,o
105,2010-019912-18,con,o
105,2010-019912-18,grupos,o
105,2010-019912-18,de,o
105,2010-019912-18,tratamiento,i
105,2010-019912-18,paralelos,o
105,2010-019912-18,para,o
105,2010-019912-18,evaluar,i
105,2010-019912-18,la,i
105,2010-019912-18,seguridad,i
105,2010-019912-18,y,o
105,2010-019912-18,el,o
105,2010-019912-18,efecto,o
105,2010-019912-18,sobre,o
105,2010-019912-18,el,o
105,2010-019912-18,resultado,o
105,2010-019912-18,clinico,o
105,2010-019912-18,de,o
105,2010-019912-18,tocilizumab,i
105,2010-019912-18,SC,o
105,2010-019912-18,frente,o
105,2010-019912-18,a,o
105,2010-019912-18,placebo,i
105,2010-019912-18,SC,o
105,2010-019912-18,en,o
105,2010-019912-18,combinacion,o
105,2010-019912-18,con,o
105,2010-019912-18,farmacos,i
105,2010-019912-18,antirreumaticos,i
105,2010-019912-18,modificadores,i
105,2010-019912-18,de,i
105,2010-019912-18,la,i
105,2010-019912-18,enfermedad,i
105,2010-019912-18,FAMEs,i
105,2010-019912-18,tradicionales,o
105,2010-019912-18,en,o
105,2010-019912-18,pacientes,o
105,2010-019912-18,con,o
105,2010-019912-18,artritis,i
105,2010-019912-18,reumatoide,i
105,2010-019912-18,activa,o
105,2010-019912-18,moderada,o
105,2010-019912-18,a,o
105,2010-019912-18,severa,o
105,2010-019912-18,Indicacion,o
105,2010-019912-18,cientifica,o
105,2010-019912-18,Artritis,i
105,2010-019912-18,Reumatoide,i
105,2010-019912-18,AR,i
105,2010-019912-18,Criterios,o
105,2010-019912-18,de,o
105,2010-019912-18,inclusion,o
105,2010-019912-18,Presentar,o
105,2010-019912-18,artritis,i
105,2010-019912-18,reumatoide,i
105,2010-019912-18,de,o
105,2010-019912-18,mayor,o
105,2010-019912-18,o,o
105,2010-019912-18,igual,o
105,2010-019912-18,a,o
105,2010-019912-18,6,o
105,2010-019912-18,meses,o
105,2010-019912-18,de,o
105,2010-019912-18,duracion,o
105,2010-019912-18,Recibir,o
105,2010-019912-18,tratamiento,i
105,2010-019912-18,de,i
105,2010-019912-18,forma,i
105,2010-019912-18,ambulatoria,i
105,2010-019912-18,Presentar,o
105,2010-019912-18,un,o
105,2010-019912-18,recuento,o
105,2010-019912-18,de,o
105,2010-019912-18,articulaciones,i
105,2010-019912-18,inflamadas,i
105,2010-019912-18,RAI,o
105,2010-019912-18,mayor,o
105,2010-019912-18,o,o
105,2010-019912-18,igual,o
105,2010-019912-18,a,o
105,2010-019912-18,6,o
105,2010-019912-18,recuento,o
105,2010-019912-18,de,o
105,2010-019912-18,66,o
105,2010-019912-18,articulaciones,i
105,2010-019912-18,y,o
105,2010-019912-18,de,o
105,2010-019912-18,articulaciones,i
105,2010-019912-18,dolorosas,i
105,2010-019912-18,RAD,o
105,2010-019912-18,mayor,o
105,2010-019912-18,o,o
105,2010-019912-18,igual,o
105,2010-019912-18,a,o
105,2010-019912-18,8,o
105,2010-019912-18,recuento,o
105,2010-019912-18,de,o
105,2010-019912-18,68,o
105,2010-019912-18,articulaciones,i
105,2010-019912-18,en,o
105,2010-019912-18,las,o
105,2010-019912-18,visitas,o
105,2010-019912-18,de,o
105,2010-019912-18,seleccion,o
105,2010-019912-18,y,o
105,2010-019912-18,basal,o
105,2010-019912-18,Los,o
105,2010-019912-18,pacientes,o
105,2010-019912-18,deben,o
105,2010-019912-18,estar,o
105,2010-019912-18,recibiendo,o
105,2010-019912-18,tratamiento,i
105,2010-019912-18,con,o
105,2010-019912-18,una,o
105,2010-019912-18,dosis,o
105,2010-019912-18,estable,o
105,2010-019912-18,de,o
105,2010-019912-18,los,o
105,2010-019912-18,FAMEs,i
105,2010-019912-18,permitidos,o
105,2010-019912-18,como,o
105,2010-019912-18,minimo,o
105,2010-019912-18,8,o
105,2010-019912-18,semanas,o
105,2010-019912-18,antes,o
105,2010-019912-18,de,o
105,2010-019912-18,la,o
105,2010-019912-18,visita,o
105,2010-019912-18,basal,o
105,2010-019912-18,Criterios,o
105,2010-019912-18,de,o
105,2010-019912-18,exclusion,o
105,2010-019912-18,Pacientes,o
105,2010-019912-18,sometidos,o
105,2010-019912-18,a,o
105,2010-019912-18,intervenciones,i
105,2010-019912-18,de,i
105,2010-019912-18,cirugia,i
105,2010-019912-18,mayor,i
105,2010-019912-18,incluyendo,o
105,2010-019912-18,cirugia,i
105,2010-019912-18,articular,i
105,2010-019912-18,en,o
105,2010-019912-18,las,o
105,2010-019912-18,8,o
105,2010-019912-18,semanas,o
105,2010-019912-18,previas,o
105,2010-019912-18,a,o
105,2010-019912-18,la,o
105,2010-019912-18,visita,o
105,2010-019912-18,de,o
105,2010-019912-18,seleccion,o
105,2010-019912-18,o,o
105,2010-019912-18,que,o
105,2010-019912-18,tengan,o
105,2010-019912-18,previsto,o
105,2010-019912-18,someterse,o
105,2010-019912-18,a,o
105,2010-019912-18,una,o
105,2010-019912-18,intervencion,i
105,2010-019912-18,de,o
105,2010-019912-18,este,o
105,2010-019912-18,tipo,o
105,2010-019912-18,en,o
105,2010-019912-18,los,o
105,2010-019912-18,6,o
105,2010-019912-18,meses,o
105,2010-019912-18,siguientes,o
105,2010-019912-18,a,o
105,2010-019912-18,la,o
105,2010-019912-18,randomizacion,i
105,2010-019912-18,Enfermedad,i
105,2010-019912-18,reumatica,i
105,2010-019912-18,autoinmune,i
105,2010-019912-18,distinta,o
105,2010-019912-18,de,o
105,2010-019912-18,AR,i
105,2010-019912-18,Se,o
105,2010-019912-18,permite,o
105,2010-019912-18,la,o
105,2010-019912-18,inclusion,o
105,2010-019912-18,de,o
105,2010-019912-18,pacientes,o
105,2010-019912-18,con,o
105,2010-019912-18,sindrome,i
105,2010-019912-18,de,i
105,2010-019912-18,Sjögren,i
105,2010-019912-18,secundario,i
105,2010-019912-18,asociado,o
105,2010-019912-18,a,o
105,2010-019912-18,AR,i
105,2010-019912-18,Clase,o
105,2010-019912-18,funcional,o
105,2010-019912-18,IV,o
105,2010-019912-18,definida,o
105,2010-019912-18,de,o
105,2010-019912-18,acuerdo,o
105,2010-019912-18,con,o
105,2010-019912-18,la,o
105,2010-019912-18,Clasificacion,o
105,2010-019912-18,del,o
105,2010-019912-18,ACR,o
105,2010-019912-18,del,o
105,2010-019912-18,Estado,o
105,2010-019912-18,Funcional,o
105,2010-019912-18,en,o
105,2010-019912-18,Artritis,i
105,2010-019912-18,Reumatoide,i
105,2010-019912-18,Artritis,i
105,2010-019912-18,idiopatica,i
105,2010-019912-18,juvenil,i
105,2010-019912-18,AIJ,i
105,2010-019912-18,o,o
105,2010-019912-18,artritis,i
105,2010-019912-18,reumatoide,i
105,2010-019912-18,juvenil,i
105,2010-019912-18,ARJ,i
105,2010-019912-18,yo,o
105,2010-019912-18,AR,i
105,2010-019912-18,diagnosticadas,i
105,2010-019912-18,antes,o
105,2010-019912-18,de,o
105,2010-019912-18,los,o
105,2010-019912-18,16,o
105,2010-019912-18,años,o
105,2010-019912-18,de,o
105,2010-019912-18,edad,o
105,2010-019912-18,Enfermedad,i
105,2010-019912-18,articular,i
105,2010-019912-18,inflamatoria,i
105,2010-019912-18,distinta,o
105,2010-019912-18,de,o
105,2010-019912-18,AR,i
105,2010-019912-18,en,o
105,2010-019912-18,el,o
105,2010-019912-18,pasado,o
105,2010-019912-18,o,o
105,2010-019912-18,en,o
105,2010-019912-18,la,o
105,2010-019912-18,actualidad,o
106,2010-019912-18,EudraCT,o
106,2010-019912-18,Nº,o
106,2010-019912-18,201001991218,o
106,2010-019912-18,Titulo,o
106,2010-019912-18,cientifico,o
106,2010-019912-18,Estudio,o
106,2010-019912-18,randomizado,o
106,2010-019912-18,doble,o
106,2010-019912-18,ciego,o
106,2010-019912-18,con,o
106,2010-019912-18,grupos,o
106,2010-019912-18,de,o
106,2010-019912-18,tratamiento,i
106,2010-019912-18,paralelos,o
106,2010-019912-18,para,o
106,2010-019912-18,evaluar,i
106,2010-019912-18,la,i
106,2010-019912-18,seguridad,i
106,2010-019912-18,y,o
106,2010-019912-18,el,o
106,2010-019912-18,efecto,o
106,2010-019912-18,sobre,o
106,2010-019912-18,el,o
106,2010-019912-18,resultado,o
106,2010-019912-18,clinico,o
106,2010-019912-18,de,o
106,2010-019912-18,tocilizumab,i
106,2010-019912-18,SC,o
106,2010-019912-18,frente,o
106,2010-019912-18,a,o
106,2010-019912-18,placebo,i
106,2010-019912-18,SC,o
106,2010-019912-18,en,o
106,2010-019912-18,combinacion,o
106,2010-019912-18,con,o
106,2010-019912-18,farmacos,i
106,2010-019912-18,antirreumaticos,i
106,2010-019912-18,modificadores,i
106,2010-019912-18,de,i
106,2010-019912-18,la,i
106,2010-019912-18,enfermedad,i
106,2010-019912-18,FAMEs,i
106,2010-019912-18,tradicionales,o
106,2010-019912-18,en,o
106,2010-019912-18,pacientes,o
106,2010-019912-18,con,o
106,2010-019912-18,artritis,i
106,2010-019912-18,reumatoide,i
106,2010-019912-18,activa,o
106,2010-019912-18,moderada,o
106,2010-019912-18,a,o
106,2010-019912-18,severa,o
106,2010-019912-18,Indicacion,o
106,2010-019912-18,cientifica,o
106,2010-019912-18,Artritis,i
106,2010-019912-18,Reumatoide,i
106,2010-019912-18,AR,i
106,2010-019912-18,Criterios,o
106,2010-019912-18,de,o
106,2010-019912-18,inclusion,o
106,2010-019912-18,Presentar,o
106,2010-019912-18,artritis,i
106,2010-019912-18,reumatoide,i
106,2010-019912-18,de,o
106,2010-019912-18,mayor,o
106,2010-019912-18,o,o
106,2010-019912-18,igual,o
106,2010-019912-18,a,o
106,2010-019912-18,6,o
106,2010-019912-18,meses,o
106,2010-019912-18,de,o
106,2010-019912-18,duracion,o
106,2010-019912-18,Recibir,o
106,2010-019912-18,tratamiento,i
106,2010-019912-18,de,i
106,2010-019912-18,forma,i
106,2010-019912-18,ambulatoria,i
106,2010-019912-18,Presentar,o
106,2010-019912-18,un,o
106,2010-019912-18,recuento,o
106,2010-019912-18,de,o
106,2010-019912-18,articulaciones,i
106,2010-019912-18,inflamadas,i
106,2010-019912-18,RAI,o
106,2010-019912-18,mayor,o
106,2010-019912-18,o,o
106,2010-019912-18,igual,o
106,2010-019912-18,a,o
106,2010-019912-18,6,o
106,2010-019912-18,recuento,o
106,2010-019912-18,de,o
106,2010-019912-18,66,o
106,2010-019912-18,articulaciones,i
106,2010-019912-18,y,o
106,2010-019912-18,de,o
106,2010-019912-18,articulaciones,i
106,2010-019912-18,dolorosas,i
106,2010-019912-18,RAD,o
106,2010-019912-18,mayor,o
106,2010-019912-18,o,o
106,2010-019912-18,igual,o
106,2010-019912-18,a,o
106,2010-019912-18,8,o
106,2010-019912-18,recuento,o
106,2010-019912-18,de,o
106,2010-019912-18,68,o
106,2010-019912-18,articulaciones,i
106,2010-019912-18,en,o
106,2010-019912-18,las,o
106,2010-019912-18,visitas,o
106,2010-019912-18,de,o
106,2010-019912-18,seleccion,o
106,2010-019912-18,y,o
106,2010-019912-18,basal,o
106,2010-019912-18,Los,o
106,2010-019912-18,pacientes,o
106,2010-019912-18,deben,o
106,2010-019912-18,estar,o
106,2010-019912-18,recibiendo,o
106,2010-019912-18,tratamiento,i
106,2010-019912-18,con,o
106,2010-019912-18,una,o
106,2010-019912-18,dosis,o
106,2010-019912-18,estable,o
106,2010-019912-18,de,o
106,2010-019912-18,los,o
106,2010-019912-18,FAMEs,i
106,2010-019912-18,permitidos,o
106,2010-019912-18,como,o
106,2010-019912-18,minimo,o
106,2010-019912-18,8,o
106,2010-019912-18,semanas,o
106,2010-019912-18,antes,o
106,2010-019912-18,de,o
106,2010-019912-18,la,o
106,2010-019912-18,visita,o
106,2010-019912-18,basal,o
106,2010-019912-18,Criterios,o
106,2010-019912-18,de,o
106,2010-019912-18,exclusion,o
106,2010-019912-18,Pacientes,o
106,2010-019912-18,sometidos,o
106,2010-019912-18,a,o
106,2010-019912-18,intervenciones,i
106,2010-019912-18,de,i
106,2010-019912-18,cirugia,i
106,2010-019912-18,mayor,i
106,2010-019912-18,incluyendo,o
106,2010-019912-18,cirugia,i
106,2010-019912-18,articular,i
106,2010-019912-18,en,o
106,2010-019912-18,las,o
106,2010-019912-18,8,o
106,2010-019912-18,semanas,o
106,2010-019912-18,previas,o
106,2010-019912-18,a,o
106,2010-019912-18,la,o
106,2010-019912-18,visita,o
106,2010-019912-18,de,o
106,2010-019912-18,seleccion,o
106,2010-019912-18,o,o
106,2010-019912-18,que,o
106,2010-019912-18,tengan,o
106,2010-019912-18,previsto,o
106,2010-019912-18,someterse,o
106,2010-019912-18,a,o
106,2010-019912-18,una,o
106,2010-019912-18,intervencion,i
106,2010-019912-18,de,o
106,2010-019912-18,este,o
106,2010-019912-18,tipo,o
106,2010-019912-18,en,o
106,2010-019912-18,los,o
106,2010-019912-18,6,o
106,2010-019912-18,meses,o
106,2010-019912-18,siguientes,o
106,2010-019912-18,a,o
106,2010-019912-18,la,o
106,2010-019912-18,randomizacion,i
106,2010-019912-18,Enfermedad,i
106,2010-019912-18,reumatica,i
106,2010-019912-18,autoinmune,i
106,2010-019912-18,distinta,o
106,2010-019912-18,de,o
106,2010-019912-18,AR,i
106,2010-019912-18,Se,o
106,2010-019912-18,permite,o
106,2010-019912-18,la,o
106,2010-019912-18,inclusion,o
106,2010-019912-18,de,o
106,2010-019912-18,pacientes,o
106,2010-019912-18,con,o
106,2010-019912-18,sindrome,i
106,2010-019912-18,de,i
106,2010-019912-18,Sjögren,i
106,2010-019912-18,secundario,i
106,2010-019912-18,asociado,o
106,2010-019912-18,a,o
106,2010-019912-18,AR,i
106,2010-019912-18,Clase,o
106,2010-019912-18,funcional,o
106,2010-019912-18,IV,o
106,2010-019912-18,definida,o
106,2010-019912-18,de,o
106,2010-019912-18,acuerdo,o
106,2010-019912-18,con,o
106,2010-019912-18,la,o
106,2010-019912-18,Clasificacion,o
106,2010-019912-18,del,o
106,2010-019912-18,ACR,o
106,2010-019912-18,del,o
106,2010-019912-18,Estado,o
106,2010-019912-18,Funcional,o
106,2010-019912-18,en,o
106,2010-019912-18,Artritis,i
106,2010-019912-18,Reumatoide,i
106,2010-019912-18,Artritis,i
106,2010-019912-18,idiopatica,i
106,2010-019912-18,juvenil,i
106,2010-019912-18,AIJ,i
106,2010-019912-18,o,o
106,2010-019912-18,artritis,i
106,2010-019912-18,reumatoide,i
106,2010-019912-18,juvenil,i
106,2010-019912-18,ARJ,i
106,2010-019912-18,yo,o
106,2010-019912-18,AR,i
106,2010-019912-18,diagnosticadas,i
106,2010-019912-18,antes,o
106,2010-019912-18,de,o
106,2010-019912-18,los,o
106,2010-019912-18,16,o
106,2010-019912-18,años,o
106,2010-019912-18,de,o
106,2010-019912-18,edad,o
106,2010-019912-18,Enfermedad,i
106,2010-019912-18,articular,i
106,2010-019912-18,inflamatoria,i
106,2010-019912-18,distinta,o
106,2010-019912-18,de,o
106,2010-019912-18,AR,i
106,2010-019912-18,en,o
106,2010-019912-18,el,o
106,2010-019912-18,pasado,o
106,2010-019912-18,o,o
106,2010-019912-18,en,o
106,2010-019912-18,la,o
106,2010-019912-18,actualidad,o
107,2010-019912-18,EudraCT,o
107,2010-019912-18,Nº,o
107,2010-019912-18,201001991218,o
107,2010-019912-18,Titulo,o
107,2010-019912-18,cientifico,o
107,2010-019912-18,Estudio,o
107,2010-019912-18,randomizado,o
107,2010-019912-18,doble,o
107,2010-019912-18,ciego,o
107,2010-019912-18,con,o
107,2010-019912-18,grupos,o
107,2010-019912-18,de,o
107,2010-019912-18,tratamiento,i
107,2010-019912-18,paralelos,o
107,2010-019912-18,para,o
107,2010-019912-18,evaluar,i
107,2010-019912-18,la,i
107,2010-019912-18,seguridad,i
107,2010-019912-18,y,o
107,2010-019912-18,el,o
107,2010-019912-18,efecto,o
107,2010-019912-18,sobre,o
107,2010-019912-18,el,o
107,2010-019912-18,resultado,o
107,2010-019912-18,clinico,o
107,2010-019912-18,de,o
107,2010-019912-18,tocilizumab,i
107,2010-019912-18,SC,o
107,2010-019912-18,frente,o
107,2010-019912-18,a,o
107,2010-019912-18,placebo,i
107,2010-019912-18,SC,o
107,2010-019912-18,en,o
107,2010-019912-18,combinacion,o
107,2010-019912-18,con,o
107,2010-019912-18,farmacos,i
107,2010-019912-18,antirreumaticos,i
107,2010-019912-18,modificadores,i
107,2010-019912-18,de,i
107,2010-019912-18,la,i
107,2010-019912-18,enfermedad,i
107,2010-019912-18,FAMEs,i
107,2010-019912-18,tradicionales,o
107,2010-019912-18,en,o
107,2010-019912-18,pacientes,o
107,2010-019912-18,con,o
107,2010-019912-18,artritis,i
107,2010-019912-18,reumatoide,i
107,2010-019912-18,activa,o
107,2010-019912-18,moderada,o
107,2010-019912-18,a,o
107,2010-019912-18,severa,o
107,2010-019912-18,Indicacion,o
107,2010-019912-18,cientifica,o
107,2010-019912-18,Artritis,i
107,2010-019912-18,Reumatoide,i
107,2010-019912-18,AR,i
107,2010-019912-18,Criterios,o
107,2010-019912-18,de,o
107,2010-019912-18,inclusion,o
107,2010-019912-18,Presentar,o
107,2010-019912-18,artritis,i
107,2010-019912-18,reumatoide,i
107,2010-019912-18,de,o
107,2010-019912-18,mayor,o
107,2010-019912-18,o,o
107,2010-019912-18,igual,o
107,2010-019912-18,a,o
107,2010-019912-18,6,o
107,2010-019912-18,meses,o
107,2010-019912-18,de,o
107,2010-019912-18,duracion,o
107,2010-019912-18,Recibir,o
107,2010-019912-18,tratamiento,i
107,2010-019912-18,de,i
107,2010-019912-18,forma,i
107,2010-019912-18,ambulatoria,i
107,2010-019912-18,Presentar,o
107,2010-019912-18,un,o
107,2010-019912-18,recuento,o
107,2010-019912-18,de,o
107,2010-019912-18,articulaciones,i
107,2010-019912-18,inflamadas,i
107,2010-019912-18,RAI,o
107,2010-019912-18,mayor,o
107,2010-019912-18,o,o
107,2010-019912-18,igual,o
107,2010-019912-18,a,o
107,2010-019912-18,6,o
107,2010-019912-18,recuento,o
107,2010-019912-18,de,o
107,2010-019912-18,66,o
107,2010-019912-18,articulaciones,i
107,2010-019912-18,y,o
107,2010-019912-18,de,o
107,2010-019912-18,articulaciones,i
107,2010-019912-18,dolorosas,i
107,2010-019912-18,RAD,o
107,2010-019912-18,mayor,o
107,2010-019912-18,o,o
107,2010-019912-18,igual,o
107,2010-019912-18,a,o
107,2010-019912-18,8,o
107,2010-019912-18,recuento,o
107,2010-019912-18,de,o
107,2010-019912-18,68,o
107,2010-019912-18,articulaciones,i
107,2010-019912-18,en,o
107,2010-019912-18,las,o
107,2010-019912-18,visitas,o
107,2010-019912-18,de,o
107,2010-019912-18,seleccion,o
107,2010-019912-18,y,o
107,2010-019912-18,basal,o
107,2010-019912-18,Los,o
107,2010-019912-18,pacientes,o
107,2010-019912-18,deben,o
107,2010-019912-18,estar,o
107,2010-019912-18,recibiendo,o
107,2010-019912-18,tratamiento,i
107,2010-019912-18,con,o
107,2010-019912-18,una,o
107,2010-019912-18,dosis,o
107,2010-019912-18,estable,o
107,2010-019912-18,de,o
107,2010-019912-18,los,o
107,2010-019912-18,FAMEs,i
107,2010-019912-18,permitidos,o
107,2010-019912-18,como,o
107,2010-019912-18,minimo,o
107,2010-019912-18,8,o
107,2010-019912-18,semanas,o
107,2010-019912-18,antes,o
107,2010-019912-18,de,o
107,2010-019912-18,la,o
107,2010-019912-18,visita,o
107,2010-019912-18,basal,o
107,2010-019912-18,Criterios,o
107,2010-019912-18,de,o
107,2010-019912-18,exclusion,o
107,2010-019912-18,Pacientes,o
107,2010-019912-18,sometidos,o
107,2010-019912-18,a,o
107,2010-019912-18,intervenciones,i
107,2010-019912-18,de,i
107,2010-019912-18,cirugia,i
107,2010-019912-18,mayor,i
107,2010-019912-18,incluyendo,o
107,2010-019912-18,cirugia,i
107,2010-019912-18,articular,i
107,2010-019912-18,en,o
107,2010-019912-18,las,o
107,2010-019912-18,8,o
107,2010-019912-18,semanas,o
107,2010-019912-18,previas,o
107,2010-019912-18,a,o
107,2010-019912-18,la,o
107,2010-019912-18,visita,o
107,2010-019912-18,de,o
107,2010-019912-18,seleccion,o
107,2010-019912-18,o,o
107,2010-019912-18,que,o
107,2010-019912-18,tengan,o
107,2010-019912-18,previsto,o
107,2010-019912-18,someterse,o
107,2010-019912-18,a,o
107,2010-019912-18,una,o
107,2010-019912-18,intervencion,i
107,2010-019912-18,de,o
107,2010-019912-18,este,o
107,2010-019912-18,tipo,o
107,2010-019912-18,en,o
107,2010-019912-18,los,o
107,2010-019912-18,6,o
107,2010-019912-18,meses,o
107,2010-019912-18,siguientes,o
107,2010-019912-18,a,o
107,2010-019912-18,la,o
107,2010-019912-18,randomizacion,i
107,2010-019912-18,Enfermedad,i
107,2010-019912-18,reumatica,i
107,2010-019912-18,autoinmune,i
107,2010-019912-18,distinta,o
107,2010-019912-18,de,o
107,2010-019912-18,AR,i
107,2010-019912-18,Se,o
107,2010-019912-18,permite,o
107,2010-019912-18,la,o
107,2010-019912-18,inclusion,o
107,2010-019912-18,de,o
107,2010-019912-18,pacientes,o
107,2010-019912-18,con,o
107,2010-019912-18,sindrome,i
107,2010-019912-18,de,i
107,2010-019912-18,Sjögren,i
107,2010-019912-18,secundario,i
107,2010-019912-18,asociado,o
107,2010-019912-18,a,o
107,2010-019912-18,AR,i
107,2010-019912-18,Clase,o
107,2010-019912-18,funcional,o
107,2010-019912-18,IV,o
107,2010-019912-18,definida,o
107,2010-019912-18,de,o
107,2010-019912-18,acuerdo,o
107,2010-019912-18,con,o
107,2010-019912-18,la,o
107,2010-019912-18,Clasificacion,o
107,2010-019912-18,del,o
107,2010-019912-18,ACR,o
107,2010-019912-18,del,o
107,2010-019912-18,Estado,o
107,2010-019912-18,Funcional,o
107,2010-019912-18,en,o
107,2010-019912-18,Artritis,i
107,2010-019912-18,Reumatoide,i
107,2010-019912-18,Artritis,i
107,2010-019912-18,idiopatica,i
107,2010-019912-18,juvenil,i
107,2010-019912-18,AIJ,i
107,2010-019912-18,o,o
107,2010-019912-18,artritis,i
107,2010-019912-18,reumatoide,i
107,2010-019912-18,juvenil,i
107,2010-019912-18,ARJ,i
107,2010-019912-18,yo,o
107,2010-019912-18,AR,i
107,2010-019912-18,diagnosticadas,i
107,2010-019912-18,antes,o
107,2010-019912-18,de,o
107,2010-019912-18,los,o
107,2010-019912-18,16,o
107,2010-019912-18,años,o
107,2010-019912-18,de,o
107,2010-019912-18,edad,o
107,2010-019912-18,Enfermedad,i
107,2010-019912-18,articular,i
107,2010-019912-18,inflamatoria,i
107,2010-019912-18,distinta,o
107,2010-019912-18,de,o
107,2010-019912-18,AR,i
107,2010-019912-18,en,o
107,2010-019912-18,el,o
107,2010-019912-18,pasado,o
107,2010-019912-18,o,o
107,2010-019912-18,en,o
107,2010-019912-18,la,o
107,2010-019912-18,actualidad,o
108,2010-019912-18,EudraCT,o
108,2010-019912-18,Nº,o
108,2010-019912-18,201001991218,o
108,2010-019912-18,Titulo,o
108,2010-019912-18,cientifico,o
108,2010-019912-18,Estudio,o
108,2010-019912-18,randomizado,o
108,2010-019912-18,doble,o
108,2010-019912-18,ciego,o
108,2010-019912-18,con,o
108,2010-019912-18,grupos,o
108,2010-019912-18,de,o
108,2010-019912-18,tratamiento,i
108,2010-019912-18,paralelos,o
108,2010-019912-18,para,o
108,2010-019912-18,evaluar,i
108,2010-019912-18,la,i
108,2010-019912-18,seguridad,i
108,2010-019912-18,y,o
108,2010-019912-18,el,o
108,2010-019912-18,efecto,o
108,2010-019912-18,sobre,o
108,2010-019912-18,el,o
108,2010-019912-18,resultado,o
108,2010-019912-18,clinico,o
108,2010-019912-18,de,o
108,2010-019912-18,tocilizumab,i
108,2010-019912-18,SC,o
108,2010-019912-18,frente,o
108,2010-019912-18,a,o
108,2010-019912-18,placebo,i
108,2010-019912-18,SC,o
108,2010-019912-18,en,o
108,2010-019912-18,combinacion,o
108,2010-019912-18,con,o
108,2010-019912-18,farmacos,i
108,2010-019912-18,antirreumaticos,i
108,2010-019912-18,modificadores,i
108,2010-019912-18,de,i
108,2010-019912-18,la,i
108,2010-019912-18,enfermedad,i
108,2010-019912-18,FAMEs,i
108,2010-019912-18,tradicionales,o
108,2010-019912-18,en,o
108,2010-019912-18,pacientes,o
108,2010-019912-18,con,o
108,2010-019912-18,artritis,i
108,2010-019912-18,reumatoide,i
108,2010-019912-18,activa,o
108,2010-019912-18,moderada,o
108,2010-019912-18,a,o
108,2010-019912-18,severa,o
108,2010-019912-18,Indicacion,o
108,2010-019912-18,cientifica,o
108,2010-019912-18,Artritis,i
108,2010-019912-18,Reumatoide,i
108,2010-019912-18,AR,i
108,2010-019912-18,Criterios,o
108,2010-019912-18,de,o
108,2010-019912-18,inclusion,o
108,2010-019912-18,Presentar,o
108,2010-019912-18,artritis,i
108,2010-019912-18,reumatoide,i
108,2010-019912-18,de,o
108,2010-019912-18,mayor,o
108,2010-019912-18,o,o
108,2010-019912-18,igual,o
108,2010-019912-18,a,o
108,2010-019912-18,6,o
108,2010-019912-18,meses,o
108,2010-019912-18,de,o
108,2010-019912-18,duracion,o
108,2010-019912-18,Recibir,o
108,2010-019912-18,tratamiento,i
108,2010-019912-18,de,i
108,2010-019912-18,forma,i
108,2010-019912-18,ambulatoria,i
108,2010-019912-18,Presentar,o
108,2010-019912-18,un,o
108,2010-019912-18,recuento,o
108,2010-019912-18,de,o
108,2010-019912-18,articulaciones,i
108,2010-019912-18,inflamadas,i
108,2010-019912-18,RAI,o
108,2010-019912-18,mayor,o
108,2010-019912-18,o,o
108,2010-019912-18,igual,o
108,2010-019912-18,a,o
108,2010-019912-18,6,o
108,2010-019912-18,recuento,o
108,2010-019912-18,de,o
108,2010-019912-18,66,o
108,2010-019912-18,articulaciones,i
108,2010-019912-18,y,o
108,2010-019912-18,de,o
108,2010-019912-18,articulaciones,i
108,2010-019912-18,dolorosas,i
108,2010-019912-18,RAD,o
108,2010-019912-18,mayor,o
108,2010-019912-18,o,o
108,2010-019912-18,igual,o
108,2010-019912-18,a,o
108,2010-019912-18,8,o
108,2010-019912-18,recuento,o
108,2010-019912-18,de,o
108,2010-019912-18,68,o
108,2010-019912-18,articulaciones,i
108,2010-019912-18,en,o
108,2010-019912-18,las,o
108,2010-019912-18,visitas,o
108,2010-019912-18,de,o
108,2010-019912-18,seleccion,o
108,2010-019912-18,y,o
108,2010-019912-18,basal,o
108,2010-019912-18,Los,o
108,2010-019912-18,pacientes,o
108,2010-019912-18,deben,o
108,2010-019912-18,estar,o
108,2010-019912-18,recibiendo,o
108,2010-019912-18,tratamiento,i
108,2010-019912-18,con,o
108,2010-019912-18,una,o
108,2010-019912-18,dosis,o
108,2010-019912-18,estable,o
108,2010-019912-18,de,o
108,2010-019912-18,los,o
108,2010-019912-18,FAMEs,i
108,2010-019912-18,permitidos,o
108,2010-019912-18,como,o
108,2010-019912-18,minimo,o
108,2010-019912-18,8,o
108,2010-019912-18,semanas,o
108,2010-019912-18,antes,o
108,2010-019912-18,de,o
108,2010-019912-18,la,o
108,2010-019912-18,visita,o
108,2010-019912-18,basal,o
108,2010-019912-18,Criterios,o
108,2010-019912-18,de,o
108,2010-019912-18,exclusion,o
108,2010-019912-18,Pacientes,o
108,2010-019912-18,sometidos,o
108,2010-019912-18,a,o
108,2010-019912-18,intervenciones,i
108,2010-019912-18,de,i
108,2010-019912-18,cirugia,i
108,2010-019912-18,mayor,i
108,2010-019912-18,incluyendo,o
108,2010-019912-18,cirugia,i
108,2010-019912-18,articular,i
108,2010-019912-18,en,o
108,2010-019912-18,las,o
108,2010-019912-18,8,o
108,2010-019912-18,semanas,o
108,2010-019912-18,previas,o
108,2010-019912-18,a,o
108,2010-019912-18,la,o
108,2010-019912-18,visita,o
108,2010-019912-18,de,o
108,2010-019912-18,seleccion,o
108,2010-019912-18,o,o
108,2010-019912-18,que,o
108,2010-019912-18,tengan,o
108,2010-019912-18,previsto,o
108,2010-019912-18,someterse,o
108,2010-019912-18,a,o
108,2010-019912-18,una,o
108,2010-019912-18,intervencion,i
108,2010-019912-18,de,o
108,2010-019912-18,este,o
108,2010-019912-18,tipo,o
108,2010-019912-18,en,o
108,2010-019912-18,los,o
108,2010-019912-18,6,o
108,2010-019912-18,meses,o
108,2010-019912-18,siguientes,o
108,2010-019912-18,a,o
108,2010-019912-18,la,o
108,2010-019912-18,randomizacion,i
108,2010-019912-18,Enfermedad,i
108,2010-019912-18,reumatica,i
108,2010-019912-18,autoinmune,i
108,2010-019912-18,distinta,o
108,2010-019912-18,de,o
108,2010-019912-18,AR,i
108,2010-019912-18,Se,o
108,2010-019912-18,permite,o
108,2010-019912-18,la,o
108,2010-019912-18,inclusion,o
108,2010-019912-18,de,o
108,2010-019912-18,pacientes,o
108,2010-019912-18,con,o
108,2010-019912-18,sindrome,i
108,2010-019912-18,de,i
108,2010-019912-18,Sjögren,i
108,2010-019912-18,secundario,i
108,2010-019912-18,asociado,o
108,2010-019912-18,a,o
108,2010-019912-18,AR,i
108,2010-019912-18,Clase,o
108,2010-019912-18,funcional,o
108,2010-019912-18,IV,o
108,2010-019912-18,definida,o
108,2010-019912-18,de,o
108,2010-019912-18,acuerdo,o
108,2010-019912-18,con,o
108,2010-019912-18,la,o
108,2010-019912-18,Clasificacion,o
108,2010-019912-18,del,o
108,2010-019912-18,ACR,o
108,2010-019912-18,del,o
108,2010-019912-18,Estado,o
108,2010-019912-18,Funcional,o
108,2010-019912-18,en,o
108,2010-019912-18,Artritis,i
108,2010-019912-18,Reumatoide,i
108,2010-019912-18,Artritis,i
108,2010-019912-18,idiopatica,i
108,2010-019912-18,juvenil,i
108,2010-019912-18,AIJ,i
108,2010-019912-18,o,o
108,2010-019912-18,artritis,i
108,2010-019912-18,reumatoide,i
108,2010-019912-18,juvenil,i
108,2010-019912-18,ARJ,i
108,2010-019912-18,yo,o
108,2010-019912-18,AR,i
108,2010-019912-18,diagnosticadas,i
108,2010-019912-18,antes,o
108,2010-019912-18,de,o
108,2010-019912-18,los,o
108,2010-019912-18,16,o
108,2010-019912-18,años,o
108,2010-019912-18,de,o
108,2010-019912-18,edad,o
108,2010-019912-18,Enfermedad,i
108,2010-019912-18,articular,i
108,2010-019912-18,inflamatoria,i
108,2010-019912-18,distinta,o
108,2010-019912-18,de,o
108,2010-019912-18,AR,i
108,2010-019912-18,en,o
108,2010-019912-18,el,o
108,2010-019912-18,pasado,o
108,2010-019912-18,o,o
108,2010-019912-18,en,o
108,2010-019912-18,la,o
108,2010-019912-18,actualidad,o
109,2010-019912-18,EudraCT,o
109,2010-019912-18,Nº,o
109,2010-019912-18,201001991218,o
109,2010-019912-18,Titulo,o
109,2010-019912-18,cientifico,o
109,2010-019912-18,Estudio,o
109,2010-019912-18,randomizado,o
109,2010-019912-18,doble,o
109,2010-019912-18,ciego,o
109,2010-019912-18,con,o
109,2010-019912-18,grupos,o
109,2010-019912-18,de,o
109,2010-019912-18,tratamiento,i
109,2010-019912-18,paralelos,o
109,2010-019912-18,para,o
109,2010-019912-18,evaluar,i
109,2010-019912-18,la,i
109,2010-019912-18,seguridad,i
109,2010-019912-18,y,o
109,2010-019912-18,el,o
109,2010-019912-18,efecto,o
109,2010-019912-18,sobre,o
109,2010-019912-18,el,o
109,2010-019912-18,resultado,o
109,2010-019912-18,clinico,o
109,2010-019912-18,de,o
109,2010-019912-18,tocilizumab,i
109,2010-019912-18,SC,o
109,2010-019912-18,frente,o
109,2010-019912-18,a,o
109,2010-019912-18,placebo,i
109,2010-019912-18,SC,o
109,2010-019912-18,en,o
109,2010-019912-18,combinacion,o
109,2010-019912-18,con,o
109,2010-019912-18,farmacos,i
109,2010-019912-18,antirreumaticos,i
109,2010-019912-18,modificadores,i
109,2010-019912-18,de,i
109,2010-019912-18,la,i
109,2010-019912-18,enfermedad,i
109,2010-019912-18,FAMEs,i
109,2010-019912-18,tradicionales,o
109,2010-019912-18,en,o
109,2010-019912-18,pacientes,o
109,2010-019912-18,con,o
109,2010-019912-18,artritis,i
109,2010-019912-18,reumatoide,i
109,2010-019912-18,activa,o
109,2010-019912-18,moderada,o
109,2010-019912-18,a,o
109,2010-019912-18,severa,o
109,2010-019912-18,Indicacion,o
109,2010-019912-18,cientifica,o
109,2010-019912-18,Artritis,i
109,2010-019912-18,Reumatoide,i
109,2010-019912-18,AR,i
109,2010-019912-18,Criterios,o
109,2010-019912-18,de,o
109,2010-019912-18,inclusion,o
109,2010-019912-18,Presentar,o
109,2010-019912-18,artritis,i
109,2010-019912-18,reumatoide,i
109,2010-019912-18,de,o
109,2010-019912-18,mayor,o
109,2010-019912-18,o,o
109,2010-019912-18,igual,o
109,2010-019912-18,a,o
109,2010-019912-18,6,o
109,2010-019912-18,meses,o
109,2010-019912-18,de,o
109,2010-019912-18,duracion,o
109,2010-019912-18,Recibir,o
109,2010-019912-18,tratamiento,i
109,2010-019912-18,de,i
109,2010-019912-18,forma,i
109,2010-019912-18,ambulatoria,i
109,2010-019912-18,Presentar,o
109,2010-019912-18,un,o
109,2010-019912-18,recuento,o
109,2010-019912-18,de,o
109,2010-019912-18,articulaciones,i
109,2010-019912-18,inflamadas,i
109,2010-019912-18,RAI,o
109,2010-019912-18,mayor,o
109,2010-019912-18,o,o
109,2010-019912-18,igual,o
109,2010-019912-18,a,o
109,2010-019912-18,6,o
109,2010-019912-18,recuento,o
109,2010-019912-18,de,o
109,2010-019912-18,66,o
109,2010-019912-18,articulaciones,i
109,2010-019912-18,y,o
109,2010-019912-18,de,o
109,2010-019912-18,articulaciones,i
109,2010-019912-18,dolorosas,i
109,2010-019912-18,RAD,o
109,2010-019912-18,mayor,o
109,2010-019912-18,o,o
109,2010-019912-18,igual,o
109,2010-019912-18,a,o
109,2010-019912-18,8,o
109,2010-019912-18,recuento,o
109,2010-019912-18,de,o
109,2010-019912-18,68,o
109,2010-019912-18,articulaciones,i
109,2010-019912-18,en,o
109,2010-019912-18,las,o
109,2010-019912-18,visitas,o
109,2010-019912-18,de,o
109,2010-019912-18,seleccion,o
109,2010-019912-18,y,o
109,2010-019912-18,basal,o
109,2010-019912-18,Los,o
109,2010-019912-18,pacientes,o
109,2010-019912-18,deben,o
109,2010-019912-18,estar,o
109,2010-019912-18,recibiendo,o
109,2010-019912-18,tratamiento,i
109,2010-019912-18,con,o
109,2010-019912-18,una,o
109,2010-019912-18,dosis,o
109,2010-019912-18,estable,o
109,2010-019912-18,de,o
109,2010-019912-18,los,o
109,2010-019912-18,FAMEs,i
109,2010-019912-18,permitidos,o
109,2010-019912-18,como,o
109,2010-019912-18,minimo,o
109,2010-019912-18,8,o
109,2010-019912-18,semanas,o
109,2010-019912-18,antes,o
109,2010-019912-18,de,o
109,2010-019912-18,la,o
109,2010-019912-18,visita,o
109,2010-019912-18,basal,o
109,2010-019912-18,Criterios,o
109,2010-019912-18,de,o
109,2010-019912-18,exclusion,o
109,2010-019912-18,Pacientes,o
109,2010-019912-18,sometidos,o
109,2010-019912-18,a,o
109,2010-019912-18,intervenciones,i
109,2010-019912-18,de,i
109,2010-019912-18,cirugia,i
109,2010-019912-18,mayor,i
109,2010-019912-18,incluyendo,o
109,2010-019912-18,cirugia,i
109,2010-019912-18,articular,i
109,2010-019912-18,en,o
109,2010-019912-18,las,o
109,2010-019912-18,8,o
109,2010-019912-18,semanas,o
109,2010-019912-18,previas,o
109,2010-019912-18,a,o
109,2010-019912-18,la,o
109,2010-019912-18,visita,o
109,2010-019912-18,de,o
109,2010-019912-18,seleccion,o
109,2010-019912-18,o,o
109,2010-019912-18,que,o
109,2010-019912-18,tengan,o
109,2010-019912-18,previsto,o
109,2010-019912-18,someterse,o
109,2010-019912-18,a,o
109,2010-019912-18,una,o
109,2010-019912-18,intervencion,i
109,2010-019912-18,de,o
109,2010-019912-18,este,o
109,2010-019912-18,tipo,o
109,2010-019912-18,en,o
109,2010-019912-18,los,o
109,2010-019912-18,6,o
109,2010-019912-18,meses,o
109,2010-019912-18,siguientes,o
109,2010-019912-18,a,o
109,2010-019912-18,la,o
109,2010-019912-18,randomizacion,i
109,2010-019912-18,Enfermedad,i
109,2010-019912-18,reumatica,i
109,2010-019912-18,autoinmune,i
109,2010-019912-18,distinta,o
109,2010-019912-18,de,o
109,2010-019912-18,AR,i
109,2010-019912-18,Se,o
109,2010-019912-18,permite,o
109,2010-019912-18,la,o
109,2010-019912-18,inclusion,o
109,2010-019912-18,de,o
109,2010-019912-18,pacientes,o
109,2010-019912-18,con,o
109,2010-019912-18,sindrome,i
109,2010-019912-18,de,i
109,2010-019912-18,Sjögren,i
109,2010-019912-18,secundario,i
109,2010-019912-18,asociado,o
109,2010-019912-18,a,o
109,2010-019912-18,AR,i
109,2010-019912-18,Clase,o
109,2010-019912-18,funcional,o
109,2010-019912-18,IV,o
109,2010-019912-18,definida,o
109,2010-019912-18,de,o
109,2010-019912-18,acuerdo,o
109,2010-019912-18,con,o
109,2010-019912-18,la,o
109,2010-019912-18,Clasificacion,o
109,2010-019912-18,del,o
109,2010-019912-18,ACR,o
109,2010-019912-18,del,o
109,2010-019912-18,Estado,o
109,2010-019912-18,Funcional,o
109,2010-019912-18,en,o
109,2010-019912-18,Artritis,i
109,2010-019912-18,Reumatoide,i
109,2010-019912-18,Artritis,i
109,2010-019912-18,idiopatica,i
109,2010-019912-18,juvenil,i
109,2010-019912-18,AIJ,i
109,2010-019912-18,o,o
109,2010-019912-18,artritis,i
109,2010-019912-18,reumatoide,i
109,2010-019912-18,juvenil,i
109,2010-019912-18,ARJ,i
109,2010-019912-18,yo,o
109,2010-019912-18,AR,i
109,2010-019912-18,diagnosticadas,i
109,2010-019912-18,antes,o
109,2010-019912-18,de,o
109,2010-019912-18,los,o
109,2010-019912-18,16,o
109,2010-019912-18,años,o
109,2010-019912-18,de,o
109,2010-019912-18,edad,o
109,2010-019912-18,Enfermedad,i
109,2010-019912-18,articular,i
109,2010-019912-18,inflamatoria,i
109,2010-019912-18,distinta,o
109,2010-019912-18,de,o
109,2010-019912-18,AR,i
109,2010-019912-18,en,o
109,2010-019912-18,el,o
109,2010-019912-18,pasado,o
109,2010-019912-18,o,o
109,2010-019912-18,en,o
109,2010-019912-18,la,o
109,2010-019912-18,actualidad,o
110,2010-019912-18,EudraCT,o
110,2010-019912-18,Nº,o
110,2010-019912-18,201001991218,o
110,2010-019912-18,Titulo,o
110,2010-019912-18,cientifico,o
110,2010-019912-18,Estudio,o
110,2010-019912-18,randomizado,o
110,2010-019912-18,doble,o
110,2010-019912-18,ciego,o
110,2010-019912-18,con,o
110,2010-019912-18,grupos,o
110,2010-019912-18,de,o
110,2010-019912-18,tratamiento,i
110,2010-019912-18,paralelos,o
110,2010-019912-18,para,o
110,2010-019912-18,evaluar,i
110,2010-019912-18,la,i
110,2010-019912-18,seguridad,i
110,2010-019912-18,y,o
110,2010-019912-18,el,o
110,2010-019912-18,efecto,o
110,2010-019912-18,sobre,o
110,2010-019912-18,el,o
110,2010-019912-18,resultado,o
110,2010-019912-18,clinico,o
110,2010-019912-18,de,o
110,2010-019912-18,tocilizumab,i
110,2010-019912-18,SC,o
110,2010-019912-18,frente,o
110,2010-019912-18,a,o
110,2010-019912-18,placebo,i
110,2010-019912-18,SC,o
110,2010-019912-18,en,o
110,2010-019912-18,combinacion,o
110,2010-019912-18,con,o
110,2010-019912-18,farmacos,i
110,2010-019912-18,antirreumaticos,i
110,2010-019912-18,modificadores,i
110,2010-019912-18,de,i
110,2010-019912-18,la,i
110,2010-019912-18,enfermedad,i
110,2010-019912-18,FAMEs,i
110,2010-019912-18,tradicionales,o
110,2010-019912-18,en,o
110,2010-019912-18,pacientes,o
110,2010-019912-18,con,o
110,2010-019912-18,artritis,i
110,2010-019912-18,reumatoide,i
110,2010-019912-18,activa,o
110,2010-019912-18,moderada,o
110,2010-019912-18,a,o
110,2010-019912-18,severa,o
110,2010-019912-18,Indicacion,o
110,2010-019912-18,cientifica,o
110,2010-019912-18,Artritis,i
110,2010-019912-18,Reumatoide,i
110,2010-019912-18,AR,i
110,2010-019912-18,Criterios,o
110,2010-019912-18,de,o
110,2010-019912-18,inclusion,o
110,2010-019912-18,Presentar,o
110,2010-019912-18,artritis,i
110,2010-019912-18,reumatoide,i
110,2010-019912-18,de,o
110,2010-019912-18,mayor,o
110,2010-019912-18,o,o
110,2010-019912-18,igual,o
110,2010-019912-18,a,o
110,2010-019912-18,6,o
110,2010-019912-18,meses,o
110,2010-019912-18,de,o
110,2010-019912-18,duracion,o
110,2010-019912-18,Recibir,o
110,2010-019912-18,tratamiento,i
110,2010-019912-18,de,i
110,2010-019912-18,forma,i
110,2010-019912-18,ambulatoria,i
110,2010-019912-18,Presentar,o
110,2010-019912-18,un,o
110,2010-019912-18,recuento,o
110,2010-019912-18,de,o
110,2010-019912-18,articulaciones,i
110,2010-019912-18,inflamadas,i
110,2010-019912-18,RAI,o
110,2010-019912-18,mayor,o
110,2010-019912-18,o,o
110,2010-019912-18,igual,o
110,2010-019912-18,a,o
110,2010-019912-18,6,o
110,2010-019912-18,recuento,o
110,2010-019912-18,de,o
110,2010-019912-18,66,o
110,2010-019912-18,articulaciones,i
110,2010-019912-18,y,o
110,2010-019912-18,de,o
110,2010-019912-18,articulaciones,i
110,2010-019912-18,dolorosas,i
110,2010-019912-18,RAD,o
110,2010-019912-18,mayor,o
110,2010-019912-18,o,o
110,2010-019912-18,igual,o
110,2010-019912-18,a,o
110,2010-019912-18,8,o
110,2010-019912-18,recuento,o
110,2010-019912-18,de,o
110,2010-019912-18,68,o
110,2010-019912-18,articulaciones,i
110,2010-019912-18,en,o
110,2010-019912-18,las,o
110,2010-019912-18,visitas,o
110,2010-019912-18,de,o
110,2010-019912-18,seleccion,o
110,2010-019912-18,y,o
110,2010-019912-18,basal,o
110,2010-019912-18,Los,o
110,2010-019912-18,pacientes,o
110,2010-019912-18,deben,o
110,2010-019912-18,estar,o
110,2010-019912-18,recibiendo,o
110,2010-019912-18,tratamiento,i
110,2010-019912-18,con,o
110,2010-019912-18,una,o
110,2010-019912-18,dosis,o
110,2010-019912-18,estable,o
110,2010-019912-18,de,o
110,2010-019912-18,los,o
110,2010-019912-18,FAMEs,i
110,2010-019912-18,permitidos,o
110,2010-019912-18,como,o
110,2010-019912-18,minimo,o
110,2010-019912-18,8,o
110,2010-019912-18,semanas,o
110,2010-019912-18,antes,o
110,2010-019912-18,de,o
110,2010-019912-18,la,o
110,2010-019912-18,visita,o
110,2010-019912-18,basal,o
110,2010-019912-18,Criterios,o
110,2010-019912-18,de,o
110,2010-019912-18,exclusion,o
110,2010-019912-18,Pacientes,o
110,2010-019912-18,sometidos,o
110,2010-019912-18,a,o
110,2010-019912-18,intervenciones,i
110,2010-019912-18,de,i
110,2010-019912-18,cirugia,i
110,2010-019912-18,mayor,i
110,2010-019912-18,incluyendo,o
110,2010-019912-18,cirugia,i
110,2010-019912-18,articular,i
110,2010-019912-18,en,o
110,2010-019912-18,las,o
110,2010-019912-18,8,o
110,2010-019912-18,semanas,o
110,2010-019912-18,previas,o
110,2010-019912-18,a,o
110,2010-019912-18,la,o
110,2010-019912-18,visita,o
110,2010-019912-18,de,o
110,2010-019912-18,seleccion,o
110,2010-019912-18,o,o
110,2010-019912-18,que,o
110,2010-019912-18,tengan,o
110,2010-019912-18,previsto,o
110,2010-019912-18,someterse,o
110,2010-019912-18,a,o
110,2010-019912-18,una,o
110,2010-019912-18,intervencion,i
110,2010-019912-18,de,o
110,2010-019912-18,este,o
110,2010-019912-18,tipo,o
110,2010-019912-18,en,o
110,2010-019912-18,los,o
110,2010-019912-18,6,o
110,2010-019912-18,meses,o
110,2010-019912-18,siguientes,o
110,2010-019912-18,a,o
110,2010-019912-18,la,o
110,2010-019912-18,randomizacion,i
110,2010-019912-18,Enfermedad,i
110,2010-019912-18,reumatica,i
110,2010-019912-18,autoinmune,i
110,2010-019912-18,distinta,o
110,2010-019912-18,de,o
110,2010-019912-18,AR,i
110,2010-019912-18,Se,o
110,2010-019912-18,permite,o
110,2010-019912-18,la,o
110,2010-019912-18,inclusion,o
110,2010-019912-18,de,o
110,2010-019912-18,pacientes,o
110,2010-019912-18,con,o
110,2010-019912-18,sindrome,i
110,2010-019912-18,de,i
110,2010-019912-18,Sjögren,i
110,2010-019912-18,secundario,i
110,2010-019912-18,asociado,o
110,2010-019912-18,a,o
110,2010-019912-18,AR,i
110,2010-019912-18,Clase,o
110,2010-019912-18,funcional,o
110,2010-019912-18,IV,o
110,2010-019912-18,definida,o
110,2010-019912-18,de,o
110,2010-019912-18,acuerdo,o
110,2010-019912-18,con,o
110,2010-019912-18,la,o
110,2010-019912-18,Clasificacion,o
110,2010-019912-18,del,o
110,2010-019912-18,ACR,o
110,2010-019912-18,del,o
110,2010-019912-18,Estado,o
110,2010-019912-18,Funcional,o
110,2010-019912-18,en,o
110,2010-019912-18,Artritis,i
110,2010-019912-18,Reumatoide,i
110,2010-019912-18,Artritis,i
110,2010-019912-18,idiopatica,i
110,2010-019912-18,juvenil,i
110,2010-019912-18,AIJ,i
110,2010-019912-18,o,o
110,2010-019912-18,artritis,i
110,2010-019912-18,reumatoide,i
110,2010-019912-18,juvenil,i
110,2010-019912-18,ARJ,i
110,2010-019912-18,yo,o
110,2010-019912-18,AR,i
110,2010-019912-18,diagnosticadas,i
110,2010-019912-18,antes,o
110,2010-019912-18,de,o
110,2010-019912-18,los,o
110,2010-019912-18,16,o
110,2010-019912-18,años,o
110,2010-019912-18,de,o
110,2010-019912-18,edad,o
110,2010-019912-18,Enfermedad,i
110,2010-019912-18,articular,i
110,2010-019912-18,inflamatoria,i
110,2010-019912-18,distinta,o
110,2010-019912-18,de,o
110,2010-019912-18,AR,i
110,2010-019912-18,en,o
110,2010-019912-18,el,o
110,2010-019912-18,pasado,o
110,2010-019912-18,o,o
110,2010-019912-18,en,o
110,2010-019912-18,la,o
110,2010-019912-18,actualidad,o
111,2010-019912-18,EudraCT,o
111,2010-019912-18,Nº,o
111,2010-019912-18,201001991218,o
111,2010-019912-18,Titulo,o
111,2010-019912-18,cientifico,o
111,2010-019912-18,Estudio,o
111,2010-019912-18,randomizado,o
111,2010-019912-18,doble,o
111,2010-019912-18,ciego,o
111,2010-019912-18,con,o
111,2010-019912-18,grupos,o
111,2010-019912-18,de,o
111,2010-019912-18,tratamiento,i
111,2010-019912-18,paralelos,o
111,2010-019912-18,para,o
111,2010-019912-18,evaluar,i
111,2010-019912-18,la,i
111,2010-019912-18,seguridad,i
111,2010-019912-18,y,o
111,2010-019912-18,el,o
111,2010-019912-18,efecto,o
111,2010-019912-18,sobre,o
111,2010-019912-18,el,o
111,2010-019912-18,resultado,o
111,2010-019912-18,clinico,o
111,2010-019912-18,de,o
111,2010-019912-18,tocilizumab,i
111,2010-019912-18,SC,o
111,2010-019912-18,frente,o
111,2010-019912-18,a,o
111,2010-019912-18,placebo,i
111,2010-019912-18,SC,o
111,2010-019912-18,en,o
111,2010-019912-18,combinacion,o
111,2010-019912-18,con,o
111,2010-019912-18,farmacos,i
111,2010-019912-18,antirreumaticos,i
111,2010-019912-18,modificadores,i
111,2010-019912-18,de,i
111,2010-019912-18,la,i
111,2010-019912-18,enfermedad,i
111,2010-019912-18,FAMEs,i
111,2010-019912-18,tradicionales,o
111,2010-019912-18,en,o
111,2010-019912-18,pacientes,o
111,2010-019912-18,con,o
111,2010-019912-18,artritis,i
111,2010-019912-18,reumatoide,i
111,2010-019912-18,activa,o
111,2010-019912-18,moderada,o
111,2010-019912-18,a,o
111,2010-019912-18,severa,o
111,2010-019912-18,Indicacion,o
111,2010-019912-18,cientifica,o
111,2010-019912-18,Artritis,i
111,2010-019912-18,Reumatoide,i
111,2010-019912-18,AR,i
111,2010-019912-18,Criterios,o
111,2010-019912-18,de,o
111,2010-019912-18,inclusion,o
111,2010-019912-18,Presentar,o
111,2010-019912-18,artritis,i
111,2010-019912-18,reumatoide,i
111,2010-019912-18,de,o
111,2010-019912-18,mayor,o
111,2010-019912-18,o,o
111,2010-019912-18,igual,o
111,2010-019912-18,a,o
111,2010-019912-18,6,o
111,2010-019912-18,meses,o
111,2010-019912-18,de,o
111,2010-019912-18,duracion,o
111,2010-019912-18,Recibir,o
111,2010-019912-18,tratamiento,i
111,2010-019912-18,de,i
111,2010-019912-18,forma,i
111,2010-019912-18,ambulatoria,i
111,2010-019912-18,Presentar,o
111,2010-019912-18,un,o
111,2010-019912-18,recuento,o
111,2010-019912-18,de,o
111,2010-019912-18,articulaciones,i
111,2010-019912-18,inflamadas,i
111,2010-019912-18,RAI,o
111,2010-019912-18,mayor,o
111,2010-019912-18,o,o
111,2010-019912-18,igual,o
111,2010-019912-18,a,o
111,2010-019912-18,6,o
111,2010-019912-18,recuento,o
111,2010-019912-18,de,o
111,2010-019912-18,66,o
111,2010-019912-18,articulaciones,i
111,2010-019912-18,y,o
111,2010-019912-18,de,o
111,2010-019912-18,articulaciones,i
111,2010-019912-18,dolorosas,i
111,2010-019912-18,RAD,o
111,2010-019912-18,mayor,o
111,2010-019912-18,o,o
111,2010-019912-18,igual,o
111,2010-019912-18,a,o
111,2010-019912-18,8,o
111,2010-019912-18,recuento,o
111,2010-019912-18,de,o
111,2010-019912-18,68,o
111,2010-019912-18,articulaciones,i
111,2010-019912-18,en,o
111,2010-019912-18,las,o
111,2010-019912-18,visitas,o
111,2010-019912-18,de,o
111,2010-019912-18,seleccion,o
111,2010-019912-18,y,o
111,2010-019912-18,basal,o
111,2010-019912-18,Los,o
111,2010-019912-18,pacientes,o
111,2010-019912-18,deben,o
111,2010-019912-18,estar,o
111,2010-019912-18,recibiendo,o
111,2010-019912-18,tratamiento,i
111,2010-019912-18,con,o
111,2010-019912-18,una,o
111,2010-019912-18,dosis,o
111,2010-019912-18,estable,o
111,2010-019912-18,de,o
111,2010-019912-18,los,o
111,2010-019912-18,FAMEs,i
111,2010-019912-18,permitidos,o
111,2010-019912-18,como,o
111,2010-019912-18,minimo,o
111,2010-019912-18,8,o
111,2010-019912-18,semanas,o
111,2010-019912-18,antes,o
111,2010-019912-18,de,o
111,2010-019912-18,la,o
111,2010-019912-18,visita,o
111,2010-019912-18,basal,o
111,2010-019912-18,Criterios,o
111,2010-019912-18,de,o
111,2010-019912-18,exclusion,o
111,2010-019912-18,Pacientes,o
111,2010-019912-18,sometidos,o
111,2010-019912-18,a,o
111,2010-019912-18,intervenciones,i
111,2010-019912-18,de,i
111,2010-019912-18,cirugia,i
111,2010-019912-18,mayor,i
111,2010-019912-18,incluyendo,o
111,2010-019912-18,cirugia,i
111,2010-019912-18,articular,i
111,2010-019912-18,en,o
111,2010-019912-18,las,o
111,2010-019912-18,8,o
111,2010-019912-18,semanas,o
111,2010-019912-18,previas,o
111,2010-019912-18,a,o
111,2010-019912-18,la,o
111,2010-019912-18,visita,o
111,2010-019912-18,de,o
111,2010-019912-18,seleccion,o
111,2010-019912-18,o,o
111,2010-019912-18,que,o
111,2010-019912-18,tengan,o
111,2010-019912-18,previsto,o
111,2010-019912-18,someterse,o
111,2010-019912-18,a,o
111,2010-019912-18,una,o
111,2010-019912-18,intervencion,i
111,2010-019912-18,de,o
111,2010-019912-18,este,o
111,2010-019912-18,tipo,o
111,2010-019912-18,en,o
111,2010-019912-18,los,o
111,2010-019912-18,6,o
111,2010-019912-18,meses,o
111,2010-019912-18,siguientes,o
111,2010-019912-18,a,o
111,2010-019912-18,la,o
111,2010-019912-18,randomizacion,i
111,2010-019912-18,Enfermedad,i
111,2010-019912-18,reumatica,i
111,2010-019912-18,autoinmune,i
111,2010-019912-18,distinta,o
111,2010-019912-18,de,o
111,2010-019912-18,AR,i
111,2010-019912-18,Se,o
111,2010-019912-18,permite,o
111,2010-019912-18,la,o
111,2010-019912-18,inclusion,o
111,2010-019912-18,de,o
111,2010-019912-18,pacientes,o
111,2010-019912-18,con,o
111,2010-019912-18,sindrome,i
111,2010-019912-18,de,i
111,2010-019912-18,Sjögren,i
111,2010-019912-18,secundario,i
111,2010-019912-18,asociado,o
111,2010-019912-18,a,o
111,2010-019912-18,AR,i
111,2010-019912-18,Clase,o
111,2010-019912-18,funcional,o
111,2010-019912-18,IV,o
111,2010-019912-18,definida,o
111,2010-019912-18,de,o
111,2010-019912-18,acuerdo,o
111,2010-019912-18,con,o
111,2010-019912-18,la,o
111,2010-019912-18,Clasificacion,o
111,2010-019912-18,del,o
111,2010-019912-18,ACR,o
111,2010-019912-18,del,o
111,2010-019912-18,Estado,o
111,2010-019912-18,Funcional,o
111,2010-019912-18,en,o
111,2010-019912-18,Artritis,i
111,2010-019912-18,Reumatoide,i
111,2010-019912-18,Artritis,i
111,2010-019912-18,idiopatica,i
111,2010-019912-18,juvenil,i
111,2010-019912-18,AIJ,i
111,2010-019912-18,o,o
111,2010-019912-18,artritis,i
111,2010-019912-18,reumatoide,i
111,2010-019912-18,juvenil,i
111,2010-019912-18,ARJ,i
111,2010-019912-18,yo,o
111,2010-019912-18,AR,i
111,2010-019912-18,diagnosticadas,i
111,2010-019912-18,antes,o
111,2010-019912-18,de,o
111,2010-019912-18,los,o
111,2010-019912-18,16,o
111,2010-019912-18,años,o
111,2010-019912-18,de,o
111,2010-019912-18,edad,o
111,2010-019912-18,Enfermedad,i
111,2010-019912-18,articular,i
111,2010-019912-18,inflamatoria,i
111,2010-019912-18,distinta,o
111,2010-019912-18,de,o
111,2010-019912-18,AR,i
111,2010-019912-18,en,o
111,2010-019912-18,el,o
111,2010-019912-18,pasado,o
111,2010-019912-18,o,o
111,2010-019912-18,en,o
111,2010-019912-18,la,o
111,2010-019912-18,actualidad,o
112,2010-019912-18,EudraCT,o
112,2010-019912-18,Nº,o
112,2010-019912-18,201001991218,o
112,2010-019912-18,Titulo,o
112,2010-019912-18,cientifico,o
112,2010-019912-18,Estudio,o
112,2010-019912-18,randomizado,o
112,2010-019912-18,doble,o
112,2010-019912-18,ciego,o
112,2010-019912-18,con,o
112,2010-019912-18,grupos,o
112,2010-019912-18,de,o
112,2010-019912-18,tratamiento,i
112,2010-019912-18,paralelos,o
112,2010-019912-18,para,o
112,2010-019912-18,evaluar,i
112,2010-019912-18,la,i
112,2010-019912-18,seguridad,i
112,2010-019912-18,y,o
112,2010-019912-18,el,o
112,2010-019912-18,efecto,o
112,2010-019912-18,sobre,o
112,2010-019912-18,el,o
112,2010-019912-18,resultado,o
112,2010-019912-18,clinico,o
112,2010-019912-18,de,o
112,2010-019912-18,tocilizumab,i
112,2010-019912-18,SC,o
112,2010-019912-18,frente,o
112,2010-019912-18,a,o
112,2010-019912-18,placebo,i
112,2010-019912-18,SC,o
112,2010-019912-18,en,o
112,2010-019912-18,combinacion,o
112,2010-019912-18,con,o
112,2010-019912-18,farmacos,i
112,2010-019912-18,antirreumaticos,i
112,2010-019912-18,modificadores,i
112,2010-019912-18,de,i
112,2010-019912-18,la,i
112,2010-019912-18,enfermedad,i
112,2010-019912-18,FAMEs,i
112,2010-019912-18,tradicionales,o
112,2010-019912-18,en,o
112,2010-019912-18,pacientes,o
112,2010-019912-18,con,o
112,2010-019912-18,artritis,i
112,2010-019912-18,reumatoide,i
112,2010-019912-18,activa,o
112,2010-019912-18,moderada,o
112,2010-019912-18,a,o
112,2010-019912-18,severa,o
112,2010-019912-18,Indicacion,o
112,2010-019912-18,cientifica,o
112,2010-019912-18,Artritis,i
112,2010-019912-18,Reumatoide,i
112,2010-019912-18,AR,i
112,2010-019912-18,Criterios,o
112,2010-019912-18,de,o
112,2010-019912-18,inclusion,o
112,2010-019912-18,Presentar,o
112,2010-019912-18,artritis,i
112,2010-019912-18,reumatoide,i
112,2010-019912-18,de,o
112,2010-019912-18,mayor,o
112,2010-019912-18,o,o
112,2010-019912-18,igual,o
112,2010-019912-18,a,o
112,2010-019912-18,6,o
112,2010-019912-18,meses,o
112,2010-019912-18,de,o
112,2010-019912-18,duracion,o
112,2010-019912-18,Recibir,o
112,2010-019912-18,tratamiento,i
112,2010-019912-18,de,i
112,2010-019912-18,forma,i
112,2010-019912-18,ambulatoria,i
112,2010-019912-18,Presentar,o
112,2010-019912-18,un,o
112,2010-019912-18,recuento,o
112,2010-019912-18,de,o
112,2010-019912-18,articulaciones,i
112,2010-019912-18,inflamadas,i
112,2010-019912-18,RAI,o
112,2010-019912-18,mayor,o
112,2010-019912-18,o,o
112,2010-019912-18,igual,o
112,2010-019912-18,a,o
112,2010-019912-18,6,o
112,2010-019912-18,recuento,o
112,2010-019912-18,de,o
112,2010-019912-18,66,o
112,2010-019912-18,articulaciones,i
112,2010-019912-18,y,o
112,2010-019912-18,de,o
112,2010-019912-18,articulaciones,i
112,2010-019912-18,dolorosas,i
112,2010-019912-18,RAD,o
112,2010-019912-18,mayor,o
112,2010-019912-18,o,o
112,2010-019912-18,igual,o
112,2010-019912-18,a,o
112,2010-019912-18,8,o
112,2010-019912-18,recuento,o
112,2010-019912-18,de,o
112,2010-019912-18,68,o
112,2010-019912-18,articulaciones,i
112,2010-019912-18,en,o
112,2010-019912-18,las,o
112,2010-019912-18,visitas,o
112,2010-019912-18,de,o
112,2010-019912-18,seleccion,o
112,2010-019912-18,y,o
112,2010-019912-18,basal,o
112,2010-019912-18,Los,o
112,2010-019912-18,pacientes,o
112,2010-019912-18,deben,o
112,2010-019912-18,estar,o
112,2010-019912-18,recibiendo,o
112,2010-019912-18,tratamiento,i
112,2010-019912-18,con,o
112,2010-019912-18,una,o
112,2010-019912-18,dosis,o
112,2010-019912-18,estable,o
112,2010-019912-18,de,o
112,2010-019912-18,los,o
112,2010-019912-18,FAMEs,i
112,2010-019912-18,permitidos,o
112,2010-019912-18,como,o
112,2010-019912-18,minimo,o
112,2010-019912-18,8,o
112,2010-019912-18,semanas,o
112,2010-019912-18,antes,o
112,2010-019912-18,de,o
112,2010-019912-18,la,o
112,2010-019912-18,visita,o
112,2010-019912-18,basal,o
112,2010-019912-18,Criterios,o
112,2010-019912-18,de,o
112,2010-019912-18,exclusion,o
112,2010-019912-18,Pacientes,o
112,2010-019912-18,sometidos,o
112,2010-019912-18,a,o
112,2010-019912-18,intervenciones,i
112,2010-019912-18,de,i
112,2010-019912-18,cirugia,i
112,2010-019912-18,mayor,i
112,2010-019912-18,incluyendo,o
112,2010-019912-18,cirugia,i
112,2010-019912-18,articular,i
112,2010-019912-18,en,o
112,2010-019912-18,las,o
112,2010-019912-18,8,o
112,2010-019912-18,semanas,o
112,2010-019912-18,previas,o
112,2010-019912-18,a,o
112,2010-019912-18,la,o
112,2010-019912-18,visita,o
112,2010-019912-18,de,o
112,2010-019912-18,seleccion,o
112,2010-019912-18,o,o
112,2010-019912-18,que,o
112,2010-019912-18,tengan,o
112,2010-019912-18,previsto,o
112,2010-019912-18,someterse,o
112,2010-019912-18,a,o
112,2010-019912-18,una,o
112,2010-019912-18,intervencion,i
112,2010-019912-18,de,o
112,2010-019912-18,este,o
112,2010-019912-18,tipo,o
112,2010-019912-18,en,o
112,2010-019912-18,los,o
112,2010-019912-18,6,o
112,2010-019912-18,meses,o
112,2010-019912-18,siguientes,o
112,2010-019912-18,a,o
112,2010-019912-18,la,o
112,2010-019912-18,randomizacion,i
112,2010-019912-18,Enfermedad,i
112,2010-019912-18,reumatica,i
112,2010-019912-18,autoinmune,i
112,2010-019912-18,distinta,o
112,2010-019912-18,de,o
112,2010-019912-18,AR,i
112,2010-019912-18,Se,o
112,2010-019912-18,permite,o
112,2010-019912-18,la,o
112,2010-019912-18,inclusion,o
112,2010-019912-18,de,o
112,2010-019912-18,pacientes,o
112,2010-019912-18,con,o
112,2010-019912-18,sindrome,i
112,2010-019912-18,de,i
112,2010-019912-18,Sjögren,i
112,2010-019912-18,secundario,i
112,2010-019912-18,asociado,o
112,2010-019912-18,a,o
112,2010-019912-18,AR,i
112,2010-019912-18,Clase,o
112,2010-019912-18,funcional,o
112,2010-019912-18,IV,o
112,2010-019912-18,definida,o
112,2010-019912-18,de,o
112,2010-019912-18,acuerdo,o
112,2010-019912-18,con,o
112,2010-019912-18,la,o
112,2010-019912-18,Clasificacion,o
112,2010-019912-18,del,o
112,2010-019912-18,ACR,o
112,2010-019912-18,del,o
112,2010-019912-18,Estado,o
112,2010-019912-18,Funcional,o
112,2010-019912-18,en,o
112,2010-019912-18,Artritis,i
112,2010-019912-18,Reumatoide,i
112,2010-019912-18,Artritis,i
112,2010-019912-18,idiopatica,i
112,2010-019912-18,juvenil,i
112,2010-019912-18,AIJ,i
112,2010-019912-18,o,o
112,2010-019912-18,artritis,i
112,2010-019912-18,reumatoide,i
112,2010-019912-18,juvenil,i
112,2010-019912-18,ARJ,i
112,2010-019912-18,yo,o
112,2010-019912-18,AR,i
112,2010-019912-18,diagnosticadas,i
112,2010-019912-18,antes,o
112,2010-019912-18,de,o
112,2010-019912-18,los,o
112,2010-019912-18,16,o
112,2010-019912-18,años,o
112,2010-019912-18,de,o
112,2010-019912-18,edad,o
112,2010-019912-18,Enfermedad,i
112,2010-019912-18,articular,i
112,2010-019912-18,inflamatoria,i
112,2010-019912-18,distinta,o
112,2010-019912-18,de,o
112,2010-019912-18,AR,i
112,2010-019912-18,en,o
112,2010-019912-18,el,o
112,2010-019912-18,pasado,o
112,2010-019912-18,o,o
112,2010-019912-18,en,o
112,2010-019912-18,la,o
112,2010-019912-18,actualidad,o
113,2010-019912-18,EudraCT,o
113,2010-019912-18,Nº,o
113,2010-019912-18,201001991218,o
113,2010-019912-18,Titulo,o
113,2010-019912-18,cientifico,o
113,2010-019912-18,Estudio,o
113,2010-019912-18,randomizado,o
113,2010-019912-18,doble,o
113,2010-019912-18,ciego,o
113,2010-019912-18,con,o
113,2010-019912-18,grupos,o
113,2010-019912-18,de,o
113,2010-019912-18,tratamiento,i
113,2010-019912-18,paralelos,o
113,2010-019912-18,para,o
113,2010-019912-18,evaluar,i
113,2010-019912-18,la,i
113,2010-019912-18,seguridad,i
113,2010-019912-18,y,o
113,2010-019912-18,el,o
113,2010-019912-18,efecto,o
113,2010-019912-18,sobre,o
113,2010-019912-18,el,o
113,2010-019912-18,resultado,o
113,2010-019912-18,clinico,o
113,2010-019912-18,de,o
113,2010-019912-18,tocilizumab,i
113,2010-019912-18,SC,o
113,2010-019912-18,frente,o
113,2010-019912-18,a,o
113,2010-019912-18,placebo,i
113,2010-019912-18,SC,o
113,2010-019912-18,en,o
113,2010-019912-18,combinacion,o
113,2010-019912-18,con,o
113,2010-019912-18,farmacos,i
113,2010-019912-18,antirreumaticos,i
113,2010-019912-18,modificadores,i
113,2010-019912-18,de,i
113,2010-019912-18,la,i
113,2010-019912-18,enfermedad,i
113,2010-019912-18,FAMEs,i
113,2010-019912-18,tradicionales,o
113,2010-019912-18,en,o
113,2010-019912-18,pacientes,o
113,2010-019912-18,con,o
113,2010-019912-18,artritis,i
113,2010-019912-18,reumatoide,i
113,2010-019912-18,activa,o
113,2010-019912-18,moderada,o
113,2010-019912-18,a,o
113,2010-019912-18,severa,o
113,2010-019912-18,Indicacion,o
113,2010-019912-18,cientifica,o
113,2010-019912-18,Artritis,i
113,2010-019912-18,Reumatoide,i
113,2010-019912-18,AR,i
113,2010-019912-18,Criterios,o
113,2010-019912-18,de,o
113,2010-019912-18,inclusion,o
113,2010-019912-18,Presentar,o
113,2010-019912-18,artritis,i
113,2010-019912-18,reumatoide,i
113,2010-019912-18,de,o
113,2010-019912-18,mayor,o
113,2010-019912-18,o,o
113,2010-019912-18,igual,o
113,2010-019912-18,a,o
113,2010-019912-18,6,o
113,2010-019912-18,meses,o
113,2010-019912-18,de,o
113,2010-019912-18,duracion,o
113,2010-019912-18,Recibir,o
113,2010-019912-18,tratamiento,i
113,2010-019912-18,de,i
113,2010-019912-18,forma,i
113,2010-019912-18,ambulatoria,i
113,2010-019912-18,Presentar,o
113,2010-019912-18,un,o
113,2010-019912-18,recuento,o
113,2010-019912-18,de,o
113,2010-019912-18,articulaciones,i
113,2010-019912-18,inflamadas,i
113,2010-019912-18,RAI,o
113,2010-019912-18,mayor,o
113,2010-019912-18,o,o
113,2010-019912-18,igual,o
113,2010-019912-18,a,o
113,2010-019912-18,6,o
113,2010-019912-18,recuento,o
113,2010-019912-18,de,o
113,2010-019912-18,66,o
113,2010-019912-18,articulaciones,i
113,2010-019912-18,y,o
113,2010-019912-18,de,o
113,2010-019912-18,articulaciones,i
113,2010-019912-18,dolorosas,i
113,2010-019912-18,RAD,o
113,2010-019912-18,mayor,o
113,2010-019912-18,o,o
113,2010-019912-18,igual,o
113,2010-019912-18,a,o
113,2010-019912-18,8,o
113,2010-019912-18,recuento,o
113,2010-019912-18,de,o
113,2010-019912-18,68,o
113,2010-019912-18,articulaciones,i
113,2010-019912-18,en,o
113,2010-019912-18,las,o
113,2010-019912-18,visitas,o
113,2010-019912-18,de,o
113,2010-019912-18,seleccion,o
113,2010-019912-18,y,o
113,2010-019912-18,basal,o
113,2010-019912-18,Los,o
113,2010-019912-18,pacientes,o
113,2010-019912-18,deben,o
113,2010-019912-18,estar,o
113,2010-019912-18,recibiendo,o
113,2010-019912-18,tratamiento,i
113,2010-019912-18,con,o
113,2010-019912-18,una,o
113,2010-019912-18,dosis,o
113,2010-019912-18,estable,o
113,2010-019912-18,de,o
113,2010-019912-18,los,o
113,2010-019912-18,FAMEs,i
113,2010-019912-18,permitidos,o
113,2010-019912-18,como,o
113,2010-019912-18,minimo,o
113,2010-019912-18,8,o
113,2010-019912-18,semanas,o
113,2010-019912-18,antes,o
113,2010-019912-18,de,o
113,2010-019912-18,la,o
113,2010-019912-18,visita,o
113,2010-019912-18,basal,o
113,2010-019912-18,Criterios,o
113,2010-019912-18,de,o
113,2010-019912-18,exclusion,o
113,2010-019912-18,Pacientes,o
113,2010-019912-18,sometidos,o
113,2010-019912-18,a,o
113,2010-019912-18,intervenciones,i
113,2010-019912-18,de,i
113,2010-019912-18,cirugia,i
113,2010-019912-18,mayor,i
113,2010-019912-18,incluyendo,o
113,2010-019912-18,cirugia,i
113,2010-019912-18,articular,i
113,2010-019912-18,en,o
113,2010-019912-18,las,o
113,2010-019912-18,8,o
113,2010-019912-18,semanas,o
113,2010-019912-18,previas,o
113,2010-019912-18,a,o
113,2010-019912-18,la,o
113,2010-019912-18,visita,o
113,2010-019912-18,de,o
113,2010-019912-18,seleccion,o
113,2010-019912-18,o,o
113,2010-019912-18,que,o
113,2010-019912-18,tengan,o
113,2010-019912-18,previsto,o
113,2010-019912-18,someterse,o
113,2010-019912-18,a,o
113,2010-019912-18,una,o
113,2010-019912-18,intervencion,i
113,2010-019912-18,de,o
113,2010-019912-18,este,o
113,2010-019912-18,tipo,o
113,2010-019912-18,en,o
113,2010-019912-18,los,o
113,2010-019912-18,6,o
113,2010-019912-18,meses,o
113,2010-019912-18,siguientes,o
113,2010-019912-18,a,o
113,2010-019912-18,la,o
113,2010-019912-18,randomizacion,i
113,2010-019912-18,Enfermedad,i
113,2010-019912-18,reumatica,i
113,2010-019912-18,autoinmune,i
113,2010-019912-18,distinta,o
113,2010-019912-18,de,o
113,2010-019912-18,AR,i
113,2010-019912-18,Se,o
113,2010-019912-18,permite,o
113,2010-019912-18,la,o
113,2010-019912-18,inclusion,o
113,2010-019912-18,de,o
113,2010-019912-18,pacientes,o
113,2010-019912-18,con,o
113,2010-019912-18,sindrome,i
113,2010-019912-18,de,i
113,2010-019912-18,Sjögren,i
113,2010-019912-18,secundario,i
113,2010-019912-18,asociado,o
113,2010-019912-18,a,o
113,2010-019912-18,AR,i
113,2010-019912-18,Clase,o
113,2010-019912-18,funcional,o
113,2010-019912-18,IV,o
113,2010-019912-18,definida,o
113,2010-019912-18,de,o
113,2010-019912-18,acuerdo,o
113,2010-019912-18,con,o
113,2010-019912-18,la,o
113,2010-019912-18,Clasificacion,o
113,2010-019912-18,del,o
113,2010-019912-18,ACR,o
113,2010-019912-18,del,o
113,2010-019912-18,Estado,o
113,2010-019912-18,Funcional,o
113,2010-019912-18,en,o
113,2010-019912-18,Artritis,i
113,2010-019912-18,Reumatoide,i
113,2010-019912-18,Artritis,i
113,2010-019912-18,idiopatica,i
113,2010-019912-18,juvenil,i
113,2010-019912-18,AIJ,i
113,2010-019912-18,o,o
113,2010-019912-18,artritis,i
113,2010-019912-18,reumatoide,i
113,2010-019912-18,juvenil,i
113,2010-019912-18,ARJ,i
113,2010-019912-18,yo,o
113,2010-019912-18,AR,i
113,2010-019912-18,diagnosticadas,i
113,2010-019912-18,antes,o
113,2010-019912-18,de,o
113,2010-019912-18,los,o
113,2010-019912-18,16,o
113,2010-019912-18,años,o
113,2010-019912-18,de,o
113,2010-019912-18,edad,o
113,2010-019912-18,Enfermedad,i
113,2010-019912-18,articular,i
113,2010-019912-18,inflamatoria,i
113,2010-019912-18,distinta,o
113,2010-019912-18,de,o
113,2010-019912-18,AR,i
113,2010-019912-18,en,o
113,2010-019912-18,el,o
113,2010-019912-18,pasado,o
113,2010-019912-18,o,o
113,2010-019912-18,en,o
113,2010-019912-18,la,o
113,2010-019912-18,actualidad,o
114,2010-019912-18,EudraCT,o
114,2010-019912-18,Nº,o
114,2010-019912-18,201001991218,o
114,2010-019912-18,Titulo,o
114,2010-019912-18,cientifico,o
114,2010-019912-18,Estudio,o
114,2010-019912-18,randomizado,o
114,2010-019912-18,doble,o
114,2010-019912-18,ciego,o
114,2010-019912-18,con,o
114,2010-019912-18,grupos,o
114,2010-019912-18,de,o
114,2010-019912-18,tratamiento,i
114,2010-019912-18,paralelos,o
114,2010-019912-18,para,o
114,2010-019912-18,evaluar,i
114,2010-019912-18,la,i
114,2010-019912-18,seguridad,i
114,2010-019912-18,y,o
114,2010-019912-18,el,o
114,2010-019912-18,efecto,o
114,2010-019912-18,sobre,o
114,2010-019912-18,el,o
114,2010-019912-18,resultado,o
114,2010-019912-18,clinico,o
114,2010-019912-18,de,o
114,2010-019912-18,tocilizumab,i
114,2010-019912-18,SC,o
114,2010-019912-18,frente,o
114,2010-019912-18,a,o
114,2010-019912-18,placebo,i
114,2010-019912-18,SC,o
114,2010-019912-18,en,o
114,2010-019912-18,combinacion,o
114,2010-019912-18,con,o
114,2010-019912-18,farmacos,i
114,2010-019912-18,antirreumaticos,i
114,2010-019912-18,modificadores,i
114,2010-019912-18,de,i
114,2010-019912-18,la,i
114,2010-019912-18,enfermedad,i
114,2010-019912-18,FAMEs,i
114,2010-019912-18,tradicionales,o
114,2010-019912-18,en,o
114,2010-019912-18,pacientes,o
114,2010-019912-18,con,o
114,2010-019912-18,artritis,i
114,2010-019912-18,reumatoide,i
114,2010-019912-18,activa,o
114,2010-019912-18,moderada,o
114,2010-019912-18,a,o
114,2010-019912-18,severa,o
114,2010-019912-18,Indicacion,o
114,2010-019912-18,cientifica,o
114,2010-019912-18,Artritis,i
114,2010-019912-18,Reumatoide,i
114,2010-019912-18,AR,i
114,2010-019912-18,Criterios,o
114,2010-019912-18,de,o
114,2010-019912-18,inclusion,o
114,2010-019912-18,Presentar,o
114,2010-019912-18,artritis,i
114,2010-019912-18,reumatoide,i
114,2010-019912-18,de,o
114,2010-019912-18,mayor,o
114,2010-019912-18,o,o
114,2010-019912-18,igual,o
114,2010-019912-18,a,o
114,2010-019912-18,6,o
114,2010-019912-18,meses,o
114,2010-019912-18,de,o
114,2010-019912-18,duracion,o
114,2010-019912-18,Recibir,o
114,2010-019912-18,tratamiento,i
114,2010-019912-18,de,i
114,2010-019912-18,forma,i
114,2010-019912-18,ambulatoria,i
114,2010-019912-18,Presentar,o
114,2010-019912-18,un,o
114,2010-019912-18,recuento,o
114,2010-019912-18,de,o
114,2010-019912-18,articulaciones,i
114,2010-019912-18,inflamadas,i
114,2010-019912-18,RAI,o
114,2010-019912-18,mayor,o
114,2010-019912-18,o,o
114,2010-019912-18,igual,o
114,2010-019912-18,a,o
114,2010-019912-18,6,o
114,2010-019912-18,recuento,o
114,2010-019912-18,de,o
114,2010-019912-18,66,o
114,2010-019912-18,articulaciones,i
114,2010-019912-18,y,o
114,2010-019912-18,de,o
114,2010-019912-18,articulaciones,i
114,2010-019912-18,dolorosas,i
114,2010-019912-18,RAD,o
114,2010-019912-18,mayor,o
114,2010-019912-18,o,o
114,2010-019912-18,igual,o
114,2010-019912-18,a,o
114,2010-019912-18,8,o
114,2010-019912-18,recuento,o
114,2010-019912-18,de,o
114,2010-019912-18,68,o
114,2010-019912-18,articulaciones,i
114,2010-019912-18,en,o
114,2010-019912-18,las,o
114,2010-019912-18,visitas,o
114,2010-019912-18,de,o
114,2010-019912-18,seleccion,o
114,2010-019912-18,y,o
114,2010-019912-18,basal,o
114,2010-019912-18,Los,o
114,2010-019912-18,pacientes,o
114,2010-019912-18,deben,o
114,2010-019912-18,estar,o
114,2010-019912-18,recibiendo,o
114,2010-019912-18,tratamiento,i
114,2010-019912-18,con,o
114,2010-019912-18,una,o
114,2010-019912-18,dosis,o
114,2010-019912-18,estable,o
114,2010-019912-18,de,o
114,2010-019912-18,los,o
114,2010-019912-18,FAMEs,i
114,2010-019912-18,permitidos,o
114,2010-019912-18,como,o
114,2010-019912-18,minimo,o
114,2010-019912-18,8,o
114,2010-019912-18,semanas,o
114,2010-019912-18,antes,o
114,2010-019912-18,de,o
114,2010-019912-18,la,o
114,2010-019912-18,visita,o
114,2010-019912-18,basal,o
114,2010-019912-18,Criterios,o
114,2010-019912-18,de,o
114,2010-019912-18,exclusion,o
114,2010-019912-18,Pacientes,o
114,2010-019912-18,sometidos,o
114,2010-019912-18,a,o
114,2010-019912-18,intervenciones,i
114,2010-019912-18,de,i
114,2010-019912-18,cirugia,i
114,2010-019912-18,mayor,i
114,2010-019912-18,incluyendo,o
114,2010-019912-18,cirugia,i
114,2010-019912-18,articular,i
114,2010-019912-18,en,o
114,2010-019912-18,las,o
114,2010-019912-18,8,o
114,2010-019912-18,semanas,o
114,2010-019912-18,previas,o
114,2010-019912-18,a,o
114,2010-019912-18,la,o
114,2010-019912-18,visita,o
114,2010-019912-18,de,o
114,2010-019912-18,seleccion,o
114,2010-019912-18,o,o
114,2010-019912-18,que,o
114,2010-019912-18,tengan,o
114,2010-019912-18,previsto,o
114,2010-019912-18,someterse,o
114,2010-019912-18,a,o
114,2010-019912-18,una,o
114,2010-019912-18,intervencion,i
114,2010-019912-18,de,o
114,2010-019912-18,este,o
114,2010-019912-18,tipo,o
114,2010-019912-18,en,o
114,2010-019912-18,los,o
114,2010-019912-18,6,o
114,2010-019912-18,meses,o
114,2010-019912-18,siguientes,o
114,2010-019912-18,a,o
114,2010-019912-18,la,o
114,2010-019912-18,randomizacion,i
114,2010-019912-18,Enfermedad,i
114,2010-019912-18,reumatica,i
114,2010-019912-18,autoinmune,i
114,2010-019912-18,distinta,o
114,2010-019912-18,de,o
114,2010-019912-18,AR,i
114,2010-019912-18,Se,o
114,2010-019912-18,permite,o
114,2010-019912-18,la,o
114,2010-019912-18,inclusion,o
114,2010-019912-18,de,o
114,2010-019912-18,pacientes,o
114,2010-019912-18,con,o
114,2010-019912-18,sindrome,i
114,2010-019912-18,de,i
114,2010-019912-18,Sjögren,i
114,2010-019912-18,secundario,i
114,2010-019912-18,asociado,o
114,2010-019912-18,a,o
114,2010-019912-18,AR,i
114,2010-019912-18,Clase,o
114,2010-019912-18,funcional,o
114,2010-019912-18,IV,o
114,2010-019912-18,definida,o
114,2010-019912-18,de,o
114,2010-019912-18,acuerdo,o
114,2010-019912-18,con,o
114,2010-019912-18,la,o
114,2010-019912-18,Clasificacion,o
114,2010-019912-18,del,o
114,2010-019912-18,ACR,o
114,2010-019912-18,del,o
114,2010-019912-18,Estado,o
114,2010-019912-18,Funcional,o
114,2010-019912-18,en,o
114,2010-019912-18,Artritis,i
114,2010-019912-18,Reumatoide,i
114,2010-019912-18,Artritis,i
114,2010-019912-18,idiopatica,i
114,2010-019912-18,juvenil,i
114,2010-019912-18,AIJ,i
114,2010-019912-18,o,o
114,2010-019912-18,artritis,i
114,2010-019912-18,reumatoide,i
114,2010-019912-18,juvenil,i
114,2010-019912-18,ARJ,i
114,2010-019912-18,yo,o
114,2010-019912-18,AR,i
114,2010-019912-18,diagnosticadas,i
114,2010-019912-18,antes,o
114,2010-019912-18,de,o
114,2010-019912-18,los,o
114,2010-019912-18,16,o
114,2010-019912-18,años,o
114,2010-019912-18,de,o
114,2010-019912-18,edad,o
114,2010-019912-18,Enfermedad,i
114,2010-019912-18,articular,i
114,2010-019912-18,inflamatoria,i
114,2010-019912-18,distinta,o
114,2010-019912-18,de,o
114,2010-019912-18,AR,i
114,2010-019912-18,en,o
114,2010-019912-18,el,o
114,2010-019912-18,pasado,o
114,2010-019912-18,o,o
114,2010-019912-18,en,o
114,2010-019912-18,la,o
114,2010-019912-18,actualidad,o
115,2010-019912-18,EudraCT,o
115,2010-019912-18,Nº,o
115,2010-019912-18,201001991218,o
115,2010-019912-18,Titulo,o
115,2010-019912-18,cientifico,o
115,2010-019912-18,Estudio,o
115,2010-019912-18,randomizado,o
115,2010-019912-18,doble,o
115,2010-019912-18,ciego,o
115,2010-019912-18,con,o
115,2010-019912-18,grupos,o
115,2010-019912-18,de,o
115,2010-019912-18,tratamiento,i
115,2010-019912-18,paralelos,o
115,2010-019912-18,para,o
115,2010-019912-18,evaluar,i
115,2010-019912-18,la,i
115,2010-019912-18,seguridad,i
115,2010-019912-18,y,o
115,2010-019912-18,el,o
115,2010-019912-18,efecto,o
115,2010-019912-18,sobre,o
115,2010-019912-18,el,o
115,2010-019912-18,resultado,o
115,2010-019912-18,clinico,o
115,2010-019912-18,de,o
115,2010-019912-18,tocilizumab,i
115,2010-019912-18,SC,o
115,2010-019912-18,frente,o
115,2010-019912-18,a,o
115,2010-019912-18,placebo,i
115,2010-019912-18,SC,o
115,2010-019912-18,en,o
115,2010-019912-18,combinacion,o
115,2010-019912-18,con,o
115,2010-019912-18,farmacos,i
115,2010-019912-18,antirreumaticos,i
115,2010-019912-18,modificadores,i
115,2010-019912-18,de,i
115,2010-019912-18,la,i
115,2010-019912-18,enfermedad,i
115,2010-019912-18,FAMEs,i
115,2010-019912-18,tradicionales,o
115,2010-019912-18,en,o
115,2010-019912-18,pacientes,o
115,2010-019912-18,con,o
115,2010-019912-18,artritis,i
115,2010-019912-18,reumatoide,i
115,2010-019912-18,activa,o
115,2010-019912-18,moderada,o
115,2010-019912-18,a,o
115,2010-019912-18,severa,o
115,2010-019912-18,Indicacion,o
115,2010-019912-18,cientifica,o
115,2010-019912-18,Artritis,i
115,2010-019912-18,Reumatoide,i
115,2010-019912-18,AR,i
115,2010-019912-18,Criterios,o
115,2010-019912-18,de,o
115,2010-019912-18,inclusion,o
115,2010-019912-18,Presentar,o
115,2010-019912-18,artritis,i
115,2010-019912-18,reumatoide,i
115,2010-019912-18,de,o
115,2010-019912-18,mayor,o
115,2010-019912-18,o,o
115,2010-019912-18,igual,o
115,2010-019912-18,a,o
115,2010-019912-18,6,o
115,2010-019912-18,meses,o
115,2010-019912-18,de,o
115,2010-019912-18,duracion,o
115,2010-019912-18,Recibir,o
115,2010-019912-18,tratamiento,i
115,2010-019912-18,de,i
115,2010-019912-18,forma,i
115,2010-019912-18,ambulatoria,i
115,2010-019912-18,Presentar,o
115,2010-019912-18,un,o
115,2010-019912-18,recuento,o
115,2010-019912-18,de,o
115,2010-019912-18,articulaciones,i
115,2010-019912-18,inflamadas,i
115,2010-019912-18,RAI,o
115,2010-019912-18,mayor,o
115,2010-019912-18,o,o
115,2010-019912-18,igual,o
115,2010-019912-18,a,o
115,2010-019912-18,6,o
115,2010-019912-18,recuento,o
115,2010-019912-18,de,o
115,2010-019912-18,66,o
115,2010-019912-18,articulaciones,i
115,2010-019912-18,y,o
115,2010-019912-18,de,o
115,2010-019912-18,articulaciones,i
115,2010-019912-18,dolorosas,i
115,2010-019912-18,RAD,o
115,2010-019912-18,mayor,o
115,2010-019912-18,o,o
115,2010-019912-18,igual,o
115,2010-019912-18,a,o
115,2010-019912-18,8,o
115,2010-019912-18,recuento,o
115,2010-019912-18,de,o
115,2010-019912-18,68,o
115,2010-019912-18,articulaciones,i
115,2010-019912-18,en,o
115,2010-019912-18,las,o
115,2010-019912-18,visitas,o
115,2010-019912-18,de,o
115,2010-019912-18,seleccion,o
115,2010-019912-18,y,o
115,2010-019912-18,basal,o
115,2010-019912-18,Los,o
115,2010-019912-18,pacientes,o
115,2010-019912-18,deben,o
115,2010-019912-18,estar,o
115,2010-019912-18,recibiendo,o
115,2010-019912-18,tratamiento,i
115,2010-019912-18,con,o
115,2010-019912-18,una,o
115,2010-019912-18,dosis,o
115,2010-019912-18,estable,o
115,2010-019912-18,de,o
115,2010-019912-18,los,o
115,2010-019912-18,FAMEs,i
115,2010-019912-18,permitidos,o
115,2010-019912-18,como,o
115,2010-019912-18,minimo,o
115,2010-019912-18,8,o
115,2010-019912-18,semanas,o
115,2010-019912-18,antes,o
115,2010-019912-18,de,o
115,2010-019912-18,la,o
115,2010-019912-18,visita,o
115,2010-019912-18,basal,o
115,2010-019912-18,Criterios,o
115,2010-019912-18,de,o
115,2010-019912-18,exclusion,o
115,2010-019912-18,Pacientes,o
115,2010-019912-18,sometidos,o
115,2010-019912-18,a,o
115,2010-019912-18,intervenciones,i
115,2010-019912-18,de,i
115,2010-019912-18,cirugia,i
115,2010-019912-18,mayor,i
115,2010-019912-18,incluyendo,o
115,2010-019912-18,cirugia,i
115,2010-019912-18,articular,i
115,2010-019912-18,en,o
115,2010-019912-18,las,o
115,2010-019912-18,8,o
115,2010-019912-18,semanas,o
115,2010-019912-18,previas,o
115,2010-019912-18,a,o
115,2010-019912-18,la,o
115,2010-019912-18,visita,o
115,2010-019912-18,de,o
115,2010-019912-18,seleccion,o
115,2010-019912-18,o,o
115,2010-019912-18,que,o
115,2010-019912-18,tengan,o
115,2010-019912-18,previsto,o
115,2010-019912-18,someterse,o
115,2010-019912-18,a,o
115,2010-019912-18,una,o
115,2010-019912-18,intervencion,i
115,2010-019912-18,de,o
115,2010-019912-18,este,o
115,2010-019912-18,tipo,o
115,2010-019912-18,en,o
115,2010-019912-18,los,o
115,2010-019912-18,6,o
115,2010-019912-18,meses,o
115,2010-019912-18,siguientes,o
115,2010-019912-18,a,o
115,2010-019912-18,la,o
115,2010-019912-18,randomizacion,i
115,2010-019912-18,Enfermedad,i
115,2010-019912-18,reumatica,i
115,2010-019912-18,autoinmune,i
115,2010-019912-18,distinta,o
115,2010-019912-18,de,o
115,2010-019912-18,AR,i
115,2010-019912-18,Se,o
115,2010-019912-18,permite,o
115,2010-019912-18,la,o
115,2010-019912-18,inclusion,o
115,2010-019912-18,de,o
115,2010-019912-18,pacientes,o
115,2010-019912-18,con,o
115,2010-019912-18,sindrome,i
115,2010-019912-18,de,i
115,2010-019912-18,Sjögren,i
115,2010-019912-18,secundario,i
115,2010-019912-18,asociado,o
115,2010-019912-18,a,o
115,2010-019912-18,AR,i
115,2010-019912-18,Clase,o
115,2010-019912-18,funcional,o
115,2010-019912-18,IV,o
115,2010-019912-18,definida,o
115,2010-019912-18,de,o
115,2010-019912-18,acuerdo,o
115,2010-019912-18,con,o
115,2010-019912-18,la,o
115,2010-019912-18,Clasificacion,o
115,2010-019912-18,del,o
115,2010-019912-18,ACR,o
115,2010-019912-18,del,o
115,2010-019912-18,Estado,o
115,2010-019912-18,Funcional,o
115,2010-019912-18,en,o
115,2010-019912-18,Artritis,i
115,2010-019912-18,Reumatoide,i
115,2010-019912-18,Artritis,i
115,2010-019912-18,idiopatica,i
115,2010-019912-18,juvenil,i
115,2010-019912-18,AIJ,i
115,2010-019912-18,o,o
115,2010-019912-18,artritis,i
115,2010-019912-18,reumatoide,i
115,2010-019912-18,juvenil,i
115,2010-019912-18,ARJ,i
115,2010-019912-18,yo,o
115,2010-019912-18,AR,i
115,2010-019912-18,diagnosticadas,i
115,2010-019912-18,antes,o
115,2010-019912-18,de,o
115,2010-019912-18,los,o
115,2010-019912-18,16,o
115,2010-019912-18,años,o
115,2010-019912-18,de,o
115,2010-019912-18,edad,o
115,2010-019912-18,Enfermedad,i
115,2010-019912-18,articular,i
115,2010-019912-18,inflamatoria,i
115,2010-019912-18,distinta,o
115,2010-019912-18,de,o
115,2010-019912-18,AR,i
115,2010-019912-18,en,o
115,2010-019912-18,el,o
115,2010-019912-18,pasado,o
115,2010-019912-18,o,o
115,2010-019912-18,en,o
115,2010-019912-18,la,o
115,2010-019912-18,actualidad,o
116,2010-019912-18,EudraCT,o
116,2010-019912-18,Nº,o
116,2010-019912-18,201001991218,o
116,2010-019912-18,Titulo,o
116,2010-019912-18,cientifico,o
116,2010-019912-18,Estudio,o
116,2010-019912-18,randomizado,o
116,2010-019912-18,doble,o
116,2010-019912-18,ciego,o
116,2010-019912-18,con,o
116,2010-019912-18,grupos,o
116,2010-019912-18,de,o
116,2010-019912-18,tratamiento,i
116,2010-019912-18,paralelos,o
116,2010-019912-18,para,o
116,2010-019912-18,evaluar,i
116,2010-019912-18,la,i
116,2010-019912-18,seguridad,i
116,2010-019912-18,y,o
116,2010-019912-18,el,o
116,2010-019912-18,efecto,o
116,2010-019912-18,sobre,o
116,2010-019912-18,el,o
116,2010-019912-18,resultado,o
116,2010-019912-18,clinico,o
116,2010-019912-18,de,o
116,2010-019912-18,tocilizumab,i
116,2010-019912-18,SC,o
116,2010-019912-18,frente,o
116,2010-019912-18,a,o
116,2010-019912-18,placebo,i
116,2010-019912-18,SC,o
116,2010-019912-18,en,o
116,2010-019912-18,combinacion,o
116,2010-019912-18,con,o
116,2010-019912-18,farmacos,i
116,2010-019912-18,antirreumaticos,i
116,2010-019912-18,modificadores,i
116,2010-019912-18,de,i
116,2010-019912-18,la,i
116,2010-019912-18,enfermedad,i
116,2010-019912-18,FAMEs,i
116,2010-019912-18,tradicionales,o
116,2010-019912-18,en,o
116,2010-019912-18,pacientes,o
116,2010-019912-18,con,o
116,2010-019912-18,artritis,i
116,2010-019912-18,reumatoide,i
116,2010-019912-18,activa,o
116,2010-019912-18,moderada,o
116,2010-019912-18,a,o
116,2010-019912-18,severa,o
116,2010-019912-18,Indicacion,o
116,2010-019912-18,cientifica,o
116,2010-019912-18,Artritis,i
116,2010-019912-18,Reumatoide,i
116,2010-019912-18,AR,i
116,2010-019912-18,Criterios,o
116,2010-019912-18,de,o
116,2010-019912-18,inclusion,o
116,2010-019912-18,Presentar,o
116,2010-019912-18,artritis,i
116,2010-019912-18,reumatoide,i
116,2010-019912-18,de,o
116,2010-019912-18,mayor,o
116,2010-019912-18,o,o
116,2010-019912-18,igual,o
116,2010-019912-18,a,o
116,2010-019912-18,6,o
116,2010-019912-18,meses,o
116,2010-019912-18,de,o
116,2010-019912-18,duracion,o
116,2010-019912-18,Recibir,o
116,2010-019912-18,tratamiento,i
116,2010-019912-18,de,i
116,2010-019912-18,forma,i
116,2010-019912-18,ambulatoria,i
116,2010-019912-18,Presentar,o
116,2010-019912-18,un,o
116,2010-019912-18,recuento,o
116,2010-019912-18,de,o
116,2010-019912-18,articulaciones,i
116,2010-019912-18,inflamadas,i
116,2010-019912-18,RAI,o
116,2010-019912-18,mayor,o
116,2010-019912-18,o,o
116,2010-019912-18,igual,o
116,2010-019912-18,a,o
116,2010-019912-18,6,o
116,2010-019912-18,recuento,o
116,2010-019912-18,de,o
116,2010-019912-18,66,o
116,2010-019912-18,articulaciones,i
116,2010-019912-18,y,o
116,2010-019912-18,de,o
116,2010-019912-18,articulaciones,i
116,2010-019912-18,dolorosas,i
116,2010-019912-18,RAD,o
116,2010-019912-18,mayor,o
116,2010-019912-18,o,o
116,2010-019912-18,igual,o
116,2010-019912-18,a,o
116,2010-019912-18,8,o
116,2010-019912-18,recuento,o
116,2010-019912-18,de,o
116,2010-019912-18,68,o
116,2010-019912-18,articulaciones,i
116,2010-019912-18,en,o
116,2010-019912-18,las,o
116,2010-019912-18,visitas,o
116,2010-019912-18,de,o
116,2010-019912-18,seleccion,o
116,2010-019912-18,y,o
116,2010-019912-18,basal,o
116,2010-019912-18,Los,o
116,2010-019912-18,pacientes,o
116,2010-019912-18,deben,o
116,2010-019912-18,estar,o
116,2010-019912-18,recibiendo,o
116,2010-019912-18,tratamiento,i
116,2010-019912-18,con,o
116,2010-019912-18,una,o
116,2010-019912-18,dosis,o
116,2010-019912-18,estable,o
116,2010-019912-18,de,o
116,2010-019912-18,los,o
116,2010-019912-18,FAMEs,i
116,2010-019912-18,permitidos,o
116,2010-019912-18,como,o
116,2010-019912-18,minimo,o
116,2010-019912-18,8,o
116,2010-019912-18,semanas,o
116,2010-019912-18,antes,o
116,2010-019912-18,de,o
116,2010-019912-18,la,o
116,2010-019912-18,visita,o
116,2010-019912-18,basal,o
116,2010-019912-18,Criterios,o
116,2010-019912-18,de,o
116,2010-019912-18,exclusion,o
116,2010-019912-18,Pacientes,o
116,2010-019912-18,sometidos,o
116,2010-019912-18,a,o
116,2010-019912-18,intervenciones,i
116,2010-019912-18,de,i
116,2010-019912-18,cirugia,i
116,2010-019912-18,mayor,i
116,2010-019912-18,incluyendo,o
116,2010-019912-18,cirugia,i
116,2010-019912-18,articular,i
116,2010-019912-18,en,o
116,2010-019912-18,las,o
116,2010-019912-18,8,o
116,2010-019912-18,semanas,o
116,2010-019912-18,previas,o
116,2010-019912-18,a,o
116,2010-019912-18,la,o
116,2010-019912-18,visita,o
116,2010-019912-18,de,o
116,2010-019912-18,seleccion,o
116,2010-019912-18,o,o
116,2010-019912-18,que,o
116,2010-019912-18,tengan,o
116,2010-019912-18,previsto,o
116,2010-019912-18,someterse,o
116,2010-019912-18,a,o
116,2010-019912-18,una,o
116,2010-019912-18,intervencion,i
116,2010-019912-18,de,o
116,2010-019912-18,este,o
116,2010-019912-18,tipo,o
116,2010-019912-18,en,o
116,2010-019912-18,los,o
116,2010-019912-18,6,o
116,2010-019912-18,meses,o
116,2010-019912-18,siguientes,o
116,2010-019912-18,a,o
116,2010-019912-18,la,o
116,2010-019912-18,randomizacion,i
116,2010-019912-18,Enfermedad,i
116,2010-019912-18,reumatica,i
116,2010-019912-18,autoinmune,i
116,2010-019912-18,distinta,o
116,2010-019912-18,de,o
116,2010-019912-18,AR,i
116,2010-019912-18,Se,o
116,2010-019912-18,permite,o
116,2010-019912-18,la,o
116,2010-019912-18,inclusion,o
116,2010-019912-18,de,o
116,2010-019912-18,pacientes,o
116,2010-019912-18,con,o
116,2010-019912-18,sindrome,i
116,2010-019912-18,de,i
116,2010-019912-18,Sjögren,i
116,2010-019912-18,secundario,i
116,2010-019912-18,asociado,o
116,2010-019912-18,a,o
116,2010-019912-18,AR,i
116,2010-019912-18,Clase,o
116,2010-019912-18,funcional,o
116,2010-019912-18,IV,o
116,2010-019912-18,definida,o
116,2010-019912-18,de,o
116,2010-019912-18,acuerdo,o
116,2010-019912-18,con,o
116,2010-019912-18,la,o
116,2010-019912-18,Clasificacion,o
116,2010-019912-18,del,o
116,2010-019912-18,ACR,o
116,2010-019912-18,del,o
116,2010-019912-18,Estado,o
116,2010-019912-18,Funcional,o
116,2010-019912-18,en,o
116,2010-019912-18,Artritis,i
116,2010-019912-18,Reumatoide,i
116,2010-019912-18,Artritis,i
116,2010-019912-18,idiopatica,i
116,2010-019912-18,juvenil,i
116,2010-019912-18,AIJ,i
116,2010-019912-18,o,o
116,2010-019912-18,artritis,i
116,2010-019912-18,reumatoide,i
116,2010-019912-18,juvenil,i
116,2010-019912-18,ARJ,i
116,2010-019912-18,yo,o
116,2010-019912-18,AR,i
116,2010-019912-18,diagnosticadas,i
116,2010-019912-18,antes,o
116,2010-019912-18,de,o
116,2010-019912-18,los,o
116,2010-019912-18,16,o
116,2010-019912-18,años,o
116,2010-019912-18,de,o
116,2010-019912-18,edad,o
116,2010-019912-18,Enfermedad,i
116,2010-019912-18,articular,i
116,2010-019912-18,inflamatoria,i
116,2010-019912-18,distinta,o
116,2010-019912-18,de,o
116,2010-019912-18,AR,i
116,2010-019912-18,en,o
116,2010-019912-18,el,o
116,2010-019912-18,pasado,o
116,2010-019912-18,o,o
116,2010-019912-18,en,o
116,2010-019912-18,la,o
116,2010-019912-18,actualidad,o
117,2010-019912-18,EudraCT,o
117,2010-019912-18,Nº,o
117,2010-019912-18,201001991218,o
117,2010-019912-18,Titulo,o
117,2010-019912-18,cientifico,o
117,2010-019912-18,Estudio,o
117,2010-019912-18,randomizado,o
117,2010-019912-18,doble,o
117,2010-019912-18,ciego,o
117,2010-019912-18,con,o
117,2010-019912-18,grupos,o
117,2010-019912-18,de,o
117,2010-019912-18,tratamiento,i
117,2010-019912-18,paralelos,o
117,2010-019912-18,para,o
117,2010-019912-18,evaluar,i
117,2010-019912-18,la,i
117,2010-019912-18,seguridad,i
117,2010-019912-18,y,o
117,2010-019912-18,el,o
117,2010-019912-18,efecto,o
117,2010-019912-18,sobre,o
117,2010-019912-18,el,o
117,2010-019912-18,resultado,o
117,2010-019912-18,clinico,o
117,2010-019912-18,de,o
117,2010-019912-18,tocilizumab,i
117,2010-019912-18,SC,o
117,2010-019912-18,frente,o
117,2010-019912-18,a,o
117,2010-019912-18,placebo,i
117,2010-019912-18,SC,o
117,2010-019912-18,en,o
117,2010-019912-18,combinacion,o
117,2010-019912-18,con,o
117,2010-019912-18,farmacos,i
117,2010-019912-18,antirreumaticos,i
117,2010-019912-18,modificadores,i
117,2010-019912-18,de,i
117,2010-019912-18,la,i
117,2010-019912-18,enfermedad,i
117,2010-019912-18,FAMEs,i
117,2010-019912-18,tradicionales,o
117,2010-019912-18,en,o
117,2010-019912-18,pacientes,o
117,2010-019912-18,con,o
117,2010-019912-18,artritis,i
117,2010-019912-18,reumatoide,i
117,2010-019912-18,activa,o
117,2010-019912-18,moderada,o
117,2010-019912-18,a,o
117,2010-019912-18,severa,o
117,2010-019912-18,Indicacion,o
117,2010-019912-18,cientifica,o
117,2010-019912-18,Artritis,i
117,2010-019912-18,Reumatoide,i
117,2010-019912-18,AR,i
117,2010-019912-18,Criterios,o
117,2010-019912-18,de,o
117,2010-019912-18,inclusion,o
117,2010-019912-18,Presentar,o
117,2010-019912-18,artritis,i
117,2010-019912-18,reumatoide,i
117,2010-019912-18,de,o
117,2010-019912-18,mayor,o
117,2010-019912-18,o,o
117,2010-019912-18,igual,o
117,2010-019912-18,a,o
117,2010-019912-18,6,o
117,2010-019912-18,meses,o
117,2010-019912-18,de,o
117,2010-019912-18,duracion,o
117,2010-019912-18,Recibir,o
117,2010-019912-18,tratamiento,i
117,2010-019912-18,de,i
117,2010-019912-18,forma,i
117,2010-019912-18,ambulatoria,i
117,2010-019912-18,Presentar,o
117,2010-019912-18,un,o
117,2010-019912-18,recuento,o
117,2010-019912-18,de,o
117,2010-019912-18,articulaciones,i
117,2010-019912-18,inflamadas,i
117,2010-019912-18,RAI,o
117,2010-019912-18,mayor,o
117,2010-019912-18,o,o
117,2010-019912-18,igual,o
117,2010-019912-18,a,o
117,2010-019912-18,6,o
117,2010-019912-18,recuento,o
117,2010-019912-18,de,o
117,2010-019912-18,66,o
117,2010-019912-18,articulaciones,i
117,2010-019912-18,y,o
117,2010-019912-18,de,o
117,2010-019912-18,articulaciones,i
117,2010-019912-18,dolorosas,i
117,2010-019912-18,RAD,o
117,2010-019912-18,mayor,o
117,2010-019912-18,o,o
117,2010-019912-18,igual,o
117,2010-019912-18,a,o
117,2010-019912-18,8,o
117,2010-019912-18,recuento,o
117,2010-019912-18,de,o
117,2010-019912-18,68,o
117,2010-019912-18,articulaciones,i
117,2010-019912-18,en,o
117,2010-019912-18,las,o
117,2010-019912-18,visitas,o
117,2010-019912-18,de,o
117,2010-019912-18,seleccion,o
117,2010-019912-18,y,o
117,2010-019912-18,basal,o
117,2010-019912-18,Los,o
117,2010-019912-18,pacientes,o
117,2010-019912-18,deben,o
117,2010-019912-18,estar,o
117,2010-019912-18,recibiendo,o
117,2010-019912-18,tratamiento,i
117,2010-019912-18,con,o
117,2010-019912-18,una,o
117,2010-019912-18,dosis,o
117,2010-019912-18,estable,o
117,2010-019912-18,de,o
117,2010-019912-18,los,o
117,2010-019912-18,FAMEs,i
117,2010-019912-18,permitidos,o
117,2010-019912-18,como,o
117,2010-019912-18,minimo,o
117,2010-019912-18,8,o
117,2010-019912-18,semanas,o
117,2010-019912-18,antes,o
117,2010-019912-18,de,o
117,2010-019912-18,la,o
117,2010-019912-18,visita,o
117,2010-019912-18,basal,o
117,2010-019912-18,Criterios,o
117,2010-019912-18,de,o
117,2010-019912-18,exclusion,o
117,2010-019912-18,Pacientes,o
117,2010-019912-18,sometidos,o
117,2010-019912-18,a,o
117,2010-019912-18,intervenciones,i
117,2010-019912-18,de,i
117,2010-019912-18,cirugia,i
117,2010-019912-18,mayor,i
117,2010-019912-18,incluyendo,o
117,2010-019912-18,cirugia,i
117,2010-019912-18,articular,i
117,2010-019912-18,en,o
117,2010-019912-18,las,o
117,2010-019912-18,8,o
117,2010-019912-18,semanas,o
117,2010-019912-18,previas,o
117,2010-019912-18,a,o
117,2010-019912-18,la,o
117,2010-019912-18,visita,o
117,2010-019912-18,de,o
117,2010-019912-18,seleccion,o
117,2010-019912-18,o,o
117,2010-019912-18,que,o
117,2010-019912-18,tengan,o
117,2010-019912-18,previsto,o
117,2010-019912-18,someterse,o
117,2010-019912-18,a,o
117,2010-019912-18,una,o
117,2010-019912-18,intervencion,i
117,2010-019912-18,de,o
117,2010-019912-18,este,o
117,2010-019912-18,tipo,o
117,2010-019912-18,en,o
117,2010-019912-18,los,o
117,2010-019912-18,6,o
117,2010-019912-18,meses,o
117,2010-019912-18,siguientes,o
117,2010-019912-18,a,o
117,2010-019912-18,la,o
117,2010-019912-18,randomizacion,i
117,2010-019912-18,Enfermedad,i
117,2010-019912-18,reumatica,i
117,2010-019912-18,autoinmune,i
117,2010-019912-18,distinta,o
117,2010-019912-18,de,o
117,2010-019912-18,AR,i
117,2010-019912-18,Se,o
117,2010-019912-18,permite,o
117,2010-019912-18,la,o
117,2010-019912-18,inclusion,o
117,2010-019912-18,de,o
117,2010-019912-18,pacientes,o
117,2010-019912-18,con,o
117,2010-019912-18,sindrome,i
117,2010-019912-18,de,i
117,2010-019912-18,Sjögren,i
117,2010-019912-18,secundario,i
117,2010-019912-18,asociado,o
117,2010-019912-18,a,o
117,2010-019912-18,AR,i
117,2010-019912-18,Clase,o
117,2010-019912-18,funcional,o
117,2010-019912-18,IV,o
117,2010-019912-18,definida,o
117,2010-019912-18,de,o
117,2010-019912-18,acuerdo,o
117,2010-019912-18,con,o
117,2010-019912-18,la,o
117,2010-019912-18,Clasificacion,o
117,2010-019912-18,del,o
117,2010-019912-18,ACR,o
117,2010-019912-18,del,o
117,2010-019912-18,Estado,o
117,2010-019912-18,Funcional,o
117,2010-019912-18,en,o
117,2010-019912-18,Artritis,i
117,2010-019912-18,Reumatoide,i
117,2010-019912-18,Artritis,i
117,2010-019912-18,idiopatica,i
117,2010-019912-18,juvenil,i
117,2010-019912-18,AIJ,i
117,2010-019912-18,o,o
117,2010-019912-18,artritis,i
117,2010-019912-18,reumatoide,i
117,2010-019912-18,juvenil,i
117,2010-019912-18,ARJ,i
117,2010-019912-18,yo,o
117,2010-019912-18,AR,i
117,2010-019912-18,diagnosticadas,i
117,2010-019912-18,antes,o
117,2010-019912-18,de,o
117,2010-019912-18,los,o
117,2010-019912-18,16,o
117,2010-019912-18,años,o
117,2010-019912-18,de,o
117,2010-019912-18,edad,o
117,2010-019912-18,Enfermedad,i
117,2010-019912-18,articular,i
117,2010-019912-18,inflamatoria,i
117,2010-019912-18,distinta,o
117,2010-019912-18,de,o
117,2010-019912-18,AR,i
117,2010-019912-18,en,o
117,2010-019912-18,el,o
117,2010-019912-18,pasado,o
117,2010-019912-18,o,o
117,2010-019912-18,en,o
117,2010-019912-18,la,o
117,2010-019912-18,actualidad,o
118,2010-019912-18,EudraCT,o
118,2010-019912-18,Nº,o
118,2010-019912-18,201001991218,o
118,2010-019912-18,Titulo,o
118,2010-019912-18,cientifico,o
118,2010-019912-18,Estudio,o
118,2010-019912-18,randomizado,o
118,2010-019912-18,doble,o
118,2010-019912-18,ciego,o
118,2010-019912-18,con,o
118,2010-019912-18,grupos,o
118,2010-019912-18,de,o
118,2010-019912-18,tratamiento,i
118,2010-019912-18,paralelos,o
118,2010-019912-18,para,o
118,2010-019912-18,evaluar,i
118,2010-019912-18,la,i
118,2010-019912-18,seguridad,i
118,2010-019912-18,y,o
118,2010-019912-18,el,o
118,2010-019912-18,efecto,o
118,2010-019912-18,sobre,o
118,2010-019912-18,el,o
118,2010-019912-18,resultado,o
118,2010-019912-18,clinico,o
118,2010-019912-18,de,o
118,2010-019912-18,tocilizumab,i
118,2010-019912-18,SC,o
118,2010-019912-18,frente,o
118,2010-019912-18,a,o
118,2010-019912-18,placebo,i
118,2010-019912-18,SC,o
118,2010-019912-18,en,o
118,2010-019912-18,combinacion,o
118,2010-019912-18,con,o
118,2010-019912-18,farmacos,i
118,2010-019912-18,antirreumaticos,i
118,2010-019912-18,modificadores,i
118,2010-019912-18,de,i
118,2010-019912-18,la,i
118,2010-019912-18,enfermedad,i
118,2010-019912-18,FAMEs,i
118,2010-019912-18,tradicionales,o
118,2010-019912-18,en,o
118,2010-019912-18,pacientes,o
118,2010-019912-18,con,o
118,2010-019912-18,artritis,i
118,2010-019912-18,reumatoide,i
118,2010-019912-18,activa,o
118,2010-019912-18,moderada,o
118,2010-019912-18,a,o
118,2010-019912-18,severa,o
118,2010-019912-18,Indicacion,o
118,2010-019912-18,cientifica,o
118,2010-019912-18,Artritis,i
118,2010-019912-18,Reumatoide,i
118,2010-019912-18,AR,i
118,2010-019912-18,Criterios,o
118,2010-019912-18,de,o
118,2010-019912-18,inclusion,o
118,2010-019912-18,Presentar,o
118,2010-019912-18,artritis,i
118,2010-019912-18,reumatoide,i
118,2010-019912-18,de,o
118,2010-019912-18,mayor,o
118,2010-019912-18,o,o
118,2010-019912-18,igual,o
118,2010-019912-18,a,o
118,2010-019912-18,6,o
118,2010-019912-18,meses,o
118,2010-019912-18,de,o
118,2010-019912-18,duracion,o
118,2010-019912-18,Recibir,o
118,2010-019912-18,tratamiento,i
118,2010-019912-18,de,i
118,2010-019912-18,forma,i
118,2010-019912-18,ambulatoria,i
118,2010-019912-18,Presentar,o
118,2010-019912-18,un,o
118,2010-019912-18,recuento,o
118,2010-019912-18,de,o
118,2010-019912-18,articulaciones,i
118,2010-019912-18,inflamadas,i
118,2010-019912-18,RAI,o
118,2010-019912-18,mayor,o
118,2010-019912-18,o,o
118,2010-019912-18,igual,o
118,2010-019912-18,a,o
118,2010-019912-18,6,o
118,2010-019912-18,recuento,o
118,2010-019912-18,de,o
118,2010-019912-18,66,o
118,2010-019912-18,articulaciones,i
118,2010-019912-18,y,o
118,2010-019912-18,de,o
118,2010-019912-18,articulaciones,i
118,2010-019912-18,dolorosas,i
118,2010-019912-18,RAD,o
118,2010-019912-18,mayor,o
118,2010-019912-18,o,o
118,2010-019912-18,igual,o
118,2010-019912-18,a,o
118,2010-019912-18,8,o
118,2010-019912-18,recuento,o
118,2010-019912-18,de,o
118,2010-019912-18,68,o
118,2010-019912-18,articulaciones,i
118,2010-019912-18,en,o
118,2010-019912-18,las,o
118,2010-019912-18,visitas,o
118,2010-019912-18,de,o
118,2010-019912-18,seleccion,o
118,2010-019912-18,y,o
118,2010-019912-18,basal,o
118,2010-019912-18,Los,o
118,2010-019912-18,pacientes,o
118,2010-019912-18,deben,o
118,2010-019912-18,estar,o
118,2010-019912-18,recibiendo,o
118,2010-019912-18,tratamiento,i
118,2010-019912-18,con,o
118,2010-019912-18,una,o
118,2010-019912-18,dosis,o
118,2010-019912-18,estable,o
118,2010-019912-18,de,o
118,2010-019912-18,los,o
118,2010-019912-18,FAMEs,i
118,2010-019912-18,permitidos,o
118,2010-019912-18,como,o
118,2010-019912-18,minimo,o
118,2010-019912-18,8,o
118,2010-019912-18,semanas,o
118,2010-019912-18,antes,o
118,2010-019912-18,de,o
118,2010-019912-18,la,o
118,2010-019912-18,visita,o
118,2010-019912-18,basal,o
118,2010-019912-18,Criterios,o
118,2010-019912-18,de,o
118,2010-019912-18,exclusion,o
118,2010-019912-18,Pacientes,o
118,2010-019912-18,sometidos,o
118,2010-019912-18,a,o
118,2010-019912-18,intervenciones,i
118,2010-019912-18,de,i
118,2010-019912-18,cirugia,i
118,2010-019912-18,mayor,i
118,2010-019912-18,incluyendo,o
118,2010-019912-18,cirugia,i
118,2010-019912-18,articular,i
118,2010-019912-18,en,o
118,2010-019912-18,las,o
118,2010-019912-18,8,o
118,2010-019912-18,semanas,o
118,2010-019912-18,previas,o
118,2010-019912-18,a,o
118,2010-019912-18,la,o
118,2010-019912-18,visita,o
118,2010-019912-18,de,o
118,2010-019912-18,seleccion,o
118,2010-019912-18,o,o
118,2010-019912-18,que,o
118,2010-019912-18,tengan,o
118,2010-019912-18,previsto,o
118,2010-019912-18,someterse,o
118,2010-019912-18,a,o
118,2010-019912-18,una,o
118,2010-019912-18,intervencion,i
118,2010-019912-18,de,o
118,2010-019912-18,este,o
118,2010-019912-18,tipo,o
118,2010-019912-18,en,o
118,2010-019912-18,los,o
118,2010-019912-18,6,o
118,2010-019912-18,meses,o
118,2010-019912-18,siguientes,o
118,2010-019912-18,a,o
118,2010-019912-18,la,o
118,2010-019912-18,randomizacion,i
118,2010-019912-18,Enfermedad,i
118,2010-019912-18,reumatica,i
118,2010-019912-18,autoinmune,i
118,2010-019912-18,distinta,o
118,2010-019912-18,de,o
118,2010-019912-18,AR,i
118,2010-019912-18,Se,o
118,2010-019912-18,permite,o
118,2010-019912-18,la,o
118,2010-019912-18,inclusion,o
118,2010-019912-18,de,o
118,2010-019912-18,pacientes,o
118,2010-019912-18,con,o
118,2010-019912-18,sindrome,i
118,2010-019912-18,de,i
118,2010-019912-18,Sjögren,i
118,2010-019912-18,secundario,i
118,2010-019912-18,asociado,o
118,2010-019912-18,a,o
118,2010-019912-18,AR,i
118,2010-019912-18,Clase,o
118,2010-019912-18,funcional,o
118,2010-019912-18,IV,o
118,2010-019912-18,definida,o
118,2010-019912-18,de,o
118,2010-019912-18,acuerdo,o
118,2010-019912-18,con,o
118,2010-019912-18,la,o
118,2010-019912-18,Clasificacion,o
118,2010-019912-18,del,o
118,2010-019912-18,ACR,o
118,2010-019912-18,del,o
118,2010-019912-18,Estado,o
118,2010-019912-18,Funcional,o
118,2010-019912-18,en,o
118,2010-019912-18,Artritis,i
118,2010-019912-18,Reumatoide,i
118,2010-019912-18,Artritis,i
118,2010-019912-18,idiopatica,i
118,2010-019912-18,juvenil,i
118,2010-019912-18,AIJ,i
118,2010-019912-18,o,o
118,2010-019912-18,artritis,i
118,2010-019912-18,reumatoide,i
118,2010-019912-18,juvenil,i
118,2010-019912-18,ARJ,i
118,2010-019912-18,yo,o
118,2010-019912-18,AR,i
118,2010-019912-18,diagnosticadas,i
118,2010-019912-18,antes,o
118,2010-019912-18,de,o
118,2010-019912-18,los,o
118,2010-019912-18,16,o
118,2010-019912-18,años,o
118,2010-019912-18,de,o
118,2010-019912-18,edad,o
118,2010-019912-18,Enfermedad,i
118,2010-019912-18,articular,i
118,2010-019912-18,inflamatoria,i
118,2010-019912-18,distinta,o
118,2010-019912-18,de,o
118,2010-019912-18,AR,i
118,2010-019912-18,en,o
118,2010-019912-18,el,o
118,2010-019912-18,pasado,o
118,2010-019912-18,o,o
118,2010-019912-18,en,o
118,2010-019912-18,la,o
118,2010-019912-18,actualidad,o
119,2010-019912-18,EudraCT,o
119,2010-019912-18,Nº,o
119,2010-019912-18,201001991218,o
119,2010-019912-18,Titulo,o
119,2010-019912-18,cientifico,o
119,2010-019912-18,Estudio,o
119,2010-019912-18,randomizado,o
119,2010-019912-18,doble,o
119,2010-019912-18,ciego,o
119,2010-019912-18,con,o
119,2010-019912-18,grupos,o
119,2010-019912-18,de,o
119,2010-019912-18,tratamiento,i
119,2010-019912-18,paralelos,o
119,2010-019912-18,para,o
119,2010-019912-18,evaluar,i
119,2010-019912-18,la,i
119,2010-019912-18,seguridad,i
119,2010-019912-18,y,o
119,2010-019912-18,el,o
119,2010-019912-18,efecto,o
119,2010-019912-18,sobre,o
119,2010-019912-18,el,o
119,2010-019912-18,resultado,o
119,2010-019912-18,clinico,o
119,2010-019912-18,de,o
119,2010-019912-18,tocilizumab,i
119,2010-019912-18,SC,o
119,2010-019912-18,frente,o
119,2010-019912-18,a,o
119,2010-019912-18,placebo,i
119,2010-019912-18,SC,o
119,2010-019912-18,en,o
119,2010-019912-18,combinacion,o
119,2010-019912-18,con,o
119,2010-019912-18,farmacos,i
119,2010-019912-18,antirreumaticos,i
119,2010-019912-18,modificadores,i
119,2010-019912-18,de,i
119,2010-019912-18,la,i
119,2010-019912-18,enfermedad,i
119,2010-019912-18,FAMEs,i
119,2010-019912-18,tradicionales,o
119,2010-019912-18,en,o
119,2010-019912-18,pacientes,o
119,2010-019912-18,con,o
119,2010-019912-18,artritis,i
119,2010-019912-18,reumatoide,i
119,2010-019912-18,activa,o
119,2010-019912-18,moderada,o
119,2010-019912-18,a,o
119,2010-019912-18,severa,o
119,2010-019912-18,Indicacion,o
119,2010-019912-18,cientifica,o
119,2010-019912-18,Artritis,i
119,2010-019912-18,Reumatoide,i
119,2010-019912-18,AR,i
119,2010-019912-18,Criterios,o
119,2010-019912-18,de,o
119,2010-019912-18,inclusion,o
119,2010-019912-18,Presentar,o
119,2010-019912-18,artritis,i
119,2010-019912-18,reumatoide,i
119,2010-019912-18,de,o
119,2010-019912-18,mayor,o
119,2010-019912-18,o,o
119,2010-019912-18,igual,o
119,2010-019912-18,a,o
119,2010-019912-18,6,o
119,2010-019912-18,meses,o
119,2010-019912-18,de,o
119,2010-019912-18,duracion,o
119,2010-019912-18,Recibir,o
119,2010-019912-18,tratamiento,i
119,2010-019912-18,de,i
119,2010-019912-18,forma,i
119,2010-019912-18,ambulatoria,i
119,2010-019912-18,Presentar,o
119,2010-019912-18,un,o
119,2010-019912-18,recuento,o
119,2010-019912-18,de,o
119,2010-019912-18,articulaciones,i
119,2010-019912-18,inflamadas,i
119,2010-019912-18,RAI,o
119,2010-019912-18,mayor,o
119,2010-019912-18,o,o
119,2010-019912-18,igual,o
119,2010-019912-18,a,o
119,2010-019912-18,6,o
119,2010-019912-18,recuento,o
119,2010-019912-18,de,o
119,2010-019912-18,66,o
119,2010-019912-18,articulaciones,i
119,2010-019912-18,y,o
119,2010-019912-18,de,o
119,2010-019912-18,articulaciones,i
119,2010-019912-18,dolorosas,i
119,2010-019912-18,RAD,o
119,2010-019912-18,mayor,o
119,2010-019912-18,o,o
119,2010-019912-18,igual,o
119,2010-019912-18,a,o
119,2010-019912-18,8,o
119,2010-019912-18,recuento,o
119,2010-019912-18,de,o
119,2010-019912-18,68,o
119,2010-019912-18,articulaciones,i
119,2010-019912-18,en,o
119,2010-019912-18,las,o
119,2010-019912-18,visitas,o
119,2010-019912-18,de,o
119,2010-019912-18,seleccion,o
119,2010-019912-18,y,o
119,2010-019912-18,basal,o
119,2010-019912-18,Los,o
119,2010-019912-18,pacientes,o
119,2010-019912-18,deben,o
119,2010-019912-18,estar,o
119,2010-019912-18,recibiendo,o
119,2010-019912-18,tratamiento,i
119,2010-019912-18,con,o
119,2010-019912-18,una,o
119,2010-019912-18,dosis,o
119,2010-019912-18,estable,o
119,2010-019912-18,de,o
119,2010-019912-18,los,o
119,2010-019912-18,FAMEs,i
119,2010-019912-18,permitidos,o
119,2010-019912-18,como,o
119,2010-019912-18,minimo,o
119,2010-019912-18,8,o
119,2010-019912-18,semanas,o
119,2010-019912-18,antes,o
119,2010-019912-18,de,o
119,2010-019912-18,la,o
119,2010-019912-18,visita,o
119,2010-019912-18,basal,o
119,2010-019912-18,Criterios,o
119,2010-019912-18,de,o
119,2010-019912-18,exclusion,o
119,2010-019912-18,Pacientes,o
119,2010-019912-18,sometidos,o
119,2010-019912-18,a,o
119,2010-019912-18,intervenciones,i
119,2010-019912-18,de,i
119,2010-019912-18,cirugia,i
119,2010-019912-18,mayor,i
119,2010-019912-18,incluyendo,o
119,2010-019912-18,cirugia,i
119,2010-019912-18,articular,i
119,2010-019912-18,en,o
119,2010-019912-18,las,o
119,2010-019912-18,8,o
119,2010-019912-18,semanas,o
119,2010-019912-18,previas,o
119,2010-019912-18,a,o
119,2010-019912-18,la,o
119,2010-019912-18,visita,o
119,2010-019912-18,de,o
119,2010-019912-18,seleccion,o
119,2010-019912-18,o,o
119,2010-019912-18,que,o
119,2010-019912-18,tengan,o
119,2010-019912-18,previsto,o
119,2010-019912-18,someterse,o
119,2010-019912-18,a,o
119,2010-019912-18,una,o
119,2010-019912-18,intervencion,i
119,2010-019912-18,de,o
119,2010-019912-18,este,o
119,2010-019912-18,tipo,o
119,2010-019912-18,en,o
119,2010-019912-18,los,o
119,2010-019912-18,6,o
119,2010-019912-18,meses,o
119,2010-019912-18,siguientes,o
119,2010-019912-18,a,o
119,2010-019912-18,la,o
119,2010-019912-18,randomizacion,i
119,2010-019912-18,Enfermedad,i
119,2010-019912-18,reumatica,i
119,2010-019912-18,autoinmune,i
119,2010-019912-18,distinta,o
119,2010-019912-18,de,o
119,2010-019912-18,AR,i
119,2010-019912-18,Se,o
119,2010-019912-18,permite,o
119,2010-019912-18,la,o
119,2010-019912-18,inclusion,o
119,2010-019912-18,de,o
119,2010-019912-18,pacientes,o
119,2010-019912-18,con,o
119,2010-019912-18,sindrome,i
119,2010-019912-18,de,i
119,2010-019912-18,Sjögren,i
119,2010-019912-18,secundario,i
119,2010-019912-18,asociado,o
119,2010-019912-18,a,o
119,2010-019912-18,AR,i
119,2010-019912-18,Clase,o
119,2010-019912-18,funcional,o
119,2010-019912-18,IV,o
119,2010-019912-18,definida,o
119,2010-019912-18,de,o
119,2010-019912-18,acuerdo,o
119,2010-019912-18,con,o
119,2010-019912-18,la,o
119,2010-019912-18,Clasificacion,o
119,2010-019912-18,del,o
119,2010-019912-18,ACR,o
119,2010-019912-18,del,o
119,2010-019912-18,Estado,o
119,2010-019912-18,Funcional,o
119,2010-019912-18,en,o
119,2010-019912-18,Artritis,i
119,2010-019912-18,Reumatoide,i
119,2010-019912-18,Artritis,i
119,2010-019912-18,idiopatica,i
119,2010-019912-18,juvenil,i
119,2010-019912-18,AIJ,i
119,2010-019912-18,o,o
119,2010-019912-18,artritis,i
119,2010-019912-18,reumatoide,i
119,2010-019912-18,juvenil,i
119,2010-019912-18,ARJ,i
119,2010-019912-18,yo,o
119,2010-019912-18,AR,i
119,2010-019912-18,diagnosticadas,i
119,2010-019912-18,antes,o
119,2010-019912-18,de,o
119,2010-019912-18,los,o
119,2010-019912-18,16,o
119,2010-019912-18,años,o
119,2010-019912-18,de,o
119,2010-019912-18,edad,o
119,2010-019912-18,Enfermedad,i
119,2010-019912-18,articular,i
119,2010-019912-18,inflamatoria,i
119,2010-019912-18,distinta,o
119,2010-019912-18,de,o
119,2010-019912-18,AR,i
119,2010-019912-18,en,o
119,2010-019912-18,el,o
119,2010-019912-18,pasado,o
119,2010-019912-18,o,o
119,2010-019912-18,en,o
119,2010-019912-18,la,o
119,2010-019912-18,actualidad,o
120,2010-019912-18,EudraCT,o
120,2010-019912-18,Nº,o
120,2010-019912-18,201001991218,o
120,2010-019912-18,Titulo,o
120,2010-019912-18,cientifico,o
120,2010-019912-18,Estudio,o
120,2010-019912-18,randomizado,o
120,2010-019912-18,doble,o
120,2010-019912-18,ciego,o
120,2010-019912-18,con,o
120,2010-019912-18,grupos,o
120,2010-019912-18,de,o
120,2010-019912-18,tratamiento,i
120,2010-019912-18,paralelos,o
120,2010-019912-18,para,o
120,2010-019912-18,evaluar,i
120,2010-019912-18,la,i
120,2010-019912-18,seguridad,i
120,2010-019912-18,y,o
120,2010-019912-18,el,o
120,2010-019912-18,efecto,o
120,2010-019912-18,sobre,o
120,2010-019912-18,el,o
120,2010-019912-18,resultado,o
120,2010-019912-18,clinico,o
120,2010-019912-18,de,o
120,2010-019912-18,tocilizumab,i
120,2010-019912-18,SC,o
120,2010-019912-18,frente,o
120,2010-019912-18,a,o
120,2010-019912-18,placebo,i
120,2010-019912-18,SC,o
120,2010-019912-18,en,o
120,2010-019912-18,combinacion,o
120,2010-019912-18,con,o
120,2010-019912-18,farmacos,i
120,2010-019912-18,antirreumaticos,i
120,2010-019912-18,modificadores,i
120,2010-019912-18,de,i
120,2010-019912-18,la,i
120,2010-019912-18,enfermedad,i
120,2010-019912-18,FAMEs,i
120,2010-019912-18,tradicionales,o
120,2010-019912-18,en,o
120,2010-019912-18,pacientes,o
120,2010-019912-18,con,o
120,2010-019912-18,artritis,i
120,2010-019912-18,reumatoide,i
120,2010-019912-18,activa,o
120,2010-019912-18,moderada,o
120,2010-019912-18,a,o
120,2010-019912-18,severa,o
120,2010-019912-18,Indicacion,o
120,2010-019912-18,cientifica,o
120,2010-019912-18,Artritis,i
120,2010-019912-18,Reumatoide,i
120,2010-019912-18,AR,i
120,2010-019912-18,Criterios,o
120,2010-019912-18,de,o
120,2010-019912-18,inclusion,o
120,2010-019912-18,Presentar,o
120,2010-019912-18,artritis,i
120,2010-019912-18,reumatoide,i
120,2010-019912-18,de,o
120,2010-019912-18,mayor,o
120,2010-019912-18,o,o
120,2010-019912-18,igual,o
120,2010-019912-18,a,o
120,2010-019912-18,6,o
120,2010-019912-18,meses,o
120,2010-019912-18,de,o
120,2010-019912-18,duracion,o
120,2010-019912-18,Recibir,o
120,2010-019912-18,tratamiento,i
120,2010-019912-18,de,i
120,2010-019912-18,forma,i
120,2010-019912-18,ambulatoria,i
120,2010-019912-18,Presentar,o
120,2010-019912-18,un,o
120,2010-019912-18,recuento,o
120,2010-019912-18,de,o
120,2010-019912-18,articulaciones,i
120,2010-019912-18,inflamadas,i
120,2010-019912-18,RAI,o
120,2010-019912-18,mayor,o
120,2010-019912-18,o,o
120,2010-019912-18,igual,o
120,2010-019912-18,a,o
120,2010-019912-18,6,o
120,2010-019912-18,recuento,o
120,2010-019912-18,de,o
120,2010-019912-18,66,o
120,2010-019912-18,articulaciones,i
120,2010-019912-18,y,o
120,2010-019912-18,de,o
120,2010-019912-18,articulaciones,i
120,2010-019912-18,dolorosas,i
120,2010-019912-18,RAD,o
120,2010-019912-18,mayor,o
120,2010-019912-18,o,o
120,2010-019912-18,igual,o
120,2010-019912-18,a,o
120,2010-019912-18,8,o
120,2010-019912-18,recuento,o
120,2010-019912-18,de,o
120,2010-019912-18,68,o
120,2010-019912-18,articulaciones,i
120,2010-019912-18,en,o
120,2010-019912-18,las,o
120,2010-019912-18,visitas,o
120,2010-019912-18,de,o
120,2010-019912-18,seleccion,o
120,2010-019912-18,y,o
120,2010-019912-18,basal,o
120,2010-019912-18,Los,o
120,2010-019912-18,pacientes,o
120,2010-019912-18,deben,o
120,2010-019912-18,estar,o
120,2010-019912-18,recibiendo,o
120,2010-019912-18,tratamiento,i
120,2010-019912-18,con,o
120,2010-019912-18,una,o
120,2010-019912-18,dosis,o
120,2010-019912-18,estable,o
120,2010-019912-18,de,o
120,2010-019912-18,los,o
120,2010-019912-18,FAMEs,i
120,2010-019912-18,permitidos,o
120,2010-019912-18,como,o
120,2010-019912-18,minimo,o
120,2010-019912-18,8,o
120,2010-019912-18,semanas,o
120,2010-019912-18,antes,o
120,2010-019912-18,de,o
120,2010-019912-18,la,o
120,2010-019912-18,visita,o
120,2010-019912-18,basal,o
120,2010-019912-18,Criterios,o
120,2010-019912-18,de,o
120,2010-019912-18,exclusion,o
120,2010-019912-18,Pacientes,o
120,2010-019912-18,sometidos,o
120,2010-019912-18,a,o
120,2010-019912-18,intervenciones,i
120,2010-019912-18,de,i
120,2010-019912-18,cirugia,i
120,2010-019912-18,mayor,i
120,2010-019912-18,incluyendo,o
120,2010-019912-18,cirugia,i
120,2010-019912-18,articular,i
120,2010-019912-18,en,o
120,2010-019912-18,las,o
120,2010-019912-18,8,o
120,2010-019912-18,semanas,o
120,2010-019912-18,previas,o
120,2010-019912-18,a,o
120,2010-019912-18,la,o
120,2010-019912-18,visita,o
120,2010-019912-18,de,o
120,2010-019912-18,seleccion,o
120,2010-019912-18,o,o
120,2010-019912-18,que,o
120,2010-019912-18,tengan,o
120,2010-019912-18,previsto,o
120,2010-019912-18,someterse,o
120,2010-019912-18,a,o
120,2010-019912-18,una,o
120,2010-019912-18,intervencion,i
120,2010-019912-18,de,o
120,2010-019912-18,este,o
120,2010-019912-18,tipo,o
120,2010-019912-18,en,o
120,2010-019912-18,los,o
120,2010-019912-18,6,o
120,2010-019912-18,meses,o
120,2010-019912-18,siguientes,o
120,2010-019912-18,a,o
120,2010-019912-18,la,o
120,2010-019912-18,randomizacion,i
120,2010-019912-18,Enfermedad,i
120,2010-019912-18,reumatica,i
120,2010-019912-18,autoinmune,i
120,2010-019912-18,distinta,o
120,2010-019912-18,de,o
120,2010-019912-18,AR,i
120,2010-019912-18,Se,o
120,2010-019912-18,permite,o
120,2010-019912-18,la,o
120,2010-019912-18,inclusion,o
120,2010-019912-18,de,o
120,2010-019912-18,pacientes,o
120,2010-019912-18,con,o
120,2010-019912-18,sindrome,i
120,2010-019912-18,de,i
120,2010-019912-18,Sjögren,i
120,2010-019912-18,secundario,i
120,2010-019912-18,asociado,o
120,2010-019912-18,a,o
120,2010-019912-18,AR,i
120,2010-019912-18,Clase,o
120,2010-019912-18,funcional,o
120,2010-019912-18,IV,o
120,2010-019912-18,definida,o
120,2010-019912-18,de,o
120,2010-019912-18,acuerdo,o
120,2010-019912-18,con,o
120,2010-019912-18,la,o
120,2010-019912-18,Clasificacion,o
120,2010-019912-18,del,o
120,2010-019912-18,ACR,o
120,2010-019912-18,del,o
120,2010-019912-18,Estado,o
120,2010-019912-18,Funcional,o
120,2010-019912-18,en,o
120,2010-019912-18,Artritis,i
120,2010-019912-18,Reumatoide,i
120,2010-019912-18,Artritis,i
120,2010-019912-18,idiopatica,i
120,2010-019912-18,juvenil,i
120,2010-019912-18,AIJ,i
120,2010-019912-18,o,o
120,2010-019912-18,artritis,i
120,2010-019912-18,reumatoide,i
120,2010-019912-18,juvenil,i
120,2010-019912-18,ARJ,i
120,2010-019912-18,yo,o
120,2010-019912-18,AR,i
120,2010-019912-18,diagnosticadas,i
120,2010-019912-18,antes,o
120,2010-019912-18,de,o
120,2010-019912-18,los,o
120,2010-019912-18,16,o
120,2010-019912-18,años,o
120,2010-019912-18,de,o
120,2010-019912-18,edad,o
120,2010-019912-18,Enfermedad,i
120,2010-019912-18,articular,i
120,2010-019912-18,inflamatoria,i
120,2010-019912-18,distinta,o
120,2010-019912-18,de,o
120,2010-019912-18,AR,i
120,2010-019912-18,en,o
120,2010-019912-18,el,o
120,2010-019912-18,pasado,o
120,2010-019912-18,o,o
120,2010-019912-18,en,o
120,2010-019912-18,la,o
120,2010-019912-18,actualidad,o
121,2010-019912-18,EudraCT,o
121,2010-019912-18,Nº,o
121,2010-019912-18,201001991218,o
121,2010-019912-18,Titulo,o
121,2010-019912-18,cientifico,o
121,2010-019912-18,Estudio,o
121,2010-019912-18,randomizado,o
121,2010-019912-18,doble,o
121,2010-019912-18,ciego,o
121,2010-019912-18,con,o
121,2010-019912-18,grupos,o
121,2010-019912-18,de,o
121,2010-019912-18,tratamiento,i
121,2010-019912-18,paralelos,o
121,2010-019912-18,para,o
121,2010-019912-18,evaluar,i
121,2010-019912-18,la,i
121,2010-019912-18,seguridad,i
121,2010-019912-18,y,o
121,2010-019912-18,el,o
121,2010-019912-18,efecto,o
121,2010-019912-18,sobre,o
121,2010-019912-18,el,o
121,2010-019912-18,resultado,o
121,2010-019912-18,clinico,o
121,2010-019912-18,de,o
121,2010-019912-18,tocilizumab,i
121,2010-019912-18,SC,o
121,2010-019912-18,frente,o
121,2010-019912-18,a,o
121,2010-019912-18,placebo,i
121,2010-019912-18,SC,o
121,2010-019912-18,en,o
121,2010-019912-18,combinacion,o
121,2010-019912-18,con,o
121,2010-019912-18,farmacos,i
121,2010-019912-18,antirreumaticos,i
121,2010-019912-18,modificadores,i
121,2010-019912-18,de,i
121,2010-019912-18,la,i
121,2010-019912-18,enfermedad,i
121,2010-019912-18,FAMEs,i
121,2010-019912-18,tradicionales,o
121,2010-019912-18,en,o
121,2010-019912-18,pacientes,o
121,2010-019912-18,con,o
121,2010-019912-18,artritis,i
121,2010-019912-18,reumatoide,i
121,2010-019912-18,activa,o
121,2010-019912-18,moderada,o
121,2010-019912-18,a,o
121,2010-019912-18,severa,o
121,2010-019912-18,Indicacion,o
121,2010-019912-18,cientifica,o
121,2010-019912-18,Artritis,i
121,2010-019912-18,Reumatoide,i
121,2010-019912-18,AR,i
121,2010-019912-18,Criterios,o
121,2010-019912-18,de,o
121,2010-019912-18,inclusion,o
121,2010-019912-18,Presentar,o
121,2010-019912-18,artritis,i
121,2010-019912-18,reumatoide,i
121,2010-019912-18,de,o
121,2010-019912-18,mayor,o
121,2010-019912-18,o,o
121,2010-019912-18,igual,o
121,2010-019912-18,a,o
121,2010-019912-18,6,o
121,2010-019912-18,meses,o
121,2010-019912-18,de,o
121,2010-019912-18,duracion,o
121,2010-019912-18,Recibir,o
121,2010-019912-18,tratamiento,i
121,2010-019912-18,de,i
121,2010-019912-18,forma,i
121,2010-019912-18,ambulatoria,i
121,2010-019912-18,Presentar,o
121,2010-019912-18,un,o
121,2010-019912-18,recuento,o
121,2010-019912-18,de,o
121,2010-019912-18,articulaciones,i
121,2010-019912-18,inflamadas,i
121,2010-019912-18,RAI,o
121,2010-019912-18,mayor,o
121,2010-019912-18,o,o
121,2010-019912-18,igual,o
121,2010-019912-18,a,o
121,2010-019912-18,6,o
121,2010-019912-18,recuento,o
121,2010-019912-18,de,o
121,2010-019912-18,66,o
121,2010-019912-18,articulaciones,i
121,2010-019912-18,y,o
121,2010-019912-18,de,o
121,2010-019912-18,articulaciones,i
121,2010-019912-18,dolorosas,i
121,2010-019912-18,RAD,o
121,2010-019912-18,mayor,o
121,2010-019912-18,o,o
121,2010-019912-18,igual,o
121,2010-019912-18,a,o
121,2010-019912-18,8,o
121,2010-019912-18,recuento,o
121,2010-019912-18,de,o
121,2010-019912-18,68,o
121,2010-019912-18,articulaciones,i
121,2010-019912-18,en,o
121,2010-019912-18,las,o
121,2010-019912-18,visitas,o
121,2010-019912-18,de,o
121,2010-019912-18,seleccion,o
121,2010-019912-18,y,o
121,2010-019912-18,basal,o
121,2010-019912-18,Los,o
121,2010-019912-18,pacientes,o
121,2010-019912-18,deben,o
121,2010-019912-18,estar,o
121,2010-019912-18,recibiendo,o
121,2010-019912-18,tratamiento,i
121,2010-019912-18,con,o
121,2010-019912-18,una,o
121,2010-019912-18,dosis,o
121,2010-019912-18,estable,o
121,2010-019912-18,de,o
121,2010-019912-18,los,o
121,2010-019912-18,FAMEs,i
121,2010-019912-18,permitidos,o
121,2010-019912-18,como,o
121,2010-019912-18,minimo,o
121,2010-019912-18,8,o
121,2010-019912-18,semanas,o
121,2010-019912-18,antes,o
121,2010-019912-18,de,o
121,2010-019912-18,la,o
121,2010-019912-18,visita,o
121,2010-019912-18,basal,o
121,2010-019912-18,Criterios,o
121,2010-019912-18,de,o
121,2010-019912-18,exclusion,o
121,2010-019912-18,Pacientes,o
121,2010-019912-18,sometidos,o
121,2010-019912-18,a,o
121,2010-019912-18,intervenciones,i
121,2010-019912-18,de,i
121,2010-019912-18,cirugia,i
121,2010-019912-18,mayor,i
121,2010-019912-18,incluyendo,o
121,2010-019912-18,cirugia,i
121,2010-019912-18,articular,i
121,2010-019912-18,en,o
121,2010-019912-18,las,o
121,2010-019912-18,8,o
121,2010-019912-18,semanas,o
121,2010-019912-18,previas,o
121,2010-019912-18,a,o
121,2010-019912-18,la,o
121,2010-019912-18,visita,o
121,2010-019912-18,de,o
121,2010-019912-18,seleccion,o
121,2010-019912-18,o,o
121,2010-019912-18,que,o
121,2010-019912-18,tengan,o
121,2010-019912-18,previsto,o
121,2010-019912-18,someterse,o
121,2010-019912-18,a,o
121,2010-019912-18,una,o
121,2010-019912-18,intervencion,i
121,2010-019912-18,de,o
121,2010-019912-18,este,o
121,2010-019912-18,tipo,o
121,2010-019912-18,en,o
121,2010-019912-18,los,o
121,2010-019912-18,6,o
121,2010-019912-18,meses,o
121,2010-019912-18,siguientes,o
121,2010-019912-18,a,o
121,2010-019912-18,la,o
121,2010-019912-18,randomizacion,i
121,2010-019912-18,Enfermedad,i
121,2010-019912-18,reumatica,i
121,2010-019912-18,autoinmune,i
121,2010-019912-18,distinta,o
121,2010-019912-18,de,o
121,2010-019912-18,AR,i
121,2010-019912-18,Se,o
121,2010-019912-18,permite,o
121,2010-019912-18,la,o
121,2010-019912-18,inclusion,o
121,2010-019912-18,de,o
121,2010-019912-18,pacientes,o
121,2010-019912-18,con,o
121,2010-019912-18,sindrome,i
121,2010-019912-18,de,i
121,2010-019912-18,Sjögren,i
121,2010-019912-18,secundario,i
121,2010-019912-18,asociado,o
121,2010-019912-18,a,o
121,2010-019912-18,AR,i
121,2010-019912-18,Clase,o
121,2010-019912-18,funcional,o
121,2010-019912-18,IV,o
121,2010-019912-18,definida,o
121,2010-019912-18,de,o
121,2010-019912-18,acuerdo,o
121,2010-019912-18,con,o
121,2010-019912-18,la,o
121,2010-019912-18,Clasificacion,o
121,2010-019912-18,del,o
121,2010-019912-18,ACR,o
121,2010-019912-18,del,o
121,2010-019912-18,Estado,o
121,2010-019912-18,Funcional,o
121,2010-019912-18,en,o
121,2010-019912-18,Artritis,i
121,2010-019912-18,Reumatoide,i
121,2010-019912-18,Artritis,i
121,2010-019912-18,idiopatica,i
121,2010-019912-18,juvenil,i
121,2010-019912-18,AIJ,i
121,2010-019912-18,o,o
121,2010-019912-18,artritis,i
121,2010-019912-18,reumatoide,i
121,2010-019912-18,juvenil,i
121,2010-019912-18,ARJ,i
121,2010-019912-18,yo,o
121,2010-019912-18,AR,i
121,2010-019912-18,diagnosticadas,i
121,2010-019912-18,antes,o
121,2010-019912-18,de,o
121,2010-019912-18,los,o
121,2010-019912-18,16,o
121,2010-019912-18,años,o
121,2010-019912-18,de,o
121,2010-019912-18,edad,o
121,2010-019912-18,Enfermedad,i
121,2010-019912-18,articular,i
121,2010-019912-18,inflamatoria,i
121,2010-019912-18,distinta,o
121,2010-019912-18,de,o
121,2010-019912-18,AR,i
121,2010-019912-18,en,o
121,2010-019912-18,el,o
121,2010-019912-18,pasado,o
121,2010-019912-18,o,o
121,2010-019912-18,en,o
121,2010-019912-18,la,o
121,2010-019912-18,actualidad,o
122,2010-019912-18,EudraCT,o
122,2010-019912-18,Nº,o
122,2010-019912-18,201001991218,o
122,2010-019912-18,Titulo,o
122,2010-019912-18,cientifico,o
122,2010-019912-18,Estudio,o
122,2010-019912-18,randomizado,o
122,2010-019912-18,doble,o
122,2010-019912-18,ciego,o
122,2010-019912-18,con,o
122,2010-019912-18,grupos,o
122,2010-019912-18,de,o
122,2010-019912-18,tratamiento,i
122,2010-019912-18,paralelos,o
122,2010-019912-18,para,o
122,2010-019912-18,evaluar,i
122,2010-019912-18,la,i
122,2010-019912-18,seguridad,i
122,2010-019912-18,y,o
122,2010-019912-18,el,o
122,2010-019912-18,efecto,o
122,2010-019912-18,sobre,o
122,2010-019912-18,el,o
122,2010-019912-18,resultado,o
122,2010-019912-18,clinico,o
122,2010-019912-18,de,o
122,2010-019912-18,tocilizumab,i
122,2010-019912-18,SC,o
122,2010-019912-18,frente,o
122,2010-019912-18,a,o
122,2010-019912-18,placebo,i
122,2010-019912-18,SC,o
122,2010-019912-18,en,o
122,2010-019912-18,combinacion,o
122,2010-019912-18,con,o
122,2010-019912-18,farmacos,i
122,2010-019912-18,antirreumaticos,i
122,2010-019912-18,modificadores,i
122,2010-019912-18,de,i
122,2010-019912-18,la,i
122,2010-019912-18,enfermedad,i
122,2010-019912-18,FAMEs,i
122,2010-019912-18,tradicionales,o
122,2010-019912-18,en,o
122,2010-019912-18,pacientes,o
122,2010-019912-18,con,o
122,2010-019912-18,artritis,i
122,2010-019912-18,reumatoide,i
122,2010-019912-18,activa,o
122,2010-019912-18,moderada,o
122,2010-019912-18,a,o
122,2010-019912-18,severa,o
122,2010-019912-18,Indicacion,o
122,2010-019912-18,cientifica,o
122,2010-019912-18,Artritis,i
122,2010-019912-18,Reumatoide,i
122,2010-019912-18,AR,i
122,2010-019912-18,Criterios,o
122,2010-019912-18,de,o
122,2010-019912-18,inclusion,o
122,2010-019912-18,Presentar,o
122,2010-019912-18,artritis,i
122,2010-019912-18,reumatoide,i
122,2010-019912-18,de,o
122,2010-019912-18,mayor,o
122,2010-019912-18,o,o
122,2010-019912-18,igual,o
122,2010-019912-18,a,o
122,2010-019912-18,6,o
122,2010-019912-18,meses,o
122,2010-019912-18,de,o
122,2010-019912-18,duracion,o
122,2010-019912-18,Recibir,o
122,2010-019912-18,tratamiento,i
122,2010-019912-18,de,i
122,2010-019912-18,forma,i
122,2010-019912-18,ambulatoria,i
122,2010-019912-18,Presentar,o
122,2010-019912-18,un,o
122,2010-019912-18,recuento,o
122,2010-019912-18,de,o
122,2010-019912-18,articulaciones,i
122,2010-019912-18,inflamadas,i
122,2010-019912-18,RAI,o
122,2010-019912-18,mayor,o
122,2010-019912-18,o,o
122,2010-019912-18,igual,o
122,2010-019912-18,a,o
122,2010-019912-18,6,o
122,2010-019912-18,recuento,o
122,2010-019912-18,de,o
122,2010-019912-18,66,o
122,2010-019912-18,articulaciones,i
122,2010-019912-18,y,o
122,2010-019912-18,de,o
122,2010-019912-18,articulaciones,i
122,2010-019912-18,dolorosas,i
122,2010-019912-18,RAD,o
122,2010-019912-18,mayor,o
122,2010-019912-18,o,o
122,2010-019912-18,igual,o
122,2010-019912-18,a,o
122,2010-019912-18,8,o
122,2010-019912-18,recuento,o
122,2010-019912-18,de,o
122,2010-019912-18,68,o
122,2010-019912-18,articulaciones,i
122,2010-019912-18,en,o
122,2010-019912-18,las,o
122,2010-019912-18,visitas,o
122,2010-019912-18,de,o
122,2010-019912-18,seleccion,o
122,2010-019912-18,y,o
122,2010-019912-18,basal,o
122,2010-019912-18,Los,o
122,2010-019912-18,pacientes,o
122,2010-019912-18,deben,o
122,2010-019912-18,estar,o
122,2010-019912-18,recibiendo,o
122,2010-019912-18,tratamiento,i
122,2010-019912-18,con,o
122,2010-019912-18,una,o
122,2010-019912-18,dosis,o
122,2010-019912-18,estable,o
122,2010-019912-18,de,o
122,2010-019912-18,los,o
122,2010-019912-18,FAMEs,i
122,2010-019912-18,permitidos,o
122,2010-019912-18,como,o
122,2010-019912-18,minimo,o
122,2010-019912-18,8,o
122,2010-019912-18,semanas,o
122,2010-019912-18,antes,o
122,2010-019912-18,de,o
122,2010-019912-18,la,o
122,2010-019912-18,visita,o
122,2010-019912-18,basal,o
122,2010-019912-18,Criterios,o
122,2010-019912-18,de,o
122,2010-019912-18,exclusion,o
122,2010-019912-18,Pacientes,o
122,2010-019912-18,sometidos,o
122,2010-019912-18,a,o
122,2010-019912-18,intervenciones,i
122,2010-019912-18,de,i
122,2010-019912-18,cirugia,i
122,2010-019912-18,mayor,i
122,2010-019912-18,incluyendo,o
122,2010-019912-18,cirugia,i
122,2010-019912-18,articular,i
122,2010-019912-18,en,o
122,2010-019912-18,las,o
122,2010-019912-18,8,o
122,2010-019912-18,semanas,o
122,2010-019912-18,previas,o
122,2010-019912-18,a,o
122,2010-019912-18,la,o
122,2010-019912-18,visita,o
122,2010-019912-18,de,o
122,2010-019912-18,seleccion,o
122,2010-019912-18,o,o
122,2010-019912-18,que,o
122,2010-019912-18,tengan,o
122,2010-019912-18,previsto,o
122,2010-019912-18,someterse,o
122,2010-019912-18,a,o
122,2010-019912-18,una,o
122,2010-019912-18,intervencion,i
122,2010-019912-18,de,o
122,2010-019912-18,este,o
122,2010-019912-18,tipo,o
122,2010-019912-18,en,o
122,2010-019912-18,los,o
122,2010-019912-18,6,o
122,2010-019912-18,meses,o
122,2010-019912-18,siguientes,o
122,2010-019912-18,a,o
122,2010-019912-18,la,o
122,2010-019912-18,randomizacion,i
122,2010-019912-18,Enfermedad,i
122,2010-019912-18,reumatica,i
122,2010-019912-18,autoinmune,i
122,2010-019912-18,distinta,o
122,2010-019912-18,de,o
122,2010-019912-18,AR,i
122,2010-019912-18,Se,o
122,2010-019912-18,permite,o
122,2010-019912-18,la,o
122,2010-019912-18,inclusion,o
122,2010-019912-18,de,o
122,2010-019912-18,pacientes,o
122,2010-019912-18,con,o
122,2010-019912-18,sindrome,i
122,2010-019912-18,de,i
122,2010-019912-18,Sjögren,i
122,2010-019912-18,secundario,i
122,2010-019912-18,asociado,o
122,2010-019912-18,a,o
122,2010-019912-18,AR,i
122,2010-019912-18,Clase,o
122,2010-019912-18,funcional,o
122,2010-019912-18,IV,o
122,2010-019912-18,definida,o
122,2010-019912-18,de,o
122,2010-019912-18,acuerdo,o
122,2010-019912-18,con,o
122,2010-019912-18,la,o
122,2010-019912-18,Clasificacion,o
122,2010-019912-18,del,o
122,2010-019912-18,ACR,o
122,2010-019912-18,del,o
122,2010-019912-18,Estado,o
122,2010-019912-18,Funcional,o
122,2010-019912-18,en,o
122,2010-019912-18,Artritis,i
122,2010-019912-18,Reumatoide,i
122,2010-019912-18,Artritis,i
122,2010-019912-18,idiopatica,i
122,2010-019912-18,juvenil,i
122,2010-019912-18,AIJ,i
122,2010-019912-18,o,o
122,2010-019912-18,artritis,i
122,2010-019912-18,reumatoide,i
122,2010-019912-18,juvenil,i
122,2010-019912-18,ARJ,i
122,2010-019912-18,yo,o
122,2010-019912-18,AR,i
122,2010-019912-18,diagnosticadas,i
122,2010-019912-18,antes,o
122,2010-019912-18,de,o
122,2010-019912-18,los,o
122,2010-019912-18,16,o
122,2010-019912-18,años,o
122,2010-019912-18,de,o
122,2010-019912-18,edad,o
122,2010-019912-18,Enfermedad,i
122,2010-019912-18,articular,i
122,2010-019912-18,inflamatoria,i
122,2010-019912-18,distinta,o
122,2010-019912-18,de,o
122,2010-019912-18,AR,i
122,2010-019912-18,en,o
122,2010-019912-18,el,o
122,2010-019912-18,pasado,o
122,2010-019912-18,o,o
122,2010-019912-18,en,o
122,2010-019912-18,la,o
122,2010-019912-18,actualidad,o
123,2010-019912-18,EudraCT,o
123,2010-019912-18,Nº,o
123,2010-019912-18,201001991218,o
123,2010-019912-18,Titulo,o
123,2010-019912-18,cientifico,o
123,2010-019912-18,Estudio,o
123,2010-019912-18,randomizado,o
123,2010-019912-18,doble,o
123,2010-019912-18,ciego,o
123,2010-019912-18,con,o
123,2010-019912-18,grupos,o
123,2010-019912-18,de,o
123,2010-019912-18,tratamiento,i
123,2010-019912-18,paralelos,o
123,2010-019912-18,para,o
123,2010-019912-18,evaluar,i
123,2010-019912-18,la,i
123,2010-019912-18,seguridad,i
123,2010-019912-18,y,o
123,2010-019912-18,el,o
123,2010-019912-18,efecto,o
123,2010-019912-18,sobre,o
123,2010-019912-18,el,o
123,2010-019912-18,resultado,o
123,2010-019912-18,clinico,o
123,2010-019912-18,de,o
123,2010-019912-18,tocilizumab,i
123,2010-019912-18,SC,o
123,2010-019912-18,frente,o
123,2010-019912-18,a,o
123,2010-019912-18,placebo,i
123,2010-019912-18,SC,o
123,2010-019912-18,en,o
123,2010-019912-18,combinacion,o
123,2010-019912-18,con,o
123,2010-019912-18,farmacos,i
123,2010-019912-18,antirreumaticos,i
123,2010-019912-18,modificadores,i
123,2010-019912-18,de,i
123,2010-019912-18,la,i
123,2010-019912-18,enfermedad,i
123,2010-019912-18,FAMEs,i
123,2010-019912-18,tradicionales,o
123,2010-019912-18,en,o
123,2010-019912-18,pacientes,o
123,2010-019912-18,con,o
123,2010-019912-18,artritis,i
123,2010-019912-18,reumatoide,i
123,2010-019912-18,activa,o
123,2010-019912-18,moderada,o
123,2010-019912-18,a,o
123,2010-019912-18,severa,o
123,2010-019912-18,Indicacion,o
123,2010-019912-18,cientifica,o
123,2010-019912-18,Artritis,i
123,2010-019912-18,Reumatoide,i
123,2010-019912-18,AR,i
123,2010-019912-18,Criterios,o
123,2010-019912-18,de,o
123,2010-019912-18,inclusion,o
123,2010-019912-18,Presentar,o
123,2010-019912-18,artritis,i
123,2010-019912-18,reumatoide,i
123,2010-019912-18,de,o
123,2010-019912-18,mayor,o
123,2010-019912-18,o,o
123,2010-019912-18,igual,o
123,2010-019912-18,a,o
123,2010-019912-18,6,o
123,2010-019912-18,meses,o
123,2010-019912-18,de,o
123,2010-019912-18,duracion,o
123,2010-019912-18,Recibir,o
123,2010-019912-18,tratamiento,i
123,2010-019912-18,de,i
123,2010-019912-18,forma,i
123,2010-019912-18,ambulatoria,i
123,2010-019912-18,Presentar,o
123,2010-019912-18,un,o
123,2010-019912-18,recuento,o
123,2010-019912-18,de,o
123,2010-019912-18,articulaciones,i
123,2010-019912-18,inflamadas,i
123,2010-019912-18,RAI,o
123,2010-019912-18,mayor,o
123,2010-019912-18,o,o
123,2010-019912-18,igual,o
123,2010-019912-18,a,o
123,2010-019912-18,6,o
123,2010-019912-18,recuento,o
123,2010-019912-18,de,o
123,2010-019912-18,66,o
123,2010-019912-18,articulaciones,i
123,2010-019912-18,y,o
123,2010-019912-18,de,o
123,2010-019912-18,articulaciones,i
123,2010-019912-18,dolorosas,i
123,2010-019912-18,RAD,o
123,2010-019912-18,mayor,o
123,2010-019912-18,o,o
123,2010-019912-18,igual,o
123,2010-019912-18,a,o
123,2010-019912-18,8,o
123,2010-019912-18,recuento,o
123,2010-019912-18,de,o
123,2010-019912-18,68,o
123,2010-019912-18,articulaciones,i
123,2010-019912-18,en,o
123,2010-019912-18,las,o
123,2010-019912-18,visitas,o
123,2010-019912-18,de,o
123,2010-019912-18,seleccion,o
123,2010-019912-18,y,o
123,2010-019912-18,basal,o
123,2010-019912-18,Los,o
123,2010-019912-18,pacientes,o
123,2010-019912-18,deben,o
123,2010-019912-18,estar,o
123,2010-019912-18,recibiendo,o
123,2010-019912-18,tratamiento,i
123,2010-019912-18,con,o
123,2010-019912-18,una,o
123,2010-019912-18,dosis,o
123,2010-019912-18,estable,o
123,2010-019912-18,de,o
123,2010-019912-18,los,o
123,2010-019912-18,FAMEs,i
123,2010-019912-18,permitidos,o
123,2010-019912-18,como,o
123,2010-019912-18,minimo,o
123,2010-019912-18,8,o
123,2010-019912-18,semanas,o
123,2010-019912-18,antes,o
123,2010-019912-18,de,o
123,2010-019912-18,la,o
123,2010-019912-18,visita,o
123,2010-019912-18,basal,o
123,2010-019912-18,Criterios,o
123,2010-019912-18,de,o
123,2010-019912-18,exclusion,o
123,2010-019912-18,Pacientes,o
123,2010-019912-18,sometidos,o
123,2010-019912-18,a,o
123,2010-019912-18,intervenciones,i
123,2010-019912-18,de,i
123,2010-019912-18,cirugia,i
123,2010-019912-18,mayor,i
123,2010-019912-18,incluyendo,o
123,2010-019912-18,cirugia,i
123,2010-019912-18,articular,i
123,2010-019912-18,en,o
123,2010-019912-18,las,o
123,2010-019912-18,8,o
123,2010-019912-18,semanas,o
123,2010-019912-18,previas,o
123,2010-019912-18,a,o
123,2010-019912-18,la,o
123,2010-019912-18,visita,o
123,2010-019912-18,de,o
123,2010-019912-18,seleccion,o
123,2010-019912-18,o,o
123,2010-019912-18,que,o
123,2010-019912-18,tengan,o
123,2010-019912-18,previsto,o
123,2010-019912-18,someterse,o
123,2010-019912-18,a,o
123,2010-019912-18,una,o
123,2010-019912-18,intervencion,i
123,2010-019912-18,de,o
123,2010-019912-18,este,o
123,2010-019912-18,tipo,o
123,2010-019912-18,en,o
123,2010-019912-18,los,o
123,2010-019912-18,6,o
123,2010-019912-18,meses,o
123,2010-019912-18,siguientes,o
123,2010-019912-18,a,o
123,2010-019912-18,la,o
123,2010-019912-18,randomizacion,i
123,2010-019912-18,Enfermedad,i
123,2010-019912-18,reumatica,i
123,2010-019912-18,autoinmune,i
123,2010-019912-18,distinta,o
123,2010-019912-18,de,o
123,2010-019912-18,AR,i
123,2010-019912-18,Se,o
123,2010-019912-18,permite,o
123,2010-019912-18,la,o
123,2010-019912-18,inclusion,o
123,2010-019912-18,de,o
123,2010-019912-18,pacientes,o
123,2010-019912-18,con,o
123,2010-019912-18,sindrome,i
123,2010-019912-18,de,i
123,2010-019912-18,Sjögren,i
123,2010-019912-18,secundario,i
123,2010-019912-18,asociado,o
123,2010-019912-18,a,o
123,2010-019912-18,AR,i
123,2010-019912-18,Clase,o
123,2010-019912-18,funcional,o
123,2010-019912-18,IV,o
123,2010-019912-18,definida,o
123,2010-019912-18,de,o
123,2010-019912-18,acuerdo,o
123,2010-019912-18,con,o
123,2010-019912-18,la,o
123,2010-019912-18,Clasificacion,o
123,2010-019912-18,del,o
123,2010-019912-18,ACR,o
123,2010-019912-18,del,o
123,2010-019912-18,Estado,o
123,2010-019912-18,Funcional,o
123,2010-019912-18,en,o
123,2010-019912-18,Artritis,i
123,2010-019912-18,Reumatoide,i
123,2010-019912-18,Artritis,i
123,2010-019912-18,idiopatica,i
123,2010-019912-18,juvenil,i
123,2010-019912-18,AIJ,i
123,2010-019912-18,o,o
123,2010-019912-18,artritis,i
123,2010-019912-18,reumatoide,i
123,2010-019912-18,juvenil,i
123,2010-019912-18,ARJ,i
123,2010-019912-18,yo,o
123,2010-019912-18,AR,i
123,2010-019912-18,diagnosticadas,i
123,2010-019912-18,antes,o
123,2010-019912-18,de,o
123,2010-019912-18,los,o
123,2010-019912-18,16,o
123,2010-019912-18,años,o
123,2010-019912-18,de,o
123,2010-019912-18,edad,o
123,2010-019912-18,Enfermedad,i
123,2010-019912-18,articular,i
123,2010-019912-18,inflamatoria,i
123,2010-019912-18,distinta,o
123,2010-019912-18,de,o
123,2010-019912-18,AR,i
123,2010-019912-18,en,o
123,2010-019912-18,el,o
123,2010-019912-18,pasado,o
123,2010-019912-18,o,o
123,2010-019912-18,en,o
123,2010-019912-18,la,o
123,2010-019912-18,actualidad,o
124,2010-019912-18,EudraCT,o
124,2010-019912-18,Nº,o
124,2010-019912-18,201001991218,o
124,2010-019912-18,Titulo,o
124,2010-019912-18,cientifico,o
124,2010-019912-18,Estudio,o
124,2010-019912-18,randomizado,o
124,2010-019912-18,doble,o
124,2010-019912-18,ciego,o
124,2010-019912-18,con,o
124,2010-019912-18,grupos,o
124,2010-019912-18,de,o
124,2010-019912-18,tratamiento,i
124,2010-019912-18,paralelos,o
124,2010-019912-18,para,o
124,2010-019912-18,evaluar,i
124,2010-019912-18,la,i
124,2010-019912-18,seguridad,i
124,2010-019912-18,y,o
124,2010-019912-18,el,o
124,2010-019912-18,efecto,o
124,2010-019912-18,sobre,o
124,2010-019912-18,el,o
124,2010-019912-18,resultado,o
124,2010-019912-18,clinico,o
124,2010-019912-18,de,o
124,2010-019912-18,tocilizumab,i
124,2010-019912-18,SC,o
124,2010-019912-18,frente,o
124,2010-019912-18,a,o
124,2010-019912-18,placebo,i
124,2010-019912-18,SC,o
124,2010-019912-18,en,o
124,2010-019912-18,combinacion,o
124,2010-019912-18,con,o
124,2010-019912-18,farmacos,i
124,2010-019912-18,antirreumaticos,i
124,2010-019912-18,modificadores,i
124,2010-019912-18,de,i
124,2010-019912-18,la,i
124,2010-019912-18,enfermedad,i
124,2010-019912-18,FAMEs,i
124,2010-019912-18,tradicionales,o
124,2010-019912-18,en,o
124,2010-019912-18,pacientes,o
124,2010-019912-18,con,o
124,2010-019912-18,artritis,i
124,2010-019912-18,reumatoide,i
124,2010-019912-18,activa,o
124,2010-019912-18,moderada,o
124,2010-019912-18,a,o
124,2010-019912-18,severa,o
124,2010-019912-18,Indicacion,o
124,2010-019912-18,cientifica,o
124,2010-019912-18,Artritis,i
124,2010-019912-18,Reumatoide,i
124,2010-019912-18,AR,i
124,2010-019912-18,Criterios,o
124,2010-019912-18,de,o
124,2010-019912-18,inclusion,o
124,2010-019912-18,Presentar,o
124,2010-019912-18,artritis,i
124,2010-019912-18,reumatoide,i
124,2010-019912-18,de,o
124,2010-019912-18,mayor,o
124,2010-019912-18,o,o
124,2010-019912-18,igual,o
124,2010-019912-18,a,o
124,2010-019912-18,6,o
124,2010-019912-18,meses,o
124,2010-019912-18,de,o
124,2010-019912-18,duracion,o
124,2010-019912-18,Recibir,o
124,2010-019912-18,tratamiento,i
124,2010-019912-18,de,i
124,2010-019912-18,forma,i
124,2010-019912-18,ambulatoria,i
124,2010-019912-18,Presentar,o
124,2010-019912-18,un,o
124,2010-019912-18,recuento,o
124,2010-019912-18,de,o
124,2010-019912-18,articulaciones,i
124,2010-019912-18,inflamadas,i
124,2010-019912-18,RAI,o
124,2010-019912-18,mayor,o
124,2010-019912-18,o,o
124,2010-019912-18,igual,o
124,2010-019912-18,a,o
124,2010-019912-18,6,o
124,2010-019912-18,recuento,o
124,2010-019912-18,de,o
124,2010-019912-18,66,o
124,2010-019912-18,articulaciones,i
124,2010-019912-18,y,o
124,2010-019912-18,de,o
124,2010-019912-18,articulaciones,i
124,2010-019912-18,dolorosas,i
124,2010-019912-18,RAD,o
124,2010-019912-18,mayor,o
124,2010-019912-18,o,o
124,2010-019912-18,igual,o
124,2010-019912-18,a,o
124,2010-019912-18,8,o
124,2010-019912-18,recuento,o
124,2010-019912-18,de,o
124,2010-019912-18,68,o
124,2010-019912-18,articulaciones,i
124,2010-019912-18,en,o
124,2010-019912-18,las,o
124,2010-019912-18,visitas,o
124,2010-019912-18,de,o
124,2010-019912-18,seleccion,o
124,2010-019912-18,y,o
124,2010-019912-18,basal,o
124,2010-019912-18,Los,o
124,2010-019912-18,pacientes,o
124,2010-019912-18,deben,o
124,2010-019912-18,estar,o
124,2010-019912-18,recibiendo,o
124,2010-019912-18,tratamiento,i
124,2010-019912-18,con,o
124,2010-019912-18,una,o
124,2010-019912-18,dosis,o
124,2010-019912-18,estable,o
124,2010-019912-18,de,o
124,2010-019912-18,los,o
124,2010-019912-18,FAMEs,i
124,2010-019912-18,permitidos,o
124,2010-019912-18,como,o
124,2010-019912-18,minimo,o
124,2010-019912-18,8,o
124,2010-019912-18,semanas,o
124,2010-019912-18,antes,o
124,2010-019912-18,de,o
124,2010-019912-18,la,o
124,2010-019912-18,visita,o
124,2010-019912-18,basal,o
124,2010-019912-18,Criterios,o
124,2010-019912-18,de,o
124,2010-019912-18,exclusion,o
124,2010-019912-18,Pacientes,o
124,2010-019912-18,sometidos,o
124,2010-019912-18,a,o
124,2010-019912-18,intervenciones,i
124,2010-019912-18,de,i
124,2010-019912-18,cirugia,i
124,2010-019912-18,mayor,i
124,2010-019912-18,incluyendo,o
124,2010-019912-18,cirugia,i
124,2010-019912-18,articular,i
124,2010-019912-18,en,o
124,2010-019912-18,las,o
124,2010-019912-18,8,o
124,2010-019912-18,semanas,o
124,2010-019912-18,previas,o
124,2010-019912-18,a,o
124,2010-019912-18,la,o
124,2010-019912-18,visita,o
124,2010-019912-18,de,o
124,2010-019912-18,seleccion,o
124,2010-019912-18,o,o
124,2010-019912-18,que,o
124,2010-019912-18,tengan,o
124,2010-019912-18,previsto,o
124,2010-019912-18,someterse,o
124,2010-019912-18,a,o
124,2010-019912-18,una,o
124,2010-019912-18,intervencion,i
124,2010-019912-18,de,o
124,2010-019912-18,este,o
124,2010-019912-18,tipo,o
124,2010-019912-18,en,o
124,2010-019912-18,los,o
124,2010-019912-18,6,o
124,2010-019912-18,meses,o
124,2010-019912-18,siguientes,o
124,2010-019912-18,a,o
124,2010-019912-18,la,o
124,2010-019912-18,randomizacion,i
124,2010-019912-18,Enfermedad,i
124,2010-019912-18,reumatica,i
124,2010-019912-18,autoinmune,i
124,2010-019912-18,distinta,o
124,2010-019912-18,de,o
124,2010-019912-18,AR,i
124,2010-019912-18,Se,o
124,2010-019912-18,permite,o
124,2010-019912-18,la,o
124,2010-019912-18,inclusion,o
124,2010-019912-18,de,o
124,2010-019912-18,pacientes,o
124,2010-019912-18,con,o
124,2010-019912-18,sindrome,i
124,2010-019912-18,de,i
124,2010-019912-18,Sjögren,i
124,2010-019912-18,secundario,i
124,2010-019912-18,asociado,o
124,2010-019912-18,a,o
124,2010-019912-18,AR,i
124,2010-019912-18,Clase,o
124,2010-019912-18,funcional,o
124,2010-019912-18,IV,o
124,2010-019912-18,definida,o
124,2010-019912-18,de,o
124,2010-019912-18,acuerdo,o
124,2010-019912-18,con,o
124,2010-019912-18,la,o
124,2010-019912-18,Clasificacion,o
124,2010-019912-18,del,o
124,2010-019912-18,ACR,o
124,2010-019912-18,del,o
124,2010-019912-18,Estado,o
124,2010-019912-18,Funcional,o
124,2010-019912-18,en,o
124,2010-019912-18,Artritis,i
124,2010-019912-18,Reumatoide,i
124,2010-019912-18,Artritis,i
124,2010-019912-18,idiopatica,i
124,2010-019912-18,juvenil,i
124,2010-019912-18,AIJ,i
124,2010-019912-18,o,o
124,2010-019912-18,artritis,i
124,2010-019912-18,reumatoide,i
124,2010-019912-18,juvenil,i
124,2010-019912-18,ARJ,i
124,2010-019912-18,yo,o
124,2010-019912-18,AR,i
124,2010-019912-18,diagnosticadas,i
124,2010-019912-18,antes,o
124,2010-019912-18,de,o
124,2010-019912-18,los,o
124,2010-019912-18,16,o
124,2010-019912-18,años,o
124,2010-019912-18,de,o
124,2010-019912-18,edad,o
124,2010-019912-18,Enfermedad,i
124,2010-019912-18,articular,i
124,2010-019912-18,inflamatoria,i
124,2010-019912-18,distinta,o
124,2010-019912-18,de,o
124,2010-019912-18,AR,i
124,2010-019912-18,en,o
124,2010-019912-18,el,o
124,2010-019912-18,pasado,o
124,2010-019912-18,o,o
124,2010-019912-18,en,o
124,2010-019912-18,la,o
124,2010-019912-18,actualidad,o
125,2010-019912-18,EudraCT,o
125,2010-019912-18,Nº,o
125,2010-019912-18,201001991218,o
125,2010-019912-18,Titulo,o
125,2010-019912-18,cientifico,o
125,2010-019912-18,Estudio,o
125,2010-019912-18,randomizado,o
125,2010-019912-18,doble,o
125,2010-019912-18,ciego,o
125,2010-019912-18,con,o
125,2010-019912-18,grupos,o
125,2010-019912-18,de,o
125,2010-019912-18,tratamiento,i
125,2010-019912-18,paralelos,o
125,2010-019912-18,para,o
125,2010-019912-18,evaluar,i
125,2010-019912-18,la,i
125,2010-019912-18,seguridad,i
125,2010-019912-18,y,o
125,2010-019912-18,el,o
125,2010-019912-18,efecto,o
125,2010-019912-18,sobre,o
125,2010-019912-18,el,o
125,2010-019912-18,resultado,o
125,2010-019912-18,clinico,o
125,2010-019912-18,de,o
125,2010-019912-18,tocilizumab,i
125,2010-019912-18,SC,o
125,2010-019912-18,frente,o
125,2010-019912-18,a,o
125,2010-019912-18,placebo,i
125,2010-019912-18,SC,o
125,2010-019912-18,en,o
125,2010-019912-18,combinacion,o
125,2010-019912-18,con,o
125,2010-019912-18,farmacos,i
125,2010-019912-18,antirreumaticos,i
125,2010-019912-18,modificadores,i
125,2010-019912-18,de,i
125,2010-019912-18,la,i
125,2010-019912-18,enfermedad,i
125,2010-019912-18,FAMEs,i
125,2010-019912-18,tradicionales,o
125,2010-019912-18,en,o
125,2010-019912-18,pacientes,o
125,2010-019912-18,con,o
125,2010-019912-18,artritis,i
125,2010-019912-18,reumatoide,i
125,2010-019912-18,activa,o
125,2010-019912-18,moderada,o
125,2010-019912-18,a,o
125,2010-019912-18,severa,o
125,2010-019912-18,Indicacion,o
125,2010-019912-18,cientifica,o
125,2010-019912-18,Artritis,i
125,2010-019912-18,Reumatoide,i
125,2010-019912-18,AR,i
125,2010-019912-18,Criterios,o
125,2010-019912-18,de,o
125,2010-019912-18,inclusion,o
125,2010-019912-18,Presentar,o
125,2010-019912-18,artritis,i
125,2010-019912-18,reumatoide,i
125,2010-019912-18,de,o
125,2010-019912-18,mayor,o
125,2010-019912-18,o,o
125,2010-019912-18,igual,o
125,2010-019912-18,a,o
125,2010-019912-18,6,o
125,2010-019912-18,meses,o
125,2010-019912-18,de,o
125,2010-019912-18,duracion,o
125,2010-019912-18,Recibir,o
125,2010-019912-18,tratamiento,i
125,2010-019912-18,de,i
125,2010-019912-18,forma,i
125,2010-019912-18,ambulatoria,i
125,2010-019912-18,Presentar,o
125,2010-019912-18,un,o
125,2010-019912-18,recuento,o
125,2010-019912-18,de,o
125,2010-019912-18,articulaciones,i
125,2010-019912-18,inflamadas,i
125,2010-019912-18,RAI,o
125,2010-019912-18,mayor,o
125,2010-019912-18,o,o
125,2010-019912-18,igual,o
125,2010-019912-18,a,o
125,2010-019912-18,6,o
125,2010-019912-18,recuento,o
125,2010-019912-18,de,o
125,2010-019912-18,66,o
125,2010-019912-18,articulaciones,i
125,2010-019912-18,y,o
125,2010-019912-18,de,o
125,2010-019912-18,articulaciones,i
125,2010-019912-18,dolorosas,i
125,2010-019912-18,RAD,o
125,2010-019912-18,mayor,o
125,2010-019912-18,o,o
125,2010-019912-18,igual,o
125,2010-019912-18,a,o
125,2010-019912-18,8,o
125,2010-019912-18,recuento,o
125,2010-019912-18,de,o
125,2010-019912-18,68,o
125,2010-019912-18,articulaciones,i
125,2010-019912-18,en,o
125,2010-019912-18,las,o
125,2010-019912-18,visitas,o
125,2010-019912-18,de,o
125,2010-019912-18,seleccion,o
125,2010-019912-18,y,o
125,2010-019912-18,basal,o
125,2010-019912-18,Los,o
125,2010-019912-18,pacientes,o
125,2010-019912-18,deben,o
125,2010-019912-18,estar,o
125,2010-019912-18,recibiendo,o
125,2010-019912-18,tratamiento,i
125,2010-019912-18,con,o
125,2010-019912-18,una,o
125,2010-019912-18,dosis,o
125,2010-019912-18,estable,o
125,2010-019912-18,de,o
125,2010-019912-18,los,o
125,2010-019912-18,FAMEs,i
125,2010-019912-18,permitidos,o
125,2010-019912-18,como,o
125,2010-019912-18,minimo,o
125,2010-019912-18,8,o
125,2010-019912-18,semanas,o
125,2010-019912-18,antes,o
125,2010-019912-18,de,o
125,2010-019912-18,la,o
125,2010-019912-18,visita,o
125,2010-019912-18,basal,o
125,2010-019912-18,Criterios,o
125,2010-019912-18,de,o
125,2010-019912-18,exclusion,o
125,2010-019912-18,Pacientes,o
125,2010-019912-18,sometidos,o
125,2010-019912-18,a,o
125,2010-019912-18,intervenciones,i
125,2010-019912-18,de,i
125,2010-019912-18,cirugia,i
125,2010-019912-18,mayor,i
125,2010-019912-18,incluyendo,o
125,2010-019912-18,cirugia,i
125,2010-019912-18,articular,i
125,2010-019912-18,en,o
125,2010-019912-18,las,o
125,2010-019912-18,8,o
125,2010-019912-18,semanas,o
125,2010-019912-18,previas,o
125,2010-019912-18,a,o
125,2010-019912-18,la,o
125,2010-019912-18,visita,o
125,2010-019912-18,de,o
125,2010-019912-18,seleccion,o
125,2010-019912-18,o,o
125,2010-019912-18,que,o
125,2010-019912-18,tengan,o
125,2010-019912-18,previsto,o
125,2010-019912-18,someterse,o
125,2010-019912-18,a,o
125,2010-019912-18,una,o
125,2010-019912-18,intervencion,i
125,2010-019912-18,de,o
125,2010-019912-18,este,o
125,2010-019912-18,tipo,o
125,2010-019912-18,en,o
125,2010-019912-18,los,o
125,2010-019912-18,6,o
125,2010-019912-18,meses,o
125,2010-019912-18,siguientes,o
125,2010-019912-18,a,o
125,2010-019912-18,la,o
125,2010-019912-18,randomizacion,i
125,2010-019912-18,Enfermedad,i
125,2010-019912-18,reumatica,i
125,2010-019912-18,autoinmune,i
125,2010-019912-18,distinta,o
125,2010-019912-18,de,o
125,2010-019912-18,AR,i
125,2010-019912-18,Se,o
125,2010-019912-18,permite,o
125,2010-019912-18,la,o
125,2010-019912-18,inclusion,o
125,2010-019912-18,de,o
125,2010-019912-18,pacientes,o
125,2010-019912-18,con,o
125,2010-019912-18,sindrome,i
125,2010-019912-18,de,i
125,2010-019912-18,Sjögren,i
125,2010-019912-18,secundario,i
125,2010-019912-18,asociado,o
125,2010-019912-18,a,o
125,2010-019912-18,AR,i
125,2010-019912-18,Clase,o
125,2010-019912-18,funcional,o
125,2010-019912-18,IV,o
125,2010-019912-18,definida,o
125,2010-019912-18,de,o
125,2010-019912-18,acuerdo,o
125,2010-019912-18,con,o
125,2010-019912-18,la,o
125,2010-019912-18,Clasificacion,o
125,2010-019912-18,del,o
125,2010-019912-18,ACR,o
125,2010-019912-18,del,o
125,2010-019912-18,Estado,o
125,2010-019912-18,Funcional,o
125,2010-019912-18,en,o
125,2010-019912-18,Artritis,i
125,2010-019912-18,Reumatoide,i
125,2010-019912-18,Artritis,i
125,2010-019912-18,idiopatica,i
125,2010-019912-18,juvenil,i
125,2010-019912-18,AIJ,i
125,2010-019912-18,o,o
125,2010-019912-18,artritis,i
125,2010-019912-18,reumatoide,i
125,2010-019912-18,juvenil,i
125,2010-019912-18,ARJ,i
125,2010-019912-18,yo,o
125,2010-019912-18,AR,i
125,2010-019912-18,diagnosticadas,i
125,2010-019912-18,antes,o
125,2010-019912-18,de,o
125,2010-019912-18,los,o
125,2010-019912-18,16,o
125,2010-019912-18,años,o
125,2010-019912-18,de,o
125,2010-019912-18,edad,o
125,2010-019912-18,Enfermedad,i
125,2010-019912-18,articular,i
125,2010-019912-18,inflamatoria,i
125,2010-019912-18,distinta,o
125,2010-019912-18,de,o
125,2010-019912-18,AR,i
125,2010-019912-18,en,o
125,2010-019912-18,el,o
125,2010-019912-18,pasado,o
125,2010-019912-18,o,o
125,2010-019912-18,en,o
125,2010-019912-18,la,o
125,2010-019912-18,actualidad,o
126,2010-019912-18,EudraCT,o
126,2010-019912-18,Nº,o
126,2010-019912-18,201001991218,o
126,2010-019912-18,Titulo,o
126,2010-019912-18,cientifico,o
126,2010-019912-18,Estudio,o
126,2010-019912-18,randomizado,o
126,2010-019912-18,doble,o
126,2010-019912-18,ciego,o
126,2010-019912-18,con,o
126,2010-019912-18,grupos,o
126,2010-019912-18,de,o
126,2010-019912-18,tratamiento,i
126,2010-019912-18,paralelos,o
126,2010-019912-18,para,o
126,2010-019912-18,evaluar,i
126,2010-019912-18,la,i
126,2010-019912-18,seguridad,i
126,2010-019912-18,y,o
126,2010-019912-18,el,o
126,2010-019912-18,efecto,o
126,2010-019912-18,sobre,o
126,2010-019912-18,el,o
126,2010-019912-18,resultado,o
126,2010-019912-18,clinico,o
126,2010-019912-18,de,o
126,2010-019912-18,tocilizumab,i
126,2010-019912-18,SC,o
126,2010-019912-18,frente,o
126,2010-019912-18,a,o
126,2010-019912-18,placebo,i
126,2010-019912-18,SC,o
126,2010-019912-18,en,o
126,2010-019912-18,combinacion,o
126,2010-019912-18,con,o
126,2010-019912-18,farmacos,i
126,2010-019912-18,antirreumaticos,i
126,2010-019912-18,modificadores,i
126,2010-019912-18,de,i
126,2010-019912-18,la,i
126,2010-019912-18,enfermedad,i
126,2010-019912-18,FAMEs,i
126,2010-019912-18,tradicionales,o
126,2010-019912-18,en,o
126,2010-019912-18,pacientes,o
126,2010-019912-18,con,o
126,2010-019912-18,artritis,i
126,2010-019912-18,reumatoide,i
126,2010-019912-18,activa,o
126,2010-019912-18,moderada,o
126,2010-019912-18,a,o
126,2010-019912-18,severa,o
126,2010-019912-18,Indicacion,o
126,2010-019912-18,cientifica,o
126,2010-019912-18,Artritis,i
126,2010-019912-18,Reumatoide,i
126,2010-019912-18,AR,i
126,2010-019912-18,Criterios,o
126,2010-019912-18,de,o
126,2010-019912-18,inclusion,o
126,2010-019912-18,Presentar,o
126,2010-019912-18,artritis,i
126,2010-019912-18,reumatoide,i
126,2010-019912-18,de,o
126,2010-019912-18,mayor,o
126,2010-019912-18,o,o
126,2010-019912-18,igual,o
126,2010-019912-18,a,o
126,2010-019912-18,6,o
126,2010-019912-18,meses,o
126,2010-019912-18,de,o
126,2010-019912-18,duracion,o
126,2010-019912-18,Recibir,o
126,2010-019912-18,tratamiento,i
126,2010-019912-18,de,i
126,2010-019912-18,forma,i
126,2010-019912-18,ambulatoria,i
126,2010-019912-18,Presentar,o
126,2010-019912-18,un,o
126,2010-019912-18,recuento,o
126,2010-019912-18,de,o
126,2010-019912-18,articulaciones,i
126,2010-019912-18,inflamadas,i
126,2010-019912-18,RAI,o
126,2010-019912-18,mayor,o
126,2010-019912-18,o,o
126,2010-019912-18,igual,o
126,2010-019912-18,a,o
126,2010-019912-18,6,o
126,2010-019912-18,recuento,o
126,2010-019912-18,de,o
126,2010-019912-18,66,o
126,2010-019912-18,articulaciones,i
126,2010-019912-18,y,o
126,2010-019912-18,de,o
126,2010-019912-18,articulaciones,i
126,2010-019912-18,dolorosas,i
126,2010-019912-18,RAD,o
126,2010-019912-18,mayor,o
126,2010-019912-18,o,o
126,2010-019912-18,igual,o
126,2010-019912-18,a,o
126,2010-019912-18,8,o
126,2010-019912-18,recuento,o
126,2010-019912-18,de,o
126,2010-019912-18,68,o
126,2010-019912-18,articulaciones,i
126,2010-019912-18,en,o
126,2010-019912-18,las,o
126,2010-019912-18,visitas,o
126,2010-019912-18,de,o
126,2010-019912-18,seleccion,o
126,2010-019912-18,y,o
126,2010-019912-18,basal,o
126,2010-019912-18,Los,o
126,2010-019912-18,pacientes,o
126,2010-019912-18,deben,o
126,2010-019912-18,estar,o
126,2010-019912-18,recibiendo,o
126,2010-019912-18,tratamiento,i
126,2010-019912-18,con,o
126,2010-019912-18,una,o
126,2010-019912-18,dosis,o
126,2010-019912-18,estable,o
126,2010-019912-18,de,o
126,2010-019912-18,los,o
126,2010-019912-18,FAMEs,i
126,2010-019912-18,permitidos,o
126,2010-019912-18,como,o
126,2010-019912-18,minimo,o
126,2010-019912-18,8,o
126,2010-019912-18,semanas,o
126,2010-019912-18,antes,o
126,2010-019912-18,de,o
126,2010-019912-18,la,o
126,2010-019912-18,visita,o
126,2010-019912-18,basal,o
126,2010-019912-18,Criterios,o
126,2010-019912-18,de,o
126,2010-019912-18,exclusion,o
126,2010-019912-18,Pacientes,o
126,2010-019912-18,sometidos,o
126,2010-019912-18,a,o
126,2010-019912-18,intervenciones,i
126,2010-019912-18,de,i
126,2010-019912-18,cirugia,i
126,2010-019912-18,mayor,i
126,2010-019912-18,incluyendo,o
126,2010-019912-18,cirugia,i
126,2010-019912-18,articular,i
126,2010-019912-18,en,o
126,2010-019912-18,las,o
126,2010-019912-18,8,o
126,2010-019912-18,semanas,o
126,2010-019912-18,previas,o
126,2010-019912-18,a,o
126,2010-019912-18,la,o
126,2010-019912-18,visita,o
126,2010-019912-18,de,o
126,2010-019912-18,seleccion,o
126,2010-019912-18,o,o
126,2010-019912-18,que,o
126,2010-019912-18,tengan,o
126,2010-019912-18,previsto,o
126,2010-019912-18,someterse,o
126,2010-019912-18,a,o
126,2010-019912-18,una,o
126,2010-019912-18,intervencion,i
126,2010-019912-18,de,o
126,2010-019912-18,este,o
126,2010-019912-18,tipo,o
126,2010-019912-18,en,o
126,2010-019912-18,los,o
126,2010-019912-18,6,o
126,2010-019912-18,meses,o
126,2010-019912-18,siguientes,o
126,2010-019912-18,a,o
126,2010-019912-18,la,o
126,2010-019912-18,randomizacion,i
126,2010-019912-18,Enfermedad,i
126,2010-019912-18,reumatica,i
126,2010-019912-18,autoinmune,i
126,2010-019912-18,distinta,o
126,2010-019912-18,de,o
126,2010-019912-18,AR,i
126,2010-019912-18,Se,o
126,2010-019912-18,permite,o
126,2010-019912-18,la,o
126,2010-019912-18,inclusion,o
126,2010-019912-18,de,o
126,2010-019912-18,pacientes,o
126,2010-019912-18,con,o
126,2010-019912-18,sindrome,i
126,2010-019912-18,de,i
126,2010-019912-18,Sjögren,i
126,2010-019912-18,secundario,i
126,2010-019912-18,asociado,o
126,2010-019912-18,a,o
126,2010-019912-18,AR,i
126,2010-019912-18,Clase,o
126,2010-019912-18,funcional,o
126,2010-019912-18,IV,o
126,2010-019912-18,definida,o
126,2010-019912-18,de,o
126,2010-019912-18,acuerdo,o
126,2010-019912-18,con,o
126,2010-019912-18,la,o
126,2010-019912-18,Clasificacion,o
126,2010-019912-18,del,o
126,2010-019912-18,ACR,o
126,2010-019912-18,del,o
126,2010-019912-18,Estado,o
126,2010-019912-18,Funcional,o
126,2010-019912-18,en,o
126,2010-019912-18,Artritis,i
126,2010-019912-18,Reumatoide,i
126,2010-019912-18,Artritis,i
126,2010-019912-18,idiopatica,i
126,2010-019912-18,juvenil,i
126,2010-019912-18,AIJ,i
126,2010-019912-18,o,o
126,2010-019912-18,artritis,i
126,2010-019912-18,reumatoide,i
126,2010-019912-18,juvenil,i
126,2010-019912-18,ARJ,i
126,2010-019912-18,yo,o
126,2010-019912-18,AR,i
126,2010-019912-18,diagnosticadas,i
126,2010-019912-18,antes,o
126,2010-019912-18,de,o
126,2010-019912-18,los,o
126,2010-019912-18,16,o
126,2010-019912-18,años,o
126,2010-019912-18,de,o
126,2010-019912-18,edad,o
126,2010-019912-18,Enfermedad,i
126,2010-019912-18,articular,i
126,2010-019912-18,inflamatoria,i
126,2010-019912-18,distinta,o
126,2010-019912-18,de,o
126,2010-019912-18,AR,i
126,2010-019912-18,en,o
126,2010-019912-18,el,o
126,2010-019912-18,pasado,o
126,2010-019912-18,o,o
126,2010-019912-18,en,o
126,2010-019912-18,la,o
126,2010-019912-18,actualidad,o
127,2010-019912-18,EudraCT,o
127,2010-019912-18,Nº,o
127,2010-019912-18,201001991218,o
127,2010-019912-18,Titulo,o
127,2010-019912-18,cientifico,o
127,2010-019912-18,Estudio,o
127,2010-019912-18,randomizado,o
127,2010-019912-18,doble,o
127,2010-019912-18,ciego,o
127,2010-019912-18,con,o
127,2010-019912-18,grupos,o
127,2010-019912-18,de,o
127,2010-019912-18,tratamiento,i
127,2010-019912-18,paralelos,o
127,2010-019912-18,para,o
127,2010-019912-18,evaluar,i
127,2010-019912-18,la,i
127,2010-019912-18,seguridad,i
127,2010-019912-18,y,o
127,2010-019912-18,el,o
127,2010-019912-18,efecto,o
127,2010-019912-18,sobre,o
127,2010-019912-18,el,o
127,2010-019912-18,resultado,o
127,2010-019912-18,clinico,o
127,2010-019912-18,de,o
127,2010-019912-18,tocilizumab,i
127,2010-019912-18,SC,o
127,2010-019912-18,frente,o
127,2010-019912-18,a,o
127,2010-019912-18,placebo,i
127,2010-019912-18,SC,o
127,2010-019912-18,en,o
127,2010-019912-18,combinacion,o
127,2010-019912-18,con,o
127,2010-019912-18,farmacos,i
127,2010-019912-18,antirreumaticos,i
127,2010-019912-18,modificadores,i
127,2010-019912-18,de,i
127,2010-019912-18,la,i
127,2010-019912-18,enfermedad,i
127,2010-019912-18,FAMEs,i
127,2010-019912-18,tradicionales,o
127,2010-019912-18,en,o
127,2010-019912-18,pacientes,o
127,2010-019912-18,con,o
127,2010-019912-18,artritis,i
127,2010-019912-18,reumatoide,i
127,2010-019912-18,activa,o
127,2010-019912-18,moderada,o
127,2010-019912-18,a,o
127,2010-019912-18,severa,o
127,2010-019912-18,Indicacion,o
127,2010-019912-18,cientifica,o
127,2010-019912-18,Artritis,i
127,2010-019912-18,Reumatoide,i
127,2010-019912-18,AR,i
127,2010-019912-18,Criterios,o
127,2010-019912-18,de,o
127,2010-019912-18,inclusion,o
127,2010-019912-18,Presentar,o
127,2010-019912-18,artritis,i
127,2010-019912-18,reumatoide,i
127,2010-019912-18,de,o
127,2010-019912-18,mayor,o
127,2010-019912-18,o,o
127,2010-019912-18,igual,o
127,2010-019912-18,a,o
127,2010-019912-18,6,o
127,2010-019912-18,meses,o
127,2010-019912-18,de,o
127,2010-019912-18,duracion,o
127,2010-019912-18,Recibir,o
127,2010-019912-18,tratamiento,i
127,2010-019912-18,de,i
127,2010-019912-18,forma,i
127,2010-019912-18,ambulatoria,i
127,2010-019912-18,Presentar,o
127,2010-019912-18,un,o
127,2010-019912-18,recuento,o
127,2010-019912-18,de,o
127,2010-019912-18,articulaciones,i
127,2010-019912-18,inflamadas,i
127,2010-019912-18,RAI,o
127,2010-019912-18,mayor,o
127,2010-019912-18,o,o
127,2010-019912-18,igual,o
127,2010-019912-18,a,o
127,2010-019912-18,6,o
127,2010-019912-18,recuento,o
127,2010-019912-18,de,o
127,2010-019912-18,66,o
127,2010-019912-18,articulaciones,i
127,2010-019912-18,y,o
127,2010-019912-18,de,o
127,2010-019912-18,articulaciones,i
127,2010-019912-18,dolorosas,i
127,2010-019912-18,RAD,o
127,2010-019912-18,mayor,o
127,2010-019912-18,o,o
127,2010-019912-18,igual,o
127,2010-019912-18,a,o
127,2010-019912-18,8,o
127,2010-019912-18,recuento,o
127,2010-019912-18,de,o
127,2010-019912-18,68,o
127,2010-019912-18,articulaciones,i
127,2010-019912-18,en,o
127,2010-019912-18,las,o
127,2010-019912-18,visitas,o
127,2010-019912-18,de,o
127,2010-019912-18,seleccion,o
127,2010-019912-18,y,o
127,2010-019912-18,basal,o
127,2010-019912-18,Los,o
127,2010-019912-18,pacientes,o
127,2010-019912-18,deben,o
127,2010-019912-18,estar,o
127,2010-019912-18,recibiendo,o
127,2010-019912-18,tratamiento,i
127,2010-019912-18,con,o
127,2010-019912-18,una,o
127,2010-019912-18,dosis,o
127,2010-019912-18,estable,o
127,2010-019912-18,de,o
127,2010-019912-18,los,o
127,2010-019912-18,FAMEs,i
127,2010-019912-18,permitidos,o
127,2010-019912-18,como,o
127,2010-019912-18,minimo,o
127,2010-019912-18,8,o
127,2010-019912-18,semanas,o
127,2010-019912-18,antes,o
127,2010-019912-18,de,o
127,2010-019912-18,la,o
127,2010-019912-18,visita,o
127,2010-019912-18,basal,o
127,2010-019912-18,Criterios,o
127,2010-019912-18,de,o
127,2010-019912-18,exclusion,o
127,2010-019912-18,Pacientes,o
127,2010-019912-18,sometidos,o
127,2010-019912-18,a,o
127,2010-019912-18,intervenciones,i
127,2010-019912-18,de,i
127,2010-019912-18,cirugia,i
127,2010-019912-18,mayor,i
127,2010-019912-18,incluyendo,o
127,2010-019912-18,cirugia,i
127,2010-019912-18,articular,i
127,2010-019912-18,en,o
127,2010-019912-18,las,o
127,2010-019912-18,8,o
127,2010-019912-18,semanas,o
127,2010-019912-18,previas,o
127,2010-019912-18,a,o
127,2010-019912-18,la,o
127,2010-019912-18,visita,o
127,2010-019912-18,de,o
127,2010-019912-18,seleccion,o
127,2010-019912-18,o,o
127,2010-019912-18,que,o
127,2010-019912-18,tengan,o
127,2010-019912-18,previsto,o
127,2010-019912-18,someterse,o
127,2010-019912-18,a,o
127,2010-019912-18,una,o
127,2010-019912-18,intervencion,i
127,2010-019912-18,de,o
127,2010-019912-18,este,o
127,2010-019912-18,tipo,o
127,2010-019912-18,en,o
127,2010-019912-18,los,o
127,2010-019912-18,6,o
127,2010-019912-18,meses,o
127,2010-019912-18,siguientes,o
127,2010-019912-18,a,o
127,2010-019912-18,la,o
127,2010-019912-18,randomizacion,i
127,2010-019912-18,Enfermedad,i
127,2010-019912-18,reumatica,i
127,2010-019912-18,autoinmune,i
127,2010-019912-18,distinta,o
127,2010-019912-18,de,o
127,2010-019912-18,AR,i
127,2010-019912-18,Se,o
127,2010-019912-18,permite,o
127,2010-019912-18,la,o
127,2010-019912-18,inclusion,o
127,2010-019912-18,de,o
127,2010-019912-18,pacientes,o
127,2010-019912-18,con,o
127,2010-019912-18,sindrome,i
127,2010-019912-18,de,i
127,2010-019912-18,Sjögren,i
127,2010-019912-18,secundario,i
127,2010-019912-18,asociado,o
127,2010-019912-18,a,o
127,2010-019912-18,AR,i
127,2010-019912-18,Clase,o
127,2010-019912-18,funcional,o
127,2010-019912-18,IV,o
127,2010-019912-18,definida,o
127,2010-019912-18,de,o
127,2010-019912-18,acuerdo,o
127,2010-019912-18,con,o
127,2010-019912-18,la,o
127,2010-019912-18,Clasificacion,o
127,2010-019912-18,del,o
127,2010-019912-18,ACR,o
127,2010-019912-18,del,o
127,2010-019912-18,Estado,o
127,2010-019912-18,Funcional,o
127,2010-019912-18,en,o
127,2010-019912-18,Artritis,i
127,2010-019912-18,Reumatoide,i
127,2010-019912-18,Artritis,i
127,2010-019912-18,idiopatica,i
127,2010-019912-18,juvenil,i
127,2010-019912-18,AIJ,i
127,2010-019912-18,o,o
127,2010-019912-18,artritis,i
127,2010-019912-18,reumatoide,i
127,2010-019912-18,juvenil,i
127,2010-019912-18,ARJ,i
127,2010-019912-18,yo,o
127,2010-019912-18,AR,i
127,2010-019912-18,diagnosticadas,i
127,2010-019912-18,antes,o
127,2010-019912-18,de,o
127,2010-019912-18,los,o
127,2010-019912-18,16,o
127,2010-019912-18,años,o
127,2010-019912-18,de,o
127,2010-019912-18,edad,o
127,2010-019912-18,Enfermedad,i
127,2010-019912-18,articular,i
127,2010-019912-18,inflamatoria,i
127,2010-019912-18,distinta,o
127,2010-019912-18,de,o
127,2010-019912-18,AR,i
127,2010-019912-18,en,o
127,2010-019912-18,el,o
127,2010-019912-18,pasado,o
127,2010-019912-18,o,o
127,2010-019912-18,en,o
127,2010-019912-18,la,o
127,2010-019912-18,actualidad,o
128,2010-019912-18,EudraCT,o
128,2010-019912-18,Nº,o
128,2010-019912-18,201001991218,o
128,2010-019912-18,Titulo,o
128,2010-019912-18,cientifico,o
128,2010-019912-18,Estudio,o
128,2010-019912-18,randomizado,o
128,2010-019912-18,doble,o
128,2010-019912-18,ciego,o
128,2010-019912-18,con,o
128,2010-019912-18,grupos,o
128,2010-019912-18,de,o
128,2010-019912-18,tratamiento,i
128,2010-019912-18,paralelos,o
128,2010-019912-18,para,o
128,2010-019912-18,evaluar,i
128,2010-019912-18,la,i
128,2010-019912-18,seguridad,i
128,2010-019912-18,y,o
128,2010-019912-18,el,o
128,2010-019912-18,efecto,o
128,2010-019912-18,sobre,o
128,2010-019912-18,el,o
128,2010-019912-18,resultado,o
128,2010-019912-18,clinico,o
128,2010-019912-18,de,o
128,2010-019912-18,tocilizumab,i
128,2010-019912-18,SC,o
128,2010-019912-18,frente,o
128,2010-019912-18,a,o
128,2010-019912-18,placebo,i
128,2010-019912-18,SC,o
128,2010-019912-18,en,o
128,2010-019912-18,combinacion,o
128,2010-019912-18,con,o
128,2010-019912-18,farmacos,i
128,2010-019912-18,antirreumaticos,i
128,2010-019912-18,modificadores,i
128,2010-019912-18,de,i
128,2010-019912-18,la,i
128,2010-019912-18,enfermedad,i
128,2010-019912-18,FAMEs,i
128,2010-019912-18,tradicionales,o
128,2010-019912-18,en,o
128,2010-019912-18,pacientes,o
128,2010-019912-18,con,o
128,2010-019912-18,artritis,i
128,2010-019912-18,reumatoide,i
128,2010-019912-18,activa,o
128,2010-019912-18,moderada,o
128,2010-019912-18,a,o
128,2010-019912-18,severa,o
128,2010-019912-18,Indicacion,o
128,2010-019912-18,cientifica,o
128,2010-019912-18,Artritis,i
128,2010-019912-18,Reumatoide,i
128,2010-019912-18,AR,i
128,2010-019912-18,Criterios,o
128,2010-019912-18,de,o
128,2010-019912-18,inclusion,o
128,2010-019912-18,Presentar,o
128,2010-019912-18,artritis,i
128,2010-019912-18,reumatoide,i
128,2010-019912-18,de,o
128,2010-019912-18,mayor,o
128,2010-019912-18,o,o
128,2010-019912-18,igual,o
128,2010-019912-18,a,o
128,2010-019912-18,6,o
128,2010-019912-18,meses,o
128,2010-019912-18,de,o
128,2010-019912-18,duracion,o
128,2010-019912-18,Recibir,o
128,2010-019912-18,tratamiento,i
128,2010-019912-18,de,i
128,2010-019912-18,forma,i
128,2010-019912-18,ambulatoria,i
128,2010-019912-18,Presentar,o
128,2010-019912-18,un,o
128,2010-019912-18,recuento,o
128,2010-019912-18,de,o
128,2010-019912-18,articulaciones,i
128,2010-019912-18,inflamadas,i
128,2010-019912-18,RAI,o
128,2010-019912-18,mayor,o
128,2010-019912-18,o,o
128,2010-019912-18,igual,o
128,2010-019912-18,a,o
128,2010-019912-18,6,o
128,2010-019912-18,recuento,o
128,2010-019912-18,de,o
128,2010-019912-18,66,o
128,2010-019912-18,articulaciones,i
128,2010-019912-18,y,o
128,2010-019912-18,de,o
128,2010-019912-18,articulaciones,i
128,2010-019912-18,dolorosas,i
128,2010-019912-18,RAD,o
128,2010-019912-18,mayor,o
128,2010-019912-18,o,o
128,2010-019912-18,igual,o
128,2010-019912-18,a,o
128,2010-019912-18,8,o
128,2010-019912-18,recuento,o
128,2010-019912-18,de,o
128,2010-019912-18,68,o
128,2010-019912-18,articulaciones,i
128,2010-019912-18,en,o
128,2010-019912-18,las,o
128,2010-019912-18,visitas,o
128,2010-019912-18,de,o
128,2010-019912-18,seleccion,o
128,2010-019912-18,y,o
128,2010-019912-18,basal,o
128,2010-019912-18,Los,o
128,2010-019912-18,pacientes,o
128,2010-019912-18,deben,o
128,2010-019912-18,estar,o
128,2010-019912-18,recibiendo,o
128,2010-019912-18,tratamiento,i
128,2010-019912-18,con,o
128,2010-019912-18,una,o
128,2010-019912-18,dosis,o
128,2010-019912-18,estable,o
128,2010-019912-18,de,o
128,2010-019912-18,los,o
128,2010-019912-18,FAMEs,i
128,2010-019912-18,permitidos,o
128,2010-019912-18,como,o
128,2010-019912-18,minimo,o
128,2010-019912-18,8,o
128,2010-019912-18,semanas,o
128,2010-019912-18,antes,o
128,2010-019912-18,de,o
128,2010-019912-18,la,o
128,2010-019912-18,visita,o
128,2010-019912-18,basal,o
128,2010-019912-18,Criterios,o
128,2010-019912-18,de,o
128,2010-019912-18,exclusion,o
128,2010-019912-18,Pacientes,o
128,2010-019912-18,sometidos,o
128,2010-019912-18,a,o
128,2010-019912-18,intervenciones,i
128,2010-019912-18,de,i
128,2010-019912-18,cirugia,i
128,2010-019912-18,mayor,i
128,2010-019912-18,incluyendo,o
128,2010-019912-18,cirugia,i
128,2010-019912-18,articular,i
128,2010-019912-18,en,o
128,2010-019912-18,las,o
128,2010-019912-18,8,o
128,2010-019912-18,semanas,o
128,2010-019912-18,previas,o
128,2010-019912-18,a,o
128,2010-019912-18,la,o
128,2010-019912-18,visita,o
128,2010-019912-18,de,o
128,2010-019912-18,seleccion,o
128,2010-019912-18,o,o
128,2010-019912-18,que,o
128,2010-019912-18,tengan,o
128,2010-019912-18,previsto,o
128,2010-019912-18,someterse,o
128,2010-019912-18,a,o
128,2010-019912-18,una,o
128,2010-019912-18,intervencion,i
128,2010-019912-18,de,o
128,2010-019912-18,este,o
128,2010-019912-18,tipo,o
128,2010-019912-18,en,o
128,2010-019912-18,los,o
128,2010-019912-18,6,o
128,2010-019912-18,meses,o
128,2010-019912-18,siguientes,o
128,2010-019912-18,a,o
128,2010-019912-18,la,o
128,2010-019912-18,randomizacion,i
128,2010-019912-18,Enfermedad,i
128,2010-019912-18,reumatica,i
128,2010-019912-18,autoinmune,i
128,2010-019912-18,distinta,o
128,2010-019912-18,de,o
128,2010-019912-18,AR,i
128,2010-019912-18,Se,o
128,2010-019912-18,permite,o
128,2010-019912-18,la,o
128,2010-019912-18,inclusion,o
128,2010-019912-18,de,o
128,2010-019912-18,pacientes,o
128,2010-019912-18,con,o
128,2010-019912-18,sindrome,i
128,2010-019912-18,de,i
128,2010-019912-18,Sjögren,i
128,2010-019912-18,secundario,i
128,2010-019912-18,asociado,o
128,2010-019912-18,a,o
128,2010-019912-18,AR,i
128,2010-019912-18,Clase,o
128,2010-019912-18,funcional,o
128,2010-019912-18,IV,o
128,2010-019912-18,definida,o
128,2010-019912-18,de,o
128,2010-019912-18,acuerdo,o
128,2010-019912-18,con,o
128,2010-019912-18,la,o
128,2010-019912-18,Clasificacion,o
128,2010-019912-18,del,o
128,2010-019912-18,ACR,o
128,2010-019912-18,del,o
128,2010-019912-18,Estado,o
128,2010-019912-18,Funcional,o
128,2010-019912-18,en,o
128,2010-019912-18,Artritis,i
128,2010-019912-18,Reumatoide,i
128,2010-019912-18,Artritis,i
128,2010-019912-18,idiopatica,i
128,2010-019912-18,juvenil,i
128,2010-019912-18,AIJ,i
128,2010-019912-18,o,o
128,2010-019912-18,artritis,i
128,2010-019912-18,reumatoide,i
128,2010-019912-18,juvenil,i
128,2010-019912-18,ARJ,i
128,2010-019912-18,yo,o
128,2010-019912-18,AR,i
128,2010-019912-18,diagnosticadas,i
128,2010-019912-18,antes,o
128,2010-019912-18,de,o
128,2010-019912-18,los,o
128,2010-019912-18,16,o
128,2010-019912-18,años,o
128,2010-019912-18,de,o
128,2010-019912-18,edad,o
128,2010-019912-18,Enfermedad,i
128,2010-019912-18,articular,i
128,2010-019912-18,inflamatoria,i
128,2010-019912-18,distinta,o
128,2010-019912-18,de,o
128,2010-019912-18,AR,i
128,2010-019912-18,en,o
128,2010-019912-18,el,o
128,2010-019912-18,pasado,o
128,2010-019912-18,o,o
128,2010-019912-18,en,o
128,2010-019912-18,la,o
128,2010-019912-18,actualidad,o
129,2010-019912-18,EudraCT,o
129,2010-019912-18,Nº,o
129,2010-019912-18,201001991218,o
129,2010-019912-18,Titulo,o
129,2010-019912-18,cientifico,o
129,2010-019912-18,Estudio,o
129,2010-019912-18,randomizado,o
129,2010-019912-18,doble,o
129,2010-019912-18,ciego,o
129,2010-019912-18,con,o
129,2010-019912-18,grupos,o
129,2010-019912-18,de,o
129,2010-019912-18,tratamiento,i
129,2010-019912-18,paralelos,o
129,2010-019912-18,para,o
129,2010-019912-18,evaluar,i
129,2010-019912-18,la,i
129,2010-019912-18,seguridad,i
129,2010-019912-18,y,o
129,2010-019912-18,el,o
129,2010-019912-18,efecto,o
129,2010-019912-18,sobre,o
129,2010-019912-18,el,o
129,2010-019912-18,resultado,o
129,2010-019912-18,clinico,o
129,2010-019912-18,de,o
129,2010-019912-18,tocilizumab,i
129,2010-019912-18,SC,o
129,2010-019912-18,frente,o
129,2010-019912-18,a,o
129,2010-019912-18,placebo,i
129,2010-019912-18,SC,o
129,2010-019912-18,en,o
129,2010-019912-18,combinacion,o
129,2010-019912-18,con,o
129,2010-019912-18,farmacos,i
129,2010-019912-18,antirreumaticos,i
129,2010-019912-18,modificadores,i
129,2010-019912-18,de,i
129,2010-019912-18,la,i
129,2010-019912-18,enfermedad,i
129,2010-019912-18,FAMEs,i
129,2010-019912-18,tradicionales,o
129,2010-019912-18,en,o
129,2010-019912-18,pacientes,o
129,2010-019912-18,con,o
129,2010-019912-18,artritis,i
129,2010-019912-18,reumatoide,i
129,2010-019912-18,activa,o
129,2010-019912-18,moderada,o
129,2010-019912-18,a,o
129,2010-019912-18,severa,o
129,2010-019912-18,Indicacion,o
129,2010-019912-18,cientifica,o
129,2010-019912-18,Artritis,i
129,2010-019912-18,Reumatoide,i
129,2010-019912-18,AR,i
129,2010-019912-18,Criterios,o
129,2010-019912-18,de,o
129,2010-019912-18,inclusion,o
129,2010-019912-18,Presentar,o
129,2010-019912-18,artritis,i
129,2010-019912-18,reumatoide,i
129,2010-019912-18,de,o
129,2010-019912-18,mayor,o
129,2010-019912-18,o,o
129,2010-019912-18,igual,o
129,2010-019912-18,a,o
129,2010-019912-18,6,o
129,2010-019912-18,meses,o
129,2010-019912-18,de,o
129,2010-019912-18,duracion,o
129,2010-019912-18,Recibir,o
129,2010-019912-18,tratamiento,i
129,2010-019912-18,de,i
129,2010-019912-18,forma,i
129,2010-019912-18,ambulatoria,i
129,2010-019912-18,Presentar,o
129,2010-019912-18,un,o
129,2010-019912-18,recuento,o
129,2010-019912-18,de,o
129,2010-019912-18,articulaciones,i
129,2010-019912-18,inflamadas,i
129,2010-019912-18,RAI,o
129,2010-019912-18,mayor,o
129,2010-019912-18,o,o
129,2010-019912-18,igual,o
129,2010-019912-18,a,o
129,2010-019912-18,6,o
129,2010-019912-18,recuento,o
129,2010-019912-18,de,o
129,2010-019912-18,66,o
129,2010-019912-18,articulaciones,i
129,2010-019912-18,y,o
129,2010-019912-18,de,o
129,2010-019912-18,articulaciones,i
129,2010-019912-18,dolorosas,i
129,2010-019912-18,RAD,o
129,2010-019912-18,mayor,o
129,2010-019912-18,o,o
129,2010-019912-18,igual,o
129,2010-019912-18,a,o
129,2010-019912-18,8,o
129,2010-019912-18,recuento,o
129,2010-019912-18,de,o
129,2010-019912-18,68,o
129,2010-019912-18,articulaciones,i
129,2010-019912-18,en,o
129,2010-019912-18,las,o
129,2010-019912-18,visitas,o
129,2010-019912-18,de,o
129,2010-019912-18,seleccion,o
129,2010-019912-18,y,o
129,2010-019912-18,basal,o
129,2010-019912-18,Los,o
129,2010-019912-18,pacientes,o
129,2010-019912-18,deben,o
129,2010-019912-18,estar,o
129,2010-019912-18,recibiendo,o
129,2010-019912-18,tratamiento,i
129,2010-019912-18,con,o
129,2010-019912-18,una,o
129,2010-019912-18,dosis,o
129,2010-019912-18,estable,o
129,2010-019912-18,de,o
129,2010-019912-18,los,o
129,2010-019912-18,FAMEs,i
129,2010-019912-18,permitidos,o
129,2010-019912-18,como,o
129,2010-019912-18,minimo,o
129,2010-019912-18,8,o
129,2010-019912-18,semanas,o
129,2010-019912-18,antes,o
129,2010-019912-18,de,o
129,2010-019912-18,la,o
129,2010-019912-18,visita,o
129,2010-019912-18,basal,o
129,2010-019912-18,Criterios,o
129,2010-019912-18,de,o
129,2010-019912-18,exclusion,o
129,2010-019912-18,Pacientes,o
129,2010-019912-18,sometidos,o
129,2010-019912-18,a,o
129,2010-019912-18,intervenciones,i
129,2010-019912-18,de,i
129,2010-019912-18,cirugia,i
129,2010-019912-18,mayor,i
129,2010-019912-18,incluyendo,o
129,2010-019912-18,cirugia,i
129,2010-019912-18,articular,i
129,2010-019912-18,en,o
129,2010-019912-18,las,o
129,2010-019912-18,8,o
129,2010-019912-18,semanas,o
129,2010-019912-18,previas,o
129,2010-019912-18,a,o
129,2010-019912-18,la,o
129,2010-019912-18,visita,o
129,2010-019912-18,de,o
129,2010-019912-18,seleccion,o
129,2010-019912-18,o,o
129,2010-019912-18,que,o
129,2010-019912-18,tengan,o
129,2010-019912-18,previsto,o
129,2010-019912-18,someterse,o
129,2010-019912-18,a,o
129,2010-019912-18,una,o
129,2010-019912-18,intervencion,i
129,2010-019912-18,de,o
129,2010-019912-18,este,o
129,2010-019912-18,tipo,o
129,2010-019912-18,en,o
129,2010-019912-18,los,o
129,2010-019912-18,6,o
129,2010-019912-18,meses,o
129,2010-019912-18,siguientes,o
129,2010-019912-18,a,o
129,2010-019912-18,la,o
129,2010-019912-18,randomizacion,i
129,2010-019912-18,Enfermedad,i
129,2010-019912-18,reumatica,i
129,2010-019912-18,autoinmune,i
129,2010-019912-18,distinta,o
129,2010-019912-18,de,o
129,2010-019912-18,AR,i
129,2010-019912-18,Se,o
129,2010-019912-18,permite,o
129,2010-019912-18,la,o
129,2010-019912-18,inclusion,o
129,2010-019912-18,de,o
129,2010-019912-18,pacientes,o
129,2010-019912-18,con,o
129,2010-019912-18,sindrome,i
129,2010-019912-18,de,i
129,2010-019912-18,Sjögren,i
129,2010-019912-18,secundario,i
129,2010-019912-18,asociado,o
129,2010-019912-18,a,o
129,2010-019912-18,AR,i
129,2010-019912-18,Clase,o
129,2010-019912-18,funcional,o
129,2010-019912-18,IV,o
129,2010-019912-18,definida,o
129,2010-019912-18,de,o
129,2010-019912-18,acuerdo,o
129,2010-019912-18,con,o
129,2010-019912-18,la,o
129,2010-019912-18,Clasificacion,o
129,2010-019912-18,del,o
129,2010-019912-18,ACR,o
129,2010-019912-18,del,o
129,2010-019912-18,Estado,o
129,2010-019912-18,Funcional,o
129,2010-019912-18,en,o
129,2010-019912-18,Artritis,i
129,2010-019912-18,Reumatoide,i
129,2010-019912-18,Artritis,i
129,2010-019912-18,idiopatica,i
129,2010-019912-18,juvenil,i
129,2010-019912-18,AIJ,i
129,2010-019912-18,o,o
129,2010-019912-18,artritis,i
129,2010-019912-18,reumatoide,i
129,2010-019912-18,juvenil,i
129,2010-019912-18,ARJ,i
129,2010-019912-18,yo,o
129,2010-019912-18,AR,i
129,2010-019912-18,diagnosticadas,i
129,2010-019912-18,antes,o
129,2010-019912-18,de,o
129,2010-019912-18,los,o
129,2010-019912-18,16,o
129,2010-019912-18,años,o
129,2010-019912-18,de,o
129,2010-019912-18,edad,o
129,2010-019912-18,Enfermedad,i
129,2010-019912-18,articular,i
129,2010-019912-18,inflamatoria,i
129,2010-019912-18,distinta,o
129,2010-019912-18,de,o
129,2010-019912-18,AR,i
129,2010-019912-18,en,o
129,2010-019912-18,el,o
129,2010-019912-18,pasado,o
129,2010-019912-18,o,o
129,2010-019912-18,en,o
129,2010-019912-18,la,o
129,2010-019912-18,actualidad,o
130,2010-019912-18,EudraCT,o
130,2010-019912-18,Nº,o
130,2010-019912-18,201001991218,o
130,2010-019912-18,Titulo,o
130,2010-019912-18,cientifico,o
130,2010-019912-18,Estudio,o
130,2010-019912-18,randomizado,o
130,2010-019912-18,doble,o
130,2010-019912-18,ciego,o
130,2010-019912-18,con,o
130,2010-019912-18,grupos,o
130,2010-019912-18,de,o
130,2010-019912-18,tratamiento,i
130,2010-019912-18,paralelos,o
130,2010-019912-18,para,o
130,2010-019912-18,evaluar,i
130,2010-019912-18,la,i
130,2010-019912-18,seguridad,i
130,2010-019912-18,y,o
130,2010-019912-18,el,o
130,2010-019912-18,efecto,o
130,2010-019912-18,sobre,o
130,2010-019912-18,el,o
130,2010-019912-18,resultado,o
130,2010-019912-18,clinico,o
130,2010-019912-18,de,o
130,2010-019912-18,tocilizumab,i
130,2010-019912-18,SC,o
130,2010-019912-18,frente,o
130,2010-019912-18,a,o
130,2010-019912-18,placebo,i
130,2010-019912-18,SC,o
130,2010-019912-18,en,o
130,2010-019912-18,combinacion,o
130,2010-019912-18,con,o
130,2010-019912-18,farmacos,i
130,2010-019912-18,antirreumaticos,i
130,2010-019912-18,modificadores,i
130,2010-019912-18,de,i
130,2010-019912-18,la,i
130,2010-019912-18,enfermedad,i
130,2010-019912-18,FAMEs,i
130,2010-019912-18,tradicionales,o
130,2010-019912-18,en,o
130,2010-019912-18,pacientes,o
130,2010-019912-18,con,o
130,2010-019912-18,artritis,i
130,2010-019912-18,reumatoide,i
130,2010-019912-18,activa,o
130,2010-019912-18,moderada,o
130,2010-019912-18,a,o
130,2010-019912-18,severa,o
130,2010-019912-18,Indicacion,o
130,2010-019912-18,cientifica,o
130,2010-019912-18,Artritis,i
130,2010-019912-18,Reumatoide,i
130,2010-019912-18,AR,i
130,2010-019912-18,Criterios,o
130,2010-019912-18,de,o
130,2010-019912-18,inclusion,o
130,2010-019912-18,Presentar,o
130,2010-019912-18,artritis,i
130,2010-019912-18,reumatoide,i
130,2010-019912-18,de,o
130,2010-019912-18,mayor,o
130,2010-019912-18,o,o
130,2010-019912-18,igual,o
130,2010-019912-18,a,o
130,2010-019912-18,6,o
130,2010-019912-18,meses,o
130,2010-019912-18,de,o
130,2010-019912-18,duracion,o
130,2010-019912-18,Recibir,o
130,2010-019912-18,tratamiento,i
130,2010-019912-18,de,i
130,2010-019912-18,forma,i
130,2010-019912-18,ambulatoria,i
130,2010-019912-18,Presentar,o
130,2010-019912-18,un,o
130,2010-019912-18,recuento,o
130,2010-019912-18,de,o
130,2010-019912-18,articulaciones,i
130,2010-019912-18,inflamadas,i
130,2010-019912-18,RAI,o
130,2010-019912-18,mayor,o
130,2010-019912-18,o,o
130,2010-019912-18,igual,o
130,2010-019912-18,a,o
130,2010-019912-18,6,o
130,2010-019912-18,recuento,o
130,2010-019912-18,de,o
130,2010-019912-18,66,o
130,2010-019912-18,articulaciones,i
130,2010-019912-18,y,o
130,2010-019912-18,de,o
130,2010-019912-18,articulaciones,i
130,2010-019912-18,dolorosas,i
130,2010-019912-18,RAD,o
130,2010-019912-18,mayor,o
130,2010-019912-18,o,o
130,2010-019912-18,igual,o
130,2010-019912-18,a,o
130,2010-019912-18,8,o
130,2010-019912-18,recuento,o
130,2010-019912-18,de,o
130,2010-019912-18,68,o
130,2010-019912-18,articulaciones,i
130,2010-019912-18,en,o
130,2010-019912-18,las,o
130,2010-019912-18,visitas,o
130,2010-019912-18,de,o
130,2010-019912-18,seleccion,o
130,2010-019912-18,y,o
130,2010-019912-18,basal,o
130,2010-019912-18,Los,o
130,2010-019912-18,pacientes,o
130,2010-019912-18,deben,o
130,2010-019912-18,estar,o
130,2010-019912-18,recibiendo,o
130,2010-019912-18,tratamiento,i
130,2010-019912-18,con,o
130,2010-019912-18,una,o
130,2010-019912-18,dosis,o
130,2010-019912-18,estable,o
130,2010-019912-18,de,o
130,2010-019912-18,los,o
130,2010-019912-18,FAMEs,i
130,2010-019912-18,permitidos,o
130,2010-019912-18,como,o
130,2010-019912-18,minimo,o
130,2010-019912-18,8,o
130,2010-019912-18,semanas,o
130,2010-019912-18,antes,o
130,2010-019912-18,de,o
130,2010-019912-18,la,o
130,2010-019912-18,visita,o
130,2010-019912-18,basal,o
130,2010-019912-18,Criterios,o
130,2010-019912-18,de,o
130,2010-019912-18,exclusion,o
130,2010-019912-18,Pacientes,o
130,2010-019912-18,sometidos,o
130,2010-019912-18,a,o
130,2010-019912-18,intervenciones,i
130,2010-019912-18,de,i
130,2010-019912-18,cirugia,i
130,2010-019912-18,mayor,i
130,2010-019912-18,incluyendo,o
130,2010-019912-18,cirugia,i
130,2010-019912-18,articular,i
130,2010-019912-18,en,o
130,2010-019912-18,las,o
130,2010-019912-18,8,o
130,2010-019912-18,semanas,o
130,2010-019912-18,previas,o
130,2010-019912-18,a,o
130,2010-019912-18,la,o
130,2010-019912-18,visita,o
130,2010-019912-18,de,o
130,2010-019912-18,seleccion,o
130,2010-019912-18,o,o
130,2010-019912-18,que,o
130,2010-019912-18,tengan,o
130,2010-019912-18,previsto,o
130,2010-019912-18,someterse,o
130,2010-019912-18,a,o
130,2010-019912-18,una,o
130,2010-019912-18,intervencion,i
130,2010-019912-18,de,o
130,2010-019912-18,este,o
130,2010-019912-18,tipo,o
130,2010-019912-18,en,o
130,2010-019912-18,los,o
130,2010-019912-18,6,o
130,2010-019912-18,meses,o
130,2010-019912-18,siguientes,o
130,2010-019912-18,a,o
130,2010-019912-18,la,o
130,2010-019912-18,randomizacion,i
130,2010-019912-18,Enfermedad,i
130,2010-019912-18,reumatica,i
130,2010-019912-18,autoinmune,i
130,2010-019912-18,distinta,o
130,2010-019912-18,de,o
130,2010-019912-18,AR,i
130,2010-019912-18,Se,o
130,2010-019912-18,permite,o
130,2010-019912-18,la,o
130,2010-019912-18,inclusion,o
130,2010-019912-18,de,o
130,2010-019912-18,pacientes,o
130,2010-019912-18,con,o
130,2010-019912-18,sindrome,i
130,2010-019912-18,de,i
130,2010-019912-18,Sjögren,i
130,2010-019912-18,secundario,i
130,2010-019912-18,asociado,o
130,2010-019912-18,a,o
130,2010-019912-18,AR,i
130,2010-019912-18,Clase,o
130,2010-019912-18,funcional,o
130,2010-019912-18,IV,o
130,2010-019912-18,definida,o
130,2010-019912-18,de,o
130,2010-019912-18,acuerdo,o
130,2010-019912-18,con,o
130,2010-019912-18,la,o
130,2010-019912-18,Clasificacion,o
130,2010-019912-18,del,o
130,2010-019912-18,ACR,o
130,2010-019912-18,del,o
130,2010-019912-18,Estado,o
130,2010-019912-18,Funcional,o
130,2010-019912-18,en,o
130,2010-019912-18,Artritis,i
130,2010-019912-18,Reumatoide,i
130,2010-019912-18,Artritis,i
130,2010-019912-18,idiopatica,i
130,2010-019912-18,juvenil,i
130,2010-019912-18,AIJ,i
130,2010-019912-18,o,o
130,2010-019912-18,artritis,i
130,2010-019912-18,reumatoide,i
130,2010-019912-18,juvenil,i
130,2010-019912-18,ARJ,i
130,2010-019912-18,yo,o
130,2010-019912-18,AR,i
130,2010-019912-18,diagnosticadas,i
130,2010-019912-18,antes,o
130,2010-019912-18,de,o
130,2010-019912-18,los,o
130,2010-019912-18,16,o
130,2010-019912-18,años,o
130,2010-019912-18,de,o
130,2010-019912-18,edad,o
130,2010-019912-18,Enfermedad,i
130,2010-019912-18,articular,i
130,2010-019912-18,inflamatoria,i
130,2010-019912-18,distinta,o
130,2010-019912-18,de,o
130,2010-019912-18,AR,i
130,2010-019912-18,en,o
130,2010-019912-18,el,o
130,2010-019912-18,pasado,o
130,2010-019912-18,o,o
130,2010-019912-18,en,o
130,2010-019912-18,la,o
130,2010-019912-18,actualidad,o
131,2010-019912-18,EudraCT,o
131,2010-019912-18,Nº,o
131,2010-019912-18,201001991218,o
131,2010-019912-18,Titulo,o
131,2010-019912-18,cientifico,o
131,2010-019912-18,Estudio,o
131,2010-019912-18,randomizado,o
131,2010-019912-18,doble,o
131,2010-019912-18,ciego,o
131,2010-019912-18,con,o
131,2010-019912-18,grupos,o
131,2010-019912-18,de,o
131,2010-019912-18,tratamiento,i
131,2010-019912-18,paralelos,o
131,2010-019912-18,para,o
131,2010-019912-18,evaluar,i
131,2010-019912-18,la,i
131,2010-019912-18,seguridad,i
131,2010-019912-18,y,o
131,2010-019912-18,el,o
131,2010-019912-18,efecto,o
131,2010-019912-18,sobre,o
131,2010-019912-18,el,o
131,2010-019912-18,resultado,o
131,2010-019912-18,clinico,o
131,2010-019912-18,de,o
131,2010-019912-18,tocilizumab,i
131,2010-019912-18,SC,o
131,2010-019912-18,frente,o
131,2010-019912-18,a,o
131,2010-019912-18,placebo,i
131,2010-019912-18,SC,o
131,2010-019912-18,en,o
131,2010-019912-18,combinacion,o
131,2010-019912-18,con,o
131,2010-019912-18,farmacos,i
131,2010-019912-18,antirreumaticos,i
131,2010-019912-18,modificadores,i
131,2010-019912-18,de,i
131,2010-019912-18,la,i
131,2010-019912-18,enfermedad,i
131,2010-019912-18,FAMEs,i
131,2010-019912-18,tradicionales,o
131,2010-019912-18,en,o
131,2010-019912-18,pacientes,o
131,2010-019912-18,con,o
131,2010-019912-18,artritis,i
131,2010-019912-18,reumatoide,i
131,2010-019912-18,activa,o
131,2010-019912-18,moderada,o
131,2010-019912-18,a,o
131,2010-019912-18,severa,o
131,2010-019912-18,Indicacion,o
131,2010-019912-18,cientifica,o
131,2010-019912-18,Artritis,i
131,2010-019912-18,Reumatoide,i
131,2010-019912-18,AR,i
131,2010-019912-18,Criterios,o
131,2010-019912-18,de,o
131,2010-019912-18,inclusion,o
131,2010-019912-18,Presentar,o
131,2010-019912-18,artritis,i
131,2010-019912-18,reumatoide,i
131,2010-019912-18,de,o
131,2010-019912-18,mayor,o
131,2010-019912-18,o,o
131,2010-019912-18,igual,o
131,2010-019912-18,a,o
131,2010-019912-18,6,o
131,2010-019912-18,meses,o
131,2010-019912-18,de,o
131,2010-019912-18,duracion,o
131,2010-019912-18,Recibir,o
131,2010-019912-18,tratamiento,i
131,2010-019912-18,de,i
131,2010-019912-18,forma,i
131,2010-019912-18,ambulatoria,i
131,2010-019912-18,Presentar,o
131,2010-019912-18,un,o
131,2010-019912-18,recuento,o
131,2010-019912-18,de,o
131,2010-019912-18,articulaciones,i
131,2010-019912-18,inflamadas,i
131,2010-019912-18,RAI,o
131,2010-019912-18,mayor,o
131,2010-019912-18,o,o
131,2010-019912-18,igual,o
131,2010-019912-18,a,o
131,2010-019912-18,6,o
131,2010-019912-18,recuento,o
131,2010-019912-18,de,o
131,2010-019912-18,66,o
131,2010-019912-18,articulaciones,i
131,2010-019912-18,y,o
131,2010-019912-18,de,o
131,2010-019912-18,articulaciones,i
131,2010-019912-18,dolorosas,i
131,2010-019912-18,RAD,o
131,2010-019912-18,mayor,o
131,2010-019912-18,o,o
131,2010-019912-18,igual,o
131,2010-019912-18,a,o
131,2010-019912-18,8,o
131,2010-019912-18,recuento,o
131,2010-019912-18,de,o
131,2010-019912-18,68,o
131,2010-019912-18,articulaciones,i
131,2010-019912-18,en,o
131,2010-019912-18,las,o
131,2010-019912-18,visitas,o
131,2010-019912-18,de,o
131,2010-019912-18,seleccion,o
131,2010-019912-18,y,o
131,2010-019912-18,basal,o
131,2010-019912-18,Los,o
131,2010-019912-18,pacientes,o
131,2010-019912-18,deben,o
131,2010-019912-18,estar,o
131,2010-019912-18,recibiendo,o
131,2010-019912-18,tratamiento,i
131,2010-019912-18,con,o
131,2010-019912-18,una,o
131,2010-019912-18,dosis,o
131,2010-019912-18,estable,o
131,2010-019912-18,de,o
131,2010-019912-18,los,o
131,2010-019912-18,FAMEs,i
131,2010-019912-18,permitidos,o
131,2010-019912-18,como,o
131,2010-019912-18,minimo,o
131,2010-019912-18,8,o
131,2010-019912-18,semanas,o
131,2010-019912-18,antes,o
131,2010-019912-18,de,o
131,2010-019912-18,la,o
131,2010-019912-18,visita,o
131,2010-019912-18,basal,o
131,2010-019912-18,Criterios,o
131,2010-019912-18,de,o
131,2010-019912-18,exclusion,o
131,2010-019912-18,Pacientes,o
131,2010-019912-18,sometidos,o
131,2010-019912-18,a,o
131,2010-019912-18,intervenciones,i
131,2010-019912-18,de,i
131,2010-019912-18,cirugia,i
131,2010-019912-18,mayor,i
131,2010-019912-18,incluyendo,o
131,2010-019912-18,cirugia,i
131,2010-019912-18,articular,i
131,2010-019912-18,en,o
131,2010-019912-18,las,o
131,2010-019912-18,8,o
131,2010-019912-18,semanas,o
131,2010-019912-18,previas,o
131,2010-019912-18,a,o
131,2010-019912-18,la,o
131,2010-019912-18,visita,o
131,2010-019912-18,de,o
131,2010-019912-18,seleccion,o
131,2010-019912-18,o,o
131,2010-019912-18,que,o
131,2010-019912-18,tengan,o
131,2010-019912-18,previsto,o
131,2010-019912-18,someterse,o
131,2010-019912-18,a,o
131,2010-019912-18,una,o
131,2010-019912-18,intervencion,i
131,2010-019912-18,de,o
131,2010-019912-18,este,o
131,2010-019912-18,tipo,o
131,2010-019912-18,en,o
131,2010-019912-18,los,o
131,2010-019912-18,6,o
131,2010-019912-18,meses,o
131,2010-019912-18,siguientes,o
131,2010-019912-18,a,o
131,2010-019912-18,la,o
131,2010-019912-18,randomizacion,i
131,2010-019912-18,Enfermedad,i
131,2010-019912-18,reumatica,i
131,2010-019912-18,autoinmune,i
131,2010-019912-18,distinta,o
131,2010-019912-18,de,o
131,2010-019912-18,AR,i
131,2010-019912-18,Se,o
131,2010-019912-18,permite,o
131,2010-019912-18,la,o
131,2010-019912-18,inclusion,o
131,2010-019912-18,de,o
131,2010-019912-18,pacientes,o
131,2010-019912-18,con,o
131,2010-019912-18,sindrome,i
131,2010-019912-18,de,i
131,2010-019912-18,Sjögren,i
131,2010-019912-18,secundario,i
131,2010-019912-18,asociado,o
131,2010-019912-18,a,o
131,2010-019912-18,AR,i
131,2010-019912-18,Clase,o
131,2010-019912-18,funcional,o
131,2010-019912-18,IV,o
131,2010-019912-18,definida,o
131,2010-019912-18,de,o
131,2010-019912-18,acuerdo,o
131,2010-019912-18,con,o
131,2010-019912-18,la,o
131,2010-019912-18,Clasificacion,o
131,2010-019912-18,del,o
131,2010-019912-18,ACR,o
131,2010-019912-18,del,o
131,2010-019912-18,Estado,o
131,2010-019912-18,Funcional,o
131,2010-019912-18,en,o
131,2010-019912-18,Artritis,i
131,2010-019912-18,Reumatoide,i
131,2010-019912-18,Artritis,i
131,2010-019912-18,idiopatica,i
131,2010-019912-18,juvenil,i
131,2010-019912-18,AIJ,i
131,2010-019912-18,o,o
131,2010-019912-18,artritis,i
131,2010-019912-18,reumatoide,i
131,2010-019912-18,juvenil,i
131,2010-019912-18,ARJ,i
131,2010-019912-18,yo,o
131,2010-019912-18,AR,i
131,2010-019912-18,diagnosticadas,i
131,2010-019912-18,antes,o
131,2010-019912-18,de,o
131,2010-019912-18,los,o
131,2010-019912-18,16,o
131,2010-019912-18,años,o
131,2010-019912-18,de,o
131,2010-019912-18,edad,o
131,2010-019912-18,Enfermedad,i
131,2010-019912-18,articular,i
131,2010-019912-18,inflamatoria,i
131,2010-019912-18,distinta,o
131,2010-019912-18,de,o
131,2010-019912-18,AR,i
131,2010-019912-18,en,o
131,2010-019912-18,el,o
131,2010-019912-18,pasado,o
131,2010-019912-18,o,o
131,2010-019912-18,en,o
131,2010-019912-18,la,o
131,2010-019912-18,actualidad,o
132,2010-019912-18,EudraCT,o
132,2010-019912-18,Nº,o
132,2010-019912-18,201001991218,o
132,2010-019912-18,Titulo,o
132,2010-019912-18,cientifico,o
132,2010-019912-18,Estudio,o
132,2010-019912-18,randomizado,o
132,2010-019912-18,doble,o
132,2010-019912-18,ciego,o
132,2010-019912-18,con,o
132,2010-019912-18,grupos,o
132,2010-019912-18,de,o
132,2010-019912-18,tratamiento,i
132,2010-019912-18,paralelos,o
132,2010-019912-18,para,o
132,2010-019912-18,evaluar,i
132,2010-019912-18,la,i
132,2010-019912-18,seguridad,i
132,2010-019912-18,y,o
132,2010-019912-18,el,o
132,2010-019912-18,efecto,o
132,2010-019912-18,sobre,o
132,2010-019912-18,el,o
132,2010-019912-18,resultado,o
132,2010-019912-18,clinico,o
132,2010-019912-18,de,o
132,2010-019912-18,tocilizumab,i
132,2010-019912-18,SC,o
132,2010-019912-18,frente,o
132,2010-019912-18,a,o
132,2010-019912-18,placebo,i
132,2010-019912-18,SC,o
132,2010-019912-18,en,o
132,2010-019912-18,combinacion,o
132,2010-019912-18,con,o
132,2010-019912-18,farmacos,i
132,2010-019912-18,antirreumaticos,i
132,2010-019912-18,modificadores,i
132,2010-019912-18,de,i
132,2010-019912-18,la,i
132,2010-019912-18,enfermedad,i
132,2010-019912-18,FAMEs,i
132,2010-019912-18,tradicionales,o
132,2010-019912-18,en,o
132,2010-019912-18,pacientes,o
132,2010-019912-18,con,o
132,2010-019912-18,artritis,i
132,2010-019912-18,reumatoide,i
132,2010-019912-18,activa,o
132,2010-019912-18,moderada,o
132,2010-019912-18,a,o
132,2010-019912-18,severa,o
132,2010-019912-18,Indicacion,o
132,2010-019912-18,cientifica,o
132,2010-019912-18,Artritis,i
132,2010-019912-18,Reumatoide,i
132,2010-019912-18,AR,i
132,2010-019912-18,Criterios,o
132,2010-019912-18,de,o
132,2010-019912-18,inclusion,o
132,2010-019912-18,Presentar,o
132,2010-019912-18,artritis,i
132,2010-019912-18,reumatoide,i
132,2010-019912-18,de,o
132,2010-019912-18,mayor,o
132,2010-019912-18,o,o
132,2010-019912-18,igual,o
132,2010-019912-18,a,o
132,2010-019912-18,6,o
132,2010-019912-18,meses,o
132,2010-019912-18,de,o
132,2010-019912-18,duracion,o
132,2010-019912-18,Recibir,o
132,2010-019912-18,tratamiento,i
132,2010-019912-18,de,i
132,2010-019912-18,forma,i
132,2010-019912-18,ambulatoria,i
132,2010-019912-18,Presentar,o
132,2010-019912-18,un,o
132,2010-019912-18,recuento,o
132,2010-019912-18,de,o
132,2010-019912-18,articulaciones,i
132,2010-019912-18,inflamadas,i
132,2010-019912-18,RAI,o
132,2010-019912-18,mayor,o
132,2010-019912-18,o,o
132,2010-019912-18,igual,o
132,2010-019912-18,a,o
132,2010-019912-18,6,o
132,2010-019912-18,recuento,o
132,2010-019912-18,de,o
132,2010-019912-18,66,o
132,2010-019912-18,articulaciones,i
132,2010-019912-18,y,o
132,2010-019912-18,de,o
132,2010-019912-18,articulaciones,i
132,2010-019912-18,dolorosas,i
132,2010-019912-18,RAD,o
132,2010-019912-18,mayor,o
132,2010-019912-18,o,o
132,2010-019912-18,igual,o
132,2010-019912-18,a,o
132,2010-019912-18,8,o
132,2010-019912-18,recuento,o
132,2010-019912-18,de,o
132,2010-019912-18,68,o
132,2010-019912-18,articulaciones,i
132,2010-019912-18,en,o
132,2010-019912-18,las,o
132,2010-019912-18,visitas,o
132,2010-019912-18,de,o
132,2010-019912-18,seleccion,o
132,2010-019912-18,y,o
132,2010-019912-18,basal,o
132,2010-019912-18,Los,o
132,2010-019912-18,pacientes,o
132,2010-019912-18,deben,o
132,2010-019912-18,estar,o
132,2010-019912-18,recibiendo,o
132,2010-019912-18,tratamiento,i
132,2010-019912-18,con,o
132,2010-019912-18,una,o
132,2010-019912-18,dosis,o
132,2010-019912-18,estable,o
132,2010-019912-18,de,o
132,2010-019912-18,los,o
132,2010-019912-18,FAMEs,i
132,2010-019912-18,permitidos,o
132,2010-019912-18,como,o
132,2010-019912-18,minimo,o
132,2010-019912-18,8,o
132,2010-019912-18,semanas,o
132,2010-019912-18,antes,o
132,2010-019912-18,de,o
132,2010-019912-18,la,o
132,2010-019912-18,visita,o
132,2010-019912-18,basal,o
132,2010-019912-18,Criterios,o
132,2010-019912-18,de,o
132,2010-019912-18,exclusion,o
132,2010-019912-18,Pacientes,o
132,2010-019912-18,sometidos,o
132,2010-019912-18,a,o
132,2010-019912-18,intervenciones,i
132,2010-019912-18,de,i
132,2010-019912-18,cirugia,i
132,2010-019912-18,mayor,i
132,2010-019912-18,incluyendo,o
132,2010-019912-18,cirugia,i
132,2010-019912-18,articular,i
132,2010-019912-18,en,o
132,2010-019912-18,las,o
132,2010-019912-18,8,o
132,2010-019912-18,semanas,o
132,2010-019912-18,previas,o
132,2010-019912-18,a,o
132,2010-019912-18,la,o
132,2010-019912-18,visita,o
132,2010-019912-18,de,o
132,2010-019912-18,seleccion,o
132,2010-019912-18,o,o
132,2010-019912-18,que,o
132,2010-019912-18,tengan,o
132,2010-019912-18,previsto,o
132,2010-019912-18,someterse,o
132,2010-019912-18,a,o
132,2010-019912-18,una,o
132,2010-019912-18,intervencion,i
132,2010-019912-18,de,o
132,2010-019912-18,este,o
132,2010-019912-18,tipo,o
132,2010-019912-18,en,o
132,2010-019912-18,los,o
132,2010-019912-18,6,o
132,2010-019912-18,meses,o
132,2010-019912-18,siguientes,o
132,2010-019912-18,a,o
132,2010-019912-18,la,o
132,2010-019912-18,randomizacion,i
132,2010-019912-18,Enfermedad,i
132,2010-019912-18,reumatica,i
132,2010-019912-18,autoinmune,i
132,2010-019912-18,distinta,o
132,2010-019912-18,de,o
132,2010-019912-18,AR,i
132,2010-019912-18,Se,o
132,2010-019912-18,permite,o
132,2010-019912-18,la,o
132,2010-019912-18,inclusion,o
132,2010-019912-18,de,o
132,2010-019912-18,pacientes,o
132,2010-019912-18,con,o
132,2010-019912-18,sindrome,i
132,2010-019912-18,de,i
132,2010-019912-18,Sjögren,i
132,2010-019912-18,secundario,i
132,2010-019912-18,asociado,o
132,2010-019912-18,a,o
132,2010-019912-18,AR,i
132,2010-019912-18,Clase,o
132,2010-019912-18,funcional,o
132,2010-019912-18,IV,o
132,2010-019912-18,definida,o
132,2010-019912-18,de,o
132,2010-019912-18,acuerdo,o
132,2010-019912-18,con,o
132,2010-019912-18,la,o
132,2010-019912-18,Clasificacion,o
132,2010-019912-18,del,o
132,2010-019912-18,ACR,o
132,2010-019912-18,del,o
132,2010-019912-18,Estado,o
132,2010-019912-18,Funcional,o
132,2010-019912-18,en,o
132,2010-019912-18,Artritis,i
132,2010-019912-18,Reumatoide,i
132,2010-019912-18,Artritis,i
132,2010-019912-18,idiopatica,i
132,2010-019912-18,juvenil,i
132,2010-019912-18,AIJ,i
132,2010-019912-18,o,o
132,2010-019912-18,artritis,i
132,2010-019912-18,reumatoide,i
132,2010-019912-18,juvenil,i
132,2010-019912-18,ARJ,i
132,2010-019912-18,yo,o
132,2010-019912-18,AR,i
132,2010-019912-18,diagnosticadas,i
132,2010-019912-18,antes,o
132,2010-019912-18,de,o
132,2010-019912-18,los,o
132,2010-019912-18,16,o
132,2010-019912-18,años,o
132,2010-019912-18,de,o
132,2010-019912-18,edad,o
132,2010-019912-18,Enfermedad,i
132,2010-019912-18,articular,i
132,2010-019912-18,inflamatoria,i
132,2010-019912-18,distinta,o
132,2010-019912-18,de,o
132,2010-019912-18,AR,i
132,2010-019912-18,en,o
132,2010-019912-18,el,o
132,2010-019912-18,pasado,o
132,2010-019912-18,o,o
132,2010-019912-18,en,o
132,2010-019912-18,la,o
132,2010-019912-18,actualidad,o
133,2010-019912-18,EudraCT,o
133,2010-019912-18,Nº,o
133,2010-019912-18,201001991218,o
133,2010-019912-18,Titulo,o
133,2010-019912-18,cientifico,o
133,2010-019912-18,Estudio,o
133,2010-019912-18,randomizado,o
133,2010-019912-18,doble,o
133,2010-019912-18,ciego,o
133,2010-019912-18,con,o
133,2010-019912-18,grupos,o
133,2010-019912-18,de,o
133,2010-019912-18,tratamiento,i
133,2010-019912-18,paralelos,o
133,2010-019912-18,para,o
133,2010-019912-18,evaluar,i
133,2010-019912-18,la,i
133,2010-019912-18,seguridad,i
133,2010-019912-18,y,o
133,2010-019912-18,el,o
133,2010-019912-18,efecto,o
133,2010-019912-18,sobre,o
133,2010-019912-18,el,o
133,2010-019912-18,resultado,o
133,2010-019912-18,clinico,o
133,2010-019912-18,de,o
133,2010-019912-18,tocilizumab,i
133,2010-019912-18,SC,o
133,2010-019912-18,frente,o
133,2010-019912-18,a,o
133,2010-019912-18,placebo,i
133,2010-019912-18,SC,o
133,2010-019912-18,en,o
133,2010-019912-18,combinacion,o
133,2010-019912-18,con,o
133,2010-019912-18,farmacos,i
133,2010-019912-18,antirreumaticos,i
133,2010-019912-18,modificadores,i
133,2010-019912-18,de,i
133,2010-019912-18,la,i
133,2010-019912-18,enfermedad,i
133,2010-019912-18,FAMEs,i
133,2010-019912-18,tradicionales,o
133,2010-019912-18,en,o
133,2010-019912-18,pacientes,o
133,2010-019912-18,con,o
133,2010-019912-18,artritis,i
133,2010-019912-18,reumatoide,i
133,2010-019912-18,activa,o
133,2010-019912-18,moderada,o
133,2010-019912-18,a,o
133,2010-019912-18,severa,o
133,2010-019912-18,Indicacion,o
133,2010-019912-18,cientifica,o
133,2010-019912-18,Artritis,i
133,2010-019912-18,Reumatoide,i
133,2010-019912-18,AR,i
133,2010-019912-18,Criterios,o
133,2010-019912-18,de,o
133,2010-019912-18,inclusion,o
133,2010-019912-18,Presentar,o
133,2010-019912-18,artritis,i
133,2010-019912-18,reumatoide,i
133,2010-019912-18,de,o
133,2010-019912-18,mayor,o
133,2010-019912-18,o,o
133,2010-019912-18,igual,o
133,2010-019912-18,a,o
133,2010-019912-18,6,o
133,2010-019912-18,meses,o
133,2010-019912-18,de,o
133,2010-019912-18,duracion,o
133,2010-019912-18,Recibir,o
133,2010-019912-18,tratamiento,i
133,2010-019912-18,de,i
133,2010-019912-18,forma,i
133,2010-019912-18,ambulatoria,i
133,2010-019912-18,Presentar,o
133,2010-019912-18,un,o
133,2010-019912-18,recuento,o
133,2010-019912-18,de,o
133,2010-019912-18,articulaciones,i
133,2010-019912-18,inflamadas,i
133,2010-019912-18,RAI,o
133,2010-019912-18,mayor,o
133,2010-019912-18,o,o
133,2010-019912-18,igual,o
133,2010-019912-18,a,o
133,2010-019912-18,6,o
133,2010-019912-18,recuento,o
133,2010-019912-18,de,o
133,2010-019912-18,66,o
133,2010-019912-18,articulaciones,i
133,2010-019912-18,y,o
133,2010-019912-18,de,o
133,2010-019912-18,articulaciones,i
133,2010-019912-18,dolorosas,i
133,2010-019912-18,RAD,o
133,2010-019912-18,mayor,o
133,2010-019912-18,o,o
133,2010-019912-18,igual,o
133,2010-019912-18,a,o
133,2010-019912-18,8,o
133,2010-019912-18,recuento,o
133,2010-019912-18,de,o
133,2010-019912-18,68,o
133,2010-019912-18,articulaciones,i
133,2010-019912-18,en,o
133,2010-019912-18,las,o
133,2010-019912-18,visitas,o
133,2010-019912-18,de,o
133,2010-019912-18,seleccion,o
133,2010-019912-18,y,o
133,2010-019912-18,basal,o
133,2010-019912-18,Los,o
133,2010-019912-18,pacientes,o
133,2010-019912-18,deben,o
133,2010-019912-18,estar,o
133,2010-019912-18,recibiendo,o
133,2010-019912-18,tratamiento,i
133,2010-019912-18,con,o
133,2010-019912-18,una,o
133,2010-019912-18,dosis,o
133,2010-019912-18,estable,o
133,2010-019912-18,de,o
133,2010-019912-18,los,o
133,2010-019912-18,FAMEs,i
133,2010-019912-18,permitidos,o
133,2010-019912-18,como,o
133,2010-019912-18,minimo,o
133,2010-019912-18,8,o
133,2010-019912-18,semanas,o
133,2010-019912-18,antes,o
133,2010-019912-18,de,o
133,2010-019912-18,la,o
133,2010-019912-18,visita,o
133,2010-019912-18,basal,o
133,2010-019912-18,Criterios,o
133,2010-019912-18,de,o
133,2010-019912-18,exclusion,o
133,2010-019912-18,Pacientes,o
133,2010-019912-18,sometidos,o
133,2010-019912-18,a,o
133,2010-019912-18,intervenciones,i
133,2010-019912-18,de,i
133,2010-019912-18,cirugia,i
133,2010-019912-18,mayor,i
133,2010-019912-18,incluyendo,o
133,2010-019912-18,cirugia,i
133,2010-019912-18,articular,i
133,2010-019912-18,en,o
133,2010-019912-18,las,o
133,2010-019912-18,8,o
133,2010-019912-18,semanas,o
133,2010-019912-18,previas,o
133,2010-019912-18,a,o
133,2010-019912-18,la,o
133,2010-019912-18,visita,o
133,2010-019912-18,de,o
133,2010-019912-18,seleccion,o
133,2010-019912-18,o,o
133,2010-019912-18,que,o
133,2010-019912-18,tengan,o
133,2010-019912-18,previsto,o
133,2010-019912-18,someterse,o
133,2010-019912-18,a,o
133,2010-019912-18,una,o
133,2010-019912-18,intervencion,i
133,2010-019912-18,de,o
133,2010-019912-18,este,o
133,2010-019912-18,tipo,o
133,2010-019912-18,en,o
133,2010-019912-18,los,o
133,2010-019912-18,6,o
133,2010-019912-18,meses,o
133,2010-019912-18,siguientes,o
133,2010-019912-18,a,o
133,2010-019912-18,la,o
133,2010-019912-18,randomizacion,i
133,2010-019912-18,Enfermedad,i
133,2010-019912-18,reumatica,i
133,2010-019912-18,autoinmune,i
133,2010-019912-18,distinta,o
133,2010-019912-18,de,o
133,2010-019912-18,AR,i
133,2010-019912-18,Se,o
133,2010-019912-18,permite,o
133,2010-019912-18,la,o
133,2010-019912-18,inclusion,o
133,2010-019912-18,de,o
133,2010-019912-18,pacientes,o
133,2010-019912-18,con,o
133,2010-019912-18,sindrome,i
133,2010-019912-18,de,i
133,2010-019912-18,Sjögren,i
133,2010-019912-18,secundario,i
133,2010-019912-18,asociado,o
133,2010-019912-18,a,o
133,2010-019912-18,AR,i
133,2010-019912-18,Clase,o
133,2010-019912-18,funcional,o
133,2010-019912-18,IV,o
133,2010-019912-18,definida,o
133,2010-019912-18,de,o
133,2010-019912-18,acuerdo,o
133,2010-019912-18,con,o
133,2010-019912-18,la,o
133,2010-019912-18,Clasificacion,o
133,2010-019912-18,del,o
133,2010-019912-18,ACR,o
133,2010-019912-18,del,o
133,2010-019912-18,Estado,o
133,2010-019912-18,Funcional,o
133,2010-019912-18,en,o
133,2010-019912-18,Artritis,i
133,2010-019912-18,Reumatoide,i
133,2010-019912-18,Artritis,i
133,2010-019912-18,idiopatica,i
133,2010-019912-18,juvenil,i
133,2010-019912-18,AIJ,i
133,2010-019912-18,o,o
133,2010-019912-18,artritis,i
133,2010-019912-18,reumatoide,i
133,2010-019912-18,juvenil,i
133,2010-019912-18,ARJ,i
133,2010-019912-18,yo,o
133,2010-019912-18,AR,i
133,2010-019912-18,diagnosticadas,i
133,2010-019912-18,antes,o
133,2010-019912-18,de,o
133,2010-019912-18,los,o
133,2010-019912-18,16,o
133,2010-019912-18,años,o
133,2010-019912-18,de,o
133,2010-019912-18,edad,o
133,2010-019912-18,Enfermedad,i
133,2010-019912-18,articular,i
133,2010-019912-18,inflamatoria,i
133,2010-019912-18,distinta,o
133,2010-019912-18,de,o
133,2010-019912-18,AR,i
133,2010-019912-18,en,o
133,2010-019912-18,el,o
133,2010-019912-18,pasado,o
133,2010-019912-18,o,o
133,2010-019912-18,en,o
133,2010-019912-18,la,o
133,2010-019912-18,actualidad,o
134,2010-019912-18,EudraCT,o
134,2010-019912-18,Nº,o
134,2010-019912-18,201001991218,o
134,2010-019912-18,Titulo,o
134,2010-019912-18,cientifico,o
134,2010-019912-18,Estudio,o
134,2010-019912-18,randomizado,o
134,2010-019912-18,doble,o
134,2010-019912-18,ciego,o
134,2010-019912-18,con,o
134,2010-019912-18,grupos,o
134,2010-019912-18,de,o
134,2010-019912-18,tratamiento,i
134,2010-019912-18,paralelos,o
134,2010-019912-18,para,o
134,2010-019912-18,evaluar,i
134,2010-019912-18,la,i
134,2010-019912-18,seguridad,i
134,2010-019912-18,y,o
134,2010-019912-18,el,o
134,2010-019912-18,efecto,o
134,2010-019912-18,sobre,o
134,2010-019912-18,el,o
134,2010-019912-18,resultado,o
134,2010-019912-18,clinico,o
134,2010-019912-18,de,o
134,2010-019912-18,tocilizumab,i
134,2010-019912-18,SC,o
134,2010-019912-18,frente,o
134,2010-019912-18,a,o
134,2010-019912-18,placebo,i
134,2010-019912-18,SC,o
134,2010-019912-18,en,o
134,2010-019912-18,combinacion,o
134,2010-019912-18,con,o
134,2010-019912-18,farmacos,i
134,2010-019912-18,antirreumaticos,i
134,2010-019912-18,modificadores,i
134,2010-019912-18,de,i
134,2010-019912-18,la,i
134,2010-019912-18,enfermedad,i
134,2010-019912-18,FAMEs,i
134,2010-019912-18,tradicionales,o
134,2010-019912-18,en,o
134,2010-019912-18,pacientes,o
134,2010-019912-18,con,o
134,2010-019912-18,artritis,i
134,2010-019912-18,reumatoide,i
134,2010-019912-18,activa,o
134,2010-019912-18,moderada,o
134,2010-019912-18,a,o
134,2010-019912-18,severa,o
134,2010-019912-18,Indicacion,o
134,2010-019912-18,cientifica,o
134,2010-019912-18,Artritis,i
134,2010-019912-18,Reumatoide,i
134,2010-019912-18,AR,i
134,2010-019912-18,Criterios,o
134,2010-019912-18,de,o
134,2010-019912-18,inclusion,o
134,2010-019912-18,Presentar,o
134,2010-019912-18,artritis,i
134,2010-019912-18,reumatoide,i
134,2010-019912-18,de,o
134,2010-019912-18,mayor,o
134,2010-019912-18,o,o
134,2010-019912-18,igual,o
134,2010-019912-18,a,o
134,2010-019912-18,6,o
134,2010-019912-18,meses,o
134,2010-019912-18,de,o
134,2010-019912-18,duracion,o
134,2010-019912-18,Recibir,o
134,2010-019912-18,tratamiento,i
134,2010-019912-18,de,i
134,2010-019912-18,forma,i
134,2010-019912-18,ambulatoria,i
134,2010-019912-18,Presentar,o
134,2010-019912-18,un,o
134,2010-019912-18,recuento,o
134,2010-019912-18,de,o
134,2010-019912-18,articulaciones,i
134,2010-019912-18,inflamadas,i
134,2010-019912-18,RAI,o
134,2010-019912-18,mayor,o
134,2010-019912-18,o,o
134,2010-019912-18,igual,o
134,2010-019912-18,a,o
134,2010-019912-18,6,o
134,2010-019912-18,recuento,o
134,2010-019912-18,de,o
134,2010-019912-18,66,o
134,2010-019912-18,articulaciones,i
134,2010-019912-18,y,o
134,2010-019912-18,de,o
134,2010-019912-18,articulaciones,i
134,2010-019912-18,dolorosas,i
134,2010-019912-18,RAD,o
134,2010-019912-18,mayor,o
134,2010-019912-18,o,o
134,2010-019912-18,igual,o
134,2010-019912-18,a,o
134,2010-019912-18,8,o
134,2010-019912-18,recuento,o
134,2010-019912-18,de,o
134,2010-019912-18,68,o
134,2010-019912-18,articulaciones,i
134,2010-019912-18,en,o
134,2010-019912-18,las,o
134,2010-019912-18,visitas,o
134,2010-019912-18,de,o
134,2010-019912-18,seleccion,o
134,2010-019912-18,y,o
134,2010-019912-18,basal,o
134,2010-019912-18,Los,o
134,2010-019912-18,pacientes,o
134,2010-019912-18,deben,o
134,2010-019912-18,estar,o
134,2010-019912-18,recibiendo,o
134,2010-019912-18,tratamiento,i
134,2010-019912-18,con,o
134,2010-019912-18,una,o
134,2010-019912-18,dosis,o
134,2010-019912-18,estable,o
134,2010-019912-18,de,o
134,2010-019912-18,los,o
134,2010-019912-18,FAMEs,i
134,2010-019912-18,permitidos,o
134,2010-019912-18,como,o
134,2010-019912-18,minimo,o
134,2010-019912-18,8,o
134,2010-019912-18,semanas,o
134,2010-019912-18,antes,o
134,2010-019912-18,de,o
134,2010-019912-18,la,o
134,2010-019912-18,visita,o
134,2010-019912-18,basal,o
134,2010-019912-18,Criterios,o
134,2010-019912-18,de,o
134,2010-019912-18,exclusion,o
134,2010-019912-18,Pacientes,o
134,2010-019912-18,sometidos,o
134,2010-019912-18,a,o
134,2010-019912-18,intervenciones,i
134,2010-019912-18,de,i
134,2010-019912-18,cirugia,i
134,2010-019912-18,mayor,i
134,2010-019912-18,incluyendo,o
134,2010-019912-18,cirugia,i
134,2010-019912-18,articular,i
134,2010-019912-18,en,o
134,2010-019912-18,las,o
134,2010-019912-18,8,o
134,2010-019912-18,semanas,o
134,2010-019912-18,previas,o
134,2010-019912-18,a,o
134,2010-019912-18,la,o
134,2010-019912-18,visita,o
134,2010-019912-18,de,o
134,2010-019912-18,seleccion,o
134,2010-019912-18,o,o
134,2010-019912-18,que,o
134,2010-019912-18,tengan,o
134,2010-019912-18,previsto,o
134,2010-019912-18,someterse,o
134,2010-019912-18,a,o
134,2010-019912-18,una,o
134,2010-019912-18,intervencion,i
134,2010-019912-18,de,o
134,2010-019912-18,este,o
134,2010-019912-18,tipo,o
134,2010-019912-18,en,o
134,2010-019912-18,los,o
134,2010-019912-18,6,o
134,2010-019912-18,meses,o
134,2010-019912-18,siguientes,o
134,2010-019912-18,a,o
134,2010-019912-18,la,o
134,2010-019912-18,randomizacion,i
134,2010-019912-18,Enfermedad,i
134,2010-019912-18,reumatica,i
134,2010-019912-18,autoinmune,i
134,2010-019912-18,distinta,o
134,2010-019912-18,de,o
134,2010-019912-18,AR,i
134,2010-019912-18,Se,o
134,2010-019912-18,permite,o
134,2010-019912-18,la,o
134,2010-019912-18,inclusion,o
134,2010-019912-18,de,o
134,2010-019912-18,pacientes,o
134,2010-019912-18,con,o
134,2010-019912-18,sindrome,i
134,2010-019912-18,de,i
134,2010-019912-18,Sjögren,i
134,2010-019912-18,secundario,i
134,2010-019912-18,asociado,o
134,2010-019912-18,a,o
134,2010-019912-18,AR,i
134,2010-019912-18,Clase,o
134,2010-019912-18,funcional,o
134,2010-019912-18,IV,o
134,2010-019912-18,definida,o
134,2010-019912-18,de,o
134,2010-019912-18,acuerdo,o
134,2010-019912-18,con,o
134,2010-019912-18,la,o
134,2010-019912-18,Clasificacion,o
134,2010-019912-18,del,o
134,2010-019912-18,ACR,o
134,2010-019912-18,del,o
134,2010-019912-18,Estado,o
134,2010-019912-18,Funcional,o
134,2010-019912-18,en,o
134,2010-019912-18,Artritis,i
134,2010-019912-18,Reumatoide,i
134,2010-019912-18,Artritis,i
134,2010-019912-18,idiopatica,i
134,2010-019912-18,juvenil,i
134,2010-019912-18,AIJ,i
134,2010-019912-18,o,o
134,2010-019912-18,artritis,i
134,2010-019912-18,reumatoide,i
134,2010-019912-18,juvenil,i
134,2010-019912-18,ARJ,i
134,2010-019912-18,yo,o
134,2010-019912-18,AR,i
134,2010-019912-18,diagnosticadas,i
134,2010-019912-18,antes,o
134,2010-019912-18,de,o
134,2010-019912-18,los,o
134,2010-019912-18,16,o
134,2010-019912-18,años,o
134,2010-019912-18,de,o
134,2010-019912-18,edad,o
134,2010-019912-18,Enfermedad,i
134,2010-019912-18,articular,i
134,2010-019912-18,inflamatoria,i
134,2010-019912-18,distinta,o
134,2010-019912-18,de,o
134,2010-019912-18,AR,i
134,2010-019912-18,en,o
134,2010-019912-18,el,o
134,2010-019912-18,pasado,o
134,2010-019912-18,o,o
134,2010-019912-18,en,o
134,2010-019912-18,la,o
134,2010-019912-18,actualidad,o
135,2010-019912-18,EudraCT,o
135,2010-019912-18,Nº,o
135,2010-019912-18,201001991218,o
135,2010-019912-18,Titulo,o
135,2010-019912-18,cientifico,o
135,2010-019912-18,Estudio,o
135,2010-019912-18,randomizado,o
135,2010-019912-18,doble,o
135,2010-019912-18,ciego,o
135,2010-019912-18,con,o
135,2010-019912-18,grupos,o
135,2010-019912-18,de,o
135,2010-019912-18,tratamiento,i
135,2010-019912-18,paralelos,o
135,2010-019912-18,para,o
135,2010-019912-18,evaluar,i
135,2010-019912-18,la,i
135,2010-019912-18,seguridad,i
135,2010-019912-18,y,o
135,2010-019912-18,el,o
135,2010-019912-18,efecto,o
135,2010-019912-18,sobre,o
135,2010-019912-18,el,o
135,2010-019912-18,resultado,o
135,2010-019912-18,clinico,o
135,2010-019912-18,de,o
135,2010-019912-18,tocilizumab,i
135,2010-019912-18,SC,o
135,2010-019912-18,frente,o
135,2010-019912-18,a,o
135,2010-019912-18,placebo,i
135,2010-019912-18,SC,o
135,2010-019912-18,en,o
135,2010-019912-18,combinacion,o
135,2010-019912-18,con,o
135,2010-019912-18,farmacos,i
135,2010-019912-18,antirreumaticos,i
135,2010-019912-18,modificadores,i
135,2010-019912-18,de,i
135,2010-019912-18,la,i
135,2010-019912-18,enfermedad,i
135,2010-019912-18,FAMEs,i
135,2010-019912-18,tradicionales,o
135,2010-019912-18,en,o
135,2010-019912-18,pacientes,o
135,2010-019912-18,con,o
135,2010-019912-18,artritis,i
135,2010-019912-18,reumatoide,i
135,2010-019912-18,activa,o
135,2010-019912-18,moderada,o
135,2010-019912-18,a,o
135,2010-019912-18,severa,o
135,2010-019912-18,Indicacion,o
135,2010-019912-18,cientifica,o
135,2010-019912-18,Artritis,i
135,2010-019912-18,Reumatoide,i
135,2010-019912-18,AR,i
135,2010-019912-18,Criterios,o
135,2010-019912-18,de,o
135,2010-019912-18,inclusion,o
135,2010-019912-18,Presentar,o
135,2010-019912-18,artritis,i
135,2010-019912-18,reumatoide,i
135,2010-019912-18,de,o
135,2010-019912-18,mayor,o
135,2010-019912-18,o,o
135,2010-019912-18,igual,o
135,2010-019912-18,a,o
135,2010-019912-18,6,o
135,2010-019912-18,meses,o
135,2010-019912-18,de,o
135,2010-019912-18,duracion,o
135,2010-019912-18,Recibir,o
135,2010-019912-18,tratamiento,i
135,2010-019912-18,de,i
135,2010-019912-18,forma,i
135,2010-019912-18,ambulatoria,i
135,2010-019912-18,Presentar,o
135,2010-019912-18,un,o
135,2010-019912-18,recuento,o
135,2010-019912-18,de,o
135,2010-019912-18,articulaciones,i
135,2010-019912-18,inflamadas,i
135,2010-019912-18,RAI,o
135,2010-019912-18,mayor,o
135,2010-019912-18,o,o
135,2010-019912-18,igual,o
135,2010-019912-18,a,o
135,2010-019912-18,6,o
135,2010-019912-18,recuento,o
135,2010-019912-18,de,o
135,2010-019912-18,66,o
135,2010-019912-18,articulaciones,i
135,2010-019912-18,y,o
135,2010-019912-18,de,o
135,2010-019912-18,articulaciones,i
135,2010-019912-18,dolorosas,i
135,2010-019912-18,RAD,o
135,2010-019912-18,mayor,o
135,2010-019912-18,o,o
135,2010-019912-18,igual,o
135,2010-019912-18,a,o
135,2010-019912-18,8,o
135,2010-019912-18,recuento,o
135,2010-019912-18,de,o
135,2010-019912-18,68,o
135,2010-019912-18,articulaciones,i
135,2010-019912-18,en,o
135,2010-019912-18,las,o
135,2010-019912-18,visitas,o
135,2010-019912-18,de,o
135,2010-019912-18,seleccion,o
135,2010-019912-18,y,o
135,2010-019912-18,basal,o
135,2010-019912-18,Los,o
135,2010-019912-18,pacientes,o
135,2010-019912-18,deben,o
135,2010-019912-18,estar,o
135,2010-019912-18,recibiendo,o
135,2010-019912-18,tratamiento,i
135,2010-019912-18,con,o
135,2010-019912-18,una,o
135,2010-019912-18,dosis,o
135,2010-019912-18,estable,o
135,2010-019912-18,de,o
135,2010-019912-18,los,o
135,2010-019912-18,FAMEs,i
135,2010-019912-18,permitidos,o
135,2010-019912-18,como,o
135,2010-019912-18,minimo,o
135,2010-019912-18,8,o
135,2010-019912-18,semanas,o
135,2010-019912-18,antes,o
135,2010-019912-18,de,o
135,2010-019912-18,la,o
135,2010-019912-18,visita,o
135,2010-019912-18,basal,o
135,2010-019912-18,Criterios,o
135,2010-019912-18,de,o
135,2010-019912-18,exclusion,o
135,2010-019912-18,Pacientes,o
135,2010-019912-18,sometidos,o
135,2010-019912-18,a,o
135,2010-019912-18,intervenciones,i
135,2010-019912-18,de,i
135,2010-019912-18,cirugia,i
135,2010-019912-18,mayor,i
135,2010-019912-18,incluyendo,o
135,2010-019912-18,cirugia,i
135,2010-019912-18,articular,i
135,2010-019912-18,en,o
135,2010-019912-18,las,o
135,2010-019912-18,8,o
135,2010-019912-18,semanas,o
135,2010-019912-18,previas,o
135,2010-019912-18,a,o
135,2010-019912-18,la,o
135,2010-019912-18,visita,o
135,2010-019912-18,de,o
135,2010-019912-18,seleccion,o
135,2010-019912-18,o,o
135,2010-019912-18,que,o
135,2010-019912-18,tengan,o
135,2010-019912-18,previsto,o
135,2010-019912-18,someterse,o
135,2010-019912-18,a,o
135,2010-019912-18,una,o
135,2010-019912-18,intervencion,i
135,2010-019912-18,de,o
135,2010-019912-18,este,o
135,2010-019912-18,tipo,o
135,2010-019912-18,en,o
135,2010-019912-18,los,o
135,2010-019912-18,6,o
135,2010-019912-18,meses,o
135,2010-019912-18,siguientes,o
135,2010-019912-18,a,o
135,2010-019912-18,la,o
135,2010-019912-18,randomizacion,i
135,2010-019912-18,Enfermedad,i
135,2010-019912-18,reumatica,i
135,2010-019912-18,autoinmune,i
135,2010-019912-18,distinta,o
135,2010-019912-18,de,o
135,2010-019912-18,AR,i
135,2010-019912-18,Se,o
135,2010-019912-18,permite,o
135,2010-019912-18,la,o
135,2010-019912-18,inclusion,o
135,2010-019912-18,de,o
135,2010-019912-18,pacientes,o
135,2010-019912-18,con,o
135,2010-019912-18,sindrome,i
135,2010-019912-18,de,i
135,2010-019912-18,Sjögren,i
135,2010-019912-18,secundario,i
135,2010-019912-18,asociado,o
135,2010-019912-18,a,o
135,2010-019912-18,AR,i
135,2010-019912-18,Clase,o
135,2010-019912-18,funcional,o
135,2010-019912-18,IV,o
135,2010-019912-18,definida,o
135,2010-019912-18,de,o
135,2010-019912-18,acuerdo,o
135,2010-019912-18,con,o
135,2010-019912-18,la,o
135,2010-019912-18,Clasificacion,o
135,2010-019912-18,del,o
135,2010-019912-18,ACR,o
135,2010-019912-18,del,o
135,2010-019912-18,Estado,o
135,2010-019912-18,Funcional,o
135,2010-019912-18,en,o
135,2010-019912-18,Artritis,i
135,2010-019912-18,Reumatoide,i
135,2010-019912-18,Artritis,i
135,2010-019912-18,idiopatica,i
135,2010-019912-18,juvenil,i
135,2010-019912-18,AIJ,i
135,2010-019912-18,o,o
135,2010-019912-18,artritis,i
135,2010-019912-18,reumatoide,i
135,2010-019912-18,juvenil,i
135,2010-019912-18,ARJ,i
135,2010-019912-18,yo,o
135,2010-019912-18,AR,i
135,2010-019912-18,diagnosticadas,i
135,2010-019912-18,antes,o
135,2010-019912-18,de,o
135,2010-019912-18,los,o
135,2010-019912-18,16,o
135,2010-019912-18,años,o
135,2010-019912-18,de,o
135,2010-019912-18,edad,o
135,2010-019912-18,Enfermedad,i
135,2010-019912-18,articular,i
135,2010-019912-18,inflamatoria,i
135,2010-019912-18,distinta,o
135,2010-019912-18,de,o
135,2010-019912-18,AR,i
135,2010-019912-18,en,o
135,2010-019912-18,el,o
135,2010-019912-18,pasado,o
135,2010-019912-18,o,o
135,2010-019912-18,en,o
135,2010-019912-18,la,o
135,2010-019912-18,actualidad,o
136,2010-019912-18,EudraCT,o
136,2010-019912-18,Nº,o
136,2010-019912-18,201001991218,o
136,2010-019912-18,Titulo,o
136,2010-019912-18,cientifico,o
136,2010-019912-18,Estudio,o
136,2010-019912-18,randomizado,o
136,2010-019912-18,doble,o
136,2010-019912-18,ciego,o
136,2010-019912-18,con,o
136,2010-019912-18,grupos,o
136,2010-019912-18,de,o
136,2010-019912-18,tratamiento,i
136,2010-019912-18,paralelos,o
136,2010-019912-18,para,o
136,2010-019912-18,evaluar,i
136,2010-019912-18,la,i
136,2010-019912-18,seguridad,i
136,2010-019912-18,y,o
136,2010-019912-18,el,o
136,2010-019912-18,efecto,o
136,2010-019912-18,sobre,o
136,2010-019912-18,el,o
136,2010-019912-18,resultado,o
136,2010-019912-18,clinico,o
136,2010-019912-18,de,o
136,2010-019912-18,tocilizumab,i
136,2010-019912-18,SC,o
136,2010-019912-18,frente,o
136,2010-019912-18,a,o
136,2010-019912-18,placebo,i
136,2010-019912-18,SC,o
136,2010-019912-18,en,o
136,2010-019912-18,combinacion,o
136,2010-019912-18,con,o
136,2010-019912-18,farmacos,i
136,2010-019912-18,antirreumaticos,i
136,2010-019912-18,modificadores,i
136,2010-019912-18,de,i
136,2010-019912-18,la,i
136,2010-019912-18,enfermedad,i
136,2010-019912-18,FAMEs,i
136,2010-019912-18,tradicionales,o
136,2010-019912-18,en,o
136,2010-019912-18,pacientes,o
136,2010-019912-18,con,o
136,2010-019912-18,artritis,i
136,2010-019912-18,reumatoide,i
136,2010-019912-18,activa,o
136,2010-019912-18,moderada,o
136,2010-019912-18,a,o
136,2010-019912-18,severa,o
136,2010-019912-18,Indicacion,o
136,2010-019912-18,cientifica,o
136,2010-019912-18,Artritis,i
136,2010-019912-18,Reumatoide,i
136,2010-019912-18,AR,i
136,2010-019912-18,Criterios,o
136,2010-019912-18,de,o
136,2010-019912-18,inclusion,o
136,2010-019912-18,Presentar,o
136,2010-019912-18,artritis,i
136,2010-019912-18,reumatoide,i
136,2010-019912-18,de,o
136,2010-019912-18,mayor,o
136,2010-019912-18,o,o
136,2010-019912-18,igual,o
136,2010-019912-18,a,o
136,2010-019912-18,6,o
136,2010-019912-18,meses,o
136,2010-019912-18,de,o
136,2010-019912-18,duracion,o
136,2010-019912-18,Recibir,o
136,2010-019912-18,tratamiento,i
136,2010-019912-18,de,i
136,2010-019912-18,forma,i
136,2010-019912-18,ambulatoria,i
136,2010-019912-18,Presentar,o
136,2010-019912-18,un,o
136,2010-019912-18,recuento,o
136,2010-019912-18,de,o
136,2010-019912-18,articulaciones,i
136,2010-019912-18,inflamadas,i
136,2010-019912-18,RAI,o
136,2010-019912-18,mayor,o
136,2010-019912-18,o,o
136,2010-019912-18,igual,o
136,2010-019912-18,a,o
136,2010-019912-18,6,o
136,2010-019912-18,recuento,o
136,2010-019912-18,de,o
136,2010-019912-18,66,o
136,2010-019912-18,articulaciones,i
136,2010-019912-18,y,o
136,2010-019912-18,de,o
136,2010-019912-18,articulaciones,i
136,2010-019912-18,dolorosas,i
136,2010-019912-18,RAD,o
136,2010-019912-18,mayor,o
136,2010-019912-18,o,o
136,2010-019912-18,igual,o
136,2010-019912-18,a,o
136,2010-019912-18,8,o
136,2010-019912-18,recuento,o
136,2010-019912-18,de,o
136,2010-019912-18,68,o
136,2010-019912-18,articulaciones,i
136,2010-019912-18,en,o
136,2010-019912-18,las,o
136,2010-019912-18,visitas,o
136,2010-019912-18,de,o
136,2010-019912-18,seleccion,o
136,2010-019912-18,y,o
136,2010-019912-18,basal,o
136,2010-019912-18,Los,o
136,2010-019912-18,pacientes,o
136,2010-019912-18,deben,o
136,2010-019912-18,estar,o
136,2010-019912-18,recibiendo,o
136,2010-019912-18,tratamiento,i
136,2010-019912-18,con,o
136,2010-019912-18,una,o
136,2010-019912-18,dosis,o
136,2010-019912-18,estable,o
136,2010-019912-18,de,o
136,2010-019912-18,los,o
136,2010-019912-18,FAMEs,i
136,2010-019912-18,permitidos,o
136,2010-019912-18,como,o
136,2010-019912-18,minimo,o
136,2010-019912-18,8,o
136,2010-019912-18,semanas,o
136,2010-019912-18,antes,o
136,2010-019912-18,de,o
136,2010-019912-18,la,o
136,2010-019912-18,visita,o
136,2010-019912-18,basal,o
136,2010-019912-18,Criterios,o
136,2010-019912-18,de,o
136,2010-019912-18,exclusion,o
136,2010-019912-18,Pacientes,o
136,2010-019912-18,sometidos,o
136,2010-019912-18,a,o
136,2010-019912-18,intervenciones,i
136,2010-019912-18,de,i
136,2010-019912-18,cirugia,i
136,2010-019912-18,mayor,i
136,2010-019912-18,incluyendo,o
136,2010-019912-18,cirugia,i
136,2010-019912-18,articular,i
136,2010-019912-18,en,o
136,2010-019912-18,las,o
136,2010-019912-18,8,o
136,2010-019912-18,semanas,o
136,2010-019912-18,previas,o
136,2010-019912-18,a,o
136,2010-019912-18,la,o
136,2010-019912-18,visita,o
136,2010-019912-18,de,o
136,2010-019912-18,seleccion,o
136,2010-019912-18,o,o
136,2010-019912-18,que,o
136,2010-019912-18,tengan,o
136,2010-019912-18,previsto,o
136,2010-019912-18,someterse,o
136,2010-019912-18,a,o
136,2010-019912-18,una,o
136,2010-019912-18,intervencion,i
136,2010-019912-18,de,o
136,2010-019912-18,este,o
136,2010-019912-18,tipo,o
136,2010-019912-18,en,o
136,2010-019912-18,los,o
136,2010-019912-18,6,o
136,2010-019912-18,meses,o
136,2010-019912-18,siguientes,o
136,2010-019912-18,a,o
136,2010-019912-18,la,o
136,2010-019912-18,randomizacion,i
136,2010-019912-18,Enfermedad,i
136,2010-019912-18,reumatica,i
136,2010-019912-18,autoinmune,i
136,2010-019912-18,distinta,o
136,2010-019912-18,de,o
136,2010-019912-18,AR,i
136,2010-019912-18,Se,o
136,2010-019912-18,permite,o
136,2010-019912-18,la,o
136,2010-019912-18,inclusion,o
136,2010-019912-18,de,o
136,2010-019912-18,pacientes,o
136,2010-019912-18,con,o
136,2010-019912-18,sindrome,i
136,2010-019912-18,de,i
136,2010-019912-18,Sjögren,i
136,2010-019912-18,secundario,i
136,2010-019912-18,asociado,o
136,2010-019912-18,a,o
136,2010-019912-18,AR,i
136,2010-019912-18,Clase,o
136,2010-019912-18,funcional,o
136,2010-019912-18,IV,o
136,2010-019912-18,definida,o
136,2010-019912-18,de,o
136,2010-019912-18,acuerdo,o
136,2010-019912-18,con,o
136,2010-019912-18,la,o
136,2010-019912-18,Clasificacion,o
136,2010-019912-18,del,o
136,2010-019912-18,ACR,o
136,2010-019912-18,del,o
136,2010-019912-18,Estado,o
136,2010-019912-18,Funcional,o
136,2010-019912-18,en,o
136,2010-019912-18,Artritis,i
136,2010-019912-18,Reumatoide,i
136,2010-019912-18,Artritis,i
136,2010-019912-18,idiopatica,i
136,2010-019912-18,juvenil,i
136,2010-019912-18,AIJ,i
136,2010-019912-18,o,o
136,2010-019912-18,artritis,i
136,2010-019912-18,reumatoide,i
136,2010-019912-18,juvenil,i
136,2010-019912-18,ARJ,i
136,2010-019912-18,yo,o
136,2010-019912-18,AR,i
136,2010-019912-18,diagnosticadas,i
136,2010-019912-18,antes,o
136,2010-019912-18,de,o
136,2010-019912-18,los,o
136,2010-019912-18,16,o
136,2010-019912-18,años,o
136,2010-019912-18,de,o
136,2010-019912-18,edad,o
136,2010-019912-18,Enfermedad,i
136,2010-019912-18,articular,i
136,2010-019912-18,inflamatoria,i
136,2010-019912-18,distinta,o
136,2010-019912-18,de,o
136,2010-019912-18,AR,i
136,2010-019912-18,en,o
136,2010-019912-18,el,o
136,2010-019912-18,pasado,o
136,2010-019912-18,o,o
136,2010-019912-18,en,o
136,2010-019912-18,la,o
136,2010-019912-18,actualidad,o
137,2010-019912-18,EudraCT,o
137,2010-019912-18,Nº,o
137,2010-019912-18,201001991218,o
137,2010-019912-18,Titulo,o
137,2010-019912-18,cientifico,o
137,2010-019912-18,Estudio,o
137,2010-019912-18,randomizado,o
137,2010-019912-18,doble,o
137,2010-019912-18,ciego,o
137,2010-019912-18,con,o
137,2010-019912-18,grupos,o
137,2010-019912-18,de,o
137,2010-019912-18,tratamiento,i
137,2010-019912-18,paralelos,o
137,2010-019912-18,para,o
137,2010-019912-18,evaluar,i
137,2010-019912-18,la,i
137,2010-019912-18,seguridad,i
137,2010-019912-18,y,o
137,2010-019912-18,el,o
137,2010-019912-18,efecto,o
137,2010-019912-18,sobre,o
137,2010-019912-18,el,o
137,2010-019912-18,resultado,o
137,2010-019912-18,clinico,o
137,2010-019912-18,de,o
137,2010-019912-18,tocilizumab,i
137,2010-019912-18,SC,o
137,2010-019912-18,frente,o
137,2010-019912-18,a,o
137,2010-019912-18,placebo,i
137,2010-019912-18,SC,o
137,2010-019912-18,en,o
137,2010-019912-18,combinacion,o
137,2010-019912-18,con,o
137,2010-019912-18,farmacos,i
137,2010-019912-18,antirreumaticos,i
137,2010-019912-18,modificadores,i
137,2010-019912-18,de,i
137,2010-019912-18,la,i
137,2010-019912-18,enfermedad,i
137,2010-019912-18,FAMEs,i
137,2010-019912-18,tradicionales,o
137,2010-019912-18,en,o
137,2010-019912-18,pacientes,o
137,2010-019912-18,con,o
137,2010-019912-18,artritis,i
137,2010-019912-18,reumatoide,i
137,2010-019912-18,activa,o
137,2010-019912-18,moderada,o
137,2010-019912-18,a,o
137,2010-019912-18,severa,o
137,2010-019912-18,Indicacion,o
137,2010-019912-18,cientifica,o
137,2010-019912-18,Artritis,i
137,2010-019912-18,Reumatoide,i
137,2010-019912-18,AR,i
137,2010-019912-18,Criterios,o
137,2010-019912-18,de,o
137,2010-019912-18,inclusion,o
137,2010-019912-18,Presentar,o
137,2010-019912-18,artritis,i
137,2010-019912-18,reumatoide,i
137,2010-019912-18,de,o
137,2010-019912-18,mayor,o
137,2010-019912-18,o,o
137,2010-019912-18,igual,o
137,2010-019912-18,a,o
137,2010-019912-18,6,o
137,2010-019912-18,meses,o
137,2010-019912-18,de,o
137,2010-019912-18,duracion,o
137,2010-019912-18,Recibir,o
137,2010-019912-18,tratamiento,i
137,2010-019912-18,de,i
137,2010-019912-18,forma,i
137,2010-019912-18,ambulatoria,i
137,2010-019912-18,Presentar,o
137,2010-019912-18,un,o
137,2010-019912-18,recuento,o
137,2010-019912-18,de,o
137,2010-019912-18,articulaciones,i
137,2010-019912-18,inflamadas,i
137,2010-019912-18,RAI,o
137,2010-019912-18,mayor,o
137,2010-019912-18,o,o
137,2010-019912-18,igual,o
137,2010-019912-18,a,o
137,2010-019912-18,6,o
137,2010-019912-18,recuento,o
137,2010-019912-18,de,o
137,2010-019912-18,66,o
137,2010-019912-18,articulaciones,i
137,2010-019912-18,y,o
137,2010-019912-18,de,o
137,2010-019912-18,articulaciones,i
137,2010-019912-18,dolorosas,i
137,2010-019912-18,RAD,o
137,2010-019912-18,mayor,o
137,2010-019912-18,o,o
137,2010-019912-18,igual,o
137,2010-019912-18,a,o
137,2010-019912-18,8,o
137,2010-019912-18,recuento,o
137,2010-019912-18,de,o
137,2010-019912-18,68,o
137,2010-019912-18,articulaciones,i
137,2010-019912-18,en,o
137,2010-019912-18,las,o
137,2010-019912-18,visitas,o
137,2010-019912-18,de,o
137,2010-019912-18,seleccion,o
137,2010-019912-18,y,o
137,2010-019912-18,basal,o
137,2010-019912-18,Los,o
137,2010-019912-18,pacientes,o
137,2010-019912-18,deben,o
137,2010-019912-18,estar,o
137,2010-019912-18,recibiendo,o
137,2010-019912-18,tratamiento,i
137,2010-019912-18,con,o
137,2010-019912-18,una,o
137,2010-019912-18,dosis,o
137,2010-019912-18,estable,o
137,2010-019912-18,de,o
137,2010-019912-18,los,o
137,2010-019912-18,FAMEs,i
137,2010-019912-18,permitidos,o
137,2010-019912-18,como,o
137,2010-019912-18,minimo,o
137,2010-019912-18,8,o
137,2010-019912-18,semanas,o
137,2010-019912-18,antes,o
137,2010-019912-18,de,o
137,2010-019912-18,la,o
137,2010-019912-18,visita,o
137,2010-019912-18,basal,o
137,2010-019912-18,Criterios,o
137,2010-019912-18,de,o
137,2010-019912-18,exclusion,o
137,2010-019912-18,Pacientes,o
137,2010-019912-18,sometidos,o
137,2010-019912-18,a,o
137,2010-019912-18,intervenciones,i
137,2010-019912-18,de,i
137,2010-019912-18,cirugia,i
137,2010-019912-18,mayor,i
137,2010-019912-18,incluyendo,o
137,2010-019912-18,cirugia,i
137,2010-019912-18,articular,i
137,2010-019912-18,en,o
137,2010-019912-18,las,o
137,2010-019912-18,8,o
137,2010-019912-18,semanas,o
137,2010-019912-18,previas,o
137,2010-019912-18,a,o
137,2010-019912-18,la,o
137,2010-019912-18,visita,o
137,2010-019912-18,de,o
137,2010-019912-18,seleccion,o
137,2010-019912-18,o,o
137,2010-019912-18,que,o
137,2010-019912-18,tengan,o
137,2010-019912-18,previsto,o
137,2010-019912-18,someterse,o
137,2010-019912-18,a,o
137,2010-019912-18,una,o
137,2010-019912-18,intervencion,i
137,2010-019912-18,de,o
137,2010-019912-18,este,o
137,2010-019912-18,tipo,o
137,2010-019912-18,en,o
137,2010-019912-18,los,o
137,2010-019912-18,6,o
137,2010-019912-18,meses,o
137,2010-019912-18,siguientes,o
137,2010-019912-18,a,o
137,2010-019912-18,la,o
137,2010-019912-18,randomizacion,i
137,2010-019912-18,Enfermedad,i
137,2010-019912-18,reumatica,i
137,2010-019912-18,autoinmune,i
137,2010-019912-18,distinta,o
137,2010-019912-18,de,o
137,2010-019912-18,AR,i
137,2010-019912-18,Se,o
137,2010-019912-18,permite,o
137,2010-019912-18,la,o
137,2010-019912-18,inclusion,o
137,2010-019912-18,de,o
137,2010-019912-18,pacientes,o
137,2010-019912-18,con,o
137,2010-019912-18,sindrome,i
137,2010-019912-18,de,i
137,2010-019912-18,Sjögren,i
137,2010-019912-18,secundario,i
137,2010-019912-18,asociado,o
137,2010-019912-18,a,o
137,2010-019912-18,AR,i
137,2010-019912-18,Clase,o
137,2010-019912-18,funcional,o
137,2010-019912-18,IV,o
137,2010-019912-18,definida,o
137,2010-019912-18,de,o
137,2010-019912-18,acuerdo,o
137,2010-019912-18,con,o
137,2010-019912-18,la,o
137,2010-019912-18,Clasificacion,o
137,2010-019912-18,del,o
137,2010-019912-18,ACR,o
137,2010-019912-18,del,o
137,2010-019912-18,Estado,o
137,2010-019912-18,Funcional,o
137,2010-019912-18,en,o
137,2010-019912-18,Artritis,i
137,2010-019912-18,Reumatoide,i
137,2010-019912-18,Artritis,i
137,2010-019912-18,idiopatica,i
137,2010-019912-18,juvenil,i
137,2010-019912-18,AIJ,i
137,2010-019912-18,o,o
137,2010-019912-18,artritis,i
137,2010-019912-18,reumatoide,i
137,2010-019912-18,juvenil,i
137,2010-019912-18,ARJ,i
137,2010-019912-18,yo,o
137,2010-019912-18,AR,i
137,2010-019912-18,diagnosticadas,i
137,2010-019912-18,antes,o
137,2010-019912-18,de,o
137,2010-019912-18,los,o
137,2010-019912-18,16,o
137,2010-019912-18,años,o
137,2010-019912-18,de,o
137,2010-019912-18,edad,o
137,2010-019912-18,Enfermedad,i
137,2010-019912-18,articular,i
137,2010-019912-18,inflamatoria,i
137,2010-019912-18,distinta,o
137,2010-019912-18,de,o
137,2010-019912-18,AR,i
137,2010-019912-18,en,o
137,2010-019912-18,el,o
137,2010-019912-18,pasado,o
137,2010-019912-18,o,o
137,2010-019912-18,en,o
137,2010-019912-18,la,o
137,2010-019912-18,actualidad,o
138,2010-019912-18,EudraCT,o
138,2010-019912-18,Nº,o
138,2010-019912-18,201001991218,o
138,2010-019912-18,Titulo,o
138,2010-019912-18,cientifico,o
138,2010-019912-18,Estudio,o
138,2010-019912-18,randomizado,o
138,2010-019912-18,doble,o
138,2010-019912-18,ciego,o
138,2010-019912-18,con,o
138,2010-019912-18,grupos,o
138,2010-019912-18,de,o
138,2010-019912-18,tratamiento,i
138,2010-019912-18,paralelos,o
138,2010-019912-18,para,o
138,2010-019912-18,evaluar,i
138,2010-019912-18,la,i
138,2010-019912-18,seguridad,i
138,2010-019912-18,y,o
138,2010-019912-18,el,o
138,2010-019912-18,efecto,o
138,2010-019912-18,sobre,o
138,2010-019912-18,el,o
138,2010-019912-18,resultado,o
138,2010-019912-18,clinico,o
138,2010-019912-18,de,o
138,2010-019912-18,tocilizumab,i
138,2010-019912-18,SC,o
138,2010-019912-18,frente,o
138,2010-019912-18,a,o
138,2010-019912-18,placebo,i
138,2010-019912-18,SC,o
138,2010-019912-18,en,o
138,2010-019912-18,combinacion,o
138,2010-019912-18,con,o
138,2010-019912-18,farmacos,i
138,2010-019912-18,antirreumaticos,i
138,2010-019912-18,modificadores,i
138,2010-019912-18,de,i
138,2010-019912-18,la,i
138,2010-019912-18,enfermedad,i
138,2010-019912-18,FAMEs,i
138,2010-019912-18,tradicionales,o
138,2010-019912-18,en,o
138,2010-019912-18,pacientes,o
138,2010-019912-18,con,o
138,2010-019912-18,artritis,i
138,2010-019912-18,reumatoide,i
138,2010-019912-18,activa,o
138,2010-019912-18,moderada,o
138,2010-019912-18,a,o
138,2010-019912-18,severa,o
138,2010-019912-18,Indicacion,o
138,2010-019912-18,cientifica,o
138,2010-019912-18,Artritis,i
138,2010-019912-18,Reumatoide,i
138,2010-019912-18,AR,i
138,2010-019912-18,Criterios,o
138,2010-019912-18,de,o
138,2010-019912-18,inclusion,o
138,2010-019912-18,Presentar,o
138,2010-019912-18,artritis,i
138,2010-019912-18,reumatoide,i
138,2010-019912-18,de,o
138,2010-019912-18,mayor,o
138,2010-019912-18,o,o
138,2010-019912-18,igual,o
138,2010-019912-18,a,o
138,2010-019912-18,6,o
138,2010-019912-18,meses,o
138,2010-019912-18,de,o
138,2010-019912-18,duracion,o
138,2010-019912-18,Recibir,o
138,2010-019912-18,tratamiento,i
138,2010-019912-18,de,i
138,2010-019912-18,forma,i
138,2010-019912-18,ambulatoria,i
138,2010-019912-18,Presentar,o
138,2010-019912-18,un,o
138,2010-019912-18,recuento,o
138,2010-019912-18,de,o
138,2010-019912-18,articulaciones,i
138,2010-019912-18,inflamadas,i
138,2010-019912-18,RAI,o
138,2010-019912-18,mayor,o
138,2010-019912-18,o,o
138,2010-019912-18,igual,o
138,2010-019912-18,a,o
138,2010-019912-18,6,o
138,2010-019912-18,recuento,o
138,2010-019912-18,de,o
138,2010-019912-18,66,o
138,2010-019912-18,articulaciones,i
138,2010-019912-18,y,o
138,2010-019912-18,de,o
138,2010-019912-18,articulaciones,i
138,2010-019912-18,dolorosas,i
138,2010-019912-18,RAD,o
138,2010-019912-18,mayor,o
138,2010-019912-18,o,o
138,2010-019912-18,igual,o
138,2010-019912-18,a,o
138,2010-019912-18,8,o
138,2010-019912-18,recuento,o
138,2010-019912-18,de,o
138,2010-019912-18,68,o
138,2010-019912-18,articulaciones,i
138,2010-019912-18,en,o
138,2010-019912-18,las,o
138,2010-019912-18,visitas,o
138,2010-019912-18,de,o
138,2010-019912-18,seleccion,o
138,2010-019912-18,y,o
138,2010-019912-18,basal,o
138,2010-019912-18,Los,o
138,2010-019912-18,pacientes,o
138,2010-019912-18,deben,o
138,2010-019912-18,estar,o
138,2010-019912-18,recibiendo,o
138,2010-019912-18,tratamiento,i
138,2010-019912-18,con,o
138,2010-019912-18,una,o
138,2010-019912-18,dosis,o
138,2010-019912-18,estable,o
138,2010-019912-18,de,o
138,2010-019912-18,los,o
138,2010-019912-18,FAMEs,i
138,2010-019912-18,permitidos,o
138,2010-019912-18,como,o
138,2010-019912-18,minimo,o
138,2010-019912-18,8,o
138,2010-019912-18,semanas,o
138,2010-019912-18,antes,o
138,2010-019912-18,de,o
138,2010-019912-18,la,o
138,2010-019912-18,visita,o
138,2010-019912-18,basal,o
138,2010-019912-18,Criterios,o
138,2010-019912-18,de,o
138,2010-019912-18,exclusion,o
138,2010-019912-18,Pacientes,o
138,2010-019912-18,sometidos,o
138,2010-019912-18,a,o
138,2010-019912-18,intervenciones,i
138,2010-019912-18,de,i
138,2010-019912-18,cirugia,i
138,2010-019912-18,mayor,i
138,2010-019912-18,incluyendo,o
138,2010-019912-18,cirugia,i
138,2010-019912-18,articular,i
138,2010-019912-18,en,o
138,2010-019912-18,las,o
138,2010-019912-18,8,o
138,2010-019912-18,semanas,o
138,2010-019912-18,previas,o
138,2010-019912-18,a,o
138,2010-019912-18,la,o
138,2010-019912-18,visita,o
138,2010-019912-18,de,o
138,2010-019912-18,seleccion,o
138,2010-019912-18,o,o
138,2010-019912-18,que,o
138,2010-019912-18,tengan,o
138,2010-019912-18,previsto,o
138,2010-019912-18,someterse,o
138,2010-019912-18,a,o
138,2010-019912-18,una,o
138,2010-019912-18,intervencion,i
138,2010-019912-18,de,o
138,2010-019912-18,este,o
138,2010-019912-18,tipo,o
138,2010-019912-18,en,o
138,2010-019912-18,los,o
138,2010-019912-18,6,o
138,2010-019912-18,meses,o
138,2010-019912-18,siguientes,o
138,2010-019912-18,a,o
138,2010-019912-18,la,o
138,2010-019912-18,randomizacion,i
138,2010-019912-18,Enfermedad,i
138,2010-019912-18,reumatica,i
138,2010-019912-18,autoinmune,i
138,2010-019912-18,distinta,o
138,2010-019912-18,de,o
138,2010-019912-18,AR,i
138,2010-019912-18,Se,o
138,2010-019912-18,permite,o
138,2010-019912-18,la,o
138,2010-019912-18,inclusion,o
138,2010-019912-18,de,o
138,2010-019912-18,pacientes,o
138,2010-019912-18,con,o
138,2010-019912-18,sindrome,i
138,2010-019912-18,de,i
138,2010-019912-18,Sjögren,i
138,2010-019912-18,secundario,i
138,2010-019912-18,asociado,o
138,2010-019912-18,a,o
138,2010-019912-18,AR,i
138,2010-019912-18,Clase,o
138,2010-019912-18,funcional,o
138,2010-019912-18,IV,o
138,2010-019912-18,definida,o
138,2010-019912-18,de,o
138,2010-019912-18,acuerdo,o
138,2010-019912-18,con,o
138,2010-019912-18,la,o
138,2010-019912-18,Clasificacion,o
138,2010-019912-18,del,o
138,2010-019912-18,ACR,o
138,2010-019912-18,del,o
138,2010-019912-18,Estado,o
138,2010-019912-18,Funcional,o
138,2010-019912-18,en,o
138,2010-019912-18,Artritis,i
138,2010-019912-18,Reumatoide,i
138,2010-019912-18,Artritis,i
138,2010-019912-18,idiopatica,i
138,2010-019912-18,juvenil,i
138,2010-019912-18,AIJ,i
138,2010-019912-18,o,o
138,2010-019912-18,artritis,i
138,2010-019912-18,reumatoide,i
138,2010-019912-18,juvenil,i
138,2010-019912-18,ARJ,i
138,2010-019912-18,yo,o
138,2010-019912-18,AR,i
138,2010-019912-18,diagnosticadas,i
138,2010-019912-18,antes,o
138,2010-019912-18,de,o
138,2010-019912-18,los,o
138,2010-019912-18,16,o
138,2010-019912-18,años,o
138,2010-019912-18,de,o
138,2010-019912-18,edad,o
138,2010-019912-18,Enfermedad,i
138,2010-019912-18,articular,i
138,2010-019912-18,inflamatoria,i
138,2010-019912-18,distinta,o
138,2010-019912-18,de,o
138,2010-019912-18,AR,i
138,2010-019912-18,en,o
138,2010-019912-18,el,o
138,2010-019912-18,pasado,o
138,2010-019912-18,o,o
138,2010-019912-18,en,o
138,2010-019912-18,la,o
138,2010-019912-18,actualidad,o
139,2010-019912-18,EudraCT,o
139,2010-019912-18,Nº,o
139,2010-019912-18,201001991218,o
139,2010-019912-18,Titulo,o
139,2010-019912-18,cientifico,o
139,2010-019912-18,Estudio,o
139,2010-019912-18,randomizado,o
139,2010-019912-18,doble,o
139,2010-019912-18,ciego,o
139,2010-019912-18,con,o
139,2010-019912-18,grupos,o
139,2010-019912-18,de,o
139,2010-019912-18,tratamiento,i
139,2010-019912-18,paralelos,o
139,2010-019912-18,para,o
139,2010-019912-18,evaluar,i
139,2010-019912-18,la,i
139,2010-019912-18,seguridad,i
139,2010-019912-18,y,o
139,2010-019912-18,el,o
139,2010-019912-18,efecto,o
139,2010-019912-18,sobre,o
139,2010-019912-18,el,o
139,2010-019912-18,resultado,o
139,2010-019912-18,clinico,o
139,2010-019912-18,de,o
139,2010-019912-18,tocilizumab,i
139,2010-019912-18,SC,o
139,2010-019912-18,frente,o
139,2010-019912-18,a,o
139,2010-019912-18,placebo,i
139,2010-019912-18,SC,o
139,2010-019912-18,en,o
139,2010-019912-18,combinacion,o
139,2010-019912-18,con,o
139,2010-019912-18,farmacos,i
139,2010-019912-18,antirreumaticos,i
139,2010-019912-18,modificadores,i
139,2010-019912-18,de,i
139,2010-019912-18,la,i
139,2010-019912-18,enfermedad,i
139,2010-019912-18,FAMEs,i
139,2010-019912-18,tradicionales,o
139,2010-019912-18,en,o
139,2010-019912-18,pacientes,o
139,2010-019912-18,con,o
139,2010-019912-18,artritis,i
139,2010-019912-18,reumatoide,i
139,2010-019912-18,activa,o
139,2010-019912-18,moderada,o
139,2010-019912-18,a,o
139,2010-019912-18,severa,o
139,2010-019912-18,Indicacion,o
139,2010-019912-18,cientifica,o
139,2010-019912-18,Artritis,i
139,2010-019912-18,Reumatoide,i
139,2010-019912-18,AR,i
139,2010-019912-18,Criterios,o
139,2010-019912-18,de,o
139,2010-019912-18,inclusion,o
139,2010-019912-18,Presentar,o
139,2010-019912-18,artritis,i
139,2010-019912-18,reumatoide,i
139,2010-019912-18,de,o
139,2010-019912-18,mayor,o
139,2010-019912-18,o,o
139,2010-019912-18,igual,o
139,2010-019912-18,a,o
139,2010-019912-18,6,o
139,2010-019912-18,meses,o
139,2010-019912-18,de,o
139,2010-019912-18,duracion,o
139,2010-019912-18,Recibir,o
139,2010-019912-18,tratamiento,i
139,2010-019912-18,de,i
139,2010-019912-18,forma,i
139,2010-019912-18,ambulatoria,i
139,2010-019912-18,Presentar,o
139,2010-019912-18,un,o
139,2010-019912-18,recuento,o
139,2010-019912-18,de,o
139,2010-019912-18,articulaciones,i
139,2010-019912-18,inflamadas,i
139,2010-019912-18,RAI,o
139,2010-019912-18,mayor,o
139,2010-019912-18,o,o
139,2010-019912-18,igual,o
139,2010-019912-18,a,o
139,2010-019912-18,6,o
139,2010-019912-18,recuento,o
139,2010-019912-18,de,o
139,2010-019912-18,66,o
139,2010-019912-18,articulaciones,i
139,2010-019912-18,y,o
139,2010-019912-18,de,o
139,2010-019912-18,articulaciones,i
139,2010-019912-18,dolorosas,i
139,2010-019912-18,RAD,o
139,2010-019912-18,mayor,o
139,2010-019912-18,o,o
139,2010-019912-18,igual,o
139,2010-019912-18,a,o
139,2010-019912-18,8,o
139,2010-019912-18,recuento,o
139,2010-019912-18,de,o
139,2010-019912-18,68,o
139,2010-019912-18,articulaciones,i
139,2010-019912-18,en,o
139,2010-019912-18,las,o
139,2010-019912-18,visitas,o
139,2010-019912-18,de,o
139,2010-019912-18,seleccion,o
139,2010-019912-18,y,o
139,2010-019912-18,basal,o
139,2010-019912-18,Los,o
139,2010-019912-18,pacientes,o
139,2010-019912-18,deben,o
139,2010-019912-18,estar,o
139,2010-019912-18,recibiendo,o
139,2010-019912-18,tratamiento,i
139,2010-019912-18,con,o
139,2010-019912-18,una,o
139,2010-019912-18,dosis,o
139,2010-019912-18,estable,o
139,2010-019912-18,de,o
139,2010-019912-18,los,o
139,2010-019912-18,FAMEs,i
139,2010-019912-18,permitidos,o
139,2010-019912-18,como,o
139,2010-019912-18,minimo,o
139,2010-019912-18,8,o
139,2010-019912-18,semanas,o
139,2010-019912-18,antes,o
139,2010-019912-18,de,o
139,2010-019912-18,la,o
139,2010-019912-18,visita,o
139,2010-019912-18,basal,o
139,2010-019912-18,Criterios,o
139,2010-019912-18,de,o
139,2010-019912-18,exclusion,o
139,2010-019912-18,Pacientes,o
139,2010-019912-18,sometidos,o
139,2010-019912-18,a,o
139,2010-019912-18,intervenciones,i
139,2010-019912-18,de,i
139,2010-019912-18,cirugia,i
139,2010-019912-18,mayor,i
139,2010-019912-18,incluyendo,o
139,2010-019912-18,cirugia,i
139,2010-019912-18,articular,i
139,2010-019912-18,en,o
139,2010-019912-18,las,o
139,2010-019912-18,8,o
139,2010-019912-18,semanas,o
139,2010-019912-18,previas,o
139,2010-019912-18,a,o
139,2010-019912-18,la,o
139,2010-019912-18,visita,o
139,2010-019912-18,de,o
139,2010-019912-18,seleccion,o
139,2010-019912-18,o,o
139,2010-019912-18,que,o
139,2010-019912-18,tengan,o
139,2010-019912-18,previsto,o
139,2010-019912-18,someterse,o
139,2010-019912-18,a,o
139,2010-019912-18,una,o
139,2010-019912-18,intervencion,i
139,2010-019912-18,de,o
139,2010-019912-18,este,o
139,2010-019912-18,tipo,o
139,2010-019912-18,en,o
139,2010-019912-18,los,o
139,2010-019912-18,6,o
139,2010-019912-18,meses,o
139,2010-019912-18,siguientes,o
139,2010-019912-18,a,o
139,2010-019912-18,la,o
139,2010-019912-18,randomizacion,i
139,2010-019912-18,Enfermedad,i
139,2010-019912-18,reumatica,i
139,2010-019912-18,autoinmune,i
139,2010-019912-18,distinta,o
139,2010-019912-18,de,o
139,2010-019912-18,AR,i
139,2010-019912-18,Se,o
139,2010-019912-18,permite,o
139,2010-019912-18,la,o
139,2010-019912-18,inclusion,o
139,2010-019912-18,de,o
139,2010-019912-18,pacientes,o
139,2010-019912-18,con,o
139,2010-019912-18,sindrome,i
139,2010-019912-18,de,i
139,2010-019912-18,Sjögren,i
139,2010-019912-18,secundario,i
139,2010-019912-18,asociado,o
139,2010-019912-18,a,o
139,2010-019912-18,AR,i
139,2010-019912-18,Clase,o
139,2010-019912-18,funcional,o
139,2010-019912-18,IV,o
139,2010-019912-18,definida,o
139,2010-019912-18,de,o
139,2010-019912-18,acuerdo,o
139,2010-019912-18,con,o
139,2010-019912-18,la,o
139,2010-019912-18,Clasificacion,o
139,2010-019912-18,del,o
139,2010-019912-18,ACR,o
139,2010-019912-18,del,o
139,2010-019912-18,Estado,o
139,2010-019912-18,Funcional,o
139,2010-019912-18,en,o
139,2010-019912-18,Artritis,i
139,2010-019912-18,Reumatoide,i
139,2010-019912-18,Artritis,i
139,2010-019912-18,idiopatica,i
139,2010-019912-18,juvenil,i
139,2010-019912-18,AIJ,i
139,2010-019912-18,o,o
139,2010-019912-18,artritis,i
139,2010-019912-18,reumatoide,i
139,2010-019912-18,juvenil,i
139,2010-019912-18,ARJ,i
139,2010-019912-18,yo,o
139,2010-019912-18,AR,i
139,2010-019912-18,diagnosticadas,i
139,2010-019912-18,antes,o
139,2010-019912-18,de,o
139,2010-019912-18,los,o
139,2010-019912-18,16,o
139,2010-019912-18,años,o
139,2010-019912-18,de,o
139,2010-019912-18,edad,o
139,2010-019912-18,Enfermedad,i
139,2010-019912-18,articular,i
139,2010-019912-18,inflamatoria,i
139,2010-019912-18,distinta,o
139,2010-019912-18,de,o
139,2010-019912-18,AR,i
139,2010-019912-18,en,o
139,2010-019912-18,el,o
139,2010-019912-18,pasado,o
139,2010-019912-18,o,o
139,2010-019912-18,en,o
139,2010-019912-18,la,o
139,2010-019912-18,actualidad,o
